(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 1 August 2002 (01.08.2002)

PCT

(10) International Publication Number WO 02/059148 A2

(51) International Patent Classification7: C07K 14/195

(21) International Application Number:

(22) International Filing Date: 21 January 2002 (21.01.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

A 130/01

26 January 2001 (26.01.2001)

(71) Applicant (for all designated States except US): CISTEM BIOTECHNOLOGIES GMBH [AT/AT]; Rennweg 95b, A-1030 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MEINKE, Andreas [DE/AT]; Piettegasse 26/1, A-3013 Pressbaum (AT). NAGY, Eszter [HU/AT]; Taborstrasse 9/15, A-1020 Vienna (AT). VON AHSEN, Uwe [DE/AT]; Shmalzhofgasse 22/25 A-1060 Vienna (AT). KLADE, Christoph [AT/AT]; Gröhrmühlgasse 1B, A-2700 Wr. Neustadt (AT). HENICS, Tamas [HU/AT]; Taborstrasse 9/15, A-1020 Vienna (AT). ZAUNER, Wolfgang [AT/AT]; Parkgasse 13/22, A-1030 Vienna (AT). MINH, Duc, Bui [VN/AT]; Rudolf Zeller Gasse 70/6/9, A-1230 Vienna (AT). VYTVYTSKA, Oresta [UA/AT]; Leystrasse 110/1/2, A-1200 Vienna (AT). ETZ, Hildegard [AT/AT]; Lortzinggasse 1/21, A-1140 Vienna (AT). DRYLA, Agnieszka [PL/AT]; Pragerstrasse 43-47/2/15, A-1210 Vienna (AT). WEICHHART, Thomas [AT/AT]; Hinterholz 10, A-3071 Böheimkirchen (AT). HAFNER, Martin [AT/AT]; Arnoldgasse 2/7/4/27, A-1210 Vienna (AT). TEMPELMAIER, Brigitte [AT/AT]; Messenhausergasse 10/20, A-1030 Vienna (AT).

- (74) Agents: SONN, Helmut et al.; Riemergasse 14, A-1010 Wien (AT).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, ΛZ, BΛ, BB, BG, BR, BY, BZ, CΛ, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

of inventorship (Rule 4.17(iv)) for US only

Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A METHOD FOR IDENTIFICATION, ISOLATION AND PRODUCTION OF ANTIGENS TO A SPECIFIC **PATHOGEN**

(57) Abstract: Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: - providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, - providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, - screening said at least one expression library with said antibody preparation, identifying antigens which bind in said screening to antibodies in said antibody preparation, - screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, - identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera and - optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.

WO 02/059148 PCT/EP02/00546

A method for identification, isolation and production of antigens to a specific pathogen

The invention relates to a method for identification, isolation and production of antigens to a specific pathogen as well as new antigens suitable for use in a vaccine for a given type of animal or for humans.

Vaccines can save more lives (and resources) than any other medical intervention. Owing to world-wide vaccination programmes the incidence of many fatal diseases has been decreased drastically. Although this notion is valid for a whole panel of diseases, e.g. diphtheria, pertussis, measles and tetanus, there are no effective vaccines for numerous infectious disease including most viral infections, such as HIV, HCV, CMV and many others. There are also no effective vaccines for other diseases, infectious or noninfectious, claiming the lifes of millions of patients per year including malaria or cancer. In addition, the rapid emergence of antibiotic-resistant bacteria and microorganisms calls for alternative treatments with vaccines being a logical choice. Finally, / the great need for vaccines is also illustrated by the fact that infectious diseases, rather than cardiovascular disorders or cancer or injuries remain the largest cause of death and disability in the world.

Several established vaccines consist of live attenuated organisms where the risk of reversion to the virulent wild-type strain exists. In particular in immunocompromised hosts this can be a live threatening scenario. Alternatively, vaccines are administered as a combination of pathogen-derived antigens together with compounds that induce or enhance immune responses against these antigens (these compounds are commonly termed adjuvant), since these subunit vaccines on their own are generally not effective.

Whilst there is no doubt that the above vaccines are valuable medical treatments, there is the disadvantage that, due to their complexity, severe side effects can be evoked, e.g. to antigens that are contained in the vaccine that display cross-reactivity with molecules expressed by cells of vaccinated individuals. In addition, existing requirements from regulatory authorities, e.g.

the World Health Organization (WHO), the Food and Drug Administration (FDA), and their European counterparts, for exact specification of vaccine composition and mechanisms of induction of immunity, are difficult to meet.

Some widely used vaccines are whole cell-vaccines (attenuated bacteria or viruses (e.g. Bacille Calmette-Guerin (BCG) (tuberculosis), Measles, Mumps, Rubella, Oral Polio Vaccine (Sabin), killed bacteria or viruses (e.g. Pertussis, Inactivated polio vaccine (Salk)), subunit-vaccines (e.g. Toxoid (Diphtheria, Tetanus)), Capsular polysaccharide (H. influenzae type B), Yeast recombinant subunit (Hepatitis B surface protein).

A vaccine can contain a whole variety of different antigens. Examples of antigens are whole-killed organisms such as inactivated viruses or bacteria, fungi, protozoa or even cancer cells. Antigens may also consist of subfractions of these organisms/tissues, of proteins, or, in their most simple form, of peptides. Antigens can also be recognized by the immune system in form of glycosylated proteins or peptides and may also be or contain polysaccharides or lipids. Short peptides can be used since for example cytotoxic T-cells (CTL) recognize antigens in form of short usually 8-11 amino acids long peptides in conjunction with major histocompatibility complex (MHC). B-cells can recognize linear epitopes as short as 4-5 amino acids, as well as three dimensional structures (conformational epitopes). In order to obtain sustained, antigen-specific immune responses, adjuvants need to trigger immune cascades that involve all cells of the immune system necessary. Primarily, adjuvants are acting, but are not restricted in their mode of action, on so-called antigen presenting cells (APCs). These cells usually first encounter the antigen(s) followed by presentation of processed or unmodified antigen to immune effector cells. Intermediate cell types may also be involved. Only effector cells with the appropriate specificity are activated in a productive immune response. The adjuvant may also locally retain antigens and co-injected other factors. In addition the adjuvant may act as a chemoattractant for other immune cells or may act locally and/or systemically as a stimulating agent for the immune system.

Antigen presenting cells belong to the innate immune system, which has evolved as a first line host defence that limits infection early after exposure to microorganisms. Cells of the innate immune system recognize patterns or relatively non-specific structures expressed on their targets rather than more sophisticated, specific structures which are recognized by the adaptive immune system. Examples of cells of the innate immune system are macrophages and dendritic cells but also granulocytes (e.g. neutrophiles), natural killer cells and others. By contrast, cells of the adaptive immune system recognize specific, antigenic structures, including peptides, in the case of T-cells and peptides as well as three-dimensional structures in the case of Bcells. The adaptive immune system is much more specific and sophisticated than the innate immune system and improves upon repeated exposure to a given pathogen/antigen. Phylogenetically, the innate immune system is much older and can be found already in very primitive organisms. Nevertheless, the innate immune system is critical during the initial phase of antigenic exposure since, in addition to containing pathogens, cells of the innate immune system, i.e. APCs, prime cells of the adaptive immune system and thus trigger specific immune responses leading to clearance of the intruders. In sum, cells of the innate immune system and in particular APCs play a critical role during the induction phase of immune responses by a) containing infections by means of a primitive pattern recognition system and b) priming cells of the adaptive immune system leading to specific immune responses and memory resulting in clearance of intruding pathogens or of other targets. These mechanisms may also be important to clear or contain tumor cells.

The antigens used for such vaccines have often been selected by chance or by easiness of availability. There is a demand to identify efficient antigens for a given pathogen or - preferably - an almost complete set of all antigens of a given pathogen which are practically (clinically) relevant. Such antigens may be preferred antigen candidates in a vaccine.

It is therefore an object of the present invention to comply with these demands and to provide a method with which such antigens may be provided and with which a practically complete set of an-

- 4 -

tigens of e.g. a given pathogen may be identified with a given serum as antibody source. Such a method should also be suitable for rapidly changing pathogens which evolve a fast resistance against common drugs or vaccines. The method should also be applicable to identify and isolate tumor antigens, allergens, autoimmune antigens.

Therefore, the present invention provides a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity, especially from a specific pathogen, said antigens being suited for use in a vaccine for a given type of animal or for humans, said method being characterized by the following steps:

- *providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity,
- *providing at least one expression library of said specific pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity,
- *screening said at least one expression library with said antibody preparation,
- identifying antigens which bind in said screening to antibodies in said antibody preparation,
- *screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,
- *identifying the hyperimmune serum-reactive antigen portion of said identified antigens which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera and
- optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.

This method is also suitable in general for identifying a practically complete set of hyperimmune serum-reactive antigens of a specific pathogen with given sera as antibody sources, if at

least three different expression libraries are screened in a pathogen/antigen identification programme using the method according to the present invention. The present invention therefore also relates to a method for identification, isolation and production of a practically complete set of hyperimmune serum-reactive antigens of a specific pathogen, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps:

- *providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen,
- *providing at least three different expression libraries of said specific pathogen,
- *screening said at least three different expression libraries with said antibody preparation,
- *identifying antigens which bind in at least one of said at least three screenings to antibodies in said antibody prepara-
- *screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen,
- *identifying the hyperimmune serum-reactive antigen portion of said identified antigens which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera,
- •repeating said screening and identification steps at least
- *comparing the identified hyperimmune serum-reactive antigens identified in the repeated screening and identification steps with the identified hyperimmune serum-reactive antigens identified in the initial screening and identification steps,
- *further repeating said screening and identification steps, if at least 5% of the hyperimmune serum-reactive antigens have been identified in the repeated screening and identification steps only, until less than 5 % of the hyperimmune serum-reactive antigens are identified in a further repeating step only to obtain a complete set of hyperimmune serum-reactive antigens of a specific pathogen and
- optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by

- 6 -

chemical or recombinant methods.

The method according to the present invention mainly consists of three essential parts, namely 1. identifying hyperimmune serum sources containing specific antibodies against a given pathogen, 2. screening of suitable expression libraries with a suitable antibody preparation wherein candidate antigens (or antigenic fragments of such antigens) are selected, and - 3. in a second screening round, wherein the hyperimmune serum-reactive antigens are identified by their ability to bind to a relevant portion of individual antibody preparations from individual sera in order to show that these antigens are practically relevant and not only hyperimmune serum-reactive, but also widely immunogenic (i.e. that a lot of individual sera react with a given antigen). With the present method it is possible to provide a set of antigens of a given pathogen which is practically complete with respect to the chosen pathogen and the chosen serum. Therefore, a bias with respect to "wrong" antigen candidates or an incomplete set of antigens of a given pathogen is excluded by the present method.

Completeness of the antigen set of a given pathogen within the meaning of the present invention is, of course, dependent on the completeness of the expression libraries used in the present method and on the quality and size of serum collections (number of individual plasmas/sera) tested , both with respect to representability of the library and usefulness of the expression system. Therefore, preferred embodiments of the present method are characterized in that at least one of said expression libraries is selected from a ribosomal display library, a bacterial surface library and a proteome.

A serum collection used in the present invention should be tested against a panel of known antigenic compounds of a given pathogen, such as polysaccharide, lipid and proteinaceous components of the cell wall, cell membranes and cytoplasma, as well as secreted products. Preferably, three distinct serum collections are used: 1. With very stable antibody repertoire: normal adults, clinically healthy people, who overcome previous encounters or currently carriers of e.g. a given pathogen without acute disease and symptoms, 2. With antibodies induced acutally by the presence of the pathogenic organism: patients with acute disease with different manifestations (e.g. S. aureus sepsis or wound infection, etc.), 3. With no specific antibodies at all (as negative controls): 5-8 months old babies who lost the maternally transmitted immunoglobulins 5-6 months after birth. Sera have to react with multiple pathogen-specific antigens in order to consider hyperimmune for a given pathogen (bacteria, fungus, worm or otherwise), and for that relevant in the screening method according to the present invention.

In the antigen identification programme for identifying a complete set of antigens according to the present invention, it is preferred that said at least three different expression libraries are at least a ribosomal display library, a bacterial surface library and a proteome. It has been observed that although all expression libraries may be complete, using only one or two expression libraries in an antigen identification programme will not lead to a complete set of antigens due to preferential expression properties of each of the different expression libraries. While it is therefore possible to obtain hyperimmune serumreactive antigens by using only one or two different expression libraries, this might in many cases not finally result in the identification of a complete set of hyperimmune serum-reactive antigens. Of course, the term "complete" according to the present invention does not indicate a theoretical maximum but is indeed a practical completeness, i.e. that at least 95% of the practically relevant antigens or antigenic determinants have been identified of a given pathogen. The practical relevance is thereby defined by the occurrence of antibodies against given antigens in the patient population.

According to the present invention also serum pools or plasma fractions or other pooled antibody containing body fluids are "plasma pools".

An expression library as used in the present invention should at least allow expression of all potential antigens, e.g. all surface proteins of a given pathogen. With the expression libraries according to the present invention, at least one set of potential antigens of a given pathogen is provided, this set being prefera-

bly the complete theoretical complement of (poly-)peptides encoded by the pathogen's genome (i.e. genomic libraries as described in Example 2) and expressed either in a recombinant host (see Example 3) or in vitro (see Example 4). This set of potential antigens can also be a protein preparation, in the case of extracellular pathogens preferably a protein preparation containing surface proteins of said pathogen obtained from said pathogen grown under defined physiological conditions (see Example 5). While the genomic approach has the potential to contain the complete set of antigens, the latter one has the advantage to contain the proteins in their naturally state i.e. including for instance post-translational modifications or processed forms of these proteins, not obvious from the DNA sequence. These or any other sets of potential antigens from a pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity are hereafter referred to as "expression library". Expression libraries of very different kinds may be applied in the course of the present invention. Suitable examples are given in e.g. Ausubel et al., 1994. Especially preferred are expression libraries representing a display of the genetic set of a pathogen in recombinant form such as in vitro translation techniques, e.g. ribosomal display, or prokaryotic expression systems, e.g. bacterial surface expression libraries or which resemble specific physiological expression states of a given pathogen in a given physiological state, such as a proteome.

Ribosome display is an established method in recombinant DNA technology, which is applicable for each specific pathogen for the sake of the present invention (Schaffitzel et al, 1999). Bacterial surface display libraries will be represented by a recombinant library of a bacterial host displaying a (total) set of expressed peptide sequences of a given pathogen on e.g. a selected outer membrane protein at the bacterial host membrane (Georgiou et al., 1997). Apart from displaying peptide or protein sequences in an outer membrane protein, other bacterial display techniques, such as bacteriophage display technologies and expression via exported proteins are also preferred as bacterial surface expression library (Forrer et al., 1999; Rodi and Makowski, 1993; Georgiou et al., 1997).

The antigen preparation for the first round of screening in the method according to the present invention may be derived from any source containing antibodies to a given pathogen. Preferably, if a plasma pool is used as a source for the antibody preparation, a human plasma pool is selected which comprises donors which had experienced or are experiencing an infection with the given pathogen. Although such a selection of plasma or plasma pools is in principle standard technology in for example the production of hyperimmunoglobulin preparations, it was surprising that such technologies have these effects as especially shown for the preferred embodiments of the present invention.

Preferably the expression libraries are genomic expression libraries of a given pathogen, or alternatively m-RNA, libraries. It is preferred that these genomic or m-RNA libraries are complete genomic or m-RNA expression libraries which means that they contain at least once all possible proteins, peptides or peptide fragments of the given pathogen are expressable. Preferably the genomic expression libraries exhibit a redundancy of at least 2x, more preferred at least 5x, especially at least 10x.

Preferably, the method according to the present invention comprises screening at least a ribosomal display library, a bacterial surface display library and a proteome with the antibody preparation and identifying antigens which bind in at least two, preferably which bind to all, of said screenings to antibodies in said antibody preparation. Such antigens may then be regarded extremely suited as hyperimmunogenic antigens regardless of their way of expression. Preferably the at least two screenings should at least contain the proteome, since the proteome always represents the antigens as naturally expressed proteins including post-translational modifications, processing, etc. which are not obvious from the DNA sequence.

The method according to the present invention may be applied to any given pathogen. Therefore, preferred pathogens are selected from the group of bacterial, viral, fungal and protozoan pathogens. The method according to the present invention is also applicable to cancer, i.e. for the identification of tumorassociated antigens, and for the identification of allergens or

WO 02/059148 PCT/EP02/00546

pathogen, even in a state where this pathogen is effectively defeated. It has been discovered within the course of the present invention, especially during performance of the S.aureus example that only 1-2% of the antibody repertoire of a patient having high titers against S.aureus are indeed antibodies directed against S.aureus. Moreover, over 70% of this specific 1% portion is directed against non-protein antigens, such as teichoic acid, so that only a total of 0.1% or less of the antibodies are directed to proteinaceous antigens.

One of the advantages of using recombinant expression libraries, especially ribsome display libraries and bacterial surface display libraries, is that the identified hyperimmune serum-reactive antigens may be instantly produced by expression of the coding sequences of the screened and selected clones expressing the hyperimmune serum-reactive antigens without further recombinant DNA technology or cloning steps necessary.

The hyperimmune serum-reactive antigens obtainable by the method according to the present invention may therefore be immediately finished to a pharmaceutical preparation, preferably by addition of a pharmaceutically acceptable carrier and/or excipient, immediately after its production (in the course of the second selection step), e.g. by expression from the expression library platform.

Preferably, the pharmaceutical preparation containing the hyperimmune serum-reactive antigen is a vaccine for preventing or treating an infection with the specific pathogen for which the antigens have been selected.

The pharmaceutical preparation may contain any suitable auxiliary substances, such as buffer substances, stabilisers or further active ingredients, especially ingredients known in connection of vaccine production.

A preferable carrier/or excipient for the hyperimmune serum-reactive antigens according to the present invention is a immunostimulatory compound for further stimulating the immune response to the given hyperimmune serum-reactive antigen. Pref-

erably the immunostimulatory compound in the pharmaceutical preparation according to the present invention is selected from the group of polycationic substances, especially polycationic peptides, immunostimulatory deoxynucleotides, alumn, Freund's complete adjuvans, Freund's incomplete adjuvans, neuroactive compounds, especially human growth hormone, or combinations thereof.

The polycationic compound(s) to be used according to the present invention may be any polycationic compound which shows the characteristic effects according to the WO 97/30721. Preferred polycationic compounds are selected from basic polypeptides, organic polycations, basic polyamino acids or mixtures thereof. These polyamino acids should have a chain length of at least 4 amino acid residues (see: Tuftsin as described in Goldman et al. (1983)). Especially preferred are substances like polylysine, polyarginine and polypeptides containing more than 20%, especially more than 50% of basic amino acids in a range of more than 8, especially more than 20, amino acid residues or mixtures thereof. Other preferred polycations and their pharmaceutical compositons are described in WO 97/30721 (e.g. polyethyleneimine) and WO 99/38528. Preferably these polypeptides contain between 20 and 500 amino acid residues, especially between 30 and 200 residues.

These polycationic compounds may be produced chemically or recombinantly or may be derived from natural sources.

Cationic (poly)peptides may also be anti- microbial with properties as reviewed in Ganz et al, 1999; Hancock, 1999. These (poly)peptides may be of prokaryotic or animal or plant origin or may be produced chemically or recombinantly (Andreu et al., 1998; Ganz et al., 1999; Simmaco et al., 1998). Peptides may also belong to the class of defensins (Ganz, 1999; Ganz et al., 1999). Sequences of such peptides can be, for example, be found in the Antimicrobial Sequences Database under the following internet address:

http://www.bbcm.univ.trieste.it/~tossi/pag2.html

Such host defence peptides or defensives are also a preferred form of the polycationic polymer according to the present inven-

WO 02/059148

tion. Generally, a compound allowing as an end product activation (or down-regulation) of the adaptive immune system, preferably mediated by APCs (including dendritic cells) is used as polycationic polymer.

Especially preferred for use as polycationic substance in the present invention are cathelicidin derived antimicrobial peptides or derivatives thereof (International patent application PCT/EP01/09529, incorporated herein by reference), especially antimicrobial peptides derived from mammal cathelicidin, preferably from human, bovine or mouse.

Polycationic compounds derived from natural sources include HIV-REV or HIV-TAT (derived cationic peptides, antennapedia peptides, chitosan or other derivatives of chitin) or other peptides derived from these peptides or proteins by biochemical or recombinant production. Other preferred polycationic compounds are cathelin or related or derived substances from cathelin. For example, mouse cathelin is a peptide which has the amino acid sequence NH,-RLAGLLRKGGEKIGEKLKKIGOKIKNFFQKLVPQPE-COOH. Related or derived cathelin substances contain the whole or parts of the cathelin sequence with at least 15-20 amino acid residues. Derivations may include the substitution or modification of the natural amino acids by amino acids which are not among the 20 standard amino acids. Moreover, further cationic residues may be introduced into such cathelin molecules. These cathelin molecules are preferred to be combined with the antigen. These cathelin molecules surprisingly have turned out to be also effective as an adjuvant for a antigen without the addition of further adjuvants. It is therefore possible to use such cathelin molecules as efficient adjuvants in vaccine formulations with or without further immunactivating substances.

Another preferred polycationic substance to be used according to the present invention is a synthetic peptide containing at least 2 KLK-motifs separated by a linker of 3 to 7 hydrophobic amino acids (International patent application PCT/EP01/12041, incorporated herein by reference).

Immunostimulatory deoxynucleotides are e.g. neutral or artificial

CpG containing DNA, short stretches of DNA derived from non-vertebrates or in form of short oligonucleotides (ODNs) containing non-methylated cytosine-guanine di-nucleotides (CpG) in a certain base context (e.g. Krieg et al., 1995) but also inosine containing ODNs (I-ODNs) as described in WO 01/93905.

Neuroactive compounds, e.g. combined with polycationic substances are described in WO 01/24822.

According to a preferred embodiment the individual antibody preparation for the second round of screening are derived from patients with have suffered from an acute infection with the given pathogen, especially from patients who show an antibody titer to the given pathogen above a certain minimum level, for example an antibody titer being higher than 80 percentile, preferably higher than 90 percentile, especially higher than 95 percentile of the human (patient or carrier) sera tested. Using such high titer individual antibody preparations in the second screening round allows a very selective identification of the hyperimmune serum-reactive antigens to the given pathogen.

It is important that the second screening with the individual antibody preparations (which may also be the selected serum) allows a selective identification of the hyperimmune serum-reactive antigens from all the promising candidates from the first round. Therefore, preferably at least 10 individual antibody preparations (i.e. antibody preparations (e.g. sera) from at least 10 different individuals having suffered from an infection to the chosen pathogen) should be used in identifying these antigens in the second screening round. Of course, it is possible to use also less than 10 individual preparations, however, selectivity of the step may not be optimal with a low number of individual antibody preparations. On the other hand, if a given hyperimmune serum-reactive antigen (or an antigenic fragment thereof) is recognized in at least 10 individual antibody preparations, preferably at least 30, especially at least 50 individual antibody preparations, identification of hyperimmune serum-reactive antigen is also selective enough for a proper identification. Hyperimmune serum-reactivity may of course be tested with as many individual preparations as possible (e.g. with more than 100 or even with

- 15 -

PCT/EP02/00546

more than 1000).

Therefore, the relevant portion of the hyperimmune serum-reactive antibody preparation according to the method of the present invention should preferably be at least 10, more preferred at least 30, especially at least 50 individual antibody preparations. Alternatively (or in combination) hyperimmune serum-reactive antigen may preferably be also identified with at least 20%, preferably at least 30%, especially at least 40% of all individual antibody preparations used in the second screening round.

According to a preferred embodiment of the present invention, the sera from which the individual antibody preparations for the second round of screening are prepared (or which are used as antibody preparations), are selected by their titer against the specific pathogen (e.g. against a preparation of this pathogen, such as a lysate, cell wall components and recombinant proteins). Preferably, some are selected with a total IgA titer above 4000 U, especially above 6000 U, and/or an IgG titer above 10 000 U, especially above 12 000 U (U = units, calculated from the OD_{405mm} reading at a given dilution) when whole organism (total lysate or whole cells) is used as antigen in ELISA. Individual proteins with Ig titers of above 800-1000 U are specifically preferred for selecting the hyperimmune serum-reactive antigens according to the present invention only for total titer. The statement for individual proteins can be derived from Fig. 9.

According to the demonstration example which is also a preferred embodiment of the present invention the given pathogen is a Staphylococcus pathogen, especially Staphylococcus aureus and Staphylococcus epidermidis. Staphylococci are opportunistic pathogens which can cause illnesses which range from minor infections to life threatening diseases. Of the large number of Staphylococci at least 3 are commonly associated with human disease: S. aureus, S. epidermidis and rarely S. saprophyticus (Crossley and Archer, 1997). S. aureus has been used within the course of the present invention as an illustrative example of the way the present invention functions. Besides that, it is also an important organism with respect to its severe pathogenic impacts on humans. Staphylococcal infections are imposing an increasing

WO 02/059148 PCT/EP02/00546

threat in hospitals worldwide. The appearance and disease causing capacity of Staphylococci are related to the wide-spread use of antibiotics which induced and continue to induce multi-drug resistance. For that reason medical treatment against Staphylococcal infections cannot rely only on antibiotics anymore. Therefore, a tactic change in the treatment of these diseases is desperately needed which aims to prevent infections. Inducing high affinity antibodies of the opsonic and neutralizing type by vaccination helps the innate immune system to eliminate bacteria and toxins. This makes the method according to the present invention an optimal tool for the identification of staphylococcal antigenic proteins.

Every human being is colonized with S. epidermidis. The normal habitats of S. epidermidis are the skin and the mucous membrane. The major habitats of the most pathogenic species, S. aureus, are the anterior nares and perineum. Some individuals become permanent S. aureus carriers, often with the same strain. The carrier stage is clinically relevant because carriers undergoing surgery have more infections than noncarriers. Generally, the established flora of the nose prevents acquisition of new strains. However, colonization with other strains may occur when antibiotic treatment is given that leads to elimination of the susceptible carrier strain. Because this situation occurs in the hospitals, patients may become colonized with resistant nosocomial Staphylococci. These bacteria have an innate adaptability which is complemented by the widespread and sometimes inappropriate use of antimicrobial agents. Therefore hospitals provide a fertile environment for drug resistance to develop (close contact among sick patients, extensive use of antimicrobials, nosocomial infections). Both S. aureus and S. epidermidis have become resistant to many commonly used antibiotics, most importantly to methicillin (MRSA) and vancomycin (VISA). Drug resistance is an increasingly important public health concern, and soon many infections caused by staphylococci may be untreatable by antibiotics. In addition to its adverse effect on public health, antimicrobial resistance contributes to higher health care costs, since treating resistant infections often requires the use of more toxic and more expensive drugs, and can result in longer hospital stays for infected patients.

WO 02/059148

- 17 -

Moreover, even with the help of effective antibiotics, the most serious staphylococcal infections have 30-50 % mortality.

Staphylococci become potentially pathogenic as soon as the natural balance between microorganisms and the immune system gets disturbed, when natural barriers (skin, mucous membrane) are breached. The coagulase-positive S. aureus is the most pathogenic staphylococcal species, feared by surgeons for a long time. Most frequently it causes surgical wound infections, and induces the formation of abscesses. This local infection might become systemic, causing bacteraemia and sepsis. Especially after viral infections and in elderly, it can cause severe pneumonia. S. aureus is also a frequent cause of infections related to medical devices, such as intravascular and percutan catheters (endocarditis, sepsis, peritonitis), prosthetic devices (septic arthritis, osteomyelitis). S. epidermidis causes diseases mostly related to the presence of foreign body and the use of devices, such as catheter related infections, cerebrospinal fluid shunt infections, peritonitis in dialysed patients (mainly CAPD), endocarditis in individuals with prosthetic valves. This is exemplified in immunocompromised individuals such as oncology patients and premature neonates in whom coagulase-negative staphylococcal infections frequently occur in association with the use of intravascular device. The increase in incidence is related to the increased used of these devices and increasing number of immunocompromised patients.

Much less is known about S. saprophyticus, another coagulasenegative staphylococci, which causes acute urinary tract infection in previously healthy people. With a few exceptions these are women aged 16-25 years.

The pathogenesis of staphylococci is multifactorial. In order to initiate infection the pathogen has to gain access to the cells and tissues of the host, that is adhere. S. aureus expresses—surface proteins that promote attachment to the host proteins such as laminin, fibronectin, elastin, vitronectin, fibrinogen and many other molecules that form part of the extracellular matrix (extracellular matrix binding proteins, ECMBP). S. epider—

WO 02/059148 PCT/EP02/00546

- 18 -

midis is equipped with cell surface molecules which promote adherence to foreign material and through that mechanism establish infection in the host. The other powerful weapons staphylococci use are the secreted products, such as enterotoxins, exotoxins, and tissue damaging enzymes. The toxins kill or misguide immune cells which are important in the host defence. The several different types of toxins are responsible for most of the symptoms during infections.

Host defence against S. aureus relies mainly on innate immunological mechanisms. The skin and mucous membranes are formidable barriers against invasion by Staphylococci. However, once the skin or the mucous membranes are breached (wounds, percutan catheters, etc), the first line of nonadaptive cellular defence begins its co-ordinate action through complement and phagocytes, especially the polymorphonuclear leukocytes (PMNs). These cells can be regarded as the cornerstones in eliminating invading bacteria. As Staphylococci are primarily extracellular pathogens; the major anti-staphylococcal adaptive response comes from the humoral arm of the immune system, and is mediated through three major mechanisms: promotion of opsonization, toxin neutralisation, and inhibition of adherence. It is believed that opsonization is especially important, because of its requirement for an effective phagocytosis. For efficient opsonization the microbial surface has to be coated with antibodies and complement factors for recognition by PMNs through receptors to the Fc fragment of the IgG molecule or to activated C3b. After opsonization, staphylococci are phagocytosed and killed. Moreover, S. aureus can attach to endothelial cells, and be internalised by a phagocytosislike process. Antibodies bound to specific antigens on the cell surface of bacteria serve as ligands for the attachment to PMNs and promote phagocytosis. The very same antibodies bound to the adhesins and other cell surface proteins are expected to neutralize adhesion and prevent colonization.

There is little clinical evidence that cell mediated immunity has a significant contribution in the defence against Staphylococci, yet one has to admit that the question is not adequately addressed. It is known, however, that Staphylococcus aureus utilizes an extensive array of molecular countermeasures to

WO 02/059148 PCT/EP02/00546

- 19 -

manipulate the defensive microenvironment of the infected host by secreting polypeptides referred to as superantigens, which target the multireceptor communication between T-cells and antigen-presenting cells that is fundamental to initiating pathogen-specific immune clearance. Superantigens play a critical role in toxic shock syndrome and food poisoning, yet their function in routine infections is not well understood. Moreover, one cannot expect a long lasting antibody (memory) response without the involvement of T-cells. It is also known that the majority of the antistaphylococcal antibodies are against T-cell independent antigens (capsular polysacharides, lipoteichoic acid, peptidoglycan) without a memory function. The T-cell dependent proteinaceous antigens can elicit long-term protective antibody responses. These staphylococcal proteins and peptides have not yet been determined.

For all these above mentioned reasons, a tactic change on the war field against staphylococcal infections is badly needed. One way of combating infections is preventing them by active immunisation. Vaccine development against S. aureus has been initiated by several research groups and national institutions worldwide, but there is no effective vaccine approved so far. It has been shown that an antibody deficiency state contributes to staphylococcal persistence, suggesting that anti-staphylococcal antibodies are important in host defence. Antibodies - added as passive immunisation or induced by active vaccination - directed towards surface components could both prevent bacterial adherence, neutralize toxins and promote phagocytosis. A vaccine based on fibronectin binding protein induces protective immunity against mastitis in cattle and suggest that this approach is likely to work in humans (refs). Taking all this together it is suggestive that an effective vaccine should be composed of proteins or polypeptides, which are expressed by all strains and are able to induce high affinity, abundant antibodies against cell surface components of S. aureus. The antibodies should be IgG1 and/or IgG3 for opsonization, and any IgG subtype and IgA for neutralisation of adherence and toxin action. A chemically defined vaccine must be definitely superior compared to a whole cell vaccine (attenuated or killed), since components of S. aureus which paralyze TH cells (superantigens) or inhibit opsonization (protein A)

can be eliminated, and the individual proteins inducing protective antibodies can be selected. Identification of the relevant antigens help to generate effective passive immunisation (humanised monoclonal antibody therapy), which can replace human immunoglobulin administration with all its dangerous side-effects. Neonatal staphylococcal infections, severe septicemia and other life-threatening acute conditions are the primary target of passive immunisation. An effective vaccine offers great potential for patients facing elective surgery in general, and those receiving endovascular devices, in particular. Moreover, patients suffering from chronic diseases which decrease immune responses or undergoing continuous ambulatory peritoneal dialysis are likely to benefit from such a vaccine.

For the illustrative example concerning Staphylococcus aureus three different approaches have been employed in parallel. All three of these methods are based on the interaction of Staphylococcus proteins or peptides with the antibodies present in human sera with the method according to the present invention. This interaction relies on the recognition of epitopes within the proteins which can be short peptides (linear epitopes) or polypeptide domains (structural epitopes). The antigenic proteins are identified by the different methods using pools of pre-selected sera and - in the second screening round - by individual selected sera.

Following the high throughput screening, the selected antigenic proteins are expressed as recombinant proteins or in vitro translated products (in case it can not be expressed in prokaryotic expression systems), and tested in a series of ELISA and Western blotting assays for the assessment of immunogeneicity with a large human serum collection (> 100 uninfected, > 50 patients sera). The preferred antigens are located on the cell surface or secreted, that is accessible extracellularly. Antibodies against the cell wall proteins (such as the Extracellular matrix binding proteins) are expected to serve double purposes: to inhibit adhesion and promote phagocytosis. The antibodies against the secreted proteins are beneficial in toxin neutralisation. It is also known that bacteria communicate with each other through secreted proteins. Neutralizing antibodies against these proteins

- 21 -

will interrupt growth promoting cross-talk between or within staphylococcal species. Bioinformatics (signal sequences, cell wall localisation signals, transmembrane domains) proved to be very useful in assessing cell surface localisation or secretion. The experimental approach includes the isolation of antibodies with the corresponding epitopes and proteins from human serum, and use them as reagents in the following assays: cell surface staining of staphylococci grown under different conditions (FACS, microscopy), determination of neutralizing capacity (toxin, adherence), and promotion of opsonization and phagocytosis (in vitro phagocytosis assay).

The recognition of linear epitopes by antibodies can be based on sequences as short as 4-5 aa. Of course it does not necessarily mean that these short peptides are capable of inducing the given antibody. in vivo. For that reason the defined epitopes, polypeptides and proteins may further be tested in animals (mainly in mice) for their capacity to induce antibodies against the selected proteins in vivo. The antigens with the proven capability to induce antibodies will be tested in animal models for the ability to prevent infections. 1.__

The antibodies produced against Staphylococci by the human immune system and present in human sera are indicative of the in vivo expression of the antigenic proteins and their immunogenicity.

Accordingly, novel hyperimmune serum-reactive antigens from Staphylococcus aureus or Staphylococcus epidermidis have been made available by the method according to the present invention. According to another aspect of the present invention the invention relates to a hyperimmune serum-reactive antigen selected from the group consisting of the sequences listed in any one of Tables 2a, 2b, 2c, 2d, 3, 4 and 5, especially selected from the group consisting of Seq.ID No. 56, 57, 59, 60, 67, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 85, 87, 88, 89, 90, 92, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 126, 128, 132, 134, 138, 140, 142, 151, 152, 154, 155 and hyperimmune fragments thereof. Accordingly, the present invention also relates to a hyperimmune serum-reactive antigen obtainable by the method according to the present invention

- 22 -

and being selected from the group consisting of the sequences listed in any one of Tables 2a, 2b, 2c, 2d, 3, 4 and 5, especially selected from the group consisting of Seq.ID No. 56, 57, 59, 60, 67, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 85, 87, 88, 89, 90, 92, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 126, 128, 132, 134, 138, 140, 142, 151, 152, 154, 155 and hyperimmune fragments thereof.

Antigens from Staphylococcus aureus and Staphylococcus epidermidis have been extracted by the method according to the present invention which may be used in the manufacture of a pharmaceutical preparation, especially for the manufacture of a vaccine against Staphylococcus aureus and Staphylococcus epidermidis infections. Examples of such hyperimmune serum-reactive antigens of Staphylococcus aureus and Staphylococcus epidermidis to be used in a pharmaceutical preparation are selected from the group consisting of the sequences listed in any one of Tables 2a, 2b, 2c, 2d, 3, 4 and 5, especially selected from the group consisting of Seq.ID No. 55, 56, 57, 58, 59, 60, 62, 66, 67, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 87, 88, 89, 90, 92, 94, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 126, 128, 130, 132, 134, 138, 140, 142, 151, 152, 154, 155, 158 and hyperimmune fragments thereof for the manufacture of a pharmaceutical preparation, especially for the manufacture of a vaccine against Staphylococcus aureus and Staphylococcus epidermidis infections.

A hyperimmune fragment is defined as a fragment of the identified antigen which is for itself antigenic or may be made antigenic when provided as a hapten. Therefore, also antigen or antigenic fragments showing one or (for longer fragments) only a few amino acid exchanges are enabled with the present invention, provided that the antigenic capacities of such fragments with amino acid exchanges are not severely deteriorated on the exchange(s). i.e. suited for eliciting an appropriate immune response in a individual vaccinated with this antigen and identified by individual antibody preparations from individual sera.

preferred examples of such hyperimmune fragments of a hyperimmune serum-reactive antigen are selected from the group consisting of

1

- 23 -

62,

peptides comprising the amino acid sequences of column "predicted immunogenic aa", "Location of identified immunogenic region" and "Serum reactivity with relevant region" of Tables 2a, 2b, 2c and 2d and the amino acid sequences of column "Putative antigenic surface areas of Table 4 and 5, especially peptides comprising amino acid No. aa 12-29, 34-40, 63-71, 101-110, 114-122, 130-138, 140-195, 197-209, 215-229, 239-253, 255-274 and 39-94 of Seq.ID No. 55, aa 5-39, 111-117, 125-132, 134-141, 167-191, 196-202, 214-232, 236-241, 244-249, 292-297, 319-328, 336-341, 365-380, 385-391, 407-416, 420-429, 435-441, 452-461, 477-488, 491-498, 518-532, 545-556, 569-576, 581-587, 595-602, 604-609, 617-640, 643-651, 702-715, 723-731, 786-793, 805-811, 826-839, 874-889, 37-49, 63-77 and 274-334, of Seq.ID No.56, aa 28-55, 82-100, 105-111, 125-131, 137-143, 1-49, of Seq.ID No. 57, aa 33-43, 45-51, 57-63, 65-72, 80-96, 99-110, 123-129, 161-171, 173-179, 185-191, 193-200, 208-224, 227-246, 252-258, 294-308, 321-329, 344-352, 691-707, 358-411 and 588-606, of Seq.ID No. 58, aa 16-38, 71-77, 87-94, 105-112, 124-144, 158-164, 169-177, 180-186, 194-204, 221-228, 236-245, 250-267, 336-343, 363-378, 385-394, 406-412, 423-440, 443-449, 401-494, of Seq.ID No. 59, aa 18-23, 42-55, 69-77, 85-98, 129-136, 182-188, 214-220, 229-235, 242-248, 251-258, 281-292, 309-316, 333-343, 348-354, 361-367, 393-407, 441-447, 481-488, 493-505, 510-515, 517-527, 530-535, 540-549, 564-583, 593-599, 608-621, 636-645, 656-670, 674-687, 697-708, 726-734, 755-760, 765-772, 785-792, 798-815, 819-824, 826-838, 846-852, 889-904, 907-913, 932-939, 956-964, 982-1000, 1008-1015, 1017-1024, 1028-1034, 1059-1065, 1078-1084, 1122-1129, 1134-1143, 1180-1186, 1188-1194, 1205-1215, 1224-1230, 1276-1283, 1333-1339, 1377-1382, 1415-1421, 1448-1459, 1467-1472, 1537-1545, 1556-1566, 1647-1654, 1666-1675, 1683-1689, 1722-1737, 1740-1754, 1756-1762, 1764-1773, 1775-1783, 1800-1809, 1811-1819, 1839-1851, 1859-1866, 1876-1882, 1930-1939, 1947-1954, 1978-1985, 1999-2007, 2015-2029, 2080-2086, 2094-2100, 2112-2118, 2196-2205, 2232-2243, 198-258, 646-727 and 2104-2206, of Seq.ID No. 60, aa 10-29, 46-56, 63-74, 83-105, 107-114, 138-145, 170-184, 186-193, 216-221, 242-248, 277-289, 303-311, 346-360, 379-389, 422-428, 446-453, 459-469, 479-489, 496-501, 83-156, of Seq.ID No.

PCT/EP02/00546 WO 02/059148

- 24 -

aa 14-22, 32-40, 52-58, 61-77, 81-93, 111-117, 124-138, 151-190, 193-214, 224-244, 253-277, 287-295, 307-324, 326-332, 348-355, 357-362, 384-394, 397-434, 437-460, 489-496, 503-510, 516-522, 528-539, 541-547, 552-558, 563-573, 589-595, 602-624, 626-632, 651-667, 673-689, 694-706, 712-739, 756-790, 403-462, of Seq.ID No. 66, aa 49-56, 62-68, 83-89, 92-98, 109-115, 124-131, 142-159, 161-167, 169-175, 177-188, 196-224, 230-243, 246-252, 34-46, of Seq. ID No. 67, aa 11-20, 26-47, 69-75, 84-92, 102-109, 119-136, 139-147, 160-170, 178-185, 190-196, 208-215, 225-233, 245-250, 265-272, 277-.284, 300-306, 346-357, 373-379, 384-390, 429-435, 471-481, 502-507, 536-561, 663-688, 791-816, 905-910, 919-933, 977-985, 1001-1010, 1052-1057, 1070-1077, 1082-1087, 1094-1112, 493-587, 633-715 and 704-760, of Seq.ID No.70, aa.6-20, 53-63, 83-90, 135-146, 195-208, 244-259, 263-314, 319-327, 337-349, 353-362, 365-374, 380-390, 397-405, 407-415, 208-287 and 286-314, of Seq.ID No. 71, - aa 10-26, 31-43, 46-58, 61-66, 69-79, 85-92, 100-115, 120-126, 128-135, 149-155, 167-173, 178-187, 189-196, 202-222, 225-231, 233-240, 245-251, 257-263, 271-292, 314-322, 325-334, 339-345, 59-74, of Seq.ID No. 72, aa 4-9, 15-26, 65-76, 108-115, 119-128, 144-153, 38-52 and 66-114, of Seq. ID No. 73, aa 5-22, 42-50, 74-81, 139-145, 167-178, 220-230, 246-253, 255-264, 137-237 and 250-267, of Seq.ID No. 74, aa 10-26, 31-44, 60-66, 99-104, 146-153, 163-169, 197-205, 216-223, 226-238, 241-258, 271-280, 295-315, 346-351, 371-385, 396-407, 440-446, 452-457, 460-466, 492-510, 537-543, 546-551, 565-582, 590-595, 635-650, 672-678, 686-701, 705-712, 714-721, 725-731, 762-768, 800-805, 672-727, of Seq.ID No. 75, aa 5-32, 35-48, 55-76, of Seq.ID No. 76, aa 7-35, 54-59, 247-261, 263-272, 302-320, 330-339, 368-374, 382-. 411, 126-143 and 168-186, of Seq.ID No. 77, aa 5-24, 88-94, 102-113, 132-143, 163-173, 216-224, 254-269, 273-278, 305-313, 321-327, 334-341, 31-61 and 58-74, of Seq.ID No.

aa 16-24, 32-39, 43-49, 64-71, 93-99, 126-141, 144-156, 210-218, 226-233, 265-273, 276-284, 158-220, of Seq.ID No. 79, aa 49-72, 76-83, 95-105, 135-146, 148-164, 183-205, 57-128, of

78,

Seq.ID No. 80, aa 6-15, 22-32, 58-73, 82-88, 97-109, 120-131, 134-140, 151-163, 179-185, 219-230, 242-255, 271-277, 288-293, 305-319, 345-356, 368-381, 397-406, 408-420, 427-437, 448-454, 473-482, 498-505, 529-535, 550-563, 573-580, 582-590, 600-605, 618-627, 677-685, 718-725, 729-735, 744-759, 773-784, 789-794, 820-837, 902-908, 916-921, 929-935, 949-955, 1001-1008, 1026-1032, 1074-1083, 1088-1094, 1108-1117, 1137-1142, 1159-1177, 1183-1194, 1214-1220, 1236-1252, 1261-1269, 1289-1294, 1311-1329, 1336-1341, 1406-1413, 1419-1432, 1437-1457, 1464-1503, 1519-1525, 1531-1537, 1539-1557, 1560-1567, 1611-1618, 1620-1629, 1697-1704, 1712-1719, 1726-1736, 1781-1786, 1797-1817, 1848-1854, 1879-1890, 1919-1925, 1946-1953, 1974-1979, 5 to 134, of Seq.ID No. 81, aa 6-33, 40-46, 51-59, 61-77, 84-104, 112-118, 124-187, 194-248, 252-296, 308-325, 327-361, 367-393, 396-437, 452-479, 484-520, 535-545, 558-574, 582-614, 627-633, 656-663, 671-678, 698-704, 713-722, 725-742, 744-755, 770-784, 786-800, 816-822, 827-837, 483-511, of Seq.ID No. 82, aa 4-19, 57-70, 79-88, 126-132, 144-159, 161-167, 180-198, 200-212, 233-240, 248-255, 276-286, 298-304, 309-323, 332-346, 357-366, 374-391, 394-406, 450-456, 466-473, 479-487, 498-505, 507-519, 521-530, 532-540, 555-565, 571-581, 600-611, 619-625, 634-642, 650-656, 658-665, 676-682, 690-699, 724-733, 740-771, 774-784, 791-797, 808-815, 821-828, 832-838, 876-881, 893-906, 922-929, 938-943, 948-953, 969-976, 1002-1008, 1015-1035, 1056-1069, 1105-1116, 1124-1135, 1144-1151, 1173-1181, 1186-1191, 1206-1215, 1225-1230, 1235-1242, 6-66, 65-124 and 590-604, of Seq.ID No. 83, aa 5-32, 66-72, 87-98, 104-112, 116-124, 128-137, 162-168, 174-183, 248-254, 261-266, 289-303, 312-331, 174-249, of Seq.ID No. 84, aa 4-21, 28-40, 45-52, 59-71, 92-107, 123-137, 159-174, 190-202, 220-229, 232-241, 282-296, 302-308, 312-331, 21-118, of Seq.ID No. 85, aa 9-28, 43-48, 56-75, 109-126, 128-141, 143-162, 164-195, 197-216, 234-242, 244-251, 168-181, of Seq.ID No. 87, aa 4-10, 20-42, 50-86, 88-98, 102-171, 176-182, 189-221, 223-244, 246-268, 276-284, 296-329, 112-188, of Seq.ID No. 88, aa 4-9, 13-24, 26-34, 37-43, 45-51, 59-73, 90-96, 99-113, 160-173, 178-184, 218-228, 233-238, 255-262, 45-105, 103-166 and 66-153, of Seq.ID No. 89,

aa 13-27, 42-63, 107-191, 198-215, 218-225, 233-250, 474-367, of Seq.ID No. 90;

aa 26-53, 95-123, 164-176, 189-199, 8-48, of Seq.ID No. 92,

aa 7-13, 15-23, 26-33, 68-81, 84-90, 106-117, 129-137, 140-159,

165-172, 177-230, 234-240, 258-278, 295-319, 22-56, 23-99, 97-

115, 233-250 and 245-265, of Seq.ID No. 94,

aa 13-36, 40-49, 111-118, 134-140, 159-164, 173-183, 208-220,

232-241, 245-254, 262-271, 280-286, 295-301, 303-310, 319-324,

332-339, 1-85, 54-121 and 103-185, of Seq.ID No. 95,

aa 39-44, 46-80, 92-98, 105-113, 118-123, 133-165, 176-208, 226-

238, 240-255, 279-285, 298-330, 338-345, 350-357, 365-372, 397-

402, 409-415, 465-473, 488-515, 517-535, 542-550, 554-590, 593-

601, 603-620, 627-653, 660-665, 674-687, 698-718, 726-739, 386-

402, of Seq.ID No. 96,

aa 5-32, 34-49, 1-43, of Seq.ID No. 97,

aa 10-27, 37-56, 64-99, 106-119, 121-136, 139-145, 148-178, 190-216, 225-249, 251-276, 292-297, 312-321, 332-399, 403-458, 183-

200, of Seq.ID No. 99,

aa 5-12, 15-20, 43-49, 94-106, 110-116, 119-128, 153-163, 175-

180, 185-191, 198-209, 244-252, 254-264, 266-273, 280-288, 290-

297, 63-126, of Seq.ID No. 100,

aa 5-44, 47-55, 62-68, 70-78, 93-100, 128-151, 166-171, 176-308,

1-59, of Seq.ID No. 101,

aa 18-28, 36-49, 56-62, 67-84, 86-95, 102-153, 180-195, 198-218,

254-280, 284-296, 301-325, 327-348, 353-390, 397-402, 407-414,

431-455, 328-394, of Seq.ID No. 102,

aa 7-37, 56-71, 74-150, 155-162, 183-203, 211-222, 224-234, 242-

272, 77-128, of Seq.ID No. 103,

aa 34-58, 63-69, 74-86, 92-101, 130-138, 142-150, 158-191, 199-

207, 210-221, 234-249, 252-271, 5-48, of Seq.ID No. 104,

aa 12-36, 43-50, 58-65, 73-78, 80-87, 108-139, 147-153, 159-172,

190-203, 211-216, 224-232, 234-246, 256-261, 273-279, 286-293,

299-306, 340-346, 354-366, 167-181, of Seq.ID No. 106,

aa 61-75, 82-87, 97-104, 113-123, 128-133, 203-216, 224-229,

236-246, 251-258, 271-286, 288-294, 301-310, 316-329, 337-346,

348-371, 394-406, 418-435, 440-452 of Seq.ID No. 112,

aa 30-37, 44-55, 83-91, 101-118, 121-128, 136-149, 175-183, 185-

193, 206-212, 222-229, 235-242 of Seq.ID No. 114,

aa 28-38, 76-91, 102-109, 118-141, 146-153, 155-161, 165-179,

186-202, 215-221, 234-249, 262-269, 276-282, 289-302, 306-314,

WO 02/059148

- 27 -

321-326, 338-345, 360-369, 385-391 of Seq.ID No. 116, aa 9-33, 56-62,75-84, 99-105, 122-127, 163-180, 186-192, 206-228, 233-240, 254-262, 275-283, 289-296, 322-330, 348-355, 416-424, 426-438, 441-452, 484-491, 522-528, 541-549, 563-569, 578-584, 624-641, 527-544, of Seq.ID No. 142, aa 37-42, 57-62, 121-135, 139-145, 183-190, 204-212, 220-227, 242-248, 278-288, 295-30, 304-309, 335-341, 396-404, 412-433, 443-449, 497-503, 505-513, 539-545, 552-558, 601-617, 629-649, 702-711, 736-745, 793-804, 814-829, 843-858, 864-885, 889-895, 905-913, 919-929, 937-943, 957-965, 970-986, 990-1030, 1038-1049, 1063-1072, 1080-1091, 1093-1116, 1126-1136, 1145-1157, 1163-1171, 1177-1183, 1189-1196, 1211-1218, 1225-1235, 1242-1256, 1261-1269, 624-684, of Seq.ID No. 151, aa 8-23, 31-38, 42-49, 61-77, 83-90, 99-108, 110-119, 140-147, 149-155, 159-171, 180-185, 189-209, 228-234, 245-262, 264-275, 280-302, 304-330, 343-360, 391-409, 432-437, 454-463, 467-474, 478-485, 515-528, 532-539, 553-567, 569-581, 586-592, 605-612, 627-635, 639-656, 671-682, 700-714, 731-747, 754-770, 775-791, 797-834, 838-848, 872-891, 927-933, 935-942, 948-968, 976-986, 1000-1007, 1029-1037, 630-700, of Seq.ID No. 152, aa 17-25, 27-55, 84-90, 95-101, 115-121, 55-101, of Seq.ID No. 154, aa 13-28, 40-46, 69-75, 86-92, 114-120, 126-137, 155-172, 182-193, 199-206, 213-221, 232-238, 243-253, 270-276, 284-290, 22-100, of Seq.ID No. 155 and aa 7-19, 46-57, 85-91, 110-117, 125-133, 140-149, 156-163, 198-204, 236-251, 269-275, 283-290, 318-323, 347-363, 9-42 and 158-174, of Seq.ID No. 158, aa 7-14, 21-30, 34-50, 52-63, 65-72, 77-84, 109-124, 129-152, 158-163, 175-190, 193-216, 219-234 of Seq.ID.No. 168, aa 5-24, 38-44, 100-106, 118-130, 144-154, 204-210, 218-223, 228-243, 257-264, 266-286, 292-299 of Seq.ID.No. 174, aa 29-44, 74-83, 105-113, 119-125, 130-148, 155-175, 182-190, 198-211, 238-245 of Seq.ID.No. 176, and fragments comprising at least 6, preferably more than 8, especially more than 10 aa of said sequences . All these fragments individually and each independently form a preferred selected aspect of the present invention.

Especially suited helper epitopes may also be derived from these

antigens. Especially preferred helper epitopes are peptides comprising fragments selected from the peptides mentioned in column "Putative antigenic surface areas" in Tables 4 and 5 and from the group of aa 6-40, 583-598, 620-646 and 871-896 of Seq.ID.No.56, aa 24-53 of Seq.ID.No.70, aa 240-260 of Seq.ID.No.74, aa 1660-1682 and 1746-1790 of Seq.ID.No. 81, aa 1-29, 680-709, and 878-902 of Seq.ID.No. 83, aa 96-136 of Seq.ID.No. 89, aa 1-29, 226-269 and 275-326 of Seq.ID.No. 94, aa 23-47 and 107-156 of Seq.ID.No. 114 and aa 24-53 of Seq.ID.No. 142 and fragments thereof being T-cell epitopes.

According to another aspect, the present invention relates to a vaccine comprising such a hyperimmune serum-reactive antigen or a fragment thereof as identified above for Staphylococcus aureus and Staphylococcus epidermidis. Such a vaccine may comprise one or more antigens against S. aureus or S. epidermidis. Optionally, such S. aureus or S. epidermidis antigens may also be combined with antigens against other pathogens in a combination vaccine. Preferably this vaccine further comprises an immunostimulatory substance, preferably selected from the group comprising polycationic polymers, especially polycationic peptides, immunostimulatory deoxynucleotides (ODNs), neuroactive compounds, especially human growth hormone, alumn, Freund's complete or incomplete adjuvans or combinations thereof. Such a vaccine may also comprise the antigen displayed on a surface display protein platform on the surface of a genetically engineered microorganism such as E. coli.

According to another aspect, the present invention relates to specific preparations comprising antibodies raised against at least one of the Staphylococcus aureus and Staphylococcus epidermidis antigens or Staphylococcus aureus and Staphylococcus epidermidis antigen fragments as defined above. These antibodies are preferably monoclonal antibodies.

Methods for producing such antibody preparations, polyclonal or monoclonal, are well available to the man skilled in the art and properly described in the prior art. A preferred method for producing such monoclonal antibody preparation is characterized by the following steps

- •initiating an immune response in a non human animal by administering a Staphylococcus antigen or a fragment thereof, as defined above, to said animal,
- •removing the spleen or spleen cells from said animal,
- •producing hybridoma cells of said spleen or spleen cells,
- •selecting and cloning hybridoma cells specific for said antigen and
- •producing the antibody preparation by cultivation of said cloned hybridoma cells and optionally further purification steps.

Preferably, removing of the spleen or spleen cells is connected with killing said animal.

Monoclonal antibodies and fragments thereof can be chimerized or humanized (Graziano et al. 1995) to enable repeated administration. Alternatively human monoclonal antibodies and fragments thereof can be obtained from phage-display libraries (McGuinnes et al., 1996) or from transgenic animals (Brüggemann et al., 1996).

A preferred method for producing polyclonal antibody preparations to said Staphylococcus aureus or Staphylococcus epidermidis antigens identified with the present invention is characterized by the following steps

- •initiating an immune response in a non human animal by administering a Staphylococcus antigen or a fragment thereof, as defined above, to said animal,
- removing an antibody containing body fluid from said animal,and
- *producing the antibody preparation by subjecting said antibody containing body fluid to further purification steps.

These monoclonal or polyclonal antibody preparations may be used for the manufacture of a medicament for treating or preventing diseases due to staphylococcal infection. Moreover, they may be used for the diagnostic and imaging purposes.

The method is further described in the following examples and in the figures, but should not be restricted thereto.

WO 02/059148 PCT/EP02/00546

Figure 1 shows the pre-selection of sera based on anti-staphylo-coccal antibody titers measured by ELISA.

Figure 2 shows the size distribution of DNA fragments in the LSA50/6 library in pMAL4.1.

Figure 3 shows the MACS selection with biotinylated human serum. The LSA50/6 library in pMAL9.1 was screened with 10 µg biotinylated, human serum in the first (A) and with 1 µg in the second selection round (B). P.serum, patient serum; B.serum, infant serum. Number of cells selected after the 2nd and 3rd elution are shown for each selection round.

Figure 4 shows the serum reactivity with specific clones isolated by bacterial surface display as analyzed by Western blot analysis with patient serum at a dilution of 1 : 5000.

Figure 5 shows peptide ELISA with serum from patients and healthy individuals with an epitope identified by ribosome display.

Figure 6 shows representative 2D Immunoblot of S. aureus surface proteins detected with human sera. 800 µg protein from S. aureus/COL grown on BHI were resolved by IEF (pI 4-7) and SDS-PAGE (9-16%), and subsequently transferred to PVDF membrane. After blocking, the membrane was incubated with sera IC35 (1:20,000). Binding of serum IgG was visualized by an anti-human IgG/HRPO conjugate and ECL development.

Figure 7 demonstrates a representative 2D gel showing S. aureus surface proteins stained by Coomassie Blue. 1 mg protein from S. aureus/COL were resolved by IEF (pI 4-7) and SDS-PAGE (9-16%). Spots selected for sequencing after serological proteome analysis are marked.

Figures 8Aand 8B show the structure of LPXTG cell wall proteins.

Figure 9 shows the IgG response in uninfected (N, C) and infected (P) patients to LPXTGV, a novel antigen and probable surface adhesin of S. aureus, discovered by both the inventive bacterial

surface-display and proteomics approaches.

Figure 10 shows the surface staining of S. aureus with purified anti-LPXTGV IgGs.

Figure 11 shows a 2D gel where S. aureus surface proteins are stained by Coomassie Blue (left). 1 mg protein from S. aureus/agr grown to early log phase was resolved by IEF (pI 6-11) and SDS-PAGE (9-16%). Spots selected for sequencing after serological proteome analysis are marked. Corresponding 2D-immunoblot (right). 800 µg protein from the same preparation was resolved in parallel by 2DE, and subsequently transferred to PVDF membrane. After blocking, the membrane was incubated with the P-pool (1:10,000). Binding of serum IgG was visualized by an anti-human IgG/HRPO conjugate and ECL development.

EXAMPLES

Discovery of novel Staphyloccocus aureus antigens

Example 1: Preparation of antibodies from human serum

The antibodies produced against staphylococci by the human immune system and present in human sera are indicative of the in vivo expression of the antigenic proteins and their immunogenicity. These molecules are essential for the identification of individual antigens in the approach as the present invention which is based on the interaction of the specific anti-staphylococcal antibodies and the corresponding S. aureus peptides or proteins. To gain access to relevant antibody repertoires, human sera were collected from I. patients with acute S. aureus infections, such as bacteriaemia, sepsis, infections of intravascular and percutan catheters and devices, wound infections, and superficial and deep soft tissue infection. S. aureus was shown to be the causative agent by medical microbiological tests. II. A collection of serum samples from uninfected adults was also included in the present analysis, since staphylococcal infections are common, and antibodies are present as a consequence of natural immunization from WO 02/059148 PCT/EP02/00546

- 32 -

previous encounters with Staphylococci from skin and soft tissue infections (furunculus, wound infection, periodontitits etc.).

The sera were characterized for S. aureus antibodies by a series of ELISA assays. Several styaphylococcal antigens have been used to prove that the titer measured was not a result of the sum of cross-reactive antibodies. For that purpose not only whole cell S. aureus (protein A deficient) extracts (grown under different conditions) or whole bacteria were used in the ELISA assays, but also individual cell wall components, such as lipoteichoic acid and peptidoglycan isolated from S. aureus. More importantly, a recombinant protein collection was established representing known staphylococcal cell surface proteins for the better characterization of the present human sera collections.

Recently it was reported that not only IgG, but also IgA serum antibodies can be recognized by the FcRIII receptors of PMNs and promote opsonization (Phillips-Quagliata et al., 2000; Shibuya et al., 2000). The primary role of IgA antibodies is neutralization, mainly at the mucosal surface. The level of serum IgA reflects the quality, quantity and specificity of the dimeric secretory IgA. For that reason the serum collection was not only analyzed for anti-staphylococcal IgG, but also for IgA levels. In the ELISA assays highly specific secondary reagents were used to detect antibodies from the high affinity types, such as IgG and IgA, and avoided IgM. Production of IgM antibodies occurs during the primary adaptive humoral response, and results in low affinity antibodies, while IgG and IgA antibodies had already undergone affinity maturation, and are more valuable in fighting or preventing disease

Experimental procedures

Enzyme linked immune assay (ELISA). ELISA plates were coated with 2-10 µg/ml of the different antigens in coating buffer (sodium carbonate pH 9.2). Serial dilutions of sera (100-100.000) were made in TBS-BSA. Highly specific (cross-adsorbed) HRP (Horse Radish Peroxidase)-labeled anti-human IgG or anti-human IgA secondary antibodies (Southern Biotech) were used according to the manufacturers' recommendations (~ 2.000x). Antigen-antibody complexes were quantified by measuring the conversion of the sub-

strate (ABTS) to colored product based on OD405nm readings in an automated ELISA reader (Wallace Victor 1420). The titers were compared at given dilution where the dilution response was linear (Table 1). The ~ 100 sera were ranked based on the reactivity against multiple staphylococcal components, and the highest ones (above 90 percentile) were selected for further analysis in antigen identification. Importantly, the anti-staphylococcal antibodies from sera of clinically healthy individuals proved to be very stable, giving the same high ELISA titers against all the staphylococcal antigens measured after 3, 6 and 9 months (data not shown). In contrast, anti-S. aureus antibodies in patients decrease, then disappear after a couple of weeks following the infection (Coloque-Navarro et al, 1998). However, antibodies from patients are very important, since these are direct proof of the in vivo expression of the bacterial antigens tested in or ELISAs or identified as immunogenic during the screens according to the present invention.

This comprehensive approach followed during antibody characterization is unique, and led to unambiguous identification of antistaphylococcal hyperimmune sera.

Purification of antibodies for genomic screening. Five sera from both the patient and the noninfected group were selected based on the overall anti-staphylococcal titers. Antibodies against E. coli proteins were removed by either incubating the heat inactivated sera with whole cell E. coli (DH5a, transformed with pHIE11, grown under the same condition as used for bacterial display) or with E. coli lysate affinity chromatography for ribosome display. Highly enriched preparations of IgG from the pooled, depleted sera were generated by protein G affinity chromatography, according to the manufacturer's instructions (UltraLink Immobilized Protein G, Pierce). IgA antibodies were purified also by affinity chromatography using biotin-labeled anti-human IgA (Southern Biotech) immobilized on Streptavidin-agarose (GIBCO BRL). The efficiency of depletion and purification was checked by SDS-PAGE, Western blotting, ELISA, and protein concentration measurements. For proteomics, the depletion the IgG and IgA preparation was not necessary, since the secondary reagent ensured the specificity.

Example 2: Generation of highly random, frame-selected, small-fragment, genomic DNA libraries of Staphylococcus aureus

Experimental procedures

Preparation of staphylococcal genomic DNA. This method was developed as a modification of two previously published protocols (Sohail, 1998, Betley et al., 1984) and originally specifically adapted for the methicillin resistant Staphylococcus aureus strain COL to obtain genomic DNA in high quality and large scale. 500 ml BHI (Brain Heart Infusion) medium supplemented with 5 μg/ml Tetracycline was inoculated with bacteria from a frozen stab and grown with aeration and shaking for 18 h at 37°. The culture was then harvested in two aliquots of 250 ml each, centrifuged with 1600 x g for 15 min and the supernatant was removed. Bacterial pellets were carefully re-suspended in 26 ml of 0.1 mM Tris-HCl, pH 7.6 and centrifuged again with 1600 x g for 15 min. Pellets were re-suspended in 20 ml of 1 mM Tris-HCl, pH 7.6, 0.1 mM EDTA and transferred into sterile 50 ml polypropylene tubes. 1 ml of 10 mg/ml heat treated RNase A and 200 U of RNase T1 were added to each tube and the solution mixed carefully. 250 ul of Lysostaphin (10 mg/ml stock, freshly prepared in ddH₂O) was then added to the tubes, mixed thoroughly and incubated at 40°C for 10 min in a shaking water bath under continuous agitation. After the addition of 1 ml 10 % SDS, 40 µl of Proteinase K (25 mg/ml stock) and 100 µl of Pronase (10 mg/ml), tubes were again inverted several times and incubated at 40°C for 5 min in a shaking water bath. 3.75 ml of 5 M NaCl and 2.5 ml of cetyl trimethyl-ammonium bromide solution (CTAB) (10% w/v, 4% w/v NaCl) were then added and tubes were further incubated at 65°C in a shaking water bath for 10 min. Samples were cooled to room temperature and extracted with PhOH/CHCl3/IAA (25:24:1) and with CHCl3/IAA (24:1). Aqueous phases were carefully collected and transferred to new sterile 50-ml tubes. To each tube 1.5 ml of Strataclean™ Resin was added, mixed gently but thoroughly and incubated for one minute at room temperature. Samples were centrifuged and the upper layers containing the DNA were collected into clean 50ml-tubes. DNA was precipitated at room temperature by adding 0.6 x volume of Isopropanol, spooled from the solution with a sterile Pasteur pipette and transferred into tubes containing 80% ice cold ethanol. DNA was recovered by centrifuging the precipitates with 10-12 000 \times g, then dried on air and dissolved in ddH₂O.

Preparation of small genomic DNA fragments. Genomic DNA fragments were mechanically sheared into fragments ranging in size between 150 and 300 bp using a cup-horn sonicator (Bandelin Sonoplus UV 2200 sonicator equipped with a BB5 cup horn, 10 sec. pulses at 100 % power output) or into fragments of size between 50 and 70 bp by mild DNase I treatment (Novagen). It was observed that sonication yielded a much tighter fragment size distribution when breaking the DNA into fragments of the 150-300 bp size range. However, despite extensive exposure of the DNA to ultrasonic wave-induced hydromechanical shearing force, subsequent decrease in fragment size could not be efficiently and reproducibly achieved. Therefore, fragments of 50 to 70 bp in size were obtained by mild DNase I treatment using Novagen's shotgun cleavage kit. A 1:20 dilution of DNase I provided with the kit was prepared and the digestion was performed in the presence of MnCl, in a 60 ul volume at 20°C for 5 min to ensure double-stranded cleavage by the enzyme. Reactions were stopped with 2 µl of 0.5 M EDTA and the fragmentation efficiency was evaluated on a 2% TAE-agarose gel. This treatment resulted in total fragmentation of genomic DNA into near 50-70 bp fragments. Fragments were then blunt-ended twice using T4 DNA Polymerase in the presence of 100 µM each of dNTPs to ensure efficient flushing of the ends. Fragments were used immediately in ligation reactions or frozen at -20°C for subsequent use.

Description of the vectors. The vector pMAL4.1 was constructed on a pEH1 backbone (Hashemzadeh-Bonehi et al., 1998) with the Kanamycin resistance gene. In addition it harbors a b-lactamase (bla) gene cloned into the multiple cloning site. The bla gene is preceded by the leader peptide sequence of ompA to ensure efficient secretion across the cytoplasmic membrane. A Sma I restriction site serves for library insertion. The Sma I site is flanked by an upstream FseI site and a downstream NotI site which were used for recovery of the selected fragments. The three restriction sites are inserted after the ompA leader sequence in such a way that the bla gene is transcribed in the -1 reading frame result-

ing in a stop codon 15 bp after the NotI site. A +1 bp insertion restores the bla ORF so that b-lactamase protein is produced with a consequent gain of Ampicillin resistance.

The vector pMAL4.31 was constructed on a pASK-IBA backbone (Skerra, 1994) with the b-lactamase gene exchanged with the Kanamycin resistance gene. In addition it harbors a b-lactamase (bla) gene cloned into the multiple cloning site. The sequence encoding mature b-lactamase is preceded by the leader peptide sequence of ompA to allow efficient secretion across the cytoplasmic membrane. Furthermore a sequence encoding the first 12 amino acids (spacer sequence) of mature b-lactamase follows the ompA leader peptide sequence to avoid fusion of sequences immediately after the leader peptidase cleavage site, since e.g. clusters of positive charged amino acids in this region would decrease or abolish translocation across the cytoplasmic membrane (Kajava et al., 2000). A Smal restriction site serves for library insertion. The Smal site is flanked by an upstream Fsel site and a downstream NotI site which were used for recovery of the selected fragment. The three restriction sites are inserted after the sequence encoding the 12 amino acid spacer sequence in such a way that the bla gene is transcribed in the -1 reading frame resulting in a stop codon 15 bp after the NotI site. A +1 bp insertion restores the bla ORF so that b-lactamase protein is produced with a consequent gain of Ampicillin resistance.

The vector pMAL9.1 was constructed by cloning the lamB gene into the multiple cloning site of pEH1. Subsequently, a sequence was inserted in lamB after amino acid 154, containing the restriction sites FseI, SmaI and NotI. The reading frame for this insertion was chosen in a way that transfer of frame-selected DNA fragments excised by digestion with FseI and NotI from plasmids pMAL4.1 or pMAL4.31 to plasmid pMAL9.1 will yield a continuous reading frame of lamB and the respective insert.

The vector pHIE11 was constructed by cloning the fhuA gene into the multiple cloning site of pEH1. Thereafter, a sequence was inserted in fhuA after amino acid 405, containing the restriction site FseI, XbaI and NotI. The reading frame for this insertion was chosen in a way that transfer of frame-selected DNA fragments excised by digestion with FseI and NotI from plasmids pMAL4.1 or

pMAL4.31 to plasmid pHIE11 will yield a continuous reading frame of fhuA and the respective insert.

- 37 -

Cloning and evaluation of the library for frame selection. Genomic S. aureus DNA fragments were ligated into the SmaI site of either the vector pMAL4.1 or pMAL4.31. Recombinant DNA was electroporated into DH10B electrocompetent E. coli cells (GIBCO BRL) and transformants plated on LB-agar supplemented with Kanamycin (50 µg/ml) and Ampicillin (50 µg/ml). Plates were incubated over night at 37°C and colonies collected for large scale DNA extraction. A representative plate was stored and saved for collecting colonies for colony PCR analysis and large-scale sequencing. A simple colony PCR assay was used to initially determine the rough fragment size distribution as well as insertion efficiency. From sequencing data the precise fragment size was evaluated, junction intactness at the insertion site as well as the frame selection accuracy (3n+1 rule).

Cloning and evaluation of the library for bacterial surface display. Genomic DNA fragments were excised from the pMAL4.1 or pMAL4.31 vector, containing the S. aureus library with the restriction enzymes FseI and NotI. The entire population of fragments was then transferred into plasmids pMAL9.1 (LamB) or pHIE11 (FhuA) which have been digested with FseI and NotI. Using these two restriction enzymes, which recognise an 8 bp GC rich sequence, the reading frame that was selected in the pMAL4.1 or pMAL4.31 vector is maintained in each of the platform vectors. The plasmid library was then transformed into E. coli DH5a cells by electroporation. Cells were plated onto large LB-agar plates supplemented with 50 µg/ml Kanamycin and grown over night at 37°C at a density yielding clearly visible single colonies. Cells were then scraped off the surface of these plates, washed with fresh LB medium and stored in aliquots for library screening at -80°C.

Results

Libraries for frame selection. Two libraries (LSA50/6 and LSA250/1) were generated in the pMAL4.1 vector with sizes of approximately 50 and 250 bp, respectively. For both libraries a total number of clones after frame selection of $1-2\times10^6$ was

received using approximately 1 µg of pMAL4.1 plasmid DNA and 50 ng of fragmented genomic S. aureus DNA. To assess the randomness of the LSA50/6 library, 672 randomly chosen clones were sequenced. The bioinformatic analysis showed that of these clones none was present more than once. Furthermore, it was shown that 90% of the clones fell in the size range of 19 to 70 bp with an average size of 25 bp (Figure 2). All 672 sequences followed the 3n+1 rule, showing that all clones were properly frame selected.

Bacterial surface display libraries. The display of peptides on the surface of E. coli required the transfer of the inserts from the LSA50/6 library from the frame selection vector pMAL4.1 to the display plasmids pMAL9.1 (LamB) or pHIE11 (FhuA). Genomic DNA fragments were excised by FseI and NotI restriction and ligation of 5ng inserts with 0.1µg plasmid DNA resulted in 2-5x 10⁶ clones. The clones were scraped off the LB plates and frozen without further amplification.

Example 3: Identification of highly immunogenic peptide sequences from S. aureus using bacterial surface displayed genomic libraries and human serum

 $\begin{bmatrix} 1 \end{bmatrix}$

Experimental procedures

MACS screening. Approximately 2.5×10^8 cells from a given library were grown in 5 ml LB-medium supplemented with 50 µg/ml Kanamycin for 2 h at 37° C. Expression was induced by the addition of 1 mM IPTG for 30 min. Cells were washed twice with fresh LB medium and approximately 2×10^7 cells re-suspended in 100 µl LB medium and transferred to an Eppendorf tube.

10 μg of biotinylated, human serum was added to the cells and the suspension incubated over night at 4°C with gentle shaking. 900 μl of LB medium was added, the suspension mixed and subsequently centrifuged for 10 min at 6000 rpm at 4°C. Cells were washed once with 1 ml LB and then re-suspended in 100 μl LB medium. 10 μl of MACS microbeads coupled to streptavidin (Miltenyi Biotech, Germany) were added and the incubation continued for 20 min at 4°C. Thereafter 900 μl of LB medium was added and the MACS microbead cell suspension was loaded onto the equilibrated MS column (Mil-

WO 02/059148 PCT/EP02/00546

tenyi Biotech, Germany) which was fixed to the magnet. (The MS columns were equilibrated by washing once with 1 ml 70% EtOH and twice with 2 ml LB medium.)

The column was then washed three times with 3 ml LB medium. The elution was performed by removing the magnet and washing with 2 ml LB medium. After washing the column with 3 ml LB medium, the 2 ml eluate was loaded a second time on the same column and the washing and elution process repeated. The loading, washing and elution process was performed a third time, resulting in a final eluate of 2 ml.

A second round of screening was performed as follows. The cells from the final eluate were collected by centrifugation and resuspended in 1 ml LB medium supplemented with 50 µg/ml Kanamycin. The culture was incubated at 37°C for 90 min and then induced with 1 mM IPTG for 30 min. Cells were subsequently collected, washed once with 1 ml LB medium and suspended in 10 µl LB medium. Since the volume was reduced, 1 µg of human, biotinylated serum was added and the suspension incubated over night at 4°C with gentle shaking. All further steps were exactly the same as in the first selection round. Cells selected after two rounds of selection were plated onto LB-agar plates supplemented with 50 µg/ml Kanamycin and grown over night at 37°C.

Evaluation of selected clones by sequencing and Western blot analysis. Selected clones were grown over night at 37°C in 3 ml LB medium supplemented with 50 µg/ml Kanamycin to prepare plasmid DNA using standard procedures. Sequencing was performed at MWG (Germany) or in a collaboration with TIGR (U.S.A.).

For Western blot analysis approximately 10 to 20 µg of total cellular protein was separated by 10% SDS-PAGE and blotted onto HybondC membrane (Amersham Pharmacia Biotech, England). The LamB or FhuA fusion proteins were detected using human serum as the primary antibody at a dilution of 1:5000 and anti human IgG antibodies coupled to HRP at a dilution of 1:5000 as secondary antibodies. Detection was performed using the ECL detection kit (Amersham Pharmacia Biotech, England). Alternatively, rabbit antification of the combination with the respective secondary antibodies couples in combination with the respective secondary antibodies couples.

- 40 -

pled to HRP for the detection of the fusion proteins.

Results

Screening of bacterial surface display libraries by magnetic activated cell sorting (MACS) using biotinylated human serum. The libraries LSA50/6 in pMAL9.1 and LSA250/1 in pHIE11 were screened with a pool of biotinylated, human patient sera (see Example 1) Preparation of antibodies from human serum). The selection procedure was performed as described under Experimental procedures. As a control, pooled human sera from infants that have most likely not been infected with S. aureus was used. Under the described conditions between 10 and 50 fold more cells with the patient compared to the infant serum were routinely selected (Figure 3). To evaluate the performance of the screen, approximately 100 selected clones were picked randomly and subjected to Western blot analysis with the same pooled patient serum. This analysis revealed that 30 to 50% of the selected clones showed reactivity with antibodies present in patient serum whereas the control strain expressing LamB or FhuA without a S. aureus specific insert did not react with the same serum. Colony PCR analysis showed that all selected clones contained an insert in the expected size range.

Subsequent sequencing of a larger number of randomly picked clones (500 to 800 per screen) led to the identification of the gene and the corresponding peptide or protein sequence that was specifically recognized by the human patient serum used for screening. The frequency with which a specific clone is selected reflects at least in part the abundance and/or affinity of the specific antibodies in the serum used for selection and recognizing the epitope presented by this clone. In that regard it is striking that some clones (ORF2264, ORF1951, ORF0222, lipase and IsaA) were picked up to 90 times, indicating their highly immunogenic property. All clones that are presented in Table 2 have been verified by Western blot analysis using whole cellular extracts from single clones to show the indicated reactivity with the pool of human serum used in the screen.

It is further worth noticing that most of the genes identified by the bacterial surface display screen encode proteins that are ei-

ther attached to the surface of S. aureus and/or are secreted. This is in accordance with the expected role of surface attached or secreted proteins in virulence of S. aureus.

Assessment of reactivity of highly immunogenic peptide sequences with different human sera. 10 to 30 different human patient sera were subsequently used to evaluate the presence of antibodies against the selected immunogenic peptide sequences that have been discovered in the screen according to the present invention. To eliminate possible cross-reactivity with proteins expressed by E. coli, all sera were pre-adsorbed with a total cellular lysate of E. coli DHa cells expressing FhuA protein.

This analysis is summarized in Table 2 and as an example shown in Figure 4 and is indicative of the validity of the present screen. It further shows that already short selected epitopes can give rise to the production of antibodies in a large number of patients (ORF1618, ORF1632, IsaA, Empbp, Protein A). Those peptide sequences that are not recognized by a larger set of patient sera may still be part of an highly immunogenic protein, but the recombinant protein itself may be tested for that purpose for each single case.

Example 4: Identification of highly immunogenic peptide sequences from genomic fragments from S. aureus using ribosome display and human serum

Experimental procedures

Ribosome display screening: 2.4 ng of the genomic library from S. aureus LSA250/1 in pMAL4.1 (described above) was PCR amplified with oligos ICC277 and ICC202 in order to be used for ribosome display.

Oligos

ICC277
(CGAATAATACGACTCACTATAGGGAGACCACAACGGTTTCCCACTAGTAATAATTTTGTTTAAC TTTAAGAAGGAGATATATCCATGCAGACCTTGGCCGGCCTCCC)

and

ICC202
(GGCCCACCCGTGAAGGTGAGCCGGCGTAAGATGCTTTTCTGTGACTGG) hybridize 5' and 3' of the Fse I-Not I insertion site of plasmid pMAL4.1, respectively. ICC277 introduces a T7 phage RNA polymerase promoter, a palindromic sequence resulting in a stem-loop structure on the RNA level, a ribosome binding site (RBS) and the translation start of gene 10 of the T7 phage including the ATG start codon.

WO 02/059148 PCT/EP02/00546

Oligo ICC202 hybridizes at nucleotide position 668 of the K-lactamase open reading frame and also introduces a stem-loop structure at the 3' end of the resulting RNA. PCR was performed with the High fidelity PCR kit (Roche Diagnostic) for 25 cycles at 50°C hybridization temperature and otherwise standard conditions.

The resulting PCR library was used in 5 consecutive rounds of selection and amplification by ribosome display similar as described previously (Hanes et al., 1997) but with modifications as described below.

One round of ribosome display contained the following steps: In vitro transcription of 2 µg PCR product with the RiboMax kit (Promega) resulted in ca. 50 µg A. In vitro translation was performed for 9 minutes at 37°C in 22 ul volume with 4.4 ul Premix Z (250 mM TRIS-acetate pH 7.5, 1.75 mM of each amino acid, 10 mM ATP, 2.5 mM GTP, 5 mM cAMP, 150 mM acetylphosphate, 2.5 mg/ml E. coli tRNA, 0.1 mg/ml folinic acid, 7.5 % PEG 8000, 200 mM potassium glutamate, 13.8 mM Mg(Ac)2, 8 µl S30 extract (x mg/ml) and about 2 µg in vitro transcribed RNA from the pool. S30 extract was prepared as described (Chen et al, 1983). Next, the sample was transferred to an ice-cold tube containing 35.2 µl 10 % milk-WBT (TRIS-acetate pH 7.5, 150 mM NaCl, 50 mM Mg(Ac)2, 0.1 % Tween-20, 10 % milk powder) and 52.8 µl WBTH (as before plus 2.5 mg/ml heparin). Subsequently, immuno precipitation was performed by addition of 10 µg purified IgGs, incubation for 90 minutes on ice, followed by addition of 30 µl MAGmol Protein G beads (Miltenyi Biotec, 90 minutes on ice). The sample was applied to a pre-equilibrated µ column (Miltenyi Biotec) and washed 5 times with ice-cold WBT buffer. Next 20 µl EB20 elution buffer (50 mM TRIS-acetate, 150 mM NaCl, 20 mM EDTA, 50 µg/ml S. cerevisiae RNA) was applied to the column, incubated for 5 minutes at 4°C. Elution was completed by adding 2 \times 50 μ l EB20. The mRNA from the elution sample was purified with the High pure RNA isolation kit (Roche Diagnostics). Subsequent reverse transcription was performed with Superscript II reverse transcriptase kit (Roche Diagnostics) according to the instruction of the manufacturer with 60 pmol oligo ICC202 for 1 hour at 50°C in 50 µl volume. 5 µl of this mix was used for the following PCR reaction with primers ICC202 and ICC277 as described above.

Three rounds of ribosome display were performed and the resulting selected PCR pool subsequently cloned into plasmid pHIE11 (described above) by cleavage with restriction endonucleases NotI and FseI.

Evaluation of selected clones by sequencing and peptide-ELISA analysis: Selected clones were grown over night at 37°C in 3 ml LB medium supplemented with 50 µg/ml Kanamycin to prepare plasmid DNA using standard procedures. Sequencing was performed at MWG (Germany) or at the Institute of Genomic Research (TIGR; Rockville, MD, U.S.A.). Peptides corresponding to the inserts were synthesized and coated in 10 mM NaHCO₃ pH 9.3 at a concentration of 10 µg/ml (50 µl) onto 96-well microtiter plates (Nunc). After blocking with 1% BSA in PBS at 37°C, 1:200 and 1:1000 dilutions of the indicated sera were diluted in 1% BSA/PBS and applied to the wells. After washing with PBS/0.1 % Tween-20, biotin-labeled anti-human IgG secondary antibodies (SBA) were added and these were detected by subsequent adding horseradish-peroxidase-coupled streptavidin according to standard procedures.

Results

The 250-bp genomic library (LSA250/1) as described above was used for screening. Purified IgGs from uninfected adults but with high titer against S. aureus as described above were used for selection of antigenic peptides.

Three rounds of ribosome display selection and amplification were performed according to Experimental procedures; finished by cloning and sequencing the resulting PCR pool.

Sequence analyses of a large number of randomly picked clones (700) led to the identification of the gene and the corresponding peptide or protein sequence that was specifically recognized by the high titer serum used for screening. The frequency with which a specific clone was selected reflects at least in part the abundance and/or affinity of the specific antibodies in the serum used for selection and recognizing the epitope presented by this clone. Remarkably, some clones (ORFs) were picked up to 50 times, indicating their highly immunogenic property. Table 2 shows the ORF name, the Seq.ID No. and the number of times it was identi-

fied by the inventive screen.

For a number of immuno-selected ORFs peptides corresponding to the identified immunogenic region were synthesized and tested in peptide-ELISA for their reactivity towards the sera pool they were identified with and also a number of additional sera from patients who suffered from an infection by S. aureus. The two examples in the graphs in figure 5 show the values of peptides from aureolysin and Pls. They are not only hyperimmune reactive against the high titer sera pool but also towards a number of individual patient's sera. All synthesized peptides corresponding to selected immunogenic regions showed reactivity towards the high titer sera pool and Table 2 summarizes the number of times the peptides were reactive towards individual patients sera, similar as described above.

In addition, it is striking that for those ORFs that were also identified by bacterial surface display described above), very often the actual immunogenic region within the ORF was identical or overlapping with the one identified by ribosome display. This comparison can be seen in Table 2.

Example 5: Identification of highly immunogenic antigens from S. aureus using Serological Proteome Analysis.

Experimental procedures

Surface protein preparations from S. aureus containing highly immunogenic antigens. S. aureus strains COL (Shafer and Iandolo, 1979) and agr- (Recsei et al., 1986) were stored as glycerol stocks at -80°C or on BHI (DIFCO) plates at 4°C. Single clones were used for inoculation of overnight cultures in either BHI ("standard conditions") or RPMI 1640 (GibcoBRL), last one depleted from iron ("stress conditions") by treating o/n with iminodiacetic acid (Sigma). Fresh medium was inoculated 1:100 the next day and bacteria were grown to O.D. 600 between 0.3 and 0.7. Bacteria were harvested by centrifugation and washed with icecold PBS. Surface proteins were prepared by lysostaphin treatment under isotonic conditions (Lim et al. 1998). Briefly, ~3x 10° bacteria (according to O.D. 600 = 1 are about 5x10° bacteria) were re-

suspended in 1 ml digestion buffer containing 35% raffinose (Aldrich Chemical Company), protease inhibitors (Roche) and 5 units lysostaphin (Sigma). After incubation at 37°C for 30 min, protoplasts were carefully sedimented by low-speed centrifugation. This treatment releases surface proteins covalently linked to the pentaglycine bridge of the peptidoglycan cell wall to the supernatant (in Crossley, 1997). Cell surface proteins were either precipitated with methanol/chlorophorm (Wessel, 1984) or concentrated in centrifugal filter-tubes (Millipore). Protein samples were frozen and stored at -80°C or dissolved in sample buffer and used for isoelectric focusing (IEF) immediately (Pasquali et al. 1997).

Serological proteome analysis of surface protein preparations from S. aureus. Samples were obtained from a) S. aureus/agr grown under "stress conditions", b) S. aureus/COL grown under "standard conditions" and c) S. aureus/COL "stress conditions". Loading onto 17 cm-strips containing immobilized pH gradients (pH 4-7, the "in-gel-reswelling procedure" done using (Pasquali et al., 1997). The gels for blotting were loaded with 100-800 µg protein, the preparative gels with 400-1,000 µgprotein. Isoelectric focusing and SDS-PAGE (9-16% gradient gels) were performed as described (Pasquali et al., 1997). For Western blotting, proteins were transferred onto PVDF-membranes (BioRad) by semi-dry blotting. Transfer-efficiency was checked by amidoblack staining. After blocking (PBS/0.1% Tween 20/10% dry milk, 4°C for 16 h), blots were incubated for two hours with serum (1:2,500-1:100,000 in blocking solution, see Table 3). After washing, specific binding of serum IgG was visualized with a goat-anti-human-IgG / peroxidase conjugate (1:25,000, Southern and development secondary antibody Biotech) as Chemiluminescence substrate (ECL $^{\text{TM}}$, Amersham). A representative result is shown in Figure 6. Membranes were stripped by treatment with 2% R-ME/Laemmli buffer for 30 min at 50-65°C, immediately re-probed with a different serum, and developed as described above. This procedure was repeated up to five times. Signals showing up with patient and/or healthy donor control sera but not with the infant pool, were matched to the Coomassie (BioRad) stained preparative gels (example shown in Figure 7). The results of these serological proteome analyses of surface protein preparations from S. aureus are summarized in Table 3.

WO 02/059148 PCT/EP02/00546

- 46 **-**

Sequencing of protein spots by peptide-fingerprint MALDI-TOF-MS and tandem MS/MS. Gel pieces were washed alternately three times with 10 ul digestion buffer (10mM NH, HCO, /CAN, 1:1). Afterwards the gel pieces were shrunken with 10 µl ACN and reswollen with 2 μl protease solution (0.05 μg/μl trypsin, Promega, Madison, USA). Digestion was performed for 10-12 h at 37°C. For MALDI-TOF-MS peptides were extracted from the gel pieces with 10 µl digestion buffer. The supernatant was concentrated with ZipTip™ (Millipore, Bedford, USA), the peptides were eluted onto the MALDI target with 0.5 μ l extraction buffer (0.1% TFA/CAN, 1:1) and 0.5 μ l matrix solution (HCCA in ACN/0.1% TFA, 1:1) was added. MALDI-TOF-MS was done using a REFLEX III (Bruker Daltonik, Bremen, Germany) equipped with a SCOUT384 ion source. The acceleration voltage was set to 25 kV, and the reflection voltage to 28.7 kV. The mass range was set from 700 Da to 4000 Da. Data acquisition was done on a SUN Ultra using XACQ software, version 4.0. Post-analysis data processing was done using XMASS software, version 4.02 (Bruker Daltonik, Bremen, Germany). The results are summarized in tables 3 and 4.

Example 6: Characterisation of highly immunogenic proteins from S. aureus

The antigens identified by the different screening methods with the IgG and IgA preparations form pre-selected sera are further characterized, by the following ways:

1. The proteins are purified, most preferably as recombinant proteins expressed in E. coli or in a Gram+ expression system or in an in vitro translation system, and evaluated for antigenicity by a series of human sera. The proteins are modified based on bioinformatic analysis: N-terminal sequences representing the signal peptide are removed, C-terminal regions downstream of the cell wall anchor are also removed, and extra amino acids as tags are introduced for the ease of purification (such as Strep-tagII, His-tag, etc.) A large number of sera is then used in ELISA assays to assess the fraction of human sera containing specific antibodies against the given protein (see Fig. 9 as an example). One of the selected antigens is a 895 aa long protein, what was called LPXTGV (see Tables 2 and 4), since it contains the Gram-cell wall anchor sequence LPXTG. This signature has been shown to

serve as cleavage site for sortase, a trans-peptidase which covalently links LPXTG motif containing proteins to the peptidoglycan cell wall. LPXTGV is also equipped with a typical signal peptide (Fig. 8). ELISA data using this protein as a Strep-tagged recombinant protein demonstrate that this protein is highly immunogenic (high titers relative to other recombinant proteins) in a high percentage of sera (Fig. 9). Importantly, patients with acute S. aureus infection produce significantly more of these anti-LPXTGV antibodies, than healthy normals, suggesting that the protein is expressed during in vivo infection. The overall ELISA titers of the individual antigenic proteins are compared, and the ones inducing the highest antibody levels (highly immunogenic) in most individuals (protein is expressed by most strains in vivo) are favored. Since the antigen specificity and quality (class, subtype, functional, nonfunctional) of the antibodies against S. aureus produced in individual patients can vary depending on the site of infection, accompanying chronic diseases (e.g. diabetes) and chronic conditions (e.g. intravascular device), and the individuals' immune response, special attention was paid to the differences detected among the different patient groups, since medical records belonging to each sera were available. In addition, each patient serum is accompanied by the pathogenic strain isolated from the patient at the time of serum sampling.

- 2. Specific antibodies are purified for functional characterization. The purity and the integrity of the recombinant proteins are checked (e.g. detecting the N-terminal Strep-tag in Western blot analysis in comparison to silver staining in SDS-PAGE). The antigens are immobilized through the tags to create an affinity matrix, and used for the purification of specific antibodies from highly reactive sera. Using as an example strep-tagged LPXTGV as the capture antigen, 20 µg of antibody from 125 mg of IgG were purified. Based on the ELISA data a pure preparation was received, not having e.g. anti-LTA and anti-peptidoglycan (both dominant with unfractionated IgG) activity. The antibodies are then used to test cell surface localization by FACS and fluorescent microscopy (Fig. 10).
- 3. Gene occurrence in clinical isolates
 An ideal vaccine antigen would be an antigen that is present in
 all, or the vast majority of, strains of the target organism to

which the vaccine is directed. In order to establish whether the genes encoding the identified Staphylococcus aureus antigens occur ubiquitously in S. aureus strains, PCR was performed on a series of independent S. aureus isolates with primers specific for the gene of interest. S. aureus isolates were obtained from patients with various S. aureus infections. In addition several nasal isolates from healthy carriers and several lab strains were also collected and analyzed. The strains were typed according to restriction fragment length polymorphism (RFLP) of the spa and coa genes (Goh et al. 1992, Frénay et al., 1994, vanden Bergh et al. 1999). From these results 30 different strains were identified - 24 patient isolates, 3 nasal isolates and 3 lab strains. To establish the gene distribution of selected antigens, the genomic DNA of these 30 strains was subjected to PCR with gene specific primers that flank the selected epitope (ORF1361: Seq.ID No. 187 and 188; ORF2268: Seq.ID No. 193 and 194; ORF1951: Seq.ID No. 195 and 196; ORF1632: Seq.ID No. 181 and 182; ORF0766: Seq.ID No. 183 and 184; ORF0576: Seq.ID No. 185 and 186; ORF0222: Seq.ID No. 189 and 190; ORF0360: Seq.ID No. 191 and 192). The PCR products were analyzed by gel electrophoresis to identify a product of the correct predicted size. ORFs 1361, 2268, 1951, 1632, 0766 and 0222 are present in 100% of strains tested and ORF0576 in 97%. However ORF0360 occurred in only 71% of the strains. Thus ORFs 1361, 2268, 1951, 1632, 0766, 0576 and 0222 each have the required ubiquitous presence among S. aureus isolates.

These antigens (or antigenic fragments thereof, especially the fragments identified) are especially preferred for use in a vaccination project against S. aureus.

4. Identification of highly promiscuous HLA-class II helper epitopes within the ORFs of selected antigens

The ORFs corresponding to the antigens identified on the basis of recognition by antibodies in human sera, most likely also contain linear T-cell epitopes. Especially the surprising finding in the course of the invention that even healthy uninfected, non-colonized individuals show extremely high antibody titers (> 100,000 for some antigens, see Example 5) which are stable for >1 year (see Example 1), suggests the existence of T-cell dependent memory most probably mediated by CD4+ helper-T-cells. The molecular

definition of the corresponding HLA class II helper-epitopes is usefull for the design of synthetic anti-staphylococcal vaccines, which can induce immunological memory. In this scenario the helper-epitopes derived from the staphylococcal antigens provide "cognate help" to the B-cell response against these antigens or fragments thereof. Moreover it is possible to use these helperepitopes to induce memory to T-independent antigens like for instance carbohydrates (conjugate vaccines). On the other hand, intracellular occurring staphylococci can be eliminated by CD8+ cytotoxic T-cells, which recognize HLA class I restricted epitopes.

T-cell epitopes can be predicted by various public domain algorithms: http://bimas.dcrt.nih.gov/molbio/hla bind/ (Parker et al. 1994),

http://134.2.96.221/scripts/MHCServer.dll/home.htm (Rammensee at al. 1999), http://mypage.ihost.com/usinet.hamme76/ (Sturniolo et al. 1999). The latter prediction algorithm offers the possibility to identify promiscuous helper-epitopes, i.e. peptides that bind to several HLA class II molecules. In order to identify highly promiscuous helper-epitopes within staphylococcal antigens the ORFs corresponding to Seq ID 64 (IsaA), Seq ID 114 (POV2), Seq ID 89 (ORF0222), Seq ID 70 (LPXTGIV), Seq ID 56 (LPXTGV), Seq ID 142 (LPXTGVI), Seq ID 81 (ORF3200), Seq ID 74 (ORF1951), Seq ID 94 (Empbp), Seq ID 83 (autolysin) and Seq ID 58 (ORF2498) were analyzed using the TEPITOPE package http://mypage.ihost.com/usi- net.hamme76/ (Sturniolo et al. 1999). The analysis was done for 25 prevalent DR-alleles and peptides were selected if they were predicted to be a) strong binders (1% threshold) for at least 10/25 alleles or b) intermediate (3% threshold) binders for at least 17/25 alleles.

The following peptides containing one or several promiscuous helper-epitopes were selected (and are claimed):

pos. 6-40, 583-598, 620-646, 871-896 Seq ID 56:

no peptide fulfills selection criteria Seq ID 58:

no peptide fulfills selection criteria Seq ID 64:

pos. 24-53 Seq ID 70:

pos. 240-260 Seq ID **74:**

pos. 1660-1682, 1746-1790 Seq ID 81:

pos. 1-29, 680-709, 878-902 Seq ID 83:

WO 02/059148 PCT/EP02/00546

Seq ID 89: pos. 96-136

Seq ID **94:** pos. 1-29, 226-269, 275-326

Seq ID **114:** pos. 23-47, 107-156

Seq ID **142:** pos. 24-53

The corresponding peptides or fragments thereof (for instance overlapping 15-mers) can be synthesized and tested for their ability to bind to various HLA molecules in vitro. Their immunogenicity can be tested by assessing the peptide (antigen)-driven proliferation (BrdU or 3H-thymidine incorporation) or the secretion of cytokines (ELIspot, intracellular cytokine staining) of T-cells in vitro (Mayer et al. 1996, Schmittel et al. 2000, Sester et al. 2000). In this regard it will be interesting to determine quantitative and qualitative differences in the T-cell response to the staphylococcal antigens or the selected promiscuous peptides or fragments thereof in populations of patients with different staphylococcal infections, or colonization versus healthy individuals neither recently infected nor colonized. Moreover, a correlation between the antibody titers and the quantity and quality of the T-cell response observed in these populations is expected. Alternatively, immunogenicity of the predicted peptides can be tested in HLA-transgenic mice (Sonderstrup et al. 1999).

Similar approaches can be taken for the identification of HLA class I restricted epitopes within staphylococcal antigens.

Synthetic peptides representing one or more promiscuous T helper epitopes from S.aureus

Partially overlapping peptides spanning the indicated regions of Seq ID 56 (LPXTGV), Seq ID 70 (LPXTGIV), Seq ID 74 (ORF1hom1), Seq ID 81 (EM_BP), Seq ID 83 (Autolysin), Seq ID 89 (ORF1hom2), Seq ID 94 (EMPBP), Seq ID 114 (POV2) and Seq ID 142 (LPXTGVI) were synthesized. Sequences of the individual peptides are given in Table 5. All peptides were synthesized using Fmoc chemistry, HPLC purified and analyzed by mass spectrometry. Lyophilized peptides were dissolved in DMSO and stored at -20°C at a concentration of 5-10 mM.

Binding of synthetic peptides representing promiscuous T helper

WO 02/059148 PCT/EP02/00546

- 51 -

epitopes to HLA molecules in vitro

Binding of peptides to HLA molecules on the surface of antigenpresenting cells is a prerequisite for activation of T cells. Binding was assessed in vitro by two independent biochemical assays using recombinant soluble versions of HLA class II molecules. One assay measures the concentration dependent competitive replacement of a labeled reference peptide by the test peptides. The second assay is based on the formation of SDS-stable complexes upon binding of high- and intermediate affinity ligands. A summary of the results obtained by the two assays is given in Table 5.

Soluble HLA molecules (DRA1*0101/DRB1*0101 DRA1*0101/DRB1*0401) were expressed in SC-2 cells and purified as described in Aichinger et al., 1997. For the competition assay (Hammer et al. 1995) HLA molecules were applied between 50 and 200 ng/well. For DRB1*0101 biotinilated indicator peptide HA (PKYVKONTLKLAT, Valli et al. 1993) was used at 0.008 µM. For DRB1*0401 biotinilated indicator peptide UD4 (YPKFVKQNTLKAA, Valli et al. 1993) was used between 0.03 and 0.06 μM. Test peptides were used in serial dilutions from 0.02 nM to 200 µM. Molecules, indicator and test peptides were incubated overnight at 37°C, pH 7. HLA:peptide complexes obtained after incubation with serial dilutions of test and reference peptides (the known highaffinity binders HA and UD4 were used as positive control) were captured in ELISA plates coated with antibody L243, which is known to recognize a conformational epitope formed only by correctly associated heterodimers. Incorporated biotin was measured by standard colorimetric detection using a streptavidin-alkaline phosphatase conjugate (Dako) with NBT/BCIP tablets (Sigma) as substrate and automated OD reading on a Victor reader (Wallac).

T cell response against promiscuous T helper epitopes assessed by IFNg ELIspot assay

Upon antigenic stimulation T cells start to proliferate and to secrete cytokines such as interferon gamma (IFNg). Human T cells specifically recognizing epitopes within S.aureus antigens were detected by IFNg-ELIspot (Schmittel et al. 2000). PBMCs from healthy individuals with a strong anti-S.aureus IgG response were isolated from 50-100 ml of venous blood by ficoll density gradient centrifugation and used after freezing and thawing. Cells were seeded at 200,000/well in 96-well plates. Peptides were added as mixtures corresponding to individual antigens, in both cases at 10 µg/ml each. Concanavalin A (Amersham) and PPD (tuberculin purified protein derivate, Statens Serum Institute) served as assay positive controls, assay medium without any peptide as negative control. After overnight incubation in Multi Screen 96well filtration plates (Millipore) coated with the anti-human IFNg monoclonal antibody B140 (Bender Med Systems) the ELIspot was developed using the biotinylated anti-human IFNg monoclonal antibody B308-BT2 (Bender Med Systems), Streptavidin-alkaline phosphatase (DAKO) and BCIP/NBT alkaline phosphatase substrate (SIGMA). Spots were counted using an automatic plate reader (Bioreader 2000, BIO-SYS). Spots counted in wells with cells stimulated with assay medium only (negative control, generally below 10 spots / 100.000 cells) were regarded as background and subtracted from spot numbers counted in wells with peptides.

Table 5: Promiscuous T helper epitopes contained in S.aureus antigens

| Amino acid | sequences within S.aureus antigens containing | binding | IFNg |
|------------|---|--------------|---------|
| | miscuous T helper epitopes | 1) | ELIspot |
| mranry bro | WIDOGOGD . Morbon ob-1-12 | | 2) |
| Sea TD 56 | (LPXTGV): pos. 6-40 | | |
| · · | >PKLRSFYSIRKSTLGVASVIVST// | + | |
| = | >VIVSTLFLISQHQAQA// | | |
| p24-40 | ↑ ↑ ↑ ↑ ↑ ↑ TIT TITE X • X • X • 1 | | |
| | | | 44;80;8 |
| | • | | ;95;112 |
| | 600 646 | | 133,111 |
| | (LPXTGV): pos. 620-646 | | |
| p620-646 | >FPYIPDKAVYNAIVKVVVANIGYEGQ// | + | |
| Seq ID 56 | (LPXTGV): pos. 871-896 | | |
| p871-896 | >QSWWGLYALLGMLALF1PKFRKESK// | | |
| Seq ID 70 | (LPXTGIV): pos. 24-53 | | |
| p24-53 | >YSIRKFTVGTASILIGSLMYLGTQQEAEA// | nd | 34;14;0 |
| 222 33 | | | ;57;16 |
| Seg ID 74 | (ORF1hom1): pos. 240-260 | | |
| | >MNYGYGFGVVTSRTISASQA// | + | 47;50;0 |
| D240-200 | | | ;85;92 |
| 1 | | • | • |

| Seq ID 81 (EM_BP): pos. 1660-1682 | 1 | 1 |
|--|---|----------|
| p1660-1682 >NEIVLETIRDINNAHTLQQVEA// | nd | |
| DIOOOIOON MILLIAMILIANS | | |
| | | |
| | | 0 14 5 |
| | | 2;14;5; |
| Seq ID 81 (EM_BP): pos. 1746-1790 | | 77;26 |
| _ | nd | 1 |
| p1746-1773 >LHMRHFSNNFGNVIKNAIGVVGTSGLLA// | nd | |
| p1753-1779 >NNFGNVIKNAIGVVGISGLLASFWFFI// | 1 | |
| p1777-1789 >FFIAKRRKEDEE/ | nd | |
| Seq ID 83 (Autolysin) pos. 1-29 | 9 | |
| p1-29: >MAKKFNYKLPSMVALTLVGSAVTAHQVQA// | nd | |
| | | 6;35;7; |
| | | 60;49 |
| Seq ID 83 (Autolysin) pos. 878-902 | _ | |
| p878-902: >NGLSMVPWGTKNQVILTGNNIAQG/ | nd | |
| Seq ID 89 (ORF1hom2): pos. 96-136 | | |
| p96-121 >GESLNIIASRYGVSVDQLMAANNLRG// | - | |
| p117-136 >NNLRGYLIMPNQTLQIPNG// | _ | 0;35;0; |
| | | 29;104 |
| Seq ID 94 (EMPBP): pos. 1-29 | | ľ |
| p4-29 : >KLLVLTMSTLFATQIMNSNHAKASV// | + | <u> </u> |
| Seq ID 94 (EMPBP): pos. 226-269 | | |
| p226-251 >IKINHFCVVPQINSFKVIPPYGHNS// | - | |
| p254-270 >MHVPSFQNNTTATHQN// | + | |
| | | 26;28;1 |
| | | 6;43;97 |
| Seq ID 94 (EMPBP): pos. 275-326 | | |
| p275-299 >YDYKYFYSYKVVKGVKKYFSFSQS// | + | |
| p284-305 >YKVVKGVKKYFSFSQSNGYKIG// | + | |
| p306-326 >PSLNIKNVNYQYAVPSYSPT// | + | |
| Seq ID 114 (POV2): pos. 23-47 | | |
| p23-47 >AGGIFYNQTNQQLLVLCDGMGGHK// | - | 49;20;4 |
| | ļ | ;77;25 |
| Seq ID 114 (POV2): pos. 107-156 | | |
| p107-124 >ALVFEKSVVIANVGDSRA/ | - | |
| p126-146 >RAYVINSRQIEQITSDHSFVN// | nd | |
| p142-158 >SFVNHLVLTGQITPEE// | nd | |
| Seq ID 142 (LPXTGVI): pos. 1-42 | | |
| p6-30 >KEFKSFYSIRKSSLGVASVAISTL// | ++ | |
| p18-42 >SSLGVASVAISTLLLLMSNGEAQA// | nd | |
| | | |
| · | | 0;41;20 |
| · | | ;88;109 |
| Seq ID 142 (LPXTGVI): pos. 209-244 | | |
| p209-233 >IKLVSYDTVKDYAYIRFSVSNGTKA// | + | |
| p218-244 >KDYAYIRFSVSNGTKAVKIVSSTHFNN// | + | |
| Seq ID 142 (LPXTGVI): pos. 395-428 | 3 | |
| p395-418 >FMVEGQRVRTISTYAINNTRCTIF// | _ | |
| p416-428 >TIFRYVEGKSLYE// | - | |
| | ı | 1 |

WO 02/059148 PCT/EP02/00546

- 54 -

| Seq ID 142 (LPXTGVI): pos. 623-647 | | |
|--|---|--|
| p623-647 >MTLPLMALLALSSIVAFVLPRKRKN // | _ | |
| | | |

"binding to soluble DRA1*0101/DRB1*0401 molecules was determined using a competition assay (+, ++: binding, -: no competition up to 200 µM test peptide; nd: not done)

2) results from 5 healthy individuals with strong anti-S.aureus IgG response. Data are represented as spots/200.000 cells (background values are subtracted

- 5. Antigens may be injected into mice - and the antibodies against these proteins can be measured.
- Protective capacity of the antibodies induced by the antigens through vaccination can be assessed in animal models.

Both 5. and 6. are methods well available to the skilled man in the art.

Example 7: Applications

- A) An effective vaccine offers great potential for patients facing elective surgery in general, and those receiving endovascular devices, in particular. Patients suffering from chronic diseases with decreased immune responses or undergoing continuous ambulatory peritoneal dialysis are likely to benefit from a vaccine with S. aureus by immunogenic serum-reactive antigens according to the present invention. Identification of the relevant antigens will help to generate effective passive immunization (humanized monoclonal antibody therapy), which can replace human immunoglobulin administration with all its dangerous side-effects. Therefore an effective vaccine offers great potential for patients facing elective surgery in general, and those receiving endovascular devices, in particular.
- S. aureus can cause many different diseases.
- 1. Sepsis, bacteriaemia
- 2. Haemodialysed patients bacteriemia, sepsis
- 3. Peritoneal dialyses patients peritonitis
- 4. Patients with endovascular devices (heart surgery, etc) docarditis, bacteriemia, sepsis

- 5. Orthopedic patients with prosthetic devices septic arthritis
- 6. Preventive vaccination of general population

B) Passive and active vaccination, both with special attention to T-cells with the latter one: It is an aim to induce a strong T helper response during vaccination to achieve efficient humoral response and also immunological memory. Up till now, there is no direct evidence that T-cells play an important role in clearing s. aureus infections, however, it was not adequately addressed, so far. An effective humoral response against proteinaceous antigens must involve T help, and is essential for developing memory. Naïve CD4+ cells can differentiated into Th1 or Th2 cells. Since, innate immunological responses (cytokines) will influence this decision, the involvement of T-cells might be different during an acute, serious infection relative to immunization of healthy individuals with subunit vaccines, not containing components which impair the immune response during the natural course of the infection. The consequences of inducing Th1 or Th2 responses are profound. Th1 cells lead to cell-mediated immunity, whereas Th2 cells provide humoral immunity.

C) Preventive and therapeutic vaccines

Preventive: active vaccination/passive immunization of people in high risk groups, before

infection

Therapeutic: passive vaccination of the already sick.

Active vaccination to remove nasal carriage

Specific example for an application

Elimination of MRSA carriage and prevention of colonization of the medical staff

Carriage rates of S. aureus in the nares of people outside of the hospitals varies from 10 to 40%. Hospital patients and personnel have higher carriage rates. The rates are especially high in patients undergoing hemodialysis and in diabetics, drug addicts and patients with a variety of dermatologic conditions. Patients at highest risk for MRSA infection are those in large tertiary-care hospitals, particularly the elderly and immunocompromised, those

in intensive care units, burn patients, those with surgical wounds, and patients with intravenous catheters.

The ELISA data strongly suggest that there is a pronounced IgA response to S. aureus, which is not obvious or known from the literature. Since the predominant mucosal immune response is the production of IgA with neutralizing activity, it is clear that the staphylococcal epitopes and antigens identified with the highly pure IgA preparations lead to an efficient mucosal vaccine.

- •Clear indication: Everybody's threat in the departments where they perform operation (esp. orthopedics, traumatology, gen. surgery)
- •Well-defined population for vaccination (doctors and nurses)
- •Health care workers identified as intranasal carriers of an epidemic strain of S. aureus are currently treated with mupirocin and rifampicin until they eliminate the bacteria. Sometimes it is not effective, and takes time.
- •Available animal model: There are mice models for intranasal carriage.

Table 1: ELISA titers of séra from non-infected individuals against multiple staphylococcal proteins.

| * | | | | | | | | • | 5 | , | | | | | \neg | | ٠, | | | | | | 1 |
|------------|----------|---|----|---|--------|-------|---|---|-----|-------|-----|----|-------|----|--------|-----|----|----|-----|----|----|--|---|
| Map-w | | | | 4 | 3 | | | 7 | | | | | | | | 8,9 | 9 | | | 1 | | 2 | |
| CIFB | | | | 7 | 1 | | | | 8,9 | 5,6 | 5,6 | | | | | | | | 4 | | | <u>, </u> | |
| SrtA | | | - | 3 | ٠. | | | | 7 | | | 9 | | | | 8 | | | | | | | |
| Fīb | | | 3 | 2 | | 15.00 | | 4 | 5 | 1 | | | | 8 | | | | | | | | | |
| coagul | | | | 2 | | | | | | | | | 4,5 | - | | | | | | | | | |
| LP342 | <u>.</u> | | 9 | | 3 | | | | | | | | | | | 7 | | | | | | | |
| LP309 | | | | 3 | 1 | | 5 | | | | | | | | | 9 | | | | | | | |
| enolase | | | · | , | 6,7 | • | | 5 | | 3,4 | | | | | | | | | | | | | |
| EBP | | | | ٠ | 2 | | | 7 | | | | | | | ٠ | | | | 3 | | | | |
| sdrC | | | | | 1 | | 4 | t | | 3 | | | [,`:] | 2 | | | | | | | | | |
| sdrE | | | | 1 | 3 | | | 7 | 8 | 1 1 | 1.7 | | | 5 | | | | | | | • | | |
| FnBPA sdrE | | | | | 2 | | | | - | | | | | | | 5 | | | | | | , | |
| D1+D3 | | | 4 | | 2 | | | | | 5 | | 9 | - | | | | | | | - | | | |
| CIfA | | | 8 | 3 | 9 | | | | | | | | | | | - | | | 1 | | | 2 | |
| PG | | | | | 11 | | | | | 5 | | | | | | 2,3 | | | 6,7 | | | | |
| LTA | | | 2 | |] **** | | | 9 | | 4 | | | | | L. | 5 | | | | | | | |
| BHI | lysate | | 22 | | ***** | | | | | 4,5,6 | | | | Ü | | 3 | • | | | | ij | ŋ | |
| Sera ID# | red | - | 7 | 3 | 4 | 5 | 9 | 1 | 8 | 6 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | |

1

:

| | | | | | | <u>1</u> | Т | | | | Т | .] | | | | \neg | | | | |
|---------------|--------|----|-------|-----|----|----------|-------|----|----|----|-----------|-----|--|-------------|-------|--------|-----|-------|----|--|
| Мар-w | | | | 8,9 | | | | | | | | | | | 4 | | | | | <u>. </u> |
| CIRB | | | 7 | | | | | | | | | | | | 3 | | | | | 8,9 |
| SrtA | | | 2 | | | | 5 | | | | | | | | | | | | | |
| Fib | | | | | | 7 | | | | | | | | 9 | | | | | | |
| 1 | | | 6,7 | | | | 4,5 | | | | 1 | | | 6,7 | | | 3 | | [] | |
| LP342 coagul | | | | | | | 4,5 | | | | | | | 1 | | | | | | 4,5 |
| ļ · | | | 7 | | | | 4 | | | | | i | | 2 | *** | | | | | |
| enolase LP309 | | | 6,7 | | | | | | 1 | | | | <u> </u> | 2 | | | | 3,4 | , | |
| EBP | | | 77 | 9 | | | ٠ | | | | | - | - | | 5 | | · | | | |
| sdrC | | | 7 | | | | 8 | | | | | | 5 | اس استار | | | | | | |
| | | | 2 | 4 | | - | | | | | | | | | | | | /-)· | | |
| FnBPA sdrE | | | 9 | | | | | | | | <u>-1</u> | | 4 | | | | | | | 3 |
| D1+D3 | | | 3 | | | | | | | | 11 | | | 7,8 | | | 7,8 | | | |
| ClfA | | | 5 | | ٦ | | 17221 | ll | | | | | 4 | ĺ | | | 7 | 1 | | |
| PG | | | | | 5 | | | | | | | 4 | Ί | | 2,3 | | | | | 6,7 |
| LTA | | | | | | | | | | | | | | | 8 | 3 | | | | 7 |
| BHI | lysate | | 4,5,6 | | | 8 | 1 | | | | | | | | 4,5,6 | | | | | |
| Sera ID# | | 52 | 23 | 24 | 25 | 56 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | | 36 | 37 | 38 | 39 | 40 |

Table I. ELISA titers of sera from non-infected individuals against multiple staphylococcal proteins.

Anti-staphylococcal antibody levels were measured individually by standard ELISA with total lysate prepared from S. aureus grown in BHI medium (BHI), lipoteichoic acid (LTA), peptidoglycan (PG), 13 recombinant proteins, representing cell surface and secreted proteins, such as clumping factor A and B (ClfA, ClfB), Fibronectinbinding protein (FnBPA), SD-repeat proteins (sdrC, sdrE), MHC Class II analogous protein (map-w), Elastin-binding protein (EBP), enolase (reported to be cell surface located and immunogenic), iron transport lipoproteins (LP309, LP342), sortase (srtA), coagulase (coa), extracellular fibrinogen-binding protein (fib). Two short synthetic peptides representing 2 of the five immunodominant D repeat domains from FnBPA was also included (D1+D3) as antigens. The individual sera were ranked based on the IgG titer, and obtained a score from 1-9. Score 1 labels the highest titer serum and score 8 or 9 labels the sera which were 8th or 9th among all the sera tested for the given antigen. It resulted in the analyses of the top 20 percentile of sera (8-9/40). The five "best sera" meaning the most hyper reactive in terms of anti-staphylococcal antibodies were selected based on the number of scores 1-8. **** means that the antibody reactivity against the particular antigen was exceptionally high (>2x ELISA units relative to the 2nd most reactive serum).

Table 2a: Immunogenic proteins identified by bacterial surface and ribosome display: S. aureus

Bacterial surface display: A, LSA250/1 library in fhuA with patient sera 1 (655); B, LSA50/6 library in lamB with patient sera 1 (484); C, LSA250/1 library in fhuA with IC sera 1 (571); E, LSA50/6 library in lamB with IC sera 2 (454); F, LSA50/6 library in lamB with patient sera P1 (1105); G, LSA50/6 library in lamb with IC sera 1 (471)); H, LSA250/1 library in fhuA with patient sera 1 (IGA, 708). Ribosome display: D, LSA250/1 library with IC sera (1686). *, identified 18 times of 33 screened; was therefore eliminated from screen C. **, prediction of antigenic sequences longer than 5 amino acids was performed with the programme ANTIGENIC (Kolaskar and Tongaonkar, 1990); #, identical sequence present twice in ORF; ##, clone not in database (not sequence by

TIGR).

| S. | Old | Putative function | predicted immunogenic aa** | No. of se- | Location of | Serum reactivity | Seq ID no: |
|-----------|-----------|-------------------|--|------------|--------------|-----------------------|------------|
| aureus | ORF | (by homology) | _ | lected | identified | with relevant re- | (DNA |
| antigenic | number | <u>.</u> | | clones per | immuno- | gion (positive/total) | +Pret) |
| protein | | | | ORF and | genic region | | i |
| F | | | | screen | | | |
| SaA0003 | ORF2963P | repC | 5-20, 37-44, 52-59, 87-94, 116-132 | C:3 | aa 112-189 | C:GSBYM94(112- | 171, 172 |
| | | | | | | 189):26/30 | |
| SaA0003 | ORF2967P | repC | 7-19, 46-57, 85-91, 110-117, 125- | C:18 | aa 9-42 | • | 150, 158 |
| | | , | 133, 140–149, 156–163, 198–204, | | aa 158-174 | 42):1/1 | |
| | | · | 236-251, 269-275, 283-290, 318- | | | | |
| | | | 323, 347–363 | | 00 100 | A CCD27 70/00 | 24.96 |
| 0093 | ORF1879 | SdrC | | A:1, D:5, | | A:GSBXL70(98- | 34, 86 |
| | | | 157, 173–180, 186–205, 215–226, | C:1, F:6, | aa 684-764 | 182):9/30 | |
| | | | 239-263, 269-274, 284-304, 317- | G:2 | aa 836-870 | D:n.d. | |
| | | - | 323, 329–336, 340–347, 360–366, | | | C:GSBYH73(815- | |
| | | | 372-379, 391-397, 399-406, 413- | | | 870):3/16 | |
| | 1 | | 425, 430–436, 444–455, 499–505, | | | , | |
| | ł | | 520-529, 553-568, 586-592, 600- | | 8.1 | | |
| | ł | | 617, 631–639, 664–678, 695–701, | | | | |
| | 0.001 | 017 | 891-903, 906-912, 926-940 | C-12 E-2 | 00 147-102 | C:GSBYH31(147- | 145 153 |
| 0095 | ORF1881 | SdrE | 25-45, 72-77, 147-155, 198-211, | C:12, E:2 | aa 147-132 | 192):2/14 | 143, 133 |
| | | | 217-223, 232-238, 246-261, 266- | | | E:GSBZA27(144- | |
| | | | 278, 281–294, 299–304, 332–340, | | | 162):23/41 | |
| | | | 353-360, 367-380, 384-396, 404- | | | 102).23/41 | |
| | | | 409, 418–429, 434–440, 448–460, | | | | |
| | 1 | | 465~476, 493~509, 517~523, 531~ | | | | |
| | į | | 540, 543–555, 561–566, 576–582, 584–591, 603–617, 633–643, 647– | 1 | | |] |
| | | | 1 | | | | |
| | | | 652, 668-674, 677-683, 696-704, | | | | |
| | | | 716-728, 744-752, 755-761, 789- | | | | |
| | | | 796, 809–815, 826–840, 854–862, | | | | |
| | | | 887-903, 918-924, 1110-1116, | | | | |
| 0123 | ORF1909 | unknown | 9-28, 43-48, 56-75, 109-126, 128- | B:3, E:7, | aa 168-181 | B:GSBXF80(168- | 35, 87 |
| V123 | Join 1909 | | 141, 143–162, 164–195, 197–216, | G:1 | | 181):5/27 | ' |
| |] |] | 234-242, 244-251 |] | 1 | E:GSBZC17(168- | ļ |
| | | | 20, 212, 211 === | | | 181):25/41 | |
| 0160 | ORF1941 | unknown | 4-10, 20-42, 50-86, 88-98, 102-171, | A:1 | aa 112-188 | A:GSBXO07(112- | 36, 88 |
| | | | 176-182, 189-221, 223-244, 246- | | | 188):5/30 | |
| | | | 268, 276-284, 296-329 | | | | |
| 0222 | ORF1988 | homology with | 4-9, 13-24, 26-34, 37-43, 45-51, | A:52, | aa 45-105 | A:GSBXM63(65- | 37, 89 |
| | | ORF1 | 59-73, 90-96, 99-113, 160-173, | C:18*, | aa 103-166 | 95):1/1 | |
| | | | 178-184, 218-228, 233-238, 255- | H:19 | aa 66-153 | A:GSBXM82(103- | |
| | | | 262 | | | 166):14/29 | |
| / | | | | | | A:GSBXK44- | |
| 17 | | | | | | bmd3(65 | |
| ·/ | | | | | | 153):47/51 | |
| 0308 | ORF2077 | Complement, un- | 13-27, 42-63, 107-191, 198-215, | A:6, B:2, | 1 | A:GSBXK03(bp473 | 38, 90 |
| | | known | 218-225, 233-250 | C:47, | bp 474-367 | 1 ' | |
| | | | | E:35 | | B:GSBXD29(bp465 | |
| | 1 | 1 | | 1 | 1 | -431):10/27 · | 1 |

| S. | Old | Putative function | predicted immunogenic aa** | No. of se- | Location of | Serum reactivity | Seq ID no: |
|----------|----------|---------------------|--|-------------|-----------------------|-----------------------|------------|
| aureus | ORF | (by homology) | | lected | identified | with relevant re- | (DNA |
| antigeni | number | | • | ciones per | immuno- | gion (positive/total) | +Prot) |
| protein | | , | | ORF and | genic region | | |
| | ľ | | | screen | | | |
| 0317 | ORF2088 | preprotein translo- | 16-29, 64-77, 87-93, 95-101, 127- | A:1 | aa 1-19 | A:GSBXP37(1- | 39, 91 |
| 1 | | case seca subunit | 143, 150-161, 204-221, 225-230, | | | 19):6/29 | |
| | | | 236-249, 263-269, 281-309, 311- | | | | |
| | | 1 | 325, 337-343, 411-418, 421-432, | | | | |
| | ļ | | 435-448, 461-467, 474-480, 483- | - | | | |
| | | | 489, 508-516, 542-550, 580-589, | | | | |
| | | | 602-611, 630-636, 658-672, 688- | | · | | |
| | | | 705, 717723, 738746, 775786, | | | | |
| | | | 800-805, 812-821, 828-834 | | | | |
| 0337 | ORF2110 | Hypothetical pro- | 26-53, 95-123, 164-176, 189-199 | D:12 | aa 8-48 | D:n.d. | 40, 92 |
| | | tein | | | 706 00 0 | , | |
| 0358 | ORF2132 | Clumping factor A | 8-35, 41-48, 59-66, 87-93, 139-144, | | aa 706-809 | D:n.d. | 41, 93 |
| | Ì | | 156-163, 198-209, 215-229, 236- | E :1 | · | | ĺ |
| 1 | | | 244, 246–273, 276–283, 285–326, | | | | • |
| 1./ | | | 328-342, 349-355, 362-370, 372- | | | | |
| | | | 384, 396–402, 405–415, 423–428, | | | | |
| 1 | | | 432-452, 458-465, 471-477, 484- | | | | |
| | | | 494, 502~515, 540~547, 554~559, | | | | |
| 0360 | ORF2135 | extracellular | 869-875, 893-898, 907-924 7-13, 15-23, 26-33, 68-81, 84-90, | A:46, | aa 22-56 | A:GSBXK24(23- | 42, 94 |
| 0300 | Empbp | matrix and plasma | 106-117, 129-137, 140-159, 165- | B:21, | aa 23-99 | 55):1/1 | 42, 54 |
| | Empop | binding protein | 172, 177–230, 234–240, 258–278, | , | aa 23 99 aa 97-115 | B:GSBXB43(39- | , |
| | | omaing protein | 295-319 | | aa 233–250 | 54):58/71 | |
| | İ | | 255-319 | H: 12 | aa 245-265 | A:GSBXK02- | |
| | | | | 11. 12. | aa 243 203 | bmd1(22-99):59/59 | |
| 1 | | , | | | | B:GSBXD82- | |
| | | | | | | bdb19(97-115):1/1 | |
| ŀ | | | | | | F;SALAL03(233~ | |
| | | | | | : | 250):15/41 | |
| 0453 | ORF2227 | coma operon | 17-25, 27-55, 84-90, 95-101, 115- | C:3 | aa 55-101 | C:GSBYG07(55- | 146, 154 |
| | | protein 2 | 121 | · | | 101):1/1 | - - |
| 0569 | ORF1640 | V8 protease | 5-32, 66-72, 87-98, 104-112, 116- | A:1, F:1 | aa 174–249 | A:GSBXS51(174- | 32, 84 |
| | 1 | | 124, 128–137, 162–168, 174–183, | | | 249):11/30 | |
| | | | 248-254, 261-266, 289-303, 312- | | | | |
| | <u> </u> | | 331 | | | | |

| Γ | S. | Old | Putative function | predicted immunogenic aa** | No. of se- | Location of | Serum reactivity | Seq ID no: |
|---|----------|-----------|-------------------|--|--------------|--------------|-----------------------|------------|
| I | aureus | ORF | (by homology) | | lected | identified | with relevant re- | (DNA |
| ١ | ntigenic | number | | • | clones per | immuno- | gion (positive/total) | +Prot) |
| ١ | protein | | | | ORF and | genic region | | i |
| ١ | • | | | | screen | | | |
| t |)576 | ORF1633 | autolysin, adhe- | 4-19, 57-70, 79-88, 126-132, 144- | A:21, | aa 6-66 | A:GSBXN93(6- | 31, 83 |
| l | | Autolysin | sion | 159, 161–167, 180–198, 200–212, | B:46, | aa 65-124 | 66):5/16 | |
| ١ | 1 | | | 233-240, 248-255, 276-286, 298- | C:55, E:5, | aa 579-592 | C:GSBYH05(45- | |
| 1 | | : | | 304, 309–323, 332–346, 357–366, | F:85, | aa 590-604 | 144):7/8 | |
| l | | | | 374-391, 394-406, 450-456, 466- | H :19 | | A:GSBXK66- | |
| ı | | | | 473, 479–487, 498–505, 507–519, | | | bmd18(65- | |
| ١ | | | | 521-530, 532-540, 555-565, 571- | | | 124):16/30 | |
| l | | | | 581, 600-611, 619-625, 634-642, | | : | B:GSBXB89(108- | |
| ١ | | | | 650-656, 658-665, 676-682, 690- | | | 123):1/1 | |
| l | | | · | 699, 724–733, 740–771, 774–784, | | | B:GSBXB02(590- | |
| ١ | | | | 791-797, 808-815, 821-828, 832- | | | 603):39/71 | |
| 1 | | | | 838, 876–881, 893–906, 922–929, | | | F:SALAM15(579- | |
| 1 | | | | 938-943, 948-953, 969-976, 1002- | | | 592):25/41 | |
| ١ | | | | 1008, 1015–1035, 1056–1069, 1105– | | | | |
| ١ | | | | 1116, 1124-1135, 1144-1151, 1173- | | | | |
| ١ | | | | 1181, 1186-1191, 1206-1215, 1225- | | | | |
| L | | | • | 1230, 1235–1242 | | | | |
| I | 0657 | ORF un- | LPXTGVI protein | 9-33, 56-62, 75-84, 99-105, 122- | | aa 527-544 | B:GSBXE07- | 1, 142 |
| ۱ | | known | · | 127, 163–180, 186–192, 206–228, | F:15 | | bdb1(527- | |
| ١ | | | | 233-240, 254-262, 275-283, 289- | | | 542):11/71 | |
| ١ | | | | 296, 322–330, 348–355, 416–424, | | | F:SALAX70(526- | |
| ۱ | | | | 426-438, 441-452, 484-491, 541- | | | 544):11/41 | |
| ŀ | 0740 | ODELACO | 0.11 | 549, 563-569, 578-584, 624-641 | C:2 | aa 630-700 | C:GSBYK17(630- | 144, 152 |
| ı | 0749 | ORF1462 | 1 - 1 | 8-23, 31-38, 42-49, 61-77, 83-90, | 1 | aa 030-700 | 700):5/9 | 144, 132 |
| 1 | | | phate synthase | 99-108, 110-119, 140-147, 149-155, | | | 100).3/9 | |
| 1 | | | | 159-171, 180-185, 189-209, 228- | 1 | | | |
| 1 | | | | 234, 245–262, 264–275, 280–302, 304–330, 343–360, 391–409, 432– | | | | |
| | | • | | 437, 454–463, 467–474, 478–485, | | | | |
| | | | ŀ | | | | | |
| ١ | | | | 515-528, 532-539, 553-567, 569- | | | | |
| | | | | 581, 586–592, 605–612, 627–635, 639–656, 671–682, 700–714, 731– | | | | |
| | | | | 747, 754–770, 775–791, 797–834, | | | | |
| | | | | 838-848, 872-891, 927-933, 935- | | | | |
| | | | | 942, 948–968, 976–986, 1000–1007, | 1 | | | |
| ı | | | | 1029-1037 | | | | |
| | 944 | ORF1414 | Yfix | 6-33, 40-46, 51-59, 61-77, 84-104, | D:4 | aa 483-511 | D :n.d. | 30, 82 |
| | - • • | 1 | - | 112-118, 124-187, 194-248, 252- | | | | |
| | | | | 296, 308–325, 327–361, 367–393, | | | | |
| | | | 1 | 396-437, 452-479, 484-520, 535- | | | | |
| | | |] | 545, 558-574, 582-614, 627-633, | | | | |
| | | | | 656-663, 671-678, 698-704, 713- | | | | |
| | | | | 722, 725-742, 744-755, 770-784, | ļ | | | |
| | | | | 786-800, 816-822, 827-837 | | | | |
| | 1050 | ORF1307 | unknown | 49-72, 76-83, 95-105, 135-146, | A:1, H:45 | aa 57-128 | A:GSBXM26(57- | 28, 80 |
| | | | | 148-164, 183-205 | <u>L</u> | <u></u> | 128):7/30 | |

| S. | Old | Putative function | predicted immunogenic aa** | No. of se- | Location of | Serum reactivity | Seq ID no: |
|---------|-----------|-------------------|--|------------|--------------|---------------------------------------|------------|
| aureus | ORF | (by homology) | | lected | identified | with relevant re- | (DNA |
| antigen | le number | | | clones per | immuno- | gion (positive/total) | +Prot) |
| proteir | , | | | ORF and | genic region | · | |
| 1 | | | ļ. | screen | | | |
| 1209 | ORF3006 | hemN homolog | 12-36, 43-50, 58-65, 73-78, 80-87, | B:7, F:8 | aa 167-181 | B:GSBXB76(167- | 54, 106 |
| | | | 108-139, 147-153, 159-172, 190- | | | 179):25/71 | |
| | | | 203, 211–216, 224–232, 234–246, | | | F:SALBC54(169- | |
| 1 | | | 256-261, 273-279, 286-293, 299- | | | 183):18/41 | |
| 1344 | ORF0212 | NifS protein | 306, 340-346, 354-366 8-16, 22-35, 49-58, 70-77, 101-121, | Δ-11 | aa 34-94 | A:GSBXK59- | 5, 141 |
| 1344 | OKI-0212 | homolog | 123-132, 147-161, 163-192, 203- | 1 | uu 54 74 | bmd21(34-94):6/29 | 5, 141 |
| | | lioniolog | 209, 216-234, 238-249, 268-274, | | | 0.12.02.1(0.1.7.1).01.22 | |
| | | | 280-293, 298-318, 328-333, 339- | | | | |
| 1 | | | 345, 355–361, 372–381 | | | | |
| 1356 | ORF0197 | Hypothetical pro- | 28-55, 82-100, 105-111, 125-131, | D:12 | aa 1-49 | D:n.d. | 4, 57 |
| <u></u> | | tease | 137-143 | | | | |
| 1361 | ORF0190 | LPXTGV protein | 5-39, 111-117, 125-132, 134-141, | A:1, B:23, | l | B:GSBXF81(37- | 3, 56 |
| | | | 167-191, 196-202, 214-232, 236- | E:3, F:31 | ва 63-77 | 49):1/1 | |
| | | | 241, 244–249, 292–297, 319–328, | | aa 274-334 | B:GSBXD45- | |
| 1 | | | 336-341, 365-380, 385-391, 407- | | | bdb4(62-77):12/70 | |
| | | | 416, 420–429, 435–441, 452–461, 477–488, 491–498, 518–532, 545– | | | A:GSBXL77(274- 334):5/30 | |
| 1 | | | 556, 569-576, 581-587, 595-602, | | | F:SALAP81(62- | |
| | | | 604-609, 617-640, 643-651, 702- | | | 77):10/41 \ | |
| | | | 715, 723-731, 786-793, 805-811, | | | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | |
| | | | 826-839, 874-889 | | | | |
| 1371 | ORF0175 | YtpT, conserved | 37-42, 57-62, 121-135, 139-145, | C:3, E:2, | aa 624-684 | C:GSBYG95(624- | 143, 151 |
| 1 | | hypothetical pro- | 183-190, 204-212, 220-227, 242- | G:1 | aa 891-905 | 684):7/22 | |
| 1 | | tein | 248, 278–288, 295–30, 304–309, | 1 | | E:GSBZB45(891- | |
| | | | 335-341, 396-404, 412-433, 443- | | | 905):10/41 | |
| 1 | | | 449, 497–503, 505–513, 539–545, | 1 | | | |
| | | | 552-558, 601-617, 629-649, 702- | | | | |
| 1 | | | 711, 736–745, 793–804, 814–829, | <u> </u> | | | |
| - [| | | 843-858, 864-885, 889-895, 905- 913, 919-929, 937-943, 957-965, | | | | 1 |
| | | | 970-986, 990-1030, 1038-1049, | | • | | |
| | | - | 1063-1072, 1080-1091, 1093-1116, | | | | |
| d | , | | 1126-1136, 1145-1157, 1163-1171, | | | | |
| l | | | 1177-1183, 1189-1196, 1211-1218, | | | | |
| 1 | | | 1225-1235, 1242-1256, 1261-1269 | | | | |
| 1491 | ORF0053 | Cmp binding fac- | 12-29, 34-40, 63-71, 101-110, 114- | A:7, C:2, | aa 39-94 | A:GSBXM13(39- | 2, 55 |
| | | tor 1 homolog | 122, 130-138, 140-195, 197-209, | E:7, F:4 | [| 94):10/29 | 1 |
| - | | | 215-229, 239-253, 255-274 | | | F:SALAY30(39- | |
| 1616 | IODE1100 | leukocidin F ho- | 16-24 20 20 42 40 64 51 02 00 | A.10 | aa 158-220 | 53):4/41 A:GSBXK06(158- | 27, 79 |
| 1616 | ORF1180 | ĺ | 16-24, 32-39, 43-49, 64-71, 93-99, 126-141, 144-156, 210-218, 226- | A:10 | | A:GSBXK06(158- 220):8/29 | 21, 17 |
| | | molog | 233, 265–273, 276–284 | | 1 | J.0167 | |
| 1618 | ORF1178 | LukM homolog | 5-24, 88-94, 102-113, 132-143, | A:13, B:3 | aa 31-61 | A:GSBXK60(31- | 26, 78 |
| | | | 163-173, 216-224, 254-269, 273- | 1 | aa 58-74 | 61):20/29 | |
| 1 | | | 278, 305-313, 321-327, 334-341 | F:12, G:2, | 1 | B:GSBXB48(58- | 1 |
| | | | | H:10 | | 74):49/71 | |
| | | | | | | F:SALAY41(58- | |
| | | | | | <u> </u> | 74):30/41 | |

| S. | Old | Putative function | predicted immunogenic aa** | No. of se- | Location of | Serum reactivity | Seq ID no: |
|-----------|----------|-------------------|------------------------------------|------------|--------------|---|------------|
| aureus | ORF | (by komology) | | lected | identified | with relevant re- | (DNA |
| antigenic | number | | | clones per | immuno- | gion (positive/total) | +Prot) |
| protein | | | · | ORF and | genic region | | |
| | | | | screen | | · | |
| 1632 | ORF1163 | SdrH homolog | 7-35, 54-59, 247-261, 263-272, | B:6, E:11, | aa 105-119 | B:GSBXG53(168- | 25, 77 |
| | | | 302-320, 330-339, 368-374, 382- | F:34 | aa 126-143 | 186):39/71 | · |
| | | | 411 | | aa 168–186 | F:SALAP07(105 | |
| | | | | | | 119):11/41 | |
| 1763 | ORF1024 | unknown | 5-32, 35-48, 55-76 | C:3 | - | C;GSBYI30(98aa):1 | 24, 76 |
| <u> </u> | | | | D 5 E 0 | bp 237-170 | /1 | 02.75 |
| 1845 | ORF0942 | Hyaluronate lyase | 10-26, 31-44, 60-66, 99-104, 146- | D:5, F:2 | aa208-224 | D;n.d. | 23, 75 |
| | | | 153, 163–169, 197–205, 216–223, | | aa 672-727 | | |
| | | | 226-238, 241-258, 271-280, 295- | | : | | |
| | | | 315, 346–351, 371–385, 396–407, | | | | |
| . | | | 440-446, 452-457, 460-466, 492- | | | | |
|]] | | | 510, 537-543, 546-551, 565-582, | | | | |
| | | ` | 590-595, 635-650, 672-678, 686- | | | | |
| | | | 701, 705–712, 714–721, 725–731, | | | | |
| | | | 762-768, 800-805 | 1.000 | . 100 000 | D CODY CO3(100 | 00.74 |
| 1951 | ORF0831 | homology with | 5-22, 42-50, 74-81, 139-145, 167- | A:223, | l | B:GSBXC07(180- | 22, 74 |
| | | ORF1 | 178, 220–230, 246–253, 255–264 | B:56, | aa 250-267 | 190):1/1 | |
| | | | | C:167, | | A:GSBXK29(177- | |
| 1 | | | , | E:43, | | 195):15/29 | |
| | | | | F:100, | | B:GSBXD43(250- | |
| | | | | G:13, | | 267):10/71 | 1 |
| | | | | H:102 | | F:SALAM13(178- | |
| | | | | 11.00 | 20.50 | 191):20/41 | 01.72 |
| 1955 | ORF0826 | homology with | 4-9, 15-26, 65-76, 108-115, 119- | A:1, B:3, | aa 38-52 | A:GSBXR10(66- | 21, 73 |
| 1 | : | ORFI | 128, 144–153 | E:1, F:8 | aa 66-114 | 114):5/30 | } |
| | | | | | | F:SALAM67(37- | |
| 2031 | ORF0749 | unknown | 10-26, 31-43, 46-58, 61-66, 69-79, | B:2, F:2 | aa 5974 | 52):16/41 B:GSBXC01(59- | 20, 72 |
| 2031 | OK1-0749 | HIKHOWH | 85-92, 100-115, 120-126, 128-135, | D.2, 1 .2 | uu 32 /4 | 71):11/26 | 20, 72 |
| | | | 149–155, 167–173, 178–187, 189– | | | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | |
| | | | 196, 202–222, 225–231, 233–240, | | | , | |
| 1 1 | | | 245-251, 257-263, 271-292, 314- | | | | |
| | | | 322, 325–334, 339–345 | | 1 | | |
| 2086 | ORF0691 | IgG binding | 6-20, 53-63, 83-90, 135-146, 195- | A:1, B:8, | aa 208-287 | A:GSBXS55(208- | 19, 71 |
| ľl | Sbi | protein | 208, 244–259, 263–314, 319–327, | E:24, F:9, | l . | 287):38/46 | [|
| } | ~~. | F | 337-349, 353-362, 365-374, 380- | G:137 | B . | B:GSBXB34(299- | 1 |
| | | | 390, 397-405, 407-415 | | | 314)::11/71 | |
| 1 1 | | | 100, 107 110 | | İ | F:SALAX32(261- | |
| | | | | | | 276):21/41 | |

| S. | Old | Putative function | predicted immunogenic na** | No. of se- | Location of | Serum reactivity | Seq ID no: |
|-----------|---------|-------------------|--|------------|--------------|--------------------------|------------|
| aureus | ORF | (by homology) | | lected | identified | with relevant re- | (DNA |
| antigenic | number | | | clones per | immuno- | gion (positive/total) | +Prot) |
| protein | | , | | ORF and | genic region | | |
| · . | | | | screen | | | |
| 2180 | ORF0594 | LPXTGIV protein | 11-20, 26-47, 69-75, 84-92, 102- | A:3, C:3, | aa 493-587 | A:GSBXS61(493- | 18, 70 |
| | | | 109, 119-136, 139-147, 160-170, | E:6, F:2, | aa 633-715 | 555):1/1 | |
| | | | 178-185, 190-196, 208-215, 225- | H: 6 | aa 704-760# | A:GSBXL64(496- | |
| | | | 233, 245–250, 265–272, 277–284, | | aa 760832 | 585):1/1 | |
| | | | 300-306, 346-357, 373-379, 384- | | (na 832- | A:GSBXS92(760- | |
| | | • | 390, 429-435, 471-481, 502-507, | | 887)" | 841):1/1 . | |
| | | | 536-561, 663-688, 791-816, 905- | | ŕ | A:bmd4(704- | |
| | | | 910, 919–933, 977–985, 1001–1010, | | | 760):16/30 [#] | |
| | | | 1052–1057, 1070–1077, 1082–1087, | | | (A:bmd4(830- | |
| | | | 1094–1112 | | | 885):16/30) [#] | |
| | | | | البسنة | | F:SALBC43(519- | |
| | | | | | | 533):4/41 | |
| 2184 | ORF0590 | FnbpB | 5-12, 18-37, 104-124, 139-145, | A:2, C:4, | aa 701-777 | A:GSBXM62(702- | 17, 69 |
| | | | 154-166, 175-181, 185-190, 193- | G:9 | aa 783822 | 777):28/28 | |
| | | | 199, 203-209, 235-244, 268-274, | | | A:GSBXR22(783- · | |
| | | | 278–292, 299–307, 309–320, 356– | | | 855):1/1 | |
| | | | 364, 375–384, 390–404, 430–440, | | | | |
| | | | 450-461, 488-495, 505-511, 527- | | | | |
| | | | 535, 551–556, 567–573, 587–593, | | | | |
| | | | 599-609, 624-631, 651-656, 665- | | | | |
| | | | 671, 714~726, 754–766, 799–804, | | | | |
| | | ٠ | 818-825, 827-833, 841-847, 855- | | | | |
| 2196 | ODEOGO | T-t- | 861, 876-893, 895-903, 927-940 | 44 64 | 710, 707 | C. CCDVDYOSCOIO | 16.69 |
| 2186 | ORF0588 | Fnbp | 8-29, 96-105, 114-121, 123-129, | A:4, C:4, | | C:GSBYN05(710- | 16, 68 |
| | | , | 141-147, 151-165, 171-183, 198- | D:5, E:2 | aa 855-975 | 787):19/25 D:n.d. | |
| | | | 206, 222~232, 253~265, 267~277, 294~300, 302~312, 332~338, 362~ | | aa 916-983 | A:GSBXP01(916- | |
| | | | 368, 377-383, 396-402, 410-416, | | | 983):17/30 | |
| | | | 451-459, 473-489, 497-503, 537- | | | 903 3.1 7/30 | |
| | · | | 543, 549~559, 581~600, 623~629, | | | | |
| | | | 643-649, 655-666, 680-687, 694- | | | | |
| | | | 700, 707-712, 721-727, 770-782, | | | | |
| | | | 810-822, 874-881, 883-889, 897- | 1 | | | |
| | | | 903, 911-917, 925-931, 933-939, | | | | |
| ĺĺĺ | | | 946-963, 965-973, 997-1010 | 1 | | | |
| 2224 | ORF0551 | unknown | 49-56, 62-68, 83-89, 92-98, 109- | B:2 | aa 34-46 | B:GSBXD89(34- | 15, 67 |
| 1 | | | 115, 124-131, 142-159, 161-167, | | | 46):1/1 | |
| | | | 169-175, 177-188, 196-224, 230- | | , | | |
| | | | 243, 246–252 | <u></u> | | | |

| S. | Old | Putative function | predicted immunogenic aa** | No. of se- | Location of | Serum reactivity | Seq ID no: |
|-----------|---------|--------------------|---|------------|--------------|-----------------------|------------|
| aureus | ORF | (by homology) | | lected | identified | with relevant re- | (DNA |
| antigenic | number | | | clones per | immuno- | gion (positive/total) | +Prot) |
| protein | | | | ORF and | genic region | | |
| | | | | screen | | | |
| 2254 | ORF0519 | Conserved hypo- | 14-22, 32-40, 52-58, 61-77, 81-93, | D:3 | aa 403-462 | D.n.d. | 14, 66 |
| | | thetical protein | 111-117, 124-138, 151-190, 193- | | | | |
| | | | 214, 224–244, 253–277, 287–295, | | | | |
| | | | 307324, 326332, 348355, 357- | | | | |
| | | | 362, 384–394, 397–434, 437–460, | | ļ ' | | |
| | | | 489-496, 503-510, 516-522, 528- | | | | |
| | | | 539, 541-547, 552-558, 563-573, | | | | |
| | , | | 589-595, 602-624, 626-632, 651- | | | | |
| , | | | 667, 673–689, 694–706, 712–739, | | | | |
| 2264 | ORF0509 | ORF1; homology | 756–790 5–31, 47–55, 99–104, 133–139, 156– | A-121 | aa 7–87 | À:GSBXP22(145- | 13, 65 |
| 2204 | ORP0309 | with putative se- | 172, 214–224, 240–247 | B:51, | aa 133-242 | 196):1/1 | 15,05 |
| | | creted antigen | 172, 214-224, 240-247 | C:13, | aa 133-242 | A:GSBXK05- | |
| | | precursor from S. | | E:43, | | bmd16(178~ | |
| | | epidermidis | | F:78, G:2, | | 218):6/29 | |
| | | cpracrimais | | H:17 | | B:GSBXE24- | |
| | | | | | | bdb20(167-178):1/1 | |
| | | | | | | F:SALAQ91(173- | |
| | | | | | | 184):15/41 | |
| 2268 | ORF0503 | IsaA, possibly ad- | 7-19, 26-45, 60-68, 94-100, 111- | A:7, B:65, | aa 67-116 | A:GSBXK88(67- | 12, 64 |
| | | hesion/aggrega- | 119, 126–137, 143–148, 169–181, | C:3, E:2, | aa 98-184 | 116):1/1 | |
| | | tion | 217–228 | F:53 | aa 182-225 | A:GSBXN19(98- | |
| | | | | | | 184):22/29 | |
| | | | 1 | | | A:GSBXN32(182- | |
| | | | | | | 225):34/71 | |
| | | | | } | | B:GSBXB71(196- | |
| | | | ` | | | 209):16/29 | |
| | | | , | | | F:SALAL22(196- | |
| 2344 | ORF0426 | Clumping foster D | 4-10, 17-45, 120-127, 135-141, | D:9, E:1, | aa 706-762 | 210):16/41 D:n.d. | 11, 63 |
| 2344 | ORF0420 | Ciumping factor B | 168-180, 187-208, 216-224, 244- | F:3, H: 4 | aa 810-852 | D.II.d. | 11,03 |
| | | | 254, 256–264, 290–312, 322–330, | 1.3, 11. 4 | aa 610 652 | 1,7 | |
| | | | 356-366, 374-384, 391-414, 421- | · . | | | |
| | | | 428, 430-437, 442-449, 455-461, | | | | |
| | | | 464-479, 483-492, 501-512, 548- | | | j | |
| | | 1 | 555, 862–868, 871–876, 891–904 | | | | |
| 2351 | ORF0418 | aureolysin | 10-29, 46-56, 63-74, 83-105, 107- | A:1, C: 6 | aa 83-156 | A:GSBXO46(83- | 10, 62 |
| | | | 114, 138–145, 170–184, 186–193, | | | 156):14/29 | |
| | | | 216-221, 242-248, 277-289, 303- | | | | |
| | | | 311, 346-360, 379-389, 422-428, | ł | | | |
| | | <u> </u> | 446-453, 459-469, 479-489, 496- | l | | | |
| | | 1 | 501 | 1 . | | | İ |

| S. | Old | Putative function | predicted immunogenic aa** | No. of se- | Location of | Serum reactivity | Seq ID no: |
|-----------|----------|--------------------|--|------------------------|--------------|-----------------------------|------------|
| aureus | ORF | (by homology) | | lected | identified | with relevant re- | (DNA |
| antigenic | number | · | | clones per | immuno- | gion (positive/total) | +Prot) |
| protein | | | | ORF and | genic region | | |
| | | | | screen | | | |
| 2359 | ORF0409 | ISSP, immuno- | 4-29, 92-99, 119-130, 228-236, | B:4, F:11 | | , | 9,61 |
| | | genic secreted | 264-269, 271-280, 311-317, 321- | | aa 206-220 | 184):1/1 | |
| | | protein precursor, | 331, 341-353, 357-363, 366-372, | | aa 297-309 | B:GSBXD62(205- | |
| | | putative | 377–384, 390–396, 409–415, 440– | | | 220):1/1 | |
| | | | 448, 458–470, 504–520, 544–563, | | | B:GSBXC17(297- | |
| | | | 568-581, 584-592, 594-603, 610- | | | 309):6/27 | |
| | | | 616 | | | F:SALAL04(205- | |
| | | | 10.02.40.55.60.57.85.00.120 | C.I. D.Z | aa 198-258 | 220):9/41 C:GSBYI73(646- | 8, 60 |
| 2378 | ORF0398 | SrpA | 18-23, 42-55, 69-77, 85-98, 129- | C:1, D:7, F:4, H:11 | | 727): 2/9 | 8,00 |
| | | | 136, 182–188, 214–220, 229–235, | F:4, II:11 | aa 846-857 | F:SALAO33(846- | |
| | | | 242-248, 251-258, 281-292, 309- 316, 333-343, 348-354, 361-367, | | aa 2104~ | 857):10/41 | · |
| | ŀ | | ! | | 2206 | D:n.d. | |
| | | | 393-407, 441-447, 481-488, 493- | | 2200 | D.n.u. | |
| | | | 505, 510-515, 517-527, 530-535, | [| | | |
| | | | 540-549, 564-583, 593-599, 608- 621, 636-645, 656-670, 674-687, | | | | |
| | | | 697-708, 726-734, 755-760, 765- | | | | |
| | ľ | | 772, 785–792, 798–815, 819–824, | | | | |
| | | | 826-838, 846-852, 889-904, 907- | | | | |
| | [| | 913, 932-939, 956-964, 982-1000, | | | | 1 |
| 1 | | | 1008-1015, 1017-1024, 1028-1034, | | | | |
| | | | 1059-1065, 1078-1084, 1122-1129, | | | | |
| | | | 1134-1143, 1180-1186, 1188-1194, | 1 | | | |
| | | | 1205-1215, 1224-1230, 1276-1283, | | | | |
| | | | 1333–1339, 1377–1382, 1415–1421, | İ | | | |
| 1 | | | 1448-1459, 1467-1472, 1537-1545, | | | | 1 |
| | | | 1556-1566, 1647-1654, 1666-1675, | | | | |
| | | | 1683-1689, 1722-1737, 1740-1754, | | | | |
| | | | 1756-1762, 1764-1773, 1775-1783, | | | | |
| | | 1 | 1800-1809, 1811-1819, 1839-1851, | | | | |
| | | | 1859-1866, 1876-1882, 1930-1939, | | | | 1 |
| | | | 1947-1954, 1978-1985, 1999-2007, | | | | ļ |
| 1 | l . | | 2015-2029, 2080-2086, 2094-2100, | | | | |
| | 1 | | 2112-2118, 2196-2205, 2232-2243 | | <u> </u> | | |
| 2466 | ORF0302 | YycH protein | 16-38, 71-77, 87-94, 105-112, 124- | D:14 | aa 401-494 | D:n.d. | 7, 59 |
| · | | | 144, 158–164, 169–177, 180–186, | | | | |
| | ŀ | - | 194–204, 221–228, 236–245, 250– | | | | |
| | | | 267, 336–343, 363–378, 385–394, | ĺ | | | |
| | lon mare | | 406-412, 423-440, 443-449 | C:1 | aa 414-455 | C:GSBYH60(414- | 169,170 |
| 2470 | ORF0299 | Conserved hypo- | 4-9, 17-41, 50-56, 63-69, 82-87, | C:3 | da 414-433 | 455):28/31 | 109,170 |
| | | thetical protein | 108-115, 145-151, 207-214, 244- | | | 7337.20131 | |
| | | | 249, 284–290, 308–316, 323–338, | 1 | | 1. | |
| | | | 348-358, 361-378, 410-419, 445- | | | | |
| | | | 451, 512–522, 527–533, 540–546, | | | | |
| | 1 | • | 553-558, 561-575, 601-608, 632- | | | | |
| ŀ | | | 644, 656–667, 701–713, 727–733, | | | | |
| 1 | 1 | | 766-780 | | | <u> </u> | |

| S. | Old | Putative function | predicted immunogenic aa** | No. of se- | Location of | Serum reactivity | Seq ID no: |
|-----------|----------|--------------------------------------|--|------------|--------------|-------------------------|------------|
| aureus | ORF | (by homology) | | lected | identified | with relevant re- | (DNA |
| antigenic | number | (=, | | clones per | immuno- | gion (positive/total) | +Prot) |
| protein | Humber | | | ORF and | genic region | , | |
| protess | | | | screen | goine region | | |
| 2498 | ORF0267 | Conserved hypo- | 33-43, 45-51, 57-63, 65-72, 80-96, | D:12 | aa 358-411 | D:17/21 | 6, 58 |
| | | thetical protein | 99-110, 123-129, 161-171, 173-179, | | aa 588-606 | | |
| | | | 185-191, 193-200, 208-224, 227- | } | | | |
| | | | 246, 252–258, 294–308, 321–329, | | | | |
| | | | 344-352, 691-707 | | | | |
| 2548 | ORF2711 | IgG binding | 4-16, 24-57, 65-73, 85-91, 95-102, | A:55, | aa 1-48 | A:GSBXK68(1 | 53, 105 |
| | | protein A | 125-132, 146-152, 156-163, 184- | B:54, | aa 47-143 | 73):21/30 | |
| | | | 190, 204–210, 214–221, 242–252, | C:35, | aa 219-285 | A;GSBXK41(47- | |
| | | | 262-268, 272-279, 300-311, 320- | F:59, | aa 345-424 | 135):1/1 | |
| | , | , · | 337, 433-440, 472-480, 505-523 | G:56, | | A:GSBXN38(219- | |
| | | | • | H:38 | | 285):19/30 | |
| l i | | | | İ | | A:GSBXL11(322- | |
| | | | | | • | 375):10/30 | |
| | | | | | | B:GSBXB22(406- | |
| | | | | | | 418):37/71 | |
| | | | | | | F:SALAM17(406 | |
| | | | | | | 418):29/41 | |
| 2577 | ORF2683 | Hypothetical pro- | 4-21, 49-56, 65-74, 95-112, 202- | C:6 | aa 99-171 | C:GSBYL56(99- | 149, 157 |
| | | tein | 208, 214–235 | | | 171):1/1 | |
| 2642 | ORF2614 | unknown | 34-58, 63-69, 74-86, 92-101, 130- | C:1, E:1 | aa 5-48 | C:bhe3(5- | 52, 104 |
| | | | 138, 142–150, 158–191, 199–207, | | } | 48):25/30 ^{##} | |
| 3664 | ORF2593 | Conserved hypo- | 210-221, 234-249, 252-271 7-37, 56-71, 74-150, 155-162, 183- | D:35 | aa 77-128 | D:n.đ. | 51, 103 |
| 2664 | OKF2593 | 1 | 203, 211–222, 224–234, 242–272 | D.33 | ad 11-120 | D.II.U. | 31, 103 |
| 2670 | ORF2588 | thetical protein Hexose transporter | | D:16 | aa 328-394 | D:n.d. | 50, 102 |
| 150,0 | 014 -000 | | 102-153, 180-195, 198-218, 254- | | | | |
| | | | 280, 284-296, 301-325, 327-348, | | | | |
| | ļ |] | 353-390, 397-402, 407-414, 431- | | | | |
| | | | 455 | | | | |
| 2680 | ORF2577 | Coagulase · | 4-18, 25-31, 35-40, 53-69, 89-102, | C:26, G:4, | aa 438-516 | C:GSBYH16(438- | 148, 156 |
| | | | 147-154, 159-165, 185-202, 215- | H:8 | aa 505-570 | 516):3/5 | |
| | | | 223, 284-289, 315-322, 350-363, | 1 | aa 569-619 | C:GSBYG24(505- | |
| | | | 384-392, 447-453, 473-479, 517- | l. | | 570):1/7 | ' |
| | | | 523, 544-550, 572-577, 598-604, | | ' | C:GSBYL82(569- | |
| 1 | | | 617–623 | <u> </u> | | 619):2/7 | |
| 2740 | ORF2515 | Hypothetical pro- | 5-44, 47-55, 62-68, 70-78, 93-100, | D:4 | aa 1-59 | D:n.d. | 49, 101 |
| | | tein | 128-151, 166-171, 176-308 | 1 77 12 | 12.62.125 | 1.00DX04046 | 40 100 |
| 2746 | ORF2507 | homology with | 5-12, 15-20, 43-49, 94-106, 110- | A:1, H:13 | aa 63-126 | A:GSBXO40(66- | 48, 100 |
| | | ORFI | 116, 119–128, 153–163, 175–180, | | | 123):8/29 | |
| | 1 | | 185-191, 198-209, 244-252, 254- | | | | |
| 0702 | ORF2470 | unknown | 264, 266–273, 280–288, 290–297 10–27, 37–56, 64–99, 106–119, 121– | B:3, E:2, | aa 183-200 | B:GSBXE85(183- | 47, 99 |
| 2797 | UKF24/0 | unknown | 136, 139–145, 148–178, 190–216, | F:13, H:3 | aa 349-363 | 200):11/27 | ", " |
| | | | 225-249, 251-276, 292-297, 312- | 1, 1 | ua 5-75 505 | F:SALAQ47(183- | |
| | | | · · | 1 | | 200):8/41 | |
| | | <u></u> | 321, 332–399, 403–458 | L | .L | 200).0/41 | |

| S. | Öld | Putative function | predicted immunogenic aa** | No. of se- | Location of | Serum reactivity | Seq ID no: |
|-----------|---------|-------------------|---|------------|--------------|-----------------------|------------|
| aureus | ORF | (by homology) | | lected | identified | with relevant re- | (DNA |
| antigenie | number | | | clones per | immuno- | gion (positive/total) | +Prot) |
| protein | | | | ORF and | genic region | | |
| • | | | | screen | | | |
| 2798 | ORF2469 | Lipase (geh) | 12-35, 93-99, 166-179, 217-227, | A:41, | aa 48-136 | C:GSBYG01(48- | 46, 98 |
| | | | 239–248, 269–276, 288–294, 296– | B:42, C:3, | aa 128-172 | 136):2/6 | |
| | | | 320, 322–327, 334–339, 344–356, | F:35, G:1, | aa 201-258 | A:GSBXM31- | |
| | | | 362-371, 375-384, 404-411, 433- | H:11 | | bmd12(128- | |
| | | | 438, 443-448, 455-464, 480-486, | | | 188):11/30 | |
| | | | 497-503, 516-525, 535-541, 561- | ł | | B:GSBXE16(165- | |
| | | | 570, 579-585, 603-622, 633-641 | 1 | | 177):10/30 | |
| | | | | | | A:GSBXN20(201- | |
| | | | | | | 258):8/30 | |
| [| | | | | | F:SALAW05(165- | |
| | | | • | | | 177):13/41 | |
| 2815 | ORF2451 | Conserved hypo- | 5-32, 34-49 | D:21 | aa 1-43 | D:n.d. | 45, 97 |
| | | thetical protein | | | | | |
| 2914 | ORF2351 | metC | 39-44, 46-80, 92-98, 105-113, 118- | | aa 386-402 | A:GSBXM18(386- | 44,96 |
| | | | 123, 133–165, 176–208, 226–238, | F:2 | | 402):17/29 | |
| | | | 240-255, 279-285, 298-330, 338- | İ | ļ | | |
| | |] | 345, 350-357, 365-372, 397-402, | | | | |
| " | | | 409-415, 465-473, 488-515, 517- | ٠. | | | |
| | | | 535, 542-550, 554-590, 593-601, | | | | |
| | | | 603-620, 627-653, 660-665, 674- | | Ì | | |
| | | | 687, 698–718, 726–739 | | | | 10.05 |
| 2960 | ORF2298 | putative Exotoxin | 13-36, 40-49, 111-118, 134-140, | C:101, | aa 1-85 | C:GSBYG32(1- | 43, 95 |
| | | | 159-164, 173-183, 208-220, 232- | E:2, H:58 | aa 54-121 | 85)::6/7 | |
| | t | | 241, 245–254, 262–271, 280–286, | | aa 103-195 | C:GSBYG61- | |
| | | İ | 295-301, 303-310, 319-324, 332- | | | bhe2(54-121):26/30 | |
| | Ta ! | İ | 339 | | | C:GSBYN80(103- | |
| | | | 10.00.10.16.60.05.06.00.114 | G2 E2 | 00 100 | 195):13/17 | 147, 155 |
| 2963 | ORF2295 | putative Exotoxin | 13-28, 40-46, 69-75, 86-92, 114- | C:3, E:3, | aa 22-100 | C:GSBYJ58(22- | 147, 155 |
| | | | 120, 126–137, 155–172, 182–193, | G:1 | | 100):9/15 | |
| | | | 199-206, 213-221, 232-238, 243- | l | | L) | |
| 2000 | ORF1704 | homology with | 253, 270-276, 284-290 4-21, 28-40, 45-52, 59-71, 92-107, | A:2, C:1, | aa 21-118 | A:GSBXL06(21- | 33, 85 |
| 3002 | OKF1704 | 1 " | | H:4 | 44 21-110 | 118):50/52 | 55, 65 |
| 1 | | ORF1 , | 123-137, 159-174, 190-202, 220- | 111.4 | | 110).30/32 | |
| 1 | | | 229, 232–241, 282–296, 302–308, | 1 | | | |
| L | l | 1 | 312-331 | 1 | | <u> </u> | <u></u> |

| S. | Old | Putative function | predicted immunogenic aa** | No. of se- | Location of | Serum reactivity | Seq ID no: |
|-----------|---------|--------------------|---|------------|--------------|-----------------------|------------|
| aureus | ORF | (by homology) | | lected | identified | with relevant re- | (DNA |
| antigenic | number | | | clones per | immuno— | gion (positive/total) | +Prot) |
| protein | | | | ORF and | genic region | | |
| | | | | screen | | | |
| 3200 | ORF1331 | putative extracel- | 6-15, 22-32, 58-73, 82-88, 97-109, | A:11, | aa 5-134 | A:GSBXL07(5- | 29, 81 |
| | | lular matrix bind- | 120-131, 134-140, 151-163, 179- | B:11, | | 134):6/28 | |
| | | ing protein | 185, 219–230, 242–255, 271–277, | C:36 | | | |
| | | | 288-293, 305-319, 345-356, 368- | | | | |
| | | | 381, 397-406, 408-420, 427-437, | | | | |
| | | | 448-454, 473-482, 498-505, 529- | | | | |
| | | | 535, 550–563, 573–580, 582–590, | | | | |
| | | | 600-605, 618-627, 677-685, 718- | | | • | |
| | | | 725, 729-735, 744-759, 773-784, | ٠ | , | | |
| | | | 789-794, 820-837, 902-908, 916- | | | | |
| | | | 921, 929–935, 949–955, 1001–1008, | | | | |
| | | | 1026-1032, 1074-1083, 1088-1094, | | | | |
| | | | 11081117, 11371142, 11591177, | | | | |
| | | | 1183-1194, 1214-1220, 1236-1252, | | • | | |
| | | | 1261-1269, 1289-1294, 1311-1329, | | | | |
| | | | 1336-1341, 1406-1413, 1419-1432, | | | | |
| | | | 1437–1457, 1464–1503, 1519–1525, | | • | | |
| | | | 1531-1537, 1539-1557, 1560-1567, | | | | |
| | | | 1611–1618, 1620–1629, 1697–1704, | | | | |
| | | | 1712–1719, 1726–1736, 1781–1786, | | | , | |
| | | | 17971817, 18481854, 18791890, | | | | |
| | | | 1919–19 25, 1946–1953, 1974–1979 | | | | |

Table 2b: Additional immunogenic proteins identified by bacterial surface and ribosome display: S. aureus

Bacterial surface display: A, LSA250/1 library in fhuA with patient sera 1 (655); B, LSA50/6 library in lamB with patient sera 1 (484); C, LSA250/1 library in fhuA with IC sera 1 (571); E, LSA50/6 library in lamB with IC sera 2 (454); F, LSA50/6 library in lamB with patient sera P1 (1105); G, LSA50/6 library in lamb with IC sera 1 (471); H, LSA250/1 library in fhuA with patient sera 1 (IgA, 708). Ribosome display: D, LSA250/1 library with IC sera (1686). **, prediction of antigenic sequences longer than 5 amino acids was performed with the programme ANTIGENIC (Kolaskar and Tongaonkar, 1990). ORF, open reading frame; CRF, reading frame on complementary strand; ARF, alternative reading frame.

| <i>aureus</i> antige ni c protein | (by homology) | | | | | |
|--|-------------------|------------------------------------|-----------|--------------|-----------------------------|----------|
| | | 1 | lected | ldentified | region (positive/total) | no: |
| c protein | | | clones | immuno- | | (DNA |
| | | | per ORF | genic region | | +Prot) |
| 1 | | | and | | | |
| | | | screen | | | |
| ARF028 I | Putative protein | 7–14 | F:6 | aa 25-43 | SALAM59(25-43): 1/1 | 401, 402 |
| CRF014 I | Putative protein | 18-28, 31-37, 40-47, 51-83, 86-126 | F:5 | aa 81∸90 | SALAZ40(81-90): 2/12 | 403, 404 |
| | Putative protein | 4-24, 26-46, 49-86 | G:8 | aa 60-76 | SALAJ87(60-76): n.d. | 365, 378 |
| | Putative protein | 40-46 | A:6, B:2, | aa 5-38 | A:GSBXK03(7-36):28/69 | 391, 392 |
| 8 | - • | | C:47, | | B:GSBXD29(10-20):10/27 | |
| | | | E:35 | | | |
| CRF033 1 | Unknown | 4–17 | D:3 | aa 1-20 | D:n.d. | 469; 486 |
| | Putative protein | 4-28, 31-53, 58-64 | B:13, F:5 | aa 18-34 | GSBXF31(19-34): 1/7 | 366, 379 |
| | Unknown | 4–20 | D: 7 | aa 1-11 | D:n.d. | 470; 487 |
| 8 CRF075 | Putative protein | 4-11, 18-24, 35-40 | G:44 | aa 25-39 | SALAG92(26-39): n.d. | 367, 380 |
| 0 | r utative protein | 11, 10 24, 33 40 | | Lat. 25 55 | 57. m. 107. (20° 57). m. 1. | 307,300 |
| CRF114 I | Unknown | 4–57 | D:28 | aa 16-32 | D:n.d. | 464; 481 |
| | Putative protein | 4-25, 27-56 | F:6 | aa 36-46 | SALAR23(36-46): n.d. | 368, 381 |
| CRF125 I | Putative protein | 19-25, 38-47, 55-74, 77-87 | G:5 | aa 5467 | SALAG65(54–67): n.d. | 369, 382 |
| | Unknown | 8-15; 18-24; 27-38 | D: 5 | aa 5-33 | D:n.d. | 471; 488 |
| CRF176 | Putative protein | 4-9, 23-41, 43-58, 71-85 | C:3 | aa 1-22 | C:GSBYI30(1-22):1/1 | 407, 408 |
| | Unknown | 8–161 | D: 5 | aa 76-127 | D:n.d. | 465; 482 |
| 1 | Unknown | 4-28; 30-36 | D: 272 | aa 1-17 | D:n.d. | 472; 489 |
| 5 CRF186 | Unknown | 6-11; 13-34; 36-50 | D:8 . | aa 4-27 | D;n.d. | 466; 483 |
| 1 CRF192 | Putative protein | 4-9, 17-30 | F:9 | aa 13-22 | SALAR41(13-22): n.d. | 370, 383 |
| 8 CRF200 | Putative protein | 18-38 | F:13 | aa 16-32 | SALAM75(16-32); n.d. | 371, 384 |
| 4 CRF215 | Putative protein | 4-15, 30-58 | F:9 | aa 54-66 | SALAQ54(54-66):1/12 | 372, 385 |
| 5 | | | | | | <u> </u> |
| CRF218 1 | Putative protein | 4-61, 65-72, 79-95, 97-106 | E:13 | aa 86-99 | GSBZE08(86-99): n.d. | 373, 386 |
| | Unknown | 4–13 | D: 3 | aa 17-39 | D:n.d. | 473; 490 |
| CRF230 | Putative protein | 4-9, 22-33, 44-60 | C:5 | aa 80-116 | GSBYL75(80-116): n.d. | 374, 387 |
| 5 CRF234 | Putative protein | 4-23, 30-44, 49-70 | F:8 | aa 46-55 | SALAW31(46-55); n.d. | 375, 388 |
| 1 CRF234 9 | Putative protein | 4-32, 39-46, 62-69, 77-83 | B:10, F:4 | aa 46-67 | GSBXC92(52-67):2/11 | 376, 389 |

| S. | Putative function | predicted immunogenic aa** | No. of se- | Location of | Serum reactivity with relevant | Seq ID |
|---------------|--------------------|------------------------------------|---------------|--------------|--------------------------------|----------|
| aureus | (by homology) | | lected | identified | region (positive/total) | no: |
| antigeni | | | clones | immuno- | | (DNA |
| c protein | | | per ORF | genic region | , | +Prot) |
| . p. 0.00 | | | and | | | |
| | | | screen | | | |
| CRF235 | Unknown | 4-18 | D: 3 | aa 3-18 | D:n.d. | 475; 492 |
| 6 | | | | | | |
| | Unknown | 4-31 | D: 9 | aa 7-21 | D:n.d. | 476; 493 |
| 2 | | , | | | | |
| CRF249 | Putative protein | 4-29, 31-41 | G:8 | aa 2-15 | SALAF30(3-15): n.d. | 377, 390 |
| 8 | | | | | | |
| CRF255 | Unknown | 4-35; 37-42 | D: 4 | aa 1-20 | D:n.d. | 474; 491 |
| 3 | | | | | | 467, 404 |
| CRF257 | Unknown | 5-25; 30-39 | D: 11 | aa 9-30 | D;n,d. | 467; 484 |
| 8 | | | | | | 477, 404 |
| CRF266 | Unknown | 11–21 | D: 17 | aa 1-14 | D:n,d. | 477; 494 |
| 4 | | | D.A | 40 50 | SALAQ25(40-56): 1/1 | 405, 406 |
| CRF272 | Putative protein | 10-41, 50-57 | F:3 | aa 40-56 | SALAQ23(40-30). 1/1 | 405,400 |
| 9 | | | D: 78 | aa 17-40 | D:n.d. | 478; 495 |
| CRF286 | Unknown | 4–43 | ט: וט | aa 17-40 | D.ii.d. | , |
| 3/1 | 77.1 | 4–46 | D: 78 | aa 44-49 | D;n.d. | 479; 496 |
| CRF286 | Unknown | 4-40 | D. 70 | | 2,2.0 | 1 |
| 3/2 CRFA00 | Unknown | 17-39;52-59 | D: 3 | aa 38-55 | D:n.d. | 463; 480 |
| | Circiowa | 1, 33,32 33 | | | ' | l |
| 2 CRFNI | Unknown | 5-20; 37-44; 52-59; 87-94; 116-132 | D: 4 | aa 94-116 | D:n.d. | 468; 485 |
| ORF018 | UDP-N-acetyl- | 11-18, 43-56, 58-97, 100-118, 120- | B:4, F:29 | aa 197-210 | SALAM14(198-209): n.d. | 397, 398 |
| 8 | D-mannosamine | 148, 152–171, 195–203, 207–214, | Į | | | |
| | transferase, puta- | 220-227, 233-244 | | | | |
| | tive | · | i | | | |
| ORF025 | Multidrug efflux | 4-33, 35-56, 66-99, 109-124, 136- | D: 3 | aa 155-175 | D: n.d. | 297,325 |
| 4 | transporter | 144, 151–180, 188–198, 201–236, | | | | |
| | 1 | 238-244, 250-260, 266-290, 294- | | | | |
| | | 306, 342–377 | | | | |
| ORF030 | Conserved hypo- | 4-23, 25-67, 76-107, 109-148 | D: 3 | aa 9 44 | D; n.d. | 298, 326 |
| 7 | thetical protein | | | | | |
| ORF045 | Conserved hypo- | 4-35, 41-47, 55-75, 77-89, 98-113, | D: 5 | aa 105-122 | D: n.d. | 299, 327 |
| 2 | thetical protein | 116-140, 144-179, 194-215, 232- | 1 | | | 1 |
| | | 254, 260-273, 280-288, 290-302, | | 1 | | |
| | | 315-323, 330-369, 372-385, 413-432 | | | | |
| ORF045 | Na+/H+Antiporter | 4-81 | D: 66 | aa 1-21 | D: n.d. | 300, 328 |
| 6 | | | 1 | | | 201 200 |
| ORF055 | | 5-23, 50-74, 92-99, 107-122, 126- | D : 10 | aa 1-18 | D: n.d. | 301, 329 |
| 6 | binding protein | 142, 152–159, 172–179, 188–196, | | | | |
| | | 211-218, 271-282 | <u> </u> | | <u> </u> | 202 22 |
| ORF062 | Hypothetical | 9-44, 63-69, 75-82, 86-106, 108- | D: 313 | aa 13 – 37 | D: n.d. | 302, 330 |
| 9 | Protein | 146, 153-161, 166-178, 185-192, | 1 | | | |
| | | 233-239, 258-266, 302-307 | | <u></u> | 1 . | |

| S. | Putative function | predicted immunogenic aa** | No. of se- | Location of | Serum reactivity with relevant | Seq ID |
|-----------|--------------------|-------------------------------------|------------|--------------|--------------------------------|----------|
| aureus | (by homology) | | lected | identified | region (positive/total) | no: |
| antigeni | | | clones | immuno- | , | (DNA |
| c protein | | | per ORF | genic region | | +Prot) |
| • | | | and | | | |
| | | | screen | | | |
| ORF063 | GTP-binding | 10-19, 22-32, 95-105, 112-119, 121- | F:3 | aa 107-119 | F:SALAX70(107-119):10/41 | 393, 395 |
| 7 | protein TypA | 133, 140-154, 162-174, 186-200, | | | | |
| | | 207-224, 238-247, 254-266, 274- | | | | |
| | | 280, 288–294, 296–305, 343–351, | j | | | |
| | | 358-364, 366-373, 382-393, 403- | | | | 1 |
| | | 413, 415-422, 440-447, 499-507, | 1 | | | |
| | | 565-575, 578-588 | | | | |
| ORF071 | Conserved | 22-51, 53-71, 80-85, 93-99, 105- | D: 3 | aa 487 - 513 | D: n.d. | 303, 331 |
| 3 | hypothetical | 112, 123-146, 151-157, 165-222, | | | • | |
| | transmembrane | 226-236, 247-270, 290-296, 301- | | | | |
| | protein, putative | 324, 330-348, 362-382, 384-391, | | | | |
| | | 396-461, 463-482, 490-515 | | | | |
| ORF078 | Cell division pro- | 104-111, 158-171, 186-197, 204- | D: 4 | aa 152 – 178 | D: n.d. | 304, 332 |
| 8 | tein | 209, 230–247, 253–259, 269–277, | | | | |
| | | 290-314, 330-340, 347-367, 378-388 | | | | |
| ORF079 | Conserved | 11-40, 56-75, 83-102, 112-117, 129- | D:12 | aa 196 -218 | D; n.d. | 305, 333 |
| 7 | hypothetical | 147, 154–168, 174–191, 196–270, | ļ | ļ | | 1 1 |
| | protein | 280-344, 354-377, 380-429, 431- | ł | | | |
| 1 | | 450, 458–483, 502–520, 525–532, | | | | |
| | | 595-602, 662-669, 675-686, 696- | | | | |
| 1 | · | 702, 704–711, 720–735, 739–748, | l | | | |
| | | 750-756, 770-779, 793-800, 813- | | | | l |
| | | 822, 834-862 | | | | 224 224 |
| ORF083 . | Cell Division Pro- | 34-91, 100-119, 126-143, 147-185, | D:5 | aa 26 – 56 | D: n.d. | 306, 334 |
| 6 | tein | 187-197, 319-335, 349-355, 363- | | | | |
| | | 395, 397-412, 414-422, 424-440, | | | · |] [|
| | | 458-465, 467-475, 480-505, 507- | | | 1 | |
| | | 529, 531-542, 548-553, 577-589, | l | 1 | | |
| i | | 614-632, 640-649, 685-704, 730- | 1 | | | |
| | | 741, 744–751, 780–786 | <u> </u> | 1.05 1.50 | n 1 | 207 225 |
| ORF131 | Amino acid per- | 11-21, 25-32, 34-54, 81-88, 93-99, | D: 8 | aa127 - 152 | D: n.d. | 307, 335 |
| 8 | mease | 105-117, 122-145, 148-174, 187- | | | | |
| | | 193, 203–218, 226–260, 265–298, | 1 | | | |
| ļ | | 306-318, 325-381, 393-399, 402- | Ì | | İ | |
| | | 421, 426-448 | P. C | 420, 422 | E:GSBZE16(420-432):5/41 | 197, 216 |
| ORF132 | Pyruvat kinase | 4-11, 50-67, 89-95, 103-109, 112- | E:6 | aa 420-432 | E.U3DAE10(42U-432);3/41 | 157, 210 |
| 11 | | 135, 139–147, 158–170, 185–204, | | | | |
| | | 213-219, 229-242, 248-277, 294- | | | | |
| | | 300, 316–323, 330–335, 339–379, | | | | |
| | | 390-402, 408-422, 431-439, 446- | |]. | | |
| | | 457, 469–474, 484–500, 506–513, | | | | 1 |
| | <u> </u> | 517-530, 538-546, 548-561 | | | | |

| S. | Putative function | predicted immunogenic aa** | No. of se- | Location of | Serum reactivity with relevant | Seq ID |
|-----------|-------------------|-------------------------------------|------------|--------------|--------------------------------|-------------|
| aureus | (by homology) | • | lected | identified | region (positive/total) | no: |
| antigeni | (0) | | clones | immuno- | | (DNA |
| c protein | | | per ORF | genic region | | +Prot) |
| c proten | | | and | | | |
| | | ļ | screen | | | |
| ORF138 | LPXTG cell wall | 11-31, 86-91, 103-111, 175-182, | D: 3 | aa 508 - 523 | D: n.d. | 308, 336 |
| 8 | anchor motif | 205-212, 218-226, 242-247, 260- | | 1 | | |
| ľ | | 269, 279-288, 304-313, 329-334, | | | | |
| | | 355-360, 378-387, 390-399, 407- | | | | 1 1 |
| | | 435, 468–486, 510–516, 535–547, | | | | |
| | | 574-581, 604-615, 635-646, 653- | | | • | |
| | | 659, 689-696, 730-737, 802-812, | | | | |
| | | 879-891, 893-906, 922-931, 954- | | | | 1 |
| | | 964, 997-1009, 1031-1042, 1089- | | | | |
| 1 | | 1096, 1107-1120, 1123-1130, 1149- | | | | 1 1 |
| · · | | 1162, 1176-1184, 1192-1207, 1209- | | | | 1. |
| | | 1215, 1253-1259, 1265-1275, 1282- | | | | |
| | | 1295, 1304-1310, 1345-1361, 1382- | | | | |
| | | 1388, 1394–1400, 1412–1430, 1457– | | | | |
| | | 1462, 1489-1507, 1509-1515, 1535- | | Ì | | . |
| | | 1540, 1571–1591, 1619–1626, 1635– | | | | |
| | | 1641, 1647–1655, 1695–1701, 1726– | | | ' | |
| | | 1748, 1750–1757, 1767–1783, 1802– | | | | |
| | 1 | 1807, 1809–1822, 1844–1875, 1883– | İ | | | |
| İ | } | 1889, 1922-1929, 1931-1936, 1951- | | | | |
| | | 1967, 1978–1989, 1999–2008, 2023– | | | · · | |
| | | 2042, 2056-2083, 2101-2136, 2161- | | | | |
| | | 2177 | | | | |
| ORF140 | 3,4-dihydroxy-2- | 18-23, 32-37, 54-63, 65-74, 83-92, | E:3 | aa 121-137 | E:GSBZB68(121-137):7/41 | 198, 217 |
| 2 | butanone-4- | 107-114, 123-139, 144-155, 157- | 1 | | | |
| | phosphate syn- | 164, 191-198, 232-240, 247-272, | | | | 1 . |
| 1 | thase | 284-290, 295-301, 303-309, 311- | | | | |
| 1 | | 321, 328-341, 367-376 | <u> </u> | | · | |
| ORF147 | hemolysin II | 4-36, 39-47, 57-65, 75-82, 108-114, | F:1 | aa 245-256 | F:SALAP76(245-256):6/41 | 199, 218 |
| 3 | (LukD-Leuktoxin) | 119-126, 135-143, 189-195, 234- | | | | |
| 1 | | 244, 250-257, 266-272, 311-316 | <u> </u> | | <u> </u> | : 000 000 |
| ORF152 | Iron uptake regu- | 13-27, 29-44, 46-66, 68-81, 97-116, | D:3 | aa 120- 135 | D: n.d. | 309, 337 |
| 3 . | lator | 138-145 | | 101 110 | E GAT DO00(104, 118)-7/41 | 200, 219 |
| ORF170 | į. | 4-23, 57-77, 89-103, 119-125, 132- | F:1 | aa 104-118 | F:SALBC82(104-118):7/41 | 200, 219 |
| 7 | protein, 60 kDa | 172, 179–197, 210–254, 256–265, | 1 | | | |
| | | 281-287 | D. 2 | aa 293 - 31 | 2 Drnd | 310, 338 |
| ORF175 | i amiB | 5-10, 16-24, 62-69, 77-96, 100-115 | D: 3 | | 2 1. 1kd. | 3.0, 550 |
| 4 | | 117-126, 137-156, 165-183, 202- | | | | |
| | | 211, 215-225, 229-241, 250-260, | | | | 1 |
| | 1 | 267-273, 290-300, 302-308, 320- | 1 | | | |
| | | 333, 336–342, 348–356, 375–382, | 1 | | | |
| | | 384-389 | | | 1 | |

| Corpute | Seq ID |
|--|----------|
| natigeni c protein c protein CRF178 Mrp protein G(mtB) 192-197, 206-213, 215-220, 225-231, 249-258, 273-279, 281-287, 300-306, 313-319, 323-332, 335-341, 344-3451, 360-382, 407-431, 443-448, 459-468, 475-496, 513-520, 522-537, 543-550, 556-565, 567-573, 580-585, 593-615, 619-631, 633-642, 670-685, 688-698, 759-766, 768-782, 799-808, 842-848, 868-877, 879-917, 945-950, 979-988, 996-1002, 1025-1036, 1065-1084, 1101-1107, 1113-1119, 1125-1142, 1163-1169, 1183-1189, 1213-1219, 1289-1301, 1307-1315, 1331-1342, 1369-1378, 1385-1391, 1410-1419, 1421-1427, 1433-1447, 1468-1475, 1487-1494, 1518-1529, 1564-1570, 1592-1609, 1675-1681, 1686-1693, 1714-1725, 1740-1747, 1767-1774, 1793-1807, 1824-1841, 1920-1937, 1953-1958, 1972-1978, 1806-1986, 1997-2011, 2048-2066, 2161-2166, 2219-2224, 2252-2257, 2292-22298, 2375-2380, 2394-2399, 2435-2440, 2449-2468 ORF188 ORF189 The motein of the drug of the drug of the drug of the drug of the drug of the drug of the drug of the drug of 5-27, 79-85, 105-110, 138-165, 183- ORF201 Putative drug of 5-27, 79-85, 105-110, 138-165, 183- D:5 aa 205 - 224 D: n.d. | no: |
| c protein | (DNA |
| ORF178 Mrp protein 5-29, 46-52, 70-76, 81-87, 155-170, F:2 aa 850-860 F:SALAQ36(850-860):8/41 192-197, 206-213, 215-220, 225- 231, 249-258, 273-279, 281-287, 300-306, 313-319, 323-332, 335- 341, 344-351, 360-382, 407-431, 443-448, 459-468, 475-496, 513- 520, 522-537, 543-550, 556-565, 567-573, 580-585, 593-615, 619- 631, 633-642, 670-686, 688-698, 759-766, 768-782, 799-808, 842- 848, 868-877, 879-917, 945-950, 979-988, 996-1002, 1025-1036, 1065-1084, 1101-1107, 1113-1119, 1125-1142, 1163-1169, 1183-1189, 1213-1219, 1289-1301, 1307-1315, 1331-1342, 1369-1378, 1385-1391, 1410-1419, 1421-1427, 1433-1447, 1468-1475, 1487-1494, 1518-1529, 1564-1570, 1592-1609, 1675-1681, 1686-1693, 1714-1725, 1740-1747, 1767-1774, 1793-1807, 1824-1841, 1920-1937, 1953-1958, 1972-1978, 1980-1986, 1997-2011, 2048-2066, 2161-2166, 2219-2224, 2252-2257, 2292-2298, 2375-2380, 2394-2399, 2435-2440, 2449-2468 2076-1876, 183-188, 18, 133-138 18, 133-138, 1 | +Prot) |
| ORF178 Mrp protein 5-29, 46-52, 70-76, 81-87, 155-170, 152 aa 850-860 F:SALAQ36(850-860):8/41 192-197, 206-213, 215-220, 225-231, 249-258, 273-279, 281-287, 300-306, 313-319, 323-332, 335-341, 344-3418, 459-468, 475-496, 513-520, 522-537, 543-550, 556-565, 567-573, 580-585, 593-615, 619-631, 633-642, 670-686, 688-698, 759-766, 768-782, 799-808, 842-848, 868-877, 879-917, 945-950, 979-988, 996-1002, 1025-1036, 1065-1084, 1101-1107, 1113-1119, 1125-1142, 1163-1169, 1183-1189, 1213-1219, 1289-1301, 1307-1315, 1331-1342, 1369-1378, 1385-1391, 1410-1419, 1421-1427, 1433-1447, 1468-4475, 1487-1494, 1518-1529, 1564-1570, 1592-1609, 1675-1681, 1686-1693, 1714-1725, 1740-1747, 1767-1774, 1793-1807, 1824-1841, 1920-1937, 1953-1958, 1972-1978, 1980-1986, 1997-2011, 2048-2066, 2161-2166, 2219-2224, 2252-2257, 2292-2298, 2375-2380, 2394-2399, 2435-2440, 2449-2468 ORF184 Map-ND2C | |
| ORF178 Mrp protein (fintB) 5-29, 46-52, 70-76, 81-87, 155-170, F:2 aa 850-860 F:SALAQ36(850-860):8/41 192-197, 206-213, 215-220, 225-231, 249-258, 273-279, 281-287, 300-306, 313-319, 323-332, 335-341, 344-351, 360-382, 407-431, 443-448, 459-468, 475-496, 513-520, 522-537, 543-550, 556-565, 567-573, 580-585, 593-615, 619-631, 633-642, 670-686, 688-698, 759-766, 768-782, 799-808, 842-848, 868-877, 879-917, 945-950, 979-988, 996-1002, 1025-1036, 1065-1084, 1101-1107, 1113-1119, 1125-1142, 1163-1169, 1183-1189, 1213-1219, 1289-1301, 1307-1315, 1331-1342, 1369-1378, 1385-1391, 1410-1419, 1421-1427, 1433-1447, 1468-1475, 1487-1494, 1518-1529, 1564-1570, 1592-1609, 1675-1681, 1686-1693, 1714-1725, 1740-1747, 1767-1774, 1793-1807, 1824-1841, 1920-1937, 1953-1958, 1972-1978, 1980-1986, 1997-2011, 2048-2066, 2161-2166, 2219-2224, 2252-2257, 2292-2298, 2375-2380, 2394-2399, 2435-2440, 2449-2468 ORF184 Map-ND2C 4-27, 42-66, 70-76, 102-107, 113- 18:5 aa 75-90 E:GSBZB15(75-90):6/41 notein 12 (rpiB) ribosomal protein 12 (rpiB) 131-39, 48-54, 61-67, 75-83, 90-98, F:4 aa 239-257 F:SALAV36(239-257):19/41 ORF201 Putative drug 5-27, 79-85, 105-110, 138-165, 183- D:5 aa 205-224 D: n.d. | |
| 3 (fmtB) 192–197, 206–213, 215–220, 225– 231, 249–258, 273–279, 281–287, 300–306, 313–319, 323–332, 335– 341, 344–351, 360–382, 407–431, 443–448, 459–468, 475–496, 513– 520, 522–537, 543–550, 556–565, 567–573, 580–585, 593–615, 619– 631, 633–642, 670–686, 688–698, 759–766, 768–782, 799–808, 842– 848, 868–877, 879–917, 945–950, 979–988, 996–1002, 1025–1036, 1065–1084, 1101–1107, 1113–1119, 1125–1142, 1163–1169, 1183–1189, 1213–1219, 1289–1301, 1307–1315, 1331–1342, 1369–1378, 1385–1391, 1410–1419, 1421–1427, 1433–1447, 1468–1475, 1487–1494, 1518–1529, 1564–1570, 1592–1609, 1675–1681, 1686–1693, 1714–1725, 1740–1747, 1767–1774, 1793–1807, 1824–1841, 1920–1937, 1953–1958, 1972–1978, 1980–1986, 1997–2011, 2048–2066, 2161–2166, 2219–2224, 2252–2257, 2292–2298, 2375–2380, 2394–2399, 2435–2440, 2449–2468 ORF184 Map–ND2C 4–27, 42–66, 70–76, 102–107, 113– 8 protein 118, 133–138 ORF189 ribosomal protein 118, 133–138 ORF189 ribosomal protein 119, 123–145, 160–167, 169– 176, 182–193, 195–206, 267–273 ORF201 Putative drug 5–27, 79–85, 105–110, 138–165, 183– D:5 aa 205 – 224 D: n.d. | 201, 220 |
| 300-306, 313-319, 323-332, 335- 341, 344-341, 360-382, 407-431, 443-448, 459-468, 475-496, 513- 520, 522-537, 543-550, 556-565, 567-573, 580-585, 593-615, 619- 631, 633-642, 670-686, 688-698, 759-766, 768-782, 799-808, 842- 848, 868-877, 879-917, 945-950, 979-988, 996-1002, 1025-1036, 1065-1084, 1101-1107, 1113-1119, 1125-1142, 1163-1169, 1183-1189, 1213-1219, 1289-1301, 1307-1315, 1331-1342, 1369-1378, 1385-1391, 1410-1419, 1421-1427, 1433-1447, 1468-1475, 1487-1494, 1518-1529, 1564-1570, 1592-1609, 1675-1681, 1686-1693, 1714-1725, 1740-1747, 1767-1774, 1793-1807, 1824-1841, 1920-1937, 1933-1958, 1972-1978, 1980-1986, 1997-2011, 2048-2066, 2161-2166, 2219-2224, 2252-2257, 2292-2298, 2375-2380, 2394-2399, 2435-2440, 2449-2468 ORF184 Map-ND2C 4-27, 42-66, 70-76, 102-107, 113- 8 protein 118, 133-138 ORF199 ribesomal protein 31-39, 48-54, 61-67, 75-83, 90-98, 12 (rplB) 103-119, 123-145, 160-167, 169- 176, 182-193, 195-206, 267-273 ORF201 Putative drug 5-27, 79-85, 105-110, 138-165, 183- D:5 aa 205-224 D: n.d. | |
| 341, 344–351, 360–382, 407–431, 443–448, 459–468, 475–496, 513– 520, 522–537, 543–550, 556–565, 567–573, 580–583, 593–615, 619– 631, 633–642, 670–686, 688–698, 759–766, 768–782, 799–808, 842– 848, 868–877, 879–917, 945–950, 979–988, 996–1002, 1025–1036, 1065–1084, 1101–1107, 1113–1119, 1125–1142, 1163–1169, 1183–1189, 1213–1219, 1289–1301, 1307–1315, 1331–1342, 1369–1378, 1385–1391, 1410–1419, 1421–1427, 1433–1447, 1468–1475, 1487–1494, 1518–1529, 1564–1570, 1592–1609, 1675–1681, 1686–1693, 1714–1725, 1740–1747, 1767–1774, 1793–1807, 1824–1841, 1920–1937, 1953–1958, 1972–1978, 1980–1986, 1997–2011, 2048–2066, 2161–2166, 2219–2224, 2252–2257, 2292–2298, 2375–2380, 2394–2399, 2435–2440, 2449–2468 ORF189 ORF184 Map–ND2C 4–27, 42–66, 70–76, 102–107, 113– 8 protein 118, 133–138 ORF189 ribosomal protein 118, 133–138 ORF189 ribosomal protein 11, 133–148, 160–167, 169– 176, 182–193, 195–206, 267–273 ORF201 Putative drug 5–27, 79–85, 105–110, 138–165, 183– D:5 aa 205 – 224 D: n.d. | 1 |
| 443–448, 459–468, 475–496, 513– 520, 522–537, 543–550, 556–565, 567–573, 580–585, 593–615, 619– 631, 633–642, 670–686, 688–698, 759–766, 768–782, 799–808, 842– 848, 868–877, 879–917, 945–950, 979–988, 996–1002, 1025–1036, 1065–1084, 1101–1107, 1113–1119, 1125–1142, 1163–1169, 1183–1189, 1213–1219, 1289–1301, 1307–1315, 1331–1342, 1369–1378, 1385–1391, 1410–1419, 1421–1427, 1433–1447, 1468–1475, 1487–1494, 1518–1529, 1564–1570, 1592–1609, 1675–1681, 1686–1693, 1714–1725, 1740–1747, 1767–1774, 1793–1807, 1824–1841, 1920–1937, 1953–1958, 1972–1978, 1980–1986, 1997–2011, 2048–2066, 2161–2166, 2219–2224, 2252–2257, 2292–2298, 2375–2380, 2394–2399, 2435–2440, 2449–2468 ORF189 ORF189 ribosomal protein 118, 133–138 ORF189 ribosomal protein 11, 133–138 ORF189 ribosomal protein 11, 133–145, 160–167, 169– 176, 182–193, 195–206, 267–273 ORF201 Putative drug 5–27, 79–85, 105–110, 138–165, 183– D:5 aa 205 – 224 D: n.d. | |
| 520, 522-537, 543-550, 556-565, 567-573, 580-585, 593-615, 619- 631, 633-642, 670-686, 688-698, 759-766, 768-782, 799-808, 842- 848, 868-877, 879-917, 945-950, 979-988, 996-1002, 1025-1036, 1065-1084, 1101-1107, 1113-1119, 11125-1142, 1163-1169, 1183-1189, 1213-1219, 1289-1301, 1307-1315, 1331-1342, 1369-1378, 1385-1391, 1410-1419, 1421-1427, 1433-1447, 1468-1475, 1487-1494, 1518-1529, 1564-1570, 1592-1609, 1675-1681, 1686-1693, 1714-1725, 1740-1747, 1767-1774, 1793-1807, 1824-1841, 1920-1937, 1953-1958, 1972-1978, 1980-1986, 1997-2011, 2048-2066, 2161-2166, 2219-2224, 2252-2257, 2292-2298, 2375-2380, 2394-2399, 2435-2440, 2449-2468 ORF184 Map-ND2C 4-27, 42-66, 70-76, 102-107, 113- 8 protein 118, 133-138 ORF189 ribosomal protein 18, 133-138 ORF189 ribosomal protein 31-39, 48-54, 61-67, 75-83, 90-98, 1 L2 (rplB) 103-119, 123-145, 160-167, 169- 176, 182-193, 195-206, 267-273 ORF201 Putative drug 5-27, 79-85, 105-110, 138-165, 183- D.5 aa 205-224 D: n.d. |] |
| 567-573, 580-585, 593-615, 619-631, 633-642, 670-686, 688-698, 759-766, 768-782, 799-808, 842-848, 868-877, 879-917, 945-950, 979-988, 996-1002, 1025-1036, 1065-1084, 1101-1107, 1113-1119, 1125-1142, 1163-1169, 1183-1189, 1213-1219, 1289-1301, 1307-1315, 1331-1342, 1369-1378, 1385-1391, 1410-1419, 1421-1427, 1433-1447, 1468-1475, 1487-1494, 1518-1529, 1564-1570, 1592-1609, 1675-1681, 1686-1693, 1714-1725, 1740-1747, 1767-1774, 1793-1807, 1824-1841, 1920-1937, 1953-1958, 1972-1978, 1980-1986, 1997-2011, 2048-2066, 2161-2166, 2219-2224, 2252-2257, 2292-2298, 2375-2380, 2394-2399, 2435-2440, 2449-2468 ORF184 Map-ND2C 4-27, 42-66, 70-76, 102-107, 113-8, protein 118, 133-138 ORF189 ribosomal protein 118, 133-138 ORF189 ribosomal protein 11-19, 123-145, 160-167, 169-176, 182-193, 195-206, 267-273 ORF201 Putative drug 5-27, 79-85, 105-110, 138-165, 183-D:5 aa 205-224 D: n.d. | |
| 631, 633–642, 670–686, 688–698, 759–766, 768–782, 799–808, 842– 848, 868–877, 879–917, 945–950, 979–988, 996–1002, 1025–1036, 1065–1084, 1101–1107, 1113–1119, 1125–1142, 1163–1169, 1183–1189, 1213–1219, 1289–1301, 1307–1315, 1331–1342, 1369–1378, 1385–1391, 1410–1419, 1421–1427, 1433–1447, 1468–1475, 1487–1494, 1518–1529, 1564–1570, 1592–1609, 1675–1681, 1686–1693, 1714–1725, 1740–1747, 1767–1774, 1793–1807, 1824–1841, 1920–1937, 1953–1958, 1972–1978, 1980–1986, 1997–2011, 2048–2066, 2161–2166, 2219–2224, 2252–2257, 2292–2298, 2375–2380, 2394–2399, 2435–2440, 2449–2468 ORF184 Map—ND2C 4–27, 42–66, 70–76, 102–107, 113– 8 protein 118, 133–138 ORF189 ribosomal protein 31–39, 48–54, 61–67, 75–83, 90–98, 1 L2 (rplB) 103–119, 123–145, 160–167, 169– 176, 182–193, 195–206, 267–273 ORF201 Putative drug 5–27, 79–85, 105–110, 138–165, 183– D:5 aa 205 – 224 D: n.d. | |
| 759-766, 768-782, 799-808, 842- 848, 868-877, 879-917, 945-950, 979-988, 996-1002, 1025-1036, 1065-1084, 1101-1107, 1113-1119, 1125-1142, 1163-1169, 1183-1189, 1213-1219, 1289-1301, 1307-1315, 1331-1342, 1369-1378, 1385-1391, 1410-1419, 1421-1427, 1433-1447, 1468-1475, 1487-1494, 1518-1529, 1564-1570, 1592-1609, 1675-1681, 1686-1693, 1714-1725, 1740-1747, 1767-1774, 1793-1807, 1824-1841, 1920-1937, 1953-1958, 1972-1978, 1980-1986, 1997-2011, 2048-2066, 2161-2166, 2219-2224, 2252-2257, 2292-2298, 2375-2380, 2394-2399, 2435-2440, 2449-2468 ORF184 Map-ND2C 4-27, 42-66, 70-76, 102-107, 113- 8 protein 118, 133-138 ORF189 ribosomal protein 31-39, 48-54, 61-67, 75-83, 90-98, 1 L2 (rplB) 103-119, 123-145, 160-167, 169- 176, 182-193, 195-206, 267-273 ORF201 Putative drug 5-27, 79-85, 105-110, 138-165, 183- D:5 aa 205-224 D: n.d. | |
| 848, 868–877, 879–917, 945–950, 979–988, 996–1002, 1025–1036, 1065–1084, 1101–1107, 1113–1119, 1125–1142, 1163–1169, 1183–1189, 1213–1219, 1289–1301, 1307–1315, 1331–1342, 1369–1378, 1385–1391, 1410–1419, 1421–1427, 1433–1447, 1468–1475, 1487–1494, 1518–1529, 1564–1570, 1592–1609, 1675–1681, 1686–1693, 1714–1725, 1740–1747, 1767–1774, 1793–1807, 1824–1841, 1920–1937, 1953–1958, 1972–1978, 1980–1986, 1997–2011, 2048–2066, 2161–2166, 2219–2224, 2252–2257, 2292–2298, 2375–2380, 2394–2399, 2435–2440, 2449–2468 ORF184 Map–ND2C 4–27, 42–66, 70–76, 102–107, 113– 8 protein 118, 133–138 ORF189 ribosomal protein 31–39, 48–54, 61–67, 75–83, 90–98, 1 L2 (rplB) 103–119, 123–145, 160–167, 169– 176, 182–193, 195–206, 267–273 ORF201 Putative drug 5–27, 79–85, 105–110, 138–165, 183– D:5 aa 205–224 D: n.d. | |
| 979–988, 996–1002, 1025–1036, 1065–1084, 1101–1107, 1113–1119, 1125–1142, 1163–1169, 1183–1189, 1213–1219, 1289–1301, 1307–1315, 1331–1342, 1369–1378, 1385–1391, 1410–1419, 1421–1427, 1433–1447, 1468–1475, 1487–1494, 1518–1529, 1564–1570, 1592–1609, 1675–1681, 1686–1693, 1714–1725, 1740–1747, 1767–1774, 1793–1807, 1824–1841, 1920–1937, 1953–1958, 1972–1978, 1980–1986, 1997–2011, 2048–2066, 2161–2166, 2219–2224, 2252–2257, 2292–2298, 2375–2380, 2394–2399, 2435–2440, 2449–2468 ORF184 Map–ND2C 4–27, 42–66, 70–76, 102–107, 113– E:5 aa 75–90 E:GSBZB15(75–90):6/41 8 protein 118, 133–138 ORF189 ribosomal protein 31–39, 48–54, 61–67, 75–83, 90–98, F:4 aa 239–257 F:SALAV36(239–257):19/41 1 L2 (rplB) 103–119, 123–145, 160–167, 169– 176, 182–193, 195–206, 267–273 ORF201 Putative drug 5–27, 79–85, 105–110, 138–165, 183– D:5 aa 205 – 224 D: n.d. | |
| 1065-1084, 1101-1107, 1113-1119, 1125-1142, 1163-1169, 1183-1189, 1213-1219, 1289-1301, 1307-1315, 1331-1342, 1369-1378, 1385-1391, 1410-1419, 1421-1427, 1433-1447, 1468-1475, 1487-1494, 1518-1529, 1564-1570, 1592-1609, 1675-1681, 1686-1693, 1714-1725, 1740-1747, 1767-1774, 1793-1807, 1824-1841, 1920-1937, 1953-1958, 1972-1978, 1980-1986, 1997-2011, 2048-2066, 2161-2166, 2219-2224, 2252-2257, 2292-2298, 2375-2380, 2394-2399, 2435-2440, 2449-2468 ORF184 Map-ND2C 4-27, 42-66, 70-76, 102-107, 113- 8 protein 118, 133-138 ORF189 ribosomal protein 31-39, 48-54, 61-67, 75-83, 90-98, 1 L2 (rplB) 103-119, 123-145, 160-167, 169- 176, 182-193, 195-206, 267-273 ORF201 Putative drug 5-27, 79-85, 105-110, 138-165, 183- D:5 aa 205-224 D: n.d. | 1 |
| 1125-1142, 1163-1169, 1183-1189, 1213-1219, 1289-1301, 1307-1315, 1331-1342, 1369-1378, 1385-1391, 1410-1419, 1421-1427, 1433-1447, 1468-1475, 1487-1494, 1518-1529, 1564-1570, 1592-1609, 1675-1681, 1686-1693, 1714-1725, 1740-1747, 1767-1774, 1793-1807, 1824-1841, 1920-1937, 1953-1958, 1972-1978, 1980-1986, 1997-2011, 2048-2066, 2161-2166, 2219-2224, 2252-2257, 2292-2298, 2375-2380, 2394-2399, 2435-2440, 2449-2468 ORF184 Map-ND2C 4-27, 42-66, 70-76, 102-107, 113- E:5 aa 75-90 E:GSBZB15(75-90):6/41 8 protein 118, 133-138 ORF189 ribosomal protein 31-39, 48-54, 61-67, 75-83, 90-98, 1 L2 (rplB) 103-119, 123-145, 160-167, 169- 176, 182-193, 195-206, 267-273 ORF201 Putative drug 5-27, 79-85, 105-110, 138-165, 183- D:5 aa 205-224 D: n.d. | 1 |
| 1213-1219, 1289-1301, 1307-1315, 1331-1342, 1369-1378, 1385-1391, 1410-1419, 1421-1427, 1433-1447, 1468-1475, 1487-1494, 1518-1529, 1564-1570, 1592-1609, 1675-1681, 1686-1693, 1714-1725, 1740-1747, 1767-1774, 1793-1807, 1824-1841, 1920-1937, 1953-1958, 1972-1978, 1980-1986, 1997-2011, 2048-2066, 2161-2166, 2219-2224, 2252-2257, 2292-2298, 2375-2380, 2394-2399, 2435-2440, 2449-2468 ORF184 Map-ND2C 4-27, 42-66, 70-76, 102-107, 113- 8 protein 118, 133-138 ORF189 ribosomal protein 31-39, 48-54, 61-67, 75-83, 90-98, 1 L2 (rplB) 103-119, 123-145, 160-167, 169- 176, 182-193, 195-206, 267-273 ORF201 Putative drug 5-27, 79-85, 105-110, 138-165, 183- D:5 aa 205-224 D: n.d. | |
| 1331–1342, 1369–1378, 1385–1391, 1410–1419, 1421–1427, 1433–1447, 1468–1475, 1487–1494, 1518–1529, 1564–1570, 1592–1609, 1675–1681, 1686–1693, 1714–1725, 1740–1747, 1767–1774, 1793–1807, 1824–1841, 1920–1937, 1953–1958, 1972–1978, 1980–1986, 1997–2011, 2048–2066, 2161–2166, 2219–2224, 2252–2257, 2292–2298, 2375–2380, 2394–2399, 2435–2440, 2449–2468 ORF184 Map–ND2C 4–27, 42–66, 70–76, 102–107, 113– 8 protein 118, 133–138 ORF189 ribosomal protein 31–39, 48–54, 61–67, 75–83, 90–98, 1 L2 (rplB) 103–119, 123–145, 160–167, 169– 176, 182–193, 195–206, 267–273 ORF201 Putative drug 5–27, 79–85, 105–110, 138–165, 183– D:5 aa 205 – 224 D: n.d. | |
| 1410-1419, 1421-1427, 1433-1447, 1468-1475, 1487-1494, 1518-1529, 1564-1570, 1592-1609, 1675-1681, 1686-1693, 1714-1725, 1740-1747, 1767-1774, 1793-1807, 1824-1841, 1920-1937, 1953-1958, 1972-1978, 1980-1986, 1997-2011, 2048-2066, 2161-2166, 2219-2224, 2252-2257, 2292-2298, 2375-2380, 2394-2399, 2435-2440, 2449-2468 ORF184 Map-ND2C 4-27, 42-66, 70-76, 102-107, 113- E:5 aa 75-90 E:GSBZB15(75-90):6/41 8 protein 118, 133-138 ORF189 ribosomal protein 31-39, 48-54, 61-67, 75-83, 90-98, 1 L2 (rplB) 103-119, 123-145, 160-167, 169- 176, 182-193, 195-206, 267-273 ORF201 Putative drug 5-27, 79-85, 105-110, 138-165, 183- D:5 aa 205-224 D: n.d. | |
| 1468-1475, 1487-1494, 1518-1529, 1564-1570, 1592-1609, 1675-1681, 1686-1693, 1714-1725, 1740-1747, 1767-1774, 1793-1807, 1824-1841, 1920-1937, 1953-1958, 1972-1978, 1980-1986, 1997-2011, 2048-2066, 2161-2166, 2219-2224, 2252-2257, 2292-2298, 2375-2380, 2394-2399, 2435-2440, 2449-2468 ORF184 Map-ND2C 4-27, 42-66, 70-76, 102-107, 113- E:5 aa 75-90 E:GSBZB15(75-90):6/41 8 protein 118, 133-138 ORF189 ribosomal protein 31-39, 48-54, 61-67, 75-83, 90-98, 1 L2 (rplB) 103-119, 123-145, 160-167, 169- 176, 182-193, 195-206, 267-273 ORF201 Putative drug 5-27, 79-85, 105-110, 138-165, 183- D:5 aa 205-224 D: n.d. | |
| 1564-1570, 1592-1609, 1675-1681, 1686-1693, 1714-1725, 1740-1747, 1767-1774, 1793-1807, 1824-1841, 1920-1937, 1953-1958, 1972-1978, 1980-1986, 1997-2011, 2048-2066, 2161-2166, 2219-2224, 2252-2257, 2292-2298, 2375-2380, 2394-2399, 2435-2440, 2449-2468 | |
| 1686–1693, 1714–1725, 1740–1747, 1767–1774, 1793–1807, 1824–1841, 1920–1937, 1953–1958, 1972–1978, 1980–1986, 1997–2011, 2048–2066, 2161–2166, 2219–2224, 2252–2257, 2292–2298, 2375–2380, 2394–2399, 2435–2440, 2449–2468 ORF184 Map–ND2C 4–27, 42–66, 70–76, 102–107, 113– 8 protein 118, 133–138 ORF189 ribosomal protein 31–39, 48–54, 61–67, 75–83, 90–98, 1 L2 (rplB) 103–119, 123–145, 160–167, 169– 176, 182–193, 195–206, 267–273 ORF201 Putative drug 5–27, 79–85, 105–110, 138–165, 183– D:5 aa 205 – 224 D: n.d. | |
| 1767-1774, 1793-1807, 1824-1841, 1920-1937, 1953-1958, 1972-1978, 1980-1986, 1997-2011, 2048-2066, 2161-2166, 2219-2224, 2252-2257, 2292-2298, 2375-2380, 2394-2399, 2435-2440, 2449-2468 ORF184 Map-ND2C 4-27, 42-66, 70-76, 102-107, 113- 8 protein 118, 133-138 ORF189 ribosomal protein 31-39, 48-54, 61-67, 75-83, 90-98, 1 L2 (rplB) 103-119, 123-145, 160-167, 169- 176, 182-193, 195-206, 267-273 ORF201 Putative drug 5-27, 79-85, 105-110, 138-165, 183- D:5 aa 205-224 D: n.d. | } |
| 1920–1937, 1953–1958, 1972–1978, 1980–1986, 1997–2011, 2048–2066, 2161–2166, 2219–2224, 2252–2257, 2292–2298, 2375–2380, 2394–2399, 2435–2440, 2449–2468 ORF184 Map–ND2C 4–27, 42–66, 70–76, 102–107, 113– E:5 aa 75–90 E:GSBZB15(75–90):6/41 protein 118, 133–138 ORF189 ribosomal protein 31–39, 48–54, 61–67, 75–83, 90–98, 1 L2 (rplB) 103–119, 123–145, 160–167, 169– 176, 182–193, 195–206, 267–273 ORF201 Putative drug 5–27, 79–85, 105–110, 138–165, 183– D:5 aa 205 – 224 D: n.d. | |
| 1980-1986, 1997-2011, 2048-2066, 2161-2166, 2219-2224, 2252-2257, 2292-2298, 2375-2380, 2394-2399, 2435-2440, 2449-2468 ORF184 Map-ND2C 4-27, 42-66, 70-76, 102-107, 113- E:5 aa 75-90 E:GSBZB15(75-90):6/41 E:D E:D E:GSBZB15(75-90):6/41 E:D E:D E:GSBZB15(75-90):6/41 E:D E:D E:GSBZB15(75-90):6/41 E:D E:D E:GSBZB15(75-90):6/41 E:D E:D E:GSBZB15(75-90):6/41 E:D E:D E:GSBZB15(75-90):6/41 E:D E:D E:GSBZB15(75-90):6/41 E:D E:D E:GSBZB15(75-90):6/41 E:D E | i |
| 2161-2166, 2219-2224, 2252-2257, 2292-2298, 2375-2380, 2394-2399, 2435-2440, 2449-2468 ORF184 Map-ND2C 4-27, 42-66, 70-76, 102-107, 113- E:5 aa 75-90 E:GSBZB15(75-90):6/41 8 protein 118, 133-138 ORF189 ribosomal protein 31-39, 48-54, 61-67, 75-83, 90-98, 1 L2 (rplB) 103-119, 123-145, 160-167, 169- 176, 182-193, 195-206, 267-273 ORF201 Putative drug 5-27, 79-85, 105-110, 138-165, 183- D:5 aa 205-224 D: n.d. | |
| 2292-2298, 2375-2380, 2394-2399, 2435-2440, 2449-2468 ORF184 Map-ND2C | |
| CRF184 Map-ND2C 4-27, 42-66, 70-76, 102-107, 113- E:5 aa 75-90 E:GSBZB15(75-90):6/41 | |
| ORF184 Map-ND2C 4-27, 42-66, 70-76, 102-107, 113- E:5 aa 75-90 E:GSBZB15(75-90):6/41 8 protein 118, 133-138 ORF189 ribosomal protein 131-39, 48-54, 61-67, 75-83, 90-98, L2 (rplB) 103-119, 123-145, 160-167, 169- 176, 182-193, 195-206, 267-273 ORF201 Putative drug 5-27, 79-85, 105-110, 138-165, 183- D:5 aa 205-224 D: n.d. | |
| 8 protein 118, 133–138 ORF189 ribosomal protein 31–39, 48–54, 61–67, 75–83, 90–98, F:4 aa 239–257 F:SALAV36(239–257):19/41 1 L2 (rplB) 103–119, 123–145, 160–167, 169– 176, 182–193, 195–206, 267–273 ORF201 Putative drug 5–27, 79–85, 105–110, 138–165, 183– D:5 aa 205 – 224 D: n.d. | |
| ORF189 ribosomal protein 31-39, 48-54, 61-67, 75-83, 90-98, F:4 aa 239-257 F:SALAV36(239-257):19/41 1 | 202, 221 |
| 1 L2 (rplB) 103-119, 123-145, 160-167, 169- 176, 182-193, 195-206, 267-273 ORF201 Putative drug 5-27, 79-85, 105-110, 138-165, 183- D:5 aa 205-224 D: n.d. | 203, 222 |
| 176, 182–193, 195–206, 267–273 ORF201 Putative drug 5-27, 79-85, 105-110, 138-165, 183- D:5 aa 205 - 224 D: n.d. | 203, 222 |
| ORF201 Putative drug 5-27, 79-85, 105-110, 138-165, 183- D:5 aa 205-224 D: n.d. | |
| OR 201 I many cores | 311, 339 |
| | 321,000 |
| transporter 202, 204–225, 233–259, 272–292, | |
| 298-320, 327-336, 338-345, 363- 376, 383-398, 400-422, 425-470, | ŀ |
| 489-495, 506-518, 536-544, 549- | |
| 554, 562–568, 584–598, 603–623 | 1 |
| ORF202 lactase permease, 10-33, 38-71, 73-103, 113-125, 132- E:2 aa 422-436 E:GSBZF58(422-436):6/41 | 204, 223 |
| 7 putative 147, 154–163, 170–216, 222–248, | |
| 250–269, 271–278, 287–335, 337– | |
| 355, 360-374, 384-408, 425-442, | |
| 453-465, 468-476, 478-501, 508-529 | |
| ORF208 Hemolysin II 8-27, 52-59, 73-80, 90-99, 104-110, D: 3 aa 126 - 147 D: n.d. | 312, 34 |
| 7 (putative) 117–124, 131–140, 189–209, 217– | - 1 |
| 232, 265–279, 287–293, 299–306 | |

| S. | Putative function | predicted immunogenic aa** | No. of se- | Location of | Serum reactivity with relevant | Seq ID |
|-------------|---------------------|--|------------|--------------|--------------------------------|----------|
| aureus | (by homology) | | lected | identified | region (positive/total) | no: |
| antigeni | | | clones | immuno- | | (DNA |
| c protein | | | per ORF | genic region | • | +Prot) |
| - | , | | and | | | |
| | | | screen | | | |
| ORF209 | preLukS | 8-26, 75-82, 118-126, 136-142, 163- | F:2 | аа 270-284 | F:SALAQ77(270-284):23/41 | 205, 224 |
| 0 | ~ | 177, 182–189, 205–215, 221–236, | | | | |
| | | 239-248, 268-274 | | | | |
| ORF209 | Hemolysin II | 5-22, 30-47, 58-65, 75-81, 87-92, | F:3 | aa 238-253 | F:SALAQ67(237-252):10/41 | 206, 225 |
| 2 | (preLUK-F) | 99–105, 107–113, 119–126, 189–195, | | | | |
| | | 217-223, 234-244, 250-257, 266-272 | | | | |
| ORF210 | Multidrug | 10-28, 30-43, 50-75, 80-113, 116- | D: 9 | aa 54 - 104 | D: n.d. | 313, 341 |
| 7 | resistance protein | 125, 136–167, 170–191, 197–245, | | | | |
| | (putative) | 253-329, 345-367, 375-396 | | | | |
| ORF219 | Transcriptional | 20-31, 46-52, 55-69, 74-79, 89-97, | D: 3 | aa 15 – 35 | D: n.d. | 314, |
| 2 | regulator GntR | 108-113, 120-128, 141-171, 188-214 | | | | 342 |
| | family, putative | | | | | |
| ORF230 | Amino acid per- | 25-79, 91-103, 105-127, 132-149, | D: 53 | aa 363 - 393 | D: n.d. | 315, 343 |
| 5 | mease | 158-175, 185-221, 231-249, 267- | | | | |
| | | 293, 307–329, 336–343, 346–359, | | , | • | |
| | | 362-405, 415-442, 446-468 | <u> </u> | | | |
| ORF232 | Citrate dransporter | 10-77, 85-96, 99-109, 111-138, 144- | D: 7 | aa 37 – 83 | D: n.d. | 316, 344 |
| 4 | | 155, 167–176, 178–205, 225–238, | | | | |
| | | 241-247, 258-280, 282-294, 304- | | ļ. | · | ٠. |
| 4. | | 309, 313–327, 333–383, 386–402, | | | | |
| | | 405-422, 429-453 | 7.16 | 077 007 | | 212 245 |
| ORF242 | i - | 7–26, 28–34, 36–53, 55–73, 75–81, | D: 16 | aa 275 – 295 | D; n.d. | 317, 345 |
| 2 | family protein | 87-100, 108-117, 121-138, 150-160, | | | | |
| | | 175-181, 184-195, 202-215, 221- | | | · | |
| | | 247, 265–271, 274–314, 324–337, | | | | |
| | | 341-412, 414-423, 425-440, 447- | | | | |
| | | 462, 464–469 | D.2 | 1 00 | D | 210 246 |
| ORF255 | SirA | 5-22, 54-78, 97-103, 113-123, 130- | D:3 | aa 1 – 22 | D: n.d. | 318, 346 |
| 3 | | 148, 166–171, 173–180, 192–201, | | | | 1 |
| OPPOSS | 211 2 2 2 2 2 2 2 | 254-261, 266-272, 310-322 | E.2 | 22_48 | E:GSBZB37(32-48):11/41 | 207, 226 |
| 1 | | 20-35, 37-50, 96-102, 109-120, 123- | E:2 | aa 32–48 | E:G8BZB37(32-46):11/41 | 207, 220 |
| 5 | aminase | 137, 141–150, 165–182, 206–224, | | | | İ |
| ĺ | | 237-256, 267-273, 277-291, 300- | | 1. | | 1 |
| OPERS | M. William and | 305, 313–324 11–63, 79–129, 136–191, 209–231, | D: 8 | aa 84 - 100 | D: n.d. | 319, 347 |
| ORF255 | Multidrug resis- | | D. 8 | aa 64 - 100 | D. 11.0. | 319, 547 |
| 8 | tance efflux pro- | 237-250, 254-276, 282-306, 311- | ļ | } | | İ |
| ORF261 | ten, putative | 345, 352–373, 376–397 4–30, 34–40, 79–85, 89–98, 104–118, | D: 13 | aa 114 - 141 | Dind | 320, 348 |
| | Cap5M | 124-139, 148-160, 167-178 | D. 13 | 24 114 - 141 | D: n.u. | 320, 346 |
| 0 ORF261 | Cap5P (UDP-N- | 4-9, 17-24, 32-38, 44-54, 68-82, | B:3, F:11 | aa 321-341 | F:SALAU27(325-337):9/41 | 208, 227 |
| 3 | | 89–95, 101–120, 124–131, 136–142, | ,11 | Jul 321 371 | A TOTAL COLICOLO SOLITORIA | |
| ľ | 2-epimerase) | 145-157, 174-181, 184-191, 196- | | | | |
| | 2 opiniciase) | 204, 215–224, 228–236, 243–250, | | | | |
| | | 259-266, 274-281, 293-301, 314- | | | | |
| | | | 1 | | | |
| <u> </u> | <u> L</u> | 319, 325-331, 355-367, 373-378 | | <u> </u> | <u> </u> | .— |

| S. | Putative function | predicted immunogenic aa** | No. of se- | Location of | Serum reactivity with relevant | Seq ID |
|-----------|--------------------|-------------------------------------|------------|--------------|--------------------------------|--|
| aureus | (by homology) | • | lected | identified | region (positive/total) | no: |
| antigeni | (5) | | clones | immuno- | | (DNA |
| e protein | | | per ORF | genic region | | +Prot) |
| o protein | | | and | g | | |
| | | | screen | | | |
| ORF262 | Hypothetical pro- | 9-15, 28-36, 44-62, 69-88, 98-104, | F:6 | aa 694-708 | F:SALBD82(1288-1303):9/41 | 209, 228 |
| 8 | tein | 111-136, 139-149, 177-186, 195- | | aa 790-800 | |]] |
| | | 217, 224–236, 241–257, 260–278, | | aa 1288 | | |
| | | 283-290, 292-373, 395-408, 411- | | 1305 | | |
| | | 443, 465-472, 475-496, 503-520, | | | | |
| | | 552-559, 569-589, 593-599, 607- | | | | |
| | | 613, 615–636, 648–654, 659–687, | | | | |
| | | 689-696, 721-733, 738-759, 783- | | | | |
| ŀ | | 789, 795-801, 811-823, 827-836, | | | | |
| | | 839-851, 867-875, 877-883, 890- | | | | |
| | | 898, 900-908, 912-931, 937-951, | | | | |
| | : | 961-992, 994-1002, 1005-1011, | • | | | |
| | | 1016-1060, 1062-1074, 1088-1096, | | | | |
| | | 1101-1123, 1137-1153, 1169-1192, | | | | i i |
| | | 1210-1220, 1228-1239, 1242-1251, | | | | |
| | | 1268-1275, 1299-1311, 1322-1330, | | | | |
| | ĺ | 1338-1361, 1378-1384, 1393-1412, | | | | |
| | | 1419-1425, 1439-1459, 1469-1482, | | | , | |
| | | 1489-1495, 1502-1519, 1527-1544, | | | ÷ | |
| | | 1548-1555, 1600-1607, 1609-1617, | | | | |
| | | 1624-1657, 1667-1691, 1705-1723, | | | | |
| | | 1727–1742, 1749–1770, 1773–1787, | | • | · | |
| | | 1804-1813, 1829-1837, 1846-1852, | | ļ | | |
| | | 1854–1864, 1869–1879, 1881–1896, | | 1 | | |
| | | 1900-1909, 1922-1927, 1929-1935, | | | | |
| | | 1942-1962, 1972-2005, 2009-2029, | | | | |
| } | , | 2031–2038, 2055–2076, 2101–2114, | | | · | |
| | | 2117-2124, 2147-2178, 2188-2202, | | | | |
| | | 2209-2217, 2224-2230, 2255-2266, | | | | |
| | | 2271-2280, 2282-2302, 2307-2316, | | | | |
| 1 | | 2319-2324, 2379-2387 | | | | |
| ORF264 | PTS system, su- | 8-15, 24-30, 49-68, 80-93, 102-107, | F:4 | aa 106-159 | F:SALAW60(106-125):3/41 | 210, 229 |
| 4 | crose-specific | 126-147, 149-168, 170-180, 185- | | | | |
| | IIBC component | 193, 241–305, 307–339, 346–355, | Ì | | | |
| | | 358-372, 382-390, 392-415, 418- | | | | |
| | | 425, 427-433, 435-444, 450-472 | | | | |
| ORF265 | Oligopeptide ABC | 5-61, 72-84, 87-99, 104-109, 124- | D: 5 | aa 182 -209 | D: n.d. | 321, 349 |
| 4 | transporter, puta- | 145, 158–170, 180–188, 190–216, | | | | 1 |
| | tive | 223-264, 270-275, 296-336, 355-372 | ļ | | | 011 000 |
| ORF266 | maltose ABC | 1, | F:1 | aa 306-323 | F:SALBC05(306-323):2/41 | 211, 230 |
| 2 | transporter, puta- | 161, 199–205, 219–235, 244–258, | | | | |
| } | tive | 265-270, 285-291, 300-308, 310- |] | |] | |
| | | 318, 322–328, 346–351, 355–361, | | 1 | | |
| | 1 | 409-416 | <u> </u> | <u> </u> | | ــــــــــــــــــــــــــــــــــــــ |

| S. | Putative function | predicted immunogenic aa** | No. of se- | Location of | Serum reactivity with relevant | Seq ID |
|-----------|--------------------|-------------------------------------|------------|--------------|--------------------------------|----------|
| aureus | (by homology) | | lected | identified | region (positive/total) | no: |
| antigeni | | | clones | immuno- | _ | (DNA |
| c protein | 1 | | per ORF | genic region | | +Prot) |
| | | | and | | | |
| | | ! | screen | , | | |
| ORF271 | sorbitol | 4-12, 19-40, 61-111, 117-138, 140- | B:2, F:4 | aa 244-257 | F:SALAX93(249-256):6/41 | 212, 231 |
| 0 | dehydrogenase | 153, 161-180, 182-207, 226-235, | | | · | |
| | } | 237-249, 253-264, 267-274, 277- | | | , | |
| | | 292, 311-323 | | İ | | |
| ORF274 | Hypothetical pro- | 4-41, 49-56, 61-67, 75-82, 88-104, | D: 188, | aa 303 - 323 | D: n.d. | 322, 350 |
| 2 | tein | 114-125, 129-145, 151-165, 171- | H:4 | Ì | | |
| } | | 178, 187-221, 224-230, 238-250, | | | | |
| | | 252-275, 277-304, 306-385 | | | | |
| ORF278 | brnQ | 4-29, 41-63, 74-95, 97-103, 107- | D: 3 | aa 26 40 | D; n.d. | 323, 351 |
| 0 | | 189, 193-209, 220-248, 260-270, | ŀ | | | ŀ |
| | | 273-299, 301-326, 328-355, 366- | } | | | |
| | | 397, 399-428 | | | | |
| ORF280 | Phage related pro- | 10-17, 23-29, 31-37, 54-59, 74-81, | F:3 | aa 104-116 | F:SALBC34:1/I | 213, 232 |
| 6 | tein | 102-115, 127-137, 145-152, 158- | | | | |
| 1 | | 165, 178–186, 188–196, 203–210, | | | | |
| | | 221-227, 232-237 | | | | |
| ORF290 | Conserved hypo- | 4-27, 34-43, 62-73, 81-90, 103-116, | D: 24 | aa 360 - 376 | D: n,d, | 324, 352 |
| 0 | thetical protein | 125-136, 180-205, 213-218, 227- | . | | | |
| } | | 235, 238-243, 251-259, 261-269, | ļ. | | | { · |
| | 1 | 275-280, 284-294, 297-308, 312- | | | | |
| } | } | 342, 355–380, 394–408, 433–458, | | | | |
| | | 470-510, 514-536, 542-567 | | <u> </u> | | |
| ORF293 | conserved | 4-19, 43-54, 56-62, 84-90, 96-102, | E:6 | aa 22~37 | E:GSBZA13(22~37):7/41 | 214, 233 |
| 1 | hypothetical | 127-135, 157-164, 181-187 | Ì | | | 1 |
| | protein | | <u> </u> | | | 202 221 |
| ORF295 | Exotoxin 2 | 7-19, 26-39, 44-53, 58-69, 82-88, | F;1 | aa 154-168 | F:SALBB59(154~168):4/41 | 215, 234 |
| 8 | | 91-107, 129-141, 149-155, 165-178, | | | | |
| | | 188-194 | 77.5 | | T. CODYTY C | 200 400 |
| ORF297 | Surface protein, | 9-23, 38-43, 55-60, 69-78, 93-101, | H:5 | aa 1-70 | H:GSBYU66: n.d. | 399, 400 |
| 0 | putative | 103-112, 132-148, 187-193, 201- | | 1 | | |
| | | 208, 216-229, 300-312, 327-352, | 1 | | | |
| l | ł | 364-369, 374-383, 390-396, 402- | | 1 | | 1 |
| <u> </u> | <u> </u> | 410, 419-426, 463-475, 482-491 | <u></u> | L | <u> </u> | <u> </u> |

Table 2c: Immunogenic proteins identified by bacterial surface and ribosome display: S. epidermidis.

Bacterial surface display: A, LSE150 library in fhuA with patient sera 2 (957); B, LSE70 library in lamB with patient sera 2 (1420); C, LSE70 library in lamB with patient sera 1 (551). Ribosome display: D, LSE150 in pMAL4.31 with P2 (1235). **, prediction of antigenic sequences longer than 5 amino acids was performed with the programme ANTIGENIC (Kolaskar and Tongaonkar,

1990). ORF, open reading frame; ARF, alternative reading frame; CRF, reading frame on complementary strand. ORF, open reading frame; CRF, reading frame on complementary strand.

| S. <i>epidermidi</i> s antigenic protein | Putative function (by homology) | predicted immunogenic aa** | No. of selected clones per ORF and screen | Location of identified immuno— genic region | Serum reactivity with relevant region (positive/total) | Seq ID no: (DNA +Prot) |
|---|---|----------------------------|--|--|--|---------------------------------|
| ARF0172 | cation-transport- ing ATPase, EI- E2 family | 4–34, 37–43 | D:6 | aa332 | D: nd | 497, 548 |
| ARF0183 | condensing en- zyme, putative, FabH-related | 4-22, 24-49 | D:4 | aa1-52 | D: nd | 498, 5 49 |
| ARF2455 | NADH dehydrogenase, putative | 4-29 | D:3 | aa1-22 | D: nd | 499, 550 |
| CRF0001 | Unknown | 4-14, 16-26 | D:3 | aa5-21 | D: nd | 500, 551 |
| CRF0002 | Unknown | 4-13, 15-23, 36-62 | D:5 | aa2170 | D: nd | 501, 552 |
| CRF0003 | Unknown | 4-12, 14-28 | D:3 | aa 4–31 | D: nd | 502, 553 |
| CRF0004 | Unknown | 5-15, 35-71, 86-94 | D:4 | aa31-72 | D: nd | 503, 554 |
| CRF0005 | Unknown | 8-26, 28-34 | D:3 | aa:9-33 | D: nd | 504, 555 |
| CRF0006 | Unknown | 4-11, 15-28 | D:3 | aa10-22 | D: nd | 505, 556 |
| CRF0007 | Unknown | 4-19, 30-36 | D:3 | aa 7-44 | D: nd | 506, 557 |
| CRF0008 | Unknown | 10-48 | D:4 | aa:9-44 | D: nd | 507, 558 |
| CRF0009 | Unknown | 41883 | D:3 | aa5-14 | D: nd | 508, 559 |
| CRF0192 | Putative protein | 4-23, 25-68 | C:4 | aa 15-34 | C:GSBBM10(15-34): n.d. | 445, 446 |

| S. | Putative function | predicted immunogenic aa** | No. of | Location of | Serum reactivity with relevant | Seq ID |
|-------------|-------------------|--|---------------|--------------|--------------------------------|-------------|
| epidermidi | (by homology) | predicted minutings and da | selected | identified | region (positive/total) | no: |
| s antigenic | (by homology) | | clones | immuno- | region (postere total) | (DNA |
| protein | | .* | per ORF | genic region | | +Prot) |
| brotein | | | - | genic region | | +Prot) |
| | | | and | | j | |
| CRF0275 | Putative protein | 4-40, 49-65 | screen B;5 | aa 35-68 | B;SELAK28(35-68); n.d. | 447, |
| CKI-02/3 | rutative protein | 14 40,45 03 | B.3 | aa 55 00 | D.5CLAR26(55 00). n.u. | 448 |
| CRF0622 | Putative protein | 4-12, 17-57, 62-70, 75-84, 86-100 | C:4 | aa 75-99 | C:GSBBR74(76-99); n.d. | 449, |
| | • | , | 1 | | | 450 |
| CRF0879 | Putative protein | 4-14, 38-44 | A:3, B:10 | aa 9-40 | B:SELAC39(10-40): n.d. | 451, |
| | | | | | | 452 |
| CRF1004 | Putative protein | 4-40 | A:3, B:5 | aa 2965 | B:SELAI63(35-63): n.d. | 453, |
| | | | | | | 454 |
| CRF2248 | Putative protein | 410, 1940, 5364, 7491 | C:30 | aa 74-111 | C:GSBBN64(16-35): n.d. | 455, |
| CDTCCC | Dati | 4 10 25 41 00 00 | A.10 | 41 07 | A. GENERAL AGAIL OCT | 456 |
| CRF2307 | Putative protein | 4-19, 35-41, 80-89 | A:19 | aa 4187 | A:SEFAL47(41-87):n.d. | 457, |
| CRF2309 | Putative protein | 15-21 | B:6 | aa 4-16 | B:SELAL02(4-16): n.d. | 458 459, |
| CIG 2309 | 1 dimerve protein | 13 21 | D.0 | 4 10 | D.O.D.C. TOJ. II.d. | 460 |
| CRF2409 | Putative protein | 625 | B:6 | aa 2-24 | B:SELAB48(5-24): n.d. | 461, |
| | - | | | | , , | 462 |
| ORF0005 | hypothetical pro- | 13-27, 33-67, 73-99, 114-129, 132- | D:3 | aa105-128 | D: nd | 509, |
| 014.0003 | - | | 15.5 | aa103 120 | D. IId | |
| | tein | 158, 167–190, 193–234, 237–267, | | | | 560 |
| | | 269-299, 316-330, 339-351, 359- | | | | |
| | | 382, 384423 | | | | |
| ORF0008 | Streptococcal he- | 9-14, 16-24, 26-32, 41-50, 71-79, | B:2 | aa 895-926 | B:SELAF79(895-926): 7/12 | 239, |
| | magglutinin | 90-96, 177-184, 232-237, 271-278, | | | | 268 |
| | | 293–301, 322–330, 332–339, 349– | | | | |
| | | 354, 375–386, 390–396, 403–409, | | | | |
| | | 453-459, 466-472, 478-486, 504- | | | | |
| | | 509, 518525, 530541, 546552, | ٠. | | | |
| | | 573-586, 595-600, 603-622, 643- | |] | | |
| | | 660, 668–673, 675–681, 691–697, | | | | |
| | | 699-711, 713-726, 732-749, 753- | | | | |
| | | 759, 798–807, 814–826, 831–841, | | | | |
| | | 846-852, 871-878, 897-904, 921- | ļ | | i . | j, |
| | | 930, 997–1003, 1026–1031, 1033– 1039, 1050–1057, 1069–1075, 1097– | | | t | |
| | | 1103, 1105–1111, 1134–1139, 1141– | | · . | | |
| | | 1147, 1168–1175, 1177–1183, 1205– | | | | |
| , | | 1211, 1213–1219, 1231–1237, 1241– | | ļ · | | |
| | | 1247, 1267–1273, 1304–1309, 1311– | | | | |
| | | 1317, 1329–1335, 1339–1345, 1347– | ļ | | · | |
| | | 1353, 1382–1389, 1401–1407, 1411– | | | | |
| | | 1417, 1447–1453, 1455–1461, 1483– | | | | 1 |
| į | | 1489, 1491–1497, 1527–1533, 1545– | | | | |
| | | 1551, 1556–1561, 1581–1587, 1591– | Ü | 1 | | |
| | | 1597, 1627–1638, 1661–1667, 1684– | | | | |
| | | 1689, 1691–1697, 1708–1715, 1719– | | | | |
| | | 1725, 1765-1771, 1813-1820, 1823- | | | | |
| | | 1830, 1835–1856 | 1 | | | 1 |
| | | · · · · · · · · · · · · · · · · · · · | | | | |

| S. | Putative function | predicted immunogenic aa** | No. of | Location of | Serum reactivity with relevant | Seq ID |
|-------------|-------------------|--|---------------|--------------|--------------------------------|-------------|
| epidermidi | (by homology) | • | selected | identified | region (positive/total) | no: |
| s antigenic | | | clones | immuno− | | (DNA |
| protein | | | per ORF | genic region | | +Prot) |
| | | | and | | | |
| ORF0038 | extracellular | 6-25, 29-35, 39-45, 64-71, 82-88, | screen C:6 | aa 136-165 | C:GSBBN08(136-165):1/1 | 353,359 |
| OKI 0050 | i i | 96-102, 107-113, 119-131, 170-176, | | | | |
| | | 186-192, 196-202, 215-220, 243- | | | | |
| | | 248, 302–312, 345–360, 362–371, | | | | |
| | | 378–384, 458–470, 478–489, 495– | | | | l |
| ORF0099 | hypothetical | 504 6-18, 31-37, 42-49, 51-67, 73-85, | D:5 | aa218-265 | D: nd | 510, |
| OKF0099 | | 87–93, 102–109, 119–126, 150–157, | 2.5 | | | 561 |
| | protein | , | | | | |
| | | 170-179; 185-191, 204-214, 217- | | | | |
| | } | 223, 237–248, 269–275, 278–316, | | | | |
| | | 320-340, 359-365 | | | | |
| ORF0101 | hypothetical | 4-10, 15-27, 67-94, 123-129, 167- | D:18 | aa26-109 | D: nd | 511, |
| | protein | 173, 179–184, 187–198, 217–222, | | | | 562 |
| • • | | 229-235, 238-246 | | | | |
| ORF0121 | C4-dicarboxylate | 4-20, 24-62, 73-86, 89-106, 110- | D:5 | aa323-379 | D: nd | 512, |
| | transporter, an- | 122, 131–164, 169–193, 204–213, | | | | 563 |
| | aerobic, putative | 219-236, 252-259, 263-281, 296- | | | | |
| | | 306, 318–324, 328–352, 356–397, | | | | |
| | | 410–429 | | | | |
| ORF0143 | amino acid per- | 25-79, 91-103, 105-127, 132-150, | D:35 | aa247-339 | D: nd | 513, |
| | mease | 157-174, 184-206, 208-219, 231- | | | | 564 |
| | | 249, 267–294, 310–329, 336–343, | | | | |
| | | 346-405, 417-468 | , | | | |
| ORF0162 | Immunodominant | 4-27, 35-45, 52-68, 83-89, 113-119, | | aa 90-227 | B:SELAA19(100-118): 1/I | 240, |
| | Antigen A | 133-150, 158-166, 171-176, 198- | B:11; | | B:SELAE24(170-190): 11/12 | 269 |
| | | 204, 219–230 | C:153 | | | |
| ORF0201 | capa protein, | 10-17, 27-53, 81-86, 98-105, 126- | D:9 | aa11-53 | D: nd | 514, |
| | putative | 135, 170-176, 182-188, 203-217, | | | ļ | 565 |
| | | 223-232, 246-252, 254-269, 274- | Ì | | | |
| | | 280, 308-314 | <u> </u> | <u> </u> | | - |
| ORF0207 | Ribokinase (rbsK) | 1 ' ' | B:10 | aa 20-45 | B:SELAQ30 (20-45): 12/12 | 241, 270 |
| | *. | 108-114, 126-132, 134-156, 161- 186, 191-197, 210-224, 228-235, | | | | |
| | | 239-248, 258-264, 275-290 | | | | |
| ORF0288 | LrgB | 7-28, 34-56, 68-119, 127-146, 149- | D:4 | aa112-149 | D: nd | 515, |
| | | 180, 182–189, 193–200, 211–230 | | | | 566 |

| S. epidermidi s antigenic protein | Putative function (by homology) | predicted immunogenic aa** | No. of selected clones per ORF | Location of identified immuno- genic region | Serum reactivity with relevant region (positive/total) | Seq ID no: (DNA +Prot) |
|-----------------------------------|---|--|---|--|---|------------------------|
| protein | | | and screen | Bama ragian | | |
| ORF0304 | Herpęsvirus saimiri ORF73 homolog, putative | 8-16, 30-36, 83-106, 116-122, 135- 143, 152-165, 177-188, 216-225 | D:8 | aa69-117 | D: nd | 516, 567 |
| ORF0340 | nitrate transporter | 7-21, 24-93, 101-124, 126-139, 141-156, 163-179, 187-199, 202- 242, 244-261, 267-308, 313-322, 340-353, 355-376 | D:5 | aa238~309 | D: nd | 517, 595 |
| ORF0346 | hypothetical pro- | 8–27, 65–73, 87–93, 95–105 | D:8 | aa 1–29 | D: nd | 518, 568 |
| ORF0355 | conserved hypothetical protein | 5-30, 37-43, 57-66, 85-94, 103-111, 118-125 | C:5 | aa 63-86 | C:GSBBL39(63-86):1/1 | 354, 360 |
| ORF0356 | conserved hypo- | 4-14, 21-53, 60-146, 161-173, 175- 182, 190-198, 200-211 | D:5 | aa51-91 | D: nd | 519, 569 |
| ORF0406 | hypothetical pro- | 12–32, 35–63, 68–102, 106–137, 139–145, 154–168, 173–185, 203– 222, 230–259, 357–364, 366–374 | D:19 | aa1-48, aa69-102 | — D: nd | 520, 570 |
| ORF0425 | amino acid per- mease | 40-58, 75-86, 93-110, 117-144, 150-173, 199-219, 229-260, 264- 300, 317-323, 329-356, 360-374, 377-390, 392-398, 408-424, 427- 452 | D:3 | ав401-440 | D: nd | 521, 571 |
| ORF0442 | SceB precursor | 7-22, 42-48, 55-66, 83-90, 109-118, 136-141 | C:38 | аа 60-102 | C:GSBBM60(65-84):1/1 | 355, 361 |
| ORF0448 | SsaA precursor | 6-25, 39-47, 120-125, 127-135, 140-148, 157-168, 200-208, 210- 220, 236-243, 245-254 | C:170 | aa 15-208 | C:GSBBN58(81-105):1/1 C:GSBBL13(167-184):1/1 C:GSBBL25(22-45):1/1 | 356, · 362 |
| ORF0503 | Ribosomal protein L2 | 31–39, 48–54, 61–67, 75–83, 90–98, 103–115, 123–145, 160–167, 169–176, 182–193, 195–206, 267–273 | A:1, B:3 | aa 212-273 | B:SELAA47(238-259):12/12 | 242, 271 |
| ORF0551 | Conserved hypo- thetical protein | 5-25, 29-36, 45-53, 62-67, 73-82, 84-91, 99-105, 121-142, 161-177, 187-193, 203-224, 242-251, 266- 271, 278-285 | A:16, B:9 | aa 162-213 | B:SELAL12(164-197): 8/12 | 243, 272 |
| ORF0556 | hypothetical pro- | 4-24, 30-41, 43-68, 82-90, 107-114, 123-143, 155-168 | D:3 | aa 126 | D: nd | 522, 596 |

| S. | Putative function | predicted immunogenic aa** | No. of | Location of | Serum reactivity with relevant | Seq ID |
|-------------|-------------------|------------------------------------|-----------|--------------|--------------------------------|-------------|
| epidermidi | (by homology) | | selected | identified | region (positive/total) | no: |
| s antigenie | (4) | | clones | immuno- | | (DNA |
| protein | | | per ORF | genic region | | +Prot) |
| | | | and | | | l |
| | | | screen | | | |
| ORF0623 | Fumble, putative | 10-17, 32-38, 55-72, 77-84, 88-96, | A:10, | aa 95-150 | B:SELAB86(95-128): 3/12 | 244, |
| | · - | 126-134, 152-160, 176-185, 190- | B:12; C:1 | | | 273 |
| | | 203, 208-214, 217-225, 233-252, | | | | |
| | | 257–262 | | | | |
| ORF0740 | Hypothetical pro- | 18-24, 47-61, 69-83, 90-96, 125- | B:3 | aa 1093- | B:SELAB23(1097-1114): 7/12 | 245, |
| | tein | 132, 140–163, 171–188, 222–249, | | 1114 | | 274 |
| | | 281-296, 305-315, 322-330, 335- | , | | | |
| | | 351, 354-368, 390-397, 411-422, | | | | i i |
| | | 424-431, 451-469, 479-485, 501- | | | | |
| | | 507, 517-524, 539-550, 560-568, | | | | |
| ļ | | 588-599, 619-627, 662-673, 678- | | | | |
| | | 689, 735-742, 744-749, 780-786, | | | | |
| | | 797-814, 821-827, 839-847, 857- | | | | |
| | | 863, 866-876, 902-911, 919-924, | | | , | |
| | | 967–982, 1005–1015, 1020–1026, | | | , | 1. |
| | | 1062-1070, 1078-1090, 1125-1131, | | | | |
| | | 1145-1150, 1164-1182, 1208-1213, | | | | |
| | | 1215-1234, 1239-1251, 1256-1270, | | | | |
| | | 1298-1303, 1316-1325, 1339-1349, | | ! | | |
| | | 1362-1369, 1373-1384, 1418-1427, | | | | |
| | | 1440-1448, 1468-1475, 1523-1532, | | | | |
| | | 1536-1542, 1566-1573, 1575-1593, | | | | |
| | | 1603-1619, 1626-1636, 1657-1667, | | ł | | |
| | ļ | 1679–1687, 1692–1703, 1711–1718, | | | | |
| | | 1740-1746, 1749-1757, 1760-1769, | l | İ | | |
| | | 1815-1849, 1884-1890, 1905-1914, | | 1 | | |
| | | 1919–1925, 1937–1947, 1955–1963, | | | | |
| | 1 | 1970–1978, 2003–2032, 2075–2089, | | · . | | |
| | | 2117-2124, 2133-2140, 2146-2151, | | | | |
| | | 2161-2167, 2173-2179, 2184-2196, | | | | |
| | İ | 2204-2220, 2244-2254, 2259-2264, | | | | |
| 1 | | 2285-2296, 2300-2318, 2328-2334, | | | | |
| | | 2347-2354, 2381-2388, 2396-2408, | | | | |
| | | 2419-2446, 2481-2486, 2493-2500, | 1 | | | |
| | | 2506-2516, 2533-2540, 2555-2567, | 1 | | | |
| 1 | 1 | 2576-2592, 2599-2606, 2615-2639, | | | | 1 |
| | | 2647-2655 | 10.6 | 060.001 | CICEDDNOLOCO COANTO | 257 |
| ORF0757 | hypothetical | 13-20, 22-28, 33-40, 60-76, 79-86, | C:6 | aa 260-284 | C:GSBBN01(260-284):1/1 | 357, 363 |
| | protein | 90-102, 112-122, 129-147, 157-170, | · | | | 303 |
| | | 178–185, 188–193, 200–205, 218– | 1 | | | |
| | | 228, 234–240, 243–250, 265–273, | | | | |
| | | 285-291, 310-316, 330-348, 361- | | | | |
| | <u> </u> | 380, 399–405, 427–446, 453–464 | <u> </u> | <u> </u> | 1 | |

| S. | Putative function | predicted immunogenic aa** | No. of | Location of | Serum reactivity with relevant | Seq ID |
|-------------|--------------------|-------------------------------------|-----------|--------------|--------------------------------|-------------|
| epidermidi | (by homology) | | selected | identified | region (positive/total) | no: |
| s antigenic | | | clones | immuno- | | (DNA |
| protein | | | per ORF | genic region | | +Prot |
| | | | and | | | |
| | | | screen | | | |
| ORF0912 | DNA mismatch | 9-16, 28-39, 47-56, 69-76, 104-121, | A:25 | aa 242-304 | SEFAT31(242-290); n.d. | 441, |
| | repair protein | 124-130, 137-144, 185-195, 199- | | | | 442 |
| | | 214, 238–243, 293–307, 317–337, | | | | |
| | | 351-370, 385-390, 411-428, 472- | | | | |
| | | 488, 498–516, 518–525, 528–535, | | | | |
| | | 538-545, 553-559, 563-568, 579- | | | | |
| | | 588, 592-607, 615-622, 632-638, | | | | |
| | | 641-648, 658-674, 676-705, 709- | | | | |
| | | 720, 727–739, 742–750, 753–760, | | | | |
| | | 768-773, 783-788, 811-819, 827- | 1 | | | |
| | | 838 | | | | <u> </u> |
| ORF0923 | GTP-binding | 4-10, 18-27, 42-55, 64-72, 77-92, | B:13 | aa 144-163 | B:SELAD55(151-163): 8/12 | 246, |
| | protein | 114-126, 132-157, 186-196, 206- | ļ | | | 275 |
| | | 217, 236–243, 257–280, 287–300, | | | | |
| | | 306-312, 321-328, 338-351, 360- | | | • | |
| 000000 | ~ | 367, 371–382, 385–399 | 1.0 P.10 | 10 61 | T) OTT ATTOLOGY 103-5/10 | 247 |
| ORF0979 | Conserved hypo- | 4-28, 44-51, 53-84, 88-107, 113- | A:9, B:18 | aa 12-51 | B:SELAH01(26-49):5/12 | 247, 276 |
| | thetical protein | 192 | | | | 276 |
| ORF0982 | sodium/alanine | 13-21, 24-50, 73-84, 91-118, 126- | D:3 | aa277-305 | D: nd | 523, |
| | symporter (alsT) | 133, 142–149, 156–175, 189–249, | | | • • | 572 |
| | | 251-273, 294-332, 339-347, 358- | | | | |
| | | 381, 393-413, 425-448, 458-463 | | | | |
| ORF1230 | Signal peptidase I | 6-33, 44-59, 61-69, 74-82, 92-98, | D:14 | aa 1-53 | D: nd | 524, |
| | | 133–146, 163–175 | | | | 573 |
| ORF1232 | Exonuclease | 4-12, 16-32, 36-48, 50-65, 97-127, | В:б | aa 188-219 | B:SELAA13(188-216): n.d. | 443, |
| - | RexA | 136-142, 144-165, 176-190, 196- | | | | 444 |
| | | 202, 211–222, 231–238, 245–251, | | | | |
| | | 268-274, 280-286, 305-316, 334- | | | | |
| • | | 356, 368–376, 395–402, 410–417, | | | | 1 |
| | | 426-440, 443-449, 474-486, 499- | | | , | 1 |
| | | 508, 510-525, 540-549, 568-576, | | | | |
| | | 608-617, 624-639, 646-661, 672- | | | • | 1 |
| | | 678, 688–703, 706–717, 727–734, | | | | 1 |
| | | 743-755, 767-773, 783-797, 806- | | 1 | | |
| | | 814, 830-839, 853-859, 863-871, | | | | İ |
| | | 877-895, 899-918, 935-948, 976- | | | | |
| | | 990, 998-1007, 1020-1030, 1050- | | | | |
| | | 1062, 1070–1077, 1111–1125, 1137– | | | | |
| | | 1149, 1153-1160, 1195-1211 | | | | <u> </u> |
| ORF1284 | permease PerM, | 10-60, 72-96, 103-109, 127-133, | D:27 | aa55-106 | D: nd | 525, |
| | putative | 146-177, 182-189, 196-271, 277- | | | | 574 |
| | Ī | 289, 301-319, 323-344, 347-354 | 1 | | | 1 |

| S. | Putative function | predicted immunogenic aa** | No. of | Location of | Serum reactivity with relevant | Seq ID |
|-------------|--------------------|------------------------------------|----------|---------------|---|--------|
| epidermidi | (by homology) | producted animalis going an | selected | identified | region (positive/total) | no: |
| s antigenic | (by nomorogy) | | clones | imnuno- | 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | (DNA |
| protein | | : | per ORF | genic region | | +Prot) |
| proton | | | and | goine region. | | |
| | | | screen | | | |
| ORF1319 | 2-oxoglularate | 9-31, 36-45, 59-67, 71-81, 86-94, | B:5; C:1 | aa 400-413 | B:SELAF54(404-413): 11/12 | 248, |
| | decarboxylase | 96-107, 111-122, 127-140, 153-168, | | | 4 | 277 |
| | (menD) | 180-211, 218-224, 226-251, 256- | | | | |
| | | 270, 272–289, 299–305, 310–323, | | · | | |
| | | 334-341, 345-353, 358-364, 369- | | | | |
| | | 379, 384-390, 396-410, 417-423, | | | |]] |
| | | 429-442, 454-464, 470-477, 497- | | | , | |
| | | 505, 540-554 | | | | |
| ORF1326 | autolysin AtlE | 6-25, 40-46, 75-81, 150-155, 200- | B:7; C:5 | aa 1282- | B:SELAD20(1282-1298): 10/12 | 249, |
| | (lytD) | 205, 237–243, 288–295, 297–306, | | 1298 | | 278 |
| | | 308-320, 341-347, 356-363, 384- | | | | |
| | | 391, 417-429, 440-452, 465-473, | | | • | |
| | | 481-514, 540-546, 554-560, 565- | 1 | | | |
| | | 577, 585-590, 602-609, 611-617, | | | | |
| | | 625-634, 636-643, 661-668, 676- | | | | 1 |
| | | 684, 718-724, 734-742, 747-754, | | 1 | | |
| | | 766-773, 775-781, 785-798, 800- | | ļ | | |
| | | 807, 825-832, 840-857, 859-879, | | | | |
| | ĺ | 886-892, 917-923, 950-956, 972- | | | • | |
| | | 978, 987-1002, 1028-1035, 1049- | l | | | |
| | | 1065, 1071–1099, 1111–1124, 1150– | İ | | | |
| | | 1172, 1185–1190, 1196–1207, 1234– | | | | |
| | · · | 1241, 1261-1271, 1276-1281, 1311- | | | | |
| | | 1320, 1325–1332 | | | · | |
| ORF1333 | quinol oxidase | 4-27, 33-55, 66-88 | D:4 | аа 3—93 | D: nd | 526, |
| | polypeptide iv (ec | | | | | 575 |
| | 1.9.3) (quinol | - | | | • | |
| · | oxidase aa3-600, | | 1 | | | |
| | subunit qoxd) | | | | ; —) | |
| ORF1356 | hypothetical pro- | 9-36, 44-67, 74-97, 99-149, 161- | D:32 | aa54—95 | D; nd | 527, |
| | tein | 181, 189–198, 211–224, 245–253, | | | | 597 |
| | | 267-273, 285-290, 303-324, 342- | | | į į | |
| | | 394, 396–427 | | | | |
| ORF1373 | dihydrolipoamide | 33-39, 42-78, 103-109, 126-136, | A:3, B:1 | aa 124-188 | A:SEFAP57(124-188): 2/12 | 250, |
| | acetyltransferase | 184-191, 225-232, 258-279, 287- | } | | | 279 |
| | | 294, 306-315, 329-334, 362-379, | | | | 1 |
| | | 381-404, 425-430 | | | | |
| ORF1381 | hypothetical pro- | 21-45, 62-67, 74-106, 108-142, | D:5 | aa744 | D: nd | 528, |
| | tein | 154-160, 230-236, 245-251, 298- | | | | 576 |
| | | 305 | | | | |
| | <u> </u> | | 1 | ٠ | <u> </u> | |

| S, | Putative function | predicted immunogenic aa** | No. of | Location of | Serum reactivity with relevant | Seq ID |
|-------------|--------------------|--|---------------|--------------|--------------------------------|--------|
| epidermidi | (by komology) | , | selected | identified | region (positive/total) | no: |
| s antigenic | | | clones | immuno- | | (DNA |
| protein | | | per ORF | genic region | | +Prot) |
| | | | and | | | |
| ORF1420 | Muts2 protein, | 8-32, 34-41, 46-55, 70-76, 81-89, | screen B:7 | aa 581-608 | B:SELAM40(581-604): 9/12 | 251, |
| ORI 1420 | putative | 97-115, 140-148, 153-159, 165-171, | | LL 201 GGO | B.OLLIMITO(301 004). 312 | 280 |
| | . | 175-188, 207-239, 256-276, 280- | | | | |
| | | 289, 297-319, 321-335, 341-347, | | | | |
| | | 352-360, 364-371, 384-411, 420- | | | | |
| | | 440, 449460, 495-502, 505-516, | | | | |
| | | 560-566, 573-588, 598-605, 607- | | | | |
| | · | 614, 616–624, 674–694, 702–717 | | | | - |
| ORF1443 | cell division | 61–66, 111–117, 148–155, 173–182, | D:4 | aa175-229 | D: nd | 529, |
| | protein (divIB) | 194-224, 263-293, 297-303, 313- | | | | 577 |
| | | 321, 334-343, 345-356, 375-381, | | | | |
| | | 384-395, 408-429, 448-454 | | | | |
| ORF1500 | Cell division pro- | 100-107, 154-167, 182-193, 200- | A:2, B:3 | aa 77-182 | B:SELAP37(139-162): 9/12 | 252, |
| | tein FtsY | 206, 223–231, 233–243, 249–257, | | | | 281 |
| | | 265-273, 298-310, 326-336, 343- | | | | |
| | | 362, 370–384 | <u> </u> | | | |
| ORF1665 | amino acid ABC | 4-25 , 4 4-55 , 66-76, 82-90, 93-99, | D :5 | aa 1~52 | D: nd | 530, |
| | transporter, | 104-109, 176-209, 227-242, 276- | | | pr. 4-, | 578 |
| | permease protein | 283, 287–328, 331–345, 347–376, | | | | |
| | i | 400-407, 409-416, 418-438, 441- | | | , | |
| | | 474 | | | (,,,,) | |
| ORF1707 | putative host cell | 12-31, 40-69, 129-137, 140-151, | D:4 | aa 20-76 | D: nd | 531, |
| | surface-exposed | 163–171, 195–202, 213–218 | | | | 598 |
| | lipoprotein | | | | | |
| | | | <u> </u> | | | |
| ORF1786 | D-3- | 4-10, 16-32, 45-55, 66-78, 87-95, | D:5 | aa400-442 | D: nd | 532, |
| | phosphoglycerate | 103-115, 118-124, 135-150, 154- | | | | 579 |
| | dehydrogenase, | 161, 166-174, 182-193, 197-207, | | | | |
| | putative | 225-231, 252-261, 266-304, 310- | | | | |
| | | 315, 339-347, 351-359, 387-402, | Ì | | | |
| | | 411-423, 429-436, 439-450, 454- | | | | |
| | | 464, 498-505, 508-515 | | | | |
| ORF1849 | yhjN protein | 8-51, 53-69, 73-79, 85-132, 139- | D:5 | aa254-301 | D: nd | 533, |
| , | | 146, 148-167, 179-205, 212-224, | | | | 580 |
| | | 231-257, 264-293, 298-304, 309- | | | | |
| | | 317, 322–351 | | 1 | | |
| | | | <u> </u> | <u> </u> | <u> </u> | |

| S. | Putative function | predicted immunogenic aa** | No. of | Location of | Serum reactivity with relevant | Seq ID |
|-------------|-------------------|--|----------|--------------|---|--------|
| epidermidi | (by homology) | • | selected | identified | region (positive/total) | no: |
| s antigenic | | | clones | immuno- | | (DNA |
| protein | | | per ORF | genic region | | +Prot) |
| | | | and | | · | 1 |
| | | | screen | | | |
| ORF1877 | protein-export | 6-19, 26-39, 41-51, 59-67, 72-85, | D:7 | aa367-409 | D: nd | 534, |
| | membrane protein | 91-98, 104-111, 120-126, 147-153, | | | | 581 |
| | SecD (secD-1) | 158-164, 171-178, 199-209, 211- | | | | |
| | | 218, 233–249, 251–257, 269–329, | | | | |
| | | 362-368, 370-385, 392-420, 424- | | | | |
| | | 432, 454-489, 506-523, 534-539, | | : | | |
| | | 550-556, 563-573, 576-596, 603- | | | | |
| | | 642, 644-651, 655-666, 685-704, | | | | |
| | | 706733, 747753 | | | | |
| | | | | 101 105 | D 1 | 535, |
| ORF1912 | unknown con- | 23-35, 37-70, 75-84, 90-112, 129- | D:4 | aa131-187 | D: nd | |
| | served protein | 135, 137–151, 155–180, 183–209, | | | | 582 |
| | (conserved) | 211-217, 219-225, 230-248, 250- | | | { | |
| | | 269, 274–284, 289–320, 325–353, | | | | _ |
| | | 357-371, 374-380, 384-399, 401- | Ì | | | |
| | | 411, | | | | |
| ORF2015 | Trehalose-6- | 8-17, 30-54, 82-89, 94-103, 157- | A:3, B:8 | aa 465-498 | B:SELAH62(465-498): 5/12 | 253, |
| | phosphate | 166, 178–183, 196–204, 212–219, | | | | 282 |
| | hydrolase | 222-227, 282-289, 297-307, 345- | | - | | |
| | | 364, 380–393, 399–405, 434–439, 443–449, 453–475, 486–492, 498– | | | · | |
| | | 507, 512–535, 538–548 | | | | 1 |
| ORF2018 | Glucose-6- | 4-16, 21-27, 39-51, 60-69, 76-83, | B:17 | aa 250-287 | B:SELAI19(250-279): 3/12 | 254, |
| | phosphate 1-DH | 97-118, 126-132, 159-167, 171-177, | | | | 283 |
| | | 192-204, 226-240, 247-259, 281- | | Ì | | |
| | | 286, 294-305, 314-320, 330-338, | | } | | |
| 1 | , | 353-361, 367-372, 382-392, 401- | | | | |
| _ | | 413, 427-434, 441-447, 457-463 | <u> </u> | <u> </u> | | |
| ORF2040 | LysM domain | 51-56, 98-108, 128-135, 138-144, | D:23 | aa259-331 | D: nd | 536, |
| | protein protein | 152-158, 177-192, 217-222, 232- | l | | ·, | 583 |
| <u> </u> | | 251, 283–305, 406–431, 433–439 | | <u> </u> | (7 | |
| ORF2098 | PilB related | 13-18, 36-43, 45-50, 73-79, 95-100, | A:60 | aa 1-57 | A:SEFAQ50(15-57): 5/12 | 255, |
| | protein | 111-126, 133-139 | - | | ₁ | 284 |
| ORF2139 | sodium:sulfate | 7-12, 22-97, 105-112, 121-128, | D:41 | aa42-118 | D: nd | 537, |
| | symporter family | 130-146, 152-164, 169-189, 192- | | | • | 584 |
| | protein, putative | 203, 211–230, 238–246, 260–281, | | | | |
| | | 304-309, 313-325, 327-357, 367- | | | | |
| 1 | | 386, 398-444, 447-476, 491-512 | | | - | |

| .s. | Putative function | predicted immunogenic aa** | No. of | Location of | Serum reactivity with relevant | Seq 1D |
|-------------|---------------------------|------------------------------------|------------------|--------------|--------------------------------|----------|
| epidermidi | (by homology) | | selected | identified | region (positive/total) | no: |
| s antigenic | | | clones | immuno- | | (DNA |
| protein | | ' | per ORF | genic region | | +Prot) |
| | | | and | | | |
| ORF2172 | SceB precursor | 4-23, 28-34, 38-43, 45-51, 63-71, | screen A:438, | aa 6-215 | B:SELAH53(188-209): 3/12 | 256, |
| Old 21/2 | (lytE) | 85-96, 98-112, 118-126, 167-174, | B:40, D:4 | da 0 213 | D.SELMISS(100 207). 3/12 | 285 |
| | | 179-185, 219-228, 234-239, 256- | | | | |
| | | 263 | | | | |
| ORF2200 | zinc ABC | 4-31, 33-40, 48-64, 66-82, 92-114, | D:19 | aa162-225 | D: nd | 538, |
| | transporter, | 118-133, 137-159, 173-246, 248- | | | | 585 |
| | permease protein, | 266 | | | | |
| | putative | | | | | |
| ORF2248 | membrane protein, | 411, 1734, 7278, 127137, 178- | D:17 | aa1-59, | D: nd | 539, |
| | MmpL family, | 227, 229-255, 262-334, 352-380, | | aa159-225, | | 586 |
| | putative | 397-405, 413-419, 447-454, 462- | | aa634-674 | | |
| | | 467, 478-490, 503-509, 517-558, | | | | , |
| | | 560-568, 571-576, 582-609, 623- | | | | |
| | | 629, 631–654, 659–710, 741–746, | | · | | |
| | | 762-767, 771-777, 788-793, 856- | | | | <u>.</u> |
| | | 867 | | | | |
| | Unknown con- | 5-10, 18-29, 31-37, 66-178, 196- | B:4 | aa 123-142 | B:SELAG77(123-142): 12/12 | 257, |
| | served protein in | 204, 206–213 | | | | 286 |
| ORF2282 | others conserved hypo- | 16-22, 41-50, 52-64, 66-74, 89-95, | A:4 | aa 51-97 | A:SEFAR88(51-97): 3/12 | 258, |
| I | thetical protein | 107-114, 123-130, 135-159, 167- | | | | 287 |
| | | 181, 193-199, 223-231, 249-264, | | | | |
| | | 279–289 | | | | |
| ORF2376 | DivIC homolog, | 27-56, 102-107, 111-116 | D:7 | aa15-58 | D: nd | 540, |
| | putative | | | | | 587 |
| ORF2439 | membrane-bound | 4-9, 11-26, 36-56, 59-73, 83-100, | A:459, | aa 10-217 | B:SELAC31(75-129): 12/12 | 259, |
| | lytic murein | 116-130, 148-163, 179-193, 264- | B:2, D:53 | | | 288 |
| 1 | transglycosidase | 270, 277–287, 311–321 | | | | |
| | D, putative | | | | | |
| ORF2493 | conserved hypo- | 4-29, 37-77, 80-119 | D:6 | aa69-113 | D: nd | 541, |
| | thetical protein | | | | | 588 |
| ORF2535 | ATP-binding | 5-28, 71-81, 101-107, 128-135, | D:8 | aa1-65 | D: nd | 542, |
| | cassette | 146-52, 178-188, 209-214, 224-233, | | | | 589 |
| | transporter-like | 279-294, 300-306, 318-325, 342- | | | | |
| | protein, putative | 347, 351–357 | 1 | | | |

| S. | Putative function | predicted immunogenic aa** | No. of | Location of | Serum reactivity with relevant | Seq ID |
|-------------|--------------------|---|-------------------|--------------|--------------------------------|--------|
| epidermidi | (by homology) | • | selected | identified | region (positive/total) | no: |
| s antigenic | | | clones | immuno- | • | (DNA |
| protein | | | per ORF | genic region | • | +Prot) |
| • | | | and | | | |
| | | | screen | | | |
| ORF2627 | cation- | 8-31, 34-80, 125-132, 143-153, | D:3 | aa61-105 | D: nd | 543, |
| | transporting | 159-165, 176-189, 193-198, 200- | | | | 590 |
| | ATPase, EI-E2 | 206, 215–242, 244–262, 264–273, | | | | |
| | family, putative | 281-289, 292-304, 318-325, 327- | | | | |
| | lainity, putative | , | | | | |
| | | 338, 347–371, 404–416, 422–429, | | | , | |
| | | 432-450, 480-488, 503-508, 517- | | | | 1 |
| | | 525, 539-544, 551-562, 574-587, | | | | |
| | | 600-631, 645-670 | | | | |
| ORF2635 | Hypothetical | 4-10, 17-24, 26-42, 61-71, 90-96, | A:2, B:2 | aa 139-169 | B:SELAB63(138-163): 7/12 | 260, |
| | protein | 102-111, 117-125, 158-164, 173- | | | | 289 |
| | | 182, 193-201, 241-255, 268-283, | | | | |
| | | 289-298, 305-319, 340-353, 360- | | | | |
| | | 376, 384–390, 394–406 | | | | |
| ORF2669 | Hypothetical | 4-21, 35-42, 85-90, 99-105, 120- | A:14, B:8 | aa 22-81 | B:SELAE27(22-51): 5/12 | 261, |
| | protein | 125, 148–155, 175–185, 190–196, | l, | | | 290 |
| | | 205-210, 217-225 | <u> </u> | | | 0.00 |
| ORF2671 | Hypothetical pro- | 4-23, 43-49, 73-84, 93-98, 107-113, | 1 | aa 2368 | B:SELAD21(36-61): 5/12 | 262, |
| | tein | 156–163, 179–190, 197–204, 208– | B:14 | | | 291 |
| | | 218, 225–231, 248–255 | A:16, B:3 | 22.69 | B:SELAE25(23-54): 2/12 | 263, |
| ORF2673 | Hypothetical | 4-20, 65-71, 99-105, 148-155, 171- 182, 190-196, 204-210, 221-228, | A:10, B :3 | aa 23-06 | D.SELAEZ3(23°34). 2/12 | 292 |
| | protein | 240-246 | | Ì | • | |
| ORF2694 | Hypothetical | 4-26, 93-98, 121-132, 156-163, | A:19, | aa 25-82 | B:SELAB26(27-60): 5/12 | 264, |
| | protein | 179-192, 198-204, 212-220, 225- | B:30 | | | 293 |
| | Processi | 238 | | | | |
| ORF2695 | Hypothetical | 4-26, 43-50, 93-98, 107-113, 156- | A:7 | aa 22-78 | A:SEFAH77(22-66): 6/12 | 265, |
| | protein | 163, 179–190, 198–204, 212–218, | | | | 294 |
| | | 225-231, 247-254 | | | | |
| ORF2719 | two-component | 5-52, 60-71, 75-84, 91-109, 127- | B:4 | aa 123132 | B:SELAA62(123-132): 6/12 | 266, |
| | sensor histidine | 135, 141-156, 163-177, 185-193, | 1 | | | 295 |
|] . | kinase, putative | 201-214, 222-243, 256-262, 270- | | | | · |
| | | 279, 287-293, 298-303, 321-328, | | | | 1 |
| | | 334-384, 390-404, 411-418, 427- | | | | |
| | | 435, 438-448, 453-479, 481-498, | | | | |
| | <u> </u> | 503-509 | | <u> </u> | | |
| ORF2728 | Accumulation→ | 4-13, 36-44, 76-86, 122-141, 164- | A:265, | aa 803 | B:SELAA10(850-878): 11/12 | 267, |
| | associated protein | 172, 204–214, 235–242, 250–269, | B:448; | 1001 | • | 296 |
| | 1 | 291-299, 331-337, 362-369, 377- | C:4, D:9 | | | |
| | | 396, 419-427, 459-469, 505-524, | | | | |
| | | 547-555, 587-597, 618-625, 633- | | | , | 1 |
| | | 652, 675-683, 715-727, 740-753, | | | | 1 |
| | | 761-780, 803-811, 842-853, 962- | | | | |
| 1 | <u> </u> | 968, 1006–1020 | | 1 | <u> </u> | |

| S. | Putative function | predicted immunogenic aa** | No. of | Location of | Serum reactivity with relevant | Seq ID |
|--------------------|-------------------|------------------------------------|---------------|--------------|--------------------------------|--------|
| <i>epiderm</i> idi | (by homology) | | selected | identified | region (positive/total) | no: |
| s antigenic | | | clones | immuno- | | (DNA |
| protein | | | per ORF | genic region | | +Prot) |
| | | | · and | | | |
| ORF2740 | lipase precursor | 4-21, 190-200, 218-228, 233-241, | screen C:3 | aa 110-177 | C:GSBBL80(110-177):1/1 | 358, |
| Old 2710 | tipuso producos | 243~261, 276~297, 303~312, 316~ | | | | 364 |
| | | 325, 346-352, 381-387, 436-442, | | | |]] |
| | 5.) | 457~462, 495~505, 518~532, 543~ | | | | |
| | ** | 557, 574-593 | | | | |
| ORF2764 | oligopeptide ABC | 14-36, 62-131, 137-147, 149-162, | D:4 | aa 6-41 | D: nđ | 544, |
| | transporter, per- | 164-174, 181-207, 212-222, 248- | | | | 591 |
| | mease protein, | 268, 279-285 | | | | |
| | putative | | | | | |
| ORF2767 | unknown con- | 7-20, 22-35, 40-50, 52-61, 63-92, | D:4 | aa276316 | D: nd | 545, |
| | served protein in | 94-101, 103-126, 129-155, 161-178, | | | | 592 |
| | others | 192-198, 200-208, 210-229, 232- | | | • | |
| | , | 241, 246-273, 279-332, 338-359, | | | | |
| | | 369-383 | | | | |
| ORF2809 | sodium:sulfate | 4-29, 37-53, 56-82, 87-100, 108- | D:9 | aa266-317, | D: nd | 546, |
| | symporter family | 117, 121-138, 150-160, 175-180, | | aa357-401 | | 593 |
| | protein | 189-195, 202-214, 220-247, 269- | | | | |
| | | 315, 324-337, 341-355, 361-412, | | } | | |
| | | 414-423, 425-440, 447-467 | | | | |
| ORF2851 | putative trans- | 7-13, 20-32, 37-90, 93-103, 107- | D:11 | aa137-185 | D: nd | 547, |
| | membrane efflux | 126, 129–155, 159–173, 178–189, | | | | 594 |
| | protein | 195-221, 234-247, 249-255, 268- | | | | |
| | | 303, 308–379 | | | | |

Table 2d: Immunogenic proteins identified by bacterial surface and ribosome display: S. aureus (new annotation)

Bacterial surface display: A, LSA250/1 library in fhuA with patient sera 1 (655); B, LSA50/6 library in lamB with patient sera 1 (484); C, LSA250/1 library in fhuA with IC sera 1 (571); E, LSA50/6 library in lamB with IC sera 2 (454); F, LSA50/6 library in lamB with patient sera P1 (1105); G, LSA50/6 library in lamb with IC sera 1 (471). Ribosome display: D, LSA250/1 library with IC sera (1686). **, prediction of antigenic sequences longer than 5 amino acids was performed with the programme ANTIGENIC (Kolaskar and Tongaonkar, 1990); #, identical sequence present twice in ORF.

| S. | Old | Putative | predicted immunogenic aa** | No. of se- | Location of | Serum reactivity with rele- | Seq |
|------------------|-----------|---------------|-----------------------------------|------------|-------------|------------------------------|--------|
| <i>aureus</i> an | ORF | function | ·(| lected | identified | vant region (positive/total) | ID no: |
| tigenic | number | (by homology) | | clones per | immuno- | | (DNA |
| protein | | | | ORF and | genic re- | | +Prot) |
| l e | | | · | screen | gion | | |
| SaA0003 | ORF2967 | repC | 7-19, 46-57, 85-91, 110-117, 125- | B:3, C:14; | aa 9-42 | C:GSBYI53(9-42):1/1 | 394, |
| | & | 1 | 133, 140-149, 156-163, 198-204, | F:29 | aa 156-241 | C:GSBYG39(156-241):1/1 | 396 |
| | ORF2963 | | 236-251, 269-275, 283-290, 318- | | aa 300-314 | C:GSBYM94(343-420):26/30 | |
| ' | | | 323, 347–363 | | aa 343-420 | | |
| ORF0123 | ORF1909 | unknown | 4-10, 25-30, 38-57, 91-108, 110- | B:3, E:7, | aa 145–163 | B:GSBXF80(150-163):5/27 | 409, |
| | 18 aa at | | 123, 125-144, 146-177, 179-198, | G:1 | | E:GSBZC17(150-163):25/41 | 410 |
| | N | | 216-224, 226-233 | | | | |
| | terminus | | | | | | |
| ORF0160 | ORF1941 | unknown | 4-26, 34-70, 72-82, 86-155, 160- | A:1 | aa 96-172 | A:GSBXO07(96-172):5/30 | 411, |
| | -16 aa at | | 166, 173–205, 207–228, 230–252, | | | | 412 |
| | N | (| 260-268 , 280-313 | | 1 | | |
| | terminus | | | | | D CCD47500 1 11 1 (600 | 413. |
| ORF0657 | ORF un- | LPXTGVI | 9-33, 56-62, 75-84, 99-105, 122- | 1 ' | aa 526-544 | B:GSBXE07-bdb1(527- | 414 |
| | known | protein | 127, 163–180, 186–192, 206–228, | F:15 | | 542):11/71 | 414 |
|] | | | 233-240, 254-262, 275-283, 289- | | | F:SALAX70(526-544):11/41 | 1 |
| • | | | 296, 322-330, 348-355, 416-424, | | | | |
| | | | 426-438, 441-452, 484-491, 541- | | | | 1 |
| | | | 549, 563-569, 578-584, 624-641 | | 50 101 | L CODYD (0///0 10/) 7/70 | 415, |
| ORF1050 | ORF1307 | unknown | 45-68, 72-79, 91-101, 131-142, | A:1, H:45 | aa 53-124 | A:GSBXM26(53-124):7/30 | 416 |
| | -4 aa at | | 144-160, 179-201 | | | | 410 |
| | N-termi- | | | | | | |
| | nus | 1 | 12 04 10 10 11 10 00 110 114 | Aiti | 24-94 | A.GCDVV60_hmd21/24_ | 417, |
| 1 | 1 | NifS protein | 13-26, 40-49, 61-68, 92-112, 114- | A:I1 | aa 24-84 | A:GSBXK59-bmd21(24- | 418 |
| | -10 aa at | homolog | 123, 138–152, 154–183, 194–200, | | | 84):6/29 | 7,10 |
| | N- | | 207-225, 229-240, 259-265, 271- | | | | 1 |
| | terminus | | 284, 289–309, 319–324, 330–336, | | | | |
| L | <u> </u> | <u> </u> | 346-352, 363-372 | 1 | | <u> </u> | |

| ſ | s. | Old | Putative | predicted immunogenic aa** | No. of se- | Location of | Serum reactivity with rele- | Seq |
|---|----------|------------|---------------|--|------------|-------------|------------------------------|--------|
| 1 | aureusan | ORF | function | _ | lected · | identified | vant region (positive/total) | ID no: |
| 1 | tigenic | number | (by homology) | | clones per | immuno– | | (DNA |
| ١ | protein | | ,, | | ORF and | | | +Prot) |
| | • | | | | screen | gion | | , |
| ŀ | ORF1632 | ORF1163 | SdrH homolog | 4-31, 50-55, 243-257, 259-268, | | | B:GSBXG53(164-182):39/71 | 419, |
| | | -4 aa at | | 298-316, 326-335, 364-370, 378- | F:34 | aa 115-139 | F:SALAP07(101-115):11/41 | 420 |
| ı | | N- | | 407 | | aa 158–186 | | |
| | | terminus | | | | | | |
| Ī | ORF2180 | ORF0594 | LPXTGIV | 9-17, 24-45, 67-73, 82-90, 100-107, | A:3, C:3, | aa 491-587 | A:GSBXS61(491-555):1/1 | 421, |
| 1 | | 2 aa at | protein | 117-134, 137-145, 158-168, 176- | E:6, F:2, | aa 633-715 | A:GSBXL64(494-585):1/1 | 422 |
| | | N- | | 183, 188–194, 206–213, 223–231, | H:6 | aa 702 | A:GSBXS92(758-841):1/I | |
| ı | | terminus | | 243-248, 263-270, 275-282, 298- | , | 757" | A:bmd4(702-757):16/30# | |
| ١ | | | | 304, 344–355, 371–377, 382–388, | | aa 758-830 | (A:bmd4(830-885):16/30)# | i i |
| ١ | | | | 427-433, 469-479, 500-505, 534- | | (aa 830- | F:SALBC43(519-533):4/41 | |
| ı | | | | 559, 597–607, 662–687, 790–815, | | 885)# | | |
| | | | | 918-943, 1032-1037, 1046-1060, | | | | |
| ١ | | | | 1104-1112, 1128-1137, 1179-1184, | | | | |
| L | | | | 1197-1204, 1209-1214, 1221-1239 | | 44.4 - 44 | | |
| ľ | ORF2184 | ORF0590 | FnbpB | 10-29, 96-116, 131-137, 146-158, | | 1 | ` ' | 423, |
| | | - 8 aa at | | 167-173, 177-182, 185-191, 195- | G:9 | aa 774-847 | A:GSBXR22(774~847):1/1 | 424 |
| ۱ | | N-termi- | | 201, 227–236, 260–266, 270–284, | | | | |
| ı | | nus | | 291-299, 301-312, 348-356, 367- | | | | |
| ı | | | | 376, 382–396, 422–432, 442–453, | | | | |
| | | | | 480-487, 497-503, 519-527, 543- | | | | |
| ı | | | | 548, 559–565, 579–585, 591–601, | | | | |
| 1 | 1 | | | 616-623, 643-648, 657-663, 706- 718, 746-758, 791-796, 810-817, | | | | |
| 1 | | | | 819-825, 833-839, 847-853, 868- | | | | |
| | | | | 885, 887–895, 919–932 | | · | | |
| ŀ | ORF2470 | ORF0299 | Conserved hv- | 4-27, 36-42, 49-55, 68-73, 94-101, | C:3 | aa 400-441 | C:GSBYH60(400-441):28/31 | 425, |
| | ŀ | - 14 aa at | | 131-137, 193-200, 230-235, 270- | | | | 426 |
| ١ | ŧ | N- | protein | 276, 294-302, 309-324, 334-344, | • | | , | |
| ı | | terminus | | 347-364, 396-405, 431-437, 498- | | | | |
| ١ | 1 | | | 508, 513-519, 526-532, 539-544, | | | | |
| ١ | | | | 547-561, 587-594, 618-630, 642- | | | , | |
| ١ | | | | 653, 687–699, 713–719, 752–766 | | | | |
| t | DRF2498 | ORF0267 | Conserved hy- | 8-19, 21-44, 63-76, 86-92, 281-286, | D:12, F:6 | aa 358-411 | D:17/21 | 427, |
| ١ | | ORF app. | pothetical | 303-322, 327-338, 344-354, 364- | | aa 588-606 | F:SALAT38(895-909):8/41 | 428 |
| l | | 580 aa | protein | 373, 379–394, 405–412, 453–460, | | aa 895–909 | | |
| - | | longer at | | 501-506, 512-518, 526-542, 560- | | | | |
| | | N termi- | | 570, 577-583, 585-604, 622-630, | | | | |
| 1 | Į | nus; plus | | 645-673, 677-691, 702-715, 727- | | | | |
| | | other | | 741, 748-753, 770-785, 789-796, | | | | |
| | | changes | | 851-858, 863-869, 876-881, 898- | | | | |
| | | | | 913, 917–924, 979–986, 991–997, | | | • | |
| | | | | 1004-1009, 1026-1041, 1045-1052, | | | | |
| | | | | 1107-1114, 1119-1125, 1132-1137, | | | | |
| | | | | 1154-1169, 1173-1192, 1198-1204, | | | | |
| | | | | 1240-1254, 1267-1274, 1290-1298, | | | | |
| L | | | | 1612-1627 | l | | | |

| S. | Old | Putative | predicted immunogenic aa** | No. of se- | Location of | Serum reactivity with rele- | Seq |
|------------------|-----------|---------------|-------------------------------------|------------|-------------|------------------------------|--------|
| <i>aureus</i> an | ORF | function | | lected | identified | vant region (positive/total) | ID no: |
| tigenic | number | (by homology) | | clones per | ·immuno- | | (DNA |
| protein | | | : | ORF and | genic re- | | +Prot) |
| - | | | <i>:</i> | screen | gion | 1 | |
| ORF2548 | ORF2711 | lgG binding | 4-37, 44-53, 65-71, 75-82, 105-112, | A:55, | aa 1-123 | A:GSBXK68(1-73):21/30 | 429, |
| | -12 aa at | protein A | 126-132, 136-143, 164-170, 184- | B:54, | aa 207-273 | A:GSBXK41(35-123):1/1 | 430 |
| İ | N- | | 190, 194-201, 222-232, 242-248, | C:35, | aa 310-410 | A:GSBXN38(207-273):19/30 | |
| | terminus | | 252-259, 280-291, 300-317, 413- | F:59, | | A:GSBXL11(310-363):10/30 | |
| | | | 420, 452-460, 485-503 | G:56, | | B:GSBXB22(394-406):37/71 | |
| | | | | H:38 | | F:SALAM17(394-406):29/41 | |
| ORF2746 | ORF2507 | homology with | 4-9, 12-17, 40-46, 91-103, 106-113, | A:1, H:13 | aa 63-126 | A:GSBXO40(66-123):8/29 | 431, |
| | - 3 aa at | ORFI | 116-125, 150-160, 172-177, 182- | | | | 432 |
| | N- | | 188, 195-206, 241-261, 263-270, | | | | |
| | terminus | | 277-285, 287-294 | | | | |
| ORF2797 | ORF2470 | unknown | 13-32, 40-75, 82-95, 97-112, 115- | B:3, E:2, | 1 | B:GSBXE85(159-176):11/27 | 433, |
| | -24 aa at | | 121, 124-154, 166-192, 201-225, | F:13, H:3 | aa 325-339 | F:SALAQ47(159-176):8/41 | 434 |
| | N-termi- | | 227-252, 268-273, 288-297, 308- | | | | |
| | nus | | 375, 379-434 | | | | |
| ORF2960 | ORF2298 | putative | 8-31, 35-44, 106-113, 129-135, | C:101, | aa 1-80 | C:GSBYG32(1-80)::6/7 | 435, |
| - | – 5 aa at | Exotoxin | 154-159, 168-178, 203-215, 227- | E:2, H:58 | aa 48-121 | C:GSBYG61-bhe2(48- | 436 |
| | N- | | 236, 240–249, 257–266, 275–281, | | aa 98-190 | 116):26/30 | |
| | terminus | | 290-296, 298-305, 314-319, 327- | | | C:GSBYN80(98-190):13/17 | |
| | | | 334 | | | | 100 |
| ORF2963 | ORF2295 | putative | 8-23, 35-41, 64-70, 81-87, 109-115, | 1 | aa 17-95 | C:GSBYJ58(17-95):9/15 | 437, |
| 1 | −5 aa at | Exotoxin | 121-132, 150-167, 177-188, 194- | G:1 | | , | 438 |
| | N- | | 201, 208–216, 227–233, 238–248, | | | | |
| | terminus | 1 | 265-271, 279-285 | | | | |

| S. | Old | Putative | predicted immunogenic aa** | No. of se- | Location of | Serum reactivity with rele- | Seq |
|------------------|----------|----------------|------------------------------------|------------|-------------|--------------------------------------|---------|
| <i>aureus</i> an | | function | F | lected | ldentified | vant region (positive/total) | ID no: |
| tigenic | number | (by homology) | | clones per | | There a organic (product to company) | (DNA |
| protein | Munici | (b) nontotogy) | | ORF and | | | +Prot) |
| protein | | , | | screen | gion | | 1 1 100 |
| ORF3200 | ORF1331 | putative | 8-32, 45-52, 92-103, 154-159, 162- | A:11, | aa 8543- | A:GSBXL07(8543-8601):6/28 | 439. |
| | +8506 aa | extracellular | 168, 207-214, 232-248, 274-280, | B:11, | 8601 | , | 440 |
| | at N- | i i | 297-303, 343-349, 362-375, 425- | C:36, | aa 8461- | | |
| | terminus | protein | 442, 477-487, 493-498, 505-512, | H:32 | 8475 | | |
| | | | 522-533, 543-550, 558-564, 568- | | | , | |
| | | | 574, 580-600, 618-630, 647-652, | | | | |
| | | | 658-672, 692-705, 711-727, 765- | | | | |
| | | | 771, 788-798, 812-836, 847-858, | | | | |
| | | | 870-898, 903-910, 1005-1015, | | | | |
| | | | 1018-1025, 1028-1036, 1058-1069, | | | | |
| | | | 1075-1080, 1095-1109, 1111-1117, | | | · | |
| | | | 1119-1133, 1166-1172, 1183-1194, | | | | |
| | | | 1200-1205, 1215-1222, 1248-1254, | | | | |
| | | | 1274-1280, 1307-1317, 1334-1340, | | | | |
| | | | 1381-1391, 1414-1420, 1429-1439, | | | | |
| | | | 1445-1467, 1478-1495, 1499-1505, | | | · | |
| | | | 1519–1528, 1538–1550, 1557–1562, | | | | |
| | · | | 1572-1583, 1593-1599, 1654-1662, | | | | |
| | | | 1668-1692, 1701-1707, 1718-1724, | | | | |
| | | | 1738–1746, 1757–1783, 1786–1793, | | | | |
| | | | 1806-1812, 1815-1829, 1838-1848, | | | | l |
| | | | 1853-1860, 1875-1881, 1887-1893, | | | | |
| | | | 1899-1908, 1933-1940, 1952-1961, | | | | |
| | | | 1964-1970, 1977-1983, 1990-1996, | | | | } |
| | | | 2011–2018, 2025–2038, 2086–2101, | | | | |
| | | | 2103-2117, 2177-2191, 2195-2213, | | | · | |
| | | | 2220–2225, 4"22372249, 2273 | | | | |
| | | | 2279, 2298–2305, 2319–2327, 2349– | | | | |
| | | | 2354, 2375–2381, 2391–2398, 2426– | | | | |
| | | | 2433, 2436–2444, 2449–2454, 2463– | | | | |
| | | | 2469, 2493–2499, 2574–2589, 2593– | | | | |
| | | | 2599, 2605–2611, 2615–2624, 2670– | • | | | |
| | | | 2684, 2687–2698, 2720–2727, 2734– | | | • | |
| | | | 2754, 2762–2774, 2846–2866, 2903– | | | | Ì |
| | | | 2923, 2950–2956, 2985–2998, 3011– | | | | |
| | | | 3031, 3057–3064, 2"3102–3117, | | 1 | | |
| | | | 3137-3143, 3186-3195, 3211-3219, | | | | |
| | | | 3255-3270, 3290-3300, 3327-3334, | | | | |
| | | | 3337-3343, 3390-3396, 3412-3419, | | | | |
| | | | 3439-3446, 3465-3470, 3492-3500, | | | | |
| | | | 3504-3510, 3565-3573, 3642-3650, | | } | | 1 |
| | | | 3691-3698, 3766-3775, 3777-3788, | | 1 | | |
| | | | 3822-3828, 3837-3847, 3859-3864, | | | | |
| | | | 3868-3879, 3895-3902, 3943-3951, | | | | |
| | | | 3963-3971, 3991-3997, 4018-4030, | | | | |
| | | | 4054-4060, 4074-4099, 4123-4129, | | | | |
| | | | 4147-4153, 4195-4201, 4250-4255, | | | , | |
| 1 | ı | I , | 14262-4267, 4270-4277, 4303-4310, | 1 | ı | i | I |

4321-4330, 4343-4352, 4396-4408, 4446-4451, 4471-4481, 4503-4509, 4516-4534, 4596-4604, 4638-4658, 4698-4710, 4719-4732, 4776-4783, 4825-4833, 4851-4862, 4882-4888, 4894-4909, 4937-4942, 5047-5054, 5094-5100, 5102-5112, 5120-5125, 5146-5153, 5155-5164, 5203-5214, 5226-5236, 5278-5284, 5315-5321, 5328-5342, 5348-5359, 5410-5420, 5454-5466, 5481-5489, 5522-5538, 5597-5602, 5607-5614, 0"5623-5629, 5650**-5**665, 5707**-**5719, 5734-5742, 5772-5778, 5785-5790, 5833-5845, 5857-5863, 5899-5904, 5908-5921, 5959-5971, 5981-5989, 6010-6017, 6034-6043, 6058-6064, 6112-6120, 6154-6169, 6210-6217, 6231-6240, 6261-6268, 6288-6294, 6318-6324, 6340-6349, 6358-6369, 6402-6407, 6433-6438, 6483-6493, 6513-6519, 6527-6546, 6561-6574, 6599-6608, 6610-6616, 6662-6673, 6696-6705, 6729-6743, 6769-6775, 6792-6801, 6819-6828, 6840-6846, 6860-6870, 6915-6928, 6966-6972, 7021-7028, 7032-7047, 7096-7101, 7109-7117, 7138-7149, 7157-7162, 7201-7206, 7238-7253, 7283-7294, 7296-7302, 7344-7365, 7367-7376, 7389-7404, 7413-7433, 7475-7482, 7493-7500, 7535-7549, 7596-7608, 7646-7651, 7661-7678, 7722-7731, 7741-7754, 7764-7769, 7776-7782, 7791-7806, 7825-7837, 7862-7875, 7891-7897, 7922-7931, 7974-7981, 7999-8005, 8039-8045, 8049-8065, 8070-8075, 8099-8112, 8119-8125, 8151-8158, 8169-8181, 8226-8232, 8258-8264, 8291-8299, 8301-8310, 8325-8335, 8375-8389, 8394-8400, 8405-8412, 8421-8436, 8478-8485, 8512-8521, 8528-8538, 8564-8579, 8587-8594, 8603-8615, 8626-8637, 8640-8646, 8657-8672, 8684-8691, 8725-8736, 8748-8761, 8777-8783, 8794-8799, 8810-8825, 8851-8862, 8874-8887, 8903-8912, 8914-8926, 8933-8943, 8954-8960, 8979-8988, 9004-9011, 9035-9041, 9056-9069, 9077-9086, 9088-9096, 9106-9111, 9124-9133, 9183-9191, 9224-9231, 9235-9241, 9250-9265, 9279-9290, 9295-

| | 9300, 9326–9343, 9408–9414, 9422- | | | |
|-------|-----------------------------------|--|---|------|
| | 9427, 9435-9441, 9455-9461, 9507- | | | |
| | 9517, 9532-9538, 9580-9589, 9594- | | • | 1 1 |
| | 9600, 9614-9623, 9643-9648, 9665- | | | |
| 1 1 | 9683, 9688-9700, 9720-9726, 9742- | | | 1 1 |
| | 9758, 9767–9775, 9795–9800, 9817– | | | |
| 1 1 . | 9835, 9842-9847, 9912-9919, 9925- | | | |
| | 9938, 9943-9963, 9970-10009, | | | l i |
| | 10025-10031, 10037-10043, 10045- | | | 1 1 |
| 1 1 | 10063, 10066-10073, 10117-10124, | | | 1 1 |
| | 10126-10136, 10203-10210, 10218- | | • | 1. 1 |
| | 10225, 10232-10242, 10287-10292, | | | 1 1 |
| 1. 1 | 10303-10323, 10352-10360, 10385- | | | 1 1 |
| | 10396, 10425-10431, 10452-10459, | | • | |
| | 10480-10485 | | | 1 i |

WO 02/059148 PCT/EP02/00546

Table 3. Serological proteome analysis of S. aureus surface proteins using human sera

a) S. aureus/agr "stress conditions"

| Spot ID/sera | IC40 1:20,000 | 1C35, N26, C4 1:50,000 each | Infant pool C2,5,6,10,12 1:10,000 | N22 1:10.000 IC40 1:50,000 |
|--------------|------------------|--------------------------------|---|-------------------------------|
| PCK2 | + | + | _ | + |
| PCK4 | + | +++ | _ | +++ |
| PCK5 | _ | (+) | · _ | + |
| PCK6 | + | + | - | + |

| Spot ID/sera | IC35, 4 1:50,00 N22 1:10, | 00 | P-pool (P6,18,25,28,29) 1:50,000 each | Infant pool C2,5,6,10,12 1:10,000 | |
|--------------|---------------------------------|----|---|---|--|
| PAC1 | ++ | | ++ | | |
| PAC2 | ++ | | +++ | <u>-</u> | |
| PAC3 | | | + | _ | |
| PAC5 | _ | | ++ | _ | |

| Spot ID/sera | P-pool (P6,18,25,28,29) 1:50,000 each | Infant 14 1:10,000 | IC pool / IgG (N26, IC34,35) 1:30,000 each | IC pool / IgA (N26, IC34,35) 1:30,000 each |
|--------------|---|-----------------------|--|--|
| PAC11 | ++ | | ++ | ++ |
| PAC12 | ++- | - | ++ | ++ |
| PAC13 | _ | _ | | ++ |
| PAC14 | _ | _ | + | + [|
| PAC15 | _ | - | +++ | +++ |
| PAC16 | + | - | + | + |
| PAC17 | + | _ | + | + |
| PAC18 | ++ | _ | _ | |
| PAC19 | | _ | ++ | ++ |
| PAC20 | ++ | _ | | - |
| POV31 | +++ | _ | _ | |
| POV32 | + . | - | _ | _ |
| POV33 | + | - | _ | _ |
| POV34 | + | _ | _ | |
| POV35 | + | _ | _ | |
| P OV36 | + | - | | _ |
| P OV37 | ++ | _ | _ | _ |

| P OV38 | ++ | | _ | |
|--------|-----|-------------|---|---|
| P OV39 | +++ | _ | - | _ |
| P OV40 | +++ | - | | - |

b) S. aureus/COL "standard conditions"

| Spot ID/sera | IC pool (N26,IC34,35) | 1C35 1:20,000 | P18 1:10,000 | P25 1:10,000 | P1 1:5,000 | P29 1:2,500 | Infant 18 1:10,000 |
|--------------|--------------------------|------------------|-----------------|-----------------|---------------|----------------|-----------------------|
| | 1:30,000 each | | | | <u> </u> | | |
| POV2 | +++ | +++ | +++ | +++ | +++ | - ' | - |
| POV3.1 | +++ | +++ | +++ | +++ | +++ | _ | _ |
| POV3.2 | +++ | +++ | +++ | +++ | +++ | _ | _ |
| POV4 | + | +++ | _ | _ | _ | . | _ |
| POV7 | - | | +++ | | _ | - | _ |
| POV10 | _ | ++ | (+) | (+) | _ | (+) | _ |
| POV12 | _ | | _ | - | _ | +++ | - |
| POV13 | ++ | +++ | +++ | ++ + | ++ | ++ | _ |
| POV14 | ++ . | +++ | +++ | ++ | ++ | ++ | _ |
| POV15 | + | + | _ | + | (+) | _ | - |

c) S. aureus/COL "stress conditions"

| Spot ID/sera | P-pool (P6,18,25,28,29) 1:50,000 each | IC34+IC35 1:20,000 each | P18 1:10,000 | P29 1:10,000 | Infant 14 1:10,000 |
|--------------|---|----------------------------|-----------------|-----------------|-----------------------|
| POV16 | _ | +++ | _ | | |
| POV17 | - | +++ | (+) | | - - |
| POV18 | + | _ | ++ | _ | <u>-</u> |
| POV19 | (+) | _ | +++ | _ | _ |
| POV21 | _ | | + | _ | |
| POV23 | _ | + | | _ | - |
| POV24 | _ | + | | - | - |
| POV25 | + | | | | |

Table 4. S. aureus antigens identified by MALDI-TOF-MS sequencing (ORFs in bold were also identified by bacterial surface display)

Prediction of antigenic regions in selected antigens identified by serological proteome analysis using human sera

| spot ID | S. aureus pro- tein (ORF no. / ab- brev.) | Putative function (by homology) | Seq ID no: (DNA, Prot) | Putative local- ization |
|-----------------------|--|---|---------------------------|----------------------------|
| PCK2 | ORF0599 | Glycinamide-ribosyl synthase | 107, 108 | cytoplasmic |
| PCK5 | ORF0484 yitU | conserved hypoth. protein (yitU) | 109, 110 | cytoplasmic |
| PCK6 | ORF2309 | membrane-associated malate-quinone oxidase | 111, 112 | peripheral mem- brane |
| POV2 | · | protein phosphatase contributing to me- thicilin resistance | 113, 114 | trans-membrane |
| POV4, 17 PAC14, 19 | | C-terminal part of 44 kDa protein similar to elongation factor Tu | 115, 116 | cytoplasmic/ se- creted |
| POV5 ¹⁾ | ORF0782 | 3-ketoacyl-acyl carrier protein reduc- tase (fabG) | 117, 118 | cytoplasmic |
| POV7 | ORF0317 SecA | protein transport across the membrane SecA | 39, 91 | cytoplasmic |
| POV10 | ORF1252 yrzC | hypothetical BACSU 11.9 kd protein (upf0074 (rff2) family) | 119, 120 | cytoplasmic |
| POV12 | ORF0621 pdhB | dihydrolipoamide acetyltransferase (pdhB) | 121, 122 | cytoplasmic |
| POV14 | ORF0072 rpoB | DNA-directed RNA polymerase ß | 125, 126 | cytoplasmic |
| POV15 | ORF0077 EF- | 85 kD vitronectin binding protein | 127, 128 | cytoplasmic |
| POV18 | not found YLY1 | general stress protein YLY1 | 129, 130 | cytoplasmic |
| POV30 ¹⁾ | ORF0069 RL7 | ribosomal protein L7 | 131, 132 | cytoplasmic |
| POV21 | ORF0103 yckG | | | cytoplasmic |
| ,POV24 | ORF0419 yurX | conserved hypothetical protein (yurX) | 137, 138 | cytoplasmic |

| spot ID | S. aureus pro- tein (ORF no. / ab- brev.) | Putative function (by homology) | Seq ID no: (DNA, Prot) | Putative local- ization |
|---------|--|--|---------------------------|----------------------------|
| POV25 | ORF2441 gidA | glucose inhibited division protein a (gidA) | 139, 140 | cytoplasmic |
| PAC1 | ORF1490 prsA | protein export protein prsa precursor (prsA) | 173, 174 | periplasmic |
| PAC2 | ORF1931 ModA | periplasmic molybdate binding protein (ModA) | 175, 176 | surface |
| PAC3 | ORF2053 | heavy metal dependent transcriptional activator, putative regulator of multidrug resistance efflux pump pmrA | 177, 178 | cytoplasmic |
| PAC5 | ORF2233 ydaP | pyruvate oxidase (ydaP) | 179, 180 | cytoplasmic . |
| PAC11 | ORF1361 | LPXTGV, extracellularmatrix-bdg. 3 | | surface |
| PAC12 | ORF1244 | alanyi-tRNA synthetase | 159, 160 | cytoplasmic |
| PAC13 | ORF0835 ymfA | RNA processing enzyme/ATP-bdg. | 161, 162 | cytoplasmic |
| PAC15 | ORF1124 bimBB | lipoamid acyltransferase component of branched-chain alpha-keto acid dehy- drogenase complex | 163, 164 | cytoplasmic |
| PAC16 | ORF0340 GAPDH | glyceraldehydes-3-phosphate dehydrogenase | 165, 166 | cytoplasmic |
| PAC17 | not found Contig83 | 5'-methylthioadenosine nucleosidase / S-adenosylhomo-cysteine nucleosidase | | cytoplasmic |
| PAC20 | ORF2711 | 75% identity to ORF2715 similar to hypothetical proteins | 167, 168 | unknown |
| POV31 | ORF0659 | 29 kDa surface protein | 236, 238 | surface |
| POV32 | ORF0659 | 29 kDa surface protein | 236, 238 | surface |
| POV33 | ORF0659 | 29 kDa surface protein | 236, 238 | surface |
| POV34 | ORF0659 | 29 kDa surface protein | 236, 238 | surface |
| POV35 | ORF0659 | 29 kDa surface protein | 236, 238 | surface |
| P OV36 | ORF00661 | LPXTG-motif cell wall anchor domain protein | 235, 237 | surface |
| P OV37 | ORF0659 | 29 kDa surface protein | 236, 238 | surface |

168

PAC20

ORF2711

| spot ID | S. aureus pro- tein (ORF no. / ab- | | Seq ID no: (DNA, Prot) | Putative local- ization |
|---------|--|--------------------------------|---------------------------|----------------------------|
| | brev.) | | | - |
| P OV38 | ORF0659 | 29 kDa surface protein | 236, 238 | surface |
| P OV39 | ORF0657 | LPXTG-anchored surface protein | 1, 142 | surface |
| P OV40 | not identified | · | | |

| Seq ID no: (Protein) | spot ID | S. aureus ORF no. / abbrev. | Putative local- ization | Putative antigenic surface areas (Antigenic package) |
|-------------------------|---------|-----------------------------|----------------------------|--|
| 112 | PCK6 | ORF2309 | peripheral | 61-75, 82-87, 97-104, 113-123, 128-133, |
| | | mqo | membrane | 203–216, 224–229, 236–246, 251–258, 271– |
| | | | | 286, 288–294, 301–310, 316–329, 337–346, |
| | | | | 348-371, 394-406, 418-435, 440-452 |
| 114 | POV2 | ORF766 aux1 | trans-mem- | 30–37, 44–55, 83–91, 101–118, 121–128, |
| | | | brane | 136–149, 175–183, 185–193, 206–212, 222– |
| | | | | 229, 235–242 |
| 116 | POV4 | ORF078 EF-Tu | cytoplasmic/ | 28–38, 76–91, 102–109, 118–141, 146–153, |
| | | | secreted | 155–161, 165–179, 186–202, 215–221, 234– |
| | | | | 249, 262–269, 276–282, 289–302, 306–314, |
| | | | | 321–326, 338–345, 360–369, 385–391 |
| 176 | PAC2 | ORF1931 | periplasmic | 29-44, 74-83, 105-113, 119-125, 130-148, |
| | | ModA | | 155–175, 182–190, 198–211, 238–245 |
| 174 | PAC1 | ORF1490 | periplasmic | 5-24, 38-44, 100-106, 118-130, 144-154, |
| : | | prsA | | 204–210, 218–223, 228–243, 257–264, 266– |

| spot ID | GI no. or TIGR no. | S. aureus pro- tein (ORF no. / ab- brev.) | ., | Seq ID no: (DNA, Prot) |
|---------|-----------------------|--|------------------------------|---------------------------|
| PCK2 | TIGR1280 | ORF0599 | Glycinamide-ribosyl synthase | 107, 108 |

unknown

286, 292–299

216, 219–234

7-14, 21-30, 34-50, 52-63, 65-72, 77-84,

109–124, 129–152, 158–163, 175–190, 193–

| N | | | | |
|----------|----------|--------------|--|----------|
| PCK4 | 7672993 | ORF2268 IsaA | possibly adhesion/aggregation | 12, 64 |
| PCK5 | TIGR6209 | ORF0484 yitU | conserved hypoth. protein (yitU) | 109, 110 |
| PCK6 | TIGR6182 | ORF2309 | membrane-associated malate-quinone | 111, 112 |
| | | | oxidase | |
| POV2 | 6434044 | ORF0766 aux1 | protein phosphatase contributing to methi- | 113, 114 |
| | | | cilin resistance | |
| POV3.1 | 7672993 | ORF2268 IsaA | possibly adhesion/aggregation | 12, 64 |
| POV3.2 | 7672993 | ORF2268 IsaA | possibly adhesion/aggregation | 12, 64 |
| POV4 | TIGR8079 | ORF0078 EF- | C-terminal part of 44 kDa protein similar | 115, 116 |
| | | Tu | to elongation factor Tu | |
| POV5 1) | TIGR8091 | ORF0782 | 3-ketoacyl-acyl carrier protein reductase | 117, 118 |
| | • | | (fabG) | |
| POV7 | 2500720 | ORF0317 SecA | protein transport across the membrane | 39, 91 |
| | | - | SecA | |
| POV10 | TIGR8097 | ORF1252 yrzC | hypothetical BACSU 11.9 kd protein | 119, 120 |
| | | | (upf0074 (rff2) family) | |
| POV12 | 2499415 | ORF0621 pdhB | dihydrolipoamide acetyltransferase (pdhB) | 121, 122 |
| POV13 | 7470965 | ORF0094 SdrD | fibrinogen-bdg. (LPXTG) protein homolog | 123, 124 |
| | | | (SdrD) | |
| POV14 | 1350849 | ORF0072 rpoB | DNA-directed RNA polymerase β | 125, 126 |
| POV15 | 6920067 | ORF0077 EF-G | 85 kD vitronectin binding protein | 127, 128 |
| POV17 | TIGR8079 | ORF0078 | C-terminal part of 44 kDa protein similar | 115, 116 |
| | | | to elongation factor Tu | |
| POV18 | 3025223 | not found | general stress protein YLY1 | 129, 130 |
| POV30 1) | 350771 | ORF0069 RL7 | ribosomal protein L7 | 131, 132 |
| POV21 | <u> </u> | ORF0103 | probable hexulose-6-phosphate synthas | 133, 134 |
| | , | | (yckG) | |
| POV23 | | ORF0182 | lipoprotein (S.epidermis) | 135, 136 |

 $^{^{1)}}$ identified from a total lysate from S. aureus 8325-4 spa- grown under standard conditions. Seroreactivity with 1/1 patient and 2/4 normal sera but not with infant serum (C5).

References

Aichinger G., Karlsson L., Jackson M.R., Vestberg M., Vaughau J.H., Teyton L., Lechler R.I. and Peterson P A. Major Histocompatibility Complex classII-dependent unfolding, transport and degradation of endogenous proteins. J. Biol. Chem., v.272, 1997, pp. 29127-29136

Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A. and Struhl, K. Eds. (1994). Current protocols in molecular biology. John Wiley & Sons, Inc.

Betley, M.J., Lofdahl, S., Kreiswirth, B.N., Bergdoll, M.S. and Novick, R.P. (1984). Staphylococcal enterotoxin A gene is associated with a variable genetic element. Proc. Natl. Acad. Sci. U.S.A. 81:5179-5183.

Bruggemann M, Neuberger MS (1996) Immunol. Today 17:391-397

Burnie, J.P., Matthews, R.C., Carter, T., Beaulieu, E., Donohoe, M., Chapman, C., Williamson, P. and Hodgetts, S.J. (2000). Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infect. Immun. 68:3200-3209.

Chen, H.Z. and Zubay, G. (1983). Methods Enzymol. 101:674-690.

Coloque-Navarro, P., Söderquist, B., Holmberg, H., Blomqvist, L., Olcen, P., and Möllby, R.(1998) Antibody response in Staphylococcus aureus septicaemia - a prospective study. J. Med. Microbiol. 47, 217-25.

Crossley, K.B. and Archer G.L., eds. (1997). The Staphylococci in Human Disease. Churchill Livingston Inc.

Flock, J.-I. (1999). Extracellular-matrix-binding proteins as targets for the prevention of Staphylococcus aureus infections. Molecular Medicine Today 5:532-537.

Forrer, P., Jung, S. and Plückthun, A. (1999). Beyond binding: using phage display to select for structure, folding and enzymatic activity in proteins. Curr. Opin. Struct. Biol. 9:514-520.

Foster, T.J. and Hook, M. (1998). Surface protein adhesins of Staphylococcus aureus. Trends Microbiol. 6:484-488.

Frénay, H. M. E., Theelen, J. P. G., Schouls, L. M., Vanden-broucke-Grauls, C. M. J. E., Vernoef, J., van Leeuwen, W. J., and Mooi, F. R. (1994). Discrimination of epidemic and nonepidemic methicillin-resistant Staphylococcus aureus on the basis of protein A gene polymorphism. J. Clin. Microbiol. 32:846-847.

Georgiou, G., Stathopoulos, C., Daugherty, P.S., Nayak, A.R., Iverson, B.L. and Curtiss III, R. (1997). Display of heterologous proteins on the surface of microorganisms: From the screening of combinatorial libraries to live recombinant vaccines. Nature Biotechnology 15:29-34.

Goh, S.-H., Byrne, S. K., Zhang, J. L., and Chow, A. W. (1992). Molecular typing of Staphylococcus aureus on the basis of coagulase gene polymorphisms. J. Clin. Microbiol. 30:1642-1645.

Graziano et al. (1995) J. Immunol. 155:4996-5002

Hammer et al. J. Exp. Med (1995) 181: 1847-1855

Hanes, J. and Plückthun, A. (1997). In vitro selection and evolution of functional proteins by using ribosome display. PNAS 94:4937-4942.

Hashemzadeh-Bonehi, L., Mehraein-Ghomi, F., Mitsopoulos, C., Jacob, J.P., Hennessey, E.S. and Broome-Smith, J.K. (1998). Importance of using lac rather than ara promoter vectors for modulating the levels of toxic gene products in Escherichia coli. Mol. Microbiol. 30:676-678.

Hryniewicz, W. (1999). Epidemiology of MRSA. Infection 27:S13-16.

Immler, D., Gremm, D., Kirsch, D., Spengler, B., Presek, P., Meyer, H.E. (1998). Electrophoresis 19:1015-1023.

Kajava, A.V., Zolov, S.N., Kalinin, A.E. and Nesmeyanova, M.A. (2000). The net charge of the first 18 residues of the mature sequence affects protein translocation across the cytoplasmic membrane of Gram-negative bacteria. J. Bacteriol. 182:2163-2169.

Kluytmans, J., van Belkum, A. and Verbrugh, H. (1997). Nasal car-

riage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin. Microbiol. Rev. 10:505-520.

Kolaskar, A.S. and Tongaonkar, P.C. (1990). A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett. 276:172-174.

Lim, Y., Shin, S.H., Jang, I.Y., Rhee, J.H. and Kim, I.S. (1998). Human transferring-binding protein of Staphylococcus aureus is immunogenic in vivo and has an epitope in common with human transferring receptor. FEMS Microbiol. Letters 166:225-230.

Lorenz, U., Ohlsen, K., Karch, H., Hecker, M., Thiede, A. and Hacker, J. (2000). Human antibody response during sepsis against targets expressed by methicillin resistant Staphylococcus aureus. FEMS Immunol. Med. Microbiol. 29:145-153.

Mamo, W., Jonsson, P. and Muller, H.P. (1995). Opsonization of Staphylococcus aureus with a fibronectin-binding protein antiserum induces protection in mice. Microb. Pathog. 19:49-55

McGuiness BT et al. (1996) Nature Biotech. 14:1149

Modun, B., Evans, R.W., Joannou, C.L. and Williams, P. (1998). Receptor-mediated recognition and uptake of iron from human transferring by Staphylococcus aureus and Staphylococcus epidermidis. Infect. Immun. 66:3591-3596.

Nilsson, I., Patti, J.M., Bremell, T., Höök, M. and Tarkowski, A. (1998). Vaccination with a Recombinant Fragment of Collagen Adhesin provides Protection against Staphylococcus aureus-mediated Septic Death. J. Clin. Invest. 101:2640-2649.

Parker, K. C., M. A. Bednarek, and J. E. Coligan (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152:163.

Pasquali, C., Fialka, I. & Huber, L.A. (1997). Electrophoresis 18:2573-2581.

Phillips-Quagliata, J.M., Patel, S., Han, J.K., Arakelov, S., Rao, T.D., Shulman, M.J., Fazel, S., Corley, R.B., Everett, M., Klein, M.H., Underdown, B.J. and Corthesy, B. (2000). The IgA/IgM receptor expressed on a murine B cell lymphoma is poly-Ig receptor. J. Immunol. 165:2544-2555

Rammensee, Hans-Georg, Jutta Bachmann, Niels Nikolaus Emmerich, Oskar Alexander Bachor, Stefan Stevanovic (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50: 213-219

Recsei P., Kreiswirth, B., O'Reilly, M., Schlievert, P., Gruss, A. and Novick, R.P. (1986). Regulation of exoprotein gene expression in Staphylococcus aureus by agr. Mol. Gen. Genet. 202:58-61.

Rodi, D.J. and Makowski, L. (1999). Phage-display technology--finding a needle in a vast molecular haystack. Curr. Opin. Biotechnol. 10:87-93.

Schaffitzel et al., Ribosome display: an in vitro method for selection and evolution of antibodies from libraries; Journal of Immunological Methods 231, 119-135 (1999).

Sanchez-Campillo, M., Bini, L., Comanducci, M., Raggiaschi, R., Marzocchi, B., Pallini, V. and Ratti, G. (1999). Electrophoresis 20:2269-2279.

Schmittel A, Keilholz U, Thiel E, Scheibenbogen C. (2000) Quantification of tumor-specific T lymphocytes with the ELISPOT assay.

J Immunother 23(3):289-95

Sester M, Sester U, Kohler H, Schneider T, Deml L, Wagner R, Mueller-Lantzsch N, Pees HW, Meyerhans A. (2000) Rapid whole blood analysis of virus-specific CD4 and CD8 T cell responses in persistent HIV infection. AIDS 14(17):2653-60.

Shafer, W.M. and Iandolo, J.J. (1979). Genetics of staphylococcal enterotoxin B in methicillin-resistant isolates of Staphylococcus aureus. Infect. Immun. 25:902-911.

Shibuya, A., Sakamoto, N., Shimizu, Y., Shibuya, K., Osawa, M., Hiroyama, T., Eyre, H.J., Sutherland, G.R., Endo, Y., Fujita, T., Miyabayashi, T., Sakano, S., Tsuji, T., Nakayama, E., Phillips, J.H., Lanier, L.L. and Nakauchi, H. (2000). Fc_a/_g receptor mediates endocytosis of IgM-coated microbes. Nature Immunology 1:441-446.)

Skerra, A. (1994). Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in Escherichia coli. Gene 151:131-135.

Sohail, M. (1998). A simple and rapid method for preparing genomic DNA from Gram-positive bacteria. Mol. Biotech. 10:191-193.

Sonderstrup G, Cope AP, Patel S, Congia M, Hain N, Hall FC, Parry SL, Fugger LH, Michie S, McDevitt HO (1999) HLA class II transgenic mice: models of the human CD4+ T-cell immune response. Immunol Rev 172:335-43

Sturniolo, T. et al., E Bono, J Ding, L Raddrizzani, O. Tuereci, U Sahin, M Braxenthaler, F Gallazzi, MP Protti, F Sinigaglia, and J Hammer (1999) Generation of tissue-specific and promiscuous HLA ligand databases using DNA chips and virtual HLA class II matrices. Nature Biotechnology 17: 555-562.

Valli et al. J. Clin. Invest. (1993) 91: 616-62

VandenBergh M. F. Q., Yzerman E. P. F., van Belkum, A., Boelens, H. A. M., Sijmons, M., and Verbrugh, H. A. (1999). Follow-up of Staphylococcus aureus nasal carriage after 8 years: redining the persistent carrier state. J. Clin. Microbiol. 37:3133-3140..

Wessel, D. and Fluegge, U.I. (1984). Anal. Biochem. 138:141-143.

Claims:

- 1. Method for identification, isolation and production of hyperimmune serum-reactive antigens from a pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, characterized by the following steps:
 - *providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,
 - *providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity
 - *screening said at least one expression library with said antibody preparation,
 - *identifying antigens which bind in said screening to antibodies in said antibody preparation,
 - *screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,
 - *identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera and
 - *optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.
- 2. Method for identification, isolation and production of a practically complete set of hyperimmune serum-reactive antigens of a specific pathogen, said antigens being suited for use in a vaccine for a given type of animal or for humans, characterized by the following steps:
 - *providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen,
 - *providing at least three different expression libraries of said specific pathogen,

WO 02/059148 PCT/EP02/00546

- *screening said at least three different expression libraries with said antibody preparation,
- *identifying antigens which bind in at least one of said at least three screenings to antibodies in said antibody preparation.
- •screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen,
- *identifying the hyperimmune serum-reactive antigen portion of said identified antigens which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera,
- *repeating said screening and identification steps at least once.
- *comparing the hyperimmune serum-reactive antigens identified in the repeated screening and identification steps with the hyperimmune serum-reactive antigens identified in the initial screening and identification steps,
- *further repeating said screening and identification steps, if at least 5% of the hyperimmune serum-reactive antigens have been identified in the repeated screening and identification steps only, until less than 5 % of the hyperimmune serum-reactive antigens are identified in a further repeating step only to obtain a complete set of hyperimmune serum-reactive antigens of a specific pathogen and
- *optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.
- 3. Method according to claim 1 or 2 characterized in that at least one of said expression libraries is selected from a ribosomal display library, a bacterial surface library and a proteome.
- 4. Method according to claim 2 characterized in that said at least three different expression libraries are at least a ribosomal display library, a bacterial surface library and a proteome.
- 5. Method according to any one of claims 1 to 4, characterized

in that said plasma pool is a human plasma pool taken from individuals having experienced or are experiencing an infection with said pathogen.

- Method according to any one of claims 1 to 5, characterized in that said expression libraries are genomic expression libraries of said pathogen.
- Method according to any one of claims 1 to 6, characterized 7. in that said expression libraries are complete genomic expression libraries, preferably with a redundancy of at least 2x, more preferred at least 5x, especially at least 10x.
- Method according to any one of claims 1 to 7, characterized 8. in that it comprises the steps of screening at least a ribosomal display library, a bacterial surface display library and a proteome with said antibody preparation and identifying antigens which bind in at least two, preferably which bind to all, of said screenings to antibodies in said antibody preparation.
- Method according to any one of claims 1 to 8, characterized in that said pathogen is selected from the group of bacterial, viral, fungal and protozoan pathogens.
- 10. Method according to any one of claims 1 to 9, characterized in that said pathogen is selected from the group of human immunedeficiency virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, Rous sarcoma virus, Epstein-Barr virus, influenza virus, rotavirus, Staphylococcus aureus, Staphylococcus epidermidis, Chlamydia pneumoniae, Chlamydia trachomatis, Mycobacterium tuberculosis, Mycobacterium leprae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Enterococcus faecalis, Bacillus anthracis, Vibrio cholerae, Borrelia burgdorferi, Plasmodium sp., Aspergillus sp. or Candida albicans.
- 11. Method according to any one of claims 1 to 10, characterized in that at least one of said expression libraries is a ribosomal display library or a bacterial surface display library and said hyperimmune serum-reactive antigens are produced by expression of the coding sequences of said hyperimmune serum-reactive antigens

WO 02/059148 PCT/EP02/00546

contained in said library.

- 12. Method according to any one of claims 1 to 11, characterized in that said produced hyperimmune serum-reactive antigens are finished to a pharmaceutical preparation, optionally by addition of a pharmaceutically acceptable carrier and/or excipient.
- 13. Method according to claim 12, characterized in that said pharmaceutical preparation is a vaccine.
- 14. Method according to claim 12 or 13, characterized in that said pharmaceutically acceptable carrier and/or excipient is an immunostimulatory compound.
- 15. Method according to claim 14, characterized in that said immunostimulatory compound is selected from the group of polycationic substances, especially polycationic peptides, immunostimulatory deoxynucleotides, alumn, Freund's complete adjuvans, Freund's incomplete adjuvans, neuroactive compounds, especially human growth hormone, or combinations thereof.
- 16. Method according to any one of claims 1 to 15, characterized in that said individual antibody preparations are derived from patients with acute infection with said pathogen, especially from patients with an antibody titer to said pathogen being higher than 80%, preferably higher than 90%, especially higher than 95% of human patient or carrier sera tested.
- 17. Method according to any one of claims 1 to 16, characterized in that at least 10, preferably at least 30, especially at least 50, individual antibody preparations are used in identifying said hyperimmune serum-reactive antigens.
- 18. Method according to any one of said claims 1 to 17, characterized in that said relevant portion of said individual antibody preparations from said individual sera are at least 10, preferably at least 30, especially at least 50 individual antibody preparations, and/or at least 20%, preferably at least 30%, especially at least 40%, of all individual antibody preparations used in said screening.

- 19. Method according to any one of claims 1 to 18, characterized in that said individual sera are selected by having an IgA titer against a lysate, cell wall components or recombinant proteins of said pathogen being above 4000 U, especially above 6000 U, and/or by having an IgG titer being above 10000 U, preferably above 12000 U.
 - 20. Method according to any one of claims 1 to 19, characterized in that said pathogen is a Staphylococcus pathogen, especially Staphylococcus aureus. and/or Staphylococcus epidermidis.
 - 21. A hyperimmune serum-reactive antigen selected from the group consisting of the sequences listed in any one of Tables 2a, 2b, 2c, 2d, 3, 4 and 5, especially selected from the group consisting of Seq.ID No. 56, 57, 59, 60, 67, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 85, 87, 88, 89, 90, 92, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 126, 128, 130, 132, 134, 138, 140, 142, 151, 152, 154, 155 and hyperimmune fragments thereof.
 - 22. A hyperimmune serum-reactive antigen obtainable by a method according to any one of claims 1 to 20 and being selected from the group consisting of the sequences listed in any one of Tables 2a, 2b, 2c, 2d, 3, 4 and 5, especially selected from the group consisting of Seq.ID No. 56, 57, 59, 60, 67, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 85, 87, 88, 89, 90, 92, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 126, 128, 130, 132, 134, 138, 140, 142, 151, 152, 154, 155 and hyperimmune fragments thereof.
 - 23. Use of a hyperimmune serum-reactive antigen selected from the group consisting of the sequences listed in any one of Tables 2a, 2b, 2c, 2d, 3, 4 and 5, especially selected from the group consisting of Seq.ID No. 55, 56, 57, 58, 59, 60, 62, 66, 67, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 87, 88, 89, 90, 92, 94, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 126, 128, 130, 132, 134, 138, 140, 142, 151, 152, 154, 155, 158 and hyperimmune fragments thereof for the manufacture of a pharmaceutical preparation, es-

- 113 -

pecially for the manufacture of a vaccine against staphylococcal infections or colonization in particular against Staphylococcus aureus or Staphylococcus epidermidis.

24. Hyperimmune fragment of a hyperimmune serum-reactive antigen selected from the group consisting of peptides comprising the amino acid sequences of column "predicted immunogenic aa", "Location of identified immunogenic region" and "Serum reactivity with relevant region" of Tables 2a, 2b, 2c and 2d and the amino acid sequences of column "Putative antigenic surface areas" of Table 4 and 5, especially peptides comprising amino acid No. aa 12-29, 34-40, 63-71, 101-110, 114-122, 130-138, 140-195, 197-209, 215-229, 239-253, 255-274 and 39-94 of Seq.ID No. 55, aa 5-39, 111-117, 125-132, 134-141, 167-191, 196-202, 214-232, 236-241, 244-249, 292-297, 319-328, 336-341, 365-380, 385-391, 407-416, 420-429, 435-441, 452-461, 477-488, 491-498, 518-532, 545-556, 569-576, 581-587, 595-602, 604-609, 617-640, 643-651, 702-715, 723-731, 786-793, 805-811, 826-839, 874-889, 37-49, 63-77 and 274-334, of Seq.ID No.56, aa 28-55, 82-100, 105-111, 125-131, 137-143, 1-49, of Seq.ID No. 57, aa 33-43, 45-51, 57-63, 65-72, 80-96, 99-110, 123-129, 161-171, 173-179, 185-191, 193-200, 208-224, 227-246, 252-258, 294-308, 321-329, 344-352, 691-707, 358-411 and 588-606, of Seq.ID No. 58, aa 16-38, 71-77, 87-94, 105-112, 124-144, 158-164, 169-177, 180-186, 194-204, 221-228, 236-245, 250-267, 336-343, 363-378, 385-394, 406-412, 423-440, 443-449, 401-494, of Seq.ID No. 59, aa 18-23, 42-55, 69-77, 85-98, 129-136, 182-188, 214-220, 229-235, 242-248, 251-258, 281-292, 309-316, 333-343, 348-354, 361-367, 393-407, 441-447, 481-488, 493-505, 510-515, 517-527, 530-535, 540-549, 564-583, 593-599, 608-621, 636-645, 656-670, 674-687, 697-708, 726-734, 755-760, 765-772, 785-792, 798-815, 819-824, 826-838, 846-852, 889-904, 907-913, 932-939, 956-964, 982-1000, 1008-1015, 1017-1024, 1028-1034, 1059-1065, 1078-1084, 1122-1129, 1134-1143, 1180-1186, 1188-1194, 1205-1215, 1224-1230, 1276-1283, 1333-1339, 1377-1382, 1415-1421, 1448-1459, 1467-1472, 1537-1545, 1556-1566, 1647-1654, 1666-1675, 1683-1689, 1722-1737, 1740-1754, 1756-1762, 1764-1773, 1775-1783, 1800-1809, 1811-1819, 1839-1851, 1859-1866, 1876-1882, 1930-1939, 1947-1954, 1978-1985,

1999-2007, 2015-2029, 2080-2086, 2094-2100, 2112-2118, 2196-2205,

No. 66,

2232-2243, 198-258, 646-727 and 2104-2206, of Seq.ID No. 60, aa 10-29, 46-56, 63-74, 83-105, 107-114, 138-145, 170-184, 186-193, 216-221, 242-248, 277-289, 303-311, 346-360, 379-389, 422-428, 446-453, 459-469, 479-489, 496-501, 83-156, of Seq.ID No. 62,

aa 14-22, 32-40, 52-58, 61-77, 81-93, 111-117, 124-138, 151-190, 193-214, 224-244, 253-277, 287-295, 307-324, 326-332, 348-355, 357-362, 384-394, 397-434, 437-460, 489-496, 503-510, 516-522, 528-539, 541-547, 552-558, 563-573, 589-595, 602-624, 626-632, 651-667, 673-689, 694-706, 712-739, 756-790, 403-462, of Seq.ID

aa 49-56, 62-68, 83-89, 92-98, 109-115, 124-131, 142-159, 161-167, 169-175, 177-188, 196-224, 230-243, 246-252, 34-46, of Seq.ID No. 67,

aa 11-20, 26-47, 69-75, 84-92, 102-109, 119-136, 139-147, 160-170, 178-185, 190-196, 208-215, 225-233, 245-250, 265-272, 277-284, 300-306, 346-357, 373-379, 384-390, 429-435, 471-481, 502-507, 536-561, 663-688, 791-816, 905-910, 919-933, 977-985, 1001-1010, 1052-1057, 1070-1077, 1082-1087, 1094-1112, 493-587, 633-715 and 704-760, of Seq.ID No.70,

aa.6-20, 53-63, 83-90, 135-146, 195-208, 244-259, 263-314, 319-327, 337-349, 353-362, 365-374, 380-390, 397-405, 407-415, 208-287 and 286-314, of Seq.ID No. 71,

aa 10-26, 31-43, 46-58, 61-66, 69-79, 85-92, 100-115, 120-126, 128-135, 149-155, 167-173, 178-187, 189-196, 202-222, 225-231, 233-240, 245-251, 257-263, 271-292, 314-322, 325-334, 339-345, 59-74, of Seq.ID No. 72,

aa 4-9, 15-26, 65-76, 108-115, 119-128, 144-153, 38-52 and 66-114, of Seq.ID No. 73,

aa 5-22, 42-50, 74-81, 139-145, 167-178, 220-230, 246-253, 255-264, 137-237 and 250-267, of Seq.ID No. 74,

aa 10-26, 31-44, 60-66, 99-104, 146-153, 163-169, 197-205, 216-

223, 226-238, 241-258, 271-280, 295-315, 346-351, 371-385, 396-

407, 440-446, 452-457, 460-466, 492-510, 537-543, 546-551, 565-

582, 590-595, 635-650, 672-678, 686-701, 705-712, 714-721, 725-

731, 762-768, 800-805, 672-727, of Seq.ID No. 75,

aa 5-32, 35-48, 55-76, of Seq.ID No. 76,

aa 7-35, 54-59, 247-261, 263-272, 302-320, 330-339, 368-374, 382-411, 126-143 and 168-186, of Seq.ID No. 77,

aa 5-24, 88-94, 102-113, 132-143, 163-173, 216-224, 254-269, 273-

278, 305-313, 321-327, 334-341, 31-61 and 58-74, of Seq.ID No. aa 16-24, 32-39, 43-49, 64-71, 93-99, 126-141, 144-156, 210-218, 226-233, 265-273, 276-284, 158-220, of Seq.ID No. 79, aa 49-72, 76-83, 95-105, 135-146, 148-164, 183-205, 57-128, of Seq.ID No. 80, aa 6-15, 22-32, 58-73, 82-88, 97-109, 120-131, 134-140, 151-163, 179-185, 219-230, 242-255, 271-277, 288-293, 305-319, 345-356, 368-381, 397-406, 408-420, 427-437, 448-454, 473-482, 498-505, 529-535, 550-563, 573-580, 582-590, 600-605, 618-627, 677-685, 718-725, 729-735, 744-759, 773-784, 789-794, 820-837, 902-908, 916-921, 929-935, 949-955, 1001-1008, 1026-1032, 1074-1083, 1088-1094, 1108-1117, 1137-1142, 1159-1177, 1183-1194, 1214-1220, 1236-1252, 1261-1269, 1289-1294, 1311-1329, 1336-1341, 1406-1413, 1419-1432, 1437-1457, 1464-1503, 1519-1525, 1531-1537, 1539-1557, 1560-1567, 1611-1618, 1620-1629, 1697-1704, 1712-1719, 1726-1736, 1781-1786, 1797-1817, 1848-1854, 1879-1890, 1919-1925, 1946-1953, 1974-1979, 5 to 134, of Seq.ID No. 81, aa 6-33, 40-46, 51-59, 61-77, 84-104, 112-118, 124-187, 194-248, 252-296, 308-325, 327-361, 367-393, 396-437, 452-479, 484-520, 535-545, 558-574, 582-614, 627-633, 656-663, 671-678, 698-704, 713-722, 725-742, 744-755, 770-784, 786-800, 816-822, 827-837, 483-511, of Seq.ID No. 82, aa 4-19, 57-70, 79-88, 126-132, 144-159, 161-167, 180-198, 200-212, 233-240, 248-255, 276-286, 298-304, 309-323, 332-346, 357-366, 374-391, 394-406, 450-456, 466-473, 479-487, 498-505, 507-519, 521-530, 532-540, 555-565, 571-581, 600-611, 619-625, 634-642, 650-656, 658-665, 676-682, 690-699, 724-733, 740-771, 774-784, 791-797, 808-815, 821-828, 832-838, 876-881, 893-906, 922-929, 938-943, 948-953, 969-976, 1002-1008, 1015-1035, 1056-1069, 1105-1116, 1124-1135, 1144-1151, 1173-1181, 1186-1191, 1206-1215, 1225-1230, 1235-1242, 6-66, 65-124 and 590-604, of Seq.ID No. 83, aa 5-32, 66-72, 87-98, 104-112, 116-124, 128-137, 162-168, 174-183, 248-254, 261-266, 289-303, 312-331, 174-249, of Seq.ID No. 84, aa 4-21, 28-40, 45-52, 59-71, 92-107, 123-137, 159-174, 190-202, 220-229, 232-241, 282-296, 302-308, 312-331, 21-118, of Seq.ID No. 85, aa 9-28, 43-48, 56-75, 109-126, 128-141, 143-162, 164-195, 197-

216, 234-242, 244-251, 168-181, of Seq.ID No. 87,

aa 4-10, 20-42, 50-86, 88-98, 102-171, 176-182, 189-221, 223-244, 246-268, 276-284, 296-329, 112-188, of Seq.ID No. 88, aa 4-9, 13-24, 26-34, 37-43, 45-51, 59-73, 90-96, 99-113, 160-173, 178-184, 218-228, 233-238, 255-262, 45-105, 103-166 and 66-153, of Seq.ID No. 89, aa 13-27, 42-63, 107-191, 198-215, 218-225, 233-250, 474-367, of Seq.ID No. 90, aa 26-53, 95-123, 164-176, 189-199, 8-48, of Seq.ID No. 92, aa 7-13, 15-23, 26-33, 68-81, 84-90, 106-117, 129-137, 140-159, 165-172, 177-230, 234-240, 258-278, 295-319, 22-56, 23-99, 97-115, 233-250 and 245-265, of Seq.ID No. 94, aa 13-36, 40-49, 111-118, 134-140, 159-164, 173-183, 208-220, 232-241, 245-254, 262-271, 280-286, 295-301, 303-310, 319-324, 332-339, 1-85, 54-121 and 103-185, of Seq.ID No. 95, aa 39-44, 46-80, 92-98, 105-113, 118-123, 133-165, 176-208, 226-238, 240-255, 279-285, 298-330, 338-345, 350-357, 365-372, 397-402, 409-415, 465-473, 488-515, 517-535, 542-550, 554-590, 593-601, 603-620, 627-653, 660-665, 674-687, 698-718, 726-739, 386-402, of Seq.ID No. 96, aa 5-32, 34-49, 1-43, of Seq.ID No. 97, aa 10-27, 37-56, 64-99, 106-119, 121-136, 139-145, 148-178, 190-216, 225-249, 251-276, 292-297, 312-321, 332-399, 403-458, 183-200, of Seq.ID No. 99, aa 5-12, 15-20, 43-49, 94-106, 110-116, 119-128, 153-163, 175-180, 185-191, 198-209, 244-252, 254-264, 266-273, 280-288, 290-297, 63-126, of Seq.ID No. 100, aa 5-44, 47-55, 62-68, 70-78, 93-100, 128-151, 166-171, 176-308, 1-59, of Seq.ID No. 101, aa 18-28, 36-49, 56-62, 67-84, 86-95, 102-153, 180-195, 198-218, 254-280, 284-296, 301-325, 327-348, 353-390, 397-402, 407-414, 431-455, 328-394, of Seq.ID No. 102, aa 7-37, 56-71, 74-150, 155-162, 183-203, 211-222, 224-234, 242-272, 77-128, of Seq.ID No. 103, aa 34-58, 63-69, 74-86, 92-101, 130-138, 142-150, 158-191, 199-207, 210-221, 234-249, 252-271, 5-48, of Seq.ID No. 104, aa 12-36, 43-50, 58-65, 73-78, 80-87, 108-139, 147-153, 159-172, 190-203, 211-216, 224-232, 234-246, 256-261, 273-279, 286-293, 299-306, 340-346, 354-366, 167-181, of Seq.ID No. 106, aa 61-75, 82-87, 97-104, 113-123, 128-133, 203-216, 224-229,

236-246, 251-258, 271-286, 288-294, 301-310, 316-329, 337-346,

348-371, 394-406, 418-435, 440-452 of Seq.ID No. 112, aa 30-37, 44-55, 83-91, 101-118, 121-128, 136-149, 175-183, 185-193, 206-212, 222-229, 235-242 of Seq.ID No. 114, aa 28-38, 76-91, 102-109, 118-141, 146-153, 155-161, 165-179, 186-202, 215-221, 234-249, 262-269, 276-282, 289-302, 306-314, 321-326, 338-345, 360-369, 385-391 of Seq.ID No. 116, aa 9-33, 56-62,75-84, 99-105, 122-127, 163-180, 186-192, 206-228, 233-240, 254-262, 275-283, 289-296, 322-330, 348-355, 416-424, 426-438, 441-452, 484-491, 522-528, 541-549, 563-569, 578-584, 624-641, 527-544, of Seq.ID No. 142, aa 37-42, 57-62, 121-135, 139-145, 183-190, 204-212, 220-227, 242-248, 278-288, 295-30, 304-309, 335-341, 396-404, 412-433, 443-449, 497-503, 505-513, 539-545, 552-558, 601-617, 629-649, 702-711, 736-745, 793-804, 814-829, 843-858, 864-885, 889-895, 905-913, 919-929, 937-943, 957-965, 970-986, 990-1030, 1038-1049, 1063-1072, 1080-1091, 1093-1116, 1126-1136, 1145-1157, 1163-1171, 1177-1183, 1189-1196, 1211-1218, 1225-1235, 1242-1256, 1261-1269, 624-684, of Seq.ID No. 151, aa 8-23, 31-38, 42-49, 61-77, 83-90, 99-108, 110-119, 140-147, 149-155, 159-171, 180-185, 189-209, 228-234, 245-262, 264-275, 280-302, 304-330, 343-360, 391-409, 432-437, 454-463, 467-474, 478-485, 515-528, 532-539, 553-567, 569-581, 586-592, 605-612, 627-635, 639-656, 671-682, 700-714, 731-747, 754-770, 775-791, 797-834, 838-848, 872-891, 927-933, 935-942, 948-968, 976-986, 1000-1007, 1029-1037, 630-700, of Seq.ID No. 152, aa 17-25, 27-55, 84-90, 95-101, 115-121, 55-101, of Seq.ID No. 154, aa 13-28, 40-46, 69-75, 86-92, 114-120, 126-137, 155-172, 182-193, 199-206, 213-221, 232-238, 243-253, 270-276, 284-290, 22-100, of Seq.ID No. 155 and aa 7-19, 46-57, 85-91, 110-117, 125-133, 140-149, 156-163, 198-204, 236-251, 269-275, 283-290, 318-323, 347-363, 9-42 and 158-174, of Seq.ID No. 158, aa 7-14, 21-30, 34-50, 52-63, 65-72, 77-84, 109-124, 129-152, 158-163, 175-190, 193-216, 219-234 of Seq.ID.No. 168, aa 5-24, 38-44, 100-106, 118-130, 144-154, 204-210, 218-223, 228-243, 257-264, 266-286, 292-299 of Seq.ID.No. 174, aa 29-44, 74-83, 105-113, 119-125, 130-148, 155-175, 182-190, 198-211, 238-245 of Seq.ID.No. 176, and fragments as depicted in Tables 2 and 4 and fragments comprising at least 6, preferably

WO 02/059148 PCT/EP02/00546

- 118 -

more than 8, especially more than 10 aa of said sequences.


- 25. Helper epitopes of an antigen or a fragment, as defined in anyone of claims 21 to 24, especially peptides comprising fragments selected from the peptides mentioned in column "Putative antigenic surface areas" in Table 4 and 5 and from the group aa 6-40, 583-598, 620-646 and 871-896 of Seq.ID.No.56, aa 24-53 of Seg.ID.No.70, aa 240-260 of Seg.ID.No.74, aa 1660-1682 and 1746-1790 of Seq.ID.No. 81, aa 1-29, 680-709, and 878-902 of Seq.ID.No. 83, aa 96-136 of Seq.ID.No. 89, aa 1-29, 226-269 and 275-326 of Seq.ID.No. 94, aa 23-47 and 107-156 of Seq.ID.No. 114 and aa 24-53 of Seq.ID.No. 142 and fragments thereof being T-cell epitopes.
- 26. Vaccine comprising a hyperimmune serum-reactive antigen or a fragment thereof, as defined in any one of claims 21 to 25.
- 27. Vaccine according to claim 25, characterized in that it further comprises an immunostimulatory substance, preferably selected from the group comprising polycationic polymers, especially polycationic peptides, immunostimulatory deoxynucleotides (ODNs), neuroactive compounds, especially human growth hormone, alumn, Freund's complete or incomplete adjuvans or combinations thereof.
- 28. Preparation comprising antibodies against at least one antigen or a fragment thereof, as defined in any one of claims 21 to 25.
- 29. Preparation according to claim 27, characterized in that said antibodies are monoclonal antibodies.
- 30. Method for producing a preparation according to claim 28, characterized by the following steps:
 - •initiating an immune response in a non human animal by administering an antigen or a fragment thereof, as defined in any one of the claims 21 to 25, to said animal,
 - •removing the spleen or spleen cells from said animal,
 - •producing hybridoma cells of said spleen or spleen cells,
 - selecting and cloning hybridoma cells specific for said anti-

gen and

producing the antibody preparation by cultivation of said cloned hybridoma cells and optionally further purification steps.

- 31. Method according to claim 29, characterized in that said removing the spleen or spleen cells is connected with killing said animal.
- 32. Method for producing a preparation according to claim 27, characterized by the following steps:
 - ·initiating an immune response in a non human animal by administering an antigen or a fragment thereof, as defined in any one of the claims 21 to 25, to said animal,
 - removing an antibody containing body fluid from said animal,and
 - producing the antibody preparation by subjecting said antibody containing body fluid to further purification steps.
- 33. Use of a preparation according to claim 27 or 28 for the manufacture of a medicament for treating or preventing staphylococcal infections or colonization in particular against Staphylococcus aureus or Staphylococcus epidermidis.
- 34. A screening method assessing the consequences of functional inhibition of at least one antigen or a fragment thereof, as defined in any one of claims 21 to 25.

IgA vs. IgG titer against total S. aureus lysate



IgA titer 10.000X

Figure 1





Figure 2






Figure 3





Figure 4



Figure




Figure (




Figure 7

EXTRACELLUEAR DOMAIN




Figure 84

Constitutive Cell Wall Proteins of S. aureus with LPXTG motif

| | Known proteins | Predicted | Things Indicophible removante domain basic C-terminus |
|----|---------------------------------|-----------|---|
| - | Mrp protein | 255/4.6 | AKTEEDTIGMSHNDDLFYAELALGAGMAFLHRRFTKKDQQTEE |
| | Pls (MRSA) | 167/4.1 | NKE EPDIGNDRONGINEGSDERALGGDETVGRERKNINBEK |
| | SdrD (SD-repeat) | 133/4.1 | AKALIPBTGNENSGSNNATIFFGGTFFATGSLIJFFGRRKKONK |
| | Cha | 126/5.6 | IKBUPKYCMGATISHIUNYFIGIIGIATAILERKRENS |
| - | SdrE | 117/4.1 | AKALPETGSENNGSNIPTIFGGGGFFALGSLILLFGRRKKONK |
| ف | FnBPA | 104/4.5 | KSELDETGGEESTNKGMLEGGIFST LGIALIRRNKKNHKA |
| + | Sdrc | 94/4.1 | AKALTERIĞSENINSINGTLEGGLERALGSILISEGREKKONK |
| 1- | FnBPB | 96/4.5 | KSELPENGGEESTINGOLFGGLEST LGLALIRRNKKNIHKA |
| 0 | ClfA (clumping factor 89/3.4 | 89/3.4 | KEPTEDYGSEDENNISTI WGLIASTGSILLI FRRKKENKDKK |
| 1_ | 10 CLEB (clumping factor 88/3.7 | 88/3.7 | TDALEBITGDKSENTRATTE GAMMATIGSTILLFRKRKODHKEKA |
| ۲. | 11 Spa (Protein A) | 48/5.2 | AOALDETIGENPETGTTVEGGESTALGAALLAGRREEL |

| | Predicted based on sequence (TIGR) | | |
|-----|------------------------------------|---------|--|
| Ü. | Anonymus I. | 79/9.3 | EKODPKTGTNKSSSPERMFVILLAGIGLITATVRRKAS |
| | Anonymus II. | 227/4.2 | EKRLPDTGDSIKONGILGGVMTILVGLGIMKRKKKKDEND |
| - | Anonymus III. | 200/4.1 | ekembentigsegad metakeralitagaarilaarrruknekes |
| - | Anonymus IV. | 122/5.8 | raempriglestokglitystigiagiallarrrn |
| 100 | Anonymus V. | 101/5.0 | SKALPKTGETTSSOSWWGIYALLCALLALFTPKFRKESK |

Figure 8B




Figure 9

- 1

Surface staining of S. aureus (strain 8325-4 spa-) with purified anti-LPXTGV IgGs

[]




Figure 10

SEQUENCE LISTING

Intercell Biomedizinische Forschungs- und Entwicklungs AG Cistem Biotechnologies GmbH

R 39035

Priority: Austrian Patent Application No. A 130/2001 of 26.01.2001

Seq.ID Nos. 1-598

Organisms: S.aureus; S.epidermidis

atgaacaacagcaaaagaatttaaatcattttattcaattagaaagtcatcactaggc gttgcatctgtagcaattagtacacttttattattaatgtcaaatggcgaagcacaagca gcagctgaagaaacaggtggtacaaatacagaagcacaaccaaaaactgaagcagttgca agtccaacaacaacatctgaaaaaagctccagaaactaaaccagtagctaatgctgtctca gtatctaataaagaagttgaggcccctacttctgaaacaaaagaagctaaagaagttaaa gaagttaaagcccctaaggaaacaaaagaagttaaaccagcagcaaaagccactaacaat gettacattegettetetytateaaaeggaacaaaagetyttaaaattyttagtteaaca caetteaataacaaagaagaaaaataegattacacattaatggaattegeacaaccaatt tataacagtgcagataaattcaaaactgaagaagattataaagctgaaaaattattagcg aaaatgactgatttacaagatacaaaatatgttgtttatgaaagtgttgagaataacgaa tctatgatggatacttttgttaaacaccctattaaaacaggtatgcttaacggcaaaaaa tatatggtcatggaaactactaatgacgattactggaaagatttcatggttgaaggtcaa gatggacaataccatgtcagaatcgttgataaagaagcatttacaaaagccaataccgat aaatotaacaaaaaagaacaacaagataactcagotaagaaggaagotactccagotacg cotagoaaaccaacacoatcacotgttgaaaaagaatcacaaaaaacaagacagocaaaaa gatgacaataaacaattaccaagtgttgaaaaagaaaatgacgcatctagtgagtcaggt aaaggcgtaacgottgctacaaaaccaactaaaggtgaagtagaatcaagtagtacaact ccaactaaggtagtatctacgactcaaaatgttgcaaaaccaacaactggttcatcaaaa acaacaaaagatgttgttcaaacttcagcaggttctagcgaagcaaaagatagtgctcca ttacaaaaagcaaacattaaacacacaaatgatggacacactcaaagccaaaacaataaa aatacacaagaaaataaagcaaaatcattaccacaaactggtgaagaatcaataaagat atgacattaccattaatggcattattagctttaagtagcatcgttgcattcgtattacct agaaaacgtaaaaactaa 2. atgagaaatatagagaatctaaatcccggagattcagttgatcactttttcttagtgcat aaagctacacagggtgtaacagcacaaggtaaagattatatgacattacatttgcaagat aaaagtggtgaaattgaagcgaaattttggacggctacaaaaaatgatatggcaacaatc aagcctgaagaaattgtacatgttaaaggtgacatcataaactatcgcggaaataaacag atgaaagtcaaccaaattagactagcgacaactgaagatcaattaaaacagaacaattt gtagatggtgcacctttatcaccggcagaaatacaagaagaatttctcattatttgcta gatattgaaaatgctaatttacaacgtatcacacgtcatttattgaaaaaatatcaagaa cgattttacacatatccagctgctagttctcatcatcataactttgcgagtggcttaagc tatcatgtattaacgatgttacgtattgcaaaatcaatttgtgacatttatccattgtta aacaaagtttgttatatatgtggtattattttgcatgatattggtaaagttagagaattg agtggtcctgttgcgacgtcgtatacagtcgaaggtaacttattaggacacatctcgatt atgtttgaaaaggcatataaaaaaactgacaagggtcagtttacagataaaatatttggt cttgaaaatcgtagattctacaatcctgaatcactcgat

3. gttgoatcggtcattgtcagtacactatttttaattacttctcaagcacaagca gcagaaaatacaaatacttcagtacactattctcagtacactcaagcacaagca gcagaaaatacaaatacttcagataaaatctcggaaaatcaaaataataatgcaactaca actcagccacctaaggatacaaatcaaacacaacctgctacgcaaccagcaaacactgcg aaaaactatcetgcagcggatgaatcacttaaagatgcaattaaagatcctgcattagaa aataaagaacatgatataggtccaagagaacaagtcaatttccagttattagataaaaac aatgaaacgcagtactatcactttttcagcatcaagatccagcagatgtgtattacact aaaaagaaagcagaagttgaattagacatcaatactgcttcaacatggaagaagtttgaa gtctatgaaaacaatcaaaaattgccagtgagacttgtatcatatagtcctgtaccagaa gaccatgcctatattcgattcccagtttcagatggcacacaagaattgaaaattgtttct tcgactcaaattgatgatggagaagaaacaaattatgattatactaaattagtatttgct aaacctatttataacgatcettcacttgtaaaatcagatacaaatgatgcagtagtaacg aatgatcaatcaagttcagtcgcaagtaatcaaacaacacgaatacatctaatcaaaat acatcaacgatcaacaatgctaataatcaaccgcaggcaacgaccaatatgagtcaacct gcacaaccaaaatcgtcaacgaatgcagatcaagcgtcaagccaaccagctcatgaaaca aattctaatggtaatactaacgataaaacgaatgagtcaagtaatcagtcggatgttaat attgaatatggtgagaacatccatgaagactatgattatacgctaatggtctttgcacag cctattactaataacccagacgactatgtggatgaagaaacatacaatttacaaaaatta ttagctccgtatcacaaagctaaaacgttagaaagacaagtttatgaattagaaaaatta caagagaaattgccagaaaaatataaggcggaatataaaaagaaattagatcaaactaga gtagagttagctgatcaagttaaatcagcagtgacggaatttgaaaatgttacacctaca aatgatcaattaacagatttacaagaagcgcattttgttgttgtttttgaaagtgaagaaaat agtgagtcagttatggacggctttgttgaacatccattctatacagcaactttaaatggt caaaaatatgtagtgatgaaaacaaaggatgacagttactggaaagatttaattgtagaa ggtaaacgtgtcactactgtttctaaagatcctaaaaataattctagaacgctgattttc ccatatatacctgacaaagcagtttacaatgcgattgttaaagtcgttgtggcaaacatt ggttatgaaggtcaatatcatgtcagaattataaatcaggatatcaatacaaaagatgat gataaagatgccgataatagcgttggtatgtcatctaatgtcgatactgataaagactct aataaaaataaagacaaagtcatacagctgaatcatattgccgatactgataaagactact ggaaaagcagcaaagcttgacgtagtgaaacaaaattataatacagacaaagttact ggtatgttagetttatteatteetaaatteagaaaagaatetaaa Atgtcagattttaatcatacagatcattctacaacaaaccatagccaaacacctagatac 4. Aaattoggtacogttoatgaaatgataaaaatogtotoocotacaatgttggagttatt Aacatgcaaaaagcatcaagtgtagacgacttattaaaaggcaaatcatctaaaccatct Gaagctggagtaggttcaggtgttatctatcaaataaacaacaattcagcttatatcgtt Acaaacaatcatgttattgatggcgcaaatgaaattagagtccaattacataataaaaaa Caagttaaagcgaaattagttggtaaagatgcagtaactgatattgctgtacttaaaatt Gaaaatacaaaaggtattaaagcgattcaatttgccaactcttcaaaagtacaaactggc Gatagcgtattcgcaatgggtaacccattaggattacaatttgctaactctgtaacatct Ggtatcatttcagcaagcgaacgtacgattgacgctgagacaactggtggcaatacaaa Gttagcgttcttcaaacagatgctgctattaacccaggtaactcaggtggcgcattagta Gatattaatggtaatttagttggtattaactcaatgaaaattgctgcgacacaagttgaa Ggtatcgggtttgctattccaagtaatgaagttaaagtaacaattgaacaacttgtaaaa Aaagatgatgttgatttaagaagctatttatatgaaaataaaaacctggtgaatcagtc Actgttaccgttatccgtgatggtaaaacaaaagaagttaaagtgaaattaaaacaacaa Aaagaacaaccaaaacgtcaaagccgatcagaacgtcaatcacctggccaaggcgataga gatttctttaga 5. caaattaatgcaatgattaattcaaaaacaaattatgatgttgtattcactagtggtgca actgaatccaataatcttgctttaaaaggtattgcctatcgtaaatttgatacagcgaag gaaataattacatccgtgttagagcatccgtccgtattagaggttgtaagatatttggaa aaggcacattttcatgtagatgcggttcaagcattggcaaaatttaaaatggatctcaat aaggcacattttcatgtagatgcggttcaagcattggcaaaatttcaaatggatctcaat aacatagatagtattagtttaagtggacacaagtttaatggtttaaaaggacaaggcgtc ttacttgtaaatcacattcaaaatgttgaaccaactgtccatggtggtggtcaaggatta ggcgttagaagtggaacagttaatttgccaaatgattattgcaatggttaaagcgatgaag atagctaatgaaaactttgaagcattgaatgcatttgttactgagttaaataatgacgtc cgtcaattttttaaataatatcatggagtttatattaattcttcaacttcaggttcacca ttcgttttaaatattagttttcctggcgtaaaaggtgaagtattagttaatgctttttca aaatatgacattatgatatctacgacaagtgcttgttcatctaaacgtaataaattaaat gaagtattggctactacaatgggattatcagacaaatctattgaaggtagtataagattatca tttggggctactacaactaaagaagatatagcgaggtttaaagaaatatttatcatcatt tatgaggaaattaaggagttgctaaaa

8.

acyaytataatolayyatoyatostyytatotaattaytaytaytatotaytaatay gtaagcotatotgattotgtgagtgoatotaagtoattaagcacatotgaaagtaatagt gtatoaagotoaacaagcacaagtttagtgaattoacaaagtgtatoatcaagcatgtog gattoagotagtaaatoaacatoattaagogattotattoaaactotagcagtactgaa

| 11. | ttgaaaaaaagaattgattatttgtcgaataagcagaataagtattcgattagacgtttt caagtaggtaccaactagtaatagtagggcaactatactatttgggataggcaatcat caagcacaagcttcagaacaatagaacgatacaagcaatcttcgaaaaatagtg caagttccgaaaaaaacaattgatagaagaatacaacgcaacttctcgaaaaatagtgaagt gcagattccgaaaaaaacaattgatagaacaaccaacagcaacttcgaacaacaagtg tctaccaaaacgagcaataccactacaacaggcagttcaacaaaagagcaagttgatgatagaacaacaacag tctacacaaacgagcaatacaactacacaacaggcagttcaacaaatgaaacacctcaa ccgacggcaattaaaaatcaagcaactgctgcaaaaatgacaaactgttccaa gaagcaaattctcaagtagataaaacacagatgtgctaatagcaagca | The state of the s |
|-----|---|--|
| 12. | atgaaaaagacaattatggcatcatcattagcagtggcattaggtgtaacaggttacgca gcaggtacaggacatcaagcacagctgctgaagtaaacgttgatcaagcacacttagtt gacttagcgcataatcaccaagatcaattaaatgcagctccaatcaaagatggtgcatat gacatccactttgtaaaagatggtttccaatataacttcacttcaaatggtactacatgg tcatggagctatgaagcagctaatggtcaaactgctggtttctcaaacgttgcaggtgca gactacactac | |
| | ttgggaggatatttaattatgaaaaaaatcgttacagctacaatcgctacagcaggactt gccactatcgcatttgcaggacatgatgcacaagccgcagaacaaataacaatggatat aattctaatgacgctcaatcatacagctatacaattgatat cattacacttggacaggaaattggaatccaagtcaattaacgaacaacaacacatactac tacaacaactacaatacttatagttataacaatgcatcttacaattaactat tcattacaatacaa | |

15.

14.

16.

gaatttaaatcagagccgccagtggagaagcatgaattgactggtacaatcgaagaagt
aatgattctaagccaattgattttgaatatcatacagctgttgaaggtgcagaaggtcat
gcagaaggtaccattgaaactgaagaagattctattcatgtagactttgaagaatcgaca
catgaaaattcaaacatcatgctgatgttgttgaatatgaagaagatacaaacccaggt
ggtggtcaggttactactgagtctaacctagttgaatttgaagaagattctacaaaaggt
attgaactggtgetgttagcgatcataacaacaattgaagataccgaagaatatacgact
gaaagtaatctgattgaactagtagatgaactacctgaagaacatggtcaagcgcaagga
ccaatcgaggaaattactgaacaacaatcatatttctcattctgttttaggaactgaa
aatggtcacggtaattatggcgtgattgaagaaatcgaagaaaatagccacgtggatatt
aagagtgaattaggttacgaaggtggccaaaatagcggtaatcgatttgaggaaga
acagaagaagataaaccgaaatatgaacaaggtggcaatatcgtagatatcgattcgat

aggagagataatagaataatgatatagatagaggagagataagagagatacagag agggtacctcaaattcatggtcaaaataatggtaaccaatcattcgaaggagatacagag aaagacaaacctaagtatgaacaaggtggtaatatcattgatatcgacttcgacagtgtg caactattcaacggattcaataaggacactgaaattattgaaggagatacaaataaagat aaaccaaattatcaattcggtggacacaatagtgttgactttgaagaagatacaacttcca caagtaagtggtcataatgaaggtcaacaatagtgttgaagaagatacaacactccaatc gtgccaccaacgccaccgacaccagaagtaccaagcggagacggaaacaccaacaccg caaccaggagtaccaagcgagccggaaacaccaacaccgccaacgccagaggtaccaac gaacctggtaaaccaataccacctgctaaagaagaacctaaaaaaccttctaaaccagtg gaacaaggtaaagtagtaacacctgttaattgaaatcaatgaaaaggttaaagcagtggta

ccaactaaaaagcacaatctaagaaatctgaactacctgaaacaggtggagaagaatca acaaacaacggcatgttgttcggcggattatttagcattttaggtttagcgttattacgc agaaataaaaagaatcacaaagca

19

atgcaaatgagagataagaaaggaccggtaaataaaagagtagattttctatcaaataaa ttgaataaatattcaataagaaaatttacagttggaacagcatctattttaattggctca ctaatgtatttgggaactcaacaagaggcagaagcagctgaaaacaatattgagaatcca agtgttgatatacaaaaaaaaccaacagatttaggggtatcagaggtaaccaggtttaat agtgttgatatacaaaaaaaccaacagatttaggggtatcagaggtaaccaggtttaat gttggtaatgaagtaatggtttgataggagctttacaattaaaaaaatagatttt agtaaggatttcaattttaaagttagatggcaaataccaactacaaccaaggt gctgatggttgggggttcttattagatgggcaaatgcagaagaatatttaactaatggt ggaatccttgggggttctatttagtacaggcagatttaaaattgatactggatac atttatacaagttccatggacaaactgaaaagcaggcaaagctgacaaggttatagagaga gagcttttgtgaaaaatgacagtctggtaattcacaaatggttggagaaaatttgat aaatcaaaaactaatttttaaactatgggacaattcaacataatacatcagatggaaag tttcatggcaacgtttaaatgatgtcatcttaacttagttgctcaactggtaaaat aaagcagaatatgctggtaaaacttggagaacattcaactagttcaactggtaaaaat aaagcagaatatgctggtaaaacttggagaacttcaataaacacagtttactaaa gytgagaagacaataacgacaccaacactaaaaaatccattaactggagtaattattagt aaaggtgaaccaaaagaagagattacaaaagatccgattaatgaattaacagaa cctgaaaccaatagcgccaggtcatcgagacgaatttgatccgaagttaccaacaggagag aaagaggaagttccaggtaaaccaggaattaagaatccagaaacaggagacgtagttaga ccgccggtcgatagcgtaacacaaatatggacctgtaaaaggagacatcgattgtagaaaaa gaagarattccattcragaaagaacgtagattaatccaggatttagcaccagggacagaa aaagtaacaaggagaaggacaaaaaggtggagaagacaataacgacgcaacaactaaaaaaa coattaacagagaagaatattaattagtacagaagaagaaaatcacaaaaaatcc acagrangaattacaaaagaccgaatttaatccgaagttaccaacaggagagaaagagtaagtt acagrangagaattaagaatccagaaacaggagatgtagttagaccaccggtcgat agcgtaacaaaatatggacctgtaaaaggagaatcgattgtagaaaaagaagaaattcca aggyaaagaacgtaaatttaatcctgatttagcaccagggacagaaaaagtaacaaga gaaggacaaaaaggtgagaagacaataacgacgccaacactaaaaaatccattaactgga gaaattattagtaaaggtgaatcgaaagaagaaatcacaaaagatccagttaatgaatta acagaatteggtggcgagaaaataccgcaaggtcataaaggatatctttgatccaaactta ccaacagatcaaacggaaaaagtaccaggtaaaccaggaatcaagaatccagacacagga aaagtgatcgaagagccagtggatgatgtgattaaacacggaccaaaaacgggtacacca atgaaaaataaatatatctcgaagttgctagttggggcagcaacaattacgttagctaca

gcatcatcaatcaaaaatacattaagtaatttattatcattctggaaa

| 22. | ggataftttaacgagttatatgattatataagttetgatatttagaggttttaattgaggattatgagatat gggggtttaaattgaatatgattattgagttattataggagattagattatgagattatt | |
|-----|---|--|
| | gtcaaatcttcagtagagtcagattcaagttataaacaaatgattattaaattcatat tcggacatagataaaatgaagtctttaatgacagataaacagtatttctaaaaacggatta acaacaacttaaaatatatatagacatggatcgtgtcaacctatcataacaagactta gactttgcatttggtttaagtatgacgtcgaaaaacgtagcacgctatgaaagtatcaac gagagagaatttaaaaggttggcacacttggtgctggaatgtcttattattataacacggat gtcaaacactatcatgataacttctgggtgcagcagatagtattattatataacagcgat gtcaaacactatcatgataacttctgggtgacagcagatagtattataaggtaca acaactttagacaatgaaactattaaaagatacggatgataaaaagtcgagtaaaactttt gttggcggaacaaaagttgatgaccaacatgctagtatcggattggattttgaaaatcat gacaaactttaactgccaaaaaatcatattatataaaggatgagttttgaaaatcag gacaaaactttaactgccaaaaaacatcatattcaaacgataaacgataaacgat ggaactggcattaaaaagtcgattacacaacaagatacagattacaacaatcgc aaagcgattggtatacgttatatacagacgataaacaacaaccaattctgataatcag gaaacaattcagtcttttagagtccacagataccaaaaagacactcggttatcatttt ttaaacaaaccgaaaatactgtaaaaaaagaaagtcatactggtagaaagaa | |
| | attaatattyaatattyttaatattyttyttattattytaattatt | |
| 24. | gtgaatgattttgaattaactaaa gtgaatgattttgaagcaattttatatattgcgttagtatgtggtgtgatagcaggtctt ggtgctttcttacatataccgcagtatccgagcatgacaattccacgtatagtagctatt ttaggaattatcagtgctatgttgacttttaaagacaagcaaatcagcgcctcattaaag tttagcgcattgttaattaatgtgctgccattatgcggtacctttgtagcttcaaat | |

| 25. | gtgtctcgtgaaatgtcatatcattggtttaagaaaatgttactttcaacaagtattta attttaagtagtagtttagggcttgcaacgcacacagttgaagcaaaggataactta aatggagaaaaaccaactactaatttgaatcataatataacttcaccatcagtaaatagt gaaatgaataatagagactgggacacctcacagatcaaatcaaacgggtaatgaagga acaggttcgaatggtgtgatgctaatcctgattcgaataaatgtgaagccagactcaaac aaccaaaacccaagtacagattcaaaaccagacccaaataaccaaaacccaagtccgaat cctaaaccagatccagattcaaaaccagacccaaatcaaccagaccaagtccaaa cctaaaccagatccagattcaaaaccagatccaaatccagatccaaatccagatcca aaccagaccag |
|-----|--|
| 26. | atgaaaataaaaacgtgttttaatagcgtcatcattatcatgtgcaatttattgtta tcagcagcaacgactcaagcaaattcagctcataaagactctcaagaccaaaataagaaa gaacatgttgataagtctcaacaaaaagacaaacgtaatgttactaataaagataaaaat tcaacagcaccggatgatattgggaaaaacgtaaaattcacaaaacgaactgaacagta tatgatgagaaacaaatatactccaaaattacacattcgacgtattactaattaaagtt tatgatgagaaacaaatatactcaaaattgacaattcacaaattcaaatttaaagtt gaatctcataaagaagaaaaaaattcaaaattggttaaagtatccaagtgagtaccatgta gattttcaaagtagaaagaaatcgtaaaactgaaatattagaccaattgccgaaaaataa atttcaactgcaaaaagtagacagtacaattttcatatagaccaattgccgaaaaataa atttcaactgcaaaaagtagacagtacattttcatatagaccaattgctgatacatgta caaaaggtattggacgaacttcatcaaaatagctactccaaaacggtagtacactggtcagt caaaattatgacaccaattgccagcgtaaaaataatactggcatgtacactggtcagtt attgcgaatgacttgaagtatggtggagaagtgaaaaatagaaatgatgatattat |
| 27. | atgtatacacgtacagctacaacaagtgatagtcaaaaaaatattactcaaagcttacaa tttaatttcttaactgaacctaattatgataaagcaacagtatttatt |
| 28. | gtggtgaaalttatgaattatcaaatggtaaaccatatcgtaaaaatagtgctatagac ggagggaaaaagaccgctgcctttagtaatattgagtatggtggacgtggtatgtcactt gaaaaggatatcgaacattcaaatacgttttatcttaaaagcgacatttgcagttattcac aaaaagcctacgccagtacaaatagttaatgtcaactatcctaagcggagtaaagctgtg attaacgaagcttattttcgtacaccttcaacaactgattacaacggcgtttatcaaggt tattatattgattttgaagcaaaggaaactaaaaacaagacgtcctttcctttaaataat attcatgaccatcaagtcgaacatatgaaaaatgcatatcaaccaaaaagggtattgtgtt ttaatgatcattttaaaacgctagatgaagttatcttttaccatattcaaaattcgaa gtattttggaaggaatataaagataatattaaaragtctataacagttgatgaaatacga aaaatggttaccatattccttatcagtatcaaccaagattagactatcaaaagcagtt gataagttgatattagatgaaagtgaggaccgcgta |

29.

gtgaatacaacgaaagcagcattacatggtgatgtgaagttacaaaatgataaagatcat gctaagcaaacggttagtcaattagcacatctaaacaatgcacaaaaacatatggaagat gcgagcagtgcatatgtcaatgcagaaccgaataaaaaacaatcctatgatgaagcagtt gugaguaguguguatatgudatguaguatugattaaataatudatututagatguaguagta caaaatgutgagtutatuattguaggattaaataatucaactatuaataaaggtaatgta tuaagtgugactuaagcagtaatatuatutaaaatguattagatggtgttgaaugatta ataaatgcagcgcctacaagaacagaggttgcacaacatgttcaaactgctactgaactt gatcacgcgatggaaacattgaaaaataaagttgatcaagtgaatacagataaggctcaa ccaaattacactgaagcgtcaactgataaaaaagaagcagtagatcaagcgttacaagct gcagaaagcattacagatccaactaatggttcaaatgcgaataaagacgctgtagaccaa gtattaactaagcttcaagaaacaactattgaccaattaacacatttaaatgctgatcaaatt gcaactgctaaacaacagcgaaacattgatcaagcgacaacttcaaccaattgctgatcaaatt gcaactgctaaacaaacattgatcaagcgacagaaacttcaaccaattgctgataagtagaacat gatcaagcaacgcaattgaatcaatctatggatcaattacaacaagcagttaatgacaa gatcaagcaacgcaattgaatcaatctatggatcaattacaacaagcagttaatgaacat gctaacgttgagcaaactgtagattacacacaagcagattcagataaacaaaatgcttat aaacaagctattgctgatgctgaaaatgtattgaaacaaatgcgaataagcaacaagtg gatcaagcacttcaaaacaattgtaatgcaaaacaagcattaaatggtgatgaacgtgta gcacttgctaaaacaaatggtaaacatgaccaattgaactaatgcattaaacaatgc caagtatatgatgaaacggttgataaagcgaaacaagcacttgataaatcgactggtcaa aacttaactgcaaaacaagttatcaaattaaatgatgcagtcactgcagctaagaaagca ttaaatggtgaagaaagacttaataatcgtaaagctgaagcattacaaagattggatcaa ttaacacatctaaacaatgctcaaagacaattagcaatccaacaaattaataatgctgaa acgotaaataaagcatctcgagcaattaatagagcaactaaattagataatgcaatgggt gcagtacaacaatatattgacgaacagcaccttggtgttatcagcagcacaaattacatc aatgcagatgacaatttgacagcacattatgataatgcaattgcgaatgcagcacatgag ttagataaagtgcaaggtaatgcaattgcaaagctgaagcagagcaattgaaacaaaat attatcgatgctgcaaaatgcattaaatggagaccaaaaaccttgcaaatgccaaagataaa gcaaatgcgtttgttaattcgttaaatggattaaatcaacagcaacaagatcttgcacat aaagcaattaacaatgccgatactgtatcagatgtaacagatattgttaataatcaaatt gcaatccaagcagtcaatgatgcaatccataatcttaatggtgatcaacgactacaagat gctaaagacaaggcaattcaatctattaatcaagctttagctaataagctaaaagaaatc gaagcttcaaatgcgacggatcaagacaagcttattgcgaaaaataaagcagaagaatt gcaaacagcatcatcaacaattaataaagcaacaagtaatcaggctgtatctcaagtt caaacagcaggcaaccacgcgattgaacaagtgcatgccaatgaaataccaaaagcaaaa attgatgccaataaagacgttgataagcaagttcaagcattaattgacgaaattgatcga aatccaaatctaacagataaggaaaaacaagcacttaaagatcgtattaatcaaatactt caacaaggtcataacggcattaacaatgcgatgactaaagaagaaattgaacaagccaaa gaacaacttgcgcaagcattacaagacatcaaagatttagtgaaagctaaagaagatgcg aaacaagatgttgataaacaagttcaagctttaattgacgaaatcgatcaaaatccaaat ctaacagataaggaaaacaagcacttaaagatcgtattaatcaaatacttcaacaaggt catarcgacattamcaatgcgatgacaaaagaagcaattgaacaagcaaaagaacgttta gcgcaagcattgcaagacatcaaagatttagtgaaagctaaagaagatgcgaaaaatgat attgataaacgtgtacaagctttaattgacgaaatcgatcaaaatccaaatctaacagat aaggaaaacaagcacttaaagatcgaattaatcaaatacttcaacaaggtcataacgac attaacaatgcgctgactaaagaagaaattgagcaggcaaaagcacaacttgcacaagca ttgcaagacatcaaagatttagtgaaagctaaagaagatgcgaaaaatgcaataaaagcc ttagctaatgcgaagcgtgatcaaatcaattcaaatccagatttaacacctgagcaaaaa gcaaaagcgctcaaagaaattgacgaagctgaaaaacgagcactacaaaacgttgagaat gctcaaactatagatcaattaaatcgaggattaaacttaggtttagatgacattagaaat acacatgtatggaggttgatgaacaacctgctgtaaatgaaatttttgaagcaacact gagcaaatcctagttaatggtgaactcattgtacatcgtgatgacatcattacagaacaa gatattetgetgeacacataaacttaattgatcagctttcagcagaagtcatcgatacacca tcaactgcaacgatttctgatagcttaacagcaaaagttgaagttacattgcttgatgga tcaaaagtgattgttaatgttcctgtaaaagttgtagaaaaagaattgtcagtagtcaaa caacaggcaattgaatcaatcgaaaatgcggcacaacaaaagattaatgaaatcaataat agtgtgacattaacactggaacaaaaagaagctgcaattgcagaagttaataagcttaaa gctcgtactgatctaacagataaagagaagcaagaagctattgctaagttaaatcaatta aaagaacaagcaattcaagcgattcaacgtgcgcaaagcatcgatgaaataagtgagcaa ttggaacaatttaaagctcaaatgaaagcagctaatccaacagcaaaagaactagctaaa ataaaagagactttagacgatacaaaacatttaccacttttatttgcgaaacgtcgcaga aaagaagatgaagaagatgttactgttgaagaaaaagattcgctaaataatggcgagtca ctcgataaagttaaacatacgccgttcttcttaccaaaacgtcgtcgtaaagaagatgaa gaagatgtggaagttacaaatgaaaacacagatgaaaaagtgttgaaagataacgaacat tcaccactcttattcgcaaaacgacgcaaagataaagaggaagatgttgaaacaacaact agtattgaatctaaagatgaggacgttcctttattattggctaaaaaggaaaaatcaaaaa gataaccaatccaaagacaaaaagtcagcatcaaaaaatacttctaaaaaaggtagcagct aaaaagaagaaaaaagacagctaagaaaaataaaaaa

32.

atggttgcattaacgcttgtaggttcagcagtcactgcacatcaagttcaagcagctgag acgacacaagatcaaactactaataaaaacgttttagatagtaataaagttaaagcaact actgaacaagcaaaagctgaggtaaaaaatccaacgcaaacaatttctggcactcaagta tatcaagacctgctattgtccaaccaaaaaacagcaaataacaaaacaggcaatgctcaa aaagacttaaatgttcaaaacttaggcaaagaagttaaaacgactcaaaaatatactgtt aataaatcaaataacggcttatcaatggttccttggggtactaaaaaccaagtcattta acaggcaataacattgctcaaggtacatttaatgcaacgaaacaagtatctgtaggcaa gatgttatttatacggtactattaataaccgcactggttgggtaaatgcaaaagattta actgcaccaactgctgtgaaaccaactacatcagctgccaaagattataactacacttat gtaattaaaaatggtaatggttattactatgtaacaccaaattctgatacagctaaatac teattaaaagcatttaatgaacaaccattcgcagttgttaaagaacaagtcattaatgga caaacttggtactatggtaaattatctaacggtaaattagcatggattaaatcaactgat aatgctaaaatcatcaaaggctactatgataaaattggcgaagtcggcaaatacttcgac

34.

atgaataataaaaagacagcaacaaatagaaaaggcatgataccaaatcgattaaacaaa atyaataataangutattotgtaggtactgcttcaattttagtagggacaacattgatt ttttggataagtggtcatgaagctaaagcggcagaacatacgaatggagaattaaatcaa tcaaaaaatgaaacgacagccccaagtgagaataaaacaactaaaaagttgatagtcgt caactaaaagacaatacgcaaactgcaactgcagatcagcctaaagtgaacaatgagtgat agtgcaacagttaaagaaactagtagtaacatgcagatcagcctaaaagtgacaacgagctaa caatctactacaaaaactagcaatgtaacaacaaatgataaatcatcaactacatatagt aatgaaactgataaaagtaatttaacacaagcaaaagatgtttcaactacacctaaaaca acgactattaaaaccaagaactttaaatcgcatggcagtgaatactgttgcagctccacaa gttgcatttgcgaaacgtaaaaatgcaacaactgataaaacagcttataaaatggaagta gttgcatttgcgaaatgatacatatgcgaagaaatcattgtcgattatggtaataaaaaagca actttaggtaatgatacatatagcgaagaaatcattgtcgattatggtaataaaaaagca caaccgcttatttcaagtacaaactatattaacaatgaagatttatcgcgtaatatgact aatggaaaaattgattatactttagacactgacaaaactaaatatagttggtcaaatagt tattcaaatgtgaatggctcatcaactgctaatggcgaccaaaagaaatataatctaggt gactatgtatgggaagatacaaataaagatggtaaacaagatgccaatgaaaaagggatt gactacycatygacatactacaaagatygaaagaattagatagtagaaaaaaaa aaaggtyttatytcattcttaaagatagtaacgytaaagaattagatagtacgacaaca gatyaaaatyytaaatatcagttcactygtttaagcaatygaacttatagtytagagttt tcaacaccagccygttatacaccgacaactycaaatytagytacagatyatyctytagat tctgatggactaactacaacaggtgtcattaaagacgctgacaacatgacattagatagt ggattctacaaaacaccaaaatatagtttaggtgattatgtttggtacgacagtaataaa gatggtaaacaagattcgactgaaaaaggaattaaaggtgttaaagttactttgcaaaac gaaaaaggcgaagtaattggtacaactgaaacagatgaaaatggtaaataccgctttgat aatttagatagtggtaaattacaaagttatctttgaaaaaacctgctggcttaactcaaaca ggtacaaatacaactgaagatgataaagatgccgatggtggcgaagttgatgtaacaatt aggatcatgatgatttcacacttgattaatggctactacgaagaagaacatcagatagc gactcagattctgacagcgattcagactcagatagcgactcagattcagattagcgactca gattcagacagcgattcagacagcgactcagattcagattcagattcagacagc gactcagactcagactcagattcagactcggattagcgactcagactcagattcagactca gattcggatagcgactcagactcagattcagattcagattcagattcagattcagactca gacagtgattcagattcagattcagattcagattcagattctgacagcgattcagactca gacagtgattcagactcagatagtgattcagattcagacagcgactcagattcagactca gacagtgattcagactcagacagtgattcagattcagacagcgactcagattcagatagcgactcagactcagattcagattcagactcagactcaga gattcagacagcgactcagattcagatagcgattcggactcagacaacgactcagattca gatagcgattcagattcagatgcaggtaaacatactccggctaaaccaatgagtacggtt aaagatcagcataaaacagctaaagcattaccagaaacaggtagtgaaaataataattca aataatggcacattattcggtggattattcgcggcattaggatcattattgttattcggt cgtcgtaaaaaacaaaataaa

35.

| 36. | gtgattgctataatgaatgtaattatcgatgaaagaaaagagaatgctatgacatttaat aaagtattattgagctggatagtcatattgattataacaactagcatatatctattttgg cagttgggcgatatcaatgatgtatttaaccagtctattttaatcaatgttagattaccg agattattagaagcattgttgacaggtatattaactgttgcaggccttatatttcaa acagtttttaaataatgcattggcagatagctttacaattaggattgcaggcgcgctaca tttggttcaggattagcattattttaggtttaacaacgttatggattcctgtatttca ataacatttagtttgataacattaataactgtattagtcattacgtcggtattgagccaa ggctatccagttagaatcttaataattaggtttaatgattggtcgttattcaattca cttctatatttttttgattttattaaaacctcgcaaattaatacaattgccaattactg tttggtggttttggtgatgcagaatactcaaatgtattattaatacaattgccaattatctg tttggtggttttggtgatgcagaatactcaaatgtattattataatacaattgccaattatct attgcattgtttggtatattattatcattcttaatcaactaaagttattgcgaattaggagaa ctaaaaagtcagtagcttaaatgttcaattgattatacaatatatcgcgttatgtata gcttctatgataacggcgataaatgtcgcatatgttggcatcattggatcattggtatg gtgataccgcaactcattagaaaaatggcagtggaaccaatcattaggaagacaattggct ttaaatattgtaactggaggacaaataatgttagtgcagtttattggtagcacaata ttgtcaccagtacaaataccggcaagtatatcattggcagtttaattggtataccagtgtta ttttacatgctaaatatctcagtcgaaacggttacac |
|-----|--|
| 37. | ttgaaaaaattagcatttgcaataacagcaacatctggtgcagctgcatttttaacgcat catgatgcacaagcttctacacaacatacagtacaatctggtgaatcattttgagagtatt gctcaaaatacaacacttcagtagaggtattaacaacattaggtgaatcatt ttggtattccctggtcaagttatctcagtaggtggaagtgatgcacaattagataacaac ttggtattccctggtcaagttatctcagtaggtggaagtgatgcacaaaatacgtcaaac acttctcacaagctggttcagcatcatctcatactgtacaagctggtgaactattaaat atcattgctagcagatatggtgtttcagttgatcaattaatggcagccaataacttacgt ggttatttaattatgcctaaccaaacattacaaattcctaatggtggatcaggtggtaca acaccaacagctacaacaggtagcaatggcaatgcatcatcttttaatcaccaaaattta tacactgctggtcaatgtacatggtacgtatttgaccgtcgtgctcaagctggtagtcca attagcacatattggtcagacgtaagtattggctggtaacgcagctaatggtgtac caagtaaacaacaccatcagttggttcaattatgcaaagcacactggtccatatggt catgttgcttatgttgaacggtcaatggtagtgatgttattctgaaatggat tacacatatggtccatacaatatgaactacogtacaattcagcttcagaagtttctagc tatgcattcatccat |
| 38. | atgccagattcaatcacaattatagatgaaaacaaagtgattgat |
| 39. | atgggattittacaaaattcttgatggcaataataaagaaattaaacagtagtaaa cttgctgataaagtaatcgctttagagaaaaaaggcaattttacatgatgaaatt cgtaataaaacgaacaattccaaacagaattagctgacattgataatgtcaaaaagaa aatgattatttagataaaatttaccagaagcattagctgacattgatagagagctctaaa cgtgtattcaatatgacaccatataaagtcaaattagcggtgtattgcaattcataaa ggtgatatcgctgagagagaaaggtgaaggtaaaacattaacagcgacaattgccaaca tactaaatgcattagctgdtagaggtgtacacgttattacaagcgacaaattgccaaca tactaaaatgcatagcgaaggagtgtatataaacattcacagcgacaaatgccaaca ggtgtcaaaggagaaaagggtgagttatataaacttcttaggtttgactgcggatta aacttaaacagtagagcaagaagaaaaacgtgaagcatacgcacaagaagattacttac |

| 40. | gtgagggaggtatgtcgaatcaaaattacgactacaataaaaatgaagatggaagtaag aagaaaatgagtacaacagcgaaagtagttagcattgcgacggtattgctattactcgga ggattagtatttgcaattttgcatatgtagatcattcgcaataaagcataaagacgtatg ggattagtatttgcaatttttgcatatgtagatcattcgaataaagctaaagaacgtatg ttgaacgaacaaaggaggaacaaagaagagcgtcaaaaagaaatgcagaaaacaa agaaagaaaagcaacaagaggaatcaatatcaatatgtgccacctcaagcaacaaccaa tatcagcaattgccacagcagaatcaatatcaatatgtgccacctcaagcacacacca acaagcaacgtcctgctaaagaagagaaatgatgataaagcatcaaaggatgagtgag |
|-----|---|
| 41. | gtgttgtaggtacgttaatcggttttggactactcagcagtaaagaagataggtaag aaaatgtgttacgcaaatcgataggcaagtaacgaaagtaatgattcaagt agogttagtgtcgcacctaaaacagacgacacaaacgtgatgatactaaaacatgtca aacactaataatggcaaacgattgtggcgcaaaatccagcaacagagaacgacaa tcatcacacaaatgcaactacggaagaaacgcggtaactggtgaagctactactacg acacgaatcaacaatcacggaagaaacgcggtaactggtgaagctactactacg tcatcatcaacaaatgcaactacggaagaaacgcggtaactggtgaagctactactuga ttagtgaatcaaacaagtaatgaaacgacttctaatgatacaagtacatctgaa ttagtgaatcaaacaatgaatcaagctccaacaggtaacagatacaatctgaa ttagtgaatcaaacaatgaatcaggccctaagaatgaagacatttaagttagcgaag aattcacctcaaaattctacaaatgggcacagatattaacaagtagagacatttagttaagacaaccttcaaacaatggacaggcacagatataaagagacagtagtaataaagac gtagttaatcaaggggttaatacaagtggcoctagaatgagagcatttagttaaacagacag gtagttggaatggacaggatggcacagaatataagacatgaagacagg gtagtagaatggaacggaggggcgcagaatatacagaatgagaagacaggacagaca |
| | tctgaagatgaagcaaatacgtcactaatttggggattattagcatcaataggttcatta ctacttttcagaagaaaaaaagaaaataaagataagaaa |
| | atgaattcaaatcacgctaaagcatcagtgacagagagtgttgacaaaaaatttgtagtt ccagaatcaggaattaataaaattattccagcttacgatgaatttaagaattcgccaaa gtaaatgttagtaatttaactgacaataaaaactttgtagcttctgaagataaattgaat aagattgcagattcatcggcagctagtaaaattgtagataaaaactttgtgccagaa tcaaagttaggaaacattgtgccagagtacaaagaaatcaataatcgcgtgaatgtagca acaaacaatccagcttcacaacaagttgataagcattttgttgctaaaggcccagaagta aatagattattacttcatacaaaatcaacacattcattactacacaagtaaaaccacatca aagaaagttattacttcatacaaaatcaacacatgtacataaacatgtaaatcattgcaaag gattctattaataaacactttattgtaaaccatcagaatcgcctagatatacacatcca tctcaatctttaattacaagcatcattttgcagttcctggatatcacggcataaattt gttacaccagggcatgctagcattaaaattaatcacttttgtgtgttgcacaaaataa agttcaaggtaattccaccatatggtcacaattcacatcgtatgcatgtaccaagttc caaaataacacaacagcaacacatcaaaatgctaaaattaaacacattgtaccaagttc caaaataacacaacagcaacacatcaaaatgctaaaatttccatttctcatttccaatca aatggttataaaattggaaaccatcattaaaattcacattcaaatttccaattccaaatca aatggttataaaattgggaaaccatcattaaatacaaaaatgtaaatttccaattccaaatcg gttccaagttataagccctacacacacactcagattcctgaatttaaggtagcttaccagcacca cgagta |

caaqaa

45

ttggagcatacaattatgaaaatgagaacaattgctaaaaccagtttagcactagggctt 43. ccatcaacaacagccacaaccaatgcaatctactaaatcagacacaccacacaatctcca accataaacaagcacaacaaccaatgcacaatgacctcaaatatgaagatttaagagcgtatta caaaaaccgagttttgaatttgaaatgcactttagatttgaatttgaatttgaatttgaatttgaatttgaatttgaatttgaccataggacgacggtttatgattttaaatgcatgtacgacgacggtttaaggtaaatgtattcaaataggtcacttacgataatatcgatgtttagtttgaaaa gatgagaaaaaatatcaattgaaaaaatattcagtttaggagacgatcactacgatgtatttatcgttttagaa gacaataaatatcaattgaaaaaatattctgtcggtgcaatcacgaagactaataataaaaagtagaattaaccaaagtagaattaactaagaagaattaccaaagaagaattaccaagaagaattaccaagaagaattacctgaagtatcaagaagatttccttgaaagagcttgatttaaattgagaaaaacaacttattgaaaaacaatttattacggtaaatatacgttgaattaccaaaaaaacggaagaatatacgttgaattaccaaaaaaactgcaaagacaacatcgtagagcaaatatacgttgaattacacaaaaaaactgcaaagagaacaacatcgaagacaaatatatgataaacatgaaagagaataaaaa

gagcatcgtatggcaggcactaatattgataacattgaagtgaatataaaa atgacaacaattaaaacatcaaacttaggattcccaagattaggtagaaaaagagaatgg ccactttataagaagtgtttgaatcattaattgatgcaggtgctgagtacattcaagtt gatgagccaatcttagttacagacgacagcgaaagctatgaaaatattacacgtgaagct tatgactatttcgaaaaagctggtgttgctaaaaaattagtcattcaaacatactttgaa attatagatgatgatgatgatgatgattagttcacaggtgaatttgaacgtaatgacatggtt caagaagacattggcttagatgtattagttcacaggtgaattttgaacgtaatgacatggtt gaattcttcggagaaaaattacaaggtttcttagtaactaaattcggttgggtgcaatca tatggttcacgtgccgtaaaaccaccaatcatttatggtgatgtaaaatggacagcgcct ctacaacaaatcgaccgctcattattctgggtaaaccctgactgtggtttaaaaacgcga aaagaagaagattaaagatgcattgactgtgcttgtgaatgctgttaaaagctaaacgc

atgagcgacacatataaaagctacctagtagcagtactatgcttcacagtcttagcaatt gtacttatgccgtttctatacttcactacagcatggtcaattgcggggattcgcaagtatc gcaacattcatattttataaagaatacttttatgaagaa

| 46. | atgttaagaggacaagaagaaagtatagtattagaaagtatcaatagagggtggtg tcagtgttagcggctacaatgtttgttgtgtatcacactgaagaccaaggctcggaaaaa acatcaactaatgcagcggcacaaaagaaacactaaatcaacgggaggaacaagggaat gcgataaagtggaacagtgacagtaggaaagcaattagacgatatgcataaaggaat ggtaaaagtggaacagtgacagaaggtaaagatacgcttcaatcatcgaaggcatcaatca | |
|-----|--|--|
| 47. | atgattcatctcattaaggggaagatgcatcatacagttttgtgtattcatttaaacaaa ggggttggttttaatgatcaatacattctaatgcacaacaaaccaagtgcattgcgtttt tttgtctatagtttagtgggcatactatgtttctttatccttttacgattaatggtaac aacactattttcgtcgatcatgttcatctagcattcgctcaatcataggtcacttatg ccctatgttgcactgattatgattttaattggtacagcgttaccaatagtgagacgtact ttatgacttcaatcacaaacttggtcattacatta | |
| 48. | atggttattatgaagaaaacaattttactgacgatgacaactcttactttattta | |
| 49. | ttggaggtatcgtcaatgaagccttatatacaacttgttgtgttcaagcaatggttacaa tacatcttgctcgtaacaaccattgtcatcgcactcgtacttattggtatcggttaccgt gtagcacatgacaacttcaaaataccgattaccattcaagatttagaccaaaccactgca tcaaaatcattcgtcaataaaattaaacaatctgactatgtaactattaaaaaagtcgat gaagatgaaagctatattgaagatgatgttactaaaaaggaagctattttaagtatgcaa attcctaaaggtttctctcaaaaaattaaaagaagaaccgtttaaaatagtagtat tatggtagagatgactttataggtggtattgctgtagaaaattgtagtagtatatata | |

| 50. | atgattgaggtgacagagatgaacttttttgatatccataagattccgaacaaaggcatt ccattatcggtacaacgtaaattatggcttagaaacttcatgcaagctttcttcgtagtg ttctttgtttatatggctatgtatttattcgaaacaactttaaggcagcacaaccgttt ttaaaagaggaaattggattatctacattagaacttggttatatcggattagcatttagt atcacgtacggtttaggaaaaacattacttggatattttgcgatggattagcatttagt atcacgtacggtttaggaaaaacattacttggatattttgcgatggactaacacaaaa cgtattatctcgttcttacttatcttat | |
|-----|---|--|
| 51. | atgacaaagaagaaaaacatattaaaagcaatcggtatttacagttttatagcgatgatg tttgtcatcattttataccactactgtggacatttggcatttcccttaatccaggtacg aacttgtatggtgccaaaatgataccagacaatgcaacatttaaaaattatggcattctta ctattcgatgacagtagtcaatacctgacttggtataaaaatacgcttatcgtagcatct gcaaatgcactgtttagtgtgatatttgtcacgttaacagcatatgctttttctagatat cgcttgttggtcgtaaatacgggctgattacatttttgattttacaaatgttccctgta ttaatggcaatggtcgcaatctatattttgctaaatacggttattaaaatgttccttgta ttttggactaacactggtatatattggtggaatcaataccgatgaatgcctttttagtgaaa ggtacttcgatacgattccaaaagaacttgatgaatcgccaaaatggatgatggtggagg catatgcgtattttcttacaaattatgctgccattagctaagccgattttagcagtgtgt gcttgttcaattttatggggccatttatggacttatattaccaaaaatactataaga agtcctgaaaaattcacattagcagttggattgtcaactttatataagaaatgcaa aataatttcacagtgtttgcagcaggggcaattatagattgacaccaaaagcat ttcttgtcattggcacgctatttagtatcaacacaggtgcgacaaaaggt | |
| 52. | gtgatggaaaatagtacgacgaaggggtaatgaaggacgatgcatcttgatgaaatg actgtggaaggaggctttaattacgatgaataaagaagatcagcaagtcccgttagcagtt caaaggacgaataccacaattgacaaagtaataaagaagatcagcaagtcccgttagcagtt caaaggacaataccacaattgacaaagtagaaaaaacaattgcacagtataaaaag ggtggacgattgatttatatcggtgcaggtacaaagtggaaggttggtgtcttagatgca gcggaggtgtgtacctacattcaatactgacctcatgaaattatagggtattattattgctggt ggacaacatgctatgacgatggctgtagaaaggtcgggaagatcacaaaaaaattagcggaa gaagatttgaaaatatagagtattaacatcaaaaaagttgcgtataagaagtgcggaagatcacaaaaaaattgccgcgagt ggcaaaacgccatatgttataagggtttaacatttgctgaaattgccgcagtggaagatcaatttcaatgcggttaaaagttgaaattgccgcagtatcaacaa gtatcaatttcatgacaacaaggttaaaagttgaaaatggtgcagaaagttaacaggttaaaagttggtgcagaaagttaacaggttcaacaatggttggt | |
| 53. | ttgaaatacataattcgttatattatgatgactttacaatacatac | |

| 54. | ttggataaaaagtctgagaagcggggcattaaaatgacggtacaaagtgcatatatacat attccattttgtgtaagaatatgtacatattgtgatttcaataaata |
|-----|--|
| 55. | MRNIENLNPGDSVDHFFLVHKATQGVTAQGKDYMTLHLQDKSGEIEAKFWTATKNDMATI KPEEIVHVKGDIINYRGNKQMKVNQIRLATTEDQLKTEQFVDGAPLSPAEIQEEISHYLL DIENANLQRITRHLLKKYQERFYTYPAASSHHHNFASGLSYHVLTMLRIAKSICDIYPLL NKSLLYSGIILHDIGKVRELSGPVATSYTVEGNLLGHISIASDEVVEAARELNIEGEEIM LLRHMILSHHGKLEYGSPKLPYLKEAEILCYIDNIDARMNMFEKAYKKTDKGQFTDKIFG LENRRFYNPESLD |
| | MNKHHPKLRSFYSIRKSTLGVASVIVSTLFLITSQHQAQAAENTNTSDKISENQNNNATT TQPPKDTNQTQPANTQANTAKNYPAADESLKDAIKDPALENKEHDIGPREQUNFQLIDKN NETQYYHFFSIKDPADVYYTKKKAEVELDINTASTWKKFEVYENNQKLPVRLVSYSPVPE DHAY1RPPVSDGTQELKTVSSTQIDDGEETNTDYTKLVFAKPIYNDPSLVKSDTNDAVVT NDQSSSVASNQTNTNTSNQNTSTINNANNQPQATTNMSQPAQPRSSTNADQASSQPAHET NSNGNTNDKTNESSNQSDVNQQYPPADESLQDAIKNPAIIDKEHTADNWRPIDFQMKNDK GERQFYHYASTVEPATVIFTKTGPIIELGIKTASTWKKFEVYEGDKKLPVELVSYDSDKD YAYIRFFVSNGTREVKLVSSIEYGENIHEDYDYTLMVFAQPITNNPDDYVDEETYNLQKL LAPYHRAKTLERQVYELEKLQEKLPEKYKAEYKKKLDQTRVELADQVKSAVTEFENVTPT NDQLTTLQEAHFVVFESEENSESVMDGFVEHPFYTATLNGQKYVVMKTKDDSYWKDLIVE GKRVTTVSKDPKNNSRTLIFPYIPDKAVYNAIVKVVVANIGYEGQYHVRIINQDINTKDD DTSQNNTSEPLNVQTGQEGKVADTDVAENSSTATNPKDASDKADVIEPESDVVKDADNNI DKDVQHDVDHLSDMSDKNHFDKYDLKEMDTQIAKDTDRNVDKDADNSVGMSSNVDTDKDS MKNKDKVIQLNHIADKNNHFDKAYLLDVVKQNINTDKVTDKKTTEHLPSDIHKTVDKTV KTKEKAGTPSKENKLSQSKMLPKTGETTSSQSWWGLYALLGMLALFIPKFRKESK |
| 57. | Msdfnhtdhsttnhsqtpryrrpkfpwfktvivaliagiigallvlgigkvlnstilnkd Gstvqttnnkggnqldgqskkfgtvhemiksvsptivgvinmqkassvddllkgksskps Eagygsgviyqinnnsayivtnnhvidganeirvqlhnkkqvkaklvgkdavtdiavlki Entkgikaiqfansskvqtpdsvfamgnplglqfansvtsgiisasertidaettgqntk Vsvlqtdaainpgnsggalvdingnlvginsmkiaatqvegigfaipsnevkvtieqlvk Hgkidrpsigiglinlkdipeeereqlhtdredgiyvakadsdidlkkgdiiteidgkki Kddvdlrsylyenkkpgesvtvtvirdgktkevkvklkqqkeqpkrqsrserqspgqgdr dffr |
| 58. | VNQQQEKTTTPTTINPLTGEKVGEGEPTTEVTKEPVDBITQFGGEEVPQGHKDEFDPNL PIDGTESVPGKFGIKNPETGEVVTPPVDDVTKHGPKAGBFBVTKEEIPFBKKREFNPDLK PGBEKVTQEGQTGEKTTTTPTTINPLTGEKVGEGBPTTEVTKEPVDBITQFGGEEVPQGH KDEFDPNLPIDGTEEVPGKPGIKNPETGEVVTPPVDDVTKHGPKAGEPEVTKEEIPYETK RVLDPTMEPGSPDKVAQKGENGEKTTTTPTTINPLTGEKVGEGEPTTEVTKEPIDEIVNY APEIIPHGTREELDPNLPEGETKVIPCKNGCKDPETGEIIEEPQDEVIIHARDDSDADS DSDADSDSDADSDSDADSDSDSDSDSDSDSDS |
| 59. | MKSLKTVIGMNNKEHIKSVILALLVLMSVVLTYMVWNFSPDIANVDNTDSKKSETKPLTT PMTAKMDTTITPFQIIHSKNDHPEGTIATVSNVMKLITKPLKNKEVKSVEHVRDHNLMIP DLMSDFILFDFTYDLPLSTYLGQVLMMMAKVPNHFMFNRLVIDHDADDNIVLVAISKDRH DYVKLITTTKNDHFLDALAAVKKDMQPYTDIITMKDTIDRTTHVFAPSKPEKLKTYRMVF MTISVEKMMAILFDDSTIVRSSKSGVTTYNNNTGVANYNDKNEKYHYKNLSBDEASSKM EETIPGTFDFINGHGFLNEDFRLFSTNNQSGELTYQRFLNGYPTFNKEGSNQIQVTWGE KGYFDYRRSLLRTDVVLNSEDNKSLPKLESVRSSLANNSDINFEKVTNIAIGYEMQDNSD HNHIEVQINSELVPRWYVEYDGEWYVYNDGRLE |

| 60. | MSKRQKAFHDSLANEKTRVRLYKSGKNWVKSGIKEIEMFKIMGLPFISHSUSQDNQSIS KKMTGYGLKTTAVIGGAFTVNMLHDQQAFAASDAPLTSELNTQSETVCNQNSTTIEASTS TADSTSVTKNSSSVQTSNSDTVSSEKSEKVTSTTNSTSNQQEKLTSTESETSSKNTTSSS DTKSVASTSSTEQPINTSTNQSTASNNTSQSTTPSSVNLINKTSTTSTSTAPVKLRTFSRL AMSTFASAATTTAVTANTITVNKDNLKQVMTTSGNATYDQSTGIVTLTQDAYSQKGALTL GTRIDSNKSFHFSGKVNLGNKYEGHGNGGDGIGFAFSPGVLGETGLNGAVGIGGLSNAF GFKLDTYHNTSKPNSAAKANADESNVAGGGAFGAFVTTDSYGVATTYTSSSTADNAAKLN VQPTNNTFQDFDINYNGDTKVMTVKYAGQTWTRNISDWIAKSGTTNFSLSMTASTGGATN LQQVQFGTFFYTESAVTQVRYVDVTTGKDIIPPKTYSGNVDQVVTIDNQSALTARGYNY LQQVQFGTFFYTESAVTQVRYVDVTTGKDIIPPKTYSGNVDQVVTIDNQSALTARGYNY TSVDSSYASTYNDTNRTVKMTNAGQSVTYYFTDVKAPTVVGNQTIEVGKTMNPIVLTTT DNGTGTVTNTVTGLPSGLSYDSATNSIIGTPTKIGQSTVTVVSTDQANKSTTTFTINVV DTTAPTVTPIDQSSEVYSPISPLKIATQDNSGNAVTNTVTGLPSGLTFDSTNNTISGTP TNIGTSTISIVSTDASGNKTTTFKYEVTRNSMSDSVSTSGSTQQSQSVSTSKADSQSAS TSTSGSIVVSTSASTSKSTSVSLSDSVSASKSLSTSESNSVSSSTSTSLVNSQSVSSSSMS DSASKSTSLSDSISNSSSTEKSESLSTSTSDSLRTSTSLSDSLSMSTSGLSKSQSLSTS LSGSSSTSASLSDSTSNASSTEKSESLSTSTSDSISINSANSQSASTTSRSGSVSSSSTSIS LSTSDSKSMSTSESLSDTSTSGSVSGSLSIAASQSVSTSTSDSMSTSGIVSDSISTSGS LSASDSKSMSVSSSMSTSQSGSTSESLSDSQSTSDSDSKSLSQSTSTSTSTSAS VRTSESQSTSGGMSAQQSDSMSISTSFSDSTSDSKSLSQSTSTSTSTSTSSSTS TSLSTSNSERTSTSMSDSTSLSTSESSTSSTSLSDSTSSTSTSLNSTSGTS SSSGSSASAFLGESLSESTSESTSSSTSSTSLSDSTSSSTSTSLSNTS DSESGSASAFLGESLSESTSESTSESVSSSTSESTSLSDSTSSSTSTSTSTSSSSTS ISTSTSLSSTSTSKASSSSSTSTSSTSSSTSSSTSSSTSSSTSSSTS | |
|-----|--|--|
| 61. | MPKNKILIYLLSTTLVLPTLVSPTAYADTPQKDTTAKTTSHDSKKSNDDETSKDTTSKDI DKADKNNTSNQDNNDKFKTIDDSTSDSNNIIDFIYKNLPQTNINQLITKNKYDDNYSLT TLIQNLFNLNSDISDYBQPRNGEKSTNDSNKNSDNSIKNDTDTQSSKQDKADNQKAPKSN NTKPSTSNKQPNSPKPTQPNQSNSQPASDDKANQKSSSKDNQSMSDSALDSILDQYSEDA KKTQKDYASQSKKDKNEKSNTKNPQLPTQDBLKHKSKPAQSFNNDVNQKDTRATSLFETD PSISNNDDSGQFNVVDSKDTRQPVKSIAKDAHRIGQDNDIYASVMIAQAILESDSGRSAL AKSPNHNLFGIKGAPEGNSVPFNTLEADGNQLYSINAGFRKYPSTKESLKDYSDLIKNGI DGNRTIYKPTWKSEADSYKDATSHLSKTYATDPNYAKKLNSIIKHYQLTQFDDERMPDLD KYERSIKDYDDSSDEFKPFREVSDSMPYPHGQCTWYVYNRMKQFGTSISGDLGDAHNWNN RAQYRDYQVSHTPKRHAAVVFEAGQFGADQHYGHVAFVEKVNSDGSIVISESNVKGLGII SHRTINAAAAEELSYITGK | |
| 62. | MRKFSRYAFTSMAALTLLSTLSPAALAIDSKNKPANSDIKFEVTQKSDAVKALKELPKSE NVKNIYQDYAVTDVKTÜKKGFTHYTLQPSVDGVHAPDKEVKVHADKSCKVVLINGDTDAK KVKPTNKVTLSKDDAADKAFKAVKIDKNKAKNLKDKVIKENKVEIDGDSNKYVYNVELIT VTPEISHWKVKIDAQTGEILEKMNLVKBAABTGKGKGVLGDTKDININSIDGGFSLEDLT HQGKLSAFSFNDQTGQATLITNEDENFVKDEQRAGVDANYYAKQTYDYYKDTFGRESYDN QGSPIVSLTHVNNYGGQDNRNNAAWIGDKMIYGDGDGRTFTSLSGANDVVAHELTHGVTQ ETANLEYKDQSGALNESFSDVFGYFVDDEDLMGEDVYTPGKEGDALRSMSNPEQFGQPA HMKDYVFTEKDNGGVHTNSGIPNKAAYNVIQAIGKSKSEQIYYRALTEYLTSNSNFKDCK DALYQAAKDLYDEQTABQVYEAWNEVGVE | |
| 63. | MKKRIDYLSNKQNKYSIRRFTVGTTSVIVGATILFGIGNHQAQASEQSNDTTQSSKNNAS ADSEKNNMI ETPQLNTTANDTSDISANTNSANVDSTTKPMSTQTSNTTTTEPASTNETPQ PTAIKNQATAAKAQDQTVPQEANSQVDNKTTNDANSIATNSELKNSQTIDLPQSSPQTIS NAQGTSKPSVRTRAVRSLAVAEPVVNAADAKGTNVNDKVTASNFKLEKTTFDPNQSGNTF MAANFTVTDKVKSGDVFTAKLPDSLTGNGDVDV SSISNNTMPIADIKSTNGDVVAKATYDI LTKTYTFVFTDYVNNKENINGQPSILPFTDRAKAPRSGTYDANINIADEMFNNKITYNYS SPIAGIDKPNGANISSQIIGVDTASGQNTYKQTVFVNPKQRVLGNTWVYIKGYQDKIESS SGKVSATDTKLRIFFVNDTTSKLSDSYYADPNDSNLKEVTDQFKNRIYYEHFNVASIKFGD ITKTYVVLVEGHYDNTGKNLKTQVIQENVDPVTNRDYSIFGWNNENVVRYGGGSADGDSA VNPKDPTPGPPVDPEPSPDPEPEPTPDPEPSPDPEPEPSPDPDDSDSDSDSDSDSDSDSSDSDS | |
| 64. | MKKTIMASSLAVALGVTGYAAGTGHQAHAAEVNVDQAHLVDLAHNHQDQLNAAPIKDGAY DIHFVKDGFQYNFTSNGTTWSWSYEAANGOTAGFSNVAGADYTTSYNQGSNVQSVSYNAQ SSNSNVEAVSAPTYHNYSTSTTSSSVRLSNGNTAGATGSSAAQIMAQRTGVSASTWAAII ARESNGOVNAYNPSGASGLFOTMPGWGPTNTVDQQINAAVKAYKAGGLGAWGF | |
| 65. | MGGYLIMKKIVTATIATAGLATIAFAGHDAQAAEQNNNGYNSNDAQSYSYTYTIDAQGNY HYTWTCNWNPSQLTQNNTYYYNNYNFYSYNNASYNNYYNHSYQYNNYTNNSGTATNNYYT GGGASYSTTSNNVHVTTTAAPSSNGRSISNGYASGSNLYTSGQCTYYVFDRVGKKIGST WGNASNWANAAASGYTVNNTPKVGAIMQTTQGYYGHVAYVEGVNSNGSVRVSEMNYGHG AGVVTSRTISANQAGSYNFIH | |

| 66. | MANTKKTTLDITGMTCAACSNRIEKKLNKLDDVNAQVNLTTEKATVEYNPDQHDVQEFIN TIQHLGYGVAVETVELDITGMTCAACSSRIEKVLNKMDGVQNATVNLTTEQAKVDYYPEE TDADKLVTRIQKLGYDASIKDNNKDQTSRKAEALQHKLIKLIISAVLSLPLLMLMFVHLF NMHPALFTNPWFQFILATPVQFIIGWQFYVGAYKNLRNGGANMDVLVAVGTSAAYFYSI YEMVRWLNGSTTQPHLYFETSAVLITLILFGKYLEARAKSQTTNALGBLLSLQAKEARIL KDGNEVMIPLNEVHVGDTLIVKPGEKIPVDGKIIKGMTAIDESMLTGBSIPVEKNVDDTV IGSTMNKNGTITMTATKVGGDTALANIIKVVEBAQSSKAPIQRLADIISGYFVPIVVGIA LLTTLVWITTUTPGTFEPALVASISVLVIACPCALGLATPTSIMVGTGRAAENGTLFKGG EFVERTHQIDTIVLDKTGTITNGRPVVTDYHGDNQTLQLLATAEKDSEHPLAEAIVNYAK EKQLLLTETTTFKAVPGHGIEATIDHHHLLVGNRKLMADNDISLPKHISDDLTHVERDGK TAMLIAVNYSLTGTIAVADTVKDHAKDAIKQLHDMGIEVAMLTGDINKNTAQAIAKQVGID TVIADILPBEKAAQIAKLQQQGKKVAMVGDGVNDAPAIVKADIGIAIGTGTEVALEAADI TILGGDLMLIFKAIYASKATIRNIRQNLFWAFGYNIAGIPIAALGLLAPWVAGAAMALSS VSVVTNALRLKKMRLEPRKDA |
|-----|---|
| 67. | MFDSTRETIDYAVENNMSFADIMVKEEMELSGKSRDEVRAQMKQNLDVMRDAVIKGTTGD GVESVTGYTGHDAAKLRDYNETHHALSGYEMIDAVKGAIATNEVNAAMGIICATPTAGSS GTIPGALFKLEKTHDLTEEQMIDFLFTSALFGRVVANNASVAGATGGCOBEVGSASAMAA AAAVAIFGGSPEASGHAMALAISNLLGLVCDPVAGLVEIPCVMRNAIGSGNALISADLAL AGIESRIPVDEVIEAMDKVGRNLPASLRETGLGGLAGTPTGEAIKRKIFGTAEDMVKNN |
| 68. | MKNNLRYGIRKHKLGAASVFLGTMIVVGMGQDKEAAASEQKTTTVEENGNSATDNKTSET QTTATMVNHIEBTQSYNATVTEQPSNATQVTTEEAPKAVQAPQTAQPANIETVKEEVVKE EAKPQVKETTQSQDNSGDQRQDLTPKKATQNQVABTQVEVAQPRTASESKPRVTRSADV AEAKEASNAKVETGTDVTSKVTVEIGSIEGHNNTNKVEPHAGQRAVLKYKLKFENGLHQG DYFDFTLSNNVMTHGVSTARKVPEIKNGSVVMATGEVLEGGKIRYFTNDIEDKVDVTAE LEINLFIDPKTVQTNGNQTITSTLNEEDTSKELDVKYKDGIGNYYANLNGSIETFNKANN RFSHVAFIKPNNGKTTSTVTGTLMKGSNQNGNQPKVRIFEYLGMNEDIAKSVYANTTDT SKFKEVTSNMSGNINLQNNGSYSLNIENLDKTVVVHYDGBYLNGTDEVDFRTQMVGHPEQ LYKYYYDRGYTLTWDNGLVLYSNKANGGKNGFILONNKFEYKBDTIKETLTGQYDKNLV TTVEEBYDSSTLDIDYHTALDGGGGYVDGYIETIEETDSSAIDIDYHTAVDSEAGHVGGY TESSEESNPIDFEESTHENSKHHADVVBYEEDTNPGGGQVTTESNLVEFDESSTKGIVTG AVSDHTTVEDTKBYTTESNLIELVDELDEHGQAGGPVEBITENNHHISHGGLGTENGHG NYDVIEEIENSHVDIKSELGYBGGQNSGNQSFEEDTEEDKPKYEQGGNIVDIDFDSVPQ THGQNKGNQSFEEDTEKDKPKYEHGGNIIDIDFDSVPHHGFNKHTEILEEDTNKDKPSY QFGGHNSVDFEEDTLPKVSGONGGQQTIEEDTTPPTPTPTPEVPSEPETTPTPPTPEV |
| 69. | EINEKUKAVAPTKKPQSKKSELPETGGEESTNKGMLFGGLFSILGLALLRRNKKNHKA LHLRENIIVKSNLRYGIRKHKLGAASVFLGTMIVVGMGQEKEAAASEQNNTTVEESGSSA |
| | TESKASETOTTTNNVNTIDETQSYSATSTEQPSQSTQVTTEEAPKTVQAPKVETSRVDLP SEKVADKETTGTQVD1AQPSNVSEIKPRMKRSTDVTAVAEKEVVEETKATGTDVTNKVEV EEGSEIVGHKQDTNVVNPHNAERVTLKYKWKFGEGIKAGDYDFDTLSDNVETHGISTLRK VPEIKSTDGQVMATGEIIGERKVRYTFKEYVQEKKDLTAELSLNLFIDPTTVTQKGNQNV EVKLGETTVSKIFNIQYLGGVRDNWGVTANGRIDTLINKVDGKFSHFAYMKPNNQSLSSVT VTGQVTKGNKPGVNNPTVKVYKHIGSDDLAESVYAKLDDVSKFEDVTDNMSLDFDTNGGY SLNFFNNLDQSKNTVIKYEGYYDSNASALEFQTHLFGYYNYYTSNLTWKNGVAFYSNNAQ GDGKDKLKEPIIEHSTPIELEFKSEPPVEKHELTGTIEESNDSKPTDFEYHTAVGAEGH AEGTIETEEDSIHVDFESTHENSKHHADVVEYEEDTNPGGGQVTTESNLVEFDEDSTKG IVTGAVSDHTTIEDTKEYTTESNLIELVDELPEENGQAQFIEBITENNHHISHSGLGTE MGHGNYGVIEELEENSHVDIKSELGYEGGQNSGNQSFEEDFEEDKFXEGGGNIVDIDFD SVPQIHGQNNGNQSFEEDFERDKFKYEGGGNIIDLDFDSVPHIHGFNKHTEILEDTNKD KRNYQFGGHNSVDFEDTLEQVSGHNEGQQTIEBTTPPTVPPTPFTPEVPSEPETPTPP TPEVPSEPETPTPPTPEVPTEPGKPIPPAKEEPKKPSKPVEQGGKVVTPVIEINEKVKAVV PTKKAQSKKSELPETGGEESTNNGMLFGGLFSILGLALLKRNKKNHKA |
| 70. | MQMRDKKGPVNKRVDFLSNKLNKYSIRKFTVGTASILIGSLMYLGTQQEAEAAENNIENP TTLKDNVQSKEVKIREVTNKDTAPQGVEAKSEVTSNKDTIBHESVKAEDISKKEDTPKE VADVAEVQPKSSVTHNAETFKVRKARSVDEGSFDITRDSKNVVESTPITIQGKEHFEGYG SVDIQKKPTDLGVSEVTRFNVGNESNGLIGALQLKNKIDFSKDFNFKVRVANNHQSNTTG ADGWGFLFSKGNAEEYLTNGGILGDKGLVNSGGFKLDTGYIYTSSMDKTEKQAGGYRGY GAPVKNDSSGNSQMYGENIDDKSKTNFLNYADNSTNTSDGKFRGQRLMVLILTVVASTGKM RABYAGKTWETSITDLGLSKNQAYNFLITSSQRWGLNQGINANGWRTDLKGSEFTFTPE APKTITELEKKVEEIPFKKERKFNPDLAPGTEKVTREGQKGEKTITTPTLKNPLTGVIIS KGBPKEEITKDP INBLTEYGPBTTAPGHRDEFDPKLPTGEKEEVPGRFGIKNPBTGDVVR PPVDSVTKYGPVKGDSIVEKEEIPFXKERKFNPDLAPGTEKVTREGQKGEKTITTPTLKN PLTGEIISKGESKEEITKDPINELTEYGPETITPGHRDEFDPKLPTGEKEEVPGRFGKN PETGDVVRPPVDSVTKYGPVKGDSIVEKEEIPFKKERKFNPDLAPGTEKVTREGQKGEKT TTTPTLKNPLTGEIISKGESKEEITKDPINELTEYGPETITTGHRDEFDPKLPTGEKEVTR EGQKGEKTITTPTLKNPLTGEIISKGESKEEITKDPINELTEYGPETTTPGHRDEFDPKLPTGEKEV PEKRGIKNPETGDVVRPPVDSVTKYGPVKGDSIVEKEEIPFEKERKFNPDLAPGTEKVTREGCKGEKT EGQKGEKTITTPTLKNPLTGEIISKGESKEEITKDPVNELTEFGGEKLPQGHKDIFDPNL PTDQTEKVPGKPGIKNPDTGKVIEEPVDDVIKHGPKTGTPETKTVEIPFETKREFNPKLQ PGBERVKOBGQPGSKTITTPTIKNPLTGEEVGEGQPTEEITKQPVDKIVEFGGEKPKDPK GPENPEKPSRPTHPSGPVNPNNFGLSKDRAKPNGPVHSMDKNDKVKKSKIAKESVANQEK KRBELPKTGLESTQKGLIFSSIIGIAGLMLLARRKN |
| 71. | MKNKYISKLLVGAATITLATMISNGEAKASENTQQTSTKHQTTQNNYVTDQQKAFYQVLH LKGITEEORNQYIKTLREHPERAQEVFSESLKDSKNFDRRVAQQNAFYNVLKNDNITEQE KNNYIAQIKENPDRSQQVWVESVQSSKAKERQNIENADKAIKDFQDNKAPHDKSAAYEAN SKLPKDLRDKNNRFVEKVSIEKAIVRHDERVKSANDAISKLNEKDIENRRLAQREVNKA PMDVKEHLQKQLDALVAQKDAEKKVAPKVEAPQIQSPQIEKPKVESPKVEVPQIQSPKVE VPQSKLLGYYQSLKDSFNYGYKYLTDTYKSYKEKYDTAKYYYNTYYKYGAIDQTVLTVL GSGSKSYIQPLKVDDKNGYLAKSYAQVRNYVTESINTGKVLYTFYQNPTLVKTAIKAQET ASSIKNTLSNILSFWK |
| 72. | MAVFSKEKKRGCIVVIETFKAFVIDKDESGKVTPTFKQLSPTDLPKGDVLIKVHYSGINY KDALATQDHNAVVKSYPMIPGIDLAGTIVESEAPGFEKGEQVIVTSYDLGVSHYGGFSEY ARVKSEWIIKLPDTLTILEESMIYGTAGYTAGLAIERLEKVGMNIEDGPVLVRGASGGVGT LAVLMLNELGYKVIASTGKQDVSDQLLELGAKEVIDRLPVEDDHKKPLASSTWQACVDPV GGEGINYVTKRINHSGSIAVIGMTAGNTYTNSVFPHLLRGVNILGIDSVFTAMKLRQRVW RRLAKDLMPENLHEIKQVITFDELPEQLNKVIKHENKGRIVIDFGVDK |
| 73. | MKKLVTATTLTAGIGTALVGQAYHADAAENYTNYNNYNYNTTOTTTTTTTTTTTTTTSSISHS GNLYTAGQCTWYVYDKVGGEIGSTWGNANNWAAAAQGAGFTVNHTPSKGAILQSSEGPFG HVAYVESVNSDGSVTISEMNYSGGPFSVSSRTISASEAGNYNYIHI |

| 74. | MKKIATATIATAGFATIAIASGNQAHASEQDNYGYNPNDPTSYSYTYTIDAQGNYHYTYK GNWHPSQLNQDNGYYSYYYNGYNNYNNYNNGYSYNNYSRYNNYSNNNQSYNTYNNYNSYN TNSYRTGGLGASYSTSSNNVQVTTTMAPSSNGRSISSGYTSGRNLYTSGQCTYYVFDRVG GKIGSTWCNASNWANAARAGYTVNNTPKAGAIMQTTQGAYGHVAYVESVNSNGSVRVSE MNYGYGPGVVTSRTISASQAAGYNFIH |
|------|--|
| 75. | MSMTYRIKKWOKLSTITLIMAGVITLNGGEFRSVDKHQIAVADTNVQTPDYELRARIWDD VNYGYDKYDENNFDMKKKFDATEKBATNLLKEMKTESGRKYLWSGAETLETNSSHMTRTY RNIEKIABAMRNPKTTLNTDENKKKVKDALEWLHKNAYGERPDKKVKELSENFTKTTGKN TNLNWWYEIGTPKSLTNTLILLNDQFSNEEKKKFTAPIKTFAPDSDKILSSVGKAELAK GONLVDISKVKLLECIIEEDKDMMKKSIDSFNKVFTXVQDSATGKERNGFYKDGSYIDHQ DVPYTGAYGVVLLEGISQMPMIKETPFNDKTQNDTTLKSWIDDGFMPLIYKGEMMDLSR GRAISRENETSHSASATVMKSLLRLSDAMDDSTKAKYKKLVKSSVESDSSYKQNDYLNSY SDIDKMKSLMTDNSISKNGLTQQLKIYNDMDRVTYHNKDLDFAFGLSMTSKNVARYESIN GENLKGWHTGAGMSYLYNSDVKHYHDNEWVTADMKRLSGTTTLDNEILKDTDDKKSSKTF VGGTKVDDQHASIGMDFENQDKTLTAKKSYFILNDKIVFLGTGIKSTDSSKNPVTTIENR KANGYTLYTDDKQTTNSDNQENNSVFLESTDTKKNIGYHFLNKPKITVKKESHTGKWKEI NKSQKDTQRTDEYYEVTQKHSNSDNKYGYVLYPGLSKDVFKTKKDEVTVVKQEDDFHVVK DNESVWAGVNYSNSTQTFDINNTKVEVKAKGMFILKKKDDNTYECSFYNPESTNSASDIE SKISMTGYSTTNKNTSTSNESGYHFELTK |
| 76. | MNDLKQFLYIALVCGVIAGLGAFLHIPQYPSMTIPRIVAILGIISAMLTFKDKQISASLK FSALLINVLPLCGTFVASN |
| 77 - | VSREMSYHWFKKMLLSTSILILSSSSLGLATHTVEAKDNINGEKPTTNINHNITSPSVNS EMNNETGTPHESNQTGNEGTGSNSRDANPDSNNVKPDSNNONPSTDSKPDPNNONPSPN PKPDPDNPRKPDPKPDPDKPKPNPDPKPPDPNPKPPDPDKPKPPPDKPPPDKPP KPPDPNKPPPNRSPDPPDQPGDSNIEGGSKNGGTWPNASDGSNGGWQPNGNQGN KPMPNPRKPPNRSPDPPDQPGDSNIEGGSKNGGTWPNASDGSNGGWQPNGNQGN SQNPTGNDFVSQRFLALANGAYKYNPYIINQINKLGKDYGEVTDEDIYNITRKQNFSGNA YINGLQQGSNYFRFQYFNPLKSERYYRNIDEQVLALTGEIGSMPDLKKPEDKPDSKQRS FEPHEKDDFTVVKKQEDNKKSASTAYSKSWLAIVCSMMVVFSIMLFLFVKRNKKNKNES ORR |
| 78. | MKNKKRVLIASSLSCAILLLSAATTQANSAHKDSQDQNKKEHVDKSQQKDKRNVTMKDKN STAPDDIGKNGKITKRTETVYDEKTNILQNLQFDFIDDPTYDKNVLLVKKQGSIHSNLKF ESHKBEKNSNMLKYPSEYHVDFQVKRNRKTEILDQLFKNKISTAKVDSTFSYSGGKFDS TKGIGRTSSNSYSKTISYNQQNYDTIASGKNNNWHVHWSVIANDLKYGGEVKNRNDELLF YRNTRIATVENPELSFASKYRYPALVRSGFNPEFLTYLSNEKSNEKTQFEVTYTRNQDIL KNRPGIHYAPPILEKNKDGORLIVTYEVDWKNKTVKVVDKYSDDNKPYKEG |
| 79. | MYTRTATTSDSQKNITQSLQFNFLTEPNYDKETVFIKAKGTIGSGLRILDPNGYWNSTLR WPGSYSVSIQNVDDNNYTNYTDFAPKNQDESREVKYTYGYKTGGDFSINRGSLTGNITKE SNYSETISYQQPSYRTLLDQSTSHKGVGWKVEAHLINNMGHDHTRQLITNDSDNRTKSEIF SLTRNGNLWAKDNFTPKDKMPVTVSEGFNPEFLAVMSHDKKDKGKSQFVVHYKRSMDEFK IDWNRHGFWGYWSGRNHVDKKEEKLSALYEVDWKTHNVKFVKVLNDNEKK |
| 80. | VVKFMNYPNGKPYRKNSAIDGGKKTAAFSNIEYGGRGMSLEKDIEHSNTFYLKSDIAVIH KKPPPVQIVNVNYPKRSKAVINEAYFRTPSTTDYNGVYQGYYIDFEAKETKNKTSFPLNN HDHQVEHMKNAYQQKGIVFLMIRFKTLDEVYLLPYSKFEVFWKRYKDNIKXSITVDEIR KNGYHIPYQYQPRLDYLKAVDKLILDESEDRV |
| 81. | WNTTKAALHGDVKLQNDRDHAKQTVSQLAHLNNAQKHMEDTLIDSETTRTAVKQDLITEAQ ALDQLMDALQQSTADKDATRASSAYVNAEPNKKQSYDEAVQNAESILAGLNNETINKGNV SSATQAVISSKNALDGVERLAQDKOTAGROSLNHLDQLTPAQQQOALENQINNATTRGEVAQ KLTEAQALNQAMEALRNSIQDQQCTEAGSKFINEDKPQKDAYQAAVQNAKDLINQTINNET LDKAQVEQLTQAVMQAKDNIHGDQKLADDKQHAVTDLNQLNGLINNPQRQALESQINNAAT RGEVAQKLABKAALDQAMQALRNSIQDQQOTESGSKFINEDKPQKDAYQAAVQNAKDLIN QTGNPTLDKSQVEQLTQAVTTAKDNLHGDQKLADDKQHAVTDLNQLNGLINNPQRQALESQINNAAT RGEVAQKLABKAALDQAMQALRNSIQDQQOTESGSKFINEDKPQKDAYQAAVQNAKDLIN QTGNPTLDKSQVEQLTQAVTTAKDNLHGDQKLARDQQQAVTTVANALPNLNHAQQQALTDA INAAPTRTEVAQHVQTATELDHAMETLKNKVDQVNTDKAQPNYTEASTDKKEAVDQALQA AESITDPTMGSNANKDAVDQVLTKLQEKENELMGNERVABAKTQAKQTIDQLTHLNADQI ATAKQNIDQATKLQPIAELVDQATQLNQSMDQLQQAVNEHANVEQTVDVTQADSDKQNAY KQALADAENVLKQNANKQQVDQALQNILNAKQALNGDERVALAKTNGKHDIDQLNALNNA QQOGFKGRIDQSNDLNQIQQIVDEAKALNRAMDQLSQEITDNEGRTKGSTNYVNADTQVK QVYDETVDKAKQALDKSTGONLTAKQVIKLNDAVTAAKKALNGEERLNNRKAEALQRLDQ LTHLNNAQRQLAIQQINNASTLNRASRAINAATKLLNAMGAVQQYTDEGHLGVISSTNYI NADDNLKANYDNAIANAAHELDKVQGNAIAKABAEQLKQNIIDAQNALNGDQNLANAKDK ANAFVNSINGLNQQQQDLAHKAINNADTVSDVTDIVNNQIDLANDAMETLKHLVDNEIPNA EQTYNYQNADDNAKTNNFDDAKRLANTLLNSDNTTNVNDINSALQAVNDALHNINLNGDQRLQD AKDKAIQSINQALANKLKEIEASNATDQDKLIAKNKABELANSIINNIKKATSNQAVSQV QTAGNHAIBQVHANEIPKAKIDANKDVDKQVQALIDEIDNANETLKHLVDNEIPNA LTDKEKQALKDRINQILQQGHNDIKNADVKQVQALIDEIDNNNLTTKEEIEQAKAQLAQA LQDIKGNINNAMTKEEIEQAKAQLAQALQDIKDLVKAKEDAKQDVDKQVQALIDEIDQNNN LTDKEKQALKDRINQILQQGHNDIXNADVKBVAGKEDAKQDLOKKQVAAQA LQDIKGNINNAMTKEEIEQAKAQLAQALQDIKDLVKAKEDAKQDUDKQVQALIDEIDQNNN AQTIDQLNRGLNLGLDDIRNTHVWEVDEQPAVNEIFEATEQILVNGELIVHRDDITTEQ DILAHINLIDQLSAEVIDTPSTATISDSITAKVEVYLLDGSKVILVNVPKVVEKELSVVK QQAIESIENAAQQKINEINNSVTLTLEQKEAAIAEVNKLKQQAIDHVNNAPDVHSVEEIQ QGQAHEGOPNPEGFTIEQAKSNAIKSIEDAIQHHDEIKARTDLTDKEKQAILVHRDDITTEQ DILAHINLIDQLSAEVIDTPSTATISDSITAKVEVYLLDGSKVILVNDVKVVEKELSVVK QQAIESIENAAQQKINEINNSVTLTLEQKEAAIAEVNKLKQQAIDHVNNAPDVHSVEEIQ QGQAHEGOPNPEGFTIEQAKSNAIKSIEDAIQHHDEIKARRIDDEIDMHHPHSNISI RNSEIGTADEKQAAMMQINEIVLETIRDINNAHTLGQVEAALNNGLAR SAVQIVPSDRA KQSSSTGNESNSHLTIGYGTANHPNSST |

| 82. | MNQEVKNKIFSILKITFATALFIFVAITLYRELSGINFKDTLVEFSKINRMSLVLLFIGG GASLVILSMYDVILSRALKMDISLGKVLRVSYIINALNAIVGFGGFTGAGVRAMVYKNYT HDKKKLWHFISLILISMLTGLSLLSLLIVFHVFDASLILDKITWNWLYVVSFFLPLFI IYSMVRPPDKNNRFVGLYCTLVSCVEWLAAAVVLYFCGVIVDAHVSFWSFTAIFIIAALS GLVSFIPGGFGAFDLVVLLGFKTLGVPEEKVLLMLLLYRFAYYFVPVIIALILSSFEFGT SAKKYIEGSKYFIPAKDVTSFLMSYQKDITAKIPSLSLAILVFFTSMIFFVNNITITVYDA LVDGNHLTYYILLAIHTSACLLLLLINVVGIYKQSRRAIIFAMISILLITVATFFTYASYI LITWLAIIFVLLIVAFRARRLKRPVRMRNIVAMLLFSLFILYVNHFIAGTLYALDIYT IEMHTSVLRYYFWLTILIATIIGMIAWLFDYQFSKVRISSKIEDCEEIINQYGGNYLSH LIYSGDKQFFTNENKTAFLMYRYKASSLVVLGDPLGDENAFDELLEAFYNYAEYLIGYDVI FYQVTDQHMPLYHNFGNQFFKLGEAIIDLTQFSTSGKKRRGFRATLMKFDELNISFEII EPPFSTEINELQHVSDLWLDDRQEMHFSVGEFNEEYLSKAPIGVMRNEENEVIAFCSLM PPTYFNDAISVDLIRWLPELDLPLMDGLYLHMLLWSKEQGYTKFNMGMATLSNVGQLHYSY LRERLAGRVFEHFNGLYRFQGERRYKSKYMPNWEPPFLVYRRDNSLWESLSKWRUTRHK |
|------|--|
| 83. | MVALITLVGSAVTAHOVQAAETTQDQTTNKNVLDSNKVKATTEQAKAEVKNPTQNISGTQV YQDPAIVQPKTANNKTGNAQVSQKVDTAQVMGDTRANQSATTNNTQPVAKSTSTTAPKTN TNVTNAGYSLVDDEDDNSENQINPELIKSAAKPAALETQYKTAAPKAATTSAPKAKTEAT PKYTTFSASAQPRSVAATPKTSLPKYKPQVMSSINDYIRKNNLKAPKIEEDYTSYFPKYA YRMGVGRPBGIVVHDTANDRSTINGEISYMKNNYQNAFVHAFVDGDRILETAPTDYLSWG VGAVGNPRFLINVEIVHTHDYASFARSMNNYADYAATQLQYYGLKPDSAEYDGNGTWTHY AVSKYLGGTDHADPHGYLRSHNYSYDQLYDLINEKYLIKMGKVAPWGTQSTTTPTTPSKP TTPSKPSTGKLTVAANNGVAQIKPTNSGLYTTVYDKTGKATNSVQKTFAVSKTATLGNQK FYLVQDYNSGNKFGWVKEGDVVYNTAKSPVNVNQSYSIKPGTKLLYTVPWGTSKQVAGSVS GSGNQTFKASKQQIDKSIYLYGGVMGKSGWVSKAYLVDTAKPTPTPTEKPSTPTTNNKL TVSSLNGVAQINAKNNGLFTTVYDKTGKFTKLYSVEWGTYKQBAGAVSGTRQTFKAK QQQIDKSIYLFGTVNGKSGWVSKAYLAVPAAPKAVAQPKTAVKAYTVTPOTTQTVSKI AQVKPNNTGTRASVYEKTAKNGAKYADRTFYVTKERAHGNETYVLLNNTSHNIPLGWFNV KDLNVQNLGKSVKTTCKYTVNKSNNGLSMVFWGTKNQVILITGNNIAQGTFNATKQVSVGK DVYLYGTINNTTGWVNAKDLTAPTAVKPTTSAAKDYNYTYVIKNGNGYYVTPNSDTAKY SLKAFNEQPFAVVKEQVINGQTWYYGKLSNGKLAWIKSTDLAKELIKYNQTGMALNQVAQ IQAGLQYKPQVQRVPGKWTGANFNDVKHAMDTKRLAQDPALKYQFLRDQPQNISIDKIN QFIKGKGVLENQGAAFNKAAQMYGINEVYLISHALLETGNGTSQLAKGADVVNNKVVTNS NTKYHNVFGIAAYDNDPLREGIKYAKQAGMTVSKAIVGGAKFTGNSYVKAGQNTLYKMR WNPAHPGTHQYATDVDWANINAKIIKGYYDKIGEVGKYFDIPQYK |
| 84. | MKGKFLKVSSLFVATLTTATLVSSPAANALSSKAMDNHPQQTQSSKQQTPKIQKGGNLKP LEQREHANVILPNNDRHQITDTTNGHYAPVTYIQVEAPTGTFIASGVVVGKDTLLTNKHV VDATHGDPHALKAFPSAINQDNYPNGGFTAEQITKYSDEGDLAIVKFSPNEQHKHIGEVV KPATMSNNADTQVNQNITVTGYPGDKPVATMWESKGKITYLKGEAMQYDLSTTGGNSGSP VFNEKNEVIGIHWXGVPNEFNGAVFINENVRNFLKQNIEDIHFATMTNLITQIILITLTI LITLTTQMNQITLTTLITLIIQTMAIXIIQTIQMQLN |
| 85. | MQKKVIAATIGTSAISAVAATQANAATTHTVKPGESVWAISNKYGISIAKLKSLNNLTSN LIFPNQVLKVSGSSNSTSNSSRPSTNSGGGSYYTVQAGDSLSLIASKYGTTYQNIMRLNG LNNFFIYPGOKLKVSGTASSSNAASNSSRPSTNSGGGSYYTVQAGDSLSLIASKYGTTYQ KIMSLNGLNNFFIYPGQKLKVTGNASTNSGSATTTNRGYNTPVFSHQNLYTWGQCTYHVF NRRAEIGKGISTYWWNANWDNAAADGYTIDNRPTVGSIAQTDVGYYGHVMFVERVNND GSILVSEMNYSAAPGILTYRTVPAYQVNNYRYIH |
| 86. | MNNKKTATNRKGMIPNRLNKFSIRKYSVGTASILVGTTLIFGLSGHEAKAAEHTNGELMQ SKNETTAPSENKTTKKVDSRQLKDNTQTATADQPKVTMSDSATVKETSSNMQSPQNATAN QSTTKRSNVTTNDKSSTTYSNETDKSNLTQAKDVSTTPRTTTIKPRTLNRMAVNTVAAPQ QGTNVNDKVHFSNIDIAIDKGHVNQTTGKTEFWATSSDVLKLKANYTIDDSVKEGDTFTF KYGQYFRYGSVRLPSQTQNLYNAQGNILAKGIYDSTTRTTTYTFTNYVDQYTNVRGSFEQ VAFARKNATTBKTAYKMEVTLGNDTYSEEIIVDYGNKKAQPLISSTNYINNEDLSRNMT AYVNQPKNTYTKQTFVTNLTGYKFNPNAKNFKIYEVTDQNQFVDSFTPDTSKLKDVTDQF DVIYSNDNKTATVDLMKGGTSSNKQYIIQQVAYPDNSSTDNGKLDYTLDTDKTKYSWSNS YSNVNGSSTANGDKKYNLDAYVWEDTNKDGKQDANEKGIKGVYVILKDSNGKELDRTTT DENGKYQFTGLSNGTYSVEFSTPAGYTPTTANVGTDDAVDSDGLTTTGVIKDADNMTLDS GFYKTFKYSLGDYVWYDSNKDGKQDSTEKGIKGVKVTLQNEKGEVIGTTETDENGKYRFD NLDSGKYKVIFEKPAGLTQTGTNTTEDDKDADGGSVDVTTTDHDDFTLDNGYYEEETSDS DSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSD |
| 87. | MDINSEEYKQEVLIKDVVMLAARILLESGAEGTRVEDTMTRIAKKLGYSESNSFVTNTVI QFTLHSESFPRIFRITSRDTMLIKISQANKISRQITNNEISLAEARTQLEKIYVAKRDSS LPFKGFAAAMIAMSFLYLQGGRLIDVLTAILAGSLGYLVTEILDRKLHAQFIPEFIGSLV IGIIAVIGHTLIPTGDLATIIIAAVMPIVPGVLITNAIQDLFGGHMIMFTTKSLEALVTA FGIGAGVGSVLILV |
| 88.3 | VIAIMNVIIDERKENAMTFNKVLLSWIVILIITTSIYLFWQLGDINDVFNQSILINVRLP RLLEALLTGMILTVAGLIFQTVLNNALADSFTLGLASGATFGSGLALFLGLTTLWIPVFS ITFSLTTLITVLVITSVLSQGYPVRILTLSGLMIGALFNSLLYFLILLKPRKLNTIANYL FGGFGDAEYSNVSIIAITFIIALFGIFIILNQLKLLQLGELKSQSLGLNVQLITYIALCI ASMITAINVAYVGIIGFIGMVIPQLIRKWQWKQSLGRQLALNIVTGGQIMVMADFIGSHI LSPVQIPASIIIALIGIPVLFYMLISQSKRLH |
| 89. | MKKLAFAITATSGAAAFLTHHDAQASTQHTVQSGESLWSTAQKYNTSVESIKQNNQLDNN LVFPGQVISVGGSDAQNTSNTSPQAGSASSHTVQAGESLNIIASRYGVSVDQLMAANNLR GYLIMPNQTLQIPNGGSGGTTPTATTGSNGNASSFNHQNLYTAGQCTWYVFDRRAQAGSP ISTYWSDAKYWAGNAANDGYQVNNTPSVGSIMQSTFGPYGHVAYVERVNGDGSILISEMN YTYGPYNMNYRTIPASEVSSYAFIH |
| 90. | MPDSITIIDENKVIDYVLIAGRILLESGAETYRVEDTMNRIAHSYGLHNTYSFVSSTAII PSLNDRTSTRLIRVQERTTDLEKIALTNSLSRKISNKELTIDEAKSEFIHLQHASLQYSF LTNFFAAAIACGFFLFMFGGVASDCWIAVIAGGSAFLTFSFVQRYIQIKFFSEFVAAAVV ISIAATFTKLGIATNQDIITIASVMPLVPGILITNAIRDLLAGELLAGMSRGVEAALTAF AIGAGVAIVLLII |

| 91. | MGFLSKILDGNNKEIKQLGKLADKVIALEEKTAILTDEEIRNKTKQFQTELADIDNVKKQ NDYLDKILPEAYALVREGSKRVFNMTPYKVQIMGGIAIHKGDIAEMRTGEGKTLITATMPT YLNALAGRGVHVITVNEYLSSVQSEEMAELYNFLGLTVGLNLNSKTTEEKREAYAQDITY YLNALAGRGVHVITVNEYLSSVQSEEMAELYNFLGLTVGLNLNSKTTEEKREAYAQDITY TQANVFARMLKQDEDYKYDEKTKAVHLTEQGADKAERMFKVENLYDVQNVDVISHINTAL RAHVTLQRDVDYMVVDGEVLIVDOFTGRTMPGRRFSEGLHQAIEAKEGVQIQNESKTMAS RIHVTLQRDVDYMVVDGEVLIVDOFTGRTMPGRRFSEGLHQAIEAKEGVQIQNESKTMAS ITFQNYFRMYNKLAGMTGTAKTEEEEFRIYINMTYQIFTNKFVQNRDKSBLIYISQKGK FDAVVEDVVEKHKAGQFVLLGTVAVETSEYISNLLKKRGIRHDVLNAKNHEREABIVAGA GQKGAVTIATNMAGRGTDIKLGEGVEELGGLAVIGTERHESRRIDDQLRGRSGRQGKGD GRFYLSLQDELMIRFGSERLQKMMSRLGLDDSTPIESKMVSRAVESAQKRVEGNNFDARK RILBYDEVLRKQREIIYNERNSIIDEEDSSQVVDAMLRSTLQRSINYYINTADDEPEYQP FIDYINDIFLQEGDITBDDIKGKDAEDIFEVVWAKIEAAYQSQKDILEEQMNEFERMILL RSIDSHWTDHIDTMDQLRQGIHLRSYAQQNPLRDYQNEGHELFDIMMQNIEEDTCKFILK SVVQVEDNIEREKTTEFGEAKHVSAEDGKEKVKPKPIVKGDQVGRNDDCPCGSGKKFKNC |
|------|---|
| 92. | MRESMSNQNYDYNKNEDGSKKKMSTTAKVVSIATVLLLLGGLVFAIFAYVDHSNKAKERM LNEOKQEQKEKRQKENAEKERKKQQEEKEQNELDSQANQYQQLPQQNQYQYVPPQQQAP TKQRPAKBENDDKASKDESKDKDDKASQDKSDDNQKKTDDNKQPAQPKPQPQQPTPKPNN NQQNNQSNQQAKPQAPQQNSQSTTNKQNNANDK |
| 93. | MMKKKEKHATRKSIGVASVLVGTLIGFGLLSSKEADASENSVTQSDSASNESKSNDSS SVSAAPKTDDTNVSDTKTSSNTNNGETSVAQNPAQQETTQSSSTNATTEETPVTGBATTT TTNQANTPATTQSSNTMAEELWAQTSNETTSNDTNTVSSVNSPQNSTNAENVGTTQTST EATPSNNESAPQSTDASNKDVVNQAVNTSAPRMRAFSLAAVAADAPAAGTDITNQLTNVT VGIDSGTTVYPHQAGYVKLNYGFSVPNSAVKGDTFKITVPKELNLNGVTSTAKVPPIMAG DQVLANGVIDSDGNVIYFTDYVMYKDDVKATLTMPAYIDPENVKKTGNVTLATGIGSTT ANKTVLVDYEKYGKFYNLSIKGTLDQIDKTNNTYRQTIYVNPSGDNVIAPVLTGNLKPNT DSNALIDQQNTSIKVYKVDNAADLSESYFVNPENFEDVTNSVNITFPNPNQYKVEFNTPD DQITTPYTVVVNGHIDPNSKGDLALRSTLYGYNSNIIWSSMSVDNEVAFNNGSGSGDGID KPVVPEQPDEPGEIEPIPEDSDSDPGSDSGSDSDSDSDSDSDSDSDSDSDSDSDSDSDS |
| 94. | MNSNIAKASVTESVOKKFVVPESGINKIIPAYDEFKNSPKVNVSNLTDNKNFVASEDKLN KIADSSAASKIVDKNFVVPESKLGNIVPEYKEINNRVNVATNNPASQQVDKHFVAKGPEV NRFITQNKVNHHFITTQPHYKKVITSYKSTHVHKHVNHAKDSINKHFIVKPSESPRYTHP SQSLIIKHHFAVPGYHAHKFVTPGHASIKINHFCVVPQINSFKVIPPYGHNSHRMHVPSF QNNTTATHQNAKVNKAYDYKYYSYKVVKGVKKYFSFSQSNGYKIGKPSLNIKNVNYQYA VPSYSPTHYVPEFKGSLPAPRV |
| 95. | LEHTIMKMRTIAKTSLALGLLTTGAITVTTQSVKAEKIQSTKVDKVPTLKAERLAMINIT AGANSATTQAANTRQERTPKLEKAPNTNEEKTSASKIEKISQPKQEEQKTLNISATPAPK QEQSQTTTESTTPKTKVTTPPSTNTPQPMQSTKSDTPQSPTIKQAQTDMTPKYBDLRAYY TKPSFEFEKQPGFMLKPWTTVRFMNVIPNFIYKIALVGKDEKKYKDGPYDNIDVFIVLE DNKYQLKKYSVGGITKTNSKKVNHKVELSITKKDNQGMISRDVGBYMITKEEISLKELDF KLRKOLIEKHNLYGNMGSGTIVIKMKNGGKYTFELHKKLQEHRMAGTNIDNIEVNIK |
| 96. | MTTIKTSNLGFPRLGRKREWKKAIESYWAKKISKEELDQTLTDLHKENLLLQKYYHLDSI PVGDFSLYDHILDTSLLFNIIPERFQGRTIDDLLFDIARGNKDHVASALIKWFTNYHY IVPEWDNVEPKVSENVLLDRFKYAGSLAVNAHPUVGFITFVKLSKGGHOFFEEKVKTLL PLYKEVFESLIDAGABYIQVDEPILVTDDSESYENITREAYDYFEKAGVAKKLVIQTYFE RAHLKFLSSLPVGGIGLDFVHDNGYNLKQIEAGDFDKSKTLYAGIIDGRNVWASDIEAKK VLIDKLLAHTNELVIQPSSSLHVPVSLDDETLDTSVGEGLSFATEKLDELDALRRLFNQ NDSVKYDKLKARYERFQNGSFKNLDYDFESVRTSRQSPFAQRIEQQQKRLNLPDLPTTTI GSFPQSREVRKYRADWKNRRITDBAYETFLKNEIARWIKIQEDIGLDVLVHGEFFRNDMV EFFGEKLQGFLVTKFGWVQSYGSRAVKPPIIYGDVKWYAPLTVDETVYAQSLTDKFVKGM LTGPVTILNWSFERVDLPRKVVQDQIALAINEEVLALEAAGIKVIQVDEPALREGLPLRS EYHEQYILKDAVLSFKLATSSVRDETQIHTHMCYSQFGQIIHAIHDLDADVISIETSRSHG DLIKDFEDINYDLGIGLGVYDIHSPRIPTKEEITTAINRSLQQIDRSLFWVNPDCGLKTR KEEEVKDALTVLVMAVKARRQE |
| 97. | MSDTYKSYLVAVLCFTVLAIVLMPFLYFTTAWSIAGFASIATFIFYKEYFYEE |
| 98. | MLRGQEERKYSIRKYSIGVVSVLAATMFVVSSIEAQASEKTSTNAAAQKETLNOPGEQGN ATTSHQMGSGKQLDDMHKENGKSGTVTEGKDTLQSSKHQSTQNSKTIRTQNDDNQVKQDSE RQGSKQSHQNNATNNTERQMDQVQNTHHABRNGSQSTTSQSNDVDKSQPSIPAQKVIPNH DKAAPTSTTPPSNDKTAPKSTKAQDATTDKHPNQQDTHQPAHQIIDAKQDDTVRQSEQKP QVGDLSKHIDGQNSPEKPTDKNTDNKQLIKDALQAPKTRSTTNAAADAKKVRPLKANQVQ PLNKYPVVFVHGFLGLVGDNAPALYPNYWGGNKFKVIEELRKQGYNVHQASVSAFGSNYD RAVELYYYIKGGRUDYGAAHAAKYGHERYGKTYKGIMPNWEPGKKVHLVGHSMGGQTIRL MEEFLRNGNKEEIAYHKAHGGEISPLFTGGHNNMVASITTLATPHKGSQAADKFGNTEAV RKIMFALNRFMGNXYSNIDLGLTQWGFKQLPNESYIDYIKRVSKSKIWTSDDNAAYDLTL DSGAKLNNMTSMNPNITYTTYTGVSSHTGPLGYENPDLGTFFLMATTSRIIGHDAREEWR KNDGVVPVISSLHPSNOPFVNVTNDEPATRGIWQVKPIIQGWD |
| 99. | MIHLIKGKMHHTVLCIHLNKGVALMNQYHSNAQQPSAWRFFVYSLVGILCFFIPFIINGN NTIFVDHVHLAIRSIIGPLMPYVALIMILIGTALPIVRTFMTSITNLVITLFKVAGAMI GIMYVFKIGPSILFKANYGPFLFEKLMMPLSILIPVGAIALSLLVGYGLLEFVGVYMEPI MRPIFKTPGKSAVDAVASFVGSYSLGLLITNRVYKQGMYNKREATIIATGFSTVSATFMI IVAKTLGLMPHWNLYFWITLVITFVVTAITAWLPPISNESTEYYNGGBGEQEVAIEGSRL KTAYAEAMKQNALTPSLVKNYWDNLKDGLEMTVGILPSILSIGFLGLIVANYTPFIDWLG YIFYPFIYIFPIADQALLAKASAISIVEMFLPSLLVTKAAMSTKFVVGVVSVSAIIFFSA LYPCILATEIKIPVWKLIIMFLRVALSLLITIPVALLIFG |
| 100. | MVIMKKTILLTMTTLTLFSMSPNSAQAYTNDSKTLEEAKKAHPNAQFKVNKDTGAYTYTY DKNNTPNNNHQNQSRTNDNHQHANQRDLNNNQYHSSLSGQYTHINDAIDSHTPPQTSFSN PLTPAIPNVEDNDDELNNAFSKDNKGLITGIDLDELYDELQIAEFNNKAKTADGKPLALG NGKIDQPLITSKNNLYTAGQCTWYVFDKRAKDGHTISTFWGDAKNWAGQASSNGFKVDR HPTRGSILQTVNGPPGHVAYVEKVNIDGSILISEMNWIGEYIVSSRTISASEVSSYNYIH |

| 101. | MEVSSMKPYIQLVVFKQWLQYILLVTTIVIALVLIGIGYRVAHDNFKIPITIQDLDQTTA SKSFVNKIKQSDYVTIKKVDEDESYIEDDVTKKEAILSMQIPKGFSQKLKENRLKETIQL |
|------|---|
| | YGRDDFIGGIAVELYSSLYEQQIPNIIYEHLEDARQRQSIDATNOSINKII SITKQAQHSISISLIFAVILFVSAVQVVLHYRLNQQAALQRLSQYHLSRFKLYSTYVMTH TILLLLVLLAVSLYLSQPLSLIFYLKSLLLILIYEIGIVFILFHIQTISHRLFMTFIYAL |
| 102. | MIEVTEMNFFDIHKIPNKGIPLSVQRKLWLRNFMQAFFVVFFVYMAMYLIRNNFKAAQPF LKEBIGLSTLELGYIGLAFSITYGLGKTLLGYFVDGRNTKRIISFLLILSAITYLIMGFV LSYFGSVMGLLIVLWGLNGVFQSVGGPASYSTISRWAPRTKRGRYLGFWNTSHNIGGAIA GGVALWGANVFFHGNVIGMFIFFSVIALLIGIATLFIGKDDPEELGWNRAEEIWEEPVDK ENIDSQGMTKWEIFKKYILGNPVIWILCVSNVFVYIVRIGIDNWAPLXVSEHLHFSKGDA VNTIFYFEIGALVASILWGYVSDLLKGRRAIVAIGCMFMTIFFVVLFYTNATSVMMVNISL FALGALIFGPQLLIGVSLTGFVPKNAISVANGMTGSFAYLFGDSMAKVGLAAIADPTRNG LNTEGYTLSGWTDVFIVFYVALFLGMILLGIVAFYEEKKIRSLKI |
| 103. | MTKKKNILKAIGIYSFTAMMFVIILYPLLWTFGISLNPGTNLYGAKMIPDNATFKNYAFL LFDDSSQYLTWYKNTLIVASANALFSVIFVTLITAYAFSRYRFVGRKYGLITFLILQMFPV LMAMVAIYILLNTIGLIDSLFGLTLVYIGGSIPMNAFLVKGYFDTIPKELDESAKIDGAG HMRIFLQIMLPLAKFILAVVALFNFMGPFMDFILPKILLRSPEKFTLAVGLFNFINDKYA NNFTVFAAGAIMIAVPIAIVFLFLQRYLVSGLTTGATKG |
| 104. | MMENSTTEARNEATMHLDEMTVEEALITMIKEDQQVPLAVRKAIPQLTKVIKKTIAQYKK GGRLIYIGAGTSGRLGVUDAAECVPTFNTDPHEIIGIIAGGHAMTMAVEGAEDHKKLAE EDLKNIDLISKDVVIGIAASGKTPYVIGGLTFANTIGATTVSISCNEHAVISEIAQYPVE VKVGPEVLITGSTRLKSGTAQKLILNMISTITMVGVGKVYDNIMIDVKATNQKLIDRSVRI IOEICAITYDEAMALYOVSEHDVKVATVMGMCGISKEEATRRLLNNGDIVKRAIRDRQP |
| 105. | LQYIIRYIMMTLQIHTGGINLKKKNIYSIRKLGVGIASVTLGTLLISGGVTPAANÄAQHD EAQQNAFYQVINMPNLNADQRNGFIQSLKDDPSQSANVLGBAQKLNDSQAPKADAQQNNF NKDQQSAFYEILMMPNLNEAQRNGFIQSLKDDPSQSTNVLGEAKKLNESQAPKADNNFNK EQQNAFYEILMPNLNEEQRNGFIQSLKDDPSQSANLLSEAKKLNESQAPKADNKFNKEQ QNAFYEILHLPNLTEEQRNGFIQSLKDDPSQSANLLSEAKKLNDAQAPKADNKFNKEQQN AFYEILHLPNLTEEQRNGFIQSLKDDPSQSANLLAEAKKLNDAQAPKEDNNKPGKEDNN KPGKEDNNKPGKEDNNKPGKEDGNKPGKEDGNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDNNKPGKEDNSTATADNKLAADNKLAKNGTADKLAADNKLADALPTGETTYFGGLSLALGAALLAGRREL |
| 106. | MDKKSEKRGIKMTVOSAYIHIPFCVRICTYCDFNKYFIQNQPVDEYLDALITEMSTAKYR ILKTMYVGGGTPTALSINQLERLLKAIRDTFTITGEYTFEANPDELITKEKVQLLEKYGVK RISMGVQTFKPBLLSVLGRTHNTEDIYTSVLNAKNAGIKSISLDLMYHLPKQTIEDFEQS LDLALDMDIQHISSYGLILEPKTQFYNMYRKGLLKLPNEDLGADMYQLLMSKIEQSPFHQ YEISNFALDGHESEHNKVYWFNEEYYGFGAGASGYVDGVRYTNIMPVNHYIKAINKESKA ILVSNKPSLTERMEEEMFLGLRLNEGVSSSRFKKKFDQSIESVFGQTINNLKEKELIVEK NDVIALTNRGKVIGNEVFEAFLIND |
| 107. | atgaatgtattagtaattggtgtgtggacgagaacatgcacttgcatataaacttaat caatcgaatctagttaaacaagtgtttgtcattccaggtaatgaggcaatgacactata gctgaagtacacactgaaatttcagaacctgatcatcaagcgatactaagttttgctaaa cggcaaaatgttgattggtggtagtattaggtccagacagcgctaattgatggattagca gacattttacgagcgaatggtttcaaagtgttggtcaaatcagcagctaaatc gaaggctcaaaattattggtcaaaaggatgtttggtccaaataagcaagc |
| 108. | MNVLVIGAGGREHALAYKLNQSNLVKQVFVIPGNEAMTPIAEVHTEISEPDHQAILDFAK RQNVDWVVIGPEQPLIDGLADILRANGFKVFGPNKQAAQIEGSKLFAKKIMEKYNIPTAD YKEVERKKDALTYIENCELPVVVKKDGLAAGKGVIIADTIEAARSAIEIMYGDEEEGTVV FETFLEGEEFSLMTFVNGDLAVPFDCIAQDHKRAFDHDEGPNTGGMGAYCPVPHISDDVL KLTNETIAQPIAKAMINEGYOFFGVLYIGALITKDGPKVIEFNARFGDPEAQVILSRMES DLMQHIIDLDEGKRTEFKWKNESIVGVMLASKGYPDAYEKGHKVSGFDLENTFVSGLKK OGDTFVTSGGRVILAIGKGDNYQDAQRDAYKKVSGDIQSDHLFYRHDIANKALQLK |
| 109. | atgcaaccacatttaatatgtctagacttagacggaacattattaaacgataacaaagaa atttcatcatatactaaacaagtattaaatgaattacaacaacgagacaccaaattatg attgcgactggcagaccttatcgtgcaagtcaagt |
| 110. | MQPHLICLDLDGTLLNDNKEISSYTKQVLNELQQRGHQIMIATGRPYRASQMYYHELNLT TPIVNFNGAYVHHPKDKNFKTCHEILDLGIAQNIIQGLQQYQVSNIIAEVKDYVFINNHD PRLFEGFSMGNPRIQTGNLLVHLKESPTSILIEAEESKIPEIKNMLTHFYADHIEHRRWG APFPVIEIVKLGINKARGIEQVRQFLNIDRNNIIAFGDEDNDIEMIEYARHGVAMENGLQ ELKDVANNITFNNNEDGIGRYLNDFFNLNIRYYC |

| 111. | gtgaaaccaatggctaatgtctaatagtaaagacatcgttttaattggagccggtgtactt agcacaacatttggttcaatgttaaaagaaattgagccagactggaatatccaggtttac gaacgcttggatcgtcctgcaatcgaaagttcaaacgaaagaaa |
|------|--|
| 112. | MKPMAKSNSKDIVLIGAGVLSTTFGSMLKEIEPDWNIHVYERLDRPAIESSNBRNNAGTG HAALCELNYTVLQPDGSIDIEKAKVINEEFEISKQFWGHHVKSGSIENPREFINPLPHIS YVRGKNNVKFLKDRYEAMKAFPMFDNIEYTEDIEVMKKWIPLMMKGREDNPGIMAASKID EGTDVNFGELTRKMAKSIEAHPNATVQFNHEVVDFEQLSNGQWEVTVKNRLTGEKFKQVT DYVFTGAGGGAIPLLQKTGIPESKHLGGFPISGQFLACTNPQVIEQHDAKVYGKEPPGTP PMTVPHLDTRYIDGQRTLLFGPFANVGPKFLKNGSNLDLFKSVKTYNITTILIAAAVKNLP LIKYSFDQVLMTKEGCMHLRTFYPEARNEDWQLYTAGKRVQVIKDTPEHGKGFIQFGTE VVNSQDHTVIALLGESFGASTSVSVALEVLERNFPEYKTEWAPKIKKMIPSYGESLIEDE KLMRKIRKQTSKDLEIGYYEN |
| 113. | atgctagaggcacaattttttactgatactggacaacatagagataagaatgagatggggttggtatttttttaataa |
| 114. | matdtghrdkndaggyntnvcdgmgghkagvaskvtdksranhanwrnnkdnyhyanayk gmgttcvcavksvvanvgdsrayvnsrtsdhsvnhvtgtathrntkvmgtdkrvsdkrny dynsdgtdyvkdnkrvkgtdhgdmadnhskdnvtaagdkv |
| 115. | atggcaaaagaaaaattcgatcgttctaaagaacatgcaatatcggtactatcggtcac gttgaccatggtaaaacaacattaacagcagcaatcgctactgtattagcaaaaaatggt gactcagttgcacaatcatatgacatgattgacaacgctcacgaagaaaaagaacgtggt atcacaatcaattctctcacattgagtaccaaactgacaaacgtcactgcacacgtt gactgcccaggacacgctgactacgttaaaaacatgatcactggtgctgctaaatggac ggcggtatcttagtagtatctgctgacggtccaatgccacaaactggtgacacacatt cttttatcacgtaacgttggtgtaccagcattagtgattcttctaaacaagttgacatg gttgacgatgaagaattattagaattagtagaattgtgagttcgtgacttattaagcgaa tatgacttcccaggtgacgatgtacctgtaaatcgctggttcagcattaaaagcttagaa ggcgatgctcaatacgagaaaaaaatcttagaattaatggaagctgtagtacattacatt ccaactccagaacgtgattctgacaaaccattcatgatgccagttgagaacgtattctca atcactggtcgtggtaactgtgctacaggccgtgttgaacgatgagaacgtattcca atcactggtcgtggtaactgttgctacaggccgtgttgaacgatgaagaagttgcca atcactggtcgtggtaactgttgctacaggccgtgttgaacgtggtcaaatcaaagttggt |
| | gaagaagttgaaattattagactacggtttacatgacacatctaaaacaactgttacaggtgttgaa atgttccgtaaattattagactacgctgaagctggtgacaacattggtgcattattacgt ggtgttgctcgtgaagacgtacaacgtggtcaagtattagctgctcctggttcaattacac ccacatactgaattcaaagcagaagtatacgtattatcaaaagacgaaggtggacgtcac actccattcttctcaaactatcgtccacaattctatttccgtactactgacgtaactggt gttgttcacttaccagaaggtactgaaatggtaatgcctggtgataacggtgaaatgaca gtagaattaatcgctccaatcgcgattgaagacggtactcgtttccaatccgtgaaggt ggacgtactgtaggaaggtactgtatactgaaatcattaaa |
| 116. | MAKEKFDRSKEHANIGTIGHVDHGKTTLTAAIATVLAKNGDSVAQSYDMIDNAPEEKERG ITINTSHIEYQTDKRHYAHVDCPGHADYVKNMITGAAQMDGGILVVSAADGPMPQTREHI LLSRNVGVPALVVFLNKVDMVDDEELLELVEMEVRDLLSEYDFPGDDVPVIAGSALKALE GDAQYEEKILELMEAVDTYIPTPERDSDKPFMMPVEDVFSITGRGTVATGRVERGQIKVG BEVEIIGLHDTSKTTVTGVEMFRKLLDYAEAGDNIGALLRGVAREEIQRGQVLAAPGSIT PHTEFKAEVYVLSKDEGGRHTPFFSNYRPQFYFRTTDVTGVVHLPEGTEMVMPGDNVEMT VELIAPIAIDEGTRFSIREGGRTVGSGVVTEITE |

| 117. | atgactaagagtgctttagtaacaggtgcatcaagaggaattggacgtagtattgcgtta caattagcagaaggatataatgtagcagtaaactatgcaggcag |
|------|--|
| 118. | MTKSALVTGASRGIGRSIALQLAEEGYNVAVNYAGSKEKAEAVVEEIKAKGVESFAIQAN VADADEVKAMIKEVVSQFGSLDVLVANAGITADNLLARMKEQENDDVIDTNLKGVFNCIQ KATPQMLRQRSGAIINLSSVVGAVGNPGQANYVATKAGVIGLTKSAARELASRGITVNAV APGFIVSDMTDALSDELKEQMLTQIPLARFGQDTDIANTVAFLASDKAKYITGQTIHVNG GMYM |
| 119. | atgaaaatttotactaaagggagatatggacttacattgatgatttotottgotaaaaaa gaggggcaaggatgtatatocattaaagtcaattgotgaaagaaaataatttgaggtgattta tattagaacagcatgattta tattagaacagcattgatgatta tattagaacagcagggtocattaagaacggggataatgaggggataccaattaagaggggaagaaaatotcagcaggggatattata agactgttagaaggtcocaattacatttgttgaaagtattgaatcagaaccacottgogcaa aaacaactatggattogatgaggagatgcagtgagagatgtttagataatacaacattg aaatatttagcaggaatacaagtgaagatgtattagaagattataatacaacatt aaatatttagcggaatatgtagaacaagtgaagatgtagagatgtattagaatgttttatatt |
| 120. | MIKISTKGRYGI/TIMIELAKKHGEGPTSLKSIAQTNNLSEHYLEQIVSPLRNAGIVKSIR GAYGGYVIGSEPDAITAGDIIRVLEGPISLLKCWKMRSLPSVSSGFASGML |
| 121. | gtggcatttgaatttagattacccgatatcggggaaggtatccacgaaggtgaaattgta aaatggttgtgtaagaaatccattgaagaaggaaggtattttagctgaggtacaa aacgataaatcagtagaagaaatccattagaagaaggatgtttagg gtagaagaaggtacagtagctgtagttggtgacgtattgttaaaatcgatgcacctgat gcagaagaatatgcaatttaaaaggtcatgatgatgatcatcatacatctaaagaagaacctgcg aaagaggaaggccagcagaagacaggtaagtagtactcaaactgaagaagatagat |
| 122. | MAFEFRLPDIGEGIHEGEIVKWFVKAGDTIEEDDVLAEVQNDKSVVELPSPVSGTVEEVM VEEGTVAVVGDVIVKLDAPDAEDMQFKGHDDDSSSKEEPAKEEAPAEQAPVATQTEEVDE NRTVKAMPSVRKYAREKGVNIKAVSGSGKNGRITKEDVDAYINGGAPTASNEGAASATSE EVAETPAAPAAVTLEGDFPETTEKIPAMRRAIAKAMVNSKHTAPHVTLMDEIDVQALWDH RKKFKEIAAEQGTKLTFLPYVVKALVSAIKKYPALNTISFNEEAGEIVHKHYWNIGIAADT DKGLLVPVVKHADRKSIFQISDEINELAVKARDGKLTADEMKGATCTISNIGSAGGQWFT PVINHPEVATLGIGRIAQKPIVKDGEIVAAPVLALSLSFDHRQIDGATGQNAMNHIKRLL |

atgctaaacagagaaaataaaacggcaataacaaggaaaggcatggtatccaatcgatta acuyanguyanaattuaykang tyutaattaatugaytyataang tygatabagat ctaaatcaagaagacaatactaaaaabgataatcaaanagaaabgytatcatctcaaggt aatgaaacgacttcaaatgggaataaattaatagaaaagaagtgtacaatctaccact ggaaataaagttgaagtttcaactgccaaatcagatgagcaagcttcaccaaaatctacg aataaaacggtgttcaagaattaggagaaaaaggcgttggcaatgtaactgtaactgta
tttgataataatacaaatacaaaggagagagagcagttactaaagaagatgggtcatac
ttgattccaaacttacctaatggagattactagaattttctaaacttacctaataggagagttactagaatttttcaaacttacctcaaaaggt
tatgaagtaaccccttcaaaacaaggtaataacgaagaattagattcaaacggcttatct
tcagttattacagttaatgcaaaggtaacattatctgcagacttaggtattcaaaacct
aaatacaacttaggtgactatgtctgggaagatacaaataaaaatggtatccaagaccaa
gatgaaaaaggtatactggcgtaacggtaacattaaaagtgaaaacggtatcaagtgtaa
aaacagttacaacagacgctgatggcaaatataaatttactgatttagataatggtag
tataaagttgaattactacaccagaaggctatacaccgactacagtaacatctggtag
gacattgaaaaagacctaatggttataacaacaacaggtgttattaaatggtgctgataac
atgacattgaaaaagacgtgtaacgagatccaaataaatttaggtaattatgg
gaagatacaaataaagatggtaagagagatcaaacgaaaaggtatttcaccaggagaacatttcaactgaaaaagggagatcaaca
ttacattgaaaaatgaaaacggtgaagtttacaacaaaaaaacaaaaagatgaaaagg gttacattgaaaatgaaaacggtgaagttttacaaacaactaattaaacagataaagatggt aaatatcaatttactggattagaaaatggaacttataaagttgaattcgaaacaccatca ggttacacaccaacacaagtaggttcaggaactgatgaaggtatagattcaaatggtaca ggttacacaccaccacagagagtttcaggatacagtagagtactagttgatttaatggatac tcaacaacaggtgtcattaaagataaagataacgatactattgactctggtttctacaaa ccgacttacaacttaggtgactatgtatgggaagatacaaataaaaacggtgttcaagat aaagatgaaaagggcatttcaggtgtaacagttacgttaaaagatgaaaacgacaaagtt ttaaaaacagttacaacagatgaaaatggtaaatacaattcagtgattaaacaagtga acttataaagttgaattcgagacacatcaggttatacacaaacttcagtaacttctgga aatgatactgaaaaagattctaatggtttaacaacaacaggtgtcattaaagatgcagat aacatgacattagacagtggtttctataaaacaccaaaatatagtttaggtgattatgtt tggtacgacagtaataaagacggcaaacaagattcaactgaaaaaggtatcaaagatgtt aggttacttattaatgaaaaaggcgaagtaattggaacaactaaaacagatgaaaat ggtaaatactgctttgataatttagatagcggtaaatacaaagttatttttgaaaagcct gctggcttaacacaaacaggtacaaatacaactgaagatgataaagatgcagatggtggc gatagcgattcagattcagacagagactcagatagtgattcagactcagatagcgactca gattcagacagcgactcagattcagacagcgactcagactcagatagtgattcagactca gatagcgactcagattcagactcagactcagactcagactcagactcagactcagatagt gactcagattcagattcagactcagactcagactcagactcagactcagatagt gactcagattcagattagcgactcagattcggacagcgattcagactcagatagcgactca gattcagatagcgattcagactcagatagcgactcagattcagatagtgattcagactca 125.

PVKPMSTTKDHHNKAKALPETGNENSGSNNATLFGGLFAALGSLLLFGRRKKONK acaattattocaaacogtggtgcatggttagaatatgaaacagatgctaaagatgttgta
tacgtacgtattgatagaacacgtagttgaacgattatgaacagatgctattgta
tacgtacgtattgatagaacacgtaaactaccattaacagtattgttacgtgcattaggt
ttctcaagcgaccaagaaattgttgaccttttaggtgacaatgaatatttacgtaatact
ttaggaaagacgcactgaaaaacactgaacaagcgttattagaaatctatgaacgttta
cgtccaggtgaaccaccaactgttgaaaatgctaaaagtctattgtattcacgtttcttt ttaaaacatogtttatttaatoaaaaattagotgagocaattgtaaatactgaaactggt gaaattgtagttgaagaaggtacagtgottgatogtogtaaaatcgacgaaatcatggat gtacttgaatcaaatgcaaacagcgaagtgtttgaattgcatggtagcgttatagacgag ccagtagaaattcaatcaattaaagtatatgttcctaacgatgatgaaggtcgtacgaca actgtaattggtaatgctttccctgactcagaagttaaatgcattacaccagcagatatc attgcttcaatgagttacttctttaacttattaaggggtattggatatacagatgatatt gaccatttaggtaaccgtcgtttacgttctgtaggtgaattactacaaaaccaattccgt atcggtttatcaagaatggaaagagttgtacgtgaaagaatgtcaattcaagatactgag tctatcacacctcaacaattaattaattcgacctgttattgcatctattaaagaattc tttggtagctctcaattatcacaattcatggaccaagcaaacccattagctgagttaacg cataaacgtcgtctatcagcattaggacgtggtggtttaacacgtgaacgtgctcaaatg gaagtacgtgacgttcactactctcactatggccgtatgtgtccaattgaaacacctgag ggaccaaacattggattgattaactcattatcaagttatgcacgtgtaaatgaattcggc tttattgaaacaccatatcgtaaagttgatttagatacacatgctatcactgatcaaatt gactatttaacagctgacgaagaagatagctatgttgtagcacaagcaaactctaaatta gatgaaaatggtcgtttcatggatgatgtagttgtatgtcgtttccgtggtaacaataca gttatggctaaagaaaaatggattatatggatgtatcgccgaagcaagttgtttcagca gcgacagcatgtattecattettagaaaatgatgactcaaaccgtgcattgatgggtgcg aacatgcaacgtcaagcagtgcctttgatgaatccagaagcaccatttgttggtacaggt atggaacacgttgcagcacgtgatcttggtgcggctattacagctaagcacagaggtcgt gttgaacatgttgcagcacgtgatcttggtcgtcgtcgtctagttgaagagaacggcgtt gagcatgaaggtgaattagatcgctatccattagctaaatttaaacgttcaaactcaggt acatgttacaaccaacgtccaatcgttgcagttggagatgttgttggtataacgagatt ttagcagatggaccatctatggaattaggagaaatggcattaggtagaaacgtagtagtt ggtttcatgacttgggacggttacaactatgaggatgccgttatcatgagtgaaagactt gtgaaagatgacgtgtatacttctattcatattgaagagtatgaatcagaagtacgtgat actaagttaggacctgaagaaatcacaagagatattcctaatgtttctgaaagtgcactt aagaacttagacgatcgtggtatcgtttatatttggtgcagaagtaaaagatggagatatt ggtgtaccatctcgtatgaacatcggacaagtattagagctacacttaggtatggctgct aaaaatcttggtattcacgttgcatcaccagtatttgacggtgcaaacgatgacgatgta tggtcaacaattgaagaagctggtatggctcgtgatggtaaaactgtactttatgatgga cgtacaggtgaaccattcgataaccgtatttcagtaggtgtaatgtacatgttgaaactt gcgcacatggttgatgataaattacatgcgcgttcaacaggaccatattcacttgttaca caacaaccacttggcggtaaagcgcaattcggtggacaacgtttttggtggagatggaggta tgggcacttgaagcatatggtgctgcatacacattacaagaaatcttaacttacaaatcc gatgatacagtaggacgtgtgaaaacatacgaggctattgttaaaggtgaaaacatctt agaccaagtgttccagaatcattccgagtattgatgaagaattacaaagtttaggttta gatgtaaaagttatggatgagcaagataatgaaatcgaaatgacagacgttgatgacgat gatgttgtagaacgcaaagtagatttacaacaaaatgatgctcctgaaacacaaaaagaa

| 126. | MAGQVVQYGRHKKRNYARISEVLELPNLIEIQTKSYEWFLREGLIEMFRDISPIEDFTG NLSLEFVDYRLGEPKYDLEBSKNRDATYAAPLRVKVRLIIKETGEVKEQEVFMGDFPHMT DTGTTFVINGABRVIVSQLVRSPSVYFNEKIDKNGRENYDATIIPNGAMLEYETDAKDVV YVRIDRFRKLPLTVLLRALGFSSDQEIVDLLGDNEYLRNTLEKDGTENTEQALLEIYERL RPGEPPTVENAKSLLYSBFFDPKRYDLASVGRYKTNKKLHLKHRLFNOKLAEFIVNTETG EIVVEEGTVLDBRKIDEIMDVLESNANSEVFELHGSVIDEPVEIQSIKVYVPNDDEGRTT TVIGNAFPDSEVKCITPADIIASMSYFFNLLSGIGYTDDIDHLGNRRLRSVGELLQNQFR IGLSRMERVVRERMSIQDTESITPQQLINIRPVIASIKEFFGSSQLSOFMDQAMPLAELT HKRRLSALGPGGLTRERAQMEVRDVHYSHYGRMCPIETPEGPNIGLINSLSSYARVNEFG FIETPYRKVDLDTHAITDQIDYLTADEEDSYVVAQANSKLDENGRFMDDEVVCRPRGNNT VMAKEKMDYMDVSPKQVVSAATACIPFLENDDSNRALMGANMORQAVPLMNPEAPFVGTG MEHVAARDSGAAITAKHRGRVEHVBSNEILVRRLVEEMGVEHGEGLDRYPLAKFKRSNSG TCYNQRPIVAVGDVVEYNEILADGPSMELGEMALGRNVVVGFMTWDGYMYEDAVIMSERL VKDDVYTSIHIEEYESRQRDTKLGPEEITRDIPNVSESALKNLDDRGIVVIGAEVKDGD LLVGKVTPKGVTELTABERLLHAITGEKAREVRDTSLRVPHGAGGIVLDVKVFMEEGDD TLSPGVNGLVRVVIVQKRITHVGDKMCGRHGNKGVISKIVPEEDMPYLPDGRPIDIMLNP LGVPSRNNIGQVLELHLGMAAKNLGIHVASPVFDGANDDDVWSTIEBAGMARDGKTVLYD GRTGEPFDNRISVGVMYMLKLAHMVDDKLHARSTGPYSLUTVQCLGGKAQFGGQRFGEME WALEAVGAAYTLQEILTYKSDDTVGGRVKTYEALVKGENISRPSVPESFRVLMKELQSLG LDVKVMDEQDNEIEMTDVDDDDVVERKVDLQQNDAPETQKSY |
|------|--|
| 127. | atgettaggcategceatatetategtatttattcagtaatataaaactggaaggagaa aaatacatggctagagaattttetatgaaaaaaactgtaatateggtacac attgatgctggtaaaacgactgaacgatttetttattacactggcegtatecac attgatgctggtaaacacacgaaggtgeteacacaaatggactggatggagcaagaacaagac cgtggtattacatcacactgctgcaacaacagcagcttggaaggtcacgtgtaaac attatcgatacacctggacacgtagacttcactgtagaaggttgaacgttgaaccgtgtaaac attatcgatacacctggacacgtagacttcactgtagaaggttgaacgttcaattacgtgta cttgacggagcagttacagtacttgatgtcacacatcaggtgttgaacctcaaactgaaca gtttggcgtcaggctacaacttatggtgttcacacatcaggtgttgaacctcaaaactgaaca gtttggcgtcaggctacaacttatggtgttcacacattacatgattgtttgaacctcaaaatggac aaattaggtgctaacttcgaatactcgtaagtacattacatgattgtttacaaggtaac gctgctccaatccaa |
| 128. | MAREFSLEKTRNIGIMAHIDAGKTTTERILYYTGRIHKIGETHEGASQMDWMEQEQDRG ITITSAATTAAWEGHRVNIINTPGHVDFTVEVERSLRVLDGAVTVLDAQSGVEPQTETVW RQATTYGVPRIVFVNKMDKLGANFEYSVSTLHDRLQANAAPIQLPIGAEDEFEAIIDLVE MKCPKYTNDLGTEIEEIEIPBDHLDRAEEARASLIEAVAETSDELMEKYLGDEEISVSEL KEAIRQATTNVEFYPVLCGTAFKNKGVQLMLDAVIDYLPSPLDVKPIIGHRASNPEEEVI AKADDSAEFAALAFKUMTDPYYGKLTFFRYYSGTMTSGSTVKNSTKGKRERVGRLLQMHA NSRQEIDTYVSGDIAAAVGLKUNTGTGDTLCGEKNDIILESMEFPEPVIHLSVEPKSKADQ DKMTQALVKLQBEDPTFHAHTDEETGQVIIGGMGELHLDILVDRMKKEFNVECNVGAPMV SYRETFKSSAQVQGKFSRQSGGRGQYGDVHIEFTPNETGAGFEFENAIVGGVVPREYIPS VEAGLKDAMENGVLAGYPLIDVKAKLYDGSVPDVDSSGMAFKIAASLALKEAAKCDPVI LEPMMKVTIEMPEEYMGDIMGDVTSRRGKVDGMEPRGNAQVVNAYVPLSEMFGYATSLRS NTQGRGTYTMYPDHYAEVPKSIAEDIIKKNKGE |
| 129. | atgactaaaaaagtagcaattattctagcaaacgaatttgaagatatagaatattcaagc cctaaaggagcattagcaggctttaatactgtagtgattggagatactgcaaat agtgaagttgttggtaaacacggtgaaaaagttactgtcgatgtagtgattgcagaagct aaaccagaagattatgatgcattattaattcctggaaggattttcaccagatcatttacgt ggagatacagaaggtcgatatggcacatttgctaaatactttactaaaaatgatgtacca acatttgccatttgtcatgggccacaaatactaatagatacagacgatttaaaaggtcgt acgttaacagcagtattaaatgtacgcaaagatttatcaaatgcaggcgcacatgtagtt gatgagtcagtagttgtagacaacaatattgtaacaagtcgagtaccagacgatttagat gattttaatcgagaaatcgttaaacaattacaa |
| 130. | MTKKVAIILANEFEDIEYSSPKEALENAGFNTVVIGDTANSEVVGKHGEKVTVDVGIAEA KPEDYDALLIPGGFSPDHLRGDTEGRYGTFAKYFTKNDVPTFAICHGPQILIDTDDLKGR TLTAVLNVRKDLSNAGAHVVDESVVVDNNIVTSRVPDDLDDFNREIVKQLQ |
| 131. | atggctaatcatgaacaaatcattgaagcgattaaagaaatgtcagtattagaattaaac gacttagtaaaagcaattgaagaagaatttggtgtaactgcagctgctccagtagcagta gcaggtgcagctggtggcgctgcagcagcagaaaaaactgaatttgacgttgagtta acttcagctggttcatctaaaatcaaagttgttaaagctgttaaagcaactggttta ggattaaaagatgctaaagaattagtagacggagctcctaaagtaatcaaagaagcttta cctaaagaagaagctgaaaaacttaaagaacaattagaagaagttggagctactgtagaa ttaaaa |
| 132. | MANHEQIIÉAIKEMSVLELNDLVKATEEEFGVTAAAPVAVAGAAGGADAAAEKTEFDVEL TSAGSSKIKVVKAVKEATGLGLKDAKELVDGAPKVIKEALPKEEAEKLKEQLEEVGATVE LK |

| 1 | gtggaattacaattagcaattgatttattaaacaaagaagacgcggctgagttagcaaat |
|------|---|
| 133. | gtggaattacaattagcaattgatttattaadaadaagaagatgggggtgtgacaatgaaggt aaagtaaaagattatgtagaatacgtagaaataggtaagacagggttacaacaaggat ttaccagcagttaaacatatggcagacaacattagtaaatgtaaaagtattagcagacatg aaaattatggatgcagctgattatgaagttagccaagcaattaaaatttaggcggggatgta attacaactactaggtgcagaaggatgcatcaattaaagacagctattgaagaagctcat aaaaattaataaacaattactagttgatattgctgttcaagatttagaaaaacgtgca aaagactagatgaaatgggtgctgattatattgcagtacacactggttatgatttacaa gcagaagggcaattcaccattagaaagtttaagaaccgttaaatctgttattaaaaattct aaagttgcagtagcaggtggattaaaccagatacaattaaagatattgtcgctgaaagt cctgatcttgttattgttggtggcggaatcacaaatgcagatgatccagtagaagctgca |
| | aaacaatgtcgcgctgcaatcgaaggtaag MELQLAIDLLNKEDAAELANKVKDYVDIVEIGTPIIXNEGLPAVKHMADNISNVKVLADM |
| 134. | KIMDAADYEVSQAIKFGADVITILGVAEDASI.KAAIEBAHKNINKQLUVUITIAVQUDENKA KELDEMGADYIAVHTGYDLQAEGQSPLBSILITVKSVIKNSKVAVAGGIKPDTIKDIVAES DDIATIVGGGTANADDPVEAAKOCRAAIEGK |
| 135. | atgaaaaattagtacctttattatgcctttattactctctagttgctgctagtagtact ggtggtaaacaaagcagtgataagtcaaatggcaaattaaaagtagtaaacgacgaattca atttatatgatattggctaaaaaatgttggtggaactcctgttgtgtcact cctgttggtcaagatcctcatgaatatgaagttaaacctaaagatattaaaaagttaact gacgctgacgttattttatacaacggattaaatttagaagtagacaggttggtt |
| 136. | MKKLVPLLIALILIVAACGTGGKQSSDKSNGKLKVVTTNSILYDMAKNVGGDNVDIHSIV PVGQDPHEYEVKPKDIKKLTDADVILYNGINLETGNGWFEKALEQAGKSLKDKKVIAVSK DVKPIYLNGEEGNKDKQDPHAWLSLDNGIKYVKTIQQTFIDNDKKKKADYEGNKYIAQ LEKLNNDSKDKFNDIPKBQRAMITSEGAFKYFSKQYGITPGYIWEINTEKQGTPEQWRQA IEFVKKHKLKHLLVETSVDKKAMESLSEETKKDIPGEVYTDSIGKEGTKGDSYYKMMKSN IETVHGSMK |
| 137. | atgacaactgatattttgaacattctgaagaacaacttgttgattattctaaagcccac aatgaaccttcttggatgacagaattacgtaaaaaagctttgaaattaacagaaacttta gaaatgccaaaacctgataaaacaaattaagaaaatgggattttgattcttttaaacaa cacgatgtaaaaggtgatgtttatcaatcttatcacaattacctgagtcagtaagagaa attattgacgtagatcattctaaaaacttagtaattcaacaataatacgattgcgtac acacaagttgatgataatgcatcgaaagatggcgttatcgttgaaggttagcagtagagagcgc cttatgaaccatagtgatttagtacaaaagtagctttatgaaggttagcgataacagtagat gaacatcgtatcacagcgctacacacggcattagttaatggtggcgtatttttttagt cctaaaaatgtagttgtagaacatccagtacaatagttgtgtgcgcaatttgttagt gcaagcttttataaccatgttatcatcgttactgaagaaagcgcgaagtcacatagtt gaaaattacttatcaaatgcatctggtgaaggaaatcaattaatt |
| 138. | MTTDILNISEEQLVDYSKAHNEPSWMTELRKKALKLTETLEMPKPDKTKLRKWDFDSFKQ HDVKGDYYQSLSQLPESVREIIDVDHSKNIVIQHNNTIAYTQVDDNASKDGVUYBGLADA LMNHSDLVQKYFMKDAVTVDEHRITALHTALVNGGVFVYVPKNVVVEHPVQYVVLHDDEN ASFYNHVIIVTEESAEVTYVENYLSNASGEGNQLNILSEVIAGANSNITYGSVDYMDKGF TGHIIRRGITEADASINWALGLMNEGSQIIDNTTNLFGDRSTSSLKSVVVGTGEQKINLT SKIVQYGKETDGYILKHGYMKEHASSVFNGIGYIKHGGTKSIANQESRVLMLSEHARGDA NPILLIDEDDVQAGHAASVGRVDPDQLYYLMSRGISQREAERLVIHGFLDPVVRELPIED VKRQLREVIERKVSK |

| 139. | gtggttcaagaatatgatgtaatcgttataggtggggacatgcaggtgtagaagcaggt ttagcatctgcaagacgtggtgctaaaacattaatgctaacaataaatttagataatatt gcatttatgccatgtaaccatctgtaggtggacagctaaaggtatcgttgttcggaa attgatgcttaggtggacaaatggcaaaaacaatcgataaaacaacaattcaaatgaga atgttaaatacaggtaaaggacctgctgtaagaagcactaagagcagcagcagataaagta ctttatcaacaagaaatgaacagcgtgattgaagatgaagaaaattgcaataatgcaa ggtatggtagacgaacttattatagaagataattatacaacgggaacattttacgtgggaa ggtatggtagacgaacttattataagaagataattatacaacgggaacaatttttacgtggtgaa atcattttaggtaatatgaagtattcaagtggaccaaatcaccaatcaat | |
|------|--|--|
| 140. | MVQEYDVIVIGAGHAGVEAGLASARRGAKTLMLTINLDNIAFMPCNPSVGGPAKGIVVRE IDALGGQMAKTIDKFHLQMRMLNTGKGPAVRALRAQADKVLYQQEMKRVIEDEENDHIMQ GWODELIEDNEVKGVRTNIGTEYLSKAVIITTGTFLRGEIILGNMKYSSGPNHQLPSIT LSDNLRELGFDIVRFKTGTPPRVNSKTIDYSKTBIDFGDDVGRAFSFETTEYILDQLPCW LTYTNAETHKVIDDNLHLSAMYSGMIKGTGPRYCPSIEDKFVRFNDKPRHQLFLEPEGRN TMEVYVQGLSTSLPEHVQRQMLETIPGLEKADMMRAGYAIEYDAIVPTQLWPTLETKMIK NLYTAGQINGTSGYEEAAGQGLMAGINAAGKVLNTGEKILSRSDAYIGVLIDDLVTKGTN EPYRLLTSRAEYRLLRHDNADLRITDMGYEIGMISEERYARFNEKRQQIDAEIKRLSDI RIKPNEHTQAIIEQHGGSRLKDGILAIDLLRRPEMTYDIILELLEEEHQLMADVEEQVEI QTKYEGYINKSLQQVEKVKRMEKKIPEDLDYSKIDSLATEAREKLSEVKPLNIAQASRI SGYNPADISILLIYLEGGKLQRVSD | |
| 141. | LMINEREVFILIYLDNAAXTKAFEEVLDTYLKVNQSMYYNPNSPHKAGLQANQLLQQART QINAMINSKINYDVVFTSGATESINILALKGIAYRKFDTAKEIITSVLEHFSULEVVRYLE AHEGFKVKYYDVVKKOGSINLEHFKELMSDKVGLUTCMYVNIVTGQIQPIPQMAKVIKNYP KAHFHVDAVQAFGKISMDINNIDSISLSGHKFNGLKGQGVLLVNHIQNVEPTVHGGGQEY GVRSGTVNLPNDIAMVKAMKIANENFEALMAFVTELMNDVRQFINKYHGVYINSSTSGSP FVLNISFPGVKGEVLVNAFSKYDLMISTTSACSSKRNKLNEVLAAMGLSDKSIEGSIRLS FGATTKEDIARFKEIFILIYEEIKELLK | |
| 142. | MNKQQKEFKSFYSIRKSSLGVASVAISTLLLIMSNGEAQAAAEETGGTNTEAQPKTEAVA SPTTTSEKAPETKPVANAVSVSNKEVEAPTSETKEAKEVKEVKAPKETKEVKPAAKATNN TYPILNQELREAIKNPAIKDKDHSAPNSRPIDFEMKKKDETQQFYHYASSVKPARVIFTD SKPEIELGLQSGQFWRKFEVYEGDKKLPIKLUSYDTVKDYAYIRFSVSNGTKAVKIVSST HFNNKEEKYDYTLMEFAQPIYNSADKFKTEEDYKAEKLLAPYKKAKTLERQVYELNKIQD KLPEKLKAEYKKLEDTKKALDBQVKSAITEFQNVQPTNEKMTDLQDTKYVVYYESVENNE SMMDTFYKHPIKTGMLNGKKYMVMETTNDDYWKDFMVEGQRVRTISKDAKNNTRTIIFPY VEGKTLYDAIVKVHVKTIDYDGQYHVRIVDKEAFTKANTDKSNKEQQDNSAKKEATPAT PSKPTPSPVEKESQKQDSQKDDNKQLPSVEKENDASSESGKGVTLATKPTKGEVESSSTT PTKUVSTTQNVAKPTTGSSKTTKDVVQTSAGSSEAKDSAPLQKANLKHTNDGHTQSQNNK NTQENKAKSLPQTGEESNKDMTLPLMALLALSSIVAFVLPRKRKN | |

atgagctggtttgataaattattcggcgaagataatgattcaaatgatgacttgattcat agaaagaaaaaagacgtcaagaatcacaaaatatagataacgatcatgactcattactg cctcaaaataatgatatttatagtcgtccgaggggaaaattccgttttcctatgagcgta gcttatgaaaatgaaaatgttgaacaatctgcagatactatttcagatgaaaaagaacaa taccatcgagactatcgcaaacaagaccacgattotcgttcacaaaaacgacatcgccgt agaagaaatcaaacaactgaagaacaaaattatagtgaacaacgtgggaattctaaaata tcacagcaaagtataaaatataaagatcattcacattaccattacgaataagccagtaca tatgtttctgcaattaatggtattgagaaggaacgcacaagccaaaacacataatatg tatctaataatacaaatcatcgtgctaaagattcaactccaaattaccacaaagaa gataaatatgtagctaagacgcaaacgtctcaaaataaacaattagaacaagaaaaacaa aatgatagtgttgtcaaacaaggaactgcatctaaatcatctgatgaaaatgtatcatca acaacaaaatcaatgcctaattattcaaaagttgataatactatcaaaattgaaaaatat agtyatatatagaaatgaataacgaagaaattacagaaaatgtgcaaaacgaagcagct gaaagtyaacaaaatgtcgaagagaaaactattgaaaacgtaaatccaaagaaacagact gaaaaggtttcaactttaagtaaaagaccatttaatgttgtcatgacgccatctgataaa aagcgtatgatggatcgtaaaaagcattcaaaagtcaatgtgcctgaattaaagcctgta caaagtaagcaagctgtgagtgaaagaatgcctgcgagtcaagccacaccatcatcaaga tctgattcacaagagtcaaatacaaatgcatataaaacaaataatagacatcaacaat gaagtaagggacataactgaagaaagggaagaaacaacacatccaaacaatactagtgga caacaagataatgatgatcaacaaaaagatttacagtcatcattttcaaataaaaatgaa gatacagctaatgaaaatagacctcggacgaaccaacaagatgttgcaacaaatcaagct gtacaacatctaagccgatgattcgtaaaggcccaaatattaaattgccaagtgtttca ttactacaagaaccacaagttattgagtcggacgaggactggattacagataaaaagaaa gaactgaatgacgcattattttactttaatgtacctgcagaagtacaagatgtaactgaa ggtccaagtgttacaagatttgaattatcagttgaaaaaggtgttaaagtttcaagaatt acggcattacaagatgacattaaaatggcattggcagcgaaagatattcgtatagaagcg cctattccaggaactagtcgtgttggtattgaagttccgaaccaaaatccaacgacagtc aacttacgttctattattgaatctccaagttttaaaaatgctgaatctaaattaacagtt gcgatggggtatagaattaataatgaaccattacttatggatattgctaaaacgccacac gcactaattgcaggtgcaactggatcagggaaatcagtttgtatcaatagtattttgatg tetttactatataaaaatcateetgaggaattaagattattacttategatecaaaaatg gttgaattageteettataatggtttgccacatttagttgcaceggtaattacagatgte aaagcagctacacagagtttaaaatgggccgtagaagaaatggaacgacgttataagtta tttgcacattaccatgtacgtaatataacagcatttaacaaaaagcaccatatgatgaa agaatgccaaaaattgtcattgtaattgatgagttggctgatttaatgatgatggctccg ataccaacaagaattgcatttatggtatcatcaagtgtagatttggagaacgatattagac agtggtggagcagaacgcttgttaggatatggcgatatgttatatcttggtagoggtatg aataaaccgattagagttcaaggtacatttgtttctgatgacgaaattgatgatgttgt gattttatcaaacaacaaagagaaccggactatctatttgaagaaaaagaattgttgaaa aaaacacaaacacaatcacaagatgaattatttgatgatgtttgtgcatttatggttaat gaaggacatatttcaacatcattaatccaaagacatttccaaattggctataatagagca gcaaggaattatcgatcaattagagcaactcggttatgtttcgagtgctaatggttcaaaa ccaagggatgtttatgttacggaagcagatttaaataaagaa

atgattaacagggataataaaaaggcaataacaaaaagggtatgatttcaaatcgctta 145. caactagaagotaaaaagaatatatatatatagaatatagaaaagataaaccttcaact gataaaactgcgacagaagatacatctgttattttagaagagaagaaagcaccaaataat acaaataacgatgtaactacaaaaccatctacaagtgaaccatctacaagtgaaattcaa gtaacaattacgatcatgatgattcacacttgataacggatacttcgaagaagataca tcagacagcgattcagactcagatagtgactcagacagcgactcagactcagacagcgac tcagactcagacagtgattcagattcagacagcgactcagattcagatagcgactcagat tcggacagcgattcagactcagatagcgactcagattcagatagcgattcagactcagac agcgactcagattcagatagcgattcggactcagacagcgattcagactcagatagcgac tcagactcagacagcgactcagattcagatagcgattcagactcagatagcgactcagat tcagacagcgattcagactcagatagcgactcagattcagacagcgattcagactcagat agcgactcagactcagacagtgattcagattcagacagcgactcagactcagatagcgac aacgcaacgttatttggtggattatttgcagcattaggttcattattgttattcggtcgt cgcaaaaaacaaacaaa atgactcatttattagagacatttgagatgtcaatagatcaccaggaagatggtttagtt gttatttctatgcctgttactgataaagtaaaacaaccatttggatatttacatggtggg 146 gcttcgattgctttaggtgaaacagcatgttcattaggatctgctaatttaattgataca aaacctttaaaa atggagcatacaactatgaaaataacaacgattgctaaaacaagtttagcactaggcctt 147. ttaacaacaggtgtaatcacaacgacaacgcaggaaaacgcggacaacaccatcttcc actaaagtggaagcaccacaatcaacaccgccctcaactaaaatagaagcaccgcaatca ataaatcctaaatttaaagatttaagagcgtattatacgaaaccaagtttagaatttaaa agaattattaggututtattaggaagaattagattttaaattgagaaaacaacttattgaa actaaagaacagatttccttgaaagaacttgattttaaattgagaaaacaacttattgaa aaaaataatctgtacggtaacgttggttcaggtaaaattgttattaaaatgaaaaacggt ggaaagtacacgtttgaattgcacaaaaaaattacaagaaaatcgcatggcagatgtcatt

tagtgaacaaattaaaaacatcgaagtgaatttgaaa

| 148. | atgaaaaagcaaataatttegetaagegcattageagttgeatetagettatttaeatgg gataacaaagcagatgegatagtaacaaaggattatagegaaattetaagtgggaaatcaaaagtaatget gggagtaaaaatgggacattaatagagaagtatttaagtgggaaatcaatattt tataaagaagctaaagataggttyttggaaaaggtattaaaggaagataatattt tataaagaagctaaaagataggttyttggaaaaggtataaaggaagaacattttg gagagaaagaaatccaatatgaagattataaaaatggatagaaatttteg gagagaaagaaatctaaatgaagattataaaaatggatagaaattttegaagaacttteg atgaaagaatacaatgaactacaggatgcattaaagagagcactggatgattttcacaga gaagttaaagaatattaaggatatacagatgtagaaacatttagaagaagaga gataaagcaactaaggaagtatacgactgatatttcagaactttagatgatgatat gataaggaatattaaggatatcagactgaaacatttagatgatgata gataaagcaactaaggaagtatacgaccagcgaaagagttacgagcaaaaaagaaga gataaagcaactaaggaagtatacgaccagcgaaagagttacagagcaaaaaagagagaagagagag |
|------|---|
| | acaacacatgcagatggtactgcgacatatgggcctagagtaacaaaa |
| 149. | atgaaaaaattagcaacagtaggttctttaattgtaacaagcactttagtattctcaagt atgccttttcaaaatgcgcatgccgacaacttcaatgaatg |
| 150. | gtgcttaggagtgatttttatatgtcttattccattgttagagtttcaaaagttaaatct |
| | ggaacaatacaacgggcatacaaaaacatgttcaaagggaaaataataatattgaaaat gaagatatagaccatagtaaaacttacttaaattatgatttggtaaatgctaataaacag aattttaatacttgattgatgaaaaaactgaacagaattatacaggcaaaagaaaaatt agaacagacgcgattaaacacattgatggtttaattacatcagacaatgattctttgat aatcaaacgccagaagatacaaagcagttttttgaatatgctaaaagatttttagaacaa gaatacggtaaagaatatttattatatgcaacagttcacatggacgaaaaaacacacat atgatggtaaagaatatttatatatgcaacagttcacatggacgaaaaaacacacat atgatataggcgttgttcaaaacaggtatgatggacgaaaaaacacacat atgatataggcgttgttcaaaaactgatgatggttaaaggattgta ggtaataaaaaagcttaacagcgtttcaagatagatttaatgagcatgttaaacaacga ggatatgattagaacgtgggcaatcaagacaagtaacaaaaaacgctaaacaagagggaaatatacaaaagaatatcaaaaaaaa |
| 151. | MSWFDKLFGEDNDSNDDLIHRKKKRRQESQNIDNDHDSLLPQNNDIYSRPRGKFRFPMSV AYENENVEQSADTISDEKEQYHRDYRKQSHDSRSQKRHRRRRNQTTEEQNYSEQRGNSKI |
| | SQSTKYKDHSHYHTNKPGTYVSAINGIEKETHKPKTHNMYSNNTNHRAKDSTPDYHKES FKTSEVESAIFGTMKPKKLENGRIPVSKPSEKVESDKYYDKYVAKTOTSONKOLEGEKO NDSVVKQGTASKSSDENVSSTTKSMPNYSKUDNTIKIENIYASQIVEETRERERKVLQK RRFKKALQCKREBHKNEEQDAIQRAIDEMYAKQAERYVGDSSLNDDSDLTDNSTDASQLH TNGIENETYSNDENKQASIQNEDTNDTHYDESPYNYEEVSLNQVSTTKQLSDDEVTVSNV TSQHQSALQHNVEVNDKDELKNQSRLIADSEEDGATNKEBYSGSQIDDAEFYELNDTEVD EDTTSNIEDNTNRNASEMHVDAPKTQEYAVTESQVNNIDKTVDNEIELAPRHKKDDQTNL SVNSLKTNDVNDNHVVEDSSMMBIEKNNABITENVQNEAAESEQNVEEKTIENVMPKKQT EKVSTLSKRPFNVVMTPSDKKRMMDRKHSKVNVPELKPVQSKQAVSERMPASQATPSSR SDSQESNTNAYKTNNMTSNNVENNQLIGHABTENDYQNAQQYSEQKPSVDSTQTEIFEES QDDNQLENEQVDQSTSSVSEVSDITESBESTTHENNTSGQQDNDDQQKDLQSSFSNKNE DTANENRPRTNQQDVATNQAVQTSKPMIRKGPNIRLIPSVSLLEBEPQVIESDEDWITDKKK ELNDALFYFNVPAEVQDVTEGFSVTRFELSVEKGVKVSRITALQDDIKMALAAKDIRIEA PIPGTSRVGIEVPNQNPTTVNLRSIIESPSFKNABSKLTVAMGYRINNBELLMDIAKTPH ALIAGATGSGKSVCINSILMSLLYKNHPEELRLLLIDPKMVELAPYNGLPHLWAPVTTDV KAATQSLKMAVEEMERRYKLFAHYHVRNITAFNKKAPYDERMFKIVTUDELADLMMMAP QEVEQSIARIAQKARACGIHMLVATQRPSVNVITGLIKANIPFRIAFMVSSSVDSRTILD SGGBERLLGYGDMLYLGSGMNKPIRVQGTFVSDDEIDDVVDFIKQQREPDYLFEEKELLK KTQTQSQDELFDDVCAFMVNEGHISTSLLQRTFVSDDEIDDVVDFIKQQREPDYLFEEKELLK KTQTQSQDELFDDVCAFMVNEGHISTSLLQRTFVSDDEIDDVVDFIKQQREPDYLFEEKELLK |

| 152. | MPKRNDIKTILVIGSGPIIIGQAABFDYAGTQACLALKEBGYRVILVNSNPATIMTDKET ADKVYIEPLTHDFIARIIRKEQPDALLPTLGGGTGLMMAIQLHESGULQDNNVQLLGTEL TSIQQAEDREMFRILMNDLNVPVPESDIVNTVEQAFKFKEQVGYPLIVRPAFTMGGTGGG ICHNDBELHELVSNGCHYSPATQCLLEKSIAGFKEIEYEVMRDKNDNAIVVCNMENIDPV GIHTGDSIVVAPSQTLSDVEYQMLRDVSLKVIRALGIEGGCNVQLALDPHSFDYYIIEVN PRVSRSSALASKATGYPIAKLAAKIAVGLITLDEMLNPITGTSYAAFEPTLDVYISKIPRF PFDKFEKGERELGTQMKATGEVMAIGRTYEESLIKAIRSLEYGVHHLGLPNGESFDLDYI KERISHQDDERLFFIGEAIRRGTTLEEIHNMTQIDYFFLHKFQNIIDIEHQLKEHQGDLE YLKVAKDYGFSDKTIAHRFNMTEESVYQLRMENDIKPVYKMVDTCAAFFESSTPYYYGTY ETENESIVTDKEKILVLGSGPIRIGGVEFDYATVHAWAIQKAGYEAIIVNNNPETVST DFSISDKLYFEPLTEEDVMNIINLEKPKGVVVQFGGQTAINLADKLAKHGVKILGTSLEN LNRAEDRKEFFBALLRKINVPQPQCKTATSPEEBALANAAEIGYPVVVRPSYVLGGRAMEIV DNDKELENYMTQAVKASPEHPVLVDRYLTGKEIEVDAICDGETVIIPGIMEHIERAGVHS GGSIAVYPPQTLTEDELATLEDYTIKLAKGINIIGLINIQFVIAHDGVVVLEVNPRSSRT VPFLSKITDIPMAQLAMRAIIGEKLTDMGYQEGVQPYABGVFVKAPVFSFNKLKNVDITL GPEMKSTGEVMGKDTTLEKALFKGLTGSGENDLLTRIQMGDVQIVINTMTKGKEVERDGF QYKILATSGTANKLAETDIPAEVVKRIGGENDLLTRIQMGDVQIVINTMTKGKEVERDGF |
|------|---|
| 153. | MINRDNKKAITKKGMISNRLNKFSIRKYTVGTASILVGTTLIFGLGNQEAKAAENTSTEN AKQDDATTSDNKEVVSETENNSTIENNSTNPIKKETNIDSQPEAKKESTSSIGKQOMV TATTETKPQNIEKENVKPSTDKTATEDTSVILEEKKAPNNINDVTKKPSTSEPSTSEIQ TKPTTPQESTNIENSQPQPTPSKVDNQVTDATNPKEPVNVSKEELKKNPEKLKELVRNDS NTDHSTKPVATAPTSVAPKRVNAKMRFAVAQPAAVASNNVNDLIKVTKQTIKVGDGKDNV AAAHDGKDIEYDTEFTIDNKVKKGDTMTINYDKNVIPSDLITDKNDPIDITDPSGEVIAKG TFDKATKQITTTFTDYVDKYEDIKSRLITLYSYIDKKTVPNETSLNLTFATAGKETSQNVT VDYQDPMVHGDSNIQSIFTKLDEDKQTIEQQIYVNPLKKSATNTKVDIAGSQVDDYGNIK LGNGSTIIDQNTEIKVYKVNSDQQLPQSNRIYDFSQYEDVTSQFDNKKSFSNNVATLDFG DINSAYIIKVVSKYTPTSDGELDIAQGTSMRTTDKYGYYNYAGYSNFIVTSNDTGGGDGT VKPEEKLYKIGDYVWEDVDKDGVQGTDSKEKPMANVLVTLTYPDGTTKSVKTDANGHVEF GGLKDGETYTVKFETPTGYLFTKVNGTTDGEKDSNGSSVTVKINGKDDMSLDTGFYKEPK YNLGDYVWEDTNKDGIQDANEPGIKDVKVTLKDSTGKVIGTTTTTDASGKYKFTDLDNGNY TVEFETPAGYTPTVKNTTADDKDSNGLTTTGVIKDADMMTLDRGFYKTPKYSLGDYVWYD SNKDGKQDSTEKGIKDVTVTLQNEKGEVIGTTKTDENGKYRFDNLDSGKYKFTDLDNGNY TVEFETPAGSTDFNDADGGEVDVTITDHDDFTLDNGYFEEDTSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSD |
| 154. | MTHLLETFEMSIDHQEDGLVVISMPVTDKVKQPFGYLHGGASIALGETACSLGSANLIDT TKFIPLGLEMNANHIHSAKDGRVTATAEIIHRGKSTHVWDIKIKNDKEQLITVMRGTVAI KPLK |
| 155. | MEHTTMKITTIAKTSLALGLLITTGVITTTTQAANATTPSSTKVEAPQSTPPSTKIEAPQS KPNATTPPSTKVEAPQQTANATTPPSTKVTTPPSTNTPQEMQSTRSDTPQSPTTKQVPTE INPKFKDLRAYYTKPSLEFKNEIGIILKKWTTIRFMNVVPDYFIYKIALVGKDDKKYGEG VHRNVDVFVVLEENNYNLEKYSVGGITKSNSKKVDHKAGVRITKEDNKGTISHDVSEFKI TKEQISLKELDFKLRKQLIEKNNLYGNVGSGKIVIKMKNGGKYTFELHKKLQENRMADVI NSEQIKNIEVNLK |
| 156. | MKKQIISLGALAVASSLFTWDNKADAIVTKDYSGKSQVNAGSKNGTLIDSRYLNSALYYL EDYIIYAIGLITKKYEYGDNIYKEAKDRLLEKVLREDQYLLERKKSQYEDYKWYANYKKE NPRTDLKMANFHKYNLEELSMKEYNELODALKRALDDFHREDVKDIKDKNSDLKTFNAAEE DKATKEVYDLVSEIDTLVVSYYGDKDYGEHAKELRAKLDLILGDTDNPHKITNERIKKEM IDDLNSIIDDFFMETKQNRPKSITKYNPTTHNYKTNSDNKPNFDKLVEETKKAVKEADDS WKKKTVKKYGETETKSPVVKBEKKVEEPQAPKVDNQQEVKTTAGKABETTQPVAQPLVKI PQGTITGEIVKGPEYPTMENKTVQGEIVGPDFTLTMEQSGPSLSNNYTNPPLTNPILEGL EGSSSKLBIKPQGTESTLKGTQGESSDIEVKPQATETTEASQYGPRPOFNKTPKYVKYRD AGTGIREYNDGTFGYEARPRFNKPSETNAYNVTTHANGQVSYGARPTYKKPSETNAYNVT THANGQVSYGARPTONKPSKTNAYNVTTHANGQVSYGARPTQNKPSKTNAYNVTTHANGQ VSYGARPTYKKPSKTNAYNVTTHADGTATYGPRVTK |
| 157. | MKKLATVGSLIVTSTLVFSSMPFONAHADTTSMNVSNKQSONVONHRPYGGVVPQGMTQA QYTELEKALPQLSAGSNMQDYNMKLYDATQNIADKYNVIITTNVGVFKPHADMNGHAL PITKLGENFYQTNVDANGVNHGGSEMVQNKTGHMSQQGHMQQNTHMNQQPHMQQGHMQSSN HQMMSPKANMHSSNHQMNQSNKKVLPAAGESMTSSILTASIAALLLVSGLFLAFRRRSTNK |
| 158. | VLRSDFYMSYSIVRVSKVKSGTNTTGIQKHVQRENNNYENEDIDHSKTYLNYDLVNANKQ NFNNLIDEKLEQNYTGKRKLIKTDAIKHLDGLITSDNDFFDNQTPEDTKQFFBYAKEFLEQ EYGKDKILLYATVHMDEKTPHHYGVVPITDDGRLSAKEVVGNKKALTAFQDRFMEHVKQR GYDLERGQSRQVTNAKHEQISQYKQKTEYHKQEYERESQKTDHIKQKNDKLMQEYQKSLN TLKKPINVPYEQBTEKVGGLFSKEIQETGNVVISQKDFNEFQKQIKAAQDISEDYEYIKS GRALDDEDKEIRERDDLLINKAVERIENADDNFNQLYENAKPLKENIEIALKLLKILLKEL ERVLGRNTFAERVNKLTEDEPMA |

atgatgaaaaagttaaaagcgagtgaaattagacaaaaatatctagatttctttgttgaa aaaggacatatggttgaaccttctgcaccattagtgccaattgatgatgatacattatta tggattaattcaggtgtagcaacattaaagaaatattttgatgacgtgaaacacctaaa 159. yatattyytyaayyyetteesyaatoyaatotattotagytygagaaaatyaacgctatett tatggacaagatecggcagaagaaatytatecaggtygagaaaatyaacgctatett gaagtatggaaettagtatttagtyaatteaateataataaagateatagttacacacca ttacetaataaaaatattyatactgycatgygyettyageytatgyeetcaytttetcaa aaagcgacaacaaatgaaattaatgggaaagatgcatttaaattgtatagtatdgtatgt ttcccaattgaattaactgaagaaatagcagtgcaagcaggattgaaagttgatatgaca acattcgagtcagaaatgcaacaacaacgtgatcgtgcacgtcaagcacgtcaaaattct caatcaatgcaagttcaaagtgaagtattgaaaaatattacatctgcaagtacttttgt ggttatgatactgcgacagctcaaacaacacactagatacgataaggtattcaaaggtagaaga gtttcacaagttgaagcgggtgaaacagtatacttcatgttaacggaaacaccattttat gcaatcagtggtggacaagttgcgggatacaggtattgtttataatgacaattttgaaatt gctgttagtgagtaaccaaagcaccaaatggtcaaaacttgcataaaggagtagtacaa tttggccaagtaaatgttggggctacagtgtctgctgaagtgaaccaaaatgatcgacgt gacattcaaaagaaccatagtgcaacacatttattacatgcagggttgaaatcagtactg ggtgatcatgttaaccaagctggttcactagtagaagcagatcgtttaagttttgatttc tctcattttggtccaatgactaatgatgaaattgatcaagttgaacgcttagtaaatgaa gaaatttggaaaggtattgacgttaacattcaagaaatggatattgcttcagctaaagaa atgggcgcaatggcattattcggtgaaaaatatggtgatgttgtgcgtgtagtaatatg gcaccattttcaattgaattatgtggtggtattcatgtccgcaatacttctgaaattggc ttattcaaaatagtaagtgagtcaggtacaggagctggtgtgcgtcgtattgaagcatta acaggtaaagcagctttcttatatttagaagatattcaagagaaatttaatacgatgaaa tcacagctgaaagtgaaatctgatgatcaagtagtcgataagttaacacaattacaagat gaagaaaaagcattattaaaacaattagagcaacgtgacaaagaaatcacatcacttaaa atgggtaatattgaagatcaagttgaagaaatcaatggctataaagtattggttactgaa gtggatgtaccaaatgcgaaagcaattcgctcgacaatggacgattttaaatctaaacta gaaaatateteaaaateattaagetttattaaagattaeattaaaaateta MMKKLKASEIROKYLDFFVEKGHMVEPSAPLVPIDDDTLLWINSGVATLKKYFDGRETPK

160. KPRIVNSOKAIRTNDIENVGFTARHHTFFEMLGNFSIGDYFKQBAIEFAWEFL/TSDKWMG MEPDKLYVTIHPEDMEAYNIWHKDIGLEESRIIRIEGNFWDIGEGPSGPNTEIFYDRGEA MEPDKLYYT LIPEDMEAYNIWHKDIGLEESRIIRIEGNFWDIGEGPSGPNTELFYDRGEA
YGQDDPAEEMYPGGENERYLEVWNLVFSEFNHNKDHSYTPLPNKNIDTGMGLERMASVSQ
NVRTNYETDLFWPIMMEIEKVSGKQYLVMNEQDVAFKVIADHLRTIAFAISDGALPANEG
RGYVLRRLLRRAVRFSQTLGINEPFMYKLVDIVADIMEPYYPNVKEKADFIKRVIKSEEB
RFHETLEDGLAILNELIKKAKATTIBLINGKDAFKLYDTYGFPIELTEEIAVQAGLKVDMT
TFESEMQQQRDRARQARQNSQSMQVQSEVLKNITSASTFVGYDTATAQTTLTHLIYNGEE
VSQVEAGETVYFMLTETPFYAISGGQVADTGIVYNDNFEIAVSEVTKAPNGQNLHKGVVQ
FGQVNVGATVSAEVNQNDRRDIQKNHSATHLLHAALKSVLGDHVNQAGSLVEADRLRFDF
SHFGPMTNDEIDQVERLIVNEEIWKGIDVNIQEMDIASAKEMGAMALFGEKYGDRVRVNM SHIPGHIND AND APPSIELCGGIHVENTSEIGLFKIVSEGGTGAGVARIEALTGKAAFLYLEDIQEKFNTMK
SQLKVKSDDQVVDKLTQLQDEEKALLKQLEQRDKEITSLKMGNIEDQVEEINGYKVLVTE
VDVPNAKAIRSTMDDFKSKLQDTIIILASNVDDKVSMVATVPKSLTNNVKAGDLIKQMAP

161

IVGGKGGGRPDMAQGGGTQPENISKSLSFIKDYIKNL atgaatagtgagtttatatatggacgggtaacaaatttaggaggtaagattttgagttta ataaagaaaagaataaagatattegattataccattaggcggtgttggcgaaattgct aaaaatatgtatatcgttgaagtagacgatgaaatgtttatgttagatgctggacttatg tttccagaagacgaaatgctaggtattgatattgttataccagacatttcatacgtactt gaaaataaagataaattgaagggtatattccttacacacggacatgagcacgcgattggt gcagtgagttatgttttagaacaattagatgcaccagtatatggatctaaattgacaata gcgttaattaaagaaaatatgaaagcccgtaatattgataaaaaagttcgctactataca gttaataatgattcaattatgagattcaaaaacgtgaatattagtttctttaatacgaca cacagtattcctgatagtttaggtgtttgtattcacacttcatatggtgccattgtgtat acaggtgaatttaagtttgaccaaagtttacatggacattatgcaccagatattaaacgt attgcgaatacattaaatgagcttgtacgtgctggcgcacatattattccaaataacaaa aagattcatgcttcaagtcatggttgcatggaagaattaaaaatgatgattaatattattg aaacctgaatactttattcctgtacaaggtgaatttaaaatgcagatagcacatgcgaag gcagaagatggtatctttattgctgttgtaacgttagatcctaaaaattagacgtatagct gcgggacctgaaattcaatctcgtgggtttgtatatgtacgtgaaagtgaagacttatta cgtgaagcagaagagaaagtacgtgaaatagtagaggctggtttacaagaaaaacgcata gaatggtctgaaattaaacaaaatatgcgtgatcaaattagtaaactattattcgaaagt acaaaacgtcgtcctatgattattccagtaatttctgaaatt

| 162. | MNSEFIYGRVTNLGGKILSLIKKKNKDIRIIPLGGVGEIAKNMYIVEVDDEMFMLDAGLM FPEDEMLGIDIVIPDISYVLENKDKLKGIFLTHGHEHAIGAVSYVLBQLDAPVYGSKLTI ALIKENMKARNIDKKVRYYTVNNDSIMRFKNVMISFFNTTHSIPDSLGVCIHTSYGAIVY TGEFKFDQSLHGHYAPDIKRMAEIGEEGVFVLIBDSTEAEKPGYMPPENVIEHHMYDAFA KVRGRLIVSCYASMFIRIQQVLNIASKLNRKVSFLGRSLESSFNIARKMGYFDIPKDLLI PITEVDNYPKNEVIIIATGMQGEPVEALSQMAQHKHKIMNIEEGDSVFLATTASANMEVI IANTLNELVRAGAHTIPNNKKIHASSHGCMEELKMMINIMKPEYFIPVGEFKMQIAHAK LAAEAGVAPEKIFLVEKGDVINYNGKDMILNEKVMSGNILIDGIGIGDVGNIVLRDRHLL AEDGIFIAVVTLDPKNRRIAAGPEIQSRGFVYVRESEDLLREAEEKVREIVEAGLQEKRI EWSEIKQNMRDQISKLLFESTRRPMIIPVISEI |
|------|--|
| 163. | atggaaataacaatgcctaagttaggtgagagtgttcatgaaggcaccattgaacaatgg ttagtttctgttggtgatcatattgatgaatatagaaccattatgtgaagttattacagat aaagtgacagctgaagtcccttccacgatatcaggaacaattatcagaaattttagttgaa gcggggcagacagtagctattgatacaattatctgtaaaattgaaactgctgatgaaaag acaaatgaaacaactgaaggaacagcaaaagtggatgagcatactcagaaatctact aaaaaggtagtgcacagtggaacagacatctactgctaaaaaaaa |
| 164. | MEITMPKLGESVHEGTIEQWLVSVGDHIDEYEPLCEVITDKVTAEVPSTISGTITEILVE AGQTVAIDTIICKIETADEKTNETTEEIQAKVDEHTOKSTKKASATVEQTSTAKKNOOPRN NGRFSPVUFKLASEHDIDLSQVVGSGFEGRVTKKDIMSVIENGGTTAQSDKQVQTKSTSV DTSSNQSSEDNSEDNSTIEVNGVRKAIAQNMVNSVTEIPHAWMMIEVDATNLVKTRNHYKN SFKNKEGYNLTFFAFFVKAVADALKAYPLLNSSWQGNEIVLHKDINISIAVADENKLYVP VIKHADEKSIKGIAREINTLATKARNKQLTAEDMQGGTFTVNNTGTFGSVSSMGIINHPQ AAILQVESIVKKPVVINDMIAIRNMVNLCISIDHRILDGLQTGKFMNHIKQRIEQYTLEN TNIY |
| 165. | |
| 166. | |
| 167. | atggaggacaacatgatttatgcaggtattttagcaggaggtattgttcgagaatgggg aacgtgccattaccaaaacaatttttagatattgataataaaccgattttaatccataca attgagaagttcattttagtgagtgaatttaatgagattattatcgcaacgccagcacg tggatttcccatacacaggatattttaaaaaaaatataacattacagatcaacgttcaaa gtagttcccatacacaggatattttaaaaaaaatatacacattacagatcaacgttcaaa gtagttgcaggtggtacggatcgaaatgatgatgtattgtaactcatgatgccgtaagaccattt ttaactcaacgtattataaaagagaacattgaagtagatgacgcaaaatatggtgcagtagat acagtcattgaagcaattgatacgattgtaatgtctaaagataaacagaacatta ttacaagatagaacaattgatacaaggccaaacaccacaatcatttaatataaatta ttacaagatagtatcgcgccttaaagtagtgaacaaaaaagaaactttaacagatgaagt aaaatcattgtcgaacttggacatgcagttaaattggtacgtggagaactatacacatt aaagtgacaacaccgtatgatttaaaagtagcaaattgccattatcaaggtgatattgc gatgat |
| 168. | MEDNMIYAGILAGGIGSRMGNVPLPKQFLDIDNKPILIHTIEKFILVSEFNEIIIATPAQ WISHTQDILKKYNITDQRVKVVAGGTDRNETIMNIIDHIRNVNGINNDDVIVTHDAVRPF LTQRIIKENIEVAAKYGAVDTVIEAIDTIVMSKDKQNIHSIPVRNEMYQGQTPQSFNIKI LQDSYRALSSEQKEILSDACKIIVESGHAVKLVRGELYNIKVTTPYDLKVANAIIQGDIA DD |

| 169. | atgataatatatggtgatagacagttaatggagggaacgaaatgaaagctttatactt aaaacagtgtatggctcgttttgctttttatagggatatacgaacgcagcaggagcagcatcaacaacgataggcaacgacaacgacaacgacaacgacaacgacaacgacaaca | |
|------|--|---|
| 170. | MITYWCMTVNGGNEMKALLKTSVWLVLLFSVMGLWQVSNAAEQHTPMKAHAVTTIDKAT TDKQQVPPTKEAAHHSGKEAATNVSASAQGTADDTNSKVTSNAPSNKPSTVVSTKVNETR DVDTQQASTOKPTHTATFKLSNAKTASLSPRMFAANAPQTTTHKLHTNDLHGRLAEEKG RVIGMAKLKTVKEQEKPDLMLDAGDAPGGLPLSNOSKGEEMKAMMAVGYDAMAVGNHEF DFGYDQLKKLEGMLDFPMLSTNVYKDGKRAFKPSTIVTKNGIRYGIIGVTTPETKTKTRP EGIKGVEPRDPLQSVTAEMMRIYKDVDTFVVISHLGIDPSTQETTWGDYLVKQLSQNPQL KKRITVIDGHSHTVLQNGQIYNNDALAQTGTALANIGKITFNYRNGEVSNIKPSLINVKD VENVTPMKALAEQINQADQTFRAQTAEVIIPNNTIDFKGERDDVRTRETNLGNAIADAME AYGVKNFSKKTDFAVTNGGGTRASIAKGKVTRYDLISVLPFGNTIAQIDVKGSDWTAFE HSLGAPTTQKDGKTVLTANGGLHHISDSIRVYYDINKPSGKRINAAQIUKKTGKFENID LKRVYHVTMNDFTASGGDGYSMFGGPREBGISLDQVLASYLKTANLAKYDTTEPQRMLLG KPAVSEQPAKGQQGSKGSKSGKDTQPIGDDKVMDPAKKPAFGKVVLLLAHRGTVSSGTEG SGRTIEGATVSSKSGKQLARMSVPKGSAHEKQLPKTGTNQSSSPEAMFVLLAGIGLIATV | |
| 171. | atgcaagagtaccaaaaatcgttaaatacgcttaaaaagcctataaatgttccgtatgag caagaaactgaaaaagtaggtggttatttagcaaagaaataccaagaaactggaaatgtt gtaataagccaaaaagattcaatgaatttcagaaaacagataaaagctgctcaagatatt tcggaagattacgagtatataaaagtctggtagagccttagatgataaagataaggaaata cgagagaaagatgatttattaaaagcagttgagcgtattgaaaacgcagacgataat tttaaccaactttacgaaaatgcaaagccacttaaaggaatatagaaatagcgttaaag cttttaaaaatcttactaaaagagttagaacgagttttaggaagaaatacctttgcggaa agagttaataagttaacagaagatgaaccaaaactaaatggtttagcaggaaacttagat aaaaaaatgaatccagaattatattcagaacaggaacagcaacaagaacaacaaaagaat caaaaacgagatagaggtatgcactta | |
| 172. | MQEYQKSLNTLKKPINVPYEQETEKVGGLFSKEIQETGNVVISQKDFNEFQKQIKAAQDI SEDYEYIKSGRALDDKDKEIREKDDLLNKAVERIENADDNFNQLYENAKPLKENIEIALK LLKILLKELERVLGRNTFAERVNKLTEDEPKLNGLAGNLDKKMNPELYSEQEQQQEQQKN QKRDRGMHL | |
| 173. | atgaagatgataaacaaattaatcgttccggtaacagctagtgctttattattaggcgct tgtggcgctagtgccacagactctaaagaaaatacattaatttcttctaaagctggagac gtaacagttgcagatacaatgaaaaaatacgtaaagatcaaattgcagaac gtaacagttgcagatacaatgaaaaaatcggtaaagatcaaattgcaaattgcatcatt actgaaatgttaaataaaattttagctgataaatataaaaataaagttaatgataagag attgacgaacaaattgaaaaaattgcaaaagcaatacaggcggtaaaagataaatttgaaaag gcccttcaacagcaaggtttaacagccgataaatataaagaaaatttacgtactgctgct tatcataaagaattactatcagataaaattaaaatcctgattctgaaattaaagaaga agcaagaaagcttcacacattttaattaaagttaaatctaagaaagcgacaaagaaggc ttagatgataaagagggaaacaaaaagctgaagaaattcaaagaaggtctaaaagaagcgcaaagaaattggtgaaatttggtgaaatcgctaaaaagaagcagacaagaagattttaaagaagatcaatggaaatttggtgaaataggttatgttctaaaggacaaactaggtgaaaattggataatggttaaggtaattggtgaagatacatt attaaagctgataaaccaacagactttaacagtgaaaacaaagcctgaaagaaa | · |
| 174. | MKMINKLIVPVTASALLLGACGASATDSKENTLISSKAGDVTVADTMKKIGKDQIANASF TEMLNKILADKYKNKVNDKKIDEQIEKMQKQYGGKDKFEKALQQQGITÄDKYKENLRTAA YHKELLSDKIKISDSEIKEDSKKASHILIKVKSKKSDKEGLDDKEAKQKAEEIQKEVSKD PSKFGEIAKKESMOTGSAKKOGELGYVLKGQTDKDFEKALFKLKDGEVSEVVKSSFGYHI IKADKPTDFNSEKQSLKEKLVDQKVQKNPKLLTDAYKDLLKEYDVDFKDRDIKSVVEDKI LNPEKLKQGGAQGGQSGMSQ | |

| 176. LILLI-LACSINSININISERKUDANINGKOGETONAAA SLIDVIKKLASERKERKRALIKE NYKOSKALKEN ESKAP VIVYKAKANIKUUDALKINKAHIKEN SINTAKUNAUTUKULANI YKOSKALKEN ESKAP VIVYKAKANIKUUDALKINKAHIKEN SINTAKUNAUTUKULANI LOOPATA LIKEVITYAA 177. LUGGATE CARLAGACH ERABAGE AL TALE UBABA IL EAGGI DETAGACHBARAKANI LEPITAA 178. LUGGATE CARLAGACH ERABAGE AL TALE UBABA IL EAGGI DETAGACHBARAKANI LEPITAA 178. LUGGATE CARLAGACH ERABAGE AL TALE UBABA IL EAGGI DETAGACHBARAKANI LEPITAA 178. LUGGATE CARLAGACH ERABAGE AL TALE UBABA IL EAGGI DETAGACHBARAKANI LUGGATAGACHBAR | 175. | atgcttttagtattagctggttgctctaattctaacgataataatgaaagtaaaaaagat gacgcagacaatggtaagaaacaagagattcaagttgcagcggcagcagtttaacagat gtaaccaagaaattagcttcagaatttaaaaaagagcataaaaatgctgatattaaattt aactatggtggatcaggggcattaagaaacaaattgaatcaggcgcacctgttgacgta tttatgtctgcaaataactaaagatgtagatgcattaaaagacaagaataaagcgcatgat acatataaatatgcgaaaaatagtctagtattaattggtgataaagatcaaattacact tcagtaaaagacttaaaagacaatgataaattagcattaggtgaagtgaaagtgaaaactgacca gcaggaaaatatgcgaaacagtattagatacaataacttattataaagaagtgaaagt aaaatcgtttatgctaaagatgtaaaatagatataaattagtgtgaaaagggtaatgcg aaacaaggttttggtgtaaaaactgacttatataaaacaaataaaattagtgaaaagtggaaatcgaaagagtgaaactgacatcaaaagaagtagaacttaagaagcaatcacaaaaataaaaaattggctacaatca gatagtaaattagcaaaagagtggaagccaatcacaaaacagaagctggtgctacatca gatagtaaattagcaaaagagtggaatggaa |
|--|------|--|
| ttggcatacachtcaagtgatattattgaattatacagtgtgtatacagtgt ttaadtattacagtgatattaggtattatattcoagtgatataagtgtaaaatt ttaadtattacagtgaagtttgaaaattacaaaagatttaattaccagt gttaaaaacagcaagcttagaaaattacaaaagatttaatacactattgaaaatt tttgatatcoctaaaataagatattatataattacacaattattaattacagt tttgatattgctaaattaaaagaagcattataatacagcagttttaatacaattaatt | 176. | NYGGSGALKQIESGAPUDVFMSANTKDVDALKDKRKAHDITKYARNSLVBIESGAPUT SVKDLKDNDKLALGEVKTVPAGKYAKQYLDNNNLFKEVESKIVYAKDVKQVLDNYVEKGNA KQGFVYKTDLYKQNKKIDTVKVIKEVELKKPITYEAGATSDSKLAKEWMEFLKSDKAKEI LEEYHFAA |
| 178. MATTYLKDILETGYNKRILHYDEIGLIJPOKNOKYNYKYKOODLEKLOKILLINSID PIJAHKYVISTNNOKRILSEDISTAKUKISIDISTAHRYOEPIKKISLELDISTINKT LOSGYDKERSIKKGETKANOSFIRKOSIGSDIRKKITTIFAKRYNEHSLELDISTINKT LOSGYDKERSIKKGETKANOSFIRKOSIGSDIRKKITTIFAKRYNEHSLELDISTINKT LUYENKARMYITADDIBETTACLIAKTYEDUTERFOURTSINNOKLASTISTANYTISTAW NKSONP 179. atggcaaaataaaaggaatgaagcattagttaaaggattacaaggattagttacgtaggattaggaagtaggaagtaggaagtaggaagtaggaagtaggaagtaggaagtaggaagtaggaagtaggaagtaggaagtaggaagtaggaagtaggaagtaggaagtaggaagtaggaagtaggaagtaggaagattaggaagtagaag | 177. | ttggcatacacatacactttaaaagatattattgaaattacaggtgtaactaaaagaact ttacattattacgatgaaataggattattagttccagataaaaaatgatactacgc gtttataaacagcaagacttatagaaaaattacaaaagattttaatacactagcagatattattagat tttgatatcgctaaaataaaa |
| cacttgtategtattccaggagactcaatcgacgagtagtcgatagtttagtagtagtagtagtagtagtagtagtagtag | 178. | MAYTYTLKDIIEITGVTKRTLHYYDEIGLLVPDKNDKNYRVYKQQDLEKLQKILLIKSFD FDIAKIKQYISYDNEQLEKLLSEQISKLDKKISDLQLITRSVCEFIKGLSLIDTSILNKT LQSQYDKEASIKYGHTKAYQSFIRRKDSLQSQDIRHKLTTIFNKFNHMSLSHYPIQDCSD LVFEWKAFMNTIADFDDETLCCIAKTYEDDTRFKDYFNSYDNQNLASYISEAVNYFLSNV NKSDDF |
| 181. gtagtagtttagggettgeaacgcac 182. caccatcatagaacatacaattgetage 183. ctgatactggacaacatagaga 184. aagtaacgttatetttegaatggt 185. attetggacatcaagtatatacaagac 186. tggettaggtgttggtgtagge 187. ataatgcaactacaactcagec 188. ttgategttgatgtattttgattagat 189. ctacaataactacagecgttaca 190. gtgaatgaagttataaccagcag | | cacttgtatggtattccaggagactcaatcgacgcagtagtcgatagtttacgtaagttg agagatcaatttaattatagtacgtcatgaagagtagacgctggyctgct ggttacacaaaatttaactggtaaaatcggtgtgcattaagtataggccctggttta attcatttattaataggtatgtatgtatgcaaaatggataatgtaccgcaattaatt |
| 183. ctgatactggacaacatagaga 184. aagtaacgttatctttcgaatggt 185. atttctggcactcaagtatatcaagac 186. tggcttaggtgttggtgtaggc 187. ataatgcaactcaagcc 188. ttgategttgatgtattttgattagat 189. ctacaataactacagccgttaca 190. gtgaatgaagttataaccagcag | | gtagtagtttagggcttgcaacgcac |
| 184. aagtaacgttatctttcgaatggt 185. atttctggcactcaagtatatcaagac 186. tggcttaggtgttggtgtaggc 187. ataatgcaactacaactcagcc 188. ttgatcgttgatgtattttgattagat 189. ctacaataactacagccgttaca 190. gtgaatgaagttataccagcag | | |
| 186. tggcttaggtgttggtgtaggc 187. ataatgcaactcagcc 188. ttgatcgttgatgtattttgattagat 189. ctacaataactacagccgttaca 190. gtgaatgaagttataaccagcag | | |
| 187. ataatgcaactacaactcagcc 188. ttgatcgttgatgtattttgattagat 189. ctacaataactacagccgttaca 190. gtgaatgaagttataaccagcag | | |
| 188. ttgatcgttgatgtattttgattagat 189. ctacaataactacagccgttaca 190. gtgaatgaagttataaccagcag | | |
| 189. ctacaataactacagccgttaca 190. gtgaatgaagttataaccagcag | | |
| 190. gtgaatgaagttataaccagcag | | |
| | | |
| LULE COMMONICALLING LUCKICOM | | |
| 192. agcattttgatgtgttgctgttgtgtt | | |

| 193. | gaatccccaagcacctaaac |
|------|--|
| 194. | gtaaacgttgatcaagcacact |
| 195. | tttgcaataacagcaacatctggtgcag |
| 196. | gaaacttctgaagctggaattgtacgg |
| 197. | atgagaaaaactaaaattgtatgtacaattggaccagcttcagaatcagaagaaatgatt |
| 40 | gagaaattaatgaatgctgctgcacgattaaacttttcacatgguaguuu. |
| | waananataaanatanaattnatacaattcotaaagtagctadaagattagacadacc |
| | gtagcaattttattagatacaaaaggtccagaaattcgtacgcataatatgaaagacggt |
| | atcattgaacttgaacgtggcaacgaagttattgttagcatgaatga |
| | cctgaaaagttctcagtaacatatgaaaacttaattaacgatgttcaagtaggttcatac |
| | atttacttgattgatgatgattaattgaattacaagttaaagatattgaccatgctaaaaaa gaagttaaatgtgatattttaaactctggtgagcttaaaaaacaaaaaaggtgttaactta |
| | gaagttaaatgtgatattttaactetggtgagttaaaaaaaatataddggtgatatcogttc cotggcgtaagagtaagtttacctggtattacagaaaaagatgctgaagatatcogtttc |
| | ggtattaaagaaatgttgacttcattgcagcaagtttcgtacgtcgtcctagtgatgtt |
| | Ftagaaattcotoaaattttagaagaacaaaaagctaacatttcagtattccctadddu |
| | gaaaagaagaagaagatattgataatattgcggaaattcttgaagtgtctgatggtttaatg |
| | the acceptant acceptant of the acceptance ac |
| | catttastcacaatctaccaattacctaaaccacttattacaccactacacacaatgtta |
| | l gattotatocaacotaacccacotoctacacotocagaagctagtgacottgccadugca |
| | =totatgatggtacagatgcagtaatgttatctggtgaaactgctgctggtttatatcct |
| | l magaaggetgttaaaaggaatgagaaatattggtgtatcaggtgaaggaggcgaagauudg |
| | aaaaagttattgtcagatcgtactaaattagttgaaacttcattagtgaatgctatcggt |
| | atttcggttgcacatacagctttaaacttaaatgttaaagcaattgtagctgctactgaa |
| | agtggttcaacggcacgtactatctccaaatatcgtccacattcagacattattgcggtg |
| | actccaagtgaagaaactgcacgtcaatgttcaattgtttggggagttcaacctgtagtt |
| | aaaaaaggacgtaagagtacagatgcattgttaaacaatgcagttgcaacagctgttgaa actggtagagtatctaatggtgatttaatcattattactgctggtgtaccaactggtgaa |
| | actggtagagtatctaatggtgatttaatcattattactgctggtgtactaattgctaattgctaat |
| | actggaactactaatatgatgaaaatccacctagttygtgatgaactgctaatygttaat ggtattggacgtggatcagttgttggtactacgttagttgctgaaactgttaaaagattta |
| | ggtattggacgtggattagttgttagtactacgttagttgttgataactgatgataacgtttgta gaaggtaaaggttatcggatgaaacgtttgta |
| | octtatotagaaaaactttagacttaattacagaagaaaatggtattacatcaccaagt |
| 5 | ccasttettecttacaaaaaggtattccaacagttgtaggtgtagaaaaagctgttaaa |
| | aacataagcaataacatgttagttacgattgatgctgctcaaggtaaaatctttgaagga |
| | tatgcaacgtacta |
| 198. | atgcaattcgataatattgacagtgctttaatggctttaaaaaatggagaaccaattatt |
| 190. | gtagtagatgatgatgagaatcgtgaaaatgaaggtgatttagtagcggttactgaatggatg |
| | l aaccataataccattaattttatggggaaagaaggaaggggttaatatggggaccagtg |
| | tctaaacatattccacaacctttccattccatacaaatccttcatgataactccgacatc |
| | tttggtacgcaatttacagtgagtattgatcatgtagatacaacaacaggaattagtgct |
| | tatgaacgtacattgactgccaaaaagctcattgatcctagtagtgaagctaaagatttt |
| | aatcgtcctggtcatttatttccattagtagcacaagataaaggcgtattagctagaaat |
| | ggacacacagaagcggctgttgatttagctaaacttactggtgccaagcccgctggtgtc |
| | atttgtgagattatgaatgatgacggcacgatggcgaaaggacaagatttacaaaagttt |
| | aaagaaaaacatcaattaaagatgattacgattgatgatttaattgaatatcgtaaaaaa |
| | ttagaaccagaaattgaatttaaggcaaaagtgaaaatgcctacagatttcggaacattt |
| | gatatgtatggttttaaagcgacatacacagatgaagagatagttgtactgacaaaaggt gcaattcgacaacatgaaaatgtacgcttacattctgcgtgccttacaggcgatattttc |
| | catagtcaacgttgtgattgtggtgctcaacttgaatcgtctatgaagtatatcaatgaa |
| | l catgotggcatgattatttatctacctcaagaaggtcgtggcataggattgttaaacaaa |
| | ttacgcgcatatgaattaattgagcaaggatatgatacagtaactgcaaatttagcatta |
| | ggttttgatgaagatttgcgagattatcatattgctgcacagattttaaaatattttaac |
| | l arcgaacatatcaatttattaagtaataatccaagtaaatttgagggattaaaacaatat |
| | qqcattqatattgcagaaagaattgaagttatcgtaccagaaacggtacataatcatgat |
| | tatatggaaacgaaaaaataaaaatgggtcatttaata |
| 199. | atgaaaatgaaaaaattagtcaaatcagttgcttcatcaattgcactgcttttgcta |
| | tcgaatacagttgatgcagctcaacatatcacacctgtaagcgagaaaaaagtagatgac |
| | aaaatcactttatacaaaacaacagcaacatctgataatgataaattgaatatttctcaa |
| | latettaacgttaatttaatttaaggataaaagttatgacaaagatacgttagtacttaag |
| | gcagccggaaacattaattcaggttataaaaaagcctaatccaaaagattacaattactca |
| | cagttttattggggcggtaagtataatgtttcggttagttcagaatcaaatgatgctgta |
| | aatgttgttgactatgcacctaaaaatcaaaatgaagaattccaagttcaacaaaca |
| | ggttattcttatggcggagatattaatatatctaatggcttatcaggtggattaaatgga tcaaaatcattttcagaaacgataaattataaacaagaaagttacagaactacgattgat |
| | agaaaacaaatcataaatcaattagctggggtgttgaggcgcacaaaattatgaataat |
| | ggttggggaccatatggtagagatagttatgacccaacatatggtaatgaactgtttta |
| | grantagagagagtagttgaaatgctggtgaaaatttcttgccaacacatcaaatgcct |
| | trafforcorofogtaactttaacccagaatttataagcgtactttctcataaacaaaat |
| | catacagagatctagagtcagagtagcttaccagagagag |
| | l caatggaatggactacactgggttggtaataactacaaaaatcaaaatacagtaacgttt |
| | acatctacttatgaagttgactggcaaaaccatactgttaaattaatcggtacggattct |
| | aaagaaactaatcctggagta |
| 200. | Atgaagaaaaagcgttactaccattatttttaggtattatggtctttttggctggttgt |
| | Gactattctaaacctgaaaaacgtagtgggtttttctacaatacattcgtagatccaatg |
| | Aaaaatotattggattgggaaataacttattaaacgacaattatggtttagctatt |
| | Attatecttgtattggtaattegtattatttattaecatteatgttgteaaaetataaa |
| | Aatagtcatatgatgcgtcaaaaaatgaaagttgcaaagccagaagttgaaaaaattcaa |
| | Gaaaaagtgaaacgtgcgcgtacacaagaagaaaaaatggctgcaaaccaagaattaatg |
| | Caagtatataaaaagtatgacatgaacccgattaagagtatgttgggttgtttaccaatg |
| | Ctaatccaattaccaatcatcatgggattatactttgtacttaaagaccaacttgtagat |
| | Ggtttgtttaaatatccacacttcttatggttcgatttaggacgtcctgatatttggatt Acaattattgccggtgttttatactttatccaagcatatgtatcaagtaaaacgatgcca |
| | Acaattattgccggtgttttatactttatccaagcatatgtatcaagtaaaacgatgcaa Gacgaacaacgtcaaatgggttacatgatgatggtcatttcaccaattatgattatctgg |
| | Atttcattaagctcagcatcagcacttggtttgtactggtcagtca |
| | Gtagttcaaacacactttgcgaacatttattatgaaaaagtcgctaaaaaagaagtacaa |
| | Cctttcattgaagcgtatgaaagagcacaacggcggcagcaataaaaaaaggcaaaaaa |
| | CCLLECALEGAAGCGLALGAAAGAGAGCACAACGGCGGCGGCGGCGGCGGCGGCGGCG |

ccagataaatctttaaaattatcatataaagttaatgttgcgaatattgatdatdctaaa aatattgatttaatgaaaaattaacatategtaattgattgatgttaattaataat gcgcaaccagaagttacactaactgcagatccattttcagtagcggttgaaatgaacaa gatgcgttgcaacaacaagtaaactcacaagtgataatagtcattacacaacagcatca attgcagaatacaataaacttaaacaacaagcagtaattatttaaatgaagatgcgaat catgttaaaactgcaaatcgtgcatctcaaggggatattgatgattagtaactaaagttcaagata caagctgcattaattgataatcaagcagcaattgctgaattagatgaattacaagatcaagat caaggtgtcacaactgaaaaagataatggtatcgcagtgttagaacaagatgtgattaca ccaacagttaaacctcaagcgaaacaagatattatccaagcagttacaactcgtaaacaa caaattaaaaagtcaaatgcatcattacaagatgaaaaagatgtagcaaatgataaaatt ggtaaaattgaaacaaaggcaattaaagatattgatgcagcaacaacaaatgcacaagta yg taaaattyaaacaaayycaattaaayatattyatycaycaacaacaacaatycataayta gaayccattaaaacaaaaycaatcaatgatattaatcaacttacacttyacacaayot aaaycaycayctettyaayaatttyacyaayttytteaaycacaaattyatcaaycacct gccattacacctgatgcaaatgtaaaccagcagcaaaacaagcaattgcagataaagta caagctcaagaaacagcaattgatggaaataacggctcaacaactgaagaaaaagcagct gctaaacaacaagttcaaactgaaaaaaacaacagctgatgccgcaatagatgcagcacat acaaatgoggaagttgaagoggotaaaaaagoagoaattgotaaaattgaagogattcag ccagcaacaacaactaaagattaatgogaaagaagcaattgotacgaaagogaatgaacgt aaacagcaatcgotcaaacgcaagacattactgotgaagaaattgcagoggotaatgog gacgtagataatgctgtgacacaagcaaatagcaacattgaagctgctaatagtcaaaat gatgtagaccaagcgaaaacgacaggtgaaaatagtattgatcaagtaacaccaacagtt aataaaaaagcaactgcacgtaatgaaatcacagcaattttaaataacaaattgcaagag gaagctaaagcaaatgcagaagcagcgattaatgcggtaacaccaaaagttgtgaagaaa dadduguytuguadaguugugdaacudadagaagaacugatadadadacuggg gotacaactgaagagaaaaatgcagcaaaagatttagttttaaaagctaaagaaaaagcg tatcaagatatotttaaatgcacaaacaactaatgatgttacgcaaattaaagataaagca gtgctgatattcaaggtattactgcagatacaacaattaaagatgttgcgaaagtaa ttagcaacaaaagcaaacgaacaaaaagcgcttattgcacaaactgcagatgcgactact gaagaaaaagaacaagcaaatcaacaagtagagcgcacaattaacacaaggtaatcaaaat attgaaaatgcacagtcaatcgatgatgtaaacactgcaaaagataatgcaattcaagca ggtaacgatattggaccagttagagcagcatatgaagaaggtttaaataatattaatgca gcaactactactaggtgatgtaactactgctaaagatacagcagtacaaaaagttcaacaa cttcatgcaaatcctgttaagaaaccagcaggtaaaaaagaattagatcaagctgcagct attgatgagtacaaaaaaagatgctttagctaaaattgaagatgcatataatgctaaagta aacgaagcggataactctaacgcatcgacttcaagtgaaattgctgaagcgaaacaaaaa cttgctgaattaaaacaaactgcggatcaaaatgttaatcaagctacttctaaagatgac attgaagttcaaattcataatgacttagataatattaacgattacacaattccaacaggt aaaaaagaatcagctacaacagatttatatgcttatgcagatcagaagaaaaataatat tcagctgacactaatgcaacacaagatgaaaagcaacaagcaattaagcaagttgaccaa aatgttcaaactgcattagaaagcattaataatggtgtgggataatggtgacgttgatgat gcattaacacaaggtaaagcagcaattgatgctattcaagtagatgctactgttaaacct aaagcgaaccaagctattgaagttaaagcagaagatacgaaagaatctattgatcaaagt

| 202. | atgaaactaaaatcatttgttactgccactttagcattgggattattatcaacggtcgga gctgcattaccgagtcacgaagcatctgcagatagtaataacggctataaagaaatgact gtggatggttatcacacctgttccttacacaattcagtagatggtattactgcattacat cgaacttactttatcttcccagaaaataaaaatgttctttatcaagaaaattgacagtaaa gtaaaaaatgaattagcttctcaacgtggtgttacaacagaaaaaattaataatgcccaa acagcaacttatacgcttactttgaatgatggtaataaaaagtagtgaatctaaagaaa aatgacgacgctaaaaattcaattgatccaagtacaatcaaacagatacaaattgtagtt aaa |
|------|--|
| 203. | atggctattaaaaagtataagccaataacaaatggtcgtcgtaatatgacttcgttagat ttcgcagaaaatcacagaaaactacacctgaaaagtcattattaaaaccgctaccgaaaaaa gcgggacgtaacaaccaaggtaaattgactgtaagacaccatggtggtggacacaaacgt caataccgtgttatcgatttcaaacgtaacaaagatggtattcaatgcaaaagttgatet attcaatatgatccaaaccgctcagcaaacatcgctttagttgtatatgcagacggtgaa aaacgatatatcattgctcctaaaggattagaagtaggtcaaatcgttgaagtggtget gaagctgacatcaaagttggtaacgcattaccattacaaaacattccagttgtaaggtgcaa gtacacaacatcgagcttaaacctggtaaaggtggacaaatcgcttgttcagctggtgca agtgctcaagtacttggtaaaggaaggtaaatcgtattaatcagattaagatctggtgaa gttcgtatgatcttatctactactgcgctgctacaatcggtcaagttagtaacgtagtgaa gttcgtatgatcttatctactactgcgctgctacaatcggtcaagttggtgacaccacacac gaattagttaacgttggtaaagccggacgttcaagatggaaaggtatccgtccaacagtt cgtggttctgtaatgaaccctaacggacaaccacacggtggtggtgaaggacgtgctcct atcggtagaccatctccaatgtcaccatgggtaaaccacacctggtcaagaacaccccccacggtgttaagaaaaacccgt cgtggtaaaaaactcatcaatgcacaaacttatcgttcgt |
| 204 | atgttagtaatacgtttaaccatttgataattattattattgtcttaattgcagca ataccgattgtactgtttttactatgtttaactgttttaaatggaaggtatttatgca gctattacaacacttgttgtaacattactaattgcaataccatttttcaaattgccagtt ggatacgctctgggcagtagtgcgaaggttcttccaaggtatcattcggacagtt ggatacgctctgggcagtattgttaacaaaattactgttgaatccggtatggcaa atcgttatgatggcagtattgtatacaaaattactgttgaatctggacaatttttaaca attcaagatagtattacaaaatattcacaagaccaacgtattcaagttttactttgga tttgcattcaacgcatttttagaaggtgcagcaggagtattggtgaccaattggaatttgt gcacttttattaacacaattaggatttaatccattaaaagctgcgatgtttagtttagtc gcaaatgcagcgtctggtgcttttggtgcgattggtatccctgtaggtgttgtagaaacg ttgaaattacctggagatgtttcagtataggtgtttctcaatcagcaactttaacattg gcaattacataaatttcattattcattattattattgatggtttagagg gtaaaggaacattaccagcaattttagtagtttcaatcacttactcaagga ttattaacagtattcagtggacctgaattagcagtattattccaccgttattaacaatg ttagcattagcagtattttctaaaaaattccaaccaaaacacatttatcgtgttaataaa gatgaagaaaattgaacctgcaaaagcaattctgcaaaagcagtattatcatggtttaaaaa gatgaagaaaattgaacctgcaaaagcaattctgcaaaagcagtattatcatggatgg |
| 205. | atgottaaaaataaaatattaactacaactttatotgtgagottacttgococtottgoc aatocgttattatagaaatgotaaagotgotaacggatactgagacatcggtaaaggaago gatatagaaattatcaaaggacaggaagataaaacaagtaataaatggggogtgactoaa aatattcaatttgattttgtaaaggataaaaaatataacaagatgotttgatattaaag atgoaaggattcattagototagaacaacaattacaactataaaatagataatatagtt aaagotatgogaattocaatataatattggtttaaaaacaaagatagataaatatgtt tottaattaattatttacotaaaaataaaattgaatotacaacgggagtoagatatta ggatacaatatoggtggtaatttocaataagococatoactggtggtaatggatcattt aactattotaaatoggtggtaatttocaataagococatoactggtggtaatggatcattt aactattotaaatoggtggtaatttocaatcagococatoactcggtggtaatggatcattt aactattotaaatggattagotatacaacacaaaaatatgtaaaggaagtagaacaacaa aactoaaaagtgttttatggggggtcaaagogaattcattcgccactgaatcaggtcaa aaatoagocttggatagogatttatttgtaggctacaaacotoatagtaaaggatcotaga gattatttogtbocagacagtgagttaccactottgtacaaagtggatttaacocottoa ttatcgccacagtatotoatgaaaaaggtcaaaggatacaagcgaatttgaaattact tacggaagaaacatggatgccataagccattaaaaggtcaacagcattatggcaacagt tattagacggacataggtccatagcaatcaaggtgaaagaactataotggaaatac gaggtcaattggaagactcatgaaatcaaggtgaaagaacagaat |
| 206. | atgaaaatgaataaattagtcaaatcatccgttgctacatctatggcattattattactt tctggtactgctaatgctgaaggtaaaataacacagtcagcgtaaaaataatcgatgac aaagttactttatacaaaacacaggcacaggcagtcaggtaaaatttaaaatttcacag atttaacatttaatttcatcaaagataaaagttatgataaaatttaaaatttcacag attttaacatttaatttcatcaaagataaaagttatgataaagatacttagacatttcaa gctactgggaatattaactcaggctttgtgaaacctaatcctaatgactatgactttca aaattatattggggagctaaatacaaatgaatgatacacaatcaaatgattcaagta aacgtcgttgattatgcaccaaaaaatcaaaatgaaggtttcaagttcaagattcaagta gcgtatacatttggtgggacattagtatctctaatggtttatctggtggacttaatgga aatacagctttttctgaaacaattaattataaacaagaaagttacagaacaacattaagt ggcaacacaaaattataaaaatgtggctggggagttgaagcacataaaattatgaataa ggttggggaccttatggaagagatagcttccaccaacatatggtaatgaactcttctta gctggcagacaaagcagtgcatacgctggccaaaacttcataggcaacacaaatgca ttatatctagaagtaacttcaatccagaatttttaagcgtactacacaaatgca ttatatctagaagtaacttcaatccagaatttttaagcgtactacacaaatgcca tcgttggaatggcttctactgggcaggcgcaaattataaaaacttaaaacataaacaaatt cgttggaatggcttctactgggcaggcgcaaattataaaaacttaaaacataaaactt cgttggaatggcttctactgggcaggcgcaaattataaaaacttaaaacataaaacatt aaatcaacatatgaaattgattggggaaaatcacaaagtgaattt aaatcaacatatgaaattgattggggaaaatcacaaagtgaaattgtaagaacaatt aactgaaaacataaaaa actgaaaacaaaaaaa |

| 207. | atgaatagagagatgttgtatttaaatagatcagatattgaacaagcgggaggtaatcat tcacaagtttatgtggacgcattaacagaagcattaacagcccatgcgcacaatgatttt gtacaaccgcttaagccgtatttaagacaggatcctgaaaatggacacatcgcagatcga attattgcaatgccaagtcatatcggtggtgaacacgcaagtttaagtggata ggtagtaagcacgacaatccatcgaaacgtaatatggagcgtgcaagtgcgcacattatt ttgaatgatccagaaacgaattatccaattgcagttattggagcaagtttaattagtagt atgcgtactgcagcagtttcagtgattgcagcaagcatttagtagt atgcgtactgcagcagtttcagtgattgcagcaagcatttggagcaaagtttaatagtagt atgcgtactgcagcagtttcagtgattgcagcaagcatttggaagcaagtttaatag gacttaacaatcattggatgcgggctaatcggagacaagcaattacaaagattttaaa gacttaacaatcgatgcggggttttgtttacgatcaattcctagaagcatgttagag caattcgatcatattgaacgcgtgtttgtttacgatcaattctctgaagcatgtgcacgc tttgttgatagatggcacaacaacagcgtccggaaattaatt |
|------|--|
| 208. | atgaaaaaattatggttattttcggtacgagacccgaagcaataaaaatggcaccatta gtaaaagaaattgatcataatgggaactttgaagcgaacattgtgattacagcacacat agagatatgttagatgtgttaagtatatttgatgtatacatgcatcatgatttaaat atatgcaagatcaacaacattagcaggccttacggcgaatgcacttgctaaacttgat agcatcattaatgaggaacaacggatatgattttagtacatggtgatactacaacgact tttgtaggaagtttggcagcatttatcatcaaattcggtcgg |

atgattatgggtaatttgagatttcaacaggaatattttcgtatatacaaaaataataca gaatcacqggacacccgtaatgcgtattgggttaaactcgctaaaaatgttgaagctact aaatgatgtatgcattatcgacaattgtgcaacaacacatgcatctataagacatttttt gatgttactaccgatgacaatttaacaatgatacttcatgaatttctgcctttattgag ataaacaagttccatcttcttccgcaaaactatgatttagaagctttttttaagcaagaa ttaagtacttaaccattttaatgattcacctttattcaagttaaattgttcagttcgct acgctgagtgacttagttcgaaatatttatttgcaaattactgaagaaaatggaaataaa cgaacaactgtagatgaacttaatttgatgacagaacgtgatattcaattatatgacgat atcaatttaagtttgcctgagatagatgatgcgcaaacagttgttaccttatttgagcaa attaggtgtgttgaaagctggtggggcttacgtgccaattgatccgaactatccaagtgat cgtcaggagtacattttaaaagatgtaacgcctaaagttgtaataacgtaccaagcttta tatgaaaatggtaaacaaaatattaatcacattgatttgaataagatagcgtggaaaaat attgataatctttctaaatgtaacacgttagaagatcatgcttatgttatttacacgtcg gggacaactggtaaccctaaagggacactaattccgcaccgaggtattgttcgcttggtc yayacaactyytaactaayyyaaactaataatyaagaagaagaagatyatytoocaacaatatatyacagaadatata gcctttgatgctgcaacatttgaaatatatggtgcattgctcaatggtggaaagetgatt gttgctaaaaaagaacaattattaaatccaatagcggtagaacaattaatcaatgaaaat gacgttaatactatgtggttaacctcctcattatttaatcagattgctagtgaacgaata gaagtattggtatcgttaaagtatttattaattggtggagaagtattgaatgctaagtgg gtggatttgcttaatcaaaaaccgaagcatcctcaaattattaatggttatggaccaact gaaaatacaacatttacaacgacgtataatatacctaacaaagttccaaatcgtattcct attggtaaaccgattctgggtactcatgtttatatcatgcaaggcgagcgtcggtgtggcgttggtattcctggagaattatgtacaagtggctttgggttagctgcaggttatttaaat gacdatacaagttaagattcgagggtttaggattggtattgtcagaggttggacacgg gacgtatacaaggtattaataaagcagttgttattgttcaaaatcatgatcaagatcag tatatcgttgcttattatgaagcgatgcatacattatcacattaataagattaaatcacaa ttacgtatgaccttaccggagtacatgataccagttaattcatgcatattgagcaaat cctattactattaatgggaaattagataagagagcattgcctatcatggactatgtcgat acggatgcctatgtagcaccgagtacagataccgaacacttgctatgccaaattttgca gatattttacatgtgaatcaagtaggtattcatgataatttctttgaattaggtggccat tcattaaaagcaacgttagtggtgaatcggatagaggcatctactgggaaacgattacaa attggtgatttattacaaaagccaactgtatttgaactagcacaagcgattgctaaggtt caagaacaaactatgaagtgattccagaaactatagttaaagatgattatgtgtgagc tctgcacaaaagcgtatgtatttattatggaaatcaaaccataaagatagttatatgtgttgagc gtaccttttttatggcggttatcatcagaacttaatgtagctcaattgcgacaagcagtg cagcgtttgatagcgcgacatgagattttacgaacacaatatattgttgtagatgatgatgaggttogacaacgtattgtggcagatgttgcagttgactttgaagaagttaacacgcatttt catcgtgatatgacgaaacatagacaatattggttatctcaattcaaagatgaagtacct attttaagcttaccgacagactatgttagaccaaatattaaaacgacaaatggagcaatg atgtcatttacaatgaatcaacaaatgagacagctacttcaaaagtatgtagaaaagcat caaattactgattttatgttctttatgagtgtggtcatgacgttgttaagtagatatgct cgaaaagatgatgttgttgtcggtagtgtgatgagtgcgcgtatgcataaaggcacggag tcaaatggtgtgggcaatggtcaacgggttgccttgtttacagaacgtagttttgaaatg attgcggcgatgttggcgacagttaaagtaggtgcatcttatatacctatcgatattgat tttccgaataaacgacaaggtgcaattttggaggatgctaaagtaactgcagtcatgtct tacggcgttgaaattgaaacgacattaccagtcattcaattggaaaatgctaaaggcttt gttgaatcaaaggaaaatgaacaatatgatgatttacatggcaatcaacttgaaaacaca gcgatgttagataatgagatgtatgctatttacacatctggtacgaccgggatgcctaaa cgtgttaatccagaacagttacaacaactcattaataagcatcgtgtgacggttgcgtcg attccgttacagatgtgtagtgttatggaagacttttatattgaaaaagttgattacaggc ggggcaactagtacggcatcctttgttaaatattgagaagcattgtggcacgtattt aatgcctatggaccatctgagtcacagtcatcacatcgtattggtcacatcattgtggt gatttgatacctgagacgattccaattggcaaacccttatctaacatccaagtgtatat gatttgatacttgagacgattccaattggcaaattttattaatattcaagtgatattt atgtcagattggtttatgcggtattgcaggcgagttgttgtattgcaggtgat agtttagcgataggatatattaatcgtccagaattaatggctgataaatggcaaaataat ccatttggtaaaggaaagttgtatcatagtggtgatttagcacgttatacatctgatggt caaattgaatttttaggaagaatagataaacaagtgaaagttaacgggtaccgtattgaa cttgatgaaattgaaatgcaatattagctattcgtggtatatctgattgtgttgtaaca

| 210. | atgaccaaagaacaacaacttgcagaacgaattattgctgcagtaggtggtatggataat atagatagtgtcatgaactgtatgacacgtgtgcgtattaaagtattagatgagataaa gtagatgaccaagaactaaggcatattgatggtgtcatgggtgtattaaacgatgaacga attcaagttgtggttggacctggtacagtcaataaagtggtcaatcatatggcggaatta agtggtgttaaactaggtgacccaataccacaccatcacaatgatagtgaaaaaacga tataaatcatatgcagctgataaaggaaagg |
|------|---|
| 211. | atgtctaaaatttaaaatgtatcacgttagccgtggtaatgttattaatcgtaactgca tgtggccctaatcgttcgaaagaagatattgataaagcattgaataaagtaattctaaa gacaagcctaaccaacttacgatgtgggtggatggcgacaagcaaatggcgttttataaa aaaattacggatcaatatactaaaaaaactggcatcaaagtaaagcttgtaaatattggt caaaatgatcaactagaaaatatttcgctagacgcctcctgcaggaaaaggtccagatatc ttttcttagcacatgataatactggaagtgcctatctacaaggcttgtaaatatta gacaatagcacaagatggttgaaaggttcaatagtgaattat gacaataagcaactagcattgccagctatcgtgaaccacctaaaggcatgaattat gacaataagcaactagcattgccagctatcgttgaaaccaccgcactttttaaaataa aaattagtgaaaaatgcaccgcaaacgttagaagattgaaggctaatgctgccaaacta actgatagtaaaaagaacaatacggtatgttatttgaagctaatgctgccaaacta actgatagtaaaaagaaccaatacggtatgttatttcaagaaaaatttctatttaat tatccgttttattcggcaatgattatattttcaagaaaaatgcagtgaatatgat attcatcagctaggactaaattcaaaaaattcgtcgtcaagaatgctgaacgattacaaaaa tggtacgacaaagggtatcttcctaaggcagcacacatgatgctgaacgattacaaaaa tggtacgacaaagggtatcttcctaaggcagcacacatgatgctgaacgattacaaaaa acgtttggtaaagatagagacaaatttgtcactgacggtggaacattaatgaaaa ccattctaggtgtacgtggttggtatttactgaatatagtagaatgtgggcaaacctatgaaa ccattctaggtgtacgtggttgaagtacaactaatgaaatacaataaagatgtgggc aaggaaattactggacgtgttgacgtgaaacacttacaaaaaatatacagatgaaatg agcgaaattactggacgtgttgacgtgaaatcattacaaaaaatatacagatgaaatg aagcaagcacgtcatgctgaaccgatgcctaatattcctgaaatgcgacaagtttggaa ccgatgggcaatgcaagcatatttattcaaaaaggtaaagaacccaacaaaggcgttagaa gaggcgacgaatgcaagcatatttattcaaaaaggtaaagaacccaacaaaaaggcgtagaa gaggcgacagaatgaatgaaaaaaaaaa |
| 212. | gtgaaagcattgaaattatatggcgtggaagatttacggtatgagggataatgaaaagcca gtcattgaaagtgcgaatgacgttattattaaagtacgagcgactggcatattgtgttca gacacgtcacgatacaaaaaaatggggccatacattaaaggtatggcaatttggtcatgaa ttttcaggtgtagtagtagccattggaagtgatgtcatttagtgggggacaaa gtgacaggttgaccagcaataccttgttatcaatgcgagtattgtttaaaaggtgaatat gcacgattgaaaagttattcgtcattggctcatatgaacctggtcatttggcggaatat gtcaaattgcaagcgcaatactttttaaaggttccagacatgtttacagtggaatat gcacgattgtgaaaagttattcgtcattggctcatatgaacctggatcgtttgcgggaatat gcaaattgcagcgcaaaatgttttaaaggttccagacaatgttgatcaattgaagca gcaatggttgagccatcagcgttgttggcaatgaggttttataaaacgaatatacaacct ggtatgactgttgcagtaattggggtgtggcagtataggtttgttagcaatatacaacct ggtatgactgttgcagtaattcatcgctatagatataggttggtagcaatcaat |
| 213. | atgcaagcattacaaacatttaattttaaagagctaccagtaagaacagtagaaattgaa aacgaaccttattttgtaggaaaagatattgctgagattttaggatatgcaagc aatgccattagaaatcatgttgatagcgaggacaagctgacgcaccaatttagtgcatca ggtcaaaacagaaatatgatcattatcaacgagttatatacagtctaatcttcgat gcttctaaacaaagcaaaaacgaaaatacagagaaaccgctcggaaattcaaacgatgg gtaacatcagatgtcctaccagctattcgcaaacacggtataatacgcaacagacaatgta attgaacaacattaaaagatccagactacatcattacagtgttgactgagtataagaaa gaaaaagagcaaaacttacttttacaacaagaaaatcggagaactaaaacccaaagcagac tatgtagatgaaatcttaaagtcaactggcacattagcaccaactcaaatcgggcagac tacggtatatcagcacaaaagttaacaaactactacacgagacaactcaaacgaaaa gtaaataaacagtgggtgctttactcagaacacatgggcaagagttacacaggaaa gtaaataacagtgggtgctttactcagaacacagttttacaaacaa |
| 214. | atgaaattaaaatcattagcagtgttatcaatgtcagcggtggtgettactgcatgtggc aatgatactccaaaagatgaaacaaatcaacagagtcaaatactaatcaagacactaat acaacaaaagatgttattgctttaaaagatgttaaaacaagcccagaagatgctgtgaaa aaagctgaagaaacttacaaaggccaaaagttgaaaggaatttcatttgaaaattctaat ggtgaatgggcttataaagtgacgcaacaaaaatctggtgaagagtcagaagtacttgtt gctgataaaaataaaaaagtgattaacaaaaaaactggaaaaagaagatacaatgaatg |

| 2 | 215. | atgaaaatgaaaaatattgcaaaaataagtttgttattaggaatattagcaacaggtgta aacactacaacggaaaaaccagttcatgccgaaaagaaacctattgtaataagtgaaaat agcaaaaaattaaaagcttattataatcaacctagtattgaatataaaaatgtgacaggt tatatcagtttcatccaaccaagtattaaaattatgaatatcatagatggtaattctgtt |
|---|------|--|
| | | aataatattgetttaattggcaaagataagcaacattatcatacggtgtacatcgtaat cttaatatattttacgttaattgaggataagagatttgaaggtgcaaagtactetattggg ggtatcacgagtgcaaacgataaagctgtcgacctaatagcagaagcaagagttattaaa gaagatcataggtgataatatgattatgacttttcccatttaaaatagataaagaagcg |
| . | | atgtcattgaaagagattgattttaaattaagaaaataccttattgataattatggtctt tacggtgaaatgagtacaagaaaattacagtcaaaaagaaatactatggaaagtataca tttgaattggataaaagttacaagaagaccgtatgtccgatgttatcaatgtcacagat attgattagaataaagttacaagatgacagtatgtccgatgttatcaatgtcacagat |
| 2 | 216. | mrktkivctigpaseseemieklinagmnvarlnfshgsheehkgridtirkvakrldki vailldtkgpeirthmmkdgiielergnevivsmnevegtpekfsvtyenlindvqvgsy illddglielqvkdidhakkevkcdilnsgelknkkgvnlpgvrvslpgitekdaedirf gikenvdfiaasfvrrpsdvleireileeqkanisvfpkienqegidniaeilevsdglm vargdmgveippekvpmvqkdlirqcnklgkpvitatqmldsmqrnpratraeasdvana iydgtdavmlsgetaaglypeeavktmrniavsaeaaqdykhllsdrtklvetslvnaig isvahtalnlnvkaivaatesgstartiskyrphsdiiavtpseetarqcsivwgvqpvv kkgrkstdallnnavatavetgrvsngdliiitagvptgetgttmmmkihlvgdeiangq gigrgsvygttlvaetvkdlegkdlsdkvivtnsidetfvpyvekalgliteengitsps aivglekgiptvvgvekavknisnnmlvtidaaqgkifegyanvl |
| 2 | 217. | mqfdnidsalmalkngepiivvddenrenegdlvavtewmndntinfmakearglicapv skdiagrldlvqmvddnsdifgtqftvsidhvdtttgisayertltakklidpsseakdf nrpghlfplvaqdkgvlarnghteaavdlakltgakpagviceimnddgtmakggdlqkf kekhqlkmitiddlieyrkklepeiefkakvkmptdfgtfdmygfkatytdeeivvltkg airqhenvrlhsacltgdifhsqrcdcgaqlessmkyinehggmiiylpqegrgigllnk lrayelieqgydtvtanlalgfdedlrdyhiaaqilkyfniehinllsnnpskfeglkqy gidiaerievivpetvhnhdymetkkikmghli |
| 2 | 218. | mkmkklvkssvassiallllsntvdaaqhitpvsekkvddkitlykttatsdndklnisq iltfnfikdksydkdtlvlkaagninsgykkpnpkdynysqfywggkynvsvssesndav nvvdyapknqneefqvqqtlgysyggdinisnglsgglngsksfsetinykqesyrttid rktnhksigwgveahkimnngwgpygrdsydptygnelflggrqsssnagqnflpthqmp llargnfnpefisvlshkqndtkkskikvtyqremdrytnqwnrlhwvgnnyknqntvtf tstyevdwqnhtvkligtdsketnpgv |
| 2 | 219. | mkkkallplflgimvflagcdyskpekrsgffyntfvdpmknvldwlgnnllndnyglai iilvlviriillpfmlsnyknshmmrqkmkvakpevekiqekvkrartqeekmaanqelm qvykkydmnpiksmlgclpmliqlpiimglyfvlkdqlvdglfkyphflwfdlgrpdiwi tiiagvlyfiqayvssktmpdeqrqmgymmmvispimiiwislssassalglywsvsaafl vvqthfaniyyekvakkevqpfieayerelnggsnkkgkntqvvskkkkk |
| | 220. | mnlfrqqkfsirkfnvgifsaliatvtfistnpttasaaeqnqpaqnqpaqpadantqm anagaqmptaqpaapaqqpaqpaqqqqqanqqqqaaqpaqaaqpaqadqnnaaq aqpqnatpanqaqqmnatpmnatpanqtqpanpaqqaaqpapvaanaqtqdpnasn tgegsintiltfddpaistdenrqdptvtvtdkvngyslinngkigfvnseltrsdmfdk mpqnyqakgnvaalgrvnandstdhqnfngisktvnvkpdseliinfttmqtnskqgat nlvikdakkntelatvnvaktgtahlfkvptdadrldlqfjpdntavadasrittnkdgy kyysfidnvglfsgshlyvknrdlapkatnnkeytinteignngnfgaslkadqfkyevt lpqgytyvnnslttfpngmedstvlkmtvnydqmankvtftsqgvttargthtkevlf pdkslklsykvavanidtpknidfnekltyrtasdvvinnaqpevtltadpfsvavemnk dalqqvnsqvdnshyttasiaeynklkqadtilnedanhvktanrasqadidglvtkl qaalidnqaalaeldtkaqekvtaaqqskkytqdevaalvtkinndknnalaeinkqtta qgvttekdngiavleqdvitptvtpqakqdiiqavttrkqdikksnaslqdekdvandki gkietkaikdidaattnaqvealktkaindinqttpattakaaaleefdevvqaqidqap lnpdttneevaealerinaakvsyvkaieatttaqdlervkneeiskienitdstqtkmd aynevkqaatarkaqnatvsnatneevaeadaavdaaqkgylhdiqvvkskqevadtksk vldkinaiqtqakvkpaadtevenayntrkqeignsnastteekqaayteldtkkqeart nldaantnsdvttakdnsiaainqvqaattkksdakaeiaqkaserktaieamndsttee qqaakdkvdqavtsnadidnaamndvdnakttneatiaaitpdanvkpaakqaladkv qaqetaidgnngstteekaaakqqvqtekttadaidaahtnaeveaakkaaiakieaiq patttkdnakeaiatkanerktaiaqtqditaeeiaaanadvdnavtqansnieaansqn dvdqakttgensidqvptvnkkatameitailnnklqqatpdatdeekqaadaean tengkanqaisaattnaqvdeakanaeaainavtpkvvkkqaakdeidqlqatqtnvinn dqmatteekeaaiqqlatavtdaklantiaatddnydqakdagknsigtpatavksna kndvdqavttqnqaidnttgatteeknaakdlvlkakekayqdilnaqttndvtqikdqa vadiqgitadttikdvakdelatkaneqkaliaqtadatteekqaaqqvdaqltqnqn ienaqsiddvntakdnaiqaidpiqastdvktnaraelltemqnkiteilnmettneek gndigpvraayeeglnninaatttgdvttakdtavqkvqqlhanyvkpagkkeldqaaa kkktjeqtpnasqqeindakqevdtelnqaktnvdqstkpanqaievkaedtkesidqs dqltaeektealamikqitdqakqgitdatthaevekakqqleidniqdstekqkai eeletaldqieaynvnnadatteekeaftnaledilskatedisqqtkaqdivnigdskdi eeletaldqieaynvnnadatteekeaftnaledilskatedisdqttnaeiatvknsal eqlkaqrinpevkknaleairevvnkqieilkmadaasakelartdlgryfafradkld ktqtnaeveslnyttjaleaivgndgdandtnngidnndatannanatpentgqnn settangkadaspttpnnsdaatgettatsatddandkpqannssvdastnappnv settangkadasp |
| | 221. | mklksfvtatlalg11stvgaalpsheasadsmgykemtvdgyhtvpytisvdgitalh rtyfifpenknvlyqeidskvknelasqrgvttekinnaqtatytltlndgnkkvvnlkk nddaknsidpstikqlqivvk maikkykpitngrrnmtsldfaeitkttpeksllkplpkkagrnmqgkltvrhhqgghkr |
| | | qyrvidfkrnkdginakvdsiqydpnrsanialvvyadgekryiiapkglevgqivesga eadikvgnalplqnipygtvvhnielkpgkggqiarsagasaqvlgkegkyvlirlrsge vrmilstcratigqvgnlqhelvnvgkagrsrwkgirptvrgsvmnpndhphgggegrap igrpspmspwgkptlgkktrrgkkssdklivrgrkkk |
| | | |

| 223. | mlvntfnpfdnlllssliaaipivlfllcltvfkmkgiyaaittlvvtlliaipffklpv giasgavvegffqgiipigyivmmavllykitvesgqfltiqdsitnisqdqriqvllig fafnaflegaagfgvpiaicallltqlgfnplkaamlclvanaasgafgaigipygvet lklpgdvsvlgvsqsatltlaiinfiipfllifiidgfrgvketlpailvvsitytltqg lltvfsgpeladiipplltmlalavfskkfqpkhiyrvnkdeeiepakahsakavlhaws pfivltvivmiwsapffknlflpngalsslvfkfnlpgtisevthkplvltlnliiqtgt ailltiiitlmskkvnfkdagrlfgvtfkelwlpvlticfilaiskittygglsaamgq giakagnvfpvlspilgwigvfmtgsvvnnnslfapiqasvaqqigtsgsllvsantvgg vaaklispqsiaiataavkqvgkesellkmtlkysvcllificiwtfilsll |
|------|--|
| 224. | mlknkiltttlsvsllaplanpllenakaandtedigkgsdieiikrtedktsnkwgvtq niqfdfvkdkkynkdalilkmqgfissrttyynykktnhvkamrwpfqyniglktndkyv slinylpknkiestnvsqilgyniggnfqsapslggngsfnysksisytqqnyvseveqq nsksvlwgvkansfatesgqksafdsdlfvgykphskdprdyfvpdselpplvqsgfnps fiatvshekgssdtsefeitygrnmdvthaikrsthygnsyldghrvhnafvnrnytvky evnwktheikvkgqn |
| 225. | mkmnklvkssvatsmallllsgtanaegkitpvsvkkvddkvtlykttatadsdkfkisq iltfnfikdksydkdtlvlkatgminsgfvkpnpndydfsklywgakynvsissgsndsv nvvdyapknqneefqvqntlgytfggdisisnglsgglngntafsetinykqesyrttls rntnyknvgwgveahkimnngwgpygrdsfhptygnelflagrqssayagqnfiaqhqmp llsrsnfnpeflsvlshrqdgakkskitvtyqremdlyqirwngfywaganyknfktrtf kstyeidwenhkvklldtketennk |
| 226. | mnremlylnrsdieqaggnhsqvyvdaltealtahahndfvqplkpylrqdpenghiadr iiampshiggehaisgikwigskhdnpskrnmerasgviilndpetnypiavmeasliss mrtaavsviaakhlakkgfkdltiigcgligdkqlqsmleqfdhiervfvydqfseacar fvdrwqqqrpeinfiatenakeavsngevvitctvtdqpyieydwlqkgafisnisimdv hkevfikadkvvvddwsqcnrekktinqlvlegkfskealhaelgqlvtgdipgreddde iillnpmgmaiedissayfiyqqaqqqnigttlnly |
| 227. | mkkimvifgtrpeaikmaplvkeidhngnfeanivitaqhrdmldsvlsifdiqadhdln imqdqqtlagltanalakldsiineeqpdmilvhgdtttffvgslaafyhqipvqhveag lrthqkyspfpeelnrumvsniaelnfaptviaaknllfenkdkerifitgntvidalst tvqndfvstiinkhkgkkvvlltahrrenigepmhqifkavrdladeykdvvfiypmhrn pkvraiaekylsgnnrieliepldaiefhnftnqsylvltdsggiqeeaptfgkpvlvlr nhterpegveagtsrvigtdydnivrnvkqlieddeayqrmsqannpygdgqasrricea ieyyfglrtdkpdefvplrhk |
| 228. | mingmlrfqqeyfriyknntestthrnaywyklaknveatkmmyalstivqqhasirhff dvttddnltmlheflpfieikqypssanydleaffkqelstyhfndsplfkvklfqfa daayilldfhvsifddsqidiflddlcnayrgntvinntrqhahinrnddkdnqdashia ldsnyfrlennsdihidsyfpikhpfeqalyqtyliddmtsidmaslavsvylahimsq qhdvtlgihypshlpndlhqmivpltltidakdkvqqftftdfnkvlqmmsqlqcakssl sletifncyhnmmscondviedvnqihdahtsladieifphqhgfkilynsaaydllsie tlsdlvrniylqiteengnkrttvdelnlmterdiqlyddinlslpeiddagtvvtlfeq qveatphhvavqfdgvfityqtlnarandlahrlrnqygvepndrvaviaeksiemiiam iqylkaggayyidpnypsdrqeyilkdvtpkvvityqalyengkqminhidlnkiawkn idnlskcntledhayvjtsgttgmpkgtliphrgivrlvhqnhyvplneettillsgti afdaatfeiygallnggklivakkeqllnplaveqlinendvntmwltsslfnqisexri evlvslkylliggevlnakwydllngkpkhpginigygyptentftfttynipnkypnrip igkpilgthvyimggerrcgygipgelctsgfglaagylngpeltadkfikdsninqlmy rsgdivrllpdgnidylyrkdkqvkirgfrielsevehaleriqginkavvivqnhdqd ylvayyeamhtlshnkiksqlrmtlpeymipvnfmhieqipitingkldkkalpimdyd tdayvapstdtehllcqifadilhvnqvgidndffelgghslkatlvvnrieastgkrlq igdllqfbytfelaqalakvqeqnyevipetivkddyvlssaqkrmyllwsnhkdtvyn vpflwrlsselnvaqlrqavqrliarheilrtgylvvddevrgrivadvavdfeevnthf tdeqeimrqfvapfnelepsgirvyirsplhaylfidthhindgmsniqlmmdlnaly qhklllplklqykdysewmshrdmtkhrqwlsqfkdevpilslptdyvrpniktngam msftmnqamrqllqkvvekhqitdfmffmsvvmtllsryarkddvvygsvmsarmhkgte qmlgmfantlvyrgopspdkmwtfflqevkemsleayehqeypfeclvndldqshdasrn plfdvmlvlqnnetnhahfghsklthiqpksvtakfdlsfileedrddytinieyntdly hsetvrhmgqncminidyilkhqdtlqiddingteellnwnthndrmlnypgnksii syfnevvsrqgnhvalvmndltmtyetlrnydaiahmllsnyonggrvalftersfem iaamlatvkyasyipididfpnkrggailedakvtavmsygveiettlpviqlenakgf veskenseqvddlhgnqlentamldnemyaiytsgttgmpkgvairqrnllnlvhawstel qlgdnevflqhanivfdasvmeiyccllnghtlyfpdreervnpeqlqqlinkhrvtvas iplgmsvybglgslsniqvyimsgllcgjgmpgelciagdslaigyinrpelmadkwqnn pfgkgklyhsgdlarytsdgqiefjgridkqkvknygyrieldeienaliarigisdevvt vshfdthdilnayyvgeqqveqdlkqylndqlpkymipktithidemplttndkvdtrl pppppiqgsnkylspsglariyvjmymyqnqgalvalpdlselytixphyrpelmadkvnyn lkfghismgtlyqyktvrqltynymyqnqgelvalpdlselythymyryliddevtrla qqhharliyvstisvgtyfdidtedvtfseadvykgqfltssytrskf |
| 229. | mtkeqqiaerilaavgmonidsvmomitvikvitakvoddeliniqyvinder iqvvvggtvnkvanhmaelsgvklgdpiphhhndsekmdyksyaadkakankeahkakq kngklnkvlksianifiplipafigagliggiaavlsnlmvagyisgawitqlitvfnvi kdgmlaylaiftginaakefgatpglggviggttlltgiagkniimmvftgaplqpqgg iigvifawilsivekrlhkivpnaidiivtptiallivglltififmplagfvsdslvs vvngiisiggvfsgfiigasflplvmlglhhiftpihieminqsgatyllplaamagagq vgaalalwvrckrnttlrntlkgalpvgflgigepliygvtlplgrpfltacigggigga viggighigakaigpsgvsllplisdnmylgyiagllaayaggfvctylfgttkamrqtd llgd |

| 230. | mskilkcitlavvmllivtacgpnrskedidkalnkdnskdkpnqltmwvdgdkqmafyk kitdqytkktgikvklvnigqndqlenisldapagkgpdifflahdntgsaylqglaaei klskdelkgfnkqalkamnydnkqlalpaivettalfynkklvknapqtleeveanaakl tdskkkqygmlfdaknfyfnypflfgnddyifkkngseydinqlglnskhvvknaerlqk wydkgylpkaathdwniglfkegkvgafvtgpwnineyqetfgkdlgvttlptdggkpmk pflgvrgwylseyskhkywakdlmlyitskdtlqkytdemseitgrvdvkssnpnlkvfe kqarhaepmpnipemrqvwepmgnasifisngknpkqaldeatnditqnikilhpsqndk kgd |
|------|--|
| 231. | vkalklygvedlryednekpviesandviikvratgicgsdtsrykkmgpyikgmpfghe fsgvvdaigsdvthvnvgdkvtgcpaipcyqceyclkgeyarceklfvigsyepgsfaey vklpaqnvlkvpdnvdyieaamvepsavvahgfyksniqpgmtvavmgcgsigllaiqwa rifgaahiiaididahkldiatslgahqtinskeenlekfienhyanqidlaiessgakv tiggaltlpkkggevvllgipyddieidrvhfekilrneltvcgswnclssnfpgkewta tlhymktkdinvkpiishflplekgpetfdklvnkkerfdkvmftiy |
| 232. | mqalqtfnfkelpvrtveienepyfvgkdiaeilgyarsdnairnhvdsedklthqfsas gqnrnmiiinesglyslifdaskqsknekiretarkfkrwvtsdvlpairkhgiyatdnv ieqtlkdpdyiitvlteykkekeqnlllqqeigelkpkadyvdeilkstgtlattqiaad ygisaqklnkllhearlqrkvnkqwvlysehmgksytesdtiaivrsdgredtvlqtrwt qkgrlkiheimtefgyeanlgga |
| 233. | mklkslavlsmsavvltacgndtpkdetkstesntnqdtnttkdvialkdvktspedavk kaeetykgqklkgisfensngewaykvtqqksgeesevlvadknkkvinkktekedtmme ndnfkysdaidykkaikegqkefdgdikewslekddgklvynidlkkgnkkqevtvdakn gkvlkseqdh |
| 234. | mkmkniakislllgilatgvntttekpvhaekkpivisenskklkayynqpsieyknvtg yisfiqpsikfmniidgnsvnnialigkdkqhyhtgvhrnlnifyvnedkrfegakysig gitsandkavdliaearvikedhtgeydydffpfkidkeamslkeidfklrkylidnygl ygemstqkitvkkkyygkytfeldkklqedrmsdvinvtdidrieikvika |
| 235. | Ttgaaaaatattttaaaagtttttaatacaacgattttagcgttaattatcatcatcgcg Acattcagtaattctgcaaatgccgcagatagcggtactttgaattattgaggtttacaaa Tacaataccaatgacacgtcaattgctaatgactatttaataaaccggcaaagtacatt Aagaaaaatggtaaattgtatgttcaaatagctgtcaaccacagtcattggattactgga Atgagtatcgaaggacataaagaaaatattattagtaaaaacactgccaaagatgaacgc Acttctgaatttgaagtaagttgaacggtaaaatagatggaaaaattgacgtttat Atcgatgaaaaagtaaatggaaagccattcaaatatgaccatcattacaacattacatat Aaatttaatggaccaactgatgtagcaggtgctaatgcaccaggtaaagatgaaaaat Tctgcttcaggtagtgacaaaggatctgatggaacgactactggtcaaagtgaatctaat Agttcgaataaagacaaagtagaaaatccacaaacaaatgctggtaacactgctaataa Agttcgaataaagacaaagtagaaaatccacaaacaaatgctggtacacctgctatataa Tatacaataccagttgcatcoctagcattattaatcgcaatcacattgtttgttagaaaa aaatccaaaggcaatgtggaa |
| 236. | atgacaaaacattatttaaacagtaagtatcaatcagaacaacgttcatcagaaa aagattacaatgggcacacagaacaagttacaatgggcacacagaacaagttacaatcagttgatacacacaagtcaacagacacacaagtcaacagacacacaagtcaacacaagtcaacacaattaatt |
| 237. | Eknilkvfnttilaliiiiatfsnsanaadsgtlnyevykyntndtsiandyfnkpakyi Kkngklyvqitvnhshwitgmsieghkeniiskntakdertsefevsklngkidgkiddy Idekvngkpfkydhynitykfngptdvaganapgkddkmsasgsdkgsdgtttgqsesn ssnkdkvenpqtnagtpayiytipvaslalliaitlfvrkkskgnve |
| 238. | mtkhylnskyqseqrssamkkitmgtasiilgslvyigadsqqvnaateatnapnnqstq vsqatsqpinfqvqkdgssekshmddymqhpgkvikqnnkyyfqtvlnnasfwkeykfyn annqelattvvndnkkadtrtinvavepgykslttkvhivvpqinynhrytthlefekai ptladaakpnnvkpvqpkpaqpktpteqtkpvqpkvekvkptvtttskvednhstkvvst dttkdqtktqtahtvktaqtaqeqnkvqtpvkdvataksesnnqavsdnksqqtnkvtkh netpkqaskakelpktgltsvdnfistvafatlallgslslllfkrkesk |

atgacaaagaaagaaaaggattataaaaaaagtcttgagcaacaaaaaaacacgggtaaaa atatacaagtcaggaaaaagctgggtaaaagcaagtataatgaaatagaattgttaaaa acaatggggctaccattttaagtaaaaacgaaatacaagaaaatgtgactgaaaagacg gtgacgtacgttggacaaacctttacgagaaatcttacagattggataaaaaacagtggg ggtacgacgttttctctatctatgactgctcaactggtggcgcaaaaaatttacaacaa gttcaatttggaacattcgagtatacagaatcagctgttgctaaagtacgctatgtagat gatgytottaaagsatgtgatttataaattcaaagatgttcaaggtcctcaaattagtgtt gatagtcaaactagagaagttggaaagaccattaatccaattacaattactacaactgac aatagtaaagacgtattaactacaactgtgacaggtctaccttcagggttatcttttgat aatagtaadgatgtattaattaattatuggattaggattaggaagtaggaactacaactgtgaaagtt caaacgactaatacaattattggcacgccaagtgaagtaggaactacaactgtgacagtt aatactactgatgctactgggaacgtaacatctaagcaattacaataacgattcaagat acaatcagccctgttgtaaatgtgacgccaagtcaagcatcagaggttttcacgccgatt agtaaaaag agtgagagtgactcaacaagtgaaagtacatcgttaagtgactcgacaagtgcgagtctt tcagaatcgacaagtacatcaacatccgacagtgcgtcacatcaacgagtgagagtgac tcagacagtgcgtcaacatcaacaagtgtgagtgagtcaagcagtacaagtaagaagtta tcagaatcagcgagtacgtcgatgtctgatagcgcatctgcatcaacgagtgaatcaaac agtacaagtacgtcattaagtggctcgacaagtacgagtctttcaggatcaacgagtga agtacaagtacgtcattaagtggctcgacaagtacgagtctttcaggatcaacgagtaca tcgacttcagaaagtgcgtcaacaacatcaacgagcgtaagtgactccaatagcgcaagtacg tcattaagtgaatcgacaagtacgagtctttcagactcaacgagtacatcgacatcagat agtacgtctgcatcaacaagtgagagtgactcaacagtacaagcacatccatgagtgaa tcattaagcacaagcgtttcagattcaacaagtacgtcaacgtcagacagtgcatcaacg tcaacaagtggagtgactccaatagcgcaagtacgtcattaagtgcatcaacagtaca agcatttcagactcaacgagtgcgtcgacatcagatagtgcgtcagaagtacaacaagtaca agtgaatcaacagtgaaagtacatcggtaagtgaatcaacaagtacaagtgagt tcaacaagtacatcggcaacaggagagtgcatcaacaagcgcagagtgaatcaacaa agtgaaagtacatcggtaagtgaatcatcaagtacaagcgtttcagattcaacaagtaca agtgaaagtacatcggtaagtgaatcatcaagtacaagcgtttcagattcaacaagtaca agtgaaagtacatcggtaagtgaatcatcaagtacaagcgagagtgaatcaacaagtacaa tcgacatcagaaagtgcatcaacgtcaacaagcgagagtgaatcaacaagtgaaagtacg tcattaagtggatcatcaagtacaagcgtttcagattcaacaagtacgtcaacgtcagaa tcagtaagtggctcaacaagtacaagtatttcagattcatcaagcacgtccacatcaatg agtacatctgaaactttcacttctcaatctcctataaatagtgaaagtcaatttattggt gatagcttgtctgaagatacaatcgtgactcaatcaaaaaatacgaatatgcttaataaa actggaaaagattatgatttacaagaacaaagaggttatactgattcagaacaacacaat gaaacacaaagtaatcaagctgataatcactcaaacaacctcgatttacttcatcaaaat cgtttacaagataaagtcgttaaacaaccgactaaaggagaagatggagttgtaagcaac ggttttatagtagcagtagcaatagtattggctatcttcggtttggcaaaaaatctaga

| 240. | atgaaaaaacagttatcgcttctacattagcagtatctttaggaattgcaggttacggt ttatcaggacatgaagcacacgcttcagaaactacaaacgttgataaagcacacttagta gatttagcacaacataatcctgaagaattaaatgctaaaccagttcaagctggtgctac gatattcatttcgtagacaatggataccaatacaacttcacttcaaatggttctgaatgg tcatggagctacgctgttcagatggttcagatgctgattacacagatgttcagaccaa gaagtagtgcaaatacacaatctagtaacacaaatgtacacagctgtttcagctccaact tcttcagaaagtcgtagctacagcacatcaactacttcatactagcaccaagccataac tacagctctcacagtagttcagtagatatacaatggtaatactgctggttctgtaggt tcatatgctgctgccaaatggctgcacgtactggtgtatctgctgttcagcagcac atcattgctagagaatcaaatggctacattacacagcagtattcaggtggaacac atcattgctagagaatcaaatggctacattacaatgcagtatactggtgtaggtgga ttattccaaactatgccaggttggggttcaactggttcagtaaatcagtcggtgga ttattccaaactatgccaggttggggttcaactggttcagtaaatcaatc |
|------|---|
| 241. | abgaabaaaataaagtgabtgtaabtggabcaacaaatgtagabaaabtbcbbaagtbaaagggagtbtccaaaagcggagcaabtacababtaabtaabcaagcbcaaaagggagtbtggt gggggcaagggagcaabtacagcabtagbagabtagcaggagabtacaacabtb abcagbaagggagcaabtaagcabtgcaactbbaabtagagcaggagabtbcaaaaagca ggbabcabaccaababbbbbaacbcagagbagaababggagaabtbcaaaaagca ggbabcabaagaggagcaagabbbbbbbaacbggbgggggggaaggabbbbaabtagacabta acbgbbgaagcaggacaaaabtaggabtbbbbbbbbbbaacbggbggggaababbbbbbbbbb |
| 242. | atggctcttaaaaaatataagccaattacaaatggtcgtcgtaatatgactactttagat ttcgctgaaatcacaaaaacacacctgaaaagtcattattacaaccgctaccgaaaga gcgggacgcaataaccaaggtaaattgactgttcgccatcatggtggtggacaacaaacgt caataccgtgttatcgattttaaacgtaacaaagatggaatcattgctaagttgattca attcaatatgatccaaaccgttcagcaaacattgcattg |
| 243. | atgaagtcaaaattcacaattctattattacaatcttttctacaaca |
| 244. | atgaagattggaattgatgcoggagggactttaattaaaattgtacaagagcatgacaat cgtagatattacagaactgaaattaacaactaatatccaaaaagtcatagattggcttaac aatgaagaaatcgaaacattaaagcttacaggtggaaatgctggagtaatagcagatcaa attcatcatcccctgaaatattgtagagttcgatgcatcaataaaaggtttagaaatt ttattggatgaacaaggtcatcaaattgaacattacatt |

atgactttaaataaccattttgcatatacatttgaggagagacctaccccaaaattatgg agtgtaatacgttcaatgaatgcaaagaatttcttatctgaaaaactttataatgaacgt gagttatatgtttttgagtctgtttggacggaagaaaatcatacagacgctcaagaatta tatgatgacgctgtaaaacaaatgaaggaacaaaagaaaatcaatagaacgattacagtt gaaatgcaattagatttccaaactaatcaagtaaaaattactattagtgatatttttgat tacaaagatttagacacaatcatcgctgaaaaattagcccaaactacctctacttcttct caagttgatttccataaacaacaaattagagagcaaaccggaagaattacagatatgact cgtcttatcgaaggtgagtgggacgcaaataaaaagcgtgtgatggctggtaatgaaaca gttgatattggttcacatggtgttaaagtcattcaaaagagagaaccttaacgaattcgta atcatggttggtggcgtaattgctatgactcgtgataacggtgaaacatttaaaactggt attacaccagaaggtatcaatgctgaaatgcttatcggtaaagatgatcgttggtgaaact ttaacttttgaaaatgagtctggtacagttaaattcgacaaagatggactttatgttaac tctaaaaacttccatttagtttcaaatgatggagaagaagactacttcgataaattaaaa cgtgaaatgtctgaaaacgctaaacaacaaacagacagaatgttagaagagtataaaaaa gaagtttcacaaactatttctgaagctactgacgttagaaacattgttgataatgcagca gatattcttcaagcagcttttgctgatggagttatcacagatgttgaaaaacgtttgat tetgaaactettgeteaacttgaaaaagaaaatagagaattegaagataaaattaactta getttaaaccaccettacatcactgaggaagatactattgaggtaaataattetategtt gaatatagctcaatgtatgaaacacttgttatttctattaatgaaagtgttagtgacaag caagctactttagaagaagcaaaagattatacaacaagagttcgtgagatattaaagat gaattaaaagacttaaataattcatttaaatctttaaatagtacagttgaagagtcatta caagataatatttttgacgctgctgaattagaagctattaaaacagttgtattagtaact aaatcagaatatcaagatattacaaatagatattcttcaatgtctgcaaatacagattta aaatcggaaagtaaattagatttaacaaaatcttataaaactttagatactagctttaat gactttgttaaatatattgacgaaatgacaatggatagaattgcagatgagactgagaaa gttaattacaaaaagaaatatgatactttacaaaagaacttatcagattatatgaaaaaa tatgataactgtattttggaaatatctaaaaagtattctaatgacgcagcagataaagtg ttaggtgacttcacagctattgctactgaattacaaaatgatttccaagatgttaaagac aattgggctgaattcaagcaaactactcttgagtcatttaaagatggtatagtaactgag gcagaaaaagctcgactaagagtacaattagatatgcttgatcgtgaaagcatggatatt gaagaacgatataaaagcttacttgctaaccaatatactaatactgatattaaaaaatcgc ttaactgcttcacgttctccttacttatcagttcatgctagtttaagaaaagtaattgaacaaataattgctgacggaaaagttgatgaaagtgaaaaacattagctaataattcactt aatacatacaacacacattaactgcttattctaaaacaattcaagaagctctaaataca ttatcacaaatcatcatctcttctgatgtagcaagtaaaaaagttgaagaattcaatggtgta ataactacaatttcttcagacgttgatacaatcaagaaacaaagagatggtgcagtaatc acttattattatagcggtgtacctacattatctaacgatcagctaaaagttggacgact aatgatttaaaagacttacatattaaagatatgtatttagcactaaaatctggttatgca tatacttcactaaatctggtactagttattcttggaaaccactaatcgaccaagttatt gttagctcattgaaacaagcaaaaaatgcacaagacacagcggacaataaacgtagagtt gttagttoattgaaacaaguaaaaatgtacaagaacaaguagaacaagaagaatatgt tttgtaaaccaacctattcctctatgacaaggagatatgtggactaaaggttcacaa ggagatatttatgtctgtggaacttcgagagctactggctcattcgtaagtagcgactgg gttaaagcgagcaaatacactgacgatacagtagctaaacaggcagcaaaagatttagaa gattataaagtcaaaatgactaaagacttcaaagatttaaatgacggtgtatctacttt aaaactgaagtggttaaagatttcaaagatggaattgtaactgaagctgagaaaactaga acaaatattactgatattcaacaagattgatggtgcaattgaagttatadadatatadada acaaatattactgatattcaacaagattgatggtgcaattgaaactttctattacagt ggagtaccaacacttactaatatccccgcttcgtattggacaactgctagtaaacgtgaa gctcatttaggtgatttatatttagacactgctactggtgttgcttatcgtttcttaaaa aaaggaacaacttcccctacttactattggtctccaatttctgatcaaaattattacagac gcattgaatagagcaaaaacagctcaagacaccgccgatggaaaaaagaagaggatttttttgta aatacacctgttccaccatacgacactggtgacatgtggacgcaaggagctagtggtgac atcttagtttgtaaaacacctaaagctaaaggtggtatttactcaataagcgactgggta aaagctagtaagtatacagatgatacagtagcaaacagtgctgttcaacaattaaatgaa ttaacaactgatgaaagacaaagtggacaaattagtgtttatccatactcccctaacgga gcaagagagacagtaaatattaaagacggtaaaattacttatacatttactgcacaaact gaaagtacacaatttcttatttataaagacgtggctggtcaatctgatgtagacttaaat gtaacaatcgagaaggctattttagtcgaaggaaataaagttacagggtggtctccagca ccagaggagacttcttctgctttacgagattataatactcgtatctcctcagcagaaaca ttcattgagaaaaacaagaaaagatttctcaaattgctactaaatctgatgttgacgct cttcctgacgcaatcactaataaaaataagaaatataatacagttaaaatgacatacaat aaaaatacaaattacccttctgtattttctaattttatttctgttggaaaaggtcaagag gtagctattggtgaacatttaacactaacttgttatgcctatatcccttcttcatctaaa ggtaaattaactggtaacatatatattgaattcgctggttactatgaaaaagaccaaaaa tcaaacccaatgattgctagacatgaaatattacctaaagattttgaatataataaatgg ttcagaatgacagctagtactgctattccttctactaactctgagggtaaaaaaatcaat agacttgacgtatttagcactgaacaattggcagctaagattgcctcaaacccagagagt gtggatattatcgcaagaatattgatttcaatactgactcaatgaagatttataattct aacggtacattaaacatttctggagatactttaacaattagtaacaacaatagttctaat gagccggggatgaatggttattacactataaatactggtgtttacaattttgcagtacaa cacaaacaactattagaggtaaataatacaaaaaatgcgagagttaacaggtatacatat cctaacaatttgccagacttttttgaattacaagctggtattgcctatggagaaaataat tctattgatggtttctttagaattagacgtatggcaatgacagatacaccaaatgcggag

| 246. | atgtataacgtgacacagcatgcgacttataaaacaaaaaataaacgagaaactgctgta ttaatcggtgtacatgctcaaacggatcgtcaatttaattttgaatctactatggaagg ctcgatgctttatcacaaacttgccaacttaatgttaaaggacaaatcactcaaaataga gagcaatttgaccataatattatgttggaaaggaagacaattcgatgaaataaaatctttc atagaattcactgatatagatgttgtcgtaaccaacgatgaattaacgacggcacagtct aaaacgttaaatgataatttgggcattaaaatcatcgatgaaccaatttagga atattcgcgttgcgagcgagaagtagaaggagaagctacaagtagaaccaaattatttagga atattcgcgttgcgagcgagaagtagaaggagaagctacaagtagaacttgcacaactc gattatttgttaccaagactacatggtcatggtaaaagcctgtcctcgtcttggtggcg ataggaacaagagcccaggtgaaacaaaattagaaatggatcgtcgccatattagaaca cgtatgaatgagattaaacatcaattaaaaacggtcgtggatcatcgggaaagaagatagaa cagtagaacgaaaaatcaagttttcaaatcgctttagtggtaaaaaaatatttgttt gcaacattagatcaaggttttagctatggtgaaggagacctatgaaaaaaatttttgttt gcaacattagatttaatgttttagctaatcaagtgaaggaag | |
|------|--|---|
| 247. | atgatgatcatcgtcatgttaatcttgagttatctgattggtgcattcccaagcgggtta attattggtaaattatttttaaaaaagatataagacaatacggtagtggaaatactgga gcaactaacagttttcgtgttcttggaagaccagctggatttatagttacgtttttagat attttcaagggatttattacagtctttttccactatggtcccagttcatgcggatgt gttataagcaccttctttacaaatggtttaatagtaggattgtttgcaatactcggtcac gtgtatccaatatotgaaatttaatggcggaaaagcagtagctaccagtgcaggagtt gtataggtgtcaatcctatttacttcttatctgcgaataatttttttt | ı |
| 248. | atgatgaatcatagtgaagctttaactgaacaagtattttcatttgcttcagagctttat gcttatggtgtaagagaagtagtaattagtccaggttcaagctcaaccattagcactt gttttcgaagcacactcaacaatattaacactgaattcaccctgatgagcaagcgaagtgctgca ttttttgctttaggtcttattaaaaggtagcgaaaaacctgtagcaaattcttttgctttagctttattaaaggtagcgaaaaacctgtagacaaatcatttgcactt ggaacagccgctgcgaactacacacccgctatagctgaaagtcaaattagtcgtttgcct ctcgttgtttaacagcgaacagaccgcatgaactgcgcagtgggtgg | |

atggcgaaaaattcaattacaattaccgtctatggttgctttaacgttatttggcaca atygcyaaadatttaattacaaattatuguttattyjttytttaatyttatugudda gettitaetgeacatcaagcaaatgetgetgaacaaaccacagaatcagttaatoataaa aatytattagatgatcaaactgecetcaaacaagcagaaaaagctaaaagcgaagttaca caatcaactacaaatgtatctggtacacaaacatatcaagaccetacccaagttcaacc gcacctaaacaagtaaaaccatctacacaaactgtaaatcaaattgctcaagtgaaagct aataattotggaataagagcatctgtatatgataaaacagccaaaagtggtacgaaatac gctaaccgtacattccttatcaataaacaacgtactcaaggtaataaacacgtatgtacta tatatggatccaacaaaagcaaaccgatattctttaaaaccatattatgaacaaactttc tatatggatccaacaaaagcaaaccgatattctttaaaaccatattatgaacaaactttc acagtcattaagcaaaaaaatattaatggcgttaaatggtactatggtcaacttttagac ggtaaatatgtttggataaaatcaactgacttagttaaggaaaaaattaaatatgcatat actggaatgactttaaataacgcgataaatatccaatctcgtcttaaaatataaaccacaa gtacaaaatgagcctttgaaatggtcaaatgctaattatgcaattctaagttagatcag gatacaaaagggtttaggtaatgattcatccttaaaatatccaatctacgttaagatcaa

250.

atgaatgaaacagacgaaatttcacaaatctataacaagcatcgattaccaagtttaagt atgaatgaacagacgaaatttcacadatctatacaagcatcgattaccagttataag ggtotagcaaaagtgtotccacttgttcatagggccagcataggaggcgttttaaatgtg gcagaattaaacagaattaaacgcctagttcaagtgcaaaatcaatttaaaacattttac aatcaaatgctagaagaagatgaagaggttaagtatcctatactgcatgataaaatgaat catctaccgatacttacagatttatttaaagaaattaatgaaacatgtgatgcacacgat ttatttgaccatgcaagttatactttacaaagtattagaagtaaaatttcaagaacaaac caacgaattcgtcaaaatttagatagaatagtgaaaaatcaagggaatcaaaaaaacta tctgatgcaattgtaacagtaagaaatgatcgcaatgttattccggtgaaagctgaatat gacgatgtagaaacagtcataattactggaccaaacacgggtggtaagacggttacttta aaaacactaggattgataattgtcatggcacaatcaggattgttaattcctacactggat ggaagtcaattaagtatctttgaaaatgtatattgtgatattggagatgaacaatctata gaacaatcattatcaacattttcatctcacatgaaaatatagtagaaatattacaagat gcagatcaaaatagtctcattttatttgatgaactaggcgcaggtacagatccaagtgaa ggtgcggcactcgcaatgagtatcttagattatgtacgccgtttagggtctttagttatg gcaacaacacattaccctgaattaaaagcttatagttataatcgtgaaggtgtcatgaat gcaagcgttgaatttgacgttgaaacactgagcccgacttataaattattaatgggtgtc ccagggagatctaatgcctttgatatatcgaaaaaacttggtctaagtctcaacatcatt adagaacatgaattaattgataaaaagaaacaacttgatgatcaatatgaggtaaaatca attaagcaacatgttcaaaagaaaaagtatgatacgattcatactggagatgaagtgaaa gttctatcttacggtcaaaaaggtgaagtgcttgaacttgtaggtgacgaagaagcagtt gtacaaatgggaatcattaaaatgaaattacctattgaagatttagaaaaaacgaaaaag aaaaaagaaaacctacaaaaatggtaacaagacaaaatagacaaactattaaaacagaa ctagatttaagaggatatcgttacgaagaagctttaaatgaattagatcaatatcttgat caggcggttttaagcaattacgaacaagtttatattattcatggtaaaggtacgggggca cttcaaaaaggtgttcaacaacatttgaaaaaacataaaagcgttagacaatttagggga ggtatgcctagtgaaggtggatttggtgtcactgtggcagaactcaag atgagtttttttaaacgtctgaaagataaattttctagtaaaaatgaagatgatattcaa 252. aaagacctggatgaatctgtagattcaaatgttaacagtgattcagattcaatggatccg aatgattctgatgaacaagttaaacccaaaaagaaacctaaaaaattaagtgaagctgat tttgacgaagatggcttgatatcgattgaagattttgaagaaatagaagctcaaaaaatt ggagcaaaattcaaggccggtttggaaaaatcacgtcaaaacttccaagaacagttaaat aatttaattgctcgatatagaaaagttgacgaagatttettcgaagctctggaagaaatg cttattactgcggacgttggttttaatactgttatgaaattaactgatgagctacgtaca gaagcacaaagacgtaatatacaagaaacagaagacttaaggaggttatagttgagaag attgtagaaatctatcatcaagaggacgatcattctgaagcaatgaatattgaagatgga cgtttaaatgtcatactgatggttggtgaatggtgtcggcaaaacaacaactagt aaattagettategttateaacaagaaggtaaaaagtaatgttagetgetggtgataet tttagagetggageaatteaacaattaaacgtetggggagaacgtgttggcgttgaagtt ccccatgaagctttattatgcttagatgcaacaactggtcaaaatgcactttcacaagca tccgttgaatctgaagaaggtaac atgaaaagaaattggtggaaagaagcagttgcatatcaagtatatccacgaagttttaat gatagtaatggagatggaataggtgatctacctggattaattgaaaaattagattatcta 253 gttactcctaatgatgctgaagaatgggtaggagaagaaatggggaaatttaattatgata ttccagtttgaacatcttggtttatggagtactggcgatacgaaattcgatgttaaatcc tataaacaagtcttaaatcgttggcaaaagcaactagaaaatgtaggttggaatgcttta tttatcgaaaaccatgatcaaccacgtcgtgttttcaacctggggtgatgataaaaattat tggtatgaatcagcaactagtcacgctactgcctacttttacaacagggcacacctttt atttaccaaggtcaagaaataggtatgactaattatccatttgaaagcattgaaagtttc aacgatgtcgcagtgaaaactgaatatcaaatagtcaaaaaagaaggtggagatgtcaat caattactagataaatataaaatggaaaaccgagacaatgcaaggactccaatgcaatgg aataattctatcaatgctggattcactactggtaagccatggtttcatgtaaaccctaac ttaattytagocaatctoacaaatgaagtatcagaactaaacctaccttttgaattagat atttcatctytagatataaaattycataattatcacttaaatgatataaatttagaccat attaaaccttatgaatcattcytcyttyaaata

| | · | 1 |
|------|---|---|
| 254. | ttgagtcatagaaagctatttccttctatattccatttatatcaacaagacaatttagat gaacatattgctattattggtataggacgtcgcgattataataacgaacaatttcgcgac caagttaaagcgtcaattcaaacttatgttaaagatacagatagaatttgatggtttatg acgcatgtttttatcataaaactgacgtgagtgataaagaattgatgggtttactt caatttagtgagcgactagattcagaatttgctttaggtgggaatcgtcgttttactt gcgatggcaccacaattttttggagtggatctcagattacctt caaactacaggatttaaacgcttagttataggagaaacaatttgggcagtgatctaaatct gctgaaccacaattttttggagtgatctcagattaccttaaatcttctggtcttact gctgaatcattaaataatcaaataagacgttcgtttaaagaagaagaagaatttacggata gatcactatcttggcaaagatatggtgcaaatattaagaagttttggcattcgcaaacgcg atgtttgaacctttatggaataataaaatacaattcaagatttcgaattggatgacctatagaag gtattaggtgtcgaagatcgtggtggctactatgaatctagtggtgcacttaaagacatg gtacaaaatcacatgctacagatggttgctttacttgcaatggaagcacgataagtttg aatagtgaagatatacgtgcagaaaagtcacaagtactaaatctctagacaattaaaa ccagaagaagttaaacagtgcagaagaatcgcgtagcaatatgatcaagacacgataagttg aaacaggttaagtcatacgagaagaatcgcgtagcaatatgatcaagacacgataagtta aaacaggttaagtcatatcgagaagaaatcggtgagcacgaattcaaggcaa tttgtatcgggtaaattaacaattgataactttagatggctggagttcctttacacgaca tttgtatcgggtaaattaacaattgataactttagatggctgaggttcctttcacatt agaacgggtaaacgattagaaatcaaaaacgatacaagtcgtagtagaatttaaagaaga cctatgaatttatattatgaaactgacaatttactagatctaaatttgctagtcattaat actcaaccaaatgaggaattccattcattgctagtcaagatagaatttaaaaatcgaatcaagtagaattgaatcaacat ggaggaagaaattacattgataatcattagatgctaagatagaacattcaacag gatgcaatatgaaaacttattgttgattgcttaaaggtgatgcgactaatttaacagat ggaggaagaattacaacttggaaatttgtcttaaaggtgatgcgactaatttaacaat tgggaagaaattaacattgttgatgtcttaaaggtgatgcaccaagatcaatggacat gttgaaccatgtttccctaaactatggaaagtggatacaccac ttttattaaacaattgataacattggaaggggatacaccaagatcaatggacat ttgaaccatgtttccctaaactatggaaattgtaagaacgaccatccaagatcaatggacat ttgaaccatgtttccctaaactatggaaggggatacacaccaccactcttgaaagtgacaccact ttgaaccatgtttccctaaactatggaagcgggatacacacac | |
| 255. | atgattaaaaaaacaaagaagaactgaatgacatggagtatctagtcactcaagaaaat ggtactgaacctccgtttcaaaacgagtattggaatcactttgaaaaaggaatttacgtt gataaattgccggcaaaccattatttacttcagaggataaatttgcggt tggccaagtttctccaaagcattatttacttcagaggataaatctgtgtgataaatctaattgcggt tggccaagtttctccaaagcattaatgatgatgaaatcgtagaacttgttgataaatca tttggtatgaatagaactgaagttcgatcagaaaaagcaaatagtcacttggggcatgtt tttaatgacggacctaaagaaaaaggtggtttaaagatactgtattaactctgctgcgatt cagtttataccttatgataaactagaagagttaggatatggagatttaattaa | |
| 256. | ttgaaaaagttagcetttgcaattacagcegcttcaggegcagcagcagtetatcacat catgatgctgaagcttctacacaacataaggtcaatctaggagaatccttatggactatt gcacaacaatacaat | |
| 257. | atggcacgtattgctacaaaattgggctatcctgaaagcaatagtttcgtgactaatact gtaattgaatttgttttacataacgaagcatatcctcggttatataggattaaaaactga gatacgaacttaataaaatttctcaagctaatgaatccacgtcaaattacaaattgc gatacgaacttaataaaatttccaagctaatgaatctcacgtcaaaattacaaatggc acgatgacgcttgaagaagctaagtatcaattagaggaaatatatgttgctaaaagagat agcagtctaccttcaacaggaggtcgtctggtgatatcatcacacgctgtattagctggaacgattgctctatcta | |
| 258. | atgacagaatttgacttatccactagagagggtcgttggaaacatttcggttctgtgac cctgtcaaaggtacgaaaccaactactaaaaatgaaatg | |
| 259. | gtgcaaaaaaatatattactgccattattggaacaactgcccttagcgcattgcatca actcatgcacaagctgcaacaacgcatacagtaaaaaagtggagaatctgtatggcaatt tctcacaaatatgggattagtattgctaaattaaaatcacttaatggattgacttccaat ttaatattccctaatcaagtattgaaagtatcaggctcatcttcaagagcaacgtcaaca aatagtggcacagtttatacagttaaagctggagattcattatcttctattgctgcaaaa tacggtacaacttatcaaaaaatcatgcaacttaatgggttaaataactatcttatttc cctggacaaaagttgaaagtttctggtaaagcgggttaaataactacttatttc cctggacaaaagttgaaagtttctggtaaagcaggttcagtgggataactacatatctgcaatt ggtctagtggtgcgtactgcaacaatatactgttaagtatggagactcactatctgcaatt gctagtaaatatgggacaacgtatcaaaaattatgcaattaagatggattaactaattctc tttatctatcctggacagagttaaaagtgcctggaggtagttctagtagctcatctct aataatactagatcaaacggtggctattatcaccaacttttaaccaacaacattgat acttggggacaatgcacatggcacgtatttaatcgcacgtgctgaaataggaaaaggtatc agtacatactggtggaatgcaaataattgggacaatgcatcagctgctgaaataggaaaggtatc attgattatcgtcctacagtaggctgaatgcacaagcatgcat | |

| 260. | gtgaccaaaaaagcttttattcttattctagaacaagtgatgaacatttaaatagagtt gtgagaataggagaagttgagattgatcatggaattgatgttattttagatgtatgg gattgcactgagggagatgacttgaattttttatggagtctatggtaatgacagagcg atagattttgttattattataagaggatttcagtatttaatagagctaatgaagaga ggaggagttggaaaagaagcacaataattacttctcaaatttatgataagcaaaagat agtaagtttatacctgctttttagatattctggataatggaaaaccatcattaccaact tttgtaatactagattcgctattgatatgacagacatcgaattagataagagaaaagagagag |
|------|--|
| 261. | atgcactatctaaagaaagtaactatatacataagtttattaattttggtgagtggttgt gagacagcaaagaaacggaaatcaaacaaaaactttaataatgtgtaaatgtgtatcca actaaaaatctagaagacttttatgataaagagggttatcgatgaagagtttgataaag gatgacaaaggaacatggattattagatctgaaatgacaaaacagccaaaaggtaagatt atgacttcaaaaggtattggtgttacatatgaatagaaatactagaagatcaactggttat tacgttattaggaaaatttctgaagataataaaagtgaaattgatgaagaaaaggaaa tatcctataaagatggtaaataacaagataattccaactcaaaaaattaatgacaataaa ttgaagaatgaaatagaaaactttaagttctttgtacaatacggaagctttaaaaattca gatgattataaagaagggatattgaatacaactcaatgcaccaaattattctgcacaa tatcatttaagtaatgatgactataataataacaattaagaaaaagatattaaa acgaaaaaaacccctagattattaatgagagggctggagatccaaaaggatcttctgta ggttataaaaaactctagattattaatgagaaggcgctggagatccaaaaggatcttctgta ggttataaaaaatcttgaatttacatttgttaagaataagagaaaatatttatt |
| 262. | gtgaaacattcgaaaaagttacttttatgcatcagtttttattaataacgttttttatt ggtggatgtggatttatgaataaagacgatggtaaagaaacggaaaatcaaacaaa |
| 263. | atgcgttatctcaagaaagtaacgatatacataagtttattaattttggtaagtggttgt ggaaacggtaaagaaacggaaatcaaacaaaactttaataaaatgttagacatgtatccg actaaaaatctagaagacttttatgataaagaaggctatcgagatgaagagtttgataaa aaggataaagggacatggatagttggatctaccatgacaattgaaccaaaaggcaagtac atggaatctagaggtatgtttctatatattaatcgcaatactagaacaactaaaggttat tattatgtgaggaaaacaacagatgacagtaaaggtagactaaaagatgatgaaaagaga tatcctgtaaaaatggaacacaataaaattattccaacgaagccaatacctaatgacaaa ctaaaaaagaaatagaaaacttcaaattttttgtacaatatggagattttaaaaactta aaggattataaagatggacattcatacaatcctaatgtacctagttattctgaaaa tatcaattgagtaataatgactataatgtaaaacattacgaaaaagagatatgatgatattccc accaaccaagcccctaaattattttataaagaggatgtgacttaaaaggccatactata ggttccaaaagtttagaatttacttttatagaaaataaagaggaatatgatatttttttt |
| 264. | atgaaacattcaagcaaaataatagtatttgtaagtttcttaattttaacgattttatt ggaggatgtggttttataaataagaagatagcaaagaagctgaaatcaaacaaa |
| 265. | atgcgttatctcaagaaagtaactatatacataagttattaatttaacgatttttatt ggaggatgtggttttaaaataaagaagatagcaaagaaacggaaatcaaacaaa |

267..

gtggatgatgtgacaaaatatggtccagttgatggagatccgattacgtcaacggaagaa attccgtttgataaaaaacgggaatttgatccaaacttagcgccaggtacagagaaagtcgttcaaaaaggtgaaccaggaacaaaaacaattacaacaccaacaactaagaacccatta gagatogttcattatggtggcgaagaaatcaagacaggccataaggatgaatttgatccg aacgcaccgaaaggtagtcaaacaacgcaaccaggtaagccaggagttaaaaatcctgat acaggcgaagtagtcacaccaccagtggatgatgtgacaaaattatggtccagttgatgga gatccgattacgtcaacggaagaaattccgtttgataaaaaacgcgaatttgatccaaac ttagcgccaggtacagagaaagtcgttcaaaaaaggtgaaccaggaacaaaaacaattaca acgccaacaactaagaacccattaacaggggaaaaagttggtgaaggtgaaccaacagaa aaaataacaacaaccagtggatgagatcgttcattatggtgggaagaaaatcaagcca ggccataaggatgaatttgatccaaacgcaccgaaaggtagccaagaggacgttccaggt aaaccaggagttaaaaatcctgatacaggcgaagtagtcacaccagcagtggatgatgtg acaaaatatggtccagttgatggagatycgattacgtcaacggaagaaattccgtttgat aaaaaacgcgaatttgatccaaacttagcgccaggtacagagaaagtcgttcaaaaaggt gaaccaggaacaaaaacaattacaacaacaactaagaaccattaacaggggaaaaa gttggcgaaggtgaaccaacagaaaaataacaacaacaacagtagatgaaatcacagaa tatggtggcgaagaaatcaagccaggccataaggatgaatttgatccgaacgcaccgaaa caaccagtggatgagatcgttcattattggtggcgaagaaatcaagacaggccataaggat gaatttgatccgaacgcaccgaaaggtagtcaaacaacgcaaccaggtaagccaggagtt aaaaatcctgatcgatcgatagtcacaccaccagtggatgatgtgacaaaattggt ccagttgatggagatccgattacgtcaacggaagaaattccgtttgataaaaaacgcgaa tttgatccaaacttagcgccaggtacagagaaagtcgttcaaaaaaggtgaaccaggaaca aaaacaattacaacgccaacaactaagaacccattaacaggggaaaaagttggtgaaggt gaaccaacagaaaaaataacaaacaaccagtggatgagatcgttcattatggtggcgaa gaaatcaagccaggccataaggatgaatttgatccaaacgcaccgaaaggtagccaagag gacgttccaggtaaaccaggagttaaaaatcctgatacaggcgaagtagtcacaccacca gtggatgatgtgacaaaatatggtccagttgatggagattcgattacgtcaacggaagaa attccqtttgataaaaaacgcgaatttgatccaaacttagcgccaggtacagagaaagtc gttcaaaaaggtgaaccaggaacaaaaacaattacaacgccaacaactaagaacccatta acaggagaaaaagttggcgaaggtgaaccaacagaaaaaataacaaaacaaccagtggat gagattgttcattatggtggtgaacaaataccacaaggtcataaagatgaatttgatcca gagattgttattatgtgggggggtaaaaattgaagttccaggtaaaccaggagttaaaaatcctgat acaggtgaagttgttaccccaccagtggatgatgtgacaaaatatggtccagttgatgga gattcgattacgtcaacggaagaaattccgtttgataaaaaaccggaatttgatccaaac ttagcgcaggtacagagaaagtcgttcaaaaaaggtgaaccaggaacaaaaacaattaca acgccaacaactaagaacccattaacaggagaaaaagttggcgaaggtaaatcaacagaa caagctaatgagggaactttagtcggatctctattagcaattgtcggatcattgttcata tttggtcgtcgtaaaaaaggtaatgaaaaat

| 268. | mtkkekdykksleqqktrvkiyksgkswvkasineiellktmglpflskneiqenvtekt kghklksaakttalvggaftfmmlmhqafaasetpitseissnsetvanqnsttikns qketvnstslesnhsnstnkqmssevtntagssekagisqgssetsngsklntyastdh vesttinndntaqqdqkssmvtskstqantsseknissnltqsietkatdslatsear tstnqisnltststsngssptsfanlrtfsrftvlntmaaptttstttssltsnsvvm kdnfnehmnlsgsatydpktgiatltpdaysqkgaislntrldsnrsfrfigkvnlgmry egyspdgvaggdgigfafspspplgqigkegaavgigglmnafgfkldtyhntstprsdak akadprnvgggafgafvstdrngmatteestaaklnvqptdnsfqdfvidyngdtkvmt vtyagqtftrnltdwiknsggttfslsmtastggaknlqqvqfgtfeytesavakvryvd antgkdiippktiagevdgtvnidkqlmnfknlgysyvgtdalkapnytetsgtptlklt nssqtviykfkdvqgpqisvdsqtrevyktinpitittidnskdvltttvtglpsglsfd qtntiigtpsevgttvvtnttdatgnvtskqfttiqdtispvvnvtpsaevftpi mpititatdnsgkvvthtvtglpgglkfdastnsivgtptqigtntitiestdasgnktt tkinyevtrnsasdststsivnsvstsisnstslsdsvkasgslstkestskslsgslsa stsnsasikasesatskklsesastskklsesastskklsesastskslsessatskslsesastskslsesastskslsesastskslsesastskslsesastskslsesastskslsesaststsesd snststslseststslsestststsdsaststsesd snststslseststslsestststsdsaststsesd snststslseststslsestststsdsaststsesd snststslsestststsdsastststsesd snsatstslsestststsdsaststststststsststststststststs |
|------|---|
| 269. | mkktviastlavslgiagyglsgheahasettnvdkahlvdlaqhnpeelnakpvqagay dihfydngyqynftsngsewswsyavagsdadytesssnqevsantqssntnvqavsapt ssesrsyststtsysapshnysshsssvrlsngntagsvgsyaaaqmaatqsvastweh iiaresngqlharnasgaaglfqtmpgwgstgsvndqinaaykaykaqglsawgm |
| 270. | mnknkvivigstnvdkflnvkrfpkpgetlhinqaqkefgggkganqaiaasrlaadttf iskvgkdgnanfiledfkkagihtqyiltseseetgqafitvdeagqntilvygganmtl satdvemsvdafigadfvvaqlevpfeaieqafkiarkqnittvlnpapaielpksllel tdiipneteaelltgisinnesdmketatyfldlgisavlitlgeqgtycayqeqykmi pacnvkaidttaagdtfigaflselnkdlsnlesairlanqassltvqrkgaqasiptrk eveaeyn |
| 271. | malkkykpitngrrnmttldfaeitkttpeksllqplpkragrnnqgkltvrhhggghkr qyrvidfkrnkdgiiakvdsiqydpnrsaniallvyadgekryiiapkglqvgqtvesga eadikvgnalplqnipvgtvihnielkpgkggqlarsagassqvlgkegkyvlirlrsge vrmilstcratigqvgnlqhelvnvgkagrsrwkgvrptvrgsvmnpndhphgggegrap igrpspmspwgkptlgkktrrgkkssdklivrgrkkk |
| 272. | mkskftillftifsttvlvlviiynktqsqsyisthysnnkikttatlflhgyggserse tfmvkqalnknvtnevitarvssegkvyfdkklsedaanpivkvefkdnkngnfkenayw ikevlsqlksqfgiqqfnfvghsmgnmsfafymknygddrhlpqlkkevniagvyngiln mnenvneiivdkqgkpsrmnaayrqllslhkiycgkeievlniygdledgshsdgrvsns ssqslqyllrgstksyqemkfkgakaqhsqlhenkdvaneiiqflwet |
| 273. | mkigidaggtlikivqehdnrryyrtelttniqkvidwlmeeietlkltggnagviadq ihhspeifvefdasskgleilldeqghqiehyifanvgtgtsfhyfdgkdqqrvggvgtg ggmiqglgyllsnitdykeltnlaqngdrdaidlkvkhiykdteppipgdltaanfgnvl hhldnqftsanklasaigvvgevittmaitlareyktkhvvyigssfnmqllrevveny tvlrgfkpyyiengafsgalgalyl |

| 274. | mtlnnhfaytfeerptpklwlckpdgtrieriadfsklggtfkftnvntlhfdlplqvfs | 1 |
|------|--|---|
| | edtkqiernkvvdlvknkylidyryngyrdifviddikksandsdfitlnldsraselnk kaaneiellgstipqmmnkilsvyaplwklghvdgkiidvkreltgsnttvnalidnics | |
| | lfdavaiynninrtisfyhkdnvgtnrglrvrensylksfedqfvskdivtrlypfgqsg ltiqsvnpagssyiedfsyfmspfkrdnnrnylqhsdymsdelchalldyqefyaskkdq | ļ |
| | agelskqysailkehsqedfrlnqlsatlqrlnervelvkpkseyidlgtkvknfkitvp kssyylimirndgsftrikfnnkqydipsgewlyiklktgkfndatkfekqleypleils | - |
| | ananlrvvytrssegdyeeedtktieekynlekykilvkdqekvvasierrlkafedqka svirsmnaknflseklynerelyvfesvwteenhtdagelyddavkqmkeqkkinrtitv | 1 |
| | dlvnfiqsldhkddwdklnvgdkvvfqnkifntkikayitemqldfqtnqvkitisdifd ykdldtiiaeklaqttstssqvdfhkqqireqtgritdmtrliegewdankkrvmagnet | ١ |
| | vdigshgvkviskenpnefvimvggviamtrdngetfktgitpeginaemligkmivget | ١ |
| , | ltfenesgtvkfdkdglyvnsknfhlvsndgeedyfdklkremsenakqqtdrmleeykk evsqtiseatdvrnivdnaadilqaafadgvitdvekrlisetlaqlekenrefedkinl | |
| | alnhpyiteedtielnnsiveyssmyetlvisinesvsdkmitpqeseeinqniinfree ikdilslveeiiertknaglgatleeakdyttrvrddikdelkdlnnsfkslnstveesl | |
| | qdnifdaaeleaiktvvlvtkseyqditnryssmsantdlkseskldltksyktldtsfn dfvkyidemtmdriadetekvnykkkydtlqknlsdymkkydncileiskkysndaadkv | |
| | lgdftaiatelqndfqdvkdnwaefkqttlesfkdgivteaekarlrvqldmldresmdi eeryksllanqytntdiknrltasrspylsvhaslrkvieqiiadgkvdesektlannsl | |
| | ntynttltaysktiqealntlsqiissdvaskkveefngvittissdvdtikkqrdgavi | |
| | tyyysgvptlsndpakswttndlkdlhikdmyldtksgyaytftksgtsyswkpltdqvi vsslkqaknaqdtadnkrrvfvtqpippydqgdmwtqgsqgdiyvcgtsratgsfvssdw | |
| | vkaskytddtvakqaakdledykvkmtkdfkdlndgvstfktevvkdfkdgivteaektr lrvqldildresqdieerynsifnsqyadtqvktsisnarstynnsltklrntiqtvied | |
| | gkvtptekttanqtltaynnaltsysaaiqealnsmskviaqkeatsqynqfneviknin tnitdiqkqvdgaietfyysgyptltnipasywttaskreahlgdlyldtatgvayrflk | |
| | kgttsptyywspisdqiitdalnraktaqdtadgkrrvfyntpyppydtgdmwtqgasgd ilycktpkakggiysisdwykaskytddtyansayqqlneykrtnnldiadlkrktsdfe | 1 |
| | ktvvnafddrvisisesssikgqlallnhekdrltrqyeniirnsnlvgaektklstays | |
| | nintklsdlsttinsaivdnkivdaesksvtskfelykasvneyqiafdnalnsiireia ssqakdrldewkrtefstdsdgiiervagakfdskwtdtwrntvnpaiqqvsnitygsen | |
| | lllnsesrsdganttthsfiryyltrpletgktytlkasvlttderqsgqisvypyspng aretvnikdgkitytftaqtestqfliykdvagqsdvdlnvtiekailvegnkvtgwspa | |
| | peetssalrdyntrissaetfieknkekisqiatksdvdaslskvatyetqynvssgtny qiplqeynqsfftdnytyevyaknnslssnnvataifvskgsnngyelveldnmsktgan | 1 |
| | prfyldskgrpsistfspqsttqdisviytkylgsasainttkslieqtassielqvkkl taeteynnillnsdfssgwegwinvdpqysivdkntfgitlpdaitnknkkyntvkmtyn | 1 |
| | kntnypsvfsnfisvgkgqevaigehltltcyayipssskgkltgniyiefagyyekdqk | |
| | snpmiarheilpkdfeynkwfrmtastaipstnsegkkinyiraclrydgknqsvnnsai fyyalpqlergskptewslsrldyfsteqlaakialnpesvdiiarnidfntdsmkiyns | |
| | ngtlnisgdtltisnnnssneviinpkgftlkkdgvvkfkngldtsdysvqayepqfssw nnikatdpaakskynyirhiepgmngyytintgvynfavqhkqllevnntknarvnryty | |
| | lynkrylkiqmsassrgksklyiifktktgdttlhqeivssssmvypditidlqaklgyp pnnlpdffelqagiaygennsidgffrirrmamtdtpnaev | ļ |
| 275. | mynvtqhatyktknkretavligvhaqtdrqfnfestmeeldalsqtcqlnvkgqitqnr eqfdhkyyygkgkideiksfiefhdidvvvtndelttaqsktlndnlgikiidrtqlile | |
| | ifalrarsregklqvelaqldyllprlhghgkslsrlgggigtrgpgetklemdrrhirt rmneikhqlktvvdhreryrnkregnqvfqialvgytnagksswfnvlaneetyeknilf | |
| | atldpktrqiqvnegfnliisdtvgfiqklpttlvaafkstleeakgadvlmhvvdashs | |
| | eyrtqidtvnqiindldmdhipqvvifnkkdlcneqmdvpvsksahvfvssrdendkqkv knlviqeiknslspyeeivdsadadrlyflkqhtlvtelifdetqasyrikgfkkl | |
| 276. | mmiivmlilsyligafpsgliigklffkkdirqygsgntgatnsfrvlgrpagfivtfld ifkgfitvffplwfpvhadgvistfftnglivglfailghvypiylkfnggkavatsagv | |
| | vlgvnpilllilaiiffsvlkifkyvslssiiaaiscvigsiiihdyillavsgivsiil iirhksnivrifkgeepkikwm | |
| 277. | mmnhsealteqvfsfaselyaygvrevvispgsrstplalvfeahpniktwihpdersaa | ٦ |
| | ffalglikgsekpvailctsgtaaanytpalaesqisrlplvvltsdrphelrsvgapqa inqvnmfsnyvnfqfdlpiadgsehtidtinyqmqiasqylygphrgpihfnlpfreplt | ١ |
| | pdldrvdlltsvtktlphyqksisvddikdilqekngliivgdmqhqavdqiltystiyd lpiladplsqlrkekhpnvittydllyraglnlevdyvirvgkpviskklnqwlkktday | l |
| | qiivqnndqidvfptpphisyeisandffrslmeeplverkkwlqqwqsleqqarieisd ylkhatdeaayvgsliqkltkedtlfvgnsmpirdvdnllfdseasvyanrgangidgvv | ١ |
| | stalgmaahknvtlligdlsfyhdmmgllmaklnelhinivlvnnngggifsylpqkrsa tkvferlfgtptglnfeytallydftfkrfdnltdfkvaelskmgshmyevitnrdenlh | |
| 278. | qhqnlyqklseivnytl | 4 |
| 2/8. | makkfnyklpsmvaltlfgtaftahqanaaeqpqnqsnhknvlddqtalkqaekaksevt qsttnvsgtqtyqdptqvqpkqdtqsttydasldemstyneissnqkqqslstddanqnq | |
| ' | tnsvtknageetndltgedktstdtnalgetasvakenekdlgananneagdkkmtasap sengaietatasnanesaaksaavtseanetatpkvsntnasgynfdyddedddsstdhl | |
| | epislnnvnatskqttsykykepaqrvttntvkketasnqatidtkqftpfsataqprtv ysvssqktsslpkytpkvnssinnyirkknmkaprieedytsyfpkygyrngvgrpegiv | |
| | vhdtandnstidgeiafmkrnytnafvhafvdgnriietaptdylswgagpygnqrfinv eivhthdydsfarsmnnyadyaatqlqyynlkpdsaendgrgtvwthaaisnflggtdha | |
| | dphqylrshnysyaelydliyekyliktkqvapwgttstkpsqpskpsggtnnkltvsan rqvaqikptnnglyttvydskghktdqvqktlsvtktatlgnnkfylvedynsgkkygwv | |
| | kqgdvvyntakapvkvnqtynvkagstlytvpwgtpkqvaskvsgtgnqtfkatkqqid katylyqtvnqksgwiskylttaskpsnptkpstnnqltvtnnsgvaqinaknsglytt | |
| | vydłkgkttnqiqrtlsvtkaatlgdkkfylvgdyntgtnygwvkqdeviyntakspvki | |
| | nqtynvkpgvklhtvpwgtynqvagtvsgkgdqtfkatkqqqidkatylygtvngksgwi skyyltapskvqalstqstpapkqvkpstqtvnqiaqvkannsgirasvydktaksgtky | |
| | anrtflinkqrtqgnntyvllqdgtsntplgwvnindvttqnigkqtqsigkysvkptnn glysiawgtknqqllapntlanqafnaskavyvgkdlylygtvnnrtgwiaakdliqnst | |
| | dagstpynytfvinnsksyfymdptkanryslkpyyeqtftvikqkningvkwyygqlld gkyvwikstdlvkekikyaytgmtlnnainiqsrlkykpqvqneplkwsnanysqiknam | |
| | dtkrlandsslkyqflrldqpqylsaqalnkllkgkgylenggaafsqaarkyglneiyl ishalvetqngtsqlakggdvskgkfttktghkyhnvfgigafdnnalvdgikyaknagw | |
| 1 | | |
| | tsvskaiiggakfignsyvkagqntlykmrwnpanpgthqyatdinwanvnaqvlkqfyd kigevgkyfeiptyk | |

| 279. | vafefrlpdigegihegeivkwfikagdtieeddvlaevqndksvveipspvsgtveevl vdegtvavvgdvivkidapdaeemqfkghgddedskkeekeqespvqeeasstgsqekte vdesktvkampsvrkyarengvnikavngsgkngritkedidaylnggsseegsntsaas estssdvvnasatqalpegdfpettekipamrkaiakamvnskhtaphvtlmdeidvqel wdhrkkfkeiaaeqgtkltflpyvvkalvsalkkypalntsfneeagevvhkhywnigia adtdkgllvpvkhadrksifeisdeinelavkardgkltseemkgatctisnigsaggq wftpvinhpevailgigriaqkpivkdgeivaapvlalslsfdhrqidgatgqnamnhik rllnmpelllmeg |
|------|---|
| 280. | mnetdeisqiynkhrlpslsglakvsplvhrasiggvlnvaelnrikrlvdvdqqtktty nqmleedeevkypilhdkmnhlpiltdlfkeinetcdahdlfdhasytlqsirskisrtn qrirqnldrivknqgnqkklsdaivtvrndrnvipvkaeyrqdfngivhdqsasgqtlyi epnsvvemnnqisrlrndeavererilteltgfvsaeadalliaesvmgqidfliakary artikgtkptfkedrtiylpnafhplldkdtvvantiefiddvetviitgpntggktvtl ktlgliivmaqsglliptldgsqlsifenvycdigdeqsieqslstfsshmkniveilqd adqmslilfdelgagtdpsegaalamsildyvrrlgslvmatthypelkaysynregvmm asvefdvetlsptykllmgvpgrsnafdiskklglslniinkaktmigtdeqeinamies leqnskrvdqqrieldrlvreaqqthdalskqyqqymytslmdeakekanqrvksatk eadeilkelrnlrdhkgaevkehelidkkkqlddqvevksikqhvqkkkydtihtgdevk vlsyqdkgevlelvgdeeavvqmgiikmklpiedlektkkkkekptkmvtrqnrqtikte ldlrgyryeealneldqyldqavlsnyeqvyiihgkgtgalqkgvqqhlkkhksvrqfrg |
| 281. | msffkrlkdkfsskneddiqkdldesvdsnvnsdsdsmdpndsdeqvkpkkkpkklsead fdedglisiedfeeieaqkigakfkagleksrqnfqeqlnnliaryrkvdedffealeem litadvgfntvmkltdelrteaqrrniqetedlrevivekiveiyhqeddhseamniedg rlnvilmvgvngvgktttigklayryqqegkkvmlaagdtfragaiqqlnvwgervgvev vsqnegsdpaavvydainaaknkdvdilicdtagrlqnksnlmqeldkmkrvinraipda pheallcldattgqnalsqarsfkevtnvsgivltkldgtakggivlairnelhipvkyv |
| 282. | mkrnwwkeavayqvyprsfndsngdgigdlpgliekldylenlgidviwlspmypsphdd ngydisdykgimsefgtmndfdqllssihqrgmklildlvvnhtsdehpwfieskssktn akrdwyiwadpkpdgsepnnwesifngstwefdestkqyyfhlfskkqpdlnwenpdvrq avfemmwwfekgidgfrvdaithikknfeagdlpvpdgkkfapafdvdmnqpgiqewlq emkdkslsrydimtvgeangvtpndaeewvgeengkfmnifqfehlglwstgdtkfdvks ykqvlnrwqkqlenvgwnalfienhdqprrvstwgddknywyesatshatayflqqgtpf iyqqqeigmtnypfesiesfndvavkteyqivkkeggdvnqlldkykmenrdnartpmqw nnsinagfttgkpwfhvnpnyteinvkqqlndkfsilsyykaliqlkksdliytygkfnm ydaenkqvfaytrtfknntvlivanltnevselnlpfeldissvdiklnnyhlndinldh ibnyesfywei |
| 283. | lshrklfpsifhlyqqdnldehiaiigigrrdynneqfrdqvkasiqtyvkdtdridefm thvfyhktdvsdkesyqsllqfserldsefalggnrlfylamapqffgvisdylkssglt qttgfkrlviekpfgsdlksaeslnnqirrsfkeeeiyridhylgkdmvqnievlrfana mfeplwmkyisniqvtssevlgvedrggyyessgalkdmvqnhmlqmvallameapisl nsediraekvkvlkslrqlkpeevkknfvrgqydqgnidgkqvksyreedrvakdsvtpt fvsgkltidnfrwagynfyirtgkrmksktiqvvvefkevpmnlyyetdnllsnllvin iqpnegislhlnakkniqgidtepvqlsyamsaqdkmtvdayenllfdclkgdatnfth veelkstykfydaigdwtmyengfpnyeagtngplesdlllsrdgnhwwddih |
| 284. | mikknkeelndmeylvtqengteppfqneywnhfekgiyvdklsgkplftsedkresnog wpsfskalnddeivelvdksfgmirtevrsekanshlghvfndgpkekgglrycinsaai afinydkleelgyddlikhfkk |
| 285. | 1kklafaitaasgaaavlshhdaeastqhkvqsgeslwtiaqqyntsvesikqnnism mvfpgqvinvggsasqntssntssssasshtvvageslniiankygvsvdalmqanhlng ylimpnqiltipnggsgsgsggtatqtsgnytspsfnhqnlytegqctwyvfdkrsqagk pistywsdakywasnaandgyqvdntpsvgaimqstpgpyghvayveringdgsilisem nyangywmmyrtipassyssvafih |
| 286. | mariatklgypesnsfythtviefylhneayprlyriktrdthlikisganelsfgithg tmtleeakygleeiyyakrdsslpfkgiaaaiiatsflylgggrlydiitavlagtigyl yveildrklhagfipefigslyigiisvighafypsgdlatiiiaavmpiypgylithai |
| 287. | mtefdlstregrwkhfgsvdpvkgtkpttknemtdlqsthknflfeieevgiknitypvl idqyqtaglfsfstslnknekginmsrilesvekhydngielefntlhqllrtlqdkmnq naagvdvsgkwffdryspvthikavghadvtyglaienhtvtrkeltiqakvttlcpcsk eiseysahnqrgivtvkayldknndviddyknkildameanassilypilkrpdekrvte |
| 288. | vqkkyitaiigttalsalasthaqaatthtvksgesvwsishkygislakiksligitsi lifpnqvlkvsgsssratstnsgtvytvkagdslssiaakygttyqkimqlnglnnylif pgqklkvsgkatssrakasgssgrtatytvkygdslsaiaskygttyqkimqlngltnf fiypoqklkvpggsssssssntrsnggyysptfnhqmlytwgqtwhvfnrraeigkgi stywmannwdnasaadgytidyrptvgsiaqtdagyyghvafvervnsdgsilvsemnw |
| 289. | vtkkafisysrtsdehlnrvvrigeslrvdhgidvildvwdctegddlnffmesmyndet idfviilsdfqyfnrandreggygkestiitsqiydkqkdskfipvfldildngkpslpt fcntrfaidmtdieldiekieeiarkihdkplfekprlgkvpdynqnqmelkkaikkltl sksynetrnfeealdiiyktleniensveeynkddlmtlkevfdtwkefityalnndnfy freliiehynrclklteeefenpmtrifnyfsflilvseslssganeflkdllnakfhfs rreanyyilslypqvlskkysyntnvkkmlaemyfegkelkkvqdadvilyteslmkkdi hsvyetwhgvllysrwpmleqqtinilinkfrskkyldqfdflfgssqrevfenydkiks |
| 290. | mhylkkvtiyisllilvsgcgdsketeikqnfnkmlnvyptknledfydkegyrdeefdk ddkgtwiirsemtkqpkgkimtskgmvlhmnrntrsttgyyvirkisednkseiddeekk ypikmvnnkiiptqkindnklkneienfkffvqygsfknsddykegdieynpnapnysaq yhlsnddynikqlrkrydiktkktprllmrgagdpkgssvgyknleftfvknneeniyft dsinfnpskgksl |
| 291. | vkhskklllcisfilitffiggggfmnkddgketeikqnfnkmlnvyptknlenfydkeg yrdeefdkddkgtwivhskmviepkgknmesrgmvlfinrntrtskgyfivneiekdrkg rpinnkkkypvkmknnkiiptkpisndklkkeienfkffvqygnfkdiknykdgdisynp nvpsysakyqlsnneynvqqlrkrydiptkkvpklllkgdgdlkgssvgsknleftfien keeniyftdsvlfspsednes |

| 292. | mrylkkvtiyisllilvsgcgngketeikqnfnkmldmyptknledfydkegyrdeefdk kdkgtwivgstmtiepkgkymesrgmflyinrntrttkgyyyvrkttddskgrlkddekr ypvkmehnkiiptkpipndklkkeienfkffvqygdfknlkdykdgdisynpnvpsysak yqlsnndynvkqlrkrydiptnqapklllkgdgdlkgssigsksleftfienkeeniffs dgvqftpsedses |
|------|--|
| 293. | mkhsskiivfvsfliltifiggcgfinkedskeaeikanfnktlsmyptknledfydkeg yrdeefdkddkgtwiinskmivepkgeemeargmvlrinrntrtakgnfiikritennkg ipdvkdkkypvkmehnkiiptkqikdkklkkeienfkffvqygnfknlkdykdgeisynp nvpsysaqyqlnnydnnvkqlrkrydiptnqapklllkgtgdlkgssvgykhleftfven kkeniyftdsinfnpsrgn |
| 294. | mrylkkvtiyislliltifiggcgfinkedsketeikqnfnkmlnvyptknledfydkeg frdeefdkgdkgtwiirsemtkqpkgkimtsrgmvlyinrntrtakgyfildeikddnsg rpienekkypvkmnhnkifptkpisddklkkeienfkffvqygdfknlkdykdgeisynp nvpsysaqyqlnnndnnvkqlrkrydiptnqapklllkgdgdlkgssvgsknleftfven keenifftdavqftpseddes |
| 295. | mktykpyrhqlrrslfastifpvfmvmiiglisfyaiyiwvehrtihqhtyqtqtelqri dkhfhtfvtqqqkqwrhvdlshptditkmkrqllkqvhqqpailyydlkgssgsftnnye qldttkmyliskyridfkddtyilkiymsstpllknikknsqqsalivdsydtvlytndd rfsiqqkyqppqfgfmmeslklnshhahliiykdihetiedgiallvvmgvvlillvifg 'yisadrmakrqsedieaivrkiddaknrhlgsyeplkkhseleeinnyiydlfesneqli qsieqterrlrdiqlkeierqfqphflfntmqtiqyliplspkvaqtviqqlsqmlrysl rtashtvklaeelsyiqqyvaiqnirfddmiqlyidapedyqhqtigkmmlqplvenaik hgrgseplkitirirltkrklhilvhdngigmspshlervrqslhhdvfdtthlglnhlh nraiiqygtyarlhifsrshqgtlmcyqiplv |
| 296. | vddvtkygpvdgdpitsteeipfdkkrefdpnlapgtekvvqkgepgtktittpttkmpl tgekvgegeptekitkqpvdeivhygeeiktghkdefdpnapkgsqttqpgkpgvkmpd tgevvtppvddvtkygpvdgdpitsteeipfdkkrefdpnlapgtekvvqkgepgtktit tpttkmpltgekvgegeptekitkqpvdeivhyggeeikpghkdefdpnapkgsqedvpg kpgvkmpdtgevvtppvddvtkygpvdgdxitsteeipfdkkrefdpnlapgtekvvqkg epgtktittpttkmpltgekvgegeptekitkqpvdeiteyggeeikpghkdefdpnapk gsqedvpgkpgvkmpdtgevvtppvddvtkygpvdgdpitsteeipfdkkrefdpnlapg tekvvqkgepgtktittpttkmpltgekvgegeptekitkqpvdeivhyggeeiktghkd efdpnapkgsqttepgkpgvkmpdtgevvtppvddvtkygpvdgdpitsteeipfdkkre fdpnlapgtekvvqkgepgtktittpttkmpltgekvgegeptekitkqpvdeivhygge eikpghkdefdpnapkgsqedvpgkpgvkmpdtgevvtppvddvtkygpvdgdsitstee ipfdkkrefdpnlapgtekvvqkgepgtktittpttkmpltgekvgegeptekitkqpvd eivhyggeqipgghkdefdpnapvdsktevpgkpgvkmpdtgevvtppvddvtkygpvdg dsitsteeipfdkkrefdpnlapgtekvvqkgepgtktittpttkmpltgekvgegeptekitkqpvd eivhyggeqipgghkdefdpnapvdsktevpgkpgvkmpdtgevvtppvddvtkyppvdg dsitsteeipfdkkrefdpnlapgtekvvqkgepgtktittpttkmpltgekvgegkste kvtkqpvdeiveygptkaepgkpaepgkpaepgtpaepgkpaepgtpaepgkpa epgkpaepgkpaepgkpaepgtpaepgkpaepgtpaepgkpa esgkpvepgtpaqsgapeqpnrsmbstdnknqlpdtgenrqanegtlvgsllaivgslfi fgrrkkgnek |
| 297. | atgaataaacagatttttgtcttatattttaatattttcttgatttttttaggtatcggt ttagtaataccagtcttgcctgtttatttaaaagatttgggattaactggtagttta ggattactagttgctgcttttgcgttatttaaaagatttgggattaactggtagtgatta ggattactagttgcgcttttgcgttatctcaaatgattatatcgccgtttggtggtacg ctagctgacaaattagggaagaattaattattatgattaggattaattttgtttcagtg tcagaatttatgtttgcagttggccacaatttttcggtattgatgtatcgagatgatt ggtggtatgagtgctggtatggta |
| 298. | atgctattttatttatttcattttacaatcagctttatatcaacagtacttttctctatc attttcaatgcacccaaacgcctcttagtagcatgtggatttgtgggtgccattgcatgg acgatttaccaattaacggtagatttagagtttggataaagttggggttcatttttggga agcttaattttagggttaatgagtttatgagtcgcagatataaacgaccggtaatt atattcatagtgccaggcattataccattagtacctggtggtgcagcttatcaagcgact cgttttttagtatcaaatgattatacaagtgctgtaaatacatttttagaagttacactg atttcaggtgcgattgctttcggtatattagttctgaaattctatattaccataccac cgtatcaaacaactgtatggtaaaatcaaaggtaagacatataaaaaatcttacaacag aataatagagtt |

| 299. | atgataaatgcagtagtaatagcagtaattttaatgattatgctatgtttatgtcgatta aacgtagttataaagcttatttatcagtgcgctagttggtggtgttaatttcaggcattgagc attgaaaaagttataaatgtatttggaaaaaataatagtcgatggtggtgaggtagcaatta agctatgctttattaggtggatttgcagcattaatttcatacagtggtacaaaagctaat ttagtaggaaaaattataaatgcaattcacgctgaaaatagtcgatggtcaaaaacttaatt cctgtacaatattgcattcattccaattgcattatatgagtatacatgagtcaaaaacttaatt cctgtacatattgcattcattccaattgtattatagctattaatgcgattaattcccgt ttaaaaatagatagacgtttaatcggtttgattatcggttttagttatgtttaatgac ttaaaaatagatagacgtttaatcggtttgattatcggttttggtttatgtttcccgtat gtgttattaccatatggattcaatttccagcaaattttccaaagtggctttgca aaggcaaatcacccaattgggtttaatatgatttggaaagcaatgcttattccttcaatg gggtatattgttggcttacttatcggtttatatggtatatcgtatatccttcaatag gggtatattgttgggcttacttatcggtttatatggtaaaaccaattatagta acacgtaaaatttcagataggtacaatgttacagagttaaaccaattatcaatgata acaattgagcaatactagctacatttttagtacaaacatttacagattcaatgat gatgctaagtttgttgaaggtattaaaaattattgagtagtagta |
|------|--|
| 300. | atgaatcataatgttattatcgttattgcattaatcatagttgtcatttctatgttagct atgctcattcgcgttgtgctaggcccatcacttgccgatcgtgttgtcgcattagatgcg attggtcttcaattaatggcagttatagcattattcagtattttattaataattaaatac atgattgtcgttattatgatgatggtatattagcttttttaggtactgcagtattctct aaatttatggacaaaggtaaggt |
| 301. | gtgaataggaatatcgttaaactagttgtgttcatgctaattttagttgtagcagtagcg ggttgtgtgtcaaaaagatactgaagagaaaactgaaatgacgacaataaaagatgaatta ggaactgaaaaaataagaaaaatcctaaacgtgttgttgtattagaatatagttttgct gattatttagcagcattagatatgaaacctgttggtattgcagatgatggcagcactaaa aatataacaaagtcagtaaggaaattagggcatatgaatcggttggatctagaccg caaccgaaattggaagtgataagtaaattagaaccggatttgatcattgatcgatgcagatgttagc agacataagaaaatcaaatc |
| 302. | atgactggagaacaatttactcaaattaaacgtccagtaagta |
| 303. | gtggaaaatacaattaatgaaagtgaaaagaaaaaacgatttaaattaaaaatgccaggt gcatttatgattttatcattttaacggttgttgcagttatagcaacatgggttattcct gctggtgcatattctaacactttettacgaaccttcatcccaagaactaaagattaac cctcataaccaagtgaaaaaggttccgggtacgcaacaggaactagacaaaatgggggtt aaaattaagaatgattaaagcaacatcagetggaccagaacaagaactagacaaattacgat actattgaaagattaaagcaacatccagetggaccagaacaaataacaagtagcatggtt gaaggtacgatagaagcggtcgatatcatggtattcattc |

305.

gtgttaaaaaagtggctaaattcaaacgtcaaacaattctttgttataactttcattagt gtaatattaacgcttattttattttctactcatatctctggattatattgtgaatggtact gttttagcggggctggagatggattccgtcaaatgatgccatttcaaatgtatttgta gaacatctacgtagtttttctagtttatatgatgcatcgtttggattaggtggcgattat atgaaaggactatattattattegotgtcacotttaatgtggctaaattttctattc attaaaataggagaaacggttggtatatttaatccgacgacaatacatttttggccgaca aaccaacttattatggctatgatacgagctatcataacatttgtcgtgaccttctactta tttaaaatattacactttaaacgctcagcaaatatgatcgctacgattttatacggcatg tcaactgtcgttatatactttaattttacttggtcattttatggaaatttattattta ttgccattatcgattcttggtttggaaagatattttcaacaacgcaaaatcggtattttc attgttgcgatagccttaacactatttagcaatttttattcagttattatcaagctatt attataggttgctactatttatatcgactcattttcacttacaaatatgacattgtctct agaacacaaaaattaatttgcgtcatatctgctacagttttgagtgtgttatcaagtgta gcactatcatcaagtgctctttgcggattgtttattcaacatttatcaacattaaatatg tttaatggagacattttaaaatattatgacaagacactccaaattaatatgccaatcgat aaaaacagcacttatagattacttggcaatcgtcaaaatttactatcactttggaatgtt aatgatcgaattagagtgaatcatgatgacaacttaccatatggatttaaaattaagtct cctacaaaacatttattacaagttaaacaaaataatggtggtctaactgtacagttgcca aaatcagtttctaatcaatttaaagatttgtattttgaaatggatttagaattactttcg ccgyataaagattatgatatgatatgaatgaatataaagatagaatataaagatacaagatataaatatagaatataaagatataaagatataaagatataaagatataaagatataaagatataaagatataaagatataaagatataagatagatataagatataagatataagatataagatataagatataagatataagatataagatataagatataagatataagatataagatataagatataagatataagatatagatagatatagatatagatagatatagatagatatagatagatatagatagatatagatagatagatatagatagatagatatagatagatagatagatagatagatagatatag ggtgttatgaccggcattaaagcacctaaaaatataacaaagattcaattgagctatacc ccaccatactattatttacttataacaattactatatttggcattatatgtagtattatt ttcacgagatgggcaagacaaaaa

gtgcgtcaattggcacaagcaaaaaagaaatcgacagctaagaaaaaaacaacatcaaaa aaaagaacaaattcgaggaaaaagaagaatgataatccgatacgttatgtcatagctatt ttagtagttgtattaatggtgttgggtgttttccaattaggaataataggtcgtctaatt gacagcttctttaattatttatttgggtacagtagatatttaacatatattttagtactc ttagcaactggttttattacatactctaaacgtattcctaaaactagacgaacggctggt tggtttggttcatttaatgaaaaaatgtcggaaagaaaccaagaaaacaattgaagcgt gaagaaaaagcaagacttaaagaagaacaaaaggcacgtcaaaatgaacagccacaata aaagatgtgagtgattttacggaagtgcctcaagaaagagatattccaatttatgggcat actgaaaatgaaagtaaaagccagagtcaaccaagtcgaaaaaaacgagtgtttgatgca gagaatagttcgaataacatcgtaaatcatcatcaagcagaatcagcaagaacaattaaca gaacaaactcataacagtgttgaaagtgaaaacactattgaagaagctggtgaagttacg aatgtatcgtatgttgttccaccgttaactttacttaatcaacctgcaaaacaaaaagca acatctaaagctgaagtgcaacgtaaaggacaagtactagagaatacattaaaagatttt ggggtaaatgcaaaagtgacacaaattaaaattggtcctgcagtaactcaatatgaaatt caaccagctcaaggggttaaagtgagtaaaattgtaaacttgcataatgatattgcatta gctttagcagcaaaagatgttagaatcgaagcgccaatacctggtcgttctgcagtaggt attgaagtgccaaatgagaaaatttcattagtttcactaaaagaagttttagatgaaaaa ttcccgtctaataataaactagaagttggattaggaagagatatatcaggtgatccaattactgttccactaaatgaaatgccacacttattggtggcaggatcgacgggtagtggtagatctgttgttgtataaatggtattattacaagtattttattattaaatgctaagccgcatgaagtt aaacttatgttaatogatoogaaaatggttgaactaaatgtttataacggaattocacacttattatatocggttgttacaaatcctcataaaggtgctcaaggtttagaaaaaattgta gctgagatggaaagacgttatgatttattccaacattcatcaactagaaacattaaaggt tataacgaattaatccgtaagcaaaatcaagaattagatgagaagcaaccagaattacct tatatcgttgttattgtagatgagcttgcagatttaatgatggtagctggtaaagaagtt gaaaatgcgattcaacgtattacacaaatggcacgtgcagcaggtatacatttaattgta gcgacacaaagaccttctgtggatgtaattacaggtatcattaaaaataatattccatct agaatagcttttgctgtgagttctcaaacagattcaagaactattattggtactggcggc ggaataagttacttggtagtttaaatagttatacgaattattggaattgggggg gcagaaaagttacttggtaaaaggtgacatgttatacgttggaaatggtgaccatcacaa acacgtattcaaggggcgtttttaagtgaccaagaggtgcaagatgttgtaaattatgta gtagaacaacaacaggcaaattatgtaaaagaaatggaaccagatgcaccagtggataaa tcggaaatgaaaagtgaagatgctttatatgatgaagcgtatttgtttyttyttgtagaaca caaaaggcaagtacatcattgttacaacgccaatttagaattggttataatagagcatct agacaagttttaatagatcttaataatgacgaggtg

307.

atgaatttgttaaagaaaaataaatatagtattaggaagtataaagtaggcatattctct cgtattcaacaagctgattatacatttgcgtcattagatatctttaatggtctgaaacga caagcatatattgattcattaactaatcaaatgcaacatacgttaattcgaagtgttgat gctgaaaatgcagttaataaaaaagttgaccaaatggaagatttagttaatcaaaatgat gaattgacagatgaagaaaaacaagcagcaatacaagttatcgaggaacataaaatgat ataattggtgaatattggtgaccaaacgactgatgatggcgttactagaatcaaagatcaa ggtatacagaccttaagtggggatactgcaacaccggttgttaaaccaaatgctaaaaaa gcaatacgtgataaagcaacgaaacaaagggaaattatcaatgcaacaccagatgttact gagacgagattcaagatgcactaaatcaatagctacggatgaaacagatgctattgat aatgttacgaatgctactacaaatgctgacgttgaaacagctaaaataatggcatcat actattggagcagttgttcctcaagtaactcataaaaaagctgcaaggaatgcaattaac caagcaacagcaacgaaaagacaacaaataaataataataaaaaaaccaacacaa ccagctacaaaagtaaaaacagatgcaaaaaatgccatcgataaaagtgcggaaacgcaa cataatacgatatttaataataatgatgcgacgctcgaagaacaacaagcagcacaacaa ttacttgatcaagctgtagcacagcgaagcaaaatattaatgcagcagatacgaatcaa gaagttgcacaagcaaaagatcagggcacacaaaatatagtagtgattcaaccggcaaca caagttaaaacggatactcgcaatgttgtaaatgataaagcgcgagaggcgataacaaat atcaatgctacaactggcgcgactcgagaagagagaaacaagaagcgataaatcgtgtcaat acacttaaaaatagagcattaactgatattggtgtgacgtctactactgcgatggtcaat agtattagagacgatgcagtcaatcaaatcggcgcagttcaaccgcatgtaacgaagaaa atcactgctgaagtggcgdagggtattgaggggttaataaacactactgaggggaggagagaagaagaagaagaagaattaatcaa gaagaaaagcaggctgctgttaatcaaattaatcaacttaaagatcaagcgattaatcaa attaatcaaaaccaaacaaatgatcaggtagacacaactacaaatcaagcggtaaatgct atagataatgttgaagctgaagtagtaattaaaccaaaggcaattgcagatattgaaaaa acagacaacy cyang cay the control of gttagaaatcaaacaatcaaggcaatagagcaaataaaacctaaagtaagacgtaaacga acaattaaaaatgacattgcacaaaacaaaacgaatgcagaagtggatcgaactgagact gatggcaacgacaacatcaaagtgatttacctaaagttcaagttaaaccagcagcgcgt caatctgttggtgtaaaagccgaagctcaaaatgcactaatcgatcaaagcgatttatca

| 309. | atgagtgttgaaatagaatcaattgaacatgaactagaagaatcaattgcatcattgcga caagcaggcgtaagaattacacctcaaagacaagcaatattacgttatttaatttcttca catactcatccaacagctgatgaaatttacaagcactttcacctgattttccaaatata agtgttgcgacaatatataataacttaagagtgtttaaagatattggaattgtaaaagaa ttaacatatggagactcatcaagtcgattcgactttaatacacataatcattatcatatt atatgtgaacaatgtggtaagattgttgattttcaatatccacagttaaatgaaattgaa agattagctcagcatatgactgactttgacgtaacacatcatcgaattgaaattgaa gtttgtaaagaatgccaagataaa |
|------|---|
| 310. | atgagtgaaaacaacaaattctcgattatatagaaacaataatagttatatcgaa atcagtcatagaattcatgaacgtcctgaaacttggtaatgaagaaatatttggtctcga actttaatagatcgtttgaaagagcatgattttgaaatgagaaacagagtgctcga gcaactgggtttatagcgacatatgatttagggcctgggccagctataggttttta gcagaatacgatgctttgccaggattgggtcatgcttgacgggccagctataggttttta gcagatgtcttggtgcaattgggtcatgcttgtggtcataatatcattggaact gcagtgttcttggtgcaattggtttgaagcaagtgattgaccaaattggtggtgaaagta gtcgttcttggtgcaattggtttgaagcaagtggtgggaaaattggtgagcgctaaagctctata gtcaaggctggtgtgattgatcaaatagacattgccttaatgattcatccgggaaatgaa acttataaaacgattgatactttggcagtgatgttttagatgttaaatttacggaaaa acttataaaacgattgatactttggcagtgatgttttagatgttaaatttacggaaaa agtgctcatgcctctgaaaatgcagatgagcgttaaatgcattagacgctatgattagt tattttaatggtgtagcacaactacgacaacatattaaaaaagatcaacggtaggt gtgattttagatggcgggaaagcagctaatattattccagacatacactgctcgttt tatactagagcaatgacgcgtaaagaattggatatattacacagaaaaagtcacact gcacgtggagctgcgatacagactggtgtgtgattatgaattggcaatacaaacgg gcagtggagctgcgatacagactggttgtgattatgaatttggtcgaattcaaaacggt gtgaatgaattcattaaaacgccgaaattagatgatttattt |
| 311. | atgactacgaccttcattattagctacattattttagcgctcattattgttggggttatc aatttattttaataagatcaagaaaaaaggcaaacgccaacaaaaggaacaacaattt acgacacgtcaatcaaatctaaatttaaagctagtgatttagacaaaacaactgat |
| | caatcgacacaacgtatgacgcatgaagagttgcgtgttgacaatcaagatgatcatagc caagttagtctaaatggttacacaaaggggtctgagaaagatcaagaagcattcactaat aataaggatgaggaagcagttgctgctaaaaatcctgaatcaagaagaatataaagtgaat gaaaaaataaaaaagaacataaaaaccttatttttggtgaaggtgtttacacgcggtaaa atattagcggcattattattcggtatgtttattgcgattttaaaccaaacataattaat |
| | tteattategggattategetatttaattggttttgtatggtttaagttatateaatat acaacaaacectaaagetgatateccaggtateatttttagtaegattggtttttgtgtget ttgttatatggttteteagaagetggcaacaaaggttggggtteagtaggagatagaaaca atgtttgegattggtattatetttattattetattegttattagagaattaagaatgaaa teaccaatgttgaatttagaagtattgaaatteceaacatttacattaacaacaattatt aatatggttgtaatgttaagtttatatggtggtatgattttatta |
| | ataatgatgccaatggtaactgcagctattaatggtatteggtatetgggactggacggacgttgcctctcat ggtaatgctttcttaaatacgatgcgtcaattagcaggctctataggtacagcaatctta gttactgtaatgacaacacaaactacacacacttatcagctttttggggaaggagttagat aaaacgaatcctgttgtacaaagatcatatgcgtgaattagcatcacaatatggcggacaa gaaggcgcaatgaaagtgttactacaatttgtaaataagctagcacaggttgaaggtatt aatgatgcatttataggttgcaacgatatttagcatcacactgctaattttatgtttattt ttacaaagtaataaaaaagcaaaagctacagctcaaaagttagatgcagataatagtatc aatcatgaa |
| 312. | atgattaaaaataaaatattaacagcaactttagcagttggtttaatagcccctttagcc aatccatttatagaaatttctaaagcagaaaataagatagaagatatcggccaaggtgca gaaatcatcaaaagaacacaagacattactagcaaacgattagctataactcaaaacatt caatttgattttgtaaaagataaaaaaattacaaagatgccctagttgttaaagatgcaa ggottcattagetctagaacaacatattcagacttaaaaaaaatatccatatattaaaaga atgatatggccatttcaatataatat |
| | aacatggatgctacatatgcttacgtgacaagacatcgtttagccgttgatagaaaacat gatgcttttaaaaaccgaaacgttacagttaaatatgaagtgaactggaaaacacatgaa gtaaaaattaaaagcatcacacctaag |

| 313. | atgcaatcaacgaaaaccaaaacgaagcattttcattttattgctaattacgttaggc gtcatgaccgcttttggcccactaactatagatatgtacgtac |
|------|--|
| 314. | atgatgtatggatatccagagaaatggttggaaggtatgacaactggagaaggtatcgcg gcagaattacgcttaggcattgtgaatggtcacatagctgaaggtacgttactcactgaa aatcaaatggcaaagcaatttaatgtgagtcgttcgccaattcgagatgcatttaaatta ttgcaacaaaatcaactcatccaattagaaagaatgggtgcacatgttgccgtttggg gaacaagaaaagaa |
| 315. | atgggaagttttttcaataaatagcacgaaaagaggatccggctatctat |
| 316. | atgaatagtgataatatgtggttaacagtaatggggctcattattattattattattatatgta ggtttactcattgccaaaaagataaatccagttgtaggtatgacaatcataccttgctta ggggcaatgattttaggatatagtgtgacagatttggttgg |

| 317. | atggaaaacacggttaaatatcgtaagtttatactccctatcgttgtaggtctccttatt tgggcacttacaccttttaaaccggatgctgtggatccaacagcatggtatatgttcgca atattcgtcgcgacaatcattgcttgtatcaccaaccgatgccaattgggggccgtctct ataattggatttacaatcatggtactcgttggcattgttgacatgaaaacggctgtcgct ggttttggtaataatagcatttggttaattgctatggcatttttcatttcgagagggattt gtgaaaacaggtcttggtagacgtatcgcacttcatttcgtcaaattattcgaaaaaa acattaggattagcatattctatcgtcggtgtagatttatctagctacacca agtaataccgcgcgtgctggtggaatcatgttcccaattatcaaatcactttctgaatca tttggttcgaaaccgaaagacggatcagcacgcaaaatggtgcatttcttgttttcaca gaattccaaggtaatttaatt |
|------|---|
| 318. | atgaataaagtaattaaaatgcttgttgttacgcttgctt |
| 319. | atgattaatcagtctatatggcgcagtaactttcgcattttatggctcagtcag |
| 320. | atgaagcgattattcgatgtagtgagttcaatatatggtttagtagttttaagtccgatt ctgttaattacagcattactaattaaaatggaatcacctggaccagccattttcaaacaa aaaagaccgacgattaataatgaattgtttaatatttataagtttagatcaatggaaata gacacacctaatgttgcaactgatttaatggttcaacatcgtatataacaaagacaggg aaggtcattcgtaagacctctattgatgaattgccacaattattgaatgttttaaacaagga gaaatgtcaattgtaggtcctagaccagcgctttataatcaatacgaattaatcgaaaaa cgtacaaaagcgaacgtgcatacgattagaccaggtgtgacaggactagctcaagtgatg gggaggatgataccatgatgatcaaaaagtagcgtatgatcattattacttaacacat caatctatgatgcttgatatgtatacatataaaacaattaaaaaatatcgttacttca gaaggtgtgcatcac |

| 321. | atggcacaacttaattcaaagatagcttccttaaaattattcgcaagttacgccatagca acttatattttagttatattaacgagtgcattaaatctttttaatggcgcgat acgttctatattgcggaacattgctaatcgttttaaccatcattttaattattta acaacggaacaaacatggaagcatcatgacctatggcgacgtatcgtgcgagtgttgtta ttgttgatgacattaacaggcaacgtatttacattattatatattata ttgttgatgacattaacaggcaacgtatttacattattatatgttgtaagtattagacgt taccaacgtacatcgcaaataccatagttataacgggtgggaatcgtttatacgaaaaact actagacatcgtattgcgattatcgggttacttattttagtctacatgcgcacattatca attggtcacaatttacatttgatacgacattggctactaaaaatcagttcaatgcactg ttaccatggaccgagtctagcctatccgtttggtactgattttcggtaggagacttattt acacgcgtagttgtaggaacgaagctgacatttcaatttcaattatttcagtagtatt gcagttattttggtgttactaggcactatcgcaggttatttaatcaatatgtgatat ttaataatgcgaattttagatgtagtgtttgcaattcatattattgttagcggtgca attattgcatcatttggagcaagtattccaaatttaattattgtttaagtaat ttaataatgcgaatttagagcactacaggtgccagtgttttagaaattaaacgcatggaatat gtagatgcagcacgtacactggtgaaaacacttggaatacatatagggttatatttta ccgaatgcgattgcgcctatgattgtacgtttttcattaaatatggcgttgttata acaacaagtagtttaagttcctaggacttggtgttgcacctgatgtggtgtgtata acaacaagtagtttaagttcctaggaacttggtgttgcacctgatgtagttagctattgacct ggtgtttgtattaggtagtagcttttaatatattagcgtgaatgcagtgacct ggtgtttgtattaggtagtgcgtgat |
|------|--|
| 322. | gcactagatccaagaattcat atgaaaacaatacatttgtttegcatctaccactctttttattgaaaaagtggtatttg attatctatttactattatatta |
| 323. | ttgaaaaacaagttattatttcgggcctcatgttattttcactattttttggagccgga aatttaatattcccgcccatgcttggccatacaacagcgggtcaaaatatgtggattg ctaggctttgcccttacaggcatattacccccttattactgttattgttgttgt tatgatgaaggtgttgaaagtgtaggcaatcgtatacatccatggttcgggtttatttt gctgtcgtgatttacatgtctatcggagcattttacggtattccacgtggtgcgcaaatgtc gcgtacgaaattggtacaagacacattttaccggtattcacatggtctgcaaatgtc gcgtacgaaattggtacaagacacatttacctgtgcataaccaatggacttaattata ttcgcagcaatcttttttgccatcgttactggattagttaaatccatcgaaaatcgtt gataatttaggtaaattatacaccgttattactgttcactaggatataattaagcat gctgtattttcaaccctgaatctgcactaagtgcactaaggataaatatataacacat ccttcatttcaggaagtttggaaggctatttacatgtcgctcatataagtat tttccgtagtcattgtcaatggctataagtttaaaggatcttgttgctgcgttagct ttttccgtagtcattgtcaatggctataagtttaaaggcctatattacttggaatgaaatt ttaaaaatagtctgcttttcaggtcttattgagccatattacttggaatgaat |
| 324. | gtgaaacattatttgactaaatttgtagcaatgctaataactgctgctatggtgtagc tttgggttactgaaaagtcaggcagcagaaacacaaaagtattagtgatgtatatatgtgtg ataacggatgcgaaatctgcactttctaataattcgattgcagatgacaataagcagaaa gcaattgagcaagtggtaagtgcagttaagaaattacgcttgaaggataattagtgaaagt aatgctgtcaaatcagatytgagaaagcttgaagatgcaaaagcgaatgataatcaaaaa gatacactttcgcaattaaagaagtattgctgatgagagaga |

| 325. | mnkqifvlyfnifliflgiglvipvlpvylkdlgltgsdlgllvaafalsqmiispfggt ladklgkkliiciglilfsvsefmfavghnfsvlmlsrviggmsagmvmpgvtgliadis pshqkaknfgymsaiinsgfilgpgiggfmaevshrmpfyfagalgilafimsivlihdp kksttsgfqklepqlltkinwkvfitpviltlvlsfglsafetlyslytadkvnyspkdi siaitgggifgalfqiyffdkfmkyfseltfiawsllysvvvlillvfandywsimlisf vvfigfdmirpaitnyfsniagerqgfagglnstftsmgnfigpliagalfdvhieapiy maigyslagyvivliekqhraklkeqmm | |
|------|--|--|
| 326. | mlfylfhftisfistvlfsiifnapkrllvacgfvgaiawtiyqltvdlefgkvgasflg slilglmshtmsrrykrpviifivpgiiplvpggaayqatrflvsndytsavntflevtl isgaiafgilvseilyylytrikqlygkikgktykksynmnnrv | |
| 327. | minavviavilmimlclcrlnvvislfisalvgglisgmsiekvinvfgknivdgaeval syallggfaalisysgitdylvgkinaihaensrwsrvkvkvtiiiallamsimsqnli pvhiafipivippllslfndlkidrrligliigfglcfpyvllpygfgqifqqiiqsgfa kanhpiefnmiwkamlipsmgyivglliglyvyrkpreyetrkisdsdnvtelkpyiliv tivailatflvqtftdsmifgalagvlvffisraynwyeldakfvegikimayigvvilt angfagvmnatgdidelvktltsitgdnklfsiimmyviglivtlgigssfatipiiasl fipfgasigldtmalialigtasalgdsgspasdstlgptaglnvdgqhdhirdtcvpnflfyniplmifgtiaamvl | |
| 328. | mnhnviivialiivvismlamlirvvlgpsladrvvaldaiglqlmavialfsillniky mivvimmigilaflgtavfskfmdkgkviehdqnhtd | |
| 329. | mnrnivklvvfmlilvvavagcggkdteektemttikdelgtekikknpkrvvvleysfa dylaaldmkpvgiaddgstknitksvrdkigayesvgsrpqpnmevisklkpdliiadvs rhkkikselskiaptimlvsgtgdynanieafktvakavgkekegekrlekhdkilaeir kkiegstlksafafgisragmfinnedtfmgqflikmgiqpevtkdktthvgerkggpyi ylnneelaninpkvmilatdgktdknrtkfidpavwkslkavkdnkvydvdrnkwlksrg iiasesmaedlekiaekak | |
| 330. | mtgeqftqikrpvsrltekvlgwlcwvmllvltvitmfialvsfsnntsianlentlnnn afiqqllagngynttqfviwlqngiwaiivyfivcllisflalismnirilsgflflisa ivtiplvlliivtllipilffiiammlfirkdkvemvapqyyeeyngpiydyrepvyerpq pkddyydvpkyekeldksntvydqeqerdkydqfpkraveseynhderteeepsvlsrqa kykqksteelgieddgyyaepevdpkelkaqqkrekaeikakkkekrkaynqrmkerrkn qpsavsqrrmmfeerrqiynndiseernssevkdkkeqe | |
| 331. | mentinesekkkrfklkmpgafmilfiltvvaviatwvipagaysklsyepssqelkivn phnqvkkvpgtqqeldkmgvkikieqfksgainkpvsipntyerlkqhpagpeqitssmv egtieavdimvfilvlggligvvqasgsfesgllaltkktkghefmlivfvsilmiiggt lcgieeeavafypilvpifialgydsivsvgaiflassvystfstinpfsvviasnaagt tftdglywrigacivgaifvisylywyckkikndpkasysyedkdafeqqwsvlkdddsa hftlrkkiiltlfvlpfpimvwgvmtqgwwfpvmasafliftiimfiagtgksglgekg tvdafvngasslvgysliiglarginlvlnegmisdtilhfssslvqhmsgplfiivllf iffclgfivpsssglavlsmpifapladtvgiprfvivttyqfgqyamlflaptglvmat lcmlnmryshwfrfwpvvafvlifgggvlitqvliys | |
| 332. | msffkrlkdkfatnkeneevkslteeggdkledthsegstqdandlaenaevkkkprkl seadfdddglisiedfeeieagkmgakfkagleksrqnfqeqlnnliaryrkvdedffea leemlitadvgfntvmtlteelrmeagrrniqdtedlrevivekiveiyhqeddnseamn ledgrlnvilmvgvngvgktttigklayrykmegkkvmlaagdtfragaidqlkvwgerv gvdvisgsegsdpaavmydainaaknkgvdilicdtagrlqnktnlmqelekvkrvinra vpdapheallcldattgqnalsqarnfkevtnvtgivltkldgtakggivlairnelhip vkyvglgeqlddlqpfnpesyvyglfadmieqneeittvendqivteekddnhgsk | |
| 333 | mlkkwlnsnvkqffvitfisviltlilfsthiydyivngtvfsgagdgfrqmmpfqmyly ehlrsfsslydasfglggdymkglsyyyslsplmwlnflfikigetvgifnpttihfwpt nqlimamiraiitfvvtfylfkilhfkrsammiatilygmstvviyfnftwsfygnllyl lplsilgleryfqqrkigifivaialtlfsnfyfsyyqaiiigcyylyrliftykydivs rtqklicvisatvlsvlssvfglftgisaflendrkqnpnvdipfltpldyhyfffsdgf yitisiltivallsfklyrfyfyrlfaivtwilfigslsqyfdsafngfsfperrwyyil alsssalcqlfiqhlstlnmkyylirtipvciiailyvllspthplalivgiillivlav ilkfslwrykkltvailvlivmiqqivildnnknmaikpyqqslstlkqhdyhsnyvnql ikkinqnatgsfnridymsdyalnspfiyhyngislyssifngdilkyydktlqinmpid knstyrllgnrqnllslwnvndrirvnhddnlpygfkiksehkdnkvrwhlskntihyps ahitnkvfsnkelkspldkeqamlqgivsnnikdvnthfkanknllsdstiklnsaawqs ptkhllqvkqnnggltvqlpksvsnqfkdlyfemdlellspdkahdvkvneytqernklt ykyrrvvtpvtirikapdririslpkgkyrvnlkgiygedyttlkdasnsleavkvsktk hgytitknknssgyivlptaynqgmkatsgdqslkveqvngvmtgikapknitkiqlsyt ppyyyllititifglicsiiftrwarqk | |
| 334. | mrqlaqakkkstakkkttskkrtnsrkkkndnpiryviailvvvlmvlgvfqlgiigrli dsffnylfgysryltyilvllatgfityskripktrrtagsivlqiallfvsqlvfhfns gikaerepvlsyvygsydhshfpnfgggvlgfyllelsvplislfgvciitilllcsvi lltnhqhrevakvalenikawfgsfnekmsernqekqlkreekarlkeeqkarqneqpqi kdvsdftevpqerdipiyghtenesksqsgpsrkkrvfdaenssnnivnhhqadqqeqlt eqthmsvesentieeagevtnvsyvvppltlnqpakqkatskaevqrkgqvlentlkdf gvnakvtqikigpavtqyeiqpaqqvkvskivnlnndialalaakdvrieapipgrsavq ievpnekislvslkevldekfpsnnklevglgrdisgdpitvplnemphllvagstgggk svcingiitsillnakphevklmlidpkmvelnvyngiphllipvvtnphkaaqalekiv aemerrydlfqhsstrnikgynelirkqnqeldekqpelpyivvivdeladlmmvagkev enaiqritqmaraagihlivatqrpsvdvitgiiknnipsriafavssqtdsrtiigtgg aekllgkgdmlyvgngdssqtriggaflsdqevqdvvnyvveqqqanyvkemepdapvdk semksedalydeaylfvveqqkastsllqrqfrigynrasrlmddlernqvigpqkgskp rqylidlnndev | |
| 335. | maeklqrelsnrhiqliaiggaigtglflgagqtialtgpsilltyiiigfmlfmfmrgl geiiiqntefksfadvtntyigpfagfvtgwtywfcwiitgmaevtavakyvsfwfpeip nwisalfcvlllmsfnllsarlfgelefwfsiikiatiiglivvgfvmilfafktqfgha sftnlyehgifakgasgffmsfqmalfsfvgiemigvtagetkdpvktipkainsvpiri lifyvgalavimsiipwqqvdpdnspfvklfaligipfaaglinfvvltaaasscnsgif snsrmlfglssqqqappnfsktnkygvphvaifassalllvaallnyifpdatkvftyvt tistvlflvvwgliiiayinysrknpdlhknatykllggkymgylifvffifvfgllfin vdtrraiyfipiwfillafmylrykriaaksnk | |

| 336. | mmllkknkysirkykygifstligtvlllsnpngaqalttdnnvqsdtnqatpvnsqdkd vannrglansaqntpnqsattnqatnqalvnhnngsivnqatptsvqsstpsaqnmhtd gnttatetvsnannndvvsnntalnvptktnengsghltlkeiqedvrhssnkyelvai aepasnrpkkrsrraapadpnatpadpaaaavqnggepvai tapytpttdpnannagqna pnevlsfddngirpstnrsvptvnvvnnlpgftlinggkvgvfshamvrtsmfdsgdnkn yqagqnvialgrihgtdtndhgdfngiekaltvnpnselifefntmttkngqgatnviik nadtndtiaektveggptlrfkwpdnvrnlkiqfvpkndaitdargjvqlkdgykyysf vdsiglhsgshvfverrtmdptatnnkeftvttslknngnsgasldtndfvyqvqlpegv eywnsltkdfpsnnsgvdvndmnvtydaanrvitikstgggtansparlmpdkildlry klrvnnyptprtvtfnetltyktytqdfinsaaeshtvstnpytidiimmkdalqaevdr riqqadytfasldifnglkrraqtildenrnnvplnkrvsqayidsltnqmqhtlirsvd aenavnkvdqmedlvnqndeltdeekqaaiqvieehkneiignigdqttddgvtrikdq giqtlsgdtatpvvkpnakkairdkatkqreiinatpdvtedeiqdalnqlatdetdaid nvtnattnadvetaknngintigavvpqvthkkaardainqatatkrqqinsnreatqee knaalneltqatnhaleqinqattnadvdnakgdglnainpiapvtvvkqaardavshda qqhiaeinanpdatgeerqaaidkvnaavtaantnilnantnadveqvktnaiqgiqait patkvktdaknaidksaetqhntifnnndatleeqqaaqqlldqavatakqninaadtnq evaqakdggtmivviqpatqvktdtrnvvndkareaitninattgatreekqeainrvn tlknraltdigvtsttamvnsirddawnqigavqphvtkkqtatgvlnlatakkqeinq ntnatteekqvalnqvdqelatainninqadtnaevdqaqqlgtkainaiqpnivkqaa laqinqnynaklaeinatpdatndeknaaintlnqdrqqaiesikqantnaevdqaatva emidavqvdvvkkqaardkitaevakrieavkqtpnatdeekqaavnqinqlkdqainq inqnqtndqvdtttnqavnaidnveaevvikpkaiadiekavkekqqidnsldstdnek evasqalakekekalaaidqaqtnsqvnqaatnysaikiiqpetkvkpaarekinqkan elrakinqdkeataeerqvaldkinefvnqamtditnnrunqvddttsqaldsialvtp dhivraaardavkqqyeakkreieqaehatdeekqvalnqlannekralqnidqaiannd |
|------|--|
| | vkrvetngiatlkgvgphivikpeaqqaikasaenqvesikdtphatvdeldeanqlisd tlkqaqqeientnqdaavtdvrnqtikaieqikpkvrrkraaldsieennknqldairnt ldttqderdvaidtlnkivntikndiaqnktnaevdrtetdgndnikvilpkvqvkpaar qsvgvkaeaqnalidqsdlsteeerlaakhlveqalnqaidqinhadktaqvnqdsinaq niiskikpattvkatalqqiqniatnkinlikanneatdeeqniaiaqvekelikakqqi asavtnadvayllhdekneireiepvinrkasareqlttlfndkkqaieaniqatveern silaqlqniydtaigqidqdrsnaqvdktaslnlqtihdldvhpikkpdaektinddlar vtalvqnyrkvsnrnkadalkaitalklqmdeelktartnadvdavlkrfnvalsdieav itekensllridniaqqtyakfkaiatpeqlakvkvlidqyvadqnrmidedatlndikq htqfivdeilaiklpaeatkvspkeiqpapkvctpikkeethesrkvekelpntgsegmd |
| 337. | lplkefalitgaallarrrtknekes msveiesieheleesiaslrqagvritpqrqailrylisshthptadeiyqalspdfpni svatiynnlrvfkdigivkeltygdsssrfdfnthnhyhiiceqcgkivdfqypqlneie rlaqmtdfdvthhrmeiygvckecqdk |
| 338. | msekqqildyietnkysyieishriherpelgneeifasrtlidrlkehdfeieteiagh atgfiatydsgldgpaigflaeydalpglghacghniigtasvigaiglkqvidqiggkv vvlgcpaeeggengsakasyvkagvidqidialmihpgnetyktidtlavdvldvkfygk sahasenadealnaldamisyfngvaqlrqhikkdqrvhgvildggkaaniipdytharf ytramtrkeldiltekvnqiargaaiqtgcdyefgriqngvnefiktpklddlfakyaee vgeavidddfgygstdtgnvshvvptihphikigsrnlvghthrfreaaasvhgdealik gakimalmglelitnqdvyddieehahlkgngk |
| 339. | mtttfiisyiilaliivgvinlflirsrkkgkrqqkeqqfttrqsnqskfkasdldkttd qstqrmtheelrvdnqddhsqvslngytkgsekdqeaftnnkdeeavaaknpeseeykvn ekikkehknfifgegvsrgkilaallfgmfiailnqtllnvalpkintefnisastgqwl mtgfnlvngilipitaylfnkysyrklflvalvlftigslicaismnfpimmvgrvlqai gagvlmplgsiviitiyppekrgaamgtmgiamilapaigptlsgyivqnyhwnvmfygm fiigiiailigfvwfklyqyttnpkadipgiifstigfgallygfseagnkgwgsveiet mfaigiifiilfvirelrmkspmlnlevlkfptftlttiinmvvmlslygmillpjylq nlrgfsaldsgllllpgslimgllgpfagklldtiglkplaifgiavmtyatweltklnm dtpymtimgiyvlrsfgmafimmpmvtaainalpgrlashgnaflntmrqlagsigtail vtvmttqttqhlsafgeeldktnpvvqdhmrelasqygqegamkvllqfvnklatvegi ndafivatifsiialilclflgsnkkakataqkldadnsinhe |
| 340. | miknkiltatlavgliaplanpfieiskaenkiedigggaelikrtqditskrlaitqni qfdfvkdkkynkdalvvkmqgfissrttysdlkkypyikrmiwpfqynislktkdsnvdl inylpknkidsadvsqklgyniggnfqsapsiggsgsfnysktisynqknyvtevesqns kgvkwgvkansfvtpngqvsaydqylfaqdptgpaardyfvpdnqlppliqsgfnpsfit tlshergkgdksefeitygrnmdatyayvtrhrlavdrkhdafknrnvtvkyevnwkthe vkiksitpk |
| 341. | mqstktktkhfsflllitlgvmtafgpltidmyvpslpkvqgdfgsttseiqltlsftmi glalgqfifgplsdafgrkriavsilliifilvsglsmfvdqlplfiltlrfiqgltgggvi viakasagdkfsgmalakflaslmvvngjitliaplagglalsvatwrsiftiltivali iligvasqlpktskdelkqvnfssvikdfgsllkkpafiipmllqgltyvmlfsyssasp fitgklynmtpqqfsimfavngvgliivsqvvallveklhrhilliiltiiqvvgvalli ltltfhlplwvlliafflnvcpvtsigplgftmameertgsgnassllglfqfilggav aplvglkgefntspymiiifitaillvslqiiyfkmikkqhva |
| 342. | mmygypekwlegmttgegiaaelrlgivnghiaegtlltenqmakqfnvsrspirdafkl lqqnqliqlermgahvlpfgegekkemydlrimlesfafsrvknqerlpivkemkkqlem mkvavkfedaesftkhdfefhetlikasnhqylnsfwshlkpvmmalvltsmrqrmqqnp qdferihhnhqvfidaveqydsqilkeafhlnfddvgkdiegfwln |
| 343. | mgsffnkiarkedpaiyonkdghlkrtlrvrdflalgvgtivstsiftlpgivaaehagp avalsfllaaivaglvaftyaemaampfagsayswnvlfgeffgwvagwallaeyfia vafvasgfsanlrglvkpigielpaalsnpfgtnggfidiiaaivilltalllsrgmsea armenilvilkvlaiilfvivgltainvsnyvpfipehkvtatgdfggwggiyagvsmif layigfdsiaansaealdpoktmprgilgslsvaivlfiavalvlvgmfhysqyannaep vgwalrogsphgvvaaivogaisvigmftaligmmlagsrllysfgrdgllpswlshlndkh lpnralviltiigvligsmfpfaflaqlisagtlvafmfvslamyrlrkegkdlpipaf klplypvlpaitfvlvllvfwglgfeaklytliwfivgiilylsyglrhskkndvaeyhp pk |

| 344. | mnsdnmwltvmgliiiisivglliakkinpvvgmtiipclgamilgysvtdlvgffakgl |
|------|---|
| 244. | dqvinvvimfifaliffgimmdsglfkplvkrlilmtrgnvvivcamtaligtlaqldga gavtfllsipallplykalnmnkyllilllalsaaimnmvpwggpmarvaavlkaksvne lwglipigigfilwnlfavvlqfkegkrikkalernelpotgdidyhklvevyerdgd |
| | vrīpvkgrartkswikwvntaltlavilsmliniappefafmigvslalvinfksvdeqm erlrahapnalmmaaviiaagmflgvlnetgmlkalatnlikvipaevgpylhiivgllg vpldlltstdayyfavlpiveqtagqfgvpsvstaysmvigniigtfvspfspalwlaig laeanmgtyikyaffwiwgfaivmlviamlmgivti |
| 345. | mentykyrkfilpiyyolliwaltofkodaydotawymfaifyatiiacitqpmpigays |
| | iigftimvlvgivdmktavagfgmnsiwliamaffisrgfvktglgrrialhfvklfgkk tlglaysivgvdlilapatpsntaraggimfpiikslsesfgskpkdgsarkmgaflvft efggmlitaamfltamagnplaqnlasstsnvhitwmnwflaalvpglvslivypfiiyk iypptvketpnakswaenelatmgkialaekfmigifvvaltlwivgsfihidatltafi alaillltgvltwqdilnetgawntlvwfsvlvlmadqlnklgfipwlsksiatslggls wpivlvililfyfyshylfasstahisamyaallgvaiaagapplfsalmlgffgnllas |
| | tthyssgpapilfssgyvtqkrwwtmnlilgfvyfiiwiglgslwmkvlgif |
| 346. | mnkvikmlvvtlafllvlagcsgnsnkqssdnkdkettsikhamgtteikgkpkrvvtly qgatdvavslgvkpvgaveswtqkpkfeyikndlkdtkivgqepapnleeisklkpdliv askvrnekvydqlskiaptvstdtvfkfkdttklmgkalgkekaeddllkkyddkvaafq kdakakykdawplkasvvnfradhtriyaggyageilndlgfkrnkdlqkqvdngkdiiq |
| | ltskesiplmnadhifvvksdpnakdaalvkktesewtsskewknldavknnqvsddlde itwnlaggyksslkliddlyeklniekqsk |
| 347. | mingsiwrsnfrilwlsgfiaiagltvlvpllpiymaslqnlsvveiqlwsgiaiaapav ttmlaspiwgklgdkisrkwmvlrallglavclflmalcttplqfvlvrllqqlfggvvd |
| | assafasaeapaedrokylorlossysagslyopliggytasilgrsallmslavitily |
| | cifgalklietthmpksqtpninkgirrsfqcllctqqtcrfiivgvlanfamygmltal splassvnhtaiddrsvigflqsafwtasilsaplwgrfndksyvksvyifatiacgcsa |
| | ilqqlatniefimaarilqqltysaliqsvmfvvvnachqqlkqtfvgttnsmlvvgqii gslsgaaitsyttpattfivmgvvfavsslflicstitnqindhtlmklwelkqksak |
| 348. | mkrlfdvvssiyglvvlspillitallikmespgpaifkqkrptinnelfniykfrsmki dtpnvatdlmdstsyitktgkvirktsidelpqllnvlkgemsivgprpalynqyeliek rtkanvhtirpgvtglaqvmgrdditddqkvaydhyylthqsmmldmyliyktiknivts |
| 349. | egyhh maqlnskiaslklfasyaiatyilviltsalnlfkgyvadtfyiaetllivltiiliiil |
| 313. | tteqtwkhhdlwrrivevllllmtltgnvftllmfvsirryqrtsqihsyngwesfirkt trhriaiigllilvymltlsivsqftfdttlatknqfnallhgpslaypfgtddfgrdlf tryvyqtkltfsisiisvviavifqyllgtiagyfnhidnlimrildvvfaipslllava |
| | iiasfgasipnliialsignipsfartmrasvleikrmeyvdaaritgentwniiwryll pnaiapmivrfslnigvvvlttsslsflglgvapdvaewgnilrtgsnylethsnlaivp gvcimfvvlafnfigdavrdaldprih |
| 350. | mktihlfriyhsfllkkwyliiyllfilaallitlttiqhvteddnhfnigvvdkdqsse tklilnsigkgsnlgknvsikayddkqahtllkkhklqgyfvfdkgmtkafykqgelpis |
| | vvtvdcqsmksvvlsqltdsvvqrlmrsmqqilafqdlapkashsdsinvmtdllitgln |
| | rsgafnlepihlydtgsyyaitgflttvfifalslftvlkmnqdtvlkarlkmfhfsker lliirtlitwfytmlwsivgvvwivfsipnifelynwptlaihlsyyvtflilwllliel |
| | lttgllnsiskvilaivilvlsgltiptiflqhiangvfniqpfavvtnqlleiilnnyi lelhpsfylsfialliinlavlvwryrq |
| 351. | mkkqviisglmlfslffgagnlifppmlghtagqnmwigmlgfaltgillpfitvivvaf ydegvesvgnrihpwfgfifavviymsigafygipraanvayeigtrhilpvhnqwtlii |
| | faaiffaivywislnpskivdnlgklltpllllmvallsiavifnpesalsapkdkyith |
| | pfisgslegyftmdlvaalafsvvivngykfkgltdrmkilkyvcfsgliaaillgmiyf alayvgastapgnfkdgtdiltynslrlfgsfynlvfgmtvilacittciglvnacatft |
| | kkhvpkfsykifalifsiigflfttlglemilkiavplltliypvsialvlisfanmfst frfswayrlatvitliisilqilnsfnllhgvilksfmmlpladidlawlvpfmlfaiig fiidvfirrpkqatt |
| 352. | mkhyltkfvamlitaamvcsfgllksqaaeqqsisdvysvitdaksalsnnsisndnkqk aieqvvsavkklslednsesnavksdvrkledakandnqkdtlsqltksliayeeklask |
| | dagskikllqqqvdakdaamtkaikdknkaeleslnnslnqiwtsnetvirnydanqygq ievallqlriaihkspldtakvshawttfksnidhvdkksntsandqyhvsqlndaleka |
| | ikaiddnglsdadaalthfietwpyyeggigtkdgalytkiedkipyygsyldehnkahy |
| | kdglvdlnnqikevvghsysfvdvmiiflreglevllivmtlttmtrnvkdkkgtasvig galaglvlsiilaitfvetlgnsgilresmeaglgivavilmfivgvwmhkrsnakrwnd |
| | miknmyanaisngnlvllatiglisvlregveviitymgmigelatkdiligialaivii iifallfrfivklipifyifrvlsififimgfkmlgvsiqklqllgamprhviegfptin |
| L | wlgfypsyepliaggayimvvailifkfkk |

| 353. | atgaagaatttttetaaattegeacttacaagtattgeegeattaactgtggeaagteet ttagteaataeggaggttgaegetaaggataaagtateageaacteaaaacategatgeg aaagtaacceaagaateteaageattgaaaggataceaaaatetgaaaat ataaaaaagaattacaaagattataaggteactgaaaaggataceaaaatetgaaaat acaaaagattacaaagattataaggteactgaaaaggataacaaaggattt acgeattacacattgeaacegaagtgggeacacagtatgeaceagacaaagaagtaaaa gtteatacgaataaaggaggtaaggtatettgteaatggtgatactgatgetaagaaa gtteaacetacgaataaggtaggegataagtaagaagtgecacagataaagettegaa gcaataaaaattgacegteaaaaagtaaaaattaatatatataaaacttacaaaceat aaagttgagattgatggagaaaaaaataaattgattataacatagaaattatacaact tcaccaaaaateteteattggaatgtgaaaattgacegtgaaactggteaaggtgtgat aaattaaatattataatagtgaagagtacaggtacaggtaaaggtgtactaggtgac acgaacaaattacattataatagtgacageggggtataacaggtaaaggtgacaaggtgacaaggaacacattecaacagaaacagaaacagaaaacagaaaaaattattatagtgaagagagacactgeagagatcactggteaaggtacaagtagacaaggagacacattattacaacaggagaaacaggtacaaggtacaaggagacacaaggagacacattattacaacagggagaaacaggaggagaaacaaggaggacacaattattacaagggagaaacaaggaggagaaacaaggaggagacaaattattacaagggagacaaacagaacaaaca |
|------|---|
| 354. | atycctaaacatagtyctagttagttattatyttttaataactttattycctattttt caatatcaagcttctycacatycgactttagaaaaatcaacaccacaacagcaagyygtt attaaagacaaaccagaagcaatcaagttagagtttaatyaacctytgaacaccaaatac tcgagtytgaccttatttgatgataaagytaaaaagattaaagacottaaaccaataaca actygatygtctcagacagttytattttcatctgagcaaattyttaatygcacgaatact attgaatycctagacagtgatggacatyaagcagaaattyttaatygcacgaatact gtgaatygcatacgytatctycggatygacatyaagtcggagatacgtttgaattttca gttggaaaagtgaggctaaagaty |
| 355. | atgaaaaaatcaaaacaatctcgacattggtagctggacttggtatagcatttctaggt cacacaacaca |
| 356. | atgaaaaaatcgctacagctacaattgcaactgcaggaatcgctactttcgcatttgca caccatgacgcacaagcaggaacaaaataatgatgggtacaatccaaaacgacccttat tcatatagctacaactgcagaacaaatgctgaaggtaactaccactacaactgacaggt aactggagtccagatcgtgtaaatacttcatataactataaataa |
| 357. | ttggaagataaaaagctccagtaaatgaagactttttaaattacatcaaaaactatgcc gatgtaagaaacatacctctttcaagacgtaagatggcctcgttgttcacacttctaaa actgcaattgatgdtccacaagaaaaactaaatacttggttacgaaacctgataag ttttacgtgaatattatcgagcttcgaaagacttatattacaaagctggtagatatcgt agcttacttaattactttattgatatggctcgtttctattatgtgattgat |

| 358. | gtgggagtcgtgtcaatcattactgggattacaatatttgtcagtggtcagcatgctcaa gctgctgaaatgacacaatcatcatcagattctaacgaacagtcacaacaaaca | |
|------|--|--|
| 359. | mknfskfaltsiaaltvasplvntevdakdkvsatqnidakvtqesqatnalkelpksen ikkhykdykvtdtekdnkgfthytlqpkvgntyapdkevkvhtnkegkvvlvngdtdakk vqptnkvaiskesatdkafeaikidrqkaknlksdviktnkveidgeknkyvynieiitt spkishwnvkidaetgqvvdklnmikeaattgtgkgvlgdtkqininsvsggytlqdltq qgtlsaynydantgqaylmqdkdknfvddeqragvdanyyaketydyykntfgresydnq gspiisiahvnnfqgqdnrnnaawigdkmiygdgdgrtftalsgandvvaheithgvtqq tanlvyrsqsgalnesfsdvfgyfiddedflmgedvytpgvggdalrsmsnperfgqpsh mndfvytnsdnggvhtnsgipnkaayntirsigkqrseqiyyraltvyltsnsdfqdaka slqqaafdlygdgiaqqvgqawdsvgv | |
| 360. | mskhsatlvimflitllpifqyqasahatlekstpqqqgvikdkpeaiklefnepvntky ssvtlfddkgkkikdlkpittgwsqtvvfsseqivngtntiewhtvsadghevgdtfefs vgkvrlkm | |
| 361. | mkkiktistlvaglgiaflghtthadaaennnqqqstynysttevsfsnsgnlytsgqct wyvydktggkigstwgnanswataaqaagftvnntpeegaimqssegafghvafvesvnn dgsitvsemnydggpfalstrtisaseassynyihln | |
| 362. | mkkiatatiatagiatfafahhdaqaaeqmndgynpndpysysytytidaegnyhytwkg nwspdrvntsynynmynnynyygynnysnynnysnynnyasnntgsqrttqptgglg asystsssnvhvtttsapssngvslsnarsasgmlytsgqctyyvfdrvggkigstwgna nnwanaaarsgytvnnspakgailqtsqgayghvayvegvnsngsirvsemnyghgagvv tsrtisasqaasynyih | |
| 363. | ledkkapvnedflnyiknyadvrniplsrrkmaslfhtsktaiddvsqeklntwlrkpdk fyvniielskdlyyksgeyrsllnyfidmarfyyvidplfssdskmskekvkkdlskisl qlnkmnlkhelakiyktevlediffgyeiedkdnyfmlkldpkycklvgisdgmytyafn lsyfdgmldllktfpeefgraylersidkgadlnwfipdftksvvfkineddptilppfs tmfeplldlndykklkkagakinnymllhqkvpmhdnankdyqadnfaisaeamdyfsel vnenlpdeigsivspmevnpikldrddktdkvleatrdvynasgvssfifnmdknstggl tysvrkdelfvinfyrqverwlnrkirygmivaknqwrisllnvtgmsedtyleqltksg tfgfsvrgriaalhgldyhtlsqslelennildldtnliplasshtgglntaveqtkgki edsggrptketkdlsdsgqanrdssnsetksleggdtnne | |
| 364. | vgvvsiitgitifvsgqhaqaaemtqsssdsneqsqqteqvehkedtthlsyelnqeget asqsktsqenqsdgnvqkksnqiqdstqtsplndqkqtsmeqqskdnhvtpnsrqdtyp kgqnqddkgkqqfkdnqhsqtehqpntqnqnndqdssdkkqhpsdqtqdssskgtqpkqs qsiedrdktvkqpsskvhkigntktdktvktnqkkqtsltsprvvkskqtkhinqltaqa qyknqypvvfvhgfvglvgedafsmypnywggtkynvkqeltklgyrvheanvgafssny dravelyyyikggrvdygaahaakyghkrygrtyegimpdwepgkkihlvghsmggqtir lmehflrngnqeeidygrqyggtvsdlfkggdqnmvstittlgtphngtpaadklgstkf ikdtinrigkiggtkaldlelgfsqwgfkqqpnesyaeyakrianskvwetedqavndlt tagaeklnqmttlnpnivytsytgaathtgplgnevpnirqfplfdltsrviggddnknv rvndgivpvssslbpsdeafkkvgmmnlatdkgiwqvrpvqydwdhldlvgldttdykrt geelgqfymsminnmlkveeldgitrk | |
| 365. | tcaataaggtgctttctaaagaatttttctccccatgtccaatctataaataa | |
| 366. | ctgttgcaccatttggtccttttgcacctaagtcaattgatacttgccagttgccatat caggaattaacattggtacgaaaaatggactcacacgtcttgggcctttatccattaatt gtttatgtgcaatttcaaatgtttccataccaccgataccagaaccaatccatacaccga ttcgatctgcagtattttcat | |
| 367. | gatgcacetttaggtetaatacetggtgttaettttaaaaatgatgtaeetaaettttea gteaacatacgaettteaagaggtgaacaaacaaegeeatetaaaceagetgcatttget aacttggcataa | |
| 368. | tacatcaaaccactatgtttacccattttcttaccatcaagtgttatcatatcacccggt tgtgcaggtaaatattgtgataaaaatgttttaaagttttttcgccgataaaacaaatg cctgtagaatctttttcttagcagtaacaagtccttgttcttcagcaattcgacgcact tcactcttttcgatgtcgccaattgggaacatcacttttgaaagttgttgt | |

| cgtttcgcatcttcatcatattctaataatggccaatctgtcacccataagaagtttaat tttgtttcatcgattaaacctaattctttagctaatttgacacgtaatgcacctaaactt tgtgcaacgacatttggtttgtctgcaacaaacattactaagtcaccagcttcagcacca gttaatgtaagtaatgtttcaacattttctgtttcaaagaaacgtccaattggacctgtc aaaccatcttccacaactttaacccacgctaatcctttagcacca | |
|---|---|
| cgtcaacgtcctgtccatgtgtttccaaaaaataataatccacatgggcaatataatcat caatatcaacatcactacgtaacgctagcaaatgctttt | |
| atgaatgaagcatetaatttaatettaaceatgecaaatgaatecaaagcegeaactaaa atagcaaagattaageegecaateactggtgetggtatacaaataegttttaaaaaatta acg | |
| attetateageegeattateeacaeeggeattattaaacaacategattetteeaaac tgtteetttatgteagacaeaaagtetaeeacttgttgttegettgeattateeacatta taegeettegeattgteacaattaetttaatttategaeagteteegataeegettea getatgtetaeegeeaataeataegeacettat | |
| cctggcgctattgtttcaggtccgtattctgttaattcattaatcggatcttttgtaatc tcttcttttggttcacctttactaataattactccagttaatggattttttagtgttggt gtcgttattgtcttctcacctttttgtccttctcttgttactttttctgtccttggtgct aaatccggattaaatttacgttctttcttgaatggaatctcttcaactttttttt | |
| ttactaacatttattgctgttaaacctacgatgacaaataaaataatagctaatactttt aaaataactaaaatattttccatacgagctgcttccgacataccacgtgatagtaataat gcagttaataaaataa | |
| gatgtgttgaaactgagttcaattaaattatatgtttttattatacactttttgacatat tttttaaatttaagaatgcgaagatttttaacatttctgatgctagctttcttt | |
| totatoattgtaaatactgtatotaagtgcataaaagttogactagttggaatttcaatt gctactacttttttaaacgtogoctgoggattttcaaaaaatacgtogogotaacttttca atagottgtgcagatgtacgttotgaaacgcotatagccaagacatottttagataaaaca agttoatogocgocttcaatattgaatgggcaatotogatotaaccagattggaatatto gcatotttaaatotagga | |
| gaagtettggccatteeettgagtaaacatgaageeeceageeatetgeteetgttgtatt acettggttgttgtttgctaetggaacagtaattgtaaagtetttattaaaatetatttt ateattatattetaa | |
| sircflknfsphvqsinkslvkncdttilirlcikpvcvnsiiaasmignpvcpshhalk sasfcdhficrylglkawyevsgycvint | |
| 11hhlvl1hlsqlilaqlpyqe1tlvrkmdshvlglyplivyvqfqmfpyhryqnqsihr fdlqyfh | · |
| daplglipgvtfkndvpnfsvnirlsrgeqttpskpaafanla | |
| yikplclpiflpssviispgcagkycdknvlkffspikqmpvesfflavtspcssairrt slfsmspignitfescc | |
| rfasssysnngqsvthkkfnfvssikpnslanltrnapklcattfglsatnitkspasap vnvsnvstfsvskkrpigpvkpssttlthanplap | |
| rqrpvhvfpknnnphgqvnhqvqhhyvtlanaf |] |
| mneasnliltmpneskaatkiakikppitgagiqirfkklt | |
| ilsaalstpallnntsilpncsfmsdtksttccslalstlyafalsplllilstvsdtas amstantyapy | |
| pgalvsgpysvnsligsfvissfgsplliitpvngffsvgvvivfspfcpslvtfsvpga ksglnlrsflngisstffsnsvivfgasgvkvnsepfksvliqpfafip | |
| lltfiavkptmtnkiiantfkitkifsiraasdiprdsnnavnkitiaaiisikppfvpn gfdnaagnsmpigftsprkfaenpdatkataikysanraqpathpknspnntltqe | |
| ipirtdlliyilq | |
| sssppsilngqsrsnqigifaslnlg | |
| | |
| cgttgcacaaagctgaatgttaaaaatgcggatccgccagcaatgactgcaatccaacaa tctgatgcgacacgaca | |
| aaattcgttaaaaaagaatattgtaatgatgcatgctgtaaa | |
| | ttyttheatogalthaaacctaattctttagetaattyaeacgaatatyaeccaacca tytaatytaagtaatytttoaccaacattttotytttoaaagtaaccagettoagcacca gttaatytaagtaatytttoaacattttotytttoaaagaaagtocaattygacctgc gchaacytcctytcatytytttocaaaaaattatateacacatyggcaatataatata cgaatacaacacacatagatacgctaaaccttaagaaccaaagacgc gataacytaagtaagctaacgcaaaaatyttt atgaatyaagcatctaatttaatttaaccatgccaaatgaatccaaagcgcaactaaa atagcaaagattaagccgcaatcatyggtgtgytacaaataagttttaaaaaatta acg attoctatcagcogcaattatcaacacgggattattaaacaacacatggattcttccaaac tyttoctttatytcagacacaaagytctaccacttyttyttgetytgattataccacatta tacgcettogcattytaccacattactttaattttatgacagatctcgcattcaccactta tacgcettogcattytcaccattacttatatttattytacgaagtctcgcattyccacattactacaccatta cctygcgctattyttcagatcacatacattacgacccttat cctygcgctattyttcacctttactactacgattctttacttttttgttytaatc gctatytctaccgccaatacatacgaccttat cctytttygttycacctttactaataattactccagttaatggattttttagtyttgg tgcyttattytcttcacctttttytctttttyaatygaatctttcaactttttytctctgyty tactaccagcaatttyttyttyttyttytaaagataaacttyaaccttttacatttttttttagtttttagatytcyttttyttytaaagataacttytactttttacattttttytcattttaatttttagattctttaaaattacttttacattacagagattcttcaacacttttttaaatttttcaatacagagattaatattttaaaataattttccatacagagagacaataaaataaat |

| 393. | atgactaataaaagagaagatgtccgcaatatagcaattattgctcacgttgaccatggt aaacaactttagtagatgagttgttaaaacaatctggtatattcagagaaaatgaacat gtcgatgaacgtgcaatggactctaacgatatcgaaagagagcgtggaattacgattcta gccaaaaatacggctgttgattataaaaggtacacgtattatgaaaatggttgatggggttgtctta gcaaaataggctgtgggaaagtagaacgtattatgaaaatggttgatggggttgtctta gtagtagatgcgtatgaaggtacaatgcctcaaacacgttttgtactggggttgtctta gtagtagatgcgtatgaaggtttgtgttgttataaaattgataaaccatcagcacgtcca gagggtgttgtagaagatgtttagatttattattattgaattagaagcaaacgatgcca aaggagtgttgtagaagattttagatttattattattgaattagaagcaaacgatgaacaa ttagaattccctgttgtttatgcttcagcagtaaatggtacacgtagatcaga tagaatgataatttacaatcattatatgaaacaattattgattatgtaccagctcca aatgataacagtgatgagccattacaattccaagtagcattgttggactacaatgattat gttggacgtattggtattggtgtgtattcagaggtaaaatgcgtgtcggagataatgta tcactaattaaatta |
|------|---|
| 394. | gtgcttaggagtgatttttatatgtcttattccattgttagagtttcaaaagttaaatct ggaacaaatacaacgggcatacaaaaacatgttcaaaggagaaaataataattatgaaaat gaagatatagaccatagtaaaacttacttaattatgatttggtaatgctaataaacag aattttaataacttgattgatgaaaaaatcgaacagaattatacaggcaaaagaaaaatt agaacagacgcgattaaacacattgatggtttaattacacgacaatgatttctttgat aatcaaacgccagaagatacaaagcagtttttgaatatgctaaagagttttagacaa gaatacggtaaagataatttattatatgcaacagttcacatggacaaagacacacac |
| 395. | mtnkredvrniaiiahvdhgkttlvdellkqsgifrenehvderamdsndierergitil akmtavdykgtrinildtpghadfggeverimkmvdgrvlvvdayegtmpqtrfvlkkal eqnlkpvvvnkidkpsarpegvvdevldlfieleandeqlefpvvyasavngtasldpe kqddnlqslyetiidyvpapidnsdeplqfqvalldyndyvgrigigrvfrgkmrvgdnv slikldgtvknfrvtkifgyfglkrleieeaqagdliavsgmedinvgetvtphdhqeal pvlrideptlemtfkvmnspfagregdfvtarqiqerlnqqletdvslkvsntdspdtwv vagrgelhlsilienmrregyelqvskpqviikeidgymcepfervqcevpqenagavie slgarkgemvdmtttdngltrlifnvpargmigyttefmsmtrgygiinhtfeefrprik aqiggrnngalismdqgsastyailgledrgvnfmepgtevyegmivgehnrendltvni tktkhqtnvrsatkdqtqtmnrpriltleealqfinddelvvvtpesirlrkkilnknvr ekeakrikqmmqene VLRSDFYMSYSIVRVSKVKSGTNTTGIQKHVQRENNNYENEDIDHSKTYLNYDLVNANKQ |
| | NFNNLIDEKIEQNYTGKRKIRTDAIKHIDGLITSDNDFFDNQTPEDTKQFFEYAKEFLEQ EYGKDNLLYATYHMDEKTPHMHYGVPITDDGRLSAKEFVGNKKALTAFQDRFNEHVKQR GYDLERGQSRQVTNAKHBQISQYKQKTEYHKQEYERESQKTDHIKQKNDKLMQEYQKSIN TLKKPINVPYEQETEKVGGLFSKEIQETGNVVISQKDFNEFQKQIKAAQDISEDYEYIKS GRALDDKDKEIREKDDLLNKAVERIENADDNFNQLYENAKPLKENIEIALKLLKILLKEL ERVLGRNTFAERVNKLTEDEPKLNGLAGNLDKKMNPELYSEQEQQQEQQKNQKRDRGMHL |
| 397. | atgactgttgaagaagatccaatacagccaaagttgacattttaggggtcgattttgat aatacaacaatgttgcaaatggttgaaaatatttaaaccttttttgcaaatcaacg aataatctttttatagtaacagccaaccctgaaatagtgaattacgcgacgacacatcaa gcgtatttagagttaataaatcaagcgagctatattgttgctgatgggacaggagtagtc aaagcttcgcatcgtttaaagcaacctctagcgcatcgtatacctggtattggtgtgtgt |
| 398. | mtveersntakvdilgvdfdnttmlqmveniktffanqstnnlfivtanpeivnyatthq aylelinqasyivadgtgvvkashrlkqplahripgielmdeclkiahvnhqkvfllgat nevveaaqyalqqrypnisfahhhgyidledetvvkriklfkpdyifvgmgfpkqeewim thenqfestvmmgyggslevfagakkrapyifrklniewiyralidwkrigrlksipifm ykiakakrkikkak |

| 399. | atgattgaaaattttaagttacgtaaaatgaaagtcggtttagtatctgttgcaattaca atgttatatatatgagacaacggacaagcagaagcatctgaaaatcaaaacgctttaatc tctaatataaatgtagacaatcaggaaaaacagaatatgtaaatcaaacgctttcagcct caaaataatactaatgaaacatcaaaagtaccggctaattttgtcaaattgaatgtatt aaaccaggtgatacttctatacaaaggaacaactttaccaaattatatactattaact attgataaaaaagatgtgagctcagttgaagattctgacagcagctttgttatgtctgat aaagatgggaattttaagattgacttaaatggtcgcaaaattgttcataatcaagaaatt gaagtgtcttcatcaagatccctatttaggtcgcaaaattgttcataatcaagaaatt gaagtgtcttcatcagatccctatttaggtgacgatgaagaagtagaagaagaagaagacagctaaaagcagacagctatataca acaccgcgatatgaaaaagcgtaggaagaagaagtagaagcagacagctaaaagcagaaga acttcaactgaagaagttggtgtgaggaagaagtagaagtagaagcaaaaagaagaga actcaccaagtttttatcgaacctattaactgaaggttcaggtattattaaaagacaaact tctgtaaaaggtaaagttgctcatctattaataaatttattaactttgagacaaaat gctaatggtggtccaaataaagaagagggaaatctggatcagaaggatctgatgcct attgatgacaaaggtactttaattttgactccaaaacgaaaggttcgatgcct attgatgacaaaggatactttaattttgactccaaaacgaaaggttcgatgcatg ttaaagaaaaatgatgagatctcattaacatttgcacctgatgacgaaggtttagag ttaagacaaagagatacttaaatttgcacctgatgacgaaggtttaagagaact aaatatgaccatactaaagtgaaaagaagtttagaagagtttaaagaagattta aagtcattaatttcaaagtgaaacagatttagaagagtttaaaagaagattta aaagaaggtactaaagtaattaaaggaaactaaattcgcaaatgcagttgaaggta taagaaggtactaaagtaattaaaggaagatctgaagaacattcctgat aaagaaggtactaaagtagaagatcatccctgatttgcaagtcgatgraaaaggtagaa ttcagctttgatgtagaagatcatacatgctggatttaaaaacata gactttgatgtagatcctattacaggtgaattataaagagaaacttaccaaagtgagaaacactaaacttc acagtagttgatcctattacaggtgaattattaagtggaaattttttgatcaaaacacac acacctgcatatcataaattacatggtgataaaaatttggaaagaaccacaaacttc acagtagttgaacctataaaattacatggtgataaaaatttggaaagaacacaaacctaaaccacacctgatttacataaattacatggtgaaaaaaacacaaacacacac |
|------|--|
| 400. | gaaaaa msenfklrkmkvglvsvaitmlyimtngqaeasenqnalisninvdnqekqnnvnqavqp qnntnetskypanfvklndikpgdtsiqgttlpnqfilltidkkdvssvedsdssfvmsd kdgnfkydlngrkivhnqeievsssdpylgddeedeeveetsteevgaeeesteakatyt tpryekayeipkeqlkekdghhqvfiepitegsgiikghtsvkgkvalsinnkfinfetn anggnkeeaksgsegiwmpiddkgyfnfdfktkrfddlelkkndeisltfapddedeal kslifktkvtsledidkaetkydhtkvekvkvlkdvkedlhvdeiygslyhtekgkgild kegtkvikgktkfanavvkvdselgegqefpdlqvdxkgefsfdvdhagfrlqngetlnf tvvdpitgellsgnfvsknidiyespeekadrefdermentpayhklhgdkivgydtngf pitwfyplgekkverkapklek |
| 401. | gtctatatgctatcaagtaccaggtttattgttaggtggtacaacaattgtaataagtcc actaatatcattaatgaaagatcaagtggatcaattaaaagcgatgggaattcaagctgc ttttttaaa |
| 402. | vymlsstrfivrwynncnkstniinerssgsiksdgnsscffk |
| 403. | tttaaatataaaaaaaaaagaaaaatacctagtattatgatgcaacaaattaaaattaat ataatattaatttaacgataaataaattggataccttottaacataaca |
| 404. | fkykknrkipsimmqqikitilysyltinkweyllnitpnktvlpatgqkelilavftmf kvsksfsliltyffgisqliigkksanhvltksiikysslyliilylgfllifsvsqsnv stsfqlvly |
| 405. | ggaatgaaaatgatttcgatttccgatgaaatcaattgtttaatttgttgcaattgtgta gggttatgttcttttttttcttctgctaagtatattttttggatttccatttcttctaac actgtagctaagacatcaataaagcgtggtaagtttttagttacagctaggtcgatacga cga |
| 406. | gmkmisisdeincliccncvglcsfissakyifwisissntvaktsikrgkflvtarsirr |
| 407. | tttgaagetacaaaggtacegeataatggeageacattaattaacaatgegetaaacttt aatgaggegetgatttgettgtetttaaaagtcaacatagcactgataattcetaaaata getactatacgtggaattgtcatgeteggatactgeggtatatgtaagaacgaccaaga cetgetatcacaccacatactaacgcaatatatagaaattgettcaaatcattcacteet aaattgttattacactattacaca |
| 408. | featkvphngstlinnalnfnealicls1kvnialiipkiatirgivmlgycgickkapr paitphtnaiyrncfksftpkll1hyyt |
| 409. | atgettgetgetegeatactattagaatetggtgeagaaggtaegegtgtagaagatace atgacacgtattgcaaaaaaacttggttacagtgaaagtaacagetttgttacaaacact gtcatccagtttacatteggaategtttectagaatatttagaattacetetega gatacaaacttaataaaaattteteaagetaataaaatttegegteaaattacaaacaat gaaatttetttageegaageaaaaaegeaacttgaaaaaattatgttgetaagegtgae agagtetteeetttaaaggttttgetgeageaatgattgaatgagtttettatattta caaggtggtagattgattgatgttttaaetgegatattagaaggtagtetaggataceta gtcactgagattttagategtagttttaactgegatattaecagaggtagtetaggtacat ttagttattgggattattggagetaaggtagetaetagagttatecaaaaggtgacttggea actattatcattgeggagtcatgeetattgteetgggtattatacaaaacgcaata caagatttatttggtgagatcatgectattgteetggtgtattaaataacaacgcaata actagegtttggcateggggtggtggtgtgtgtagagcattaatttagta |
| 410. | mlaarillesgaegtrvedtmtriakklgysesnsfvtntviqftlhsesfprifritsr dtnlikisqankisrqitnneislaeaktqlekiyvakrdsslpfkgfaaamiamsflyl qggrlidvltailagslgylvteildrklhaqfipefigslvigiiavightliptgdla tiiiaavmpivpgvlitnaiqdlfgghmlmfttkslealvtafgigagvgsvlilv |

| 411. | atgacatttaataaagtattattgagctggatagtcatattgattataacaactagcata tatctattttggcagttgggcgatatcaatgatgtatttaaccagtctattttaatcaat gttagattaccgagattattagaagcattgttgacaggtatgatattaactgttgcaggc cttatatttcaaacagttttaaatacattggcagatatgatttaacattaggattggca agcggcgctacatttggttcaggattagcattattttaagtttaacaacgttatggat cctgtattttcaataacatttagttgataacattaataactgtattagcattacgtcg gtattgagccaaggctatccagttagaatcttaatattaagtggttaatgattggtgg gtattcacttcatattttttgatttaattattaagtggttaatgattggtgg |
|------|---|
| 412. | mtfnkvllswiviliittsiylfwqlgdindvfnqsilinvrlprllealltgmiltvag lifqtvlnnaladsftlglasgatfgsglalflglttlwipvfsitfslitlitvlvits vlsqgypvrililsglmigalfnsllyffillkprklntianylfggfgdaeysnvsiia itfiialfgifiilnqlkllqlgelksqslglnvqlityialciasmitainvayvgiig figmvipqlirkwqwkqslgrqlalnivtggqimvmadfigshilspvqipasiiialig ipvlfymlisqskrlh |
| 413. | atgaacaaacagcaaaagaatttaaatcattttattcaattagaaagtcatcactaggc gttgcatctgtagcaattagtacacttttattattaatgcaaatggcgaagcacaagca gcagctgaagaaacaggtggtacaaatacagaagcacaaccaaaaactgaagcagttgca agtccaacaacacatctgaaaaagctccagaaactaaaccagtagctaatgctgca gtatctaattaaagaagttgaggccctacttctgaaacaaaagaagctaaagattaaa gcagttaaagcccctaaggaaacaaaagaagttaaaaccagcagcaaaagccactaacaat acatatcctatttgaatcaggaacttagagaaggttaaaccagcagcaaaagccactaacaat acatatcctatttgaatcaggaacttagagaaggttattttgaaatgaaaagatgga aactcaacagtttatcattatgcaagttctgttaaaactgctagagttattttcactgat tcaacagtttatcattatgcaagttctgttaaaactgctagagttatttcacaggtcattttcacatggattatttagaagtt tagaaggtgacaaaaaggtgccaaattaaatt |
| 414. | agaaacgtaaaac MNKQKBFKSFYSIRKSSLGVASVAISTLLLIMSNGEAQAAAEETGGTNTEAQPKTEAVA SPTTTSBKAPETKPVANAVSVSNKEVEAPTSBTKEAKBVKEVKAPKETKEVKPAAKATNN TYPILNQELREAIKNPAIKDKDHSAPNSRPIDFEMKKKDGTQQFYHYASSVKPARVIFTD SKPEIEGLQSGQFWRKFBVYEGDKKLPIKLVSYDTVKDYAYIRFSVSNGTKAVKIVSST HFNNKEEKYDYTLMEFAQPIYNSADKFKTBEDYKAEKLLAPYKKAKTLERQVYELNKIQD KLPEKLKAEYKKLEDTKKALDEQVKSAITEFQNVQPTNEKMTDLQDTKXVVYESVENNE SMMDTFVKHPIKTGMLNGKKYMVMETTNDDYWKDFMVEGQRVRTISKDAKNNTRTIIFPY VEGKTLYDAIVKVHVKTIDYDGQYHVRIVDKEAFTKANTDKSNKKEQQDNSAKKAETPAT PSKPTPSPVEKESQKQDSQKDDNKQLPSVEKENDASSESGKDKTPATKPTKGEVESSSTT PTKVVSTTQNVARPTTASSKTTKDVVQTSAGSSRAKDSAPLQKANIKNTNDGHTQSQNNK NTQENKAKSLPQTGEESNKDMTLPLMALLALSSIVAFVLPRKRKN |
| 415. | atgaattatccaaatggtaaaccatatcgtaaaaatagtgctatagacggagggaaaaag accgctgcctttagtaatattgagtatggtagtggcgtggtatgtcacttgaaaaagatatc gaacattcaaatacgttttatcttaaaaagcgacattgcagttattcacaaaaagcctacg ccagtacaaatagttaatgtcaactatcctaagcggagtaaagctgtgattaacgaagct tatttcgtacaccttcaacacactgattacaacgggggttaaaagctgtgattaatattgat tttgaagcaaaggaaactaaaaacagacgtctttcctttaaataatattcatgaccat caagtcgaacatatgaaaatgcatatcaacaaaaaggtattgtttttaatgattttaaacgctagatgaacattcttttacacaaaaaggtatttttggaag agatataaaggtagatgatatatcttttaccctattcaaaattcgaagtattttggaag agatataaaagatattaaaaragctaacacatccattcctatcagtatcagtatgacaattccttatcagtatcaacaagattgataacagtgataaattctcttatcagtatcaacaagttgataacagatgagtgataattcataacagttgatgaaaatggataagttgataa ttagatgaaagtgagaaggacgcgta |
| 416. | mnypngkpyrknsaidggkktaafsnieyggrgmslekdiehsntfylksdiavihkkpt pvqivnvnypkrskavineayfrtpsttdyngvyqgyyidfeaketknktsfplnnihdh qvehmknayqqkgivflmirfktldevyllpyskfevfwkrykdnikxsitvdeirkngy hipyqyqprldylkavdklildesedrv |

| 417. | ttgatatatctagataatgcggcaacgacgaaggcatttgaagaagtgttagatacttat ttaaaagtaaatcaatcaatgtattataatccgaatagtcgcataaagctggtttgcag gcaaatcaattactacaacaagcaaaaacccaaattaatgcaatgattaattcaaaaaca aattatgatgttgtattcactagtggtgcaactgaatccaataatcttgctttaaaaggt attgctatcgtaaatttgatacagcgaaggaaataatatacatccgtgttagagcatccg tccgtattagaggttgtaagatatttggaagcacacgaaggatttaaagttaaagttagatg gatgtaaagaaag |
|------|---|
| 418. | liyldnaattkafeevldtylkvnqsmyynpsphkaqlqanqllqqaktqinaminskt nydvvftsgatesmlalkgiayrkfdtakeiitsvlehpsvlevvryleahegfkvkyv dvkkdgsinlehfkelmsdkvglvtcmyvnnvtgqiqpipqmakviknypkahfhvdavq afgkismdlmnidsislsghkfnglkqqgvllvnhiqnveptvhggqqeygvrsgtvnlp ndiamvkamkianenfealnafvtelnndvrqfinkyhgvyinsstsgspfvlnisfpgv kgevlvnafskydimisttsacsskrnklnevlaamglsdksiegsirlsfgatttkedi arfkeifiliveeikellk |
| 419. | atyteatateattggtttaagaaaatgttaettteaacaagtattttaattttaagtagt agtagtttagggettgeaacgcacagttgaagcaaaaggataacttaaatggagaaaaa ccaactactaatttgaatcataatataactteaccatcagtaaataagtgaaatgaataat aatgagactggacacctcacgaatcaaatca |
| 420. | msyhwfkkmllstsililsssslglathtveakdnlngekpttnlnhnitspsvnsemnn netgtphesnqtgnegtgsnsrdanpdsnnvkpdsnnqnpstdskpdpnnqnpspnpkpd pdnpkpdpdkpkpnpdpkpdpdnpkpnpdpkpdpdlpkpnpdpkpdpdkpkpnp npkpdpnkpnpnpspdpdqpgdsnhsggsknggtwnpnasdgsnqgwmpngngnsqnp tgndfvsqrflalangaykynpyilnqinklgkdygevtdediyniirkqnfsgnaylng lqqqsnyfrfqyfnplkseryyrnldeqvlalitgeigsmpdlkkpedkpdskqrsfeph ekddftvvkkqednkksastayskswlaivcsmmvvfsimlflfvkrnkkknknesqrr |

422.

gatatacaaaaaaaaccaacagatttaggggtatcagaggtaaccaggtttaatgttggt gy togggataaaggtotggtaaattcagggggattttaaattgatactggatacatttat acaagttccatggacaaaactgaaaagcaagctggacaaggttatagaggatacggagct actagtteettiggacaaattgataatteattgatagttggagaaaattattgataaatca aaaactaattttttaaactatggggacaattcaactaatacatcagatggaaagtttcat gggcaacgtttaaatgatgtcatcttaacttatgttgcttcaactggtaaaatgagagca gggtaatgctadatggggaggacttcaataacagatttaggtttatctaaaaatcag gcatataatttcttaattacatctagtcaaagatggggccttaatcaagggataaatgca aatggctggatgagaactgacttgaaaggttcagagtttacttttacaccagaagggcca acaagagaaggacaaaaaggtgagaagacaataacgacaccaacactaaaaaatccatta actggagtaattattagtaaaggtgaaccaaaagaagaaatcacaatagatccgattaat gaattaacagaatacggaccagaaacgataacaccaggtcatcgagacgaatttgatccg gaaatcacaaaagatccgattaatgaattaacagaatacggaccagaaacgataacacca ggtcatcgagacgaatttgatccgaagttaccaacaggaggaaagaggaagttccaggtaaaccaggaattaagaatccaggaaacaggagacgtagttagaccaccggtcgatagcgta acaaaatatggacetgtaaaaggagactcgattgtagaaaagaagaaattccattcaag aaagaacgtaaatttaatcctgatttagcaccagggacagaaaaagtaacaagagaagga caaaaaggtgagaagacaataacgacgccaacactaaaaaatccattaactggagaaatt attagtaaaggtgaatcgaaagaagaaatcacaaaagatcgattaatgaattaacagaa tacggaccagaaacgataacaccaggtcatcgagacgaatttgatcgaagttaccaaca ggagagaaagagaagttccaggtaaaccaggaattaagaatccagaaacaggagatgta gttagaccaccggtcgatagcgtaacaaaatatggacctgtaaaaggagactcgattgta gaaaaaggagaaattccattcgagaaaggacgtaaatttaatcctgatttagcaccaggg acagaaaaggtaacaagagaaggacaaaaaggtgagaagacaataacgacgccaacacta tttaatccaaaattacaacctggtgaagagcgagtgaaacaagaaggacaaccaggaagt aagacaatcacaacaccaatcacagtgaacccattaacaggtgaaaaagttggcgagggt caaccaacagaagagatcacaaaacaaccagtagataaagattgtagagttggagag aaaccaaaagatcaaaaggacctgaaaacccagagaagccgagcagaccaactcatcca agtggcccagtaaatcctaacaatccaggattatcgaaagacagagcaaaaccaaatggc ccagttcattcaatggataaaaatgataaagttaaaaaatctaaaattgctaaagaatca gtagctaatcaagagaaaaaacgagcagaattaccaaaaacaggtttagaaagcacgcaa aaaggtttgatctttagtagtataattggaattgctggattaatgttattggctcgtaga

agaagaat
mrdkkgpvnkrvdflsnklnkysirkftvgtasiligslmylgtqqaaaaannienptt
lkdnvqskevkieevtnkdtapqgveaksevtsnkdtiehepsvkaediskkedtpkeva
dvaevqpkssvthnaetpkvrkarsvdegsfditrdsknvvestpitiqgkehfegygsv
diqkptdlgvsevtrfnvgnesngligalqlknkidfskdfnfkvrvannhqsnttgad
gwfflfskgnaeeyltnggilgdkglvnsggfkidtgyjytssmdktekqagggyrgyga
fvkndssgnsqmvgenidksktnflnyadnstntsdgkfngqrlndviltyvastgkmra
evagktwetsitdlglsknqaynflitssgrwglnqginangwmrtdlkgseftftpeap
ktitelektveeipfkkerkfnpdlapgtekvtregqkgektittptlkmpltgviiskg
epkeeitkdpinelteygpetiapghrdefdpklptgekeevpgkgrikmpetgdvvrpp
vdsvtkygpvkgdsivekeeipfekerkfnpdlapgtekvtregqkgektittptlkmpl
tgviiskgepkeeitkdpinelteygpetitpghrdefdpklptgekeevpgkpgikmpe
tgdvvrppvdsvtkygpvkgdsivekeeipfkkerkfnpdlapgtekvtregqkgektit
tptlkmpltgeiiskgeskeeitkdpinelteygpetitpghrdefdpklptgekeevpg
kpgikmpetgdvvrppvdsvtkygpvkgdsivekeeipfkkerkfnpdlapgtekvtreg
gkgektittptlkmpltgeiiskgeskeeitkdpinelteygpetitpghrdefdpklpt
gekeevpgkpgikmpetgdvvrppvdsvtkygpvkgdsivekeeipfekerkfnpdlapg
tekvtreggkgektittptlkmpltgeiiskgeskeeitkdpvneltefggekipgghkd
ifdpnlptdqtekvpgkpgiknpdtgkvieepvddvikhgpktgtpetktveipfetkre
fnpklqpgeervkqegqpgsktittpitvnpltgekygegqpteeitkqpvdkivefgge
kpkdkgpenpekpsrpthpsgvnnnnpglskdrakpngpvhsmdkndkvkkskiakes
vangekkraelpktglestqkglifssiigiaglmllarrrkm

ggattatttagcattttaggtttaggttattacgcagaaataaaaagaatcacaaagca vksnlrygirkhklgaasvflgtmivvgmgqekeaaaseqnnttveesgssateskaset qtttnnvntidetqsysatsteqpsqstqvtteeapktvqapkvetsrvdlpsekvadke ttgtqvdiaqpsnvseikprmkrstdvtavaekevveetkatgtdvtnkveveegseivg hkqdtnvvnphnaervtlkykwkfgegikagdyfdftlsdnvethgistlrkvpeikstd gqwatgeiigerkvrytfkeyvqekkdltaelslnlfidpttvtqkgnqnvevklgett vskifniqylggvrdnwgvtangridtlnkvdgkfshfaymkpnnqslssvtvtgqvtkg nkpgvmptvkvykhigsddlaesvyaklddvskfedvtdnmsldfdtnggyslnfnnld qsknyvikyegyydsnasnlefqthlfgyynyytsnltwkngvafysnnaggdgkdklk epiiehstpielefkseppvekheltgtieesndskpidfeyhtavegaeghaegtiete edsihvdfeesthenskhhadvveyeedtnpggqqvttesnlvefdedstkgivtgavsd httiedtkeyttesnlielvdelpeehgaqgpieitennhhishsglgtenghgnygv ieeieenshvdikselgyeggmsgnqsfeedteedkpkyeggnivdidfdsvpqihgq nngnqsfeedtekdkpkyeggmiididfdsvphihgfnkhteiieedtnkdkpnyqfg hmsvdfeedtlpqvsghnegqtieedttppivpptpevpsepetptpptpevpsep etptpptpevptepgkpippakeepkkpskpveggkvvtpvieinekvkavvptkkaqsk kselpetggeestnngmlfgglfsilglallrrnkknhka

atgaaagetttattaettaaacaagtgtatggetegttttgetttttagtgtaatggga ttatggeaagtetegaaegeggetgageageataeaeeaatgaaageaeatgeagtaaca 425. acgatagacaaagcaacaacagataagcaacaagtaccgccaacaaaggaagcggctcat ctagccgaagaaaaagggcgtgtcatcggtatggctaaattaaaaacagtaaaagaacaa gaaaagcctgatttaatgttagacgcaggagacgccttccaaggtttaccactttcaaac cagtctaaaggtgaagaaatggctaaagcaatgaatgcagtaggttatgatgctatggca

mkalllktsvwlvllfsvmglwqvsnaaeqhtpmkahavttidkattdkqqvpptkeaah hsgkeaatnvsasaqgtaddtnskvtsnapsnkpstvvstkvnetrdvdtqqastqkpth tatfklsnaktaslspmfaanapqttthkilhtndihgrlaeekgrvigmaklktvkeq ekpdlmldagdafqglplsnqskgeemakamnavgydamavgnhefdfgydqlkklegml dfpmlstnyykdgkrafkpstivtkngirygiigvttpetktktrpegikgvefrdplqs vtaemmriykdvdtfvvishlgidpstqetwrgdylvkqlsqnpqlkkritvidghshtvlqmgqiynndalaqtgtalanigkitfnyrngevsnikpslinvkdvenvtpnkalaeqinqadqffraqtaeviipnntidfkgerddvrtretnlgnaiadameaygvknfsktdfavtngggirasiakgkvtrydlisvlpfgmtiaqidvkgsdvwtafehslgapttqkdgktvltanggllhisdsirvyydinkpsgkrinaiqilnketgkfenidlkryhvtmndftasggdgysmfggpreegisldqvlasylktanlakydttepqrmllgkpavseqpakgqqgskgsksgkdtqpjgddkvmdpakkpapgkvvlllahrgtvssgtegsgrtiegatvssksgkqlarmsvpkgsahekqlpktgtngssspeamfvllagigliatvrrrkas 426.

atgaataaaaattcgaagaagaagctcgattttcttccaaacaagcttaataagtactca attagacgtttcactgtagggacagcttcgattttagtaggagctactttaattttcggt gttgcaaatgatcaagcagaagccgctgagaataacacaactcaaaagcaagatgatagt tcagatgcaagtaaagtaaaagtaatgttcaaactattgaacaatcttctgcaaattca aatgaatctgatattcctgaacaagttgatgtaactaaagatacaactgaacaagcatca acagaagaaaaagcaaatacaactgaacaagcatcaacagaagaaaaagcagatacaact gaacaagcaacaagaagaagcgccaaaagctgaaggaacagacaaagtagaaacagaa gaagcgccaaaagctgaagaaacagacaaaagcaacaacagaagaagcgccaaaagctgaa gaaacagacaaagcaacagaagaagcaccaaaaactgaagaaacagacaaagcaacaaca gagagaactcaagttgtagatacagttgctaagagtacttaaacgctcaactatcagaact gagagagaactcaagttgtagatacagttgctaaagatttatataaaaaatctgaagttaca gaagcagaaaaagctgaaattgaaaaagtattaccaaaagatatttcaaacttatctaat gaagaaattaaaaaaatagctttaagtgaagtacttaaagaaacagctaacaaagaaaac gcacaaccaagagcaacattccgttcagtaagcagcaatgctagaacaacaaatgttaac tattcagcaacagcattaagagcagctgcacaagacacagttactaaaaaaaggaactggt aactttactgcatggagatataatccataaaacttataaagaagaattccctaatgaa ggcacgctaactgcattcaatacaaacttcaatcctaatacaggaactaaaggcgcatta gaatataatgataaaatagattttaataaagactttacaattactgttccagtagcaaac aacaaccaaggtaatacaacaggagcagatggctggggcttcatgtttactcaagggaat ggccaagacttcttaaaccaaggtggtattttaagagacaaaggtatggcaaatgcatct ggttttaaaattgatacggcatataataatgttaatggtaaagtcgataaactcgatgca catggccaaagattaaatgatgtagtattaaattatgatgcagcaacaagtacaataact gctacatatgcaggaaaacatggaaagctactacagatgatttaggaattgataaatca caaaaatataattcttaattacttcaagtcatatgcaaaatagatattctaatggaatt atgagaacaaatcttgaaggtgtaacaattacaacgcctcaagctgatttaattgatgat gtggaagtaacgaaacaaccaattcctcataaaactattcgtgagtttgatccaactcta gaaccaggctcacctgatgttattgtacaaaaaggtgaagatggagagaaaacaacaact acaccaactaaagttgaccctgatacaggagatgtagttgaacgtggtgaaccaacaaca gaagttacaaaaaatccagttgacgagattgtacactttacacctgaagaagtaccaca ggtcataaagatgagttcgatccaaacttaccaattgacggtacagaagaagtaccaggt aaaccaggcatcaagaatcctgaaacaggtgaagtagtaacacctccggttgacgatgtc acaaaacatggtccaaaagcaggcgaaccagaggttactaaagaagaaataccattcgag aaaaaacgtgagttcaatccagacttaaaaccaggtgaaggaaagtaacgcaagaagga caaactggagagaaacaacaacaacacacaacaattaatccattaacgggagaaaaa gtaggcgaaggtgaaccaacaacagaagtaacaaaagaaccagtagatgaaatcacacaa ttcggtggagaagaagtaccacaaggtcataaagatgagttcgatccaaacttaccaatt gacggtacagaagaagtaccaggtaaaccaggcatcaagaatcctgaaacaggtgaagta gtaacacctccggttgacgatgtcacaaaaacatggtccaaaaagcaggcgaaccagaggt attaatccattaacgggagaaaaagtaggcgaaggtgaaccaacaacagaagtaacaaaa attattrattrattatugggagadadagtaggagagagagagagagagagaggacadadagat gaaccagtagatgaaaccacaattcggtgagagagagtaccacaggtaaaccaggatt gagttcgatccaaacttaccaattgacggtacagaagaagtaccaggtaaaccaggattc aagaatcctgaaaccaggtgaagtagtaacacctccggttgacgatgtcacaaaacatgg ccaaaagcaggcgaaccagaggttactaaagaagaaataccattcgagaaaaaacgtgag ttcaatccagacttaaaaccaggtgaagagaaagtaacgcaagaaggacaaactggaga aaaacaacaacgccaacaacaattaatccattaacgggagaaaaagtaggcgaaggt gaaccaacaacagcagtaacaaaagaaccagtagatgaaatcacacaattcggtggagaa gaagtaccacaaggtcataaagatgagttcgatccaaacttaccaattgacggtacagaa gaagtaccaggtaaaccaggcatcaagaatcctgaaacaggtgaagtagtaacaccacca gtagacgatgtcacaaaacatggtccaaaagcaggcgaaccagaggttactaaagaagaa attccatatgaaactaaacgcgtattagatccaacaatggaaccaggtagtcctgataaa gattcagatgcggacagcgattcagacgcagattcagacagcgattcagatgcgattcagactca gacgcagatagcgactctgatgcggacagcgattcagacagcgatagcgattcagattca gatagcgactctgatgcggacagcgattcagacagcgatagcgattcagacgcagatagcgattcagatgcgattcagatgcgattcagatgc gattctgatgcagacagcgactcagacgcagatagcgactcagattcagactcagattcagacgcagatagcgactcagattcagactca gattcagacagcgattcagacgcagatagcgattcagattcagatagtagactctgatgcg gacagcgactcagacgcagatagcgactctgatgcggacagcgactcagacgcagatagc gacagcgactcagacgagattagtactctyatguggactctgagacgagatagattag gattctgattcagacgagattcagacgcagatagcgactcagacgagatagcgattcag gacgcagatagcgattcagattcagatgugattcagattcagatagcgactctgatgcg gacagcgatagcgattcagattcagacgagcgactcagacgcagatagcgactcagacga gatagcgatagcgattctgatgcagacagcgactcagacgagatagcgactctgatgcg gacggcgactcagacgcagatagcgattctgatgcagacagcgactcagacagcgattag gattctgattcagacgcagtattcagacgcagatagcgactcagattcagacagcgattca gacgcagatagagatcataatgacaaaacagataaaccaaataataaagagttaccagat actggtaatgatgctcaaaataatggcacattatttggttcactattcgctgcgcttgga ggattattcttagttggcagacgtcgtaaaaacaaaaataatgaagaaaa

| 428. | mnknskkldflpnklnkysirrftvgtasilvgatlifgvandgaeaaennttqkqdds sdaskvkgnvqtiegssansnesdipeqvdvtkdttegasteekanttegasteekadtt egatteeapkaegtdkveteeapkaeetdkatteeapkaeetdkatteeapkteetdkte eeapaaeetskaateeapkaeetskaateeapkaeetektateeapkteetdkveteeap kaeetskaateeapkaeetnkveteeapaaeetnkaateetpavedtnaksnsnaqpset ertqvvdtvakdlykksevteaekaeiekvlpkdisnlsneeikkialsevlketanken aqpratfrsvssnarttnvnysatalraaaqdtvtkkgtgnftaigdilihktykeefpne giltafntnfnpntgtkgaleyndkidfnkdftitvpvannnqgnttgadgwgfmftqgn gqdflnqggilrdkgmanasgfkidtaynnvngkvdkldadktnnlsqigaakvgygtfv kngadgvtnqvgqnalntkdkpvnkiiyadnttnhldgqfhgqrlndvvlnydaatstit atvagktwkattddlgidksqkynflitsshmqnrysngimrtnlegvtittpqadlidd vevtkqpiphktirefdptlepgspdvivqkgedgekttttptkvdpdtgdvvergeptt evtknpvdeivhftpeevpqghkdefdpnlpidgteevpgkpgiknpetgevvtppvddv tkhgpkagepevtkeeipfekkrefnpdlkpgeekvtqegqtgekttttpttinpltgek vgegepttevtkepvdeitqfggeevpqghkdefdpnlpidgteevpgkpgiknpetgev tippldgvkygegepttevtkepvdeitqfggeevpqghkdefdpnlpidgteevpgkpgi knpetgevvtppvddvtkhgpkagepevtkeeipfekkrefnpdlkpgeekvtqegqtgekttttptt inpltgekvgegepttevtkepvdeitqfggeevpqghkdefdpnlpidgteevpgkpgi knpetgevvtppvddvtkhgpkagepevtkeeipfekkrefnpdlkpgeekvtqegqtge ktttpttinpltgekvgegepttevtkepvdeitqfggeevpqghkdefdpnlpidgte evpgkpgiknpetgevvtppvddvtkhgpkagepevtkeeipfekkrefnpdlkpgeekvtqegqtge ktttpttinpltgekvgegepttevtkepvdeitqfggeevpqghkdefdpnlpidgte evpgkpgiknpetgevvtppvddvtkhgpkagepevtkeeipfekrrefnpdlkptmepgspdk vagkgengekttttpttinpltgekvgegepttevtkepideivnyapeiiphgtreeid pnlpegetkvipgkdglkdpetgeiieepqdeviihgakdsdadsdadsdadsdsdadsd dadsdadsdsdadsdsdsds | |
|------|--|--|
| 429. | ttgaaaagaaaaacatttattcaattcgtaaactagtgtaggtattgcatctgtaact ttaggtacattacttatatctggtggcgtaacactggtgcgaaatgctgcgcaacacgat gaagctcaacaaaatgcttttatacaagtcttaaatatgcctaacttaaatgctgatcaa cgcaatggttttatccaaagccttaaagatgatccaagccaaagtgctaacgttttaggt gaagctcaaaaacttaatgactctcaagctccaaaagctgatgcgcaacaaaataccttc aacaagatcaacaaagcgcttcatgaaatcttgaacattgctaacttaaacgaagcg caacgtaacggcttcattcaaagctcttaaagacgccaaagccaaagcactaacgtttta ggtgaagctaacaaattaaacgaatctcaagcaccgaaagccaaagcactaacgtttta ggtgaagctaaaaaattaaacgaatctcaagcaccgaaagctgataaccaattcaaccaa gaacaacaaatgctttctatgaaatcttgaatatgcctaacttaacgaaggacaaag gataaaaggttaaatgaatctcaagcacgaaagcggataacaattcaacaaagaacaa gctaaaaagttaaatgaatctcaagcacgaaagcggataacaaattcaacaagaacaa gctaaaaggttaaatgaatctcaagcaccgaagcggataacaattcaacaagaacaa aagctaaatgatgctcaagcaccaaagcctgacaaagcgtaaccttttagcagaagctaaa agctaaatgatgctcaagcaccaaagctgacaacaaattcaacaaagacaacaaaa agcttactagaaatttacatttacctaacttaact | |
| 430. | lkkkniysirklgygiasvtlgtllisggvtpaanaaqhdeaqqnafyqvlnmpnlnadq rngfigslkddpsqsanvlgeaqklndsqapkadaqqmnfnkdqqsafyeilmmpnlneaq rngfiqslkddpsqstnvlgeaqklndsqapkadnnfnkeqqmafyeilmmpnlneeqr ngfiqslkddpsqsanllseakklnesqapkadnnfnkeqqmafyeilhlpnlneeqrn fiqslkddpsqsanllaeakklndaqapkadnkfnkeqmafyeilhlpnlneeqrn gslkddpsyskeilaeakklndaqapkednnkpgkednnkpgkednnkpgkednnkpgk edgnkpgkednkkpgkedgnkpgkednktpgkedgnkpgkedgngvhvvvkpg dtvndiakangttadkiaadnkladknmikpgqelvvdkkqpanhadankaqalpetgee npfigttvfgglslalgaallagrrrel | |
| 431. | atgaagaaaacaattttactgacgatgacaactcttactttattta | |
| 432. | mkktilltmttltlfsmspnsaqaytndsktleeakkahpnaqfkvnkdtgaytytydkn ntpnnnhqnqsrtndnhqhanqrdlnmqyhsslsgqythindaidshtppqtspsnplt paipnvednddelnnafskdnkglitgidldelydelqiaefndkaktadgkplalgngk iidqplitsknnlytagqctwyvfdkrakdghtistfwgdaknwagqassngfkvdrhpt rgsilqtvngpfghvayvekvnidgsilisemnwigeyivssrtisasevssynyih | |

| 433. | atgaatcaatatcattctaatgcacaacaaccaagtgcatggcgtttttttgtctatagt ttagtgggcatactatgttctttattccttttacgattaatggggatacaacacactatttc gtcgatcatgttcatctagccattcgctcaatcatcagtgcaccttatgcca ctgattatgattttaattggtacagcgttaccaattagtgcagcgtacttatttat |
|--------|--|
| 434. | mnqvhsnaqqpsawrffvyslvgilcffipftingnntifvdhvhlairsiigplmpyva limiligtalpivrrtfmtsitnlvitlfkvagamigimyvfkigpsilfkanygpflfe klmmplsilipvgaialsllvgygllefvgvymepimrpifktpgksavdavasfvgsys lgllitnrvykqgmynkreatiiatgfstvsatfmiivaktlglmphwnlyfwitlvitf vvtaitawlppisnesteyyngqegeqevaiegsrlktayaeamkqmaltpslvknvwdn lkdglemtvgilpsilsigflglivanytpfidwlgyifypfiyifpiadqallakasai sivemflpsllvtkaamstkfvvgvvsvsaiiffsalvpcilateikipvwkliiiwflr valsllitipvallifg |
| . 435. | atgaaaatgagaacaattgctaaaaccagtttagcactagggcttttaacaacaggcgca attacagtaacgacgcaatcggtcaaaggagaaaaatacaatcaactaaagttgacaaa gtaccaacgcttaaagcaggagattagcaatgataaacactaaacagcaggtgcaaattca gcgacaacacaagcagcatcagcttagcaatgaaaacacacac |
| 436. | mkmrtiaktslalgllttgaitvttqsvkaekiqstkvdkvptlkaerlaminitagans attqaantrqertpklekapntneektsaskiekisqpkqeeqktlnisatpapkqeqsq tttesttpktkvttppstntpqpmqstksdtpqsptikqaqtdmtpkyedlrayytkpsf efekqfgfmlkpwttvrfmnvipnrfiykialvgkdekkykdgpydnidvfivlednkyq lkkysvggitktnskkvnhkvelsitkkdnqqmisrdvseymitkeeislkeldfklrkq liekhnlyqmqsqtivikmknggkytfelhkklqehrmagtnidnievnik |
| 437. | atgaaaataacaacgattgctaaaacaagtttagcactaggccttttaacaacaggtgta atcacaacgacaacgcagcaacaacgcgacaacaccatcttccactaaagttgaagca ccacaatcaacaccgccctcaactaaaatagaagcaccgcaatcaaaacaaac |
| 438. | mkittiaktslalgllttgvittttqaanattpsstkveapqstppstkieapqskpnat tppstkveapqqtanattppstkvttppstntpqpmqstksdtpqspttkqvpteinpkf kdlrayytkpslefkneigiilkkwttirfmnvvpdyfiykialvgkddkkygegvhrnv dvfvvleennynlekysvggitksnskkvdhkagvritkednkgtishdvsefkitkeqi slkeldfklrkqlieknnlygnvgsgkivikmknggkytfelhkklqenrmadvinseqi knievnlk |

gtgaattategtgataaaatteaaaagtttagtattegtaaatatacagttggtacattt teaaetgteattgegacattggtattttaggatteaatacateacaageacatgetget gaaaccaaatcaaccagcagcgtggttaaacagaaacaacaaagtaataatgaacagact gagaatcgagaatctcaagtacaaaattctcaaaattcacaaaatggtcaatcattatct gctactcatgaaaatgagcaaccaaatattagtcaagctaatttagtagatcaaaaagta aatacattgaaggcetetgaeteaaaggaaattgetettatgaeagcgaaacaaaetgga gaegggtaecaatgggttattaagtttaataaaggacatgeteeacatcaaaatatggt ttttggtttgeattaecageagaecaagtgeeagtaggaagaaetgaetttgtaacagtt gatttatctagagcgagtgattattttagtgaagctggagcgacacctgctactaaagct tttggtagacaaaattttgaatatattaatggtcaaaaacctgctgaatcaccgggtgtt cctaaagtttatactttcatcggtcaaggtgatgcaagttatacaatttcatttaaaaca caaggtccaactgttaataaattgtactatgcagcaggtgggcgtgctttagagtacaat caattatttatgtacagtcaactatacgtcgaatcaacgcaagaccatcaacaacgtctt aatggtttaagacaagtggttaatcgtacatatcgcataggtacaactaaacgtgtagaa gtgagtcaaggaaatgtacaaacgaaaaaggtattagaaagtacaaacctaaatatagat gattttgttgatgatcctttaagttatgttaagacgccgagtaataaagtgttaggattt attcaaccattacggtattaatttaacaagtaatgagaattttacagataaagattggcaa attaacaggtattccgcgtacatttaacacattgagaattttacagataaagactgaca attacaggtattccgcgtacattacacattgaaaactcgacaaatagacctaataatgcc agagaacgcaatattgaactgttggtaacttattaccaggggattactttggaacgat cgttttggacgtaaagaacattattcgaaattcgtgttaaaccacatacaccaaata acaacgacagctgagcaattaagaggtacagcattacaaaaagtgcctgttaatatttcg ggaataccgttggatccatcggcattggtttatttagttgcaccaacaatcaaactacg aatggtggtagtgaggcagatcaaataccatctggttatacgatacttgcgactggtaca cctgatggggtgcataatacaattactatacgaccgcaagattatgttgtattcatacca gatgaaaagcaaaagcataattactgcctttatgaataaaaaccaaaatataagaggatat ttagcatcaactgatccagtaactgtcgataataataggtaatgtcacattacattaccgt gatggctcatcgacaacgcttgatgctacaaatgtgatgacatacgaaccagttgtgaaa cctgaataccaaactgtcaatgctgctaaaacagcaacggtaacgattgctaaaggacaa tcatttagtattggtgatattaaacaatattttactttaagtaatggacaacctattcca agtggcacatttacaaatattacatctgatagaactattccaactgcacaagaagttagt caaatgaacgcaggcacgcagttataccatataactgctacaaatgcgtatcataaagat agtgaagacttctatattagtttgaaaatcatcgatgtgaaacaaccagaaggcgatcaa cgtgtatatcgtacatcaacatatgatttaactactgatgaaatctcaaaagtaaaacaa gcatttattattgcaaatagagatgtaattacgcttgccgaaggtgatatttcagttaca aatacacctaatggtgctaatgtaagtactattacagtaaatattaataaaggtcgatta acgaaatcattcgcgtcaaacctagctaatatgaatttcttgcgttgggttaatttccca caagattatacagtgacatggacgaatgcaaaaattgcaaacagaccaacagatggtggt ttatcatggtctgatgaccataaatctttaatttatcgttatgatgctacattaggtact tratcatggtcgatgaccataaatctttaatttatcgttatgatgctacattaggtact caaattacgacgaatgatattttaaccaatgtaaaaagcaacaactacagtgcctggattg cgaaataacattactggtaatgaaaaatcacaagcagaagctggcggaagacctaacttt agaacgactggttattcacaatcaaatggacaactgatggtcaacgtcaatttacgttg aatggtcaaagtgattcaagtgttagacatcatcaacccttcaaacggttataatggtgggcaa cctgttacaaattcaaatactcgtgcaaaccatagtaactcaactgttgttaacgtaaac gaaccggcagctaatggtgctggcgcatttacaattgaccacgttgtaaaaaggtaattc acacataatgcaagtgatgcagtttataaagcacagttatacttaacgccatatggtcca aaacaatatgttgaacatttaaatcaaaatacaggaaatactactgacgctattaacatt tattttgtaccaagtgacttagtgaatccaacaatttcagtaggtaattacactaatcat caagtgttctcaggtgaaacatttacaaatactattacagcgaatgataactttggtgtg caatctgtaactgtaccaaatacatcacaaattacaggtactgttgataataaccatcaa gcaactgatacaageggeaatacagetacaacttegtteaatgtaacagtgaaacetttg egtgataaatategagttggtaetteateaaeggetgetaateetgtgagaattgeeaat atttcgaataatgcgacagtatcacaagctgatcaaacgacaattattaattcgttaacg tttactgaaacagtaccaaatagaagttatgcaagagcaagtgcgaatgaaatcactagt aaaacagttagtaatgtcagtcgtactggaaataatgccaatgtcacagtaactgttact tatcaagatggaacaacatcaacagtgactgtacctgtaaagcatgtcattccagaaatc gttgcacattcgcattacactgtacaaggccaagacttcccagcaggtaatggttctagt gcatcagattactttaagttatctaatggtagtgacattgcagatgcaactattacatgg gtaagtggacaagcgccaaataaagataatacacgtattggtgaagatataactgtaact gcacatatettaattgatggcgaaacaacgccgattacgaaaacagcaacatataaagta gtaagaactgtaccgaaacatgtetttgaaacagccagaggtgttttatacccaggtgtt tcagatatgtatgatgcgaaacaatatgttaagccagtaaataattettggtcgacaaat gcgcaacatatgaatttccaatttgttggaacatatggtcctaacaaagatgttgtaggc atatctactcgtcttattagagtgacatatgataatagacaaacagaagatttaactatt tatctaaagttaaacctgacccacctagaattgacgcaaactctgtgacatataaagca

ggtottacaaaccaagaaattaaagttaataacgtattaaataactcgtcagtaaaatta ggtcttacaaaccaagaaattaaagttaataacgtattaaataactcgtcagtaaaatta
tttaaagcagataatacaccattaaatgtcacaaatattactcatggtagcggttttagt
tcggttgtgacagtaagtgacgcgttaccaaatggcggaattaaagcaaaatcttcaatt
tcaatgaacaatgtgacgtatacgacgcaagacgaacatggtcaagttgttacagtaaca
agaaatgaatctgttgattcaaatgacagtgcaacagtaacagtgacaccacaattacaa
gcaactactgaaggcgctgtatttattaaaggtggcgacggttttgatttcggacacgta
gaaagatttattcaaaacccgccacatggggcaacggttgcatggcatgatagtccagat
gaaagatttattcaaaatgcgcacatggggcaacggttgcatgacacgataccagat acatacgctgataaattagttattaaacgtaatggtaacgttgtgacgacatttacacgt cgcaataatacgagtccatgggtgaaagaagcatctgcagcaactgtagcaggtattgct ggaactaataatggtattactgttgcagcaggtactttcaaccctgctgatacaattcaa gatatcacgcctaataatccatcaggacatttaattaatccaactcaagcaatggatatt gottacactgaaaagtgggtaatggtgcagaacatagtaagacaattaatgttgttcgt ggtcaaaataatcaatggacaattgcgaatagcctgactatgtaacgttagatgcacaa gaaattaacaatgcagttcaagttgctaataaacgtactgcaacgattaaaaatggcaca gcaatgcctactaatttagctggtggtagcacaacgacgattcctgtgacagtaacttac aatgatggtagtactgaagaagtacaagagtccattttcacaaaagcggataaacgtgag ataagaacagtacaagaagtgcaatctgcgttaacaaatgtaaatcgtgtcaatgagcga ttaacgcaagcaattaatcaattagtacctttagctgataatagtgctttaaaaactgct aagacgaaacttgatgaagaaatcaataaatcagtaactactgatggtatgacacaatca toaatccaagcatatgaaaatgctaaaacgtgcgggtcaaacagaatcaacaaatgcacaa aatgttattaacaatggtgatgcgactgaccaacaaattgccgcagaaaaaacaaaagta gaagaaaaatataatagcttaaaacaagcaattgctggattaactccagacttggcacca tacaaactgcaaaaactcagttgcaaaatgatattgatcagccaacgagtacgactggt atgacaagcgcatctattgcagcatttaatgaaaaactttcagcagctagaactaaaatt caagaaattgatcgtgtattagcctcacatccagatgttgcgacaatacgtcaaaacgtg acagcagcgaatgcgctaaatcagcacttgatcaagcacgtaatggcttaacagtcgat aaagcgcctttagaaaatgcgaaaaatcaactacaatatagtattgacacgcaaacaagt acaactggtatgacacaagactctataaatgcatacaatgcgaagttaacagctgcacgt actactygtatyacacaayactctataaatygatataatygaagttaacaayygaagtaaaaaattaat aataagattcaacaaatcaatcaagtattagcaggttcaccgactgtagaacaaaattaat acaactagtctacagcaaatcaagctaaatctgatttagatcatgcacgtcaagcttta acaccagataaagcgccgcttcaaactgcgaaaacgcaattagaacaaagcattaatcaa ccaacggatacaacaggtatgacgacgcttcgttaaatgcgtacaaccaaaaatttacaa gcagcgcgtcaaaagttaactgaaattaactaagtgttgaatggcaacccaactgtccaa aatatcaatgataaagtgacagaggcaaaccaagctaaggatcaattaaatacagcacgt caaggtttaacattagatagacagccagcgttaacaacattacatggtgcatctaactta aaccaagcacaacaaaataatttcacgcaacaaattaatgctgctcaaaatcatgctgcg cttgaaacaattaagtctaacattacggctttaaatactgcgatgacgaaattaaaagac agtgttgcggataataatacaattaaatcagatcaaaattacactgacgcaacaccagct aataaacaagcgtatgataatgcagttaatgcggctaaaggtgtcattggagaaacgact aatccaacgatggatgttaacacagtgaaccaaaaagcagcatctgttaaatcgacgaaa gatgctttagatggtcaacaaaacttacaacgtgcgaaaacagaagcaacaaatgcgatt acgcatgcaagtgatttaaaccaagcacaaaagaatgcattaacacaacaagtgaatagt gcacaaaacgtgcaagcagtaaatgatattaaacaaacgactcaaaagcttaaatactgct atgacaggtttaaaacgtggcgttgctaatcataaccaagtcgtacaaagtgataattat gtcaacgcagatactaataagaaaaatgattacaacaatgcatacaaccatgcgaatgac attattaatggtaatgcacaacatccagttataacaccaagtgatgttaacaatgcttta tcaaatgtcacaagtaaagaacatgcattgaatggtgaagctaagttaaatgctgcgaaa caagaagcgaatactgcattaggtcatttaaacaatttaaataatgcacaacgtcaaaac ttacaatcgcaaattaatggtgcgcatcaaattgatgcagttaatacaattaagcaaaat gcaacaaacttgaatagtgcaatgggtaacttaagacaagctgttgcagataaagatcaa gtgaaacgtacagaagattatgcggatgcagatacagctaaacaaaatgcatataacagt gcagtttcaagtgccgaaacaatcattaatcaaacaacaatccaacgatgtctgttgat gatgttaatcgtgcaacttcagctgttacttctaataaaaatgcattaaatggttatga aaattagcacaatctaaaacagatgctgcaagagcaattgatgcattaccacatttaaat aatgcacaaaaagcagatgttaaatctaaaattaatgctgcatcaaatattgctggcgta aatactgttaaacaacaaggtacagatttaaatacagcgatgggtaacttgcaaggtgca actactgtcgctggtgttcaaacggttcaatcaaatgccaatacattagatcaagccatg aatacgttaagacaaagtattgccaacaaagatgcgactaaagcaagtgaagattacgta gatgctaataatgataagcaaacagcatataacaacgcagtagctgctgctgaaacgatt attaatgctaatagtaatccagaaatgaatccaagtacgattacacaaaaagcagagcaa aaactggcagaagcgaaagcggcagctaaacaaaactaggcactttaaacaattatcg aatgcacaacgtactgacttagaaggccaaaacaatcaagcgacgactgttgatggcgtt aatgcacaacgtactgacttagaaggccaaaaacaatcaagcgacgactgttgatggcgtt aatactgtaaaaacaaatgccaatacattagacggcgcaatgaatagcttacaaaggtca caaaatgtagcaggtgtaaatggtgttaaagataactggagtactaagttaagttaactgcaatg ggtgcattacgtacaagtatccaaaatgataatacgacgaaaacaagtcaaaattatctt gatgcatctgcacagcaacaaaaataattacaatactgctgtaaataatgcaaaatggtgt catactgcgactgaattaaatactgcgatgacagctttaaagcgtgccattgctgataaa gctgagacaaaagctagtggtaactatgtcaatgctgatgcgaataaacgtcaagcatat gatgaaaaagttacagctgccgaaaatatcgttagtggtacaccaacaccaacgttaaca ccagcagatgttacaaatgcagcaacgcaagtaacgaatgctaagacgcagttaaacgcaattaatattaagaagtagcgaaacaaaatgctaacactgcaattgatggttaacttct ttaaatgtccgcaaaaagcaaaacttaaagaacaagtggtcaagcgacgacgttgca aatgttcaaactgttcgtgataatgcacaaacattaaacactgcaatgaaaggtctacga gatagcattgcgaatgaagcaagcaattaaagcaggtcaaaactacacagatgcaagtca ttgaacggcttaatggacttaactgacgctcaaaaagatgcaagtgaacgt ttgaacggcttaagtgacttaactgacgctcaaaaagatgcaagtgaaacgtcaaatcgaa ggtgcaacgcatgttaatgaagtaacacaagcacaaaataatgcggatgcattaaatcga gctatgacgaacttgaaaaatggtattcaagatcagaatacgattaagcaaggtgttaac ttcactgatgccgacgaagcgaaacgtaatgcattatacaaatgcagtgacgcaagctgaa caaattttaaataaagcacaaggtccaaatacttcaaaagacggtgtcgaaactgcgtta gaaaatgtacaacgtgctaaaaacgaattgaacggtaatcaaaatgttgcgaacgctaag acaactgcgaaaaatgcattgaataacctaacatcaattaataatgcacaaaaaggagca ttgaaatcacaaattgaaggtgcgacaacagttgcaggtgtaaatcaagtgtctacaacg gcatctgaattaaatacagcaatgagcaacttacaaaatggtattaatgatgaagcagct acaaaagcagctcaaaacgttattagataaaacagctggttcaaatgac gctgtaacagcagctaaaacgttattagataaaacagctggttcaaatgac gctgttgaacaagcattacaacgtgtgaatactgctaaacagcattaaatggtgacgag cgattaaatgaagcgaagaacacagctaaacaacagtagcgacaatgtcacacttaact gatgctcaaaaagcaaacttaacatcgcaaatcgaaagtggtacgactgttgcaggtgt caaggtattcaagctaatgcggtactttagatcaagcaatgaatcaattaagacaaagt attgcttctaaagatgcgactaaatcaagcgaagattatcaagacgcgaatgcagatta caaaatgcatacaatgatgcggtaactaatgctgaaggtattattagtgcaacgaataac ggtgacgcgaacttacaacgcgctaaaactgaagctatacaagctatcgataacttgacacatttgaatacaccacaaaaaacagcattaaaacaacaagtgaacgctgcgcaacgtgta gatagcgcgadacaagtaactggcgttcaaagtgtgaaagacaacgcggacaaatcttgat aatgcaatgaatcaacttcgaaatagtattgcgaataaagatgatgtaaaagcgggtcaa ccatatgttgatgcagatagagataaacaaaatgcatacaatacagcagttacaaatgct gaaaatatcattaatgcaacgagtcagccgacacttgatccatctycagtaacacaagca gctaatcaagtgagcactaacaaaactgcgcttaatggtgcacaaaacttagcggaataaa gcagcgcttaatggtactcaaaaccttgaaaaagctaaacaacacgcaaattacagcaatt gacggtttaagccatttaacaaatgcacaaaaagcggcattaaaacaattggtacaacaa tcgactactgttgcagaagcacaaggtaatgagcaaaaagcaaacaatgttgatgcagca actgatcaaattaatggcgcgcatactgttgatgaagcaaatcaaattaagcaaaatgcg caaaacttaaattacagcgatgggtaacttgaaacaagcgatagctgacaaagatgctacg aaagcgacagttaacttcactgatgcagatcaagcaaaacaagcatataacactgct adayogatua gttacaaatgctgaaaatatcatttcaaaaagctaatggcggcaatgcaacacaagctgaa gttgaacaagcaatcaaacaagttaatgctgcaaaacaagcattaaatggtaatgccaac gttcaacatgcaaaagacgaagcaacagcattaattaatagctctaatgaccttaaccaa gcacaaaaagacgcattaaaacaacaagttcaaaatgcaactactgtagctggtgtaaac aatgttaaacaaacagcacaagagttaaacaatgctatgacacaattaaaacaaggcatt gcagataaagaacaacaacaacaggtgatggtaactttgtcaatgcagatcctgataagcaa

caagttgaacaagcaccagatattgcaacagttaataatgttaagcaaaatgctcaaaat ctgaataatgctatgactaacttaaacaatgcattacaagataaaactgagacattaaat agcattaactttactgatgcagatcaagctaagaaagatgcttatactaatgcggtttca catgcaggaggtattttatctaaagcaaatgcagcaatgcaagtcaaactgaagtggaa adayaccadaccadagadadaccadagadaaatactagacaacagagataacagagagataacagagagataacaacaatgagaacacaacagagagataacaacaatgagaacaacagagagatcaacagagagataacgagagataacaggagataacaggagataacaggagataacaggagataacaggagataacaggagataacaggagataacaggagataacaggagatacaaggagatacaaggagatacaaggagatacaaggagaacaatgacaatgacaatgacaatgacaatgacaatgacaatgatacag caagacaaacaagattataacaatgaggctaaccaagcgcaacaaatcgcaaatggc ataccaacacctgtattgacgcctgatacagtaacacaagcggtgacaactatgaatcaa gcgaaagatgcattaaacggtgatgaaaaattagcacaagcgaaacaagaagctttagca aatctgatacgttacgcgatttaaatcaaccacacgtgatgcattacgtaaccaaatc aatcaagcacaaggttagctacagttgaacaaactaaacaaaatgcacaaaatgtgaat acagcaatgagtaacttgaaacaaggtattgcaaacaagatactgtcaaagcaagtgag acagcaaugagtaautugaacaaggtatugcaacaaagatacugtcaaagcaagtgag aactatcatgatgctgatgccgataagcaaacagcatatacaaatgcagtgtctcaagcg gaaggtattatcaatcaaacgacaaatccaacgcttaacccagatgaaataacacgtgca ttaactcaagtgactgatgctaaaaatggcttaaacggtgaagctaaattggcaactgaa aagcaaaatgctaaagatgccgtaagtgggatgacgcatttaaacgatgctcaaaaacaa gcattaaaaggtcaaatcgatcaatcgctgaaattgcttacagtgaaccaagttaaacaa caggcagtagcadagctydagcattartydataatacaaagtygtaattaatggagtaat gcacaagttgaaagcatcactaatgaagtgaacgcagcgaaacaagcattaataatggtaat gacaatttggcaaatgcaaaacaacaagcacaaacaacaattaggcgaacttaacacactta aatgatgcacaaaaacaatcatttgaaagtcaaattacacaagcgccacttgttacagat gtcactacgattaatcaaaagcacataagctgcaagatcatgcgatggaattattaagaaa aggttggggataatcaaacgacattagcgtctgaagattatcatgatgcaactgcgcaa agacaaaatgactataaccaagctgtaacagctgctaataatatcattaatcaactaca tcgcctacgatgaatccagatgatgttaatggtgcaacgacacaagtgaataatacgaaa gttgcattagatggtgatgaaaaccttgcagcagctaaacaacaagcaaacaacagactt gatcaattagatcatttgaataatgcgcaaaagcaacagttacaatcacaattaggcaa tcatctgatattgctgcagttaatggtcacaaacaaacagcagaatctttaaattactgcg atgggtaacttaattaatgcgattgcagatcatcaagccgttgaacaacgtggtaacttc aatgcccaagcaattaatgctcttaacaagcttaaatgatcctcaaaaaacagcatta aaagaccaagttacagctgcaactttagtaactgcagttcatcaaattgaacaaaatgcg aatacgcttaaccaagcaatgcatggtttaagacagagcattcaagataacgcagcaact aaagcaaatagcaaatatatcaacgaagatcaaccagagcaacaaaactatgatcaagct gttcaagccgcaaataatattatcaatgaacaactgcaacattagataataatgcgatt aatcaagcagcgacaactgtgaatacaacgaaagcagcattacatggtgatgtgaagtta caaaatgataaagatcatgctaagcaaacggttagtcaattagcacatctaaacaatgca caaaaacatatggaagatacgttaattgatagtgaaacaactagaacagcagttaagcaa gatttgactgaagcacaagcattagatcaacttatggatgcattacaacaaagtattgct gacaaagatgcaacacgtgcgagcagtgcatatgtcaatgcagaaccgaataaaaaacaa tcctatgatgaagcagttcaaaatgctgagtctatcattgcaggattaaataatccaact atcaataaaggtaatgtatcaagtgcgactcaagcagtaatatcatctaaaaatgcatta gatggtgttgaacgattagctcaagataagcaaactgctggaaattctctaaatcattta gatcaattaacaccagctcaacaacaagcgctagaaaatcaaattaataatgcaacaact caaactaacaatccaacgcttgataaagcacaagttgaacaattgacacaagctgttaac caagctaaagataacctacacggtgatcaaaaacttgcagacgataaacaacatgcggtt actgatttaaatcaattaaatggtttgaataatccgcaacgtcaagcacttgaaagccaa actgatttaatcaattgatttgattaateggtaatgetaatgetaatgetaagatetaataagtaa ataaacaacgcagcaactegtggcgaagtagcacaaaaattagctgaagcaaaagcgctt gatcaagcaatgcaagcattacgtaatagtattcaagatcaacaacaagaagcagcattagcaacagtttaatcaacaacgcagcagttcaaaat gcaaaagtttaattaaccaaaaccgcaaaaaagatgcttaccaaagcagcagtagaacaa tcgacacaagcagtaacaactgcaaaagataatctacatggtgatcaaaaacttgctcgt gatcaacaacaagcagtaacaactgtaaatgcattgccaaacttaaatcatgcacaacaa caagcattaactgatgctataaatgcagcgcctacaagaacagaggttgcacaacatgtt caaactgctactgaacttgatcacgcgatggaaacattgaaaaataaagttgatcaagtg aatacagataaggctcaaccaaattacactgaagcgtcaactgataaaaaagaagcagta gatcaagcgttacaagctgcagaaagcattacagatccaactaatggttcaaatgcgaat aaagacgctgtagaccaagtattaactaagcttcaagaaaaagaaaatgagttaaatggt aatgagagagtegetgaagetaaaacacaagegaaacaaactattgaccaattaacacat ttaaatgetgatcaaattgcaactgetaaacaaaacattgatcaagegacgaaacttcaa caagcagttaatgaacatgctaacgttgagcaaactgtagattacacacaagcagattca gataaacaaaatgcttataaacaagctattgctgatgctgaaaatgtattgaaacaaaa gcgaataagcaacaagtggatcaagcacttcaaaatattttaaatgcaaaacaagcatta ttgtcacaagaaatcactgacaatgaaggacgcacgaaaggtagcacgaactatgtcaat gcagatacacaagtcaaacaagtatatgatgaaacggttgataaagcgaaacaagcactt

gataaatcgactggtcaaaacttaactgcaaaacaagttatcaaattaaatgatgcagtc actgcagctaagaaagcattaaatggtgaagaaagacttaataatcgtaaagctgaagca ttacaaagattggatcaattaacacatctaaacaatgctcaaagacaattagcaatccaa caaattaataatgctgaaacgctaaataaagcatctcgagcaattaatagagcaactaaa ttagataatgcaatgggtgcagtacaacaatatattgacgaacagcaccttggtgttatc agcagcacaaattacatcaatgcagatgacaatttgaaagcaaattatgataatgcaatt gcgaatgcagcacatgagttagataaagtgcaaggtaatgcaattgcaaaagctgaagca gagcaattgaaacaaaatattatcgatgctcaaaatgcattaaatggagaccaaaacctt gcaaatgccaaagataaagcaaatgcgtttgttaattcgttaaatggattaaatcaacag caacaagatcttgcacataaagcaattaacaatgccgatactgtatcagatgtaacagat attgttaataatcaaattgacttaaatgatgcaatggaaacattgaaacatttagttgac aatgaaattccaaatgcagagcaaactgtcaattaccaaaacgctgacgataatgctaaa acaaacttcgatgatgccaaacgtctagcaaatacattgctaaatagtgataacacaaat gtgaatgatatcaatggcgcaatccaagcagtcaatgatgcaatccataatcttaatggt gatcaacgactacaagatgctaaagacaaggcaattcaatctattaatcaagctttagct aataagctaaaagaaatcgaagcttcaaatgcgacggatcaagacaagcttattgcgaaa aataaagcagaagaattggcaaacagcatcatcaacaacattaataaagcaacaagtaat caggctgtatctcaagttcaaacagcaggcaaccagggattgaacaagtgcatgccaat gaaataccaaaagcaaaaattgatgccaataaagacgttgataagcaagttcaagcatta attgacgaaattgatcgaaatccaaatctaacagataaggaaaaacaagcacttaaagat cgtattaatcaaatacttcaacaaggtcataacggcattaacaatgcgatgactaaagaa gaaattgaacaagccaaagcacaacttgcgcaagcattacaagacatcaaagatttagtg aaagctaaagaagatgcgaaacaagatgttgataaacaagttcaagctttaattgacgaa atcgatcaaaatccaaatctaacagataaggaaaaacaagcacttaaagatcgtattaatcaaatacttcaacaaggtcatarcgacattamcaatgcgatgacaaaagaagcaattgaa caagcaaaagaacgtttagcgcaagcattgcaagacatcaaagatttagtgaaagctaaa gaagatgcgaaaaatgatattgataaacgtgtacaagctttaattgacgaaatcgatcaa aatccaaatctaacagataaggaaaaacaagcacttaaagatcgaattaatcaaatactt caacaaggtcataacgacattaacaatgcgctgactaaagaagaaaattgagcaggcaaaa gcacaacttgcacaagcattgcaagacatcaaagatttagtgaaagctaaagaagatgcg aaaaatgcaataaaagccttagctaatgcgaagcgtgatcaaatcaattcaaatccagat ttaacactgagcaaaaagcaaaagcgctcaaagaaattgacgaagctgaaaacgagcactacaaaacgttgagaatgctcaaactatagatcaattaaatcgaggattaaacttaggttaagatgacattagaatgacattagatgacgatgatgaacaacctgctgtaaaatgaa attittgaagcaacacctgagcaaatcctagttaatggtgaactcattgtacatcgtgat gacatcattacagaacaagatattcttgcacacataaacttaattgatcagctttcagca gaagtcatcgatacaccatcaactgcaacgatttctgatagcttaacagcaaaagttgaa gttacattgcttgatggatcaaaagtgattgttaatgttcctgtaaaagttgtagaaaaa gaattgtcagtagtcaaacaacaggcaattgaatcaatcgaaaatgcggcacaacaaaag attaatgaaatcaataatagtgtgacattaacactggaacaaaaagaagctgcaattgca gatgaaataagtgagcaattggaacaatttaaagctcaaatgaaagcagctaatccaaca gcaaaagaactagctaaacgcaagcaagaagctattagtagaattaaagacttttcaaat gaaaaaataaatagtattcgaaatagtgaaattggcacagctgatgaaaaacaagcagca atgaatcaaattaacgaaattgtgcttgaaacaattagagatattaataatgcgcataca ttacagcaagttgaggctgcattgaacaatggtattgctcgaatttcagcagtacaaatt gtaacatotgatcgtgctaaacaatcgtcaagtactggaatctaaattaacttta acaattggttatggaactgcaaatcatccatttaacagttcgactattggacataaaaag aaacttgatgaagatgatgacattgatccacttcatatgcgtcactttagtaataatttc ggtaatgttattaaaaacgctattggtgtgggtatctctggtttactagtatt tggttcttcattgccaaacgtcgtcgtaaagaagatgaagaggaagaattagaaataaga gataataataaagattcaataaaagagactttagacgatacaaaacatttaccactttta tttgcgaaacgtcgcagaaaagaagatgaagaagatgttactgttgaagaaaaagattcg ctaaataatggcgagtcactcgataaagttaaacatacgccgttcttcttaccaaaacgt cgtcgtaaagaagatgaagaagatgtggaagttacaaatgaaaacacagatgaaaaagtg ttgaaagataacgaacattcaccactcttattcgcaaaacgacgcaaagataaagaggaa gatgttgaaacaacaactagtattgaatctaaagatgaggacgttcctttattattggctaaaaagataaaccaatccaaaagatgagacgttcagtatcaaaaaatcaaaaagataaccaatccaaagacaaaaagtcagcatcaaaaaaatact tctaaaaaggtagcagctaaaaagaagaaaaagaaagctaagaaaaataaaaaataa

vnyrdkiqkfsirkytvgtfstviatlvflgfntsqahaaetnqpasvvkqkqqgsmeqt enresqvqnsqnsqngqslsatheneqpnisqanlvdqkvaqssttndeqpasqnvntkk dsataattqpdkeqskhkqnesqsankngndnraahvenheanvvtasdssdngnvqhdr nelqaffdanyhdyrfidrenadsgtfnyvkgifdkintllgsndpinnkdlqlaykele qavalirtmpqrqqtsrrsnriqtrsvesraaeprsvsdyqnanssyyvenandgsgypv gtyinasskgapynlpttpwntlkasdskeialmtakqtgdgyqwvikfnkghaphqnmi gtyinasskgapynlpttpwntlkasdskeialmtakqtgdgyqwvlkfnkghaphqnmi fwfalpadqypvgrtdfvtvnsdgtnvqwshgagagankplqqmweygyndphrshdfki rnrsqqviydwptvhiysledlsrasdyfseagatpatkafgrqnfeyingqkpaespgv pkvytfigqgdasytisfktqgptvnklyyaaggraleynqlfmysqlyvestqdhqqrl nglrqvvnrtyrigttkrvevsggnvqtkkvlestnlniddfvddplsyvktpsnkvlgf ysnnantnafrpggaqqlneyqlsqlftdqklqeaartrnpirlmigfdypdaygnsetl vpvnltvlpeiqhnikffknddtqniaekpfskqaghpvfyvyagnqgnasvnlggsvts igplrinltsnenftdkdwqitgiprtlhienstnrpnnarernielvgnllpgdyfgti rfgrkeqlfeirvkphtptitttaeqlrgtalqkvpvnisgipldpsalvylvaptnqtt nggseadqipsgytilatgtpdgvhntitirpqdyvvfippvgkqiravyyynkvvasnm snavtilpddipptinnpvginakyyrgdevnftmgvsdrhsgiknttittlpngwtsnl tkadknngslsitgrvsmqafnsditfkvsatdnvnnttndsqskhvsihvgiksedah pivlgntekyvvynbtavsndekgsiitafmkncmirgylastdpvtvdnngnvtlhyr pivlgntekvvvnptavsndekqsiitafmmknqmirgylastdpvtvdnngnvtlhyr dgssttldatnvmtyepvvkpeyqtvnaaktatvtiakgqsfsigdikqyftlsnqqpip sqtftnitsdrtiptaqevsqmmagtqlyhitatnayhkdsedfyislkiidvkqpegdq ryyrtstydlttdeiskvkqafinanrdvitlaegdisvtntpnganvstitvninkgrl tksfasnlammflrwvnfpqdytvtwtnakianrptdgglswsddhksliyrydatlgt qittndiltmlkatttvpglrnnitgneksqaeaggrpnfrttgysqsnattdgqqqftl ngqviqvldiinpsngygqpvtnsntranhsnstvvnvnepaangagaftidhvvksns thnasdavykaqlyltpygpkqyvehlnqntgnttdainiyfvpsdlvnptisvgnytnh qvfsgetftntitandnfgvqsvtvpntsqitgtvdnnhqhvsatapnvtsatnktinll atdtsgntattsfnvtvkplrdkyrvgtsstaanpvrianisnnatvsqadqttiinslt ftetvpnrsyarasaneitsktvsnvsrtgnmanvtvtvtyqdgttstvtvpvkhvipei rtetvpnrsyarasaneltsktvsnvsitginantvtvtvydugttstvtvpvntvper vahshytvqgddfpagngssasdyfklsngsdiadatitwvsgqapnkdntrigeditvt ahilidgettpitktatykvvrtvpkhvfetargvlypgvsdmydakqyvkpvnnswstn aqhmnfqfvgtygpnkdvvgistrlirvtydnrqtedltilskvkpdppridansvtyks gltnqeikvnnvlmssvklfkadntplnvtnithgsgfssvvtvsdalpnggikakssi smnnvtyttqdehgqvvtvtrnesvdsndsatvtvtpqlqattegavfikgdgdfdfphv erfiqnpphgatvawhdspdiwkntvgnthktavvtlpngqgtrnvevpvkvypvanaka erfiqnpphgatvawhdspdtwkntvgnthktavvtlpngqgtrnvevpvkvypvanaka psrdvkgqnltngtdammyitfdpntntngitaawanrqqnnqqagvqhlnvdvtypgi saakrvpvtvnvyqfefpqttytttvggtlasgtqasgyahmqnatglptdgftykwnrd ttgtndanwsamnkpnvakvvnakydviynghtfatslpakfvvkdvqpakptvtetaag aitiapganqtvnthagnvttyadklvikrngnvvttftrrnntspwvkeasaatvagia gtnngitvaagtfnpadtiqvvatqgsgetvsdeqrsddftvvapqnpattkiwqnghi ditpmpsghlinptqamdiaytekvgngaehsktinvvrgqnnqwtiankpdyvtldaq tgkvtfnantikpnssititpkagtghsvssnpstltapaalitvntteivkdygsnvtaa einnavqvankrtatikngtamptnlaggstttipvtvtyndgsteevqesiftkadkre litaknhlddpvstegkpgtitqynnamhnaqqqintakteaqqvinneratpqqvsdaltkvraaqtkidqakallqnkednsqlvtskmnlgssvnqvpstagmtqqsidnynakkreaeteitaaqrvidngdataqqisdekhrvdnaltalnqakhdltadthaleqavqlnrtgtttgkkpasitavnnsiralgsdltsaknsnaijdkpirtvgevgsaltnynrvner tgtttgkkpasitaynnsiralgsdlsaknsanaiiqkpirtvqevqsaltnvnrvner tgattgkkpasitaynnsiralgsdlsaknsanaiiqkpirtvqevqsaltnvnrvner ltqainqlvpladnsalktaktkldeeinksvttdgmtqssiqayenakragqtestnaq nvinngdatdqqiaaektkveekynslkqaiagltpdlaplqtaktqlqmdidqprsttg mtsasiaafneklsaartkiqeidrvlashpdvatirqnvtaanaaksaldqarngltvd kaplenaknqlqysidtqtsttgmtqdsinaynakltaarnkiqqinqvlagsptveqin tntstanqaksdldharqaltpdkaplqtaktqleqsinqbtdttgmttaslnaynqklq thtstanqaksdidnarqaltpdkaplqtaktqleqsinqptdttgmttasinaynqkiq aarqklteinqvlngnptvqnindkvteanqakdqlntarqgltldrqpalttlhgasnl nqaqqnnftqqinaaqnhaaletiksnitalntamtklkdsvadnmtiksdqnytdatpa nkqaydnavnaakgvigettnptmdvntvnqkaasvkstkdaldgqqnlqrakteatnai thasdlnqaqknaltqqvnsaqnvqavndikqttqslntamtglkrqvanhnqvvqsdny vnadtnkkndynnaynhandiingnaqhpvitpsdvnnalsnvtskehalngeaklnaak qeantaljhlnnlmaqrqnlqsqinqahqidavntikqnatnlnsamgnlrqavadkd vkrtedyadadtakqnaynsavssaetiinqttnptmsvddvnratsavtsnknalngve klaqsktdaaraidalphlnnaqkadvkskinaasniagvntvkqqgtdlntamgnlqga klaqsktdaaraidalphlnnaqkadvkskinaasniagvntvkqqgtdlntamgnlqga
indeqttlnsqnyqdatpskktaytnavqaakdilnksngqnktkdqvteamnqvnsakn
nldgtrlldqakqtakqqlnnmthlttaqktnltnqinsgttvagvqtvqsnantldqam
ntlrqsiankdatkasedyvdanndkqtaynnavaaaetiinansnpemmpstitqkaeq
vnssktalngdenlaaakqnaktylntltsitdaqknnlisqitsatrvsgvdtvkqnaq
hldqamaslqnginnesqvkssekyrdadtnkqqeydnaitaakailnkstgpntaqnav
eaalqrvnnakdalngdakliaaqnaakqhlgtlthittaqrndltnqisqatnlagves
vkqnansldgamgnlqtaindksgtlasqnfldadeqkrnaynqavsaaetilnkqtgpn
taktaveqalnnvnnakhalngtqnlnnakqaaitaingasdlnqkqkdalkaqngaqr
vsnaqdvqhnatelntamgtlkhaiadktntlasskyvnadstkqnayttkvtnaehiis
gtptvvttpsevtaaanqvnsakqelngderlreakqmantaidaltqlntpqkaklkeq
vqqanrledvdtvqtngqalnnamkglrdsianettvktsqnytdaspnnqstynsavsn
akriingtnnntmdtsaitgattqvnnaknglngaenlrnacmtakmlntlshltnnqk akgiinqtnnptmdtsaitqattqvnnaknglngaenlrnaqmtakqnlntlshltmnqk saissqidraghvsevtatknaatelntqmgnleqaihdqntvkqsvkftdadkakrday tnavsraeailnktqgantskqdveaaiqnvssaknalngdqnvtnaknaaknalnnlts innagkrdlttkidgattvagveavsntstqlntamanlqngindktntlasenyhdads dkktaytqavtnaenilnknsgsnldktavenalsqvanakgalngnhnleqaksnantt inglqhlttagkdklkqqvqqaqnvagvdtvkssantlngamgtlrnsiqdntatkngqn yldaternktnynnavdsangvinatsnpnmdanainqiatqvtstknaldgthnltqak qtatnaidgatnlnkaqkdalkaqvtsaqrvanvtsiqqtanelntamgqlqhgiddena tkqtqkyrdaeqskktaydqavaaakailnkqtgsnsdkaavdralqqvtstkdalngda klaeakaaakgnlgtlnhitnaqrtdlegqnnqattvdgvntvktnantldgammslqgs indkdatlrnqnyldadeskrnaytqavtaaegilnkqtggntskadvdnalnavtraka alngadnlrnaktsatntidglpnltqlqkdnlkhqveqaqnvagvngvkdkgntlntam galrtsiqndnttktsqnyldasdsnknnyntavnnangvinatnnnndanaingmanq vnttkaalngaqnlaqaktnatntinnahdlnqkqkdalktqvnnaqrvsdannvqhtat elnsamtalkaaiadkertkasgnyvnadqekrqaydskvtnaeniisgtpnatltvndv nsaasqynaaktalngdnnlrvakehanntidglaqlnnaqkaklkeqyqsattldgyqt vknssqtlntamkglrdsianeatikagqnytdaspnnrneydsavtaakaiinqtsnpt mepntitqvtsqvttkeqalngarnlaqakttaknnlnnltsinnaqkdaltrsidgatt meghirtiytelytelytelingininadakteaninitsinintsinintsitystevagyngetakatelmamhslqngindetqtkqtqkyldaepskksaydqavnaakailt kasgqnvdkaaveqalqnynstktalngdaklneakaaakqtlgtlthinnaqrtaldne itqatnvegvntvkakaqqldgamgqletsirdkdttlqsqnyqdaddakrtaysqavna aatilnktaggntpkadveramqavtqantalngiqnldrakqaantaitnasdlntkqk ealkaqvtsagrvsaangvehtatelntamtalkraiadkaetkasgnyvnadankrqay

dekvtaaenivsgtptptltpadvtnaatqvtnaktqlngnhnlevakqnantaidglts lngpqkaklkeqvgqattlpnvqtvrdnaqtlntamkglrdsianeatikagqnytdasq nkqtdynsavtaakaiigqttspsmnaqeinqakdqvtakqqalngqenlrtaqtnakqh nglsdltdagkdavkrqiegathvnevtqaqnnadalntamtnlkngiqdqntikqgvn ftdadeakrnaytnavtqaeqilnkaqgpntskdgvetalenvqraknelngnqnvanak ttaknalnnltsinnaqkealksqiegattvagvnqvsttaselntamsnlqqqindeaa tkaaqkytdadrekqtayndavtaaktlldktagsndnkaaveqalqrvntaktalngde rlneakntakqqvatmshltdaqkanltsqiesgttvagvqgiqanagtldqamnqlrqs iaskdatkssedyqdanadlqnayndavtnaeqiisatmpempdtinqkasqvnsaks iaskdatkssedyddanadlqnayndavtnaegiisatnnpempdtinqkasqwnsaks
alngdeklaaakqtaksdigrltdlnnaqrtaanaevdqapnlaavtaaknkatslntam
gnlkhalaekdntkrsvnytdadqpkqqaydtavtqaeaitnangsnanetqvqaalnql
nqakndlngdnkvaqakesakralasysnlnnaqstaatsqidnattvagvtaaqntane
Intamgqlqngindqntvkqqvnftdadqgkkdaytnavtnaqgildkahgqnntkaqve
aalnqvttaknalngdanvrqaksdakanlgtlthlnnaqkqdltsqiegattvngvngv
ktkaqdldgamqrlqsaiankdqtkasenyidadptkktafdnaitqaesylnkdhgank
dkqaveqaiqsvtstenalngdanlqrakteaiqaidnlthlntpqktalkqqvnaaqrv
sgvtdlknsatslnnamdqlkqaiadhdtivasgnytnaspdkqgaytdaynaaknivng spnvitnaadvtaatqrvnnaetglngdtnlatakqqakdalrqmthlsdaqkqsitgqidsatqvtgvqsvkdnatnldnamnqlrnsiankddvkasqpyvdadrdkqnayntavtnaeniinatsqptldpsavtqaanqvstnktalngaqnlankkqettaninqlshlnnaqkq dlntqvtnapnistvnqvktkaeqldqamerlingiqdkdqvkqsvmftdadpekqtayn navtaaeniinqangtnanqsqveaalstvtttkqalngdrkvtdakmnanqtlstldnl nnaqkgavtgninqahtvaevtqaiqtaqelntamgnlknslndkdttlgsqnfadadpe maqkgavigninqantvaevtaqtaqtaqtantaminkisinkistististiadatie khayneavinaenilnkstytniykdqveammqvnatkaalngtqnlekakqhantai dglshltnaqkealkqlvqqsttvaeaqqneqkannvdaamdklrqsiadnattkqnqny tdasqnkkdaynnavttaqqiidqttsptldptvinqaaqqvsttknalnqnenleaakq qasqslysldnlnnaqkqtvtdqinqahtvdeanqikqnaqnlntamqnlkqaiadkdat katvnftdadqakqqayntavtnaeniiskanqqnatqaeveqaikqvnaakqalnqnan yqhakdeatalinssndlnqaqkdalkqqvqnattvagvnnvkqtaqelnnamtqlkqqi wqhakdeatalinssndlnqaqkdalkqqqqnattvagvnnykqtaqelnmamtqlkqqi adkeqtkadgnfynadpdkqnaynqavakaealisatpdvvvtpseitaalnkvtqaknd lngntnlatakqnvqhaidqlpnlnqaqrdeyskqitqatlypnynaiqqaattlndamt qlkqqiankaqikqsenyhdadtdkqtaydnavtkaeellkqttnptmdpntiqqaltkv ndtnqalngnqkladakqdakttlgtldhlndaqkqalttqveqapdiatvnnvkqnaqn lnnamtnlnnalqdktetlnsinftdadqakkdaytnavshaegilskangsnasqteve qamqrvneakqalngndnvqrakdaakqvitnandlnqaqkdalkqqvdaaqtvanvnti kqtaqdlnqamtqlkqgiadkdqtkangnfynadtdkqnaynnavahaeqilsgtpnanv dpqqvaqalqqvnqakqdlngnhnlqvakdnantaidqlpnlnqpqktalkdqvshaelv tgvnaikqnadalnnamgtlkqqiansaqpqsvdftqadqdkqqaynnaanqaqqiang iptpvltpdtvtqavttmnqakdalngdeklaqakqealanldtlrdlnqpqrdalrnqi nqaqalatveqtkqnaqmvntamsnlkqqiankdtvkasenyhdadadkqtaytnavsqa egiinqttnptlnpdeitraltqvtdaknglngeaklatekqmakdavsgmthlndaqkq alkqqidqspeiatvnqvkqtatsldqamdqlsqaindkqtladgnylnadpdkqnayk qavakaeallnkqsgtnevqaqvesitnevnaakqalngndnlanakqqakqqlanlthl ndaqkqsfesqitqaplvtdvttinqkaqtldhamellrnsvadnqttlasedyhdataq rqndynqavtaanniinqttsptmnpddvngattqvnntkvaldqdenlaaakqqannrl dqldhlnnaqkqqlqqitqsqitqssdiaavnqhkqtaeslntamgnlinaiadhqavqqqnfi ndakasisaitapitvuvtinkaatinimimiinisvandetiaasakaannilaakagainri
qoldhlnnaqkqqlqsqitqssdiaavnghkqtaeslntamgolinaiadhqaveqrgnf
inadtdkqtayntavneaaminkqtqqnanqteveqaitkvqttlqalngdmlqvakt
natqaidaltslndpqktalkdqvtaatlvtavhqieqnantlnqamblqrssiqdnaat
kanskyinedqpeqqnydqavqaanniineqtatldnnainqaattvnttkaalhgdvkl
qodkdhakqtvsqlahlnnaqkhmedtlidsettrtavkqdlteaqaldqlmdalqqsia
dkdatrassayvnaepnkkqsydeavqnaesiiaglnnptinkgnvssatqavissknal
dyverlaqdkqtagnslnhldqltpaqqqalenqinnattrgevaqklteaqalqqamea
lrnsiqdqqteagskfinedkpqkdayqaavqnakdlinqtnnptldkaqveqltqavn
qakdnlhgdqkladdkqhavtdlnqlnglnnpqrqalesqinnaatrgevaqklaeakal
dqamqalrnsiqdqqtesgskfinedkpqkdayqaavqnakdlinqtnptldkaqveqltqavn
qakdnlhgdqklardqqqavttvnalpnlnhaqqqaltdainaaptrtevaqhv
qtateldhametlknkvdqvntdkaqpnyteastdkkeavdqalqaaesitdptngsnan
kdavdqvltklqekenelngnervaeaktqakqtidqlthlnadqiatakqnidqatklq
piaelvdqatqlnqsmdqlqqavnehanveqtvdytqadsdkqnaykqaiadaenvlkqn
ankqqvdqalqnilnakqalngdervalaktngkhdidqlnalnnaqqdgfkgridqsnd
lnqiqqivdeakalnramdqlsqeitdnegrtkgstnyvnadtqvkqvydetvdkakqal
dkstqqnltakqviklndavtaakkalngeerlnnrkaealqrldqtthlnnaqqqlaiq
qinnaetlnkasrainratkldnamgavqqvideqhlgvisstnyinaddnlkanydnai qinnaetlnkasrainratkldnamgavqqyideqhlgvisstnyinaddnlkanydnai anaaheldkvqqnaiakaeaeqlkqniidaqnalngdqnlanakdkanafvnslnglnqq qqdlahkainnadtvsdvtdivnnqidlndametlkhlvdneipnaeqtvnyqnaddnak qqdlahkainnadtvsdvtdivnnqidlndametlkhlvdneipnaeqtvnyqnaddnak tnfddakrlantllnsdntnvndingaiqavndaihnlngdqrlqdakdkaiqsinqala nklkeieasnatdqdkliaknkaeelansinninkatsnqaavsqvtganhaieqvhan eipkakidankdvdkqvqalideidrnpnltdkekqalkdrinqilqqqhnginnamtke eieqakaqlaqalqdikdlvkakedakqdvdkqvqalideidqnpnltdkekqalkdrinqilqqqhnginnamtke eieqakaqlaqalqdikdlvkakedakndidkrvqalideidq npnltdkekqalkdrinqilqqqhndinnaltkeeieqakaqlaqalqdikdlvkakeda knaikalamakrdqinsnpdltpeqkakalkeideaekralqnvenaqtidqlnrglnlq iddirnthwevdeqpavneifeatpeqilvnqeljivntdditeqdilahinlidqlsa evidtpstatisdsltakvevtlldgskvivnvpvkvvekelsvvkqaiesienaaqqk ineinnsvtltleqkeaaiaevnklkqqaidhvnnapdvhsveeiqqqeqahieqfnpeqftieqaksnaiksiedaiqhmideikartdltdkekqeaiaklnqlkeqaiqaiqraqsi deiseqleqfkaqmkaanptakelakrkqeaisrikdfsnekinsirnseigtadekqaa mnqineivletirdinnahtlqqveaalnngiarisavqivtsdrakqssstynesnshl tigygtanhpfnsstighkkldedddidplhmrisnnfgnuknaigvysispllasf wffiakrrrkedeeeleirdnnkdsiketlddtkhlpllfakrrrkedeedvtveekds lnngesldkykhtpfflpkrrrkedeedvevtnentdekvlkdnehspllfakrrkdkee dvetttsieskdedvplllakkkngkdngskdkksaskntskkvaakkkkkkakknkk

mffddakeasrvleitltkrdakkenpipmcgvpyhsadnyietlinkgykvaiceqmed pkqtkgmvrrevvriitpgtvmdqngmdekknnyilsfieneefglcycdystgelkvth fkdtatllneittinpneivikqalseelkrqinmitetitvredisdedydmnqlthql mhdttqllldyihhtqkrdlshieevleyaavdymkmdyyakrnleltesirlkskkgtl lwlmdetktpmgarrlkqwidrplinkqqindrlniveefmdrfierdtlrnhlnqydi erlvgrvsygnvaardliqlkhsiseiphikallnelgaqtttqfkeleplddllqllee slveeppisikdgglfkngfnaqldeyleaskngktwlaelqakerertgikslkisfnk vfgyfieitranlnnfqpeafgynrkqtlsnaerfitdelkekediilgaedkaveleye lfvklrehiktyterlqkqakiiseldclqsfaeiaqkynyvkptfsddkvlhlensrhp vvervmdyndyvpndchlddetfiylltgpnmsgkstymrqvaiisimagmgayvpcdsa tlpifdqiftrigaaddlvsgkstfmvemleaqkaltyatensliifdeigrgtstydgl alaqamieyvaqtshaktlfsthyheltsldqmlkclknvhvaaneyggliflhkvkdg avddsygiqvakladlpnevidraqvilnafeqkpsyqlshentdnqdtvpsyndfgrte eegsviethtsnhnyeqatfdlfdgynqqsevecqirelnlsnmtplealiklnelqsqlk

| 443. | atgattccaactaaacctcatgatgtgatttggacagatgcacaatggcaagtattat gcgaaaggacaggac | |
|------|--|---|
| 444. | miptkphdviwtdaqwqsiyakgqdilvaaaagsgktavlveriiqrilrddvdvdrllv vtftnlsaremkhrvdkriqeasfkdpnnehlknqrikihqaqistlhsfclkliqqhyd vldidphfrtsseaenillleqtiddvleqhydkldphfielteqlssdrnddqfrsiik qlyffsianpqpfewlnqlaqpykeenkqqqlmqlindlamifmkagyeelqksydlfsm mesvdkqlevietermfitkaiegkvlntdvitqhefmsrfpainskikeanegmedaln eakqhydkykslvmkvkndyfsrnaedlqrdmqqlaprvaylaqivqdviqsfyvqkrsr nildfsdyehfalriltnedgspsriaetyrehfkeilvdeyqdtnrvqekilsciktge ehdgnlfmvgdvkqsiykfrqadpslfiekynrfsssgnesglridlsqnfrsrqevlst tnylfkhmmdeqvgeisyddaaqlyfgspydevshpvqlralveassensdltgseqean yiveqvkdiinhqnvydmktgqyrkatykdivilersfggarnlqqafknndipfhvnsk egyfeqtevrlvlsflrtidnplqdiylvglmrsviyqfteeelaeirvvsphddyfyqs iknymidekadsrlvdklnrfiqdigkyqnysqsqpvyqlidkfyndhfviqyfsgligg kgrranlyglfnkavefenssfrglfqfirfidelidrkdfgeenvvgpndnvvrmmti hsskglefpfviysglskkfnkgdlnapvilnqqyglgmdyfdvnkdmafpslasvayra inekeliseemrliyvaltrakeqlilvgrvkdekslikyeqlavsdthiavnerltatn pfvliygvlakhqspslpndqrferdidqlnsevkprvsividhyedvsteevndneir tieelkaintomedvkikihqqlsydypfkvntmkpskgsvselkrqleteesntnydrv | |
| 445. | rgyrigvasyerpkfltqtkkrkaneigtlmhtvmghlpfreqrltkdelfqyldrlidk qlidedakedirideimhfidgplymeiaqadnvytelpfvvnqikvdgltsededvsii qgmidliyesdgqfyfvdyktdafnrrkgmsdeeignqlkekyqiqmtyyrntletilkr pvkgylyffkfgtleidd ctgtaccatcaaattggtgctacaatttctcctgaatctggtacaaatccgataccatcac ccatcatcttttcagagaaaactttatcaggtacttagatacaggtattatctaccat gtccaggtgcgtaaatttctgtttctacaatatcttccacatgtacaggatcatctgaca | |
| | cttcttcatcaattqttqtttcacttggttttg | 4 |
| 446. | lyhqmvlqfllnlvqiryhhpssfqrklyqvlqitvlshhvqvrkflflqylphvqdhlt llhqllfhlvl | |

| 447. | cgcatactttggtcatcactatgcgtaatccacaaaatggcaatccctttatctgctagt ttaaatataatttcttcaattttctttttattatgtgtatctaaagcgctagtagcttcg tccaataataaaacttcaggttcatacatgagttgtctagcgatggtaatacgttgttgc tctcccccagacatgtgctcaatt |
|------|---|
| 448. | rilwsslcvihkmaiplsaslniissiffllcvskalvassnnktsgsymsclamvircc sppdmcsi |
| 449. | tcacgtactttacgcgctctactcttaatactccaaacaggcatgatgtgtggtttgtta tggtcatcatctgaaatcataataaaattcttttcacctttgtttg |
| 450. | srtlralllilqtgmmcgllwssseiiikffsplfvnpytssyfatslinslilissnsd inssviltistmfpssplftltktlspgskissisyvtkrsisalmils |
| 451. | gcaggatttttgactaaagcagtacttaaatcaacttcatctctgtcatcaaacacttct tetacgacttctttacgtgcaatcactctaaatgaaccttcgtccatatttaattctact cttacatttctggcactatca |
| 452. | agfltkavlkstsslssntssttslraitlnepssifnstltflals |
| 453. | tatttetttataagetttttaattagaetaatateatgeteattgattaeegaaaeaatt tegatttgteeatttttagatataattgageeattaeeaeeaateaaggtateateegea aatteaggaatgaetggaageaagtetetaatgggaegtgetgatgeaaaeattaeattg |
| 454. | yffisflirliscslitetisicpfldiieplppikyssansgmtgskslmgradanitl |
| 455. | ttatcttettetaaagettacetteaaegtetaggeaataetgeacetaaceat ttaggaaggtaceatgaagetttaceaaagagtttegteaatgetggaattaatgteata egtacgaegaatgegtegaataaeaeaeegaaaeetaatgegataceeattgaettaatt geaetgteatettggaagaegaatgegatgaatacaetgaaeataaatagtgeageaget acgataaeaggteeaetttettetteataectaeaeggattgaa |
| 456. | lssskalpststfgntapnhlgryhealpksfvnaginvirttnasnntpkpnaipidli alsswktnammtlniisaaatitqplsliptrie |
| 457. | tcatcaactgcttgcattaagtctaagattttttgttcgtattcagcatcgccttctaat gcttttaatgcagaaccagcgattacaggtacatcgtcacctgggaagtcatattcgctt aataagtcacgaacttccatttcaactaattctaataattcttcgtcgtctaccatgtca actttgtttaagaatacaactaatgctggtacaccaacgttacgtgataataagatgtt tcacgagtttgtggcattggaccgtcagcagcagatacaactaagataccgccgtccatt tga |
| 458. | sstacikskifcsysaspsnafnaepaitgtsspgksyslnksrtsistnsnnsssstms tlfknttnagtptlrdnkmcsrvcgigpsaadttkippsi |
| 459. | ttagaaccacctacacgacgagetttaacttctaatactggcatgatattattaattgct tcttcgaacacttctaattgcatcacgaccactacgttgttcaacaagatcaaatgcagaa |
| 460. | lepptrraltsntgmilliassntsnasrplrcstrsnae |
| 461. | aggaggegacegeceagteaaactgeeegeetgacactgteteecaccacgataagtgg tgegggttagaaagecaacacage |
| 462. | rrrppqsncppdtvshhdkwcglesqhs |
| 463. | tgtgctattattccccctattgaaggacctaacccttcacctaaagctacaattgatcct ataaaaccaaaggctttgccttgtttttttttt |
| 464. | gccagtcacttctcgttccatttgattcaatacaaacaaa |
| 465. | tgtcgtattaatactgccttcaccagtattgctagcatttggatcttgagtttgtgcgtt tgctgctacaaggtgctgctggttgcgctgctgctggagaattcgctggctg |
| 466. | atccaacgtttcaggaataaatgttttcaaaccactttgaaatggatcgcggtgttgtgc ttgatatactttgtagcgataacgtttacctacacaatcataacgacaatgaaaatcgtc atcgactgtaactacattgttgacataaatatcatcagg |
| 467. | cggtataaaggtaaagcaaaatgcatcagcttgcttagaatgattgtcctttttttgata atagcgttccattgcaatgacggcagaaggatggtttgcaaacaaa |
| 468. | atgcaagagtaccaaaaatcgttaaatacgcttaaaaagcctataaatgttccgtatgag caagaaactgaaaagtaggtgtttatttagcaaagaaatacaagaaactggaaatgtt gtaataagccaaaaagatttcaatgaatttcagaaagaaa |
| 469. | atgctaactactttcgctgttgtactcattttcttcttacttccatcttcatttttattg |
| 470. | ttgagcatctgcatcattattatcattcatgcgatcatttttgttcacattattaaaaat ggcattcaaaataacaat |
| 471. | ttgcctataccaagtactagaagtgcaccaataattccagcaatcaat |
| 472. | atgetttttgagttaetteataataeteateagttttttgtgtateetttttgaettttatt tatttettteeaettaeeagtatgaetttetttttttaeagttatttteggtttgtt |

| 473. | atgacttgtgaaaaactggaaaatttettgaccagtagcaaagceggcaccaacgacaac accaacaaaggcaaatgccacaataatggactcttt |
|--------------|---|
| 474. | ttgattgtcattagtaacgttattgccattattttgatttttatctgtttttgtctgcact atcatcttgttgatcattttcttcggtttctgtcttttatgcgtagatttattt |
| 475. | atgtgcagaaattgcccagcattcaccagttgtttcattagggatatcatagttaaatgc ttt |
| 476. | gtggtatacaacgcaacgtatatgcatcttgtacacgtatttctgattgtcgcgtcgtta atgttgatccttctaaccaatcacgcatacgcgctgccacat |
| 477. | gtgacaaatatcacactaaacagtgcatttgcagatgctacgataagcgtatttttatac caagtcaggtat |
| 478. | ttgtgcagtagtagcttggttactattcttaagcttttgttctgcatctctcaactgttt aagtttttgatacgcatcttgtttacgttgatttgtacgtttatattgattttcagcttt tttaagttctgtattcga |
| 479. | ttgccttcttgtttatattgttcaacaagtgctttatgcttagcggactgcttctgtact gcgtcacttgctctttttagttgtgcagtagtagcttggttactattcttaagcttttgt tctgcatctctcaactgtttaagtttt |
| 480. | caiippiegpnpspkatidpikpkalpcfflviflatttiisegnaadptpctnlpkiki kk |
| 481. | ashfsfhliqykqiilnifrstvasillffcllfmiyfrtvkfflnfliindfcfymafn rkrhilsflk |
| 482. | crintaftsiasiwilslevecyrecwlrccwsirwleliereciiireclvisltelve reelisrlelesvirislitlsswleiwleessewislstlvewlycwlslvgreswlee rislstsievrleigiswlewlilerlilleerreervsryksnsgn |
| 483. | igrfrnkcfqttlkwiavlcliyfvaitftytiittmkividcnyivdiniir |
| 484. | rykgkakcisl1rmiv1fliiafhendgrrmvckqmiciftf |
| 485. | mqeyqkslntlkkpinvpyeqetekvgglfskeiqetgnvvisqkdfnefqkqikaaqdi sedyeyiksgralddkdkeirekddllnkaverienaddnfnqlyenakplkenielalk llkillkelervlgrntfaervnkltedepklnglagnldkkmnpelyseqeqqqeqqkn qkrdrgmhl |
| 486. | mlttfavvliffllpssfll |
| 487. | lsiciiiihaiifvhiikngiqnnn |
| 488. | lpipstrsapiipainatmtvlnhgnlgllylgvwlwfvve |
| 489. | mllsyfiilisflcilltfiyffpltsmtfffysyfrfv |
| 490. | mtceklenfltsskagtndntnkgkchnnglf |
| 491. | livisnviaiilificfvctiilliiffgfclfmrrfiflflvit |
| 492. 493. | mcrncpaftscfirdiivkcf vvynatymhlvhvflivaslmlilltnhayalph |
| 494. | vtnitlnsafadatisvflygvry |
| 495. | lcssslvtilkllfcisqlfkflirilftlictfilifsffkfcir |
| 496. | lpsclycstsalcladcfctaslalfscavvawllflsfcsaslnclsf |
| 497. | caagtgetgaaaatgetteagaacateetettgetgatgetattgttaettatgetaaag ataaaggtettaatttaettgataatgacaettttaaateaatteegggaeatggtatta aagetaegatteateaacaacaateettgtgggeaategaaaat |
| 498. | aagaggettgttatgcagcaacacctgcaattcaacttgccaaagattatcttgctcaac gccctaacgaaaaggttettgtcattgctagtgacacagctcgttatggtattcattc |
| 499. | ctgcgcctacgccagtttcagctattatgcacgctggtattgttaatgctggtggcgtta ttettacacgettttctccggtatttaatgacgaaa |
| 500. | cgtttacgatatacttcatacatcattaaacttgcagccacagacgcgttcaagctattg acatgtccaaccattggaatcttaata |
| 501. | tcaagcgtttttgctatacgacttactatcactttttctcgattttcaaatgttggatgc aaaaaacatatcaagggagccataataatgaagaaagaaa |
| 502. | agatotgtaccacatattgtcgtcttaactatgcgaataatagcgtcagtactgctcgta atagttggcttctctttatccgtaagttgtgca |
| 503. | actgccaataatatcatcagcttcataattacgcttaccaacatttacaaaaccaaactg atgggatatttctttaacataatcgaattgaggaataagttcatcaggaggtgctggggg atttgtttatagccatcatacatttcattt |
| 504. | ttcttttgtagattgactcaactcaactggctcaaatacttgtccgttagaatgctttac' atgtattttatgattttcagtataatgaatcatattgtaagtaccatttgt |
| 505. | atttttatatctacatgcgggtgtagtacaacatcagcttggaaggctgaggttttgcca ttaagggttcgattcccatcacccgctccattt |
| 506. | ctaaagaatatattgaggattgtatttattgctggtttgacagttttcttctctggtcct ggccaaacttattcaaacgcagcatttattgatgaatatattcaaacatttggatgga |
| 507. | aggaattccaatcaaatgtaccaaacatttacagcggatattgtacttatatttatgatt attgtacttggaggacttgtagttcaagttccaatgccaattttagcaggtattatggtt atggtttctgagacaatctactgtttgcacctgat |
| 508. | aatcaacgactcgaggaaacaatttcctctccccatcacagctcagcctta |

| 509. | atgaaacaatttttaaacatcactcaacgtaaatttatcgaatggttgattatcttatcc atttttatagttagcattcctaataaatggacattaatgatatctatc |
|------|---|
| | attgctataataaatcaaccatatttatcatcttttattaacactatcttaaaaggg aagaatagccaagaggtctttatgccgagtgatatgaatattaaagctattgattatgcg ctaactgagcatcctttttaggaagcggttttggtataccaatgataaaagcgagttca gaattacaatactttaatgtagcaacgagtaatatcatcttcggtatgattatctttact ggaataataggacttactttatgtacgatatacatgcttcatatggtacttttagttact tttccaatgagtattactattttattatttttaatcactatctttgttaatatggattat attattttatt |
| | atgacaaatcaaaaaactgtgggtctagtcgtcgtccaggtgttactgaacgccttgca gaaaatctcatacaagaaatgcctaaaatgttatctacacattatgatcatcagaaaa tggatttttgatttagttacggatccgttactggttttgctgaatctgtagatgaaatt tttggattttggtttgcggatcgtgtttgctgaatctgtagatgaaatt tttgggaaagtagccgattatcacgatagagacaatgggattatgtgatagcaattaca gatttaccgatgtttgcggacaagcaagtgatggcattagatattaatatggaaaatggt gcagctatattctcatatccggcatttggctggggtccagttaaaaaacgtttcaagcat gcagttataaatattattcaagaattaaatgaagctgaacaagaaagtcgtaattatgat aataataagcaaatagaaaattcagtaaaaaaacaatttccgctctctaaaatagataaa gaacaaatatatatgaaagaaacagaccttatcacttaagatattatcaagttcacgt tctagaaggcatgtttcgccttgttagtggaatgacctttgcgaatattatcaagttcacgt tctagaaggcatgtttcgccttgttagtggaatgacctttgcgaataatccattaaatatg atggcaagtttaagtaaatatgatgctattcaattgcggcgttattttggaatttca tttacaacgatgtggcaaatggctattacatttcaatgtggcgcttatttggaatttca attattgcgattattggaatgctaatatggttaatgatgcacatgatttatggagcca gttaataaaagcaaccataagcatattacttggttatacaatcttacaacaataadgaca ttgatttttgccattaaatttattattattttttattatatttttacttatattat |
| 511. | atgaaattetgeceteattgtggaaateegataaaaaaggaacagteattitgtaataaa tgtggaaaacatttaaagacategacacaaagaaaaagtgaaaateaaattgaacatatg cgtgaacagcaategtaatttetegtgtgaggaaagacaateatgatteaacattttat aaggacaacaacategttggetaattgtattateaattatttgtettgttgata gcagegetattgtatggtgegtactatgettacaatcatatattatgtgettggtaagget caccaaacaacagagtetcagcaatcaaatgaaagtgatcaaaatagggaccaatccact ggtccaagcattgatgttttagtgagtgactttgatcaaggtataatgaggetcaa acaagtggatatagaggtgtttataatggaatgacacgtgaagaagttgaagataaattt ggaacatccaatggttetgagaaagtttgaagtgagttacgaacatatggtgatta gctgtagcctacgatgataatgaagttgttagcgatgaggtacaatcaat |
| .' | atgttatigtttatcatagaaatcataatcatgattctagcgatattatataggattaaga actgctggtgcactgggatgtggcatctttgctatagtagcgcagcttatcatagtattt ggattccagttacctccaggttcagcacagtgaaggcagtgttaactatattatt ggattaccagttacctccaggttcagcacagtggtattgactatttagtatactatt ggtatagcaggtggtacgttacaagccactggtggtattgactatttagtatacattgca tcaggtggattgaacgcttccaaatcaattatttattagcacattgattg |

| 513. | atgggaagtttttttaatcggatgactcgaaaagagaatcctactatttatcaaaataaa gatgggcatcttaagcgcacgttacgtgtacgtgactttcttgcactaggtgttggtaca attgtctctacatctatcttcactttaccaggtgttgcgggctgagcatgccggacct gcgtgggattatcattcttattagctgcattgttgcaggtcttgtagcctttacttat gcagaaatggcatctctatatgcgcattgttgcaggtttgtacggattaacttattattgt gcagaaatggcatctcacaatgccttttgctgagctttattcatggattaatgtactt tttggtgaattattctggatggggttgccggtttatgcaggattaatgtactt tttggtgaattattctgagtggtgcggttttagcagaataactttattgct gttgctttcgttgcttcaggcttttctgctaacttaaggaggtgttattgcaccattaggc atttcttaccaaacattatactaatcacattaggaagtaacggtggtgcastgaacgagcc gctcgtaggaaaatgtattggttatattaacattatacaagggtgttaagcatcattttttgtgatt gttgggctaactggaattattcagtagaaatagtttactattatcagagaaatgaaggtt accggaactggagttaatttcgtggggattaattatgggtgaaactgggagtttcaatgatttc ttagcttatattggtttggaaggttggcaaggtattatcgagaggtttaaccagaaaaggtgacaatgggtggcaggattaatccacag aagcaatggctatggtggcaggttcaaggaattttctttaggttggcaggttggcaggatttaatgggcgggtgggggggg |
|------|--|
| 514. | atgacaaagaaaaaacgtttatcgcctagtgagtggttgcttaaacaatctaaaagacat aaaaggaaaaatacactttacacggcaattgtacttttagtagtgttagttctactcata tttgctgttaaatcaatacaagtagaacctgtaaaaagtgatacgagagacaaagatagc attcgtatcacctatttaggtaacgtcactttaaataaacatattcgacaaactaact |
| 515. | atgattgaacatttaggaattaatacaccttattttgggatattagtatcattaatacca tttgtcataggacttatttttataaaaaaagaatggtttctttttactagcaccttta ttcgtaaggtattggttgcaggtattgctttttttgaaattgacaggaattagttatgagaat tataaaatcggtggcgacattattaatttcttcctagaaccagctacaatatgctttgcg attcctttatatcgcaagcgcgaagtattaaaaaaaatattggttacaaatatttggtgg atacctttatattgccttgttattaatttatcttgttgccaataacattccaa tttggcaatcaaattattgccttgttattaatttatcttgttgcaataacattccaa tttggcaatcaaattatagcatctatgctacctcaagctgcaacgacagcaattgcatta cctgtatctgacggtatcggtgtgtcaaaagaattaacctcactcgcagttattttaaat gcagttgtcatttctgctttaggtgctaaaatagttaaattattatatata |
| 516. | atgaaaagaacagataaatatagagattcatacaaatatgatgaccaatatcaaaatcat cgtaaacgttcagaagaagatatgtatcgacaacatcaaagagtcccaacagagagacaat tcaaatcgtgcaacacaagtgaaaatgatagagagtatgaaaatcatcctgaacgttat 'tacaatggaagagactatcgacgtgagcagcaattggaagaagaaaatgaaaatcaagc aaaactaaaaaatggctgattgcaatcatagttattttactcattattgtagctatcttt atcacgcgtgcaattatcaatcataataatgataaagtaagt |
| 517. | atgaacatgaaaaagggtgtttctcagcttacgttacagacattgagtttggtcgcaggc tttatggcattggagtatcattttctccattaatgccatttattt |

| 518. | atgaaaaataaaaaaggattaggcataggtcttatcacaattatgattatcgtttgtatt gtactagtaatcatgatgttcgtgggtggtaagaaagaatcatactacggtattatgaaa gatagcacgactattgataaaatgataaatactaaaaaatgaaaaaattgaaaaaaaggta gaattacctaaagatgctaatgtatcagttaaaaaaagaagattttgtgatgctctttaaa gatgaaaaactggaaaaattactaagataagtaagaagttaatcacgatgacgtacctcat ggtttaatgtcaaaaatccatgatatgggtaatatgaggtaacatgacgtacctcat |
|------|---|
| 519. | atggctatgtcattactcgtgagtcttgtggtttatatgatgacactcacatctgatata ttagaagatattctatcatttaaattagaagtgataatgcaatttccgtatatattaagc tctatttcactaatcattttgttatactttcattttaaaagattattggaaaaaatatgg tactggctcatttcaatagttatgattgctgtgataagtatgtcggacacgtgtggtca caacaagtgccattatggtcaattatcataagaacaattcatcttatagggctaacgtta tggttaggttcactcgtttatctcatttgttatgctattaaagtgaaaattaatcagttg acgagtgtaagacgtatgcttttaaaagttaatatcattgctgtgatatatgctcgttttt acagggattttaatggctattgatgaaacgaatactttaacactttggaataatgtgagc gcttggtctatttatctgtcataaaaatcgcaggaattattgctatgatgctattaggt ttctatcaaacgatgcgtgctttgagacaacgacacaggtccatcgttttgcactgatg actgaattgttaattggtatgatattaatttgcaggtatca actgaattgttaattggtatgatattaatttgcaggtatca actgaattgttaattggtatgatattaatttgcaggtatca |
| 520. | atgaaaaactctagattttctgggttccaatgggctatgatggtctttgtatttttcgtt atcacaatggcattgtccgtgatactcagagattttcaagcgactatcggagtgaaccgt tttgtcttagtatataagaatttagctcetttcatagctgcaattgtgtgcatattagta tttaagcacagaaaagaacaattagcaggattgaaattttctatcagtttaaaagtgatt gagcgtctacttttagcactcattctaccacttatcattttaatgattggcttgttagc tttaatacttatgctgatagttctactcattacaaacttcagatttatcagtatcatta ttaactatattatgtgcatattttaatggcttttgtagtggagtttggttccgttc tacttacaaaatattcttgaaccagaatgaaccaatttttttgcgagtattgtcgttggt cttattatacagtattacagctaacacgacatttgttggagatttggtcgttggt cttattatacagtatttacagctaacacgacatttgtggagatttggcggataccat ttcttatatacattcatgttttcaatgattattgggtgaaattagtcgtggg cgtacaatttatattgcaactgcttttcacgcaccatgacttttgccctgcttttta tttagtgaagaaacaggcgaccttttctcaatgaagatcatcgcactttctacaacaatt gtgggtgtttcatttattattattagtcaatcaatcgatgctattgttataaaacgacg aaacaaagtttagacgaagttgatcctaataattattattatctcatattcaagatgaaga ccaagtcaagaagacgcctcttcaacttcaaatcatgatgtatcatcaaagatgaaga aagcacaagatattgataatgacaacaacaacaacaaaca |
| 521. | atggaaaataatgagttgcaaaggggattgaatgcaqtcagatgcagatgattgctctt ggtggaacaattggtgttgttgtttttatgggaqcaqtcagatgcagatgattgctctt ggtggaacaattggtgttgttttttattgggaqcaacaagcacaattaagtggacaggt ccatcagttattttgcatatttaattcgtggtattttttattttaattcatgagagcc atgggtgaaatgatatatatatcaaccactggttcttttggagcagtttgctagtgac tatattcatccagcagctggctacatgactgcttggagcaatgtatttcaatgggttgc gtcggcatgagtgaagtga |
| 522. | gtgaaaagacttaagaattttattctcggcttactcattgtggctatagttggcttccta ttatttatgtatatagatgatagtcgcattcaaagttatcaaagattacttcttacaattt aattggttccaaccactattgattgggcttgcaggattacttatattatattatattgatttgattgcaggattacttatattatattattgattg |

| 523. | ttgcaagattttgataacttaattcctggctggtttaaaacatttgttcaagtcgggaat gacttaatttggtctcaatatcttattggattattataacagcaggttttttctttaca attagttctaaatttattcaactcagaatgttaccagagatgttagagcattaactgaa aagccagaaactttaagtagtgggaaagggtatttcaccattcaagcttttgcgatt agtgctgggtcaagagtaggaactggaaatattgccggtgttgcaactgctattgtctt ggtgggcccggtgcagtctctggatggagtatttgcagctattgttctt ggtggaccaggctattctcggatgtggatattgctttattggtgcagctagtgca tttatggaagcaacgcttgctcaagttataaggtacatgacaagaaggtggattccgt ggcggaccagcctattacataacaaaagggctaaaccaaaaatggcttggaattgtatt gctgttttaattacagttacatttgcttttgtatttaatactgttcaagcgaatacaatt gctgaatcattaaatacacaatacataatcagccggtaattactggaatagtactgca gttattacaggtattatcatctttggtggtgttcgtagcagctaactacttcactt attgtgcctattatggctattgtttaataggtaggttttaatcattttattacaca gttactacaggtattgacctatgtttaataggtagttttaatcattttatacaca atagatcaaattgtacctatgattggcactattattaaaagtgcatcgcactacctcc gttaaacaaggttgatgggactgcactattattaaaagtgctgttttatctca aacgaagctggtatgggatcgcactaatctcaaggtattaaaccgtggttttgtaca gctacagcaattatgatttaattatatctggttgcacatctgctggtttgtaca ggtgtagcaggttacgcaatcaggttgaacgattaggttgatagcggcctcaa ggtgtagcaggttacgcaatcaggttgaacgaacatttaggttcagcaggaggtatttc ttaactgtagcagttaccttatttgcattttcatctgttgaggtaaccattatctatgga caatccaatattgaattttatctaacaataagatgatatttttttt |
|------|---|
| 524. | ttgaaaaaagaaattttagagtggattgttgcatagccgttgccattgcacttattgcc ataatcactaaatttgtcggaaaatcatatctattaaaggtgattcaatggatcctaca ttaaaagatggggagcgtgtagtggtaaatattattggctataaattaagtggcgttgaa aaaggaaatgtcattgtatttcatgctaataaaaaagatgattatgttaaaagagttatt ggaactccaggagatagtgttgaatataaaaaatgatacactctatgttaatggtaaaaag caatcagaaccatacttgaactataaatgaaaaacgtaagcaaactgagtatattacacaggt agttcaaaacaaaa |
| 525. | atgttcaataaggtttggtttagaacaggaatattttttattatgctgttcatactcatc aaactatttatggaagtgcatgaagtatttgctccaatagctactatcattggttcagtc ttccttccatttttaattagggatttcettttacataggttacatct ttagaaaagtggggctttccacgttgggctagtataacaacaatattcataggattaata gctatcatcgctattgtggtatcatttatagcacctatcattatttccaatattaataac ttagtaaacaacacacactacattattattacatcgtta agacaaatggataaattaccagatgatgtcacacatcgtattaataattcctcgtta agacaaatggataaattaccagatgatgtcacacatcgtattaataatacc atgggagatggcgcaacgtctattttatctaattcagtgtcatatatat |
| 526. | atgaatacaatcgtaaaacatacagtaggttttattgcttctatcgtactaacgctttta gcagttlttgtaactctatacactaatatgacattccatgctaaggtaactatcatcttt ggttttgcttcattcaagctgcccttcaattattattatgttcatgcatttaactgaaggt aaagatggacgtttacaatcgttcaaagttatctttgcaattactttagtaact gttatcggaacatactgggtaatgcaaggtggacactcttctcactta |
| 527 | attetttettaggaaaccaccgaaattatattagttatatactcgttacgtttca cttttacaggtctcattattttatt |

| 528. | atgttaggagagcaatatacacaaattaagcgtccagcaaatcggctaactgaaaaata ttaggttggtttagttgggtattcttactcatattaactattgtttcaatgtttattgg ctcgtatcttttagtaatggtcaatgccaattgcaatttagaaacacacttaataat gaactcgtacaacaaattttagccaattatgattagaacacacttaataat gaactcgtacaacaaattttagcaattattgttatttagttgctaatttggtatttgg ttacaaaatggagtttgggcaattattgttttatttattattgttgctcaatttgtgatttgg ttacaaaatggagtttgggcaattattgtttgttgttgttgttgttgctcatctcgttt ttagcgttaatttctatgaatataagaattttgtctggtttactttttttt |
|------|--|
| 529. | atggaagaataaaatcaacctaataatgagaatatgtcgaataaagacgataataca atcaatttgaatgatagtcaaagtaatgaagacttagagctttttagacggaataaaaac gctcgccaacgcagaagacgtcgcatagataaccaaagtaaaagaaaagatgctacgtct acacaatcacagttagaaactaaaccaatggataaatttattgataatcacaagtcgcat aatcaagataaagaaataaaaagagtattaattgaggataaatttattgataatgacgaatgac aatcaaagataaagaagagaatttaattgaggataaatgttaatgagagatgac aatcaaaatataataatgataaattaaat |
| 530. | atgaagtgtttgttcaaaatgctatcaatcataataataatgttaagtactttcacctta ttcatcagtccgagtacatatgcaaatgaagatgaaaattggactaaaataagaa ggagaaactaagagttggatttgtcagctgattatgcaactttaagaatttgaaaagacgata catggtaaaactgaatatgcgggtgtagatatagaattagctaaaaaagattgcgaaagat aatcatctaaagctaaaaattgtaaacatgcaatttgatagctattaggtgcacttaag accggtaaaatcgatattattatctccggtatgacaccaactcccgaacgaa |
| 531. | atgcaaccaagaaaccgacatcatggtacaaacaagaatggtttatagttttatcactttta ttcatttttccactaggtttatttdtcatgtggaaatttagcaagtggccatctattgca agaacaatcattactgttgcaatttcagttatcgtattagcaagtggccatctattatggt aatctacaaatgatgttgcaatttcagttatcgtattagcaagca |

atgagtcataagatattagtatcagacccaatttctgaggatggtttacaaagtatttta aaacatccagaatttgacgtagatatacaaacagatttatctgaaaatgatttagtaaat atgatttcaacttatgatgctcttatcgtacgaagtcaaacccaagtaacagagcgaatt 532. attictgctacagaacattcagtagctatgttgcttgcattggtagdadatattcttda gcacaccaatctttacgtagcaatggtagtagtagattggtaggggttgaactt tatggcaaaaccttaggtgttatcggtggtaggtaggattggtttgggcgtcgctaaacgt gcgcagagtttcggtatgaaaattttagcgttcgatccttatttacagaagagaatcattagaatattcaaattgcaactgttgtagtaattcgaacttgta aagttcacacaccattaacacctaaaactgtagcagagaggggtattatagaact aagctaaacaaaacttacaaatcataaatgttgccagaagggggtattatagaact attgaaattctaactaaagggaatgttgagcatgctgtgaatgctccaaaaatggattta agcaaagttgataaaacaactcaaagctttataggtttaagtacaactattggtgagttt gctattcagcttctcgatggtgctccgagtgaaattaaagttaaatatgctggtgactta gcgcaaaatgacactagtttaattacaagaacaattataacgaacatcttgaagaagaa gcgcaaaatgacactagtttaattacaagaacaattataacgaacatcttgaaagaagat ttaggtaatgaagtcaatattattaatgcaatagcaatacttaaccaacaaggtgtcacg tataattatagaacaacaaaagaaacattctggctttagtagttacattgagctagaacta gttaatgatcaagataaaatcaaaattggcgcaacggtattcgcaggttttggcccaaga atagtacgtattaatgattactcacttgattttaaacctaaccaatatcaattagtaaca ttcaacaaaattattagcactaagttaacaatt ttgaagcggaattttattaataatttaatcatattattaattgctattatgttaagtctg 533. acacttteteagactttaaatatatggedaatadteatettatteteattytygydate atetatataggaatgteaaaaattaactteeceaactaaacaattattaggeaeetataata gttttaattatatggaatatgaeaacacatttaacatttteaetagateattggttgtta gccacagcgcaacttattatatgatacgtattggattacagattgccaacttaatgagt gattaaagggaagaattgcaatagcaatagcctttcaaaatataatgctcatagtcaca acgtttataatgataataggaatacatttgattactaatgaatccatcaatgaattgtt gtgaagaaaacgagtagaataattgcattcatactcctcatagctctactattcacagga atgggtatgacgtataagaatgtagttaaaaatgttaatttaggtctagatttgcaaggt 534. gattatgtttaatgtetggtetggatttaatgtagatoosgatoogatagataaatttaagaaa caagaaactaatcaaccaacagttacatttaaagtaaaaagtaaaagataaatttaagaaa gtaactgaaaagatttctaaaaaaacgtgacaatgtcatggtagtttggttagatttcgaa aaaggcgatagttacaagaaagaagctaaaaagcaacaagaaggtaaaaaagcctaaattt atatctgcagcgagtgtagaccaacctattaattctagtagtgttgaaatttcaggtggc ttcaatgggaaaaaggtgttgaagaagcgaaacaaatagctgagttattaaatgccggc tcattaccagttgatttaaaagaaatttactctaactctgttggtgcacaatttggtcaa atcttagtt

| 535. | atgggggaaaatacaaaacaagatttcaatcaaaaaggacaaaattttaaattcacaaaa aaacatagacgattattatatggttcagtttttttaatggctacatcagctattggtca gcatttctgactcaaactgcagtgtttactgcacaattttatgctagttttgcat atattaattctattattatagatataggcgctcaaataaat |
|------|--|
| 536. | gtglctaataataatttaaagatgatttcgaaaagaatcgtcaatctattaatccagac gaacatcaaacagaattaaaagaagatgataaaacaaattcctccgagaaaagccgac tctcaaaacagtttatctaataactcaaaattacacaaatttcctccgagaaaatgccaaacga cgaaaaagacgcaggaagacagcaactaatcaaaagaagcagcaaacaacaacaa aaaaatagtgacgctaaaactacagaaggtcattagatgacgttatgacgaagcacag ttacagcaacaacatgataaatcgcaacaacaaaaataaaactgaaaaacaatcaacaagat aatagaatgaaagatggaaaaagatgcagcatttytaaatggaacatctgagtcaccaga cataaatcaaaatcaacacaaaatagacccggcctaaagctcaacaacaacaacaacaacaacaacaacaacaacaaca |
| 537. | atggctaaaggggaccaatatcaagctcatactgaaaatatcatgataaaaagtctaaa aaaagttataaacctgtgtggattatcattagttttatttttattttaattatcttgtta ttaccacaccagcaggattacctgtaatggctaaagcagcactagctattttagctttc gctgtagttatgtgggttaccagaagcagttacttatccagtttctgcaacattaatttta ggattaatgatacttttaccaggtttaagtccagtcaagatttatccgaaaaacttgga aaccctaaaagtggcgacataatactaaaagggtagcgatatttaggaaacgaaactgga cttagtcacgcttttagtggttttcaacctcagccgtagcacttgtagctgcagcatta tttttagcagtagctatgcaggaaaccaatttaccagacacttgtagctgcagcatta tttttagcagtagctatgcaggaaaccaatttacataaacggcttgcagtatacttttgtt ctagcattctttgtaccatcagcagcacttgtggtgtgtgt |
| 538. | atgttagtattgattgttggttggttattggaatggttggttggattatggattatcgg atgttagtttgattgatggtatgtattgatatgttttaaatcgtgcattaatcaca tctattttagttgggattgtatggaacgatgggtaggattattgttttacgtggtctt tctttaatggtgatgcatgagtcatgctgttttaccaggtgttgctttatcttcta tttaatattccaatgtttatcggggcacttgtaacgggaatgcttgcaagtttgttatt ggttttattacttcaaacagtaaaacaaaac |

| 539. | ttggcaaagctattatacaaactaggaaaatttatagctaagaacaaatggctaagtt tataggatggcttyttatactaggtyttatatacaccacaag tttgacagtgacatcactaggatggcataagtcattaagataaactcaccgaag tttgacagtgacatcactaggacggcataagtcattagacacaacagtaaaatcagt aaagaatttcatcaggacagtgagaaagcctgatgaaaatagtcttcattca | |
|------|--|--|
| 540. | cgatcatctcaacatcgtcatgatgacgaacttagagac atgaataaaaaagtagaacatatcggtaaccaatatacgtcacaagaaaataagaaaaaa caacgacaaaaaatggaagttgtatgtagtagacgtattgctttattcggaggtatt cttttagcgattatcctcattctacttgtattgcttgtacttcaaagacataataacgat caagatgcagttgaaaggaaag | |
| 541. | atgaagatacgtttaacatttattatcttagcaatactatccaccatcggcttagtactt gttttagcaaaatatccaacaggcccacacacaatcaactatacagcaccttatacagta ctcatagccattacagcaatatatataatggttttaccagcactcatattaggtatattt aatcatcttgcatgtagaatcatatcggcgatattacaaataagtgcactgatgatggg gggtttttagtaatcattagcttaattatgggacaaattgtcattatggcttcc ttaacgatacttgcattacttgttagttctattgtcacactttcagtgcacccatctact tcagataaaataaa | |
| 542. | atgaataagaaactattgtggagcatcattggtattgtaattattgtcgtattaatcatt gctgcttttatattaaacaagttaatggttcaggtagtaaagatagtaatgcttacgat acatatacagtaagaaagaacacctattagtttagaaggcaaaggcgtctccagaatct gtgaaaacttataacaataatcaatctgtggtaacttcttaagtgtttcagtacaagat ggtcaaacagttaaacaaggtgaacgtatcacaattatgattatagtttcagtacaagat ggtcaaacagttaaacaaggtgaacgatcacaatctcaagttaatgagaattacaacag caacacctattgaacaaagtgaatcaagcacaatctcaagttaatgatgattacaaaa gtaaatcaaagtcctaacaattacaaattacaagttaaattgacagatcaaagtgct ttaaatgaagctcagcagtcattgtcacaatatgacagaca | |

543. tttgcgattttaccagccatgtttatggcggctatgcctgcgatgaatcatttgaatatt trigegattitaceagecatgittalggeggetatgeetgegatgaatettitatgatatt atgeatetgeatteacetgaateageagtattatetgegttaatettaatgegttgatt atgtattattgatteegattgegatgaaaggegtgaaatttaaaggtgeeteaaegeaa aceatattgatgaaaaatatgttagtttaeggettaggeggtatgategtgeeatttate ggeattaageteattgateteateateeaectetttgte ggcattaagctcattgatctcatcatccaactctttytc.

atgattgtyttacgtcytctatttcaagatagaggtyccatatttyctatagctattatt
acaatctacgtagtycttygagttttagctctttaattacattctatgaaccgaatcac
attgatacagcaaataaatttyctygtataagtgytccactygtytyggaacagaccat
ttagttogagatytattaacacgyataatatacgcoataagacctagttyttatatyta
tttgtogcattgattattccgttytygataggagcyatacttygytttatttcca
agctattgtygtcacattygcattagttagtyttyggatgygyttytagaaaatatttcca
agctatytygtcacattygcattygtatacytyttytygcatygytytagaaaaatattatt
attgcatttatattygactcgatyggcytytttytcgcayggtytagaaaaatattatt
attgcatttatattygactcgatyggcytytttytcgcgytyattcgaaccaytyaaty
caataattygaagctgatcatytaaaatttygcaaagtaattygtatagaaccaytyaaty
tcgatygttcaaacattttygcaactaacctttactgacatagcyattattgctagtag
tcgatygttcaatgatattacaaatycaagattctcattccttygattagytytaag
gcacctacagccgaatggyggatgatyctaatgaagacagaaaagtaatytcacacat
cctygaatgatgatcacaacaggtgtygctatcgtcataattytgatygcyttaactt
ttatcagatycttacaaatggcgattgatcctcytagtccgctaaagaaaaacgacty
gcctygaagaaaagtytygaaagcacgtgacactyct
atgaaaggtyccatgtcttygccttttttaagattatatattttaacattgatyttttt 544 atgaaaggtgccatgtcttggccttttttaagattatatattttaacattgatgtttttt 545. actgrandgy tycking the transfer of the state rgggcrggrcaaallattgcacglattggtccgaltaaaglattggdattatatattgattga attaatgctatggcactggtattaatgggtttacaggacttgaaggtatttgattgca cgtatcatgcaaggtgtgtgtacggcattcttctcaatgtctttacaattgggtattata gatgctttacctgagaaatatcgttcagaaggtgtatctctctattcattattttcaacg attccaatttattaggaccattaattgcagttgggatttggcacgtggaaaattgtcc atatttgctattgttatgatttttattgcagtaacaacaaccttatttggttatagaact atatttgctattgttatgatttttattgcagtaacaacaaccttatttggttatagaact
acttttgcaaatacacaaaaagaggtatcaccaaaagacgaagtcttgccttttaatgca
atgactgtatatgtccaattttttaaaaaataaagcactttctgcagtggtatgattattg
atcttgtcatctatcgtgttttggtgcgatgagtacttttataccattatatacggttagg
gaaggtttcgcgaatgcaggtatttcctcacaattcaagccattacagtagtgatagct
agattttatttacgtaagtatgtaccatctgatggttattggcatcaccgttttatgatg
attgtcttaacgtactgatggtgctcagtcattgtagcttttaggacacattagatg
agtatatttgtatataaagtgcaatctttatggaataacacaagcgctcgtttatcg
acattgacaacgtatttaagttgtcttaccaaagaatagaacgtaatagttattagga
ttgttatagcatgtgcagatttaagggatttcactaggaggtgtctaatggggccaata teggatacggtaggatttaaatggatgtatattttatgcgctttattggttactattgca atgacactaagtaaaattagacaaagacaaagtgtttcaaaagcctca

| 546. | gtgggaagtactgttaaatatcgtaagtttattctacctattgtcgttggtttaattatc tgggcattgacgcctattaaaccagatgccttaaatgatcaagcttggtttatgtttgct attttgtgtcaaccatcattgcttgtattacccaacctatgactataaggtgcagtaca atcattggttttacaatcatgattttggttgaattgttgatacaaaaactgccgttcaa ggcttcggttatagatatttggcttattgcaattgttgatacaaaaactgccgttcaa ggcttcggttaatagtagtatttggcttattgcaattgctcattattcaagaggattt gtaaaacaagggctaggtcgacgtattgctctgcaattcgttaaattatttggaaagaaa |
|--------------|--|
| 547. | atgaaagataataaaatgttgttcattattttatgataggaacatttacagtaggaatg gctgaatatgtagtgacaggattacttacacaaatcgctgacgatatgaaggtttctatt tcgagtgcaggttattaattagtgtttatgctattagtgttgcattgaagggctttta atgcgaatcataacattgaaagttcacgcacacgtctgttaccgattgaagggctttt attataataagtaatttagtgggaatgttagcaccgaattttaatgtattgttattaca agactcatgtcgggcaatgcgtgcattcttcggtgtgtgt |
| 548. | qvlkmlqnilllmllllmlkikvliylimtllnqfrdmvlklrfinnkslwaien |
| 549. | krlvmqqhlqfnlpkiillnaltkrflsllvtqlvmvfilvvsllkvpvqlq |
| 550. | lrlrqfql1ctlvl1mlvalflhaf1ry1mtk |
| 551. | rlrytsyiiklaatdafklltcptigili |
| 552. | ssvfairltitfsrfsnvgckkhikgaiimkkeiiewivaiivaivivtlvqkflfasyt vkgasnviyh |
| 553. | rsvphivvltmriiasvllvivgfslsvsca tanniisfiitltniyktklmgyffniielrnkfirrcwailfiaiihfisecflphipt |
| 554. | tammisfiltiniykckingitiniterinkiirtewalifiaiinifisetiimipt ncyvsrfdfldsakmmsyktlnticrnsfrivhkliv ffcrltqlnwlkylsvrmlymyfmifsimnhivstic |
| 555. 556. | ifistcgcsttsawkaevlplrvrfpspapf |
| 557. | lknilrivfiagltvffsgpgqtysnaafideyiqtfgwsrtev |
| 558. | rnsnqmyqtftadivlifmiivlgglvvqvpmpilagimvmvsetiyclhl |
| 559. | ngrleetissphhssal |
| 560. | mkqflnitqrkfiewliilsifivsipnkwtlmisialsllllkrgalgvvqliilymlr sqiytpydtqemahyivsmkyiliyvigyfflfkyvkhwirnemilrfikstmilmllyi imslvvsndpiesilkllnffiplilivmyvslikkiknlinwinqfitlviaftflfiv iapksylideeslrsvfkdahsfavilamglvlymvtilkqdqydvfnllllnigmiely lsnsrhifisvilclmlllplshikkrikhpiigamilmaiaiinqpyiyhlfiklilkg knsqevfmpsdmnikaidyaltehpflgsgfgipmikasseiqyfnvatsniifgmiift giigltlctiymlhmvllvtfpmsitillflitifvnmdyiilfdsvglgilcyifwgiy lkegmyqynngqw |
| 561. | mtnqktvglvvapgvterlaenliqempkmlsthydhqqewifdlvtdpltgfaesvdei fgkvadyhdkrqwdyviaitdlpmfadkqvmaldinmengaaifsypafgwrpvkkrfkh aiyniiqelneaeqesrnydnnkqiensvkkqfplskidketiymketdsyhlrylsssr srgmfrlvsgmtfannplnmmaslsnivaiafttgafglvfttmwqmaynfsmwrlfgis iiaiigmliwimmshdlwepvnksnhkhitwlynlttimtlifaiiiyyiilyllfliae ivllpsgflgqqvglkgpagidlylsipwfaasistvagaigagllndelikestygyrq rvryeeqrr |
| 562. | mkfcphcgnpikkeqsfcnkcgkhlktstqrksenqiehmreqqsyisreerqhhdstfy keqkhtgwlivlsiifvlliaallygayyaynhyisdeqshqttesqqsnesdqnrdqst gpsidvfsddfdqgymksastsgyrgvyngmtreevedkfgtsngsveslkwsyetygdl avayddnevvsvgvapnhisedqflsmynepddrnssqliydsnkdndfsvlanvkngdv tvienvnqi |
| 563. | mllfiieiiimilaillglrtagalgcgifaivaqlimifgfqlppgsapvtavliilsi giaggtlqatggidylvyiasrvierfpksiifiapmivfvfvfgigtanialslepiia ktaqkariqpkraltasvltanlallcspaasatayiisvlagyeismgkylsivlptal ismlmlstfctfvgrkehvrdeserlvqmpeveikndfslkvkigvisfllcvmgiltfg ifpnlmpqfnvngdvvkvemteivqffmylsatinlllikintsdilssnitqsamgalf avlgpgwlgatifnaphnlkilkndigsiisevpwlviilvsvvamivisqtatasimvp ivmslgippiyfvamvqtlnvnfvipaqptllfaveldetgrtrptsfmipgffvitvsv itgfviktilgy |

| 564. | mgsffnrmtrkenptiyqnkdghlkrtlrvrdflalgvgtivstsiftlpgvvaaehagp avalsfllaaivaglvaftyaemastmpfagsayswinvlfgelfgwvagwallaeyfia vafvasgfsanlrgliaplgislpkslsnpfgsnggviddiaavviiltalllsrgmnea armenvlvilkvlaiilfvivgltainfsnyipfipehkvtetgdfggwggjyagvsmif layigfdsiaansaeainpqktmprgilgslivaivlfvavalvlvgmfhysgyadnaep vgwalresghgiiaaivqaisvigmftaligmmlagsrllysfgrdgllpswlsqlnhkh lpnralviltiigvvigsmfpfaflaqlisagtlvafmfvslamyrlrkregkdlpkpef klplypilpaitfilvllvfwglsfeaklytliwfivgiiiyliygirhskkndeeayqv pre |
|------|---|
| 565. | mtkkkrlspsewllkqskrhkrkntlytaivllvalvllifavksiqvepvksdtrdkds iritylgnvtlnkhirqtnlndvfkgiqdtldhsdfstgslivndfsrnqkdninknien imflrkhnvksvnlinesmdniqatammrkidsqagynfltgngsnpinsktvqqdikgk kianvsftdiesnytnslknttsisldpaifyplikklkenndyvvvnvdwgipnernvt trqkeyahalanagadviighntviqkvenykrtpifyslgnttsdnflsknqkgmivqq dwkgshnqfhitpiqskdgkiskdnmnkmdhirfknnikdksidlksdqnggytfey |
| 566. | miehlgintpyfgilvslipfviatyfykktngffllaplfvsmvagiaflkltgisyen ykiggdiinfflepaticfaiplyrkrevlkkywlqifggiavgtiiallliylvaitfq fgnqiiasmlpqaattaialpvsdgiggvkeltslavilnavvisalgakivklfkisnp iarglalgtsghtlgvaaakelgeteesmgsiavvivgvivvavvpilapill |
| 567. | mkrtdkyrdsykyddgymhrkrseedmyrqhqesqqransnratqsendreyenhpery yngrdyrreqqleeenekssktkkwliaiivilliivaifitraiinhnndkvandpnvs qnykkevenqnddinrqvdsaksdiknkkdtqsqidklqnqidqlkqneetnadskftkf yqnqidklknannaqlnnengskynnmledintkfdsikaklenilngsnsgn |
| 568. | mknkkglgiglitimiivcivlvimmfyggkkesyygimkdsttidkmintknekieknv elpkdanysykkedfymlfkdektgkitkykkynhddyphglmskihdmgnmkhgm |
| 569. | mamsllvslvvymmtltsdiledilsfklevimqfpyilssisliilfilfilkdmekiw ywlisivmiavismsghvwsqqvplwsiiirtihligltlwlgslvylicyaikvkinql tsvrrmllkvniiavimlvftgilmaidetntltlwnnvsawsiylvikiagiiammllg fyqtmralrqrqqvhrfalmtelligmilllqvs |
| 570. | mknsrfsgfqwammvfvffvitmalsvilrdfqatigvkrfvfsikdlapfiaaivcilv fkhrkeqlaglkfsislkvierlllalilpliilmiglfsfntyadsfillqtsdlsvsl ltilighilmafvvefgfrsylqmiletrmmtffasivvgliysvftanttygveyagyh flytfmfsmiigeliratngrtfyiatafhasmtfalvflfseetgdlfsmkvialstti vgvsfiiislliraivykttkgsldevdpnnylshiqdeepsqedasstsnhdvsskdet kqqdidndkhqskkpnksddalttsnykedassvnketdtthndnikdhstytedrhssv yndykdeihevedhkadtdksh |
| 571. | mennelqrglnarqmqmialggtigvglfmgatstikwtgpsvilayliagiflflimra mgemiyinpttgsfatfasdyihpaagymtawsnvfqwvvymseviavgeymnywfpsl pnwipgviavlflmaanlvsvkafgefefwfalikvvtivlmiiaglglilfgignggnp igisnlwshggfmpngfigfffalsivigsyggveligisagetknpqtnivkavngviw rilifyigaifvivsvypwnqlgsigspfvatfakvgitfaaglinfvvltaalsgcnsg ifsasrmiytlakkgqmpkvftkvmkngvpfytvfavsmgiligallnvilpliidgads ifvyvysasilpgmipwfmilfshlrfrrlhpekvhnhpfkmpggaianyltimflllvl vgmllnketvvsvvigivfltavtlyyliryhkkerqi |
| 572. | lqdfdnlipgwfktfvqvgndliwsqyligllltagffftisskfiqlrmlpemfralte kpetlssgekgispfqafaisagsrygtgniagvataivlggpgavfwmwiiaflgaasa fmeatlaqvykvhdkeggfrggpayyitkglnqkwlgivfavlitvtfafvfntvqanti aeslntqynispvitgivlavitgiiifggvrsiatlsslivpimaivyjgmvliillln idqivpmigtiiksafgvqqvtggavgaailqgikrglfsneagmgsapnaaatsavphp vkqgliqslgvffdtmlvctataimillysglqfgdsapqgvavtqsalnehlgsaggif ltvavtlfafssvvgnyyygqsnieflsnnkmilfifrcfvvllvfygavaktetvwsta dlfmglmaivniisiiglsniafavmkdyqrqrkegkrpvfkpenleinlfgietwgqha kmpkk |
| 573. | lkkeilewivaiavaialiaiitkfvgksysikgdsmdptlkdgervvvniigyklggve kgnviyfhankddyvkrvigtpgdsveykndtlyvngkkqsepylnynekrkqteyitg sfktknlpnanpqsnvipkgkylvlgdnrevskdsrsfglidkdqivgkvslrywpfsef ksnfnpnntkn |
| 574. | mfnkvwfrtgiffimlfiliklfmevhevfapiatiigsvflpflisgflfyiclpfqmi lekwgfprwasittifigliaiiaivvsfiapiiisnimlikqtpslqkeaeqlinfsl rqmdklpddvthrinkavksmgdgatsilsnsvsyitsfistvfllimvpffliymlkdh ekfipaigkffkgerkvfvvdllkdlnftlksyiqgqvtvsiilgiilyigyttiiglpyt pllvlfagvanlipflgpwlsfapaailgiidqpstfiwvcvvtliaqqlegnvitpnvm gkslsihpltiivvilaagdlggftlilvavplyaviktlvsnifkyrqrivdkansnvkd |
| 575. | mntivkhtvgfiasivltllavfvtlytnmtfhakvtiifgfafiqaalqllmfmhlteg kdgrlgsfkvifaiiitlvtvigtywvmggghsshl |
| 576. | mlgeqytqikrpanrltekilgwfswvflliltivsmfialvsfsndtsianlentlnnn elvqqilanndlsttqfviwlqngvwaiivyfivcllisflalismnirilsgllfliaa ivtiplvlliivtliipilffiiammmfarrdrietvpsyyneydqpyydergfyepesrn ehgynddvyepmhtkkedrntrrqfnrnaqqdsyngitdnqpdedtssdqlysdeyvdn edkysqfpkraveseyasqqtedeptvmsrqakynkkskntdfedaqqehmegnqfddvg vvepqidpkelkaqrkrekaeirakkkekrkaynkrmkerrknqpsavnqrrmnyeerrq minneqedtdnnlnqqedskken |
| 577. | meenknapnnenmsnkddntihlndsqsnedlelfrrnknarqrrrridngskekdats tqsqletkpmdkfidnhksinadkeiksdliednvndeddnakynndklndrsvaqtset rqsnedeeefltdhqsekqtkdsrhskkhkllskftskkeketftsfnsnekvtqikpls leekrairrkkqkriqytiitllillilvivlillymftplskisnvnikgnnnvstskikke lnvtsrsrmytfsknkairnlkanplikevdihkqlpntltvnvteyqivgleknkdkyv piiedgkelteykdevshdapiidgfkgdkktriikalsemspkvrnliaevsyaptknk qsrikiftkanmqvigdittiadkmqvypqmsgslsrddsgelktngyidlsvgasfipy qgsstvqsgteqmvtkstqeendakeelqnvlnkinkqskenn |

| 578. | mkclfkmlsiiiimlstftlfispstyanedenwtkiknrgelrvglsadyaplefekti hgkteyagvdielakkiakdnhlklkivnmqfdsllgalktgkidiiisgmtttperkke vdftkpymitnnvmmikkddakryqnikdfegkkiaaqkgtdqekiaqteiedskissln rlpeailslksgkvagvvvekpvgeaylkqnseltfskikfneekkqtciavpknspvll dklnqtidnvkeknlidqymtkaaedmqddgnfiskygsffikgikntilislvgvvlgs ilgsfiallkiskirplqwiasiyieflrgtpmlvqvfivffgttaalgldisalicgti alvinssaylaeiiraginavdkgqteaarslglnyrqtmqsvvmpqalkkilpalgnef vtlikessivstigvseimfnaqvvqgisfdpftpllvaallyflltfaltrvmnfiegr msasd |
|------|---|
| 579. | mshkilvsdpisedglqsilkhpefdvdiqtdlsendlvnmistydalivrsqtqvteri inaatnlkviaragvgvdninieaatlkgilvinapdgntisatehsvamllamarnipq ahqslrnkewnrkafrgvelygktlgvigagriglgvakraqsfgmkilafdpyltedka ksldiqiatvdeiaeksdfvtvhtpltpktrgivgssffnkakqmlqiinvarggiidet aliealdnnlidraaidvfehepptdspliqhdkiivtphlgastveaqekvavsvseei ieiltkgnvehavnapkmdlskvdkttqsffglsttigefaiqlldgapseikvkyagdl aqndtslitrtiitnilkedlgnevniinalailnqqgvtyniekqkkhsgfssyielel vndqdkikigatvfagfgprivrindysldfkpnqyqlvtchkdkpgiygqtgnllgshg iniasmtlgrndaggdalmilsidqqaseevikilnetsgfnkiistklti |
| 580. | lkrnfinnliilliaimlslllkmlhvilpfmfgpilaallcvkvlklkirwpfwlsqig lillgvqigstftqqvikdisknwltivfvtillillaliiafffkkiaqvnletailsv ipgalsqmlvmaeenkkanilvvsltqtsrvifvvilvplisyffqdnhhemnhtmevp tlsqtlniwqiiilfsmvgiiyigmskinfptkqllapiivliiwnmtthltfsldhwll ataqliymiriglqianlmsdlkgriaiaiafqnimlivttfimiigihlitnesinelf lgaapggmsqivlvamatgadvamissyhifriffilfviapligyfinvklnmk |
| 581. | vkktsriiafilliallftgmgmtyknvvknvnlgldlqggfevlfqvdplnkgdkidkk alqatsqtlenrvnvlgysepkiqiedpnriivqlagikdqaqarkllstqanltirdae dhvlmsgsdikqgsakqefkqetnqptvtfkykskdkfkkvtekiskkrdnvmvvwldfe kgdsykkeakkqqegkkpkfisaasvdqpinsssveisggfngkkgveeakqiaellnag slpvdlkeiysnsvgaqfgqdaldktmfasivgialiylfmlgfyrlpglvaiialttyi yltlvafnfisgvltlpglaalvlgvgmavdaniimyerikdelrigrtlkqayskanks sfltifdsnlttviaaavlfffgessvkgfatmlllgilmifvtavflsrgllsllvssn ffkkqywlfgvkkkdrhdinegkdvhdlktsyerlnfvklakplislsiliviigliiis ifklnlgidfssgtradiqsknaitqaqvektvksvglepdqiqingsgnknatvqfkkd lsreednklsakvksefgdnpqintvspligqelaknavtaiilasigiiiyvsIrfewr mglssvlallhdvfiiiaifslfflevdltfiaavltivgysindtivtfdrvrenlhkv kvithtdqiddivnrsirqtmtrsintvltvvvvvaililgaptifnfslalligllsg vfssifiavplwgmlkkrqfkktknnklvvhkekksndekilv |
| 582. | mgentkqdfnqkgqnfkftkkhrrllygsvflmatsaigpafltqtavftaqfyasfafa ilisiiidigaqiniwrilvvtglrqqeisnkvlpglgtiisiliafgglafnigniaga glglnamfgldvkwgaaitaifailifvsrsqqkimdvismilgivmilvvayvmvvsnp pygdalvhtfapehpfklilpiitlvggtvggyitfagahrildsgikgksylpfvnrsa vagilttgvmrtllflavlgvvvtgvtlssenppasvfqhalgpigknifgvvifaaams svigsaytsatflktlhksllnknnlivitfivistfvflfigkpvslliiagaingwil pitlgailiasrkksivgnyqhptwmlvfgiiavivtimtgifslqdlaslwkg |
| 583. | vsnnnfkddfeknrqsinpdehqtelkeddktnenkkeadsqnslsnnsnqqfpprnaqrrkrrretatnqskqqddkhqknsdakttegslddrydeaqlqqqhdksqqqnktekqsqd nrmkdgkdaaivngtsespehkskstqnrpgpkaqqqkrksestqskpstnkdkkaatga giagaagvagaaetskrhhnkkdkqdskhsnhendeksvknddqkqskkqrkaavgagaa agvgaagvahhnnqnkhhneeknsnqnnqyndqsegkkkggfmkillpliaaililgaia ifggmalnnhndsksddqkianqskkdsdkkdgaqsednkdkksdsnkdkksdsdknadd dsdnsssnpnatstnnndnvamnnsnytnqnqqdnanqnsnnqqatqgqqshtvygqenl yriaiqyygegtqanvdkikranglssnninngqtlvipq |
| 584. | makgdqyqahtekyhdkkskksykpvwiiisfiilitilllptpaglpvmakaalailaf avvmwvteavtypvsatlilglmilllglspvqdlseklgnpksgdiilkgsdilgtnna lshafsgfstsavalvaaalflavamqetnlhkrlallvlsivynktrnivigailvsiv laffvpsataragavvpillgmiaafnvskdsrlaslliitavqavsiwnigiktaaaqn ivainfinqnlghdvswgewflyaapwsiimsialyfimikfmppehdaieggkelikke lnklgpvshrewrlivisvlllffwstekvlhpidsasitlvalgiilmpkigvitwkgv ekkipwgtiivfgvgislgnvllktgaaqwlsdqtfglmglkhlpiiatialitlfnili hlgfasatslasalipvfisltstlnlgdhaigfvliqqfvisfgfllpvsapqnmlayg tgtftvkdflktgipltivgyilvivfsltywkwlglv |
| 585. | mldfinhllsyqflnralitsilvgivcgtmgsiivlrglslmgdamshavlpgvalsfl fnipmfigalvtgmlas1figfitsnsktkpdaaigisftaflasgviiislinsttdly hilfgnllaithqsfwttivitvlvilliiifyrplmistfdatfsrmsglnttlihyfv mlllalvtvasiqtvgiilvvallitpastafliskqlyammviasiisvissiiglyfs yiynipsgativictfmiyivtlsitriknkqkrsalt |
| 586. | lakllyklgkfiaknkwlsvigwlvilgviitplminspkfdsditmnglksldtndkis kefhqdsekasmkivfhsnkndglnnkdtkkdiedaldnirqnddyiqnisngydsgqnn degdtaianvsyvvpqtglkdsskhiidkelkdvtdnhnvqiektqggamnsepggtsei vgiivafvillitfgsliaagmpiisaiiglgssvgiialltyifdipnftltlavmigl avgidyslfiifrfkelkkkgvdtveaiatavgtagsavifagltvmiavcglslvgidf lavmgfasaisvlfavlaaltllpalisifhksikikdkptkskdpkdhswakfivgkpv iavivsliililaaipvsgmrlgipddslkptdsseykayklisdnfgegyngqivmlvn tkdggskstierdlnnmrsdledidnvdtvskaqltdnnnyalftiipekgpnsqstenl vydlrdyhsqaqekydygteisgqsvinidmseklnnaipvfagvivvlaffllmivfrs ilvplkavlgfilslmatlgfttlviqhgfmgslfgientgpllaflpvitigllfglai dyelflmtrvheeysktgdndhsirvgikesgpvivaaalimfsvfiafvfdddsaiksm gialgfgvlfdafvvrmtlipaltklfgkaswylpkwlgavlpnvdvegkaleednhhdt ssekghvndknseysrqdkdnyvyqndkrnynrnyndedynrsvhlnnhhdqhhrqhqyd nqrddidyeslytqdgdhthhdernyndrhyqdnydrnddyrhnnhdhqndnhdyhdsnf dkttnlykeltdsnidqdvlfkalmlyarennkgvydrynrssqhrhddelrd |
| 587. | mnkkvehignqytsqenkkkqrqkmkmrvvrrrialfggillaiilillvllviqrhnnd qdaverkeketefqkqqdeeialkeklnnlndkdyiekiarddyylsnkgevifrlpddk kssqsktsnekgn |
| 588. | mkirltfiilailstiglvlvlakyptgphtinynepytvliaittivimalpalilgif nhlacriisailqisalmmwgflviislimgqivimlmasltilallvssivtlsvhpst sdkin |

| 589. | mnkkllwsiigiviivvliiaafilkqvngsgskdsnaydtytvrketpislegkaspes vktynnnqsvgnflsvsvqdgqtvkqgeriinydtngnkrqqllnkvnqagsqvnddyqk vnqspnnhqlqvkltqdqsalneaqqslsqydrqlndsmnasfdgkinikndsdvgegqp ilqlissnpqinatitefdinkikegdevnvtvnstgkkgkgkilkidelptsydtsdds tassaqagaqdseegtemttsnptinqptggksgetskykviigdldipvrsgfsmdak iplktkklpnnvltkdnnvfvvdknnkvhkreikiernngeiivkkglksgdkvlkspkg nlndgekvevss |
|------|--|
| 590. | maettkifeshlvkqalkdsvlklypvymiknpimfvvevgmllalgltiypdlfhqesv srlyvfsifiilltlvfanfsealaegrgkaqanalrqtqtemkarrikqdgsyemida sdlkkghivrvatgeqipndgkvikglatvdesaitgesapvikesggdfdnviggtsva sdwleveitsepghsfldkmiglvegatrkktpneialftllmtltiiflvviltmypla kflnfnlsiamlialavclipttiggllsaigiagmdrvtqfnilaksgrsvetgdvnv lildktgtitygnrmadafipvksssferlvkaayessiaddtpegrsivklaykqhidl pqevgeyipftaetrmsgvkfttrevykgapnsmvkrvkeagghipvdldalvkgvskkg qtplvvledneilgviylkdvikdglverfrelremgietvmctgdneltaatiakeagv drfvaeckpedkinvireeqakghivamtgdgtndapalaeanvglamnsgtmsakeaan lidldsnptklmevvligkqllmtrgslttfsiandiakyfailpamfmaampamnhlni mhlhspesavlsalifnaliivllipiamkgvkfkgastqtilmknmlvyglggmivpfi giklidliiqlfv |
| 591. | mivlrrlfqdrgaifaiaiitiyvvlgvlaplitfyepnhidtankfagiswshwlgtdh lgrdvltriiyairpsllyvfvaliisvvigailgfisgyfpgyidaiimricdvmlafp syvvtlalitlfgmgveniiiafiltrwawfcrvirtsvmqyieadhvkfakvigmndlt iirkhilpltftdiaiiasssmcsmilqmsgfsflglgvkaptaewgmmlnearkvmfth pgmmmttgvaiviivmafnflsdalqmaidprmsakekrlalkkgvkardta |
| 592. | mkgamswpflrlyiltlmffsanailnvfiplrghdlgatntvigivmgaymltamlcrp wagqiiarigpikvlriillinamalvlyyftglegyliarimggvctaffsmslqlgii dalpekyrsegvslyslfstipnllgpliavgiwhvenmsifaivmifiavtttlfgyrt tfantgkevspkdevlpfnamtvyvqffknkalfcsgmimilssivfgamstfiplytvr egfanagifltiqaitvviarfylrkyvpsdglwhhrfmmivltllmvasvivafgphiv sifvyisaifigitqalvyptlttylsfvlpkigrnmllglfiacadlgislggvlmgpi sdtyqfkwmyilcallytiamtlskirqrqsvskas |
| 593. | vgstvkyrkfilpivvgliiwaltpikpdalndqawfmfaifvstiiacitqpmtigavs iigftimilvgivdtktavqgfgnssiwliamaffisrgfvkktglgrrialqfvklfgkk tlglayslvgvdlilapatpsntaraggimfpiikslsesfgssprdgserkmgaffift efqgnlitsamfltamagnpiagslaektahvqitwmnwfvaailpglislivvpfiiyk lypptvketpnakkwateqleemghmsiaeklmvgifiialalwvlgsfinvdatltafi alallltgylawsdilnetgawmtlvwfsvlvlmaeqlnklgfipwlskliaqglngfs wpivlvllilfyfyshylfasatahvsamyaallgvavasgapplfsalmlgffgnllas tthyssgpapilyaagyvtqkrwwtmnivlgivyfiiwigvgslwmkligmm |
| 594. | mkdnkmlfiifmigtftvgmaeyvvtglltqiaddmkvsissagllisvyaisvaligpl mriitlkvhahrllpilvaifiisnlvgmlapnfnvlllsrlmsaamhapffgvcmsvaa tvappakktqaialvqaqltiavmlqvpfgsflggfamwrvvfgfmivlaiitmlgmikf vpnvslsaeaniskeltvfknphiliviaiivfgysgvfttytfmepmirdfspfkivgl tvclfmfglggvignlitgnvpedkltknlyltflllfvtiilfvtviqnsilaliicfl fgfgtfgttpllnskiilsgkeapllastlaasifnvanflgaiigsillsiglpyiqit lisggiivlgmllnlvnqlyekkhitfneys |
| 595. | MAVKVAINGFGRIGRLAFRRIQEVEGLEVVAVNDLTDDMLAHLLKYDTMQGRFTGEVEV VDGGFRVNGKEVKSFSEPDASKLPWKDLNIDVVLECTGFYTDKDKAQAHIBAGAKKVLIS APATGDLKTIVFNTNHQBLDGSETTVSGASCTTNSLAFVAKVLNDDFGLVEGLMTTIHAY TGDQNTQDAPHRKGDKRRARAAAENIIPNSTGAAKAIGKVIPEIDGKLDGGAQRVPVATG SLTBLTVVLEKQDVTVEQVNEAMKWASNESFGYTEDEIVSSDVVGMTYGSLFDATQTRVM SVGDRQLVKVAAWYDNEMSYTAQLVRTLAYLABLSK |
| 596. | vkrlknfilgllivaivgfllfmyiddsriqsyqdyflqfnwfqplliglaglliligli lvlsifkpthrkpglyknfddghiyvsrkavektiydtiakydqvrqpnvvsklynkknk sfidikadffvpnhvqvksltesiradiksnvehfteipvrklevnvrdqktsgprvl |
| 597. | msflrkhteiifsyiigivslftgliifinlplikqfkgdkkvdthvhnvweflnaffae iikvmskfiggfpitsaiviivfgilvmllghtlfrtikydydisifflvigimyfiitl llmtqvygffaivfiipftvhigyivykdelnqdnrknhymwiivtygmsylitqislyg ridaneiesidilsvntffiimwllgqmaiwnfiflrrslpltkeelgeeepelsrtnkg nvsnqtkvhlkqlqnktteyarktrrsvdldkirakrdkfkqkinsivdiqeddipnwmk kpkwvkpmyvqlfcgviilffaflefmrnalfitgewelsqtqyvvewvtlllllfiii iyiattltyylrdkyyylqlfmgsilffkfltefinimvhglllsifitpilllmliami vavslqlrek |
| 598. | mqqettswykqewfivlsllfifplglflmwkfskwpsiartiitvaisvivlasityyg nlqmivpatsnsnnetkettennvndkdernhktaveetktnydstkentkepgkenesa trlensalekaksyyddfhmsklgiydiltseygekfdkedaqyaidhleadyeknalek aksyakdmhmsndsiydllvsnygekfteseakyaiehldn |